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1 INTRODUCTION 
1.1 The mucin glycoprotein family 
Mucins belong to a family of highly glycosylated proteins expressed by epithelial cells.1 Up to 
now, 21 members of this family have been identified. The carbohydrate-content of the 
mucins is usually higher than 50 wt% of the protein. These glycoproteins are a major part of 
the innate immune system. Secreted mucins form the mucus layer that protects the epithelial 
tissues of the gastrointestinal and respiratory tract and the ductal surfaces of breast, 
pancreas and kidney tissue against invading pathogens and chemical or physical stress 
factors.2 While most mucins are restricted to specific tissues, the MUC1 glycoprotein is 
ubiquitously distributed.3 MUC1 was first identified by murine monoclonal antibodies raised 
against human milk fat globule (HMFG).4 Mucins can be subdivided into two major classes, 
the secreted or gel-forming mucins and the membrane-bound mucins. The ubiquitous MUC1 
belongs to the class of the membrane tethered mucins. It is embedded into the membrane 
lipid bilayer by a single trans-membrane domain. The N-terminal ectodomain has a rod-like 
structure and stretches out 200-500 nm into the extracellular space, significantly surpassing 
the thickness of the glycocalyx (ca. 10 nm).5 The short transmembrane domain connects to 
the 72 amino acids cytoplasmatic domain, which is involved in cell signaling processes.6,7  
The MUC5B glycoprotein is belongs to the class of the secreted mucins and is mainly 
expressed in the respiratory system. Together with MUC5AC, it is the major airway mucin. 
Most secreted mucins have cysteine-rich regions, enabling formation of disulfide bridges and 
thus protein networks.8 Almost all mucins have an extracellular domain rich in proline, serine 
and threonine and arranged in domains called VNTR-regions (variable number of tandem 
repeats). In MUC1, a VNTR of 20 amino acids with the sequence 
PAHGVTSAPDTRPSAPGSTAP is repeated 20-125 times, in MUC5B a VNTR region 
consisting of 29 amino acids with the sequence ATGSTATPSSTPGTTHTPPVLTTTRTTPT is 
repeated in total 11 times.9,10 The overall number of VNTRs in MUC1 depends on genetic 
polymorphism and is different in each individual. A MUC1 tandem repeat contains five 
glycosylation sites (3x threonine, 2x serine) and the high proline content disturbs the 
formation of secondary structures, giving MUC1 a stretched, rod-like appearance.11,12 MUC1 
is expressed as a single precursor protein with a proteolytic cleavage site within a SEA (sea 
urchin sperm protein, enterokinase and agrin) domain between the ecto- and transmembrane 
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domain. This site is auto-catalytically cleaved during posttranslational processing and the 
extracellular domain is then non-covalently associated with the transmembrane domain.13 All 
O-glycosylated proteins are posttranslational modified during the passage through the golgi 
complex. Here, the carbohydrate decoration is added by the sequential addition of 
monosaccharides which requires an ensemble of various different glycosyltransferases. After 
the exocytotic transport to the cell membrane, MUC1 is internalized and transported back to 
the trans-golgi with subsequent re-localization to the cell membrane. During this cyclic 
process, the glycosylation pattern is further matured.14  
Mucin-like O-glycosylation is commonly found on threonine and serine amino acid residues. 
Recently, tyrosine was identified as a mucin-type glycosylation site, however, only a few 
examples of glycosylated proteins with this new posttranslational modification were found 
until now.15,16 Mucin-type glycosylation is characterized by eight core structures, namely core 
1 to core 8.17 All cores structures have in common, that the first added carbohydrate is 
N-acetylgalactosamine in α-configuration, which is attached by a family of polypeptide N-
acetylgalactosaminyltransferases (ppGalNAcT). This structure alone is known as the TN-
antigen (Thomsen-Nouveau antigen). Further elongation by the action of a β1,3-galactose 
transferase (C1GalT, T-synthase), results in the basic core 1 motif, also named T-antigen (or 
TF for Thomsen-Friedenreich antigen). Instead of a galactose, a glucosamine can be 
attached by the core 3 N-acetylglucosaminyltransferase (C3GnT) resulting in the core 3 
glycan. Core 3 structures are specifically found on mucins of the gastrointestinal tract.18 
Elongation on the 6-position of the first N-acetylgalactosamine of core 1 or core 3 by different 
members of the core 2 N-acetylglucosaminyltransferase family (C2GnT) results in the core 2 
and core 4 glycans, respectively. Core 1 to core 4 are the most abundant core motifs, while 
core 5 to 8 are very rare and only found in a few mucins. The genes encoding for the 
glycosyltransferases involved in core 7 and core 8 biosynthesis have not been identified yet 
(figure 1.1). 
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Figure 1.1: Structures of the common O-glycan core motifs.  
The O-glycan core structures can be elongated by the alternating action of a β1,3-GlcNAc-
transferase (β1,3GlcNAcT) and by either a β1,3- or β1,4-Gal-transferase (β1,3GalT, 
β1,4GalT) (figure 1.2).  
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Figure 1.2: Biosynthesis of mucin type O-glycosylation. 
Like this, the core structures are elongated either by a Galβ1,3-GlcNAcβ (type-1 N-
acetyllactosamine, LacNAc) or by a Galβ1,4-GlcNAcβ (type-2 LacNAc) disaccharide unit 
(figure 1.2).17 Chain termination may occur by the performance of a family of six α2,3-
sialyltransferases (ST3Gal-I to -VI), which attach a sialic acid (e.g. N-acetylneuraminic acid, 
Neu5Ac) to the terminal galactose of the carbohydrate chains. Sialylation may also occur by 
a α2,6-linkage on a terminal Gal or the initial αGalNAc of the TN- or T-antigen. Terminal α2,6-
sialylation on galactose is mainly performed on N-glycans by a family of α2,6-galactose 
sialyltransferases (ST6Gal-I and -II), while O-glycans are mainly sialylated on the initial 
αGalNAc by a family of α2,6-N-acetylgalactosamine sialyltransferases (ST6GalNAc-I to 
-VI).17,19 Many glycosyltransferases do not recognize sialylated glycans, and therefore further 
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chain growth is prevented. An exception is the α1,3/4-fucosyltransferases (FUT3) which adds 
a fucose monosaccharide, either to the 3- or the 4-position of the GlcNAc of the 
corresponding type-1 and type-2 LacNAc disaccharide units, even when sialylated. This 
results in the formation of the Lewisx (Lex) and the Lewisa (Lea) antigens or the corresponding 
sialyl-Lewisx (sLex) and sialyl-Lewisa (sLea) glycans. Sialylated Le antigens are important 
motifs, involved in leukocyte recruitment and emigration during inflammations.20 The 
carbohydrates may also be terminated by sulfation (figure 1.2). The number of carbohydrates 
per O-glycan chain on mucins on healthy cells, usually varies between 2 and 20 
monosaccharides.21 
 
1.2 Abnormal glycosylation and the role of MUC1 in cancer 
In epithelial carcinomas, expression of MUC1 undergoes a number of fundamental changes. 
The expression of the MUC1 glycoprotein is dramatically increased and the epithelial cell 
polarity is lost.22 Usually, MUC1 and other membrane-bound mucins are expressed only on 
the apical site of the cells, which is exposed to the ductal environment. However, in 
carcinoma cells, MUC1 is found also on the lateral and basal sites of the cells. In cases of 
cellular stress, e.g. in acute or chronic inflammatory insults, the cell polarity may further be 
lost. Cells can perform a repair program to regain polarity as soon as the stress response is 
terminated.23 In cancer however, the stress response is irreversible. During these processes, 
the cytoplasmatic domain of the dislocated MUC1 can now interact with receptor tyrosine 
kinases (RTKs) that are located on the basal cell membranes. For instance, MUC1 interacts 
with the RTK ERBB2 (HER2) and its activation is associated with the loss of tight junctions24 
between the cells.25 Also, MUC1 binds β-catenin, which is usually bridging between actin 
filaments and the cell-cell-adherence molecule E-cadherin. As a result, adherence junctions 
between the cells are lost.26 Overexpression of the rod-shaped MUC1 extracellular domain 
also masks the cell surface, resulting in destabilization of integrin-mediated adhesion of the 
cell with the extracellular matrix.27,28 These factors promote a separation of tumor cells from 
normal cell clusters and trigger metastasis.  
Additionally to overexpression of the MUC1 glycoprotein, the glycan structures attached to 
the mucin polypeptide tandem repeats are altered due to changes in the expression levels of 
various glycosyltransferases. These aberrantly structured glycans are referred to as TACAs 
(tumor associated carbohydrate antigens). In mammary cancer, the levels of C2GnT1 are 
downregulated or even completely obliterated.29 The branching to core 2 glycan motifs is 
therefore inhibited and core 1 structure formation is favored instead. Concomitantly, an 
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overexpression of sialyltransferases results in premature sialylation of the truncated 
carbohydrates.30,31,32,33 After sialylation further glycosylation is prevented. As a result, tumor 
cell glycosylation consists of short and often sialylated glycans. TN- and T-antigens and the 
corresponding sialylated STN- and ST-antigens are the most prominent glycans on cancer-
associated MUC1 (figure 1.3).  
 
Figure 1.3: Structures of tumor-associated carbohydrate antigens (TACAs) on mucins. 
TACAs were found on several human and murine breast cancer cell lines, on tissue samples 
of breast cancer patients and as well as on shed or secreted MUC1 in the serum of 
advanced breast cancer patients.30,34 Interestingly, expression of sLex epitopes, which are a 
ligands for E-selectins, also occurs in breast cancer.35 For normal O-glycosylation in the 
gastric, colorectal, pancreatic and hepatic tissue, the expression of core 3 β1,3-
N-acetylglucosaminyltransferase (C3GnT) is pivotal. Disturbed expression of this enzyme 
consequently results in higher levels of TN-antigen instead, which is correlated to cancer 
growth and susceptibility for metastasis.36,37,38  
The reasons for the aberrant levels of glycosyltransferase expression are not fully 
understood. The increased levels of TN- and STN-antigen are related to a genetic mutation in 
the gene Cosmc (core 1 β3-Gal-T-specific molecular chaperone).39,40,41 This gene encodes 
for the chaperone Cosmc, required for the correct folding of the C1GnT (β1,3GalT, T-
synthase). A lack of this chaperone leads to C1GnT aggregation and subsequent 
degradation in the proteasome. Consequently, appearance of TN-antigens increases 
because of faulty core 1 glycan elongation.40 Increased levels of ST3Gal-I in cancer cells 
could be related to hypoxia, which also influences expression levels of various other 
glycosyltransferases.42 In colon cancers, increased T-antigen and sLex and sLea 
glycosylation is not only related to glycosyltransferase expression rates. Rather higher 
transcription of the UDP-Gal transporter gene leads to increased amounts of galactose-donor 
in Golgi network.43 
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As a consequence, aberrant glycosylation results in a higher content of short and truncated 
carbohydrates. The tumor associated TN- and T-antigen have been identified in about 90% of 
all carcinomas.44,45 Because of the smaller glycans, the protein backbone is not effectively 
covered any more. Peptide epitopes are exposed, which in normal mucins would be masked 
by extensive glycosylation. These distinct differences of healthy and malignant cells, permits 
the humoral immune reactions to unique protein epitopes in cancer.  
The PDTR peptide domain within the MUC1 tandem repeat sequence has been identified as 
an immune-relevant peptide epitope, which is recognized by many MUC1 antibodies.46,47,48,49 
A secondary structure in this peptide sequence was found and identified as either a type I or 
II β-turn.50,51,52 Later NMR studies confirmed a type I turn,53,54,55 but also consecutive γ-turns 
leading to s-shaped structures were proposed.56,57 The reported variations might be referred 
to different experimental conditions and the interplay between the different analyzed peptide 
backbones and attached glycoforms, resulting in conformational variations. However, the 
secondary turn structure in the PDTR motif is usually regarded as the reason for its 
pronounced immune reactivity as it forms a “knob-like” structure that projects out of the 
straight protein. The GSTA domain of the tandem repeat was later identified as a novel 
cancer specific epitope, by the generation of MUC1 mAbs.58 In further experiments, a MUC1 
glycopeptide microarray system was presented for the screening of serum antibodies. 
Former breast cancer patients who were classified as disease-free were treated with a 
MUC1 triple tandem repeat sequence, perglycosylated with TN-antigen (25 x TN) and 
conjugated to KLH (keyhole limpet hemocyanin) as carrier protein. Antisera were extracted 
before and after administration. The sera of 18 out of 20 patients showed recognition of 
glycopeptides with double TN-antigen glycosylation in the GSTA domain after the 
injection.59,60 Further tests with sera from large cohorts of breast-, ovary- and prostate cancer 
patients, revealed auto-antibodies directed against the GSTA epitope.61,62 Of the reported 
monoclonal antibodies against MUC1 tandem repeats, only a few were directed against the 
VTSA peptide domain, however, this region seems to be less immunogenic.63,64 According to 
the site-specificities of the relevant ppGalNAcTs, involved in MUC1 glycosylation, the VTSA 
domain is likely to be glycosylated on the endogenous protein. However, in between the 
VT/SA motif is a cleavage site (/) for the protease cathepsin L, which is involved in antigen 
processing in the endosomes in mammals. Glycosylation in VTSA, whether on threonine or 
serine, obstructs the action of the protease. The resulting peptide fragments may not be in 
the optimal size range for MHC II (major histocompatibility complex II) protein presentation to 
the T-cells. This might be one reason for the low immunogenicity of this motif.65,66 In many 
cases not only the peptide sequence is part of the epitope. A carbohydrate hapten may be 
included in the antigenic determinant. Several MUC1 antibodies that have been raised, show 
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better reactivity, when the peptide/protein contains glycosylation and many are exclusively 
reactive on glycosylated MUC1.46  
 
1.3 Galectins and the role of galectin-3 in cancer 
Galectins are a family of lectins with conserved C-terminal carbohydrate recognition domains 
(CDRs) for recognition of β-galactosides. The 15 found members of the family of mammal 
galectins are divided into three main classes: 1) The prototype galectins (galectin-1, -2, -5, 
-7, -10, -11, -13, -14, -15) consisting of two dimerized CDR chains, 2) the tandem repeat type 
galectins (galectin-4, -6, -8, -9, -12) consisting of a single chain with a CRD at each end and 
3) chimera type galectin-3 with one CRD, connected to a tandem repeat of a collagen-like 
sequence, which enables oligomerization to pentamers. Although all members of the galectin 
family have a general affinity for β-galactosides, each galectin has a fine specificity regarding 
the type of galactosyl-oligosaccharide.67 In contrast to other common mammalian lectins, 
such as C-type lectins, selectins and siglecs, galectins are not membrane-bound. They 
appear on the intracellular side in the cytosol, in the nucleus and are also secreted into the 
extracellular space. Accordingly, galectins are involved in a plethora of different physiological 
cell functions, such as involvement in cell-cell junctions, adhesion to extracellular matrix, 
signaling pathways, cell cycle progression, apoptosis, regulation of RNA splicing, modulation 
of signal transduction and cell migration.68  
Galectin-3 is one of the most studied galectins and shows increased expression in various 
carcinomas. Further, galectin-3 plays several roles in tumorgenesis and metastasis.69 For 
example, cytosolic galectin-3 binds selectively to the oncogene K-Ras but not to the isoforms 
H- and N-Ras.70 The galectin-3 interaction with K-Ras increases the amount of activated 
GTP-K-Ras, leading to enhanced activation of downstream effectors, preventing apoptosis or 
promoting cell proliferation.71 Further, upon an exogenous apoptotic stimuli, cytosolic 
galectin-3 is translocated to the mitochondrial membrane where it prevents release of 
cytochrome C, thereby preventing apoptosis.72 The mechanism might be similar to the anti-
apoptotic properties of Bcl-2 (B-cell lymphoma 2), which shows significant sequence 
homology to galectin-3. Tumor promotion may further be executed by galectin-3 involvement 
in the Wnt/β-catenin pathway. Galectin-3 prevents phosphorylation of β-catenin and thereby 
degradation in the proteasome. As a result β-catenin translocates into the nucleus, 
accumulates and activates gene expression of the cell cycle progressor cyclin D or the proto-
oncogene c-Myc.73,74 These examples show the various tumor-promoting effects of 
intracellular galectin-3. Galectin-3 was co-immunoprecipitated with several proteins involved 
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in the mentioned pathways, such as K-Ras70 or β-catenin75, indicating a recognition mode 
independent of glycosylation. Many more examples for intracellular, carbohydrate-
independent interactions are reported.76 In general, intracellular galectin-3 mediates cancer 
promoting effects by preventing apoptosis and providing tumor cell survival.  
Extracellular galectin-3 is able to bind galactosides on glycoproteins presented on the cell 
surface. For instance, mucin glycoproteins on different epithelial carcinoma cells are primary 
binding partners for galectin-3.77,78 Furthermore, co-immunoprecipitation from colon cancer 
cell lines showed that cancer associated MUC1 is a natural target for galectin-3 and binding 
seems to be mediated by glycosylation77 with the tumor-associated T-antigen.79 MUC1 
proteins with T-antigen presentation on cancer cells are proposed to permit adhesion to 
endothelial cells in the presence of galectin-3.80,81,82 Binding was increased when the cells 
were pretreated with sialidase and depletion of binding occurred by O-glycanase treatment 
(T-antigen specific endoglycosidase from Streptococcus pneumoniae). MUC1-transfected 
melanoma cells with T-antigen glycosylation exhibited stronger endothelial cell binding when 
treated with galectin-3, while no effect was visible on the MUC1 negative revertants.83 It was 
therefore proposed that galectin-3 captures overexpressed MUC1 on the surface of 
circulating tumor cells and through clustering of MUC1, several shorter adhesion molecules, 
such as E-cadherin, CD44 and E-selectin ligands are revealed which are then exposed on 
the cell surface and are able to interact with their corresponding binding partners on the 
endothelial side (figure 1.4, mechanism A).79 By this mechanism, galectin-3 supports settling 
of metastasizing tumor cells. Also, adhesion of the circulating tumor cells to each other is 
increased through mucin/galectin-3 interaction, leading to aggregation of tumor cells (figure 
1.4, mechanism B).84 The cell adhesion prevents apoptosis of the tumor cells, induced by the 
loss of cell-cell or cell-matrix interactions (anoikis).85,86 By recognizing tumor related 
glycosylation on overexpressed MUC1 and following mediated adhesion to epithelial tissue, 
galectin-3 promotes installation of secondary tumors. Furthermore, extracellular galectin-3 
has been shown to be immunosuppressive. T- and B-leukocytes, which were exposed  to 
galectin-3, became apoptotic (figure 1.4, mechanism C).87,88,89,90,91 As molecular receptors on 
the leukocytes CD7, CD29 (β1-integrin), CD45 (protein tyrosine phosphatase) and RAGE 
were identified.87,88,92,93,94 All interactions are mediated by protein N- and O-glycosylation with 
varying contributions. For example, CD45 contains N- and O-glycans, but the splice isoform 
CD45RO, which lacks the heavily O-glycosylated protein domain, shows almost no galectin-3 
binding, highlighting the significance of O-glycosylation for galectin-3 induced apoptosis.94 
Overexpressed galectin-3 in circulation and membrane-associated to the tumor cells is 
therefore suspected to be beneficial for the tumor cells and helps to escape immune 
surveillance. Apart from apoptosis of immune cells, the human colon adenocarcinoma cell 
line SW48 was also shown to enter apoptosis after removal of N-acetylneuraminic acid by 
10 1 INTRODUCTION
 
 
sialidase treatment and contact with galectin-3.93 CD7 and CD29 were identified as galectin-3 
receptors. CD29 was found to be α2,6-oversialylated on this carcinoma cell line, thus 
hindering galectin-3 interaction. It was therefore proposed, that overexpression of galectin-3 
and oversialylation is advantageous for cancer progression in several ways. The cancer cells 
benefit from the intracellular anti-apoptotic effects and are at the same time protected from 
apoptotic effects of extracellular galectin-3 by extensive α2,6-sialylation of the galectin-3 
receptor CD29 (figure 1.4, mechanism D).  
 
Figure 1.4: Proposed effects of extracellular galectin-3 on tumor metastasis and immune evasion. A: Clustering 
of MUC1 by galectin-3 exposes cell adhesion molecules. B: Tumor cell aggregation through exposed cell 
adhesion molecules prevents anoikis. C: Galectin-3 mediated apoptosis of T-cells results in tumor immune 
escape. D: Extensive α2,6-sialylation blocks galectin-3 mediated apoptosis of tumor cells. 
Other members of the galectin family were found to share the same metastasis promoting 
features.95 MUC1 and galectin-3 act in a tumor-promoting interplay. The N-glycosylated (Asn-
36) intracellular, C-terminal part of MUC1 further signals an increase of galectin-3 mRNA 
translation by stabilizing the transcript through decrease of the inherent, galectin-3 
suppressing miRNA-322. Tumor-related MUC1 overexpression is therefore correlated with 
increase in galectin-3 expression. In return, galectin-3 binds the MUC1 N-glycosylation at 
Asn-36 and bridges to ERBB1, integrating MUC1 into EGRF signaling.96  
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Galectin-3 may be involved in tumor progression in several ways. In general, intracellular 
galectin-3 acts anti-apoptotic and therefore promotes cancer development via carbohydrate-
independent protein-protein interactions. Extracellular galectin-3 promotes metastasis and 
regulates cell apoptosis via carbohydrate-dependent mechanisms. Through direct contact 
with cell surface glycans, for example the tumor-associated T-antigen, it is probably involved 
in installment of daughter tumors, which makes it an interesting subject for further 
carbohydrate-lectin binding studies.  
 
1.4 MUC1 carbohydrate vaccines 
The fact that MUC1 is overexpressed and aberrantly glycosylated made it a prime target in 
immunotherapy and immunodiagnostics of carcinomas, including breast, ovarian, lung, colon 
and pancreatic cancers. Anti-MUC1 auto-antibodies are found in serum of cancer patients 
and their identification is in general associated with a better prognosis.11,61,97 Treatment of 
cancer relies on the removal of the tumor burden by chemotherapy, radiation or surgery. 
Hence, immunotherapeutic methods are a valuable asset to established tumor therapy. 
Passive immunization with monoclonal antibodies is a successful and relatively safe 
approach in immunotherapy. Several cancer target reactive monoclonal antibody drugs have 
already entered the market and second generation approaches, such as engineered 
antibody fragments or antibody-drug-conjugates (ADCs), are in the focus of contemporary 
pharmaceutical research and clinical studies, with first products already launched.98 
However, the protection by passive immunization with monoclonal antibodies is not long-
lasting, most available therapeutic antibodies on the market and in late stage clinical trials 
are chimeric or humanized antibody drugs,99 which can still provoke an unwanted immune 
response100 and full human sequence antibody production by in vitro affinity maturation 
through biological display systems or in vivo expression in transgenic animals is complex. 
Active immunization with an anti-tumor vaccine on the other hand, could induce inherent 
antibody production against tumor related tissue. Especially against metastasizing tumors, 
an augmented immune surveillance would be helpful. Although auto-antibodies are found in 
the serum of patients, the induced immune reaction by the inherent tumor-associated 
antigens is obviously not strong enough to eradicate the tumor burden. The reason is, that 
the tumor-associated antigens are often seen as self-antigens and are only poorly 
immunogenic, although being abnormal.101  
An organism has a natural tolerance for antigens regarded as “own”. All lymphocytes are 
generated in the bone morrow. To avoid autoimmunity, lymphocytes are selected for 
12 1 INTRODUCTION
 
 
tolerance against endogenous tissues. Cells that recognize self-antigens are selected for cell 
lysis. For B-cells, this education happens directly in the bone morrow and for the T-cells in 
the thymus. Dendritic cells, macrophages and B-cells are antigen-presenting cells (APCs) 
and can detect and internalize exogenic pathogens. After digestions, parts of the pathogens 
are linked to major histocompatibility complex II (MHC II) proteins, which are presented at the 
surface of the APCs to CD4+ T-cells.102 If a presented antigen is of endogenous nature, the 
T-cell receptor (TCR) will only bind weakly to the MHC-antigen-complex, according to 
maturation in the thymus. Important costimulatory signals cannot emerge and the T-cell 
remains inactive. If the APC is a B-cell, it can proliferate into a plasma cell and start to secret 
antibodies in a T-cell independent reaction. These antibodies are of the IgM-type and are 
short-lived and of low affinity (figure 1.5, A). In general, sole carbohydrates are T-cell-
independent antigens.103 Tumor related MUC1 IgM antibodies are found in cancer patient 
sera but immune response is too weak to successfully generate immunity. On the other 
hand, if an APC presents an unknown antigen to the T-cell, then the MHC-II-antigen-complex 
is bound with high affinity. Costimulation takes place and the T-cell proliferates into a T-
helper (Th) cell and secretes cytokines which dock to cytokine receptors at the B-cell to 
induce proliferation into an antibody-producing plasma cell (figure 1.5, B). The antibodies 
generated by the T-cell-dependent pathway are long-lived, high affinity IgG antibodies. 
Furthermore, B-cells may also proliferate into memory B-cells. This class change from IgM to 
IgG antibodies characterizes an effective humoral immune response. 
 
Figure 1.5: A: T-cell independent response by carbohydrate antigens elicits IgM antibody production. B: 
Costimulatory signals enables proliferation of B-cells into plasma cells and IgG antibody production. 
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At any time, the immune effector cells patrol for unusual structures and start an immune 
reaction if necessary. However, tumor cells also develop mechanisms to escape the 
permanent immune surveillance. For instance, the ability to express MHC I molecules may 
be gradually lost during increasing stages of tumorgenesis.104,105 Some solid tumors also 
start to overexpress cytokines with immunosuppressive functions, such as IL-10, IL-4 or 
vascular endothelial growth factor (VEGF).106 It has been found, that MUC1 itself is an 
immunosuppressive factor. Shed and secreted MUC1 in tumor tissue arrests T-lymphocytes 
in their cell cycle and proliferation of naïve T-cells is blocked.107,108 
A suitable vaccine must therefore be able to overcome natural tolerance and effectively 
augment the immune response. Commonly, a chemically synthesized antigenic B-cell 
epitope is conjugated to an immunostimulant. A common strategy is the conjugation to a 
carrier protein. Carbohydrate antigens may be directly linked to a carrier, such as keyhole 
limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid. Immunological 
studies in mice revealed, that the induced immune reactions by such a conjugate elicits 
modest responses, often significantly of the IgM-type, indicating insufficient antibody class 
change.109,110,111,112,113 Variants of using unglycosylated peptide epitopes, in form of multi 
tandem repeat peptides or as carrier protein conjugates have been tested. Most of the 
formulations used with unglycosylated peptides suffer from low humoral response or lack of 
class switching to IgG isoforms.114,115,116,117,118 The reasons might be related to missing 
conformational effects of the carbohydrates on the peptide backbone. Tecemotide (L-BLP25, 
Stimuvax®, Merck KGaA) is a liposomal formulation of an unglycosylated MUC1 tandem 
repeat peptide (25mer), conjugated to monophosphoryl lipid A (MPL). The compound went 
into clinical trials with application in NSCLC (non-small cell lung cancer). After not meeting 
the primary end point in an initial phase III clinical trial,119 the formulation was withdrawn in 
2014, shortly after the beginning of a second phase III trial and is discontinued.120 
Vaccine designs based on glycopeptides seem to be more promising.103 In comparison, 
glycosylated peptide vaccine candidates usually elicit stronger immune responses than the 
unglycosylated counterpart.121 An early study already showed that serum antibodies of breast 
cancer patients react stronger with glycosylated MUC1 tandem repeats than with the 
unglycosylated tandem repeats.47 Commonly, MUC1 glycopeptides are also conjugated to 
immunostimulants to enhance immune response, to overcome tolerance and ensure 
antibody class switching. Several glycopeptide vaccine conjugate designs have been 
reported in the literature. A MUC1 glycopeptide may be attached to a carrier protein, for 
instance bovine serum albumin (BSA),122,123 keyhole limpet hemocyanin (KLH)124,125 or 
tetanus toxoid (TT) (figure 1.6, A).126,127,128 Carrier proteins fortify immune responses by 
presenting T-cell-epitopes for T-cell-dependent immune reactions and multivalent 
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presentation of the B-cell epitopes enhances the tendency for receptor clustering on the 
antigen presenting cells (APC), such as dendritic cells (DCs), B-cells or macrophages. 
Exogenous proteins also provoke a response against carrier epitopes, which sustains the 
risk of overriding the immune reaction against the selected B-cell-epitope.129,130,115 
Alternatively, short peptide sequences may be used as T-cell epitopes (figure 1.6, B). 
Examples are peptides coming from ovalbumin,131 the polio virus132 or rationally designed 
peptides like the PADRE-sequence.133 The P30-sequence, a 30mer peptide derived from 
tetanus toxoid, has recently been reported to give robust antibody titers. Also, this peptide 
may function as a built-in adjuvant, making the use of additional adjuvants in immunotherapy 
obsolete.134,135 Other common immunostimulants are Toll-like-receptor (TLR) ligands, like the 
lipopeptide Pam3CSK4.
136 As a mitogen, the lipopeptide is not immunogenic but stimulates 
TLR-1/2,137 which initiates induction of costimulatory proteins in B- and T-cells. Conjugation 
of these components, with spatial separation via a non-immunogenic spacer, results in two- 
and three component vaccines.  
 
Figure 1.6: Design examples for potential glycopeptide vaccine conjugates: A: Two-component peptide-protein 
vaccine. B: Two-component peptide-peptide vaccine. C: Three-component peptide vaccine with TLR-lipopeptide. 
In addition to a humoral antibody response, it would be beneficial if the vaccine could induce 
cytotoxic T-cell responses. In that way, malignant tumor cells would also be opposed to 
cytotoxic T-lymphocytes (CTLs), which could directly lyse the cells or induce apoptosis. 
Exogenous substrates, such as the potential vaccine, are endocytotically internalized, 
processed by digestion and the resulting (glyco-)peptides loaded onto MHC II molecules. 
The loaded antigens are then exclusively presented to CD4+-T-cells and differentiation into T-
helper cells proceeds. CTL activation, on the other hand, relies on antigen presentation by 
MHC I to CD8+ T-cells. Nevertheless, CTLs with specificity against the MHC-unrestricted 
epitope localized to the DTR domain have been isolated from tumor patients.138,139 Since 
then, MHC I restricted peptide sequences within or outside the MUC1 tandem repeat were 
also reported and specific CTL-responses could be induced in mouse models.140,141,142,143,144 
Moreover, it was documented that glycosylation is able to stabilize the binding to MHC I.142,144 
It is not clear though, how the tandem repeat sequences get access to the MHC I pathway. 
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This would involve mechanisms of cross-presentation. The antigen could for example escape 
into the cytosol and be processed by the proteasome,145,146 or be digested by cathepsins to 
yield 8-11mer peptides which would fit into the MHC I binding groove.147 It was also shown, 
that the C-type lectin MGL (macrophage galactose c-type lectin) can mediate internalization 
of glycopeptides into APCs upon which the glycopeptides are directed into MHC II as well as 
into MHC I compartments.148,149 The uncertainties regarding efficient MHC I presentation 
makes addressing cytotoxic immune responses by vaccines difficult and so far no example of 
a CTL-response, being able to successfully neutralize human cancer cells is reported (for 
example in transgenic mouse models).143  
 
1.5 Mucins in airway diseases 
The glycans on mucin glycoproteins are covering the epithelial cell-surface and determine 
physical and biological properties of the mucus. The glycans are effecting the conformation 
of the protein and the hydrophilic glycans are preventing dehydration, thus influencing the 
mucus flow properties. The different carbohydrate structures also function as ligands to 
different pathogens, which during normal flow properties to a large extend are cleared by the 
mucus.150 This process is an important part of the innate immune system. In airway diseases, 
the binding of pathogens to glycan ligands results in inflammatory-infective responses in the 
respiratory tract contributing to the mucin overproduction and causing an aberrant flow of the 
mucus, which further is an important factor in the morbidity and mortality of COPD, CF and 
asthma patients. Changes in terminal mucin glycosylation has been found in these patient 
groups, e.g. altered levels of sialylation, sulfation and fucosylation.151 These alterations of the 
O-glycosylation influence both biophysical and biological (binding to bacteria, viruses and 
cells) properties of specific mucins. The changes in glycosylation and mucin production in 
COPD, CF and Asthma are probably one of the major factors involved in the non-optimal 
transport properties of the mucus and rather than protecting the host, the gel instead 
provides an environment where the pathogens thrive and contribute even more to 
inflammation and disease.152 
 
  
2 Motivation 
Oligosaccharides attached to proteins and lipids form the glycocalyx, which covers the 
surface of most animal and some bacterial cells. These glycoproteins and lipids are the first 
interaction partners dealing with extracellular stimuli. The specific recognition by receptors, 
carbohydrate binding proteins or antibodies is the first step in a process leading to various 
kinds of biological outcomes. The development of microarray technology and the application 
in the field of glyco-sciences during the last decade, allows evaluation of carbohydrate-
protein interactions in a high-throughput manner and with smaller amounts of precious, 
complex carbohydrates. The bottleneck in many cases is the availability of defined 
carbohydrate structures which are not easily isolated from biological material due to their 
heterogeneity regarding site-specific glycosylation and stoichiometric carbohydrate 
occupancy. The aim of this work was to establish a unified strategy for the synthesis of 
complex mucin type O-glycans and the incorporation into peptides in order set up a 
comprehensive glycopeptide library. The glycopeptides serve as substrates for the build-up 
of a glycopeptide microarray platform. The combination of peptide and glycan motifs, allows 
the evaluation of specificities of carbohydrate and glycoprotein binding proteins, such as 
lectins or antibodies, in the most natural way of glycan presentation.  
As peptide scaffolds, tandem repeat sequences from MUC1 and MUC5B are chosen for solid 
phase peptide synthesis. MUC1 is overexpressed and aberrantly glycosylated on cancer 
cells, representing a potential candidate for vaccine development. Here, a designed MUC1 
glycopeptide array will serve for epitope mapping of serum antibodies generated from 
administration of potential synthetic vaccine candidates to mice. Further, it is possible to 
elucidate MUC1 glycopeptide interactions with human lectins involved in cancer progression, 
such as the interaction of galectin-3 with MUC1. Also plant lectins, commonly used in affinity-
based enrichment methods of glycans, glycopeptides and -proteins, will be screened for their 
binding specificity. The build-up of a library of MUC5B glycopeptides, in addition to the MUC1 
peptides, can potentially serve as model system for multivalent lectin association of airway-
invading pathogens. Knowledge about virus and microbe airway pathogen interactions are 
important in order to generate new point-of-care diagnostic tools or can function as starting 
points for development of new anti-adhesive drugs. An array of mucin glycopeptides may be 
useful to map pathogen strain fine specificity to different glycan ligands. 
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The synthesis strategy is envisioned to constitute from a few basic building blocks that could 
be assembled to diverse glycosylated amino acid building blocks. The synthesis involves 
construction of two glycosylated threonine amino acid acceptors, which allow chemical 
elongation into the common mucin-type O-glycan core structures. A second central motif is 
the assembly of type-1 and type-2 LacNAc (Galβ-1,3/4GlcNAcβ) disaccharides, for O-glycan 
core synthesis. The glycan elongation with the LacNAc disaccharides is mimicking the 
alternating biosynthetic action of GlcNAc- and Gal-transferases. From the stock of the 
common basic building blocks, a route was planned to synthesize T-antigen, extended core 
1, 2 and 3 glycosylated amino acids (figure 2.1).  
 
Figure 2.1: Basic pool of glycosyl donors and acceptors for convergent assembly of O-glycan mucin core amino 
acids. 
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The threonine glycosyl amino acids were then aimed to be introduced into MUC1 and 
MUC5B peptide sequences of the corresponding tandem repeats. The focus lies on the 
synthesis of mono-, di- and triglycosylated glycosyl peptides which are homogeneously 
decorated and arranged in an identical pattern for each glycosyl amino acid (figure 2.1).  
 
Figure 2.2: Construction of mucin glycopeptide libraries with multivalent glycosylation patterns by solid phase 
synthesis using the O-glycosylated threonine amino acids. 
Glycopeptide diversity can be further increased by applying glycosyl transferases such as 
sialyltransferases for termination of the glycan structures. Optimal would be a time and 
resources saving enzymatic approach on immobilized glycopeptides such as a glycopeptide 
microarray. Three sialyltransferases are planned to be used for the synthesis of sialylated 
glycopeptides. It is necessary to first evaluate the activity and specificity of the transferases 
towards the mucin glycoproteins in solution before applying them on a microarray surface 
and to further generate modified glycopeptide standards for later evaluation of the on-slide 
enzyme performance. With the sialic acid modified peptide standards in hand and knowledge 
about the substrate specificity regarding the glycan core structures on the mucin peptide 
backbones, on-slide enzymatic modification can be approached.  
For immobilization of the synthetic glycopeptides, amine reactive, N-hydroxysuccinimide 
functionalized, microarray slides were selected. All glycopeptides are going to be conjugated 
with a triethylene glycol spacer amino acid with a terminal amine to the N-terminal end. In 
previous studies it has been observed that ligand presentation to surface is dependent on the 
size of the spacer and a spacer length of at least 6-carbons is recommended. In both mucin 
peptide sequences the N-terminal linker contains the only free amine and will connect the 
glycopeptides site-specific to the slides. The established glycopeptide array will then be 
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utilized in carbohydrate/glycopeptide binding studies. The glycopeptide array is aimed for 
epitope mapping of serum antibodies from mice, which have been treated with potential 
synthetic vaccine candidates. Points of interest are the peptide epitopes and the dependence 
on glycosylation, influences of different glycans according to their structure or size and 
influences of multivalent glycosylation. An important issue regarding the safe application of 
potential anti-tumor vaccines, is the specificity of the induced immune reaction. Generated 
antibodies should selectively target tumor-associated epitopes and omit natural structures, in 
order to prevent autoimmune reactions. The planned glycopeptide microarray contains short 
tumor-associated and larger non-tumor-associated glycans in order to evaluate the fine-
specificity of the induced antibodies. Further, the array system will be used with carbohydrate 
binding lectins, such as common plant lectins or human galectins with significance in tumor 
progression, for instance galectin-3. The carbohydrate binding properties are evaluated when 
connected to an authentic peptide as a carrier. This work is further supposed to lay the 
fundament for studies on host-pathogen interactions. 
The chemically defined, synthetic glycopeptides synthesized in this work, will also be used in 
mass spectrometry HCD fragmentation studies. Access to defined carbohydrate or 
glycopeptide specimens is restricted due to carbohydrate heterogeneity. A biological sample 
of a glycoprotein has many different glycoforms at the same glycosylation site and variances 
in occupancy of the glycosylation sites. In typical bottom-up proteomic approaches, the 
digestion of a set of proteins gives rise to several peptides for mass spectrometric analysis. 
Protein glycosylation is important for the biological functionality of a protein and the diverse 
processes in which it is involved. However, glycopeptides obtained in bottom-up proteomics 
propose a special challenge in mass spectrometric analysis. Differentiation of isobaric 
fragments of glycan-derived ions and elucidation of the linkage connectivity of the 
carbohydrates is difficult by means of mass spectrometry. Often, when analysis of protein 
glycosylation is restricted due to technologic or methodic limitations, carbohydrate structure 
determination is based indirectly on the knowledge of specificities and expression of glycosyl 
transferases, glycosidases or carbohydrate binding lectins. However, the carbohydrate 
specificities of these proteins may not be fully explored and structural influences of the 
underlying glycan or protein in the substrate alter the activity of the recognizing proteins and 
enzymes. Absolute and direct methods of analysis of protein glycosylation are needed. The 
chemically defined, synthetic glycopeptides synthesized in this work, can serve as 
glycopeptide standards in HCD fragmentation studies. Typical carbohydrate fragmentation 
products of O-glycopeptides will be studied. The relative intensities of the extracted ions will 
be compared and examined for regularities which will aid in determination of carbohydrate 
structures from glycoprotein samples. The focus lies on structural glycan determination on 
the level of the glycopeptide which will facilitate typical glycoproteomic workflows. 
  
3 SYNTHETIC STRATEGIES 
3.1 Glycopeptide synthesis strategies 
Obtaining chemically homogenous glycopeptides or glycoproteins from biological sources 
remains still a difficult task, due to the microheterogenic nature of carbohydrate 
biosynthesis.153,154 Chemical or chemoenzymatic synthesis is a reliable method to make 
precise glycoforms available. For the synthesis of glycopeptides, three general approaches 
are commonly utilized (figure 3.1): 
A) Synthesis of protected peptides and carbohydrates for convergent fragment 
condensation 
B) Synthesis of simple glycosyl amino acids for solid phase peptide synthesis (SPPS) 
and chemical or chemoenzymatic elaboration  
C) Synthesis of fully glycosylated amino acids for SPPS  
 
Figure 3.1: Different strategies in glycopeptide synthesis. A: Carbohydrate and peptide fragment condensation. 
B: Glycopeptide elaboration on peptide level. C: Introduction of full extended glycosyl amino acids in SPPS. 
Conveniently protected peptides and carbohydrates can be synthesized in a convergent 
fashion and then condensed to form glycopeptides (figure 3.1, A). Convergent assembly 
often results in low yields since the large structures suffer from sterical hindrance or from 
poor solubility of the peptides under common glycosylation conditions. This approach is 
usually applied for the syntheses of N-glycopeptides. The common procedure is to convert 
the unprotected saccharide by Kochetkov β-amination into a glycosylamine followed by 
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Lansbury aspartylation of these glycosylamines,155,156 for example glycosylation of the N-
glycan heptasaccharide Man5GlcNAc2NH2 with aspartic acid containing peptides.
157 The 
approach of using simple glycosyl amino acids in SPPS and further elaboration on 
glycopeptide level is convenient for the synthesis of N-glycopeptides (figure 3.1, B). 
Endoglycosidases, such as Endo M (Mucor hiemalis) and Endo A (Arthrobacter 
protophormiae) can be used to extend the initial, asparagine-linked GlcNAcβ of the N-glycan 
chitobiose core en bloc with a presynthesized complex oligosaccharide.158 Comparable 
enzymes for O-glycan synthesis are not known. O-glycans need to be assembled by a 
stepwise enzymatic elongation protocol using various different glycosyl transferases. An 
example for the stepwise enzymatic synthesis of a sLex containing PSGL-1 O-glycopeptide 
fragment was reported by C.H. Wong.159 The most commonly applied method for generation 
of glycopeptides, especially of O-glycopeptides, is the use of Fmoc-protected, glycosyl amino 
acid building blocks in Fmoc-SPPS (figure 3.1, C).  
In this research work, complex O-glycosylated amino acids were applied, since stepwise 
chemical and chemoenzymatical manipulations on peptide level are difficult when 
homogenous products, especially multivalent glycopeptides, should be formed. Thus, a 
retrosynthetic strategy for the generation of the various glycan core amino acid building 
blocks regarding glycosylation methods and protecting group chemistry needs to be worked 
out, also with regards to the demands of the following Fmoc-SPPS (see chapter 3.2.3). This 
approach can still be extended by enzymatic termination of the complex glycan moiety by 
e.g. sialylation, fucosylation or sulfation, to increase diversity and generate specific glycan 
motifs.  
 
3.1.1 Glycopeptide synthesis on solid phase  
Although glycosylation is a highly abundant posttranslational modification, isolation and 
characterization is difficult due to the microheterogenic nature of glycoproteins.154,160 Often 
when glycopeptides are applied in biological experiments, the glycans need to be attached 
on specific glycosylation sites on the peptide backbone as a homogenous glycoforms. SPPS 
can provide defined glycopeptides in preparative amounts. When SPPS was introduced in 
1963 by Merrifield, a simple tetrapeptide model was synthesized, to demonstrate the 
applicability of the method.161 In SPPS the peptide sequence is build-up stepwise, amino acid 
by amino acid, on a polymer resin as insoluble support. Unreacted amino acids and coupling 
reagents are washed away after each step by simple filtration of the resin. One year after the 
method was introduced, it demonstrated a huge potential, by the synthesis of the biologically 
active nonapeptide bradykinin.162 Merrifields method relied on N-terminal tert-butyl 
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oxycarbonyl (Boc) protection and aqueous hydrogen fluoride for release of the peptides from 
the resin. After Fmoc was introduced as a base labile N-terminal protecting group,163 a milder 
variant of SPPS based on Fmoc protection was developed.164,165 The Fmoc-SPPS is also 
suitable for the synthesis of glycopeptides, since the conditions applied, neither harm the 
acid sensitive acetal groups of the glycosidic bonds nor the base labile connection of O-
glycans to the peptide backbone.  
Fmoc-SPPS utilizes an orthogonal protecting group strategy. The base labile Fmoc is 
cleaved after each elongation step and the acid labile amino acid side-chain protecting 
groups are cleaved along with the release of the peptide from the resin. The peptide is 
attached by the C-terminal end to the resin and the chain grows towards the N-terminal end 
(opposed to natural protein biosynthesis). The general process consists of 1) attachment of a 
Nα-protected amino acid and 2) removal of the Nα-protection. These steps are repeated in 
cycles until the desired chain length is reached and the peptide is 3) deprotected on the N-
terminal side and 4) released from the resin (figure 3.2). 
 
Figure 3.2: Principle of solid phase peptide synthesis (SPPS). R = amino acid side-chain. PG
1
 = N-terminal 
protecting group. PG
2 
= Side-chain protecting group.  
The peptide chain is synthesized on a polymer resin in the form of beads. The beads usually 
consist of polystyrene (PS), cross-linked with 1% divinylbenzene. TentaGel®-resins (Rapp 
Polymere GmbH, Tübingen) are copolymers of polyethylene glycol (PEG) attached to the PS 
matrix. The PEG chains contribute with hydrophilic properties and render the polymer more 
polar, which increases the ability to swell in polar solvents. Thereby, the reaction centers on 
the resin become more accessible. A linker moiety can be attached to the end of the PEG-
chains. These linkers are stable under the conditions applied in peptide synthesis and serve 
as cleavable handles for the release of the peptide at the end of the synthesis. The linker 
chemistry determines the cleavage conditions and the nature of the C-terminal functional 
group of the peptide. Also, commercial resins can be obtained preloaded with the first C-
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terminal Fmoc-protected amino acid. In this work, Fmoc-amino acid preloaded TentaGel® R 
Trt resins were used (figure 3.3).  
 
Figure 3.3: Representation of Tentagel® trityl resin.   
The peptide ester is cleaved from the trityl-linker under acidic conditions with neat 
trifluoroacetic acid (TFA), usually with addition of cation scavengers such as 
triisopropylsilane (TIPS), thiophenol or water. Albeit lower amounts of acid could be used for 
the trityl ester cleavage (1% TFA), higher amounts of TFA also remove all acid labile 
protecting groups from the side-chains of the amino acids. Among the amino acids used for 
the MUC1 and MUC5B sequences, arginine, histidine, threonine, serine and aspartate 
carried acid labile protecting groups (figure 3.4).  
 
Figure 3.4: Acid labile protecting groups on amino acids used for MUC1 and MUC5B glycopeptide syntheses. 
The coupling of the Fmoc-amino acids is in general mediated by in situ activation of the C-
terminus as an active anhydride/ester intermediate. Typical coupling reagents are 
carbodiimids like N,Nꞌ-dicyclohexylcarbodiimide (DCC),166 N,Nꞌ-diisopropylcarbodiimde (DIC) 
or N-ethyl-Nꞌ-(dimethyaminopropyl)-carbodiimide-hydrochloride (EDC∙HCl), phosphonium 
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salts like benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophoshat (PyBOP)167 or 
aminium/uronium salts like O-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylunronium 
hexafluorophosphate (HBTU),168 O-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylunronium 
tetrafluoroborate (TBTU)169 or O-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethylunronium 
hexafluorophosphate (HATU). Commonly, the hydroxybenzotriazoles HOBt170 or HOAt171 are 
used as additives along with the corresponding aminium/uronium salt, to further increase 
reaction speed and reduce the tendency for racemization (figure 3.5).172  
 
Figure 3.5: Common used carbodiimide and benzotriazole peptide coupling reagents.  
In terms of reactivity and lower tendency for racemization on Cα of the amino acids, the 
phosphonium and aminium salts are more effective than the carbodiimids. DCC forms 
dicyclohexylurea with low solubility. In Boc-SPPS the urea is dissolved in TFA during Boc-
removal, but during Fmoc-SPPS the urea precipitates and cannot be removed by washing. 
Aminium salts derived from the corresponding benzotriazoles 1-hydroxybenzotriazole and 7-
aza-1-hydroxybenzotriazole are very commonly used soluble coupling reagents. When the 
aminium salts were introduced, they were first described as uronium salts. Later, it was 
shown that HBTU and HATU actually crystallize in the aminium (guanidinium N-oxide) form, 
when synthesized by the originally reported procedure.173,174 However, they are still often 
referred to as uronium salts. Both forms can be synthesized selectively but in solution and 
under basic conditions the O-form (uronium) isomerizes into the N-form (aminium). Both 
forms are able to activate carboxylic acids, albeit the O-isomer is reported to be more 
reactive than the thermodynamically more stable N-isomer (figure 3.6).  
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Figure 3.6: Uronium and aminium forms of benzotriazole coupling reagents. 
The HATU/HOAt-system is reported to be more effective in terms of reactivity and lower 
epimerization tendencies, compared to HBTU/HOBt-systems and is preferred in couplings 
with sterically demanding amino acids. The increased reactivity of the 7-aza-1-
hydroxybenzotriazoles could is based on a neighboring effect of the pyridine nitrogen during 
formation of the active ester intermediate (figure 3.7).171 The carboxylic acid component is 
preactivated with HATU and HOAt and N-ethyldiisopropylamine (DIPEA, Hünigs Base). The 
deprotonated acid attacks the electrophilic carbon in the guanidyl group of the guanidinium 
N-oxide to form an O-acylisouronium salt. This further reacts with the HOAt to give an active 
ester intermediate. The pyridine nitrogen of this intermediate presumably helps in 
coordination of the approaching amine by hydrogen bonding. Finally the amine can attack 
the ester carbonyl group and replace the benzotriazole to form a peptide bond (figure 3.7). 
 
Figure 3.7: Reaction mechanism of HATU mediated peptide coupling.  
In this work HBTU/HOBt was used in formations of peptide bonds between unglycosylated 
amino acids. The more reactive HATU/HOAt system was utilized for couplings with the 
glycosylated amino acids. If not otherwise stated, commercial Fmoc amino acids were used 
26 3 SYNTHETIC STRATEGIES
 
 
in excess of 8 equivalents relative to the molar resin binding capacity. The ratio of the 
reagents donor amino acid/HBTU/HOBt/DIPEA was 1 : 0.95 : 0.95 : 2. HBTU and HATU 
were applied in slightly substoichiometric amounts compared to the donor amino acid. The 
aminium salts are known to guanylate free amines and even hydroxyl groups. Capping of the 
N-terminus may occur, if too much of the coupling reagent is applied (figure 3.8). 
 
Figure 3.8: Guanidylation of N-terminal amino groups by excess of used aminium/uronium reagent. 
All peptide syntheses were conducted by applying the Fmoc-based SPPS protocol. The 
Fmoc group is base-labile and can be cleaved off with 20%-50% piperidine, morpholine or a 
mixture of DBU (1,8-diazabicycloundecene) and piperidine.175,176 The piperidine serves also 
as a scavenger for the cleaved dibenzofulvene, which could otherwise block the liberated 
N-terminus. The base-catalyzed deprotection proceeds via an E1cb mechanism. The H9 
proton of the fluorene ring is acidic due to the cyclopentadienyl-type anion as intermediate 
(figure 3.9).  
 
Figure 3.9: Piperidine mediated Fmoc-deprotection and reaction with dibenzofulvene. 
 
3.1.2 Side reactions in solid phase glycopeptide synthesis  
Side-reactions in SPPS can lower yields or even prevent product formation at all. A very 
prominent side-reaction is the diketopiperazine formation. Although also present in Boc-
SPPS, diketopiperazine formation is a prominent problem in basic Fmoc-deprotection.177 On 
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the level of a synthesized dipeptide, the liberated amine may attack the ester bond between 
the linker and the peptide leading to the cyclic piperazinedione (figure 3.10). 
Diketopiperazine formation is favored on sterical less demanding alkoxybenzyl-linkers (e.g. 
Wang resins). Bulky linkers, like the used trityl-linker, can suppress this side-reaction. C-
terminal glycine and proline amino acids are prone to form diketopiperazines. In these cases, 
it may be helpful to elongate with a preformed dipeptide onto the first attached amino acid.  
 
Figure 3.10: Diketopiperazine secession from dipeptide loaded solid phase resin.  
Another prominent side-reaction is the formation of aspartimides. The nitrogen on the α-
carboxylic acid may react with the ester on the side chain of a protected aspartate ester to 
form a cyclic succinimide (figure 3.12). This intermediate can be hydrolyzed later in solution 
to form α-and β-aspartidyl peptides or it may react with piperidine during the Fmoc-
deprotection procedure to yield α- and β-piperidyl peptides. Aspartimide formation may 
happen during chain elongation as well as under the acidic conditions applied during peptide 
release from the resin. It is sequence dependent and related to the amino acid coupled 
before the aspartate in the chain.178 For Fmoc-SPPS it is reported that a preceding Thr(tBu) 
and Thr residues can promote aspartimide formation.179  
 
Figure 3.11: Aspartimide formation and reaction with water during peptide cleavage and with piperidine during 
Fmoc-deprotection.  
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In O-glycopeptide synthesis, a common side-reaction is related to the stability of the 
glycosidic bond connecting the αGalNAc to the threonine amino acid in the synthesized 
peptides. The O-glycosylated amino acids are introduced to the peptides during syntheses 
with O-acetyl ester protecting groups on the carbohydrate hydroxyl-groups. Treatment with a 
base is needed to liberate the glycans after cleavage from the resin. Strongly basic 
conditions may result in abstraction of the Cα-hydrogen by the base and initiate β-elimination 
of the glycan by an E1cB mechanism (figure 3.12).180  
 
Figure 3.12: β-Elimination of glycans at high pH. 
Related to β-elimination, elevated pH during deacetylation may result in epimerization of the 
stereogenic centers on Cα of the amino acids (figure 3.13). However, epimerization and β-
elimination are reported to be surprisingly low during basic acetyl removal, probably due to a 
protection by the deprotonation of the nitrogen in the peptide amide bond.180 
 
Figure 3.13: Base-induced epimerization of glycosylated peptides. 
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3.2 Strategies in carbohydrate synthesis 
3.2.1 Glycosylation methods 
An important issue in chemical glycosylations, is the choice of appropriate anomeric leaving 
groups and suitable promoters or catalysts for glycosylation reactions. Many different 
glycosylation procedures are reported and it is not always obvious which is the most suitable 
for formation of a certain glycosidic bond. The first reported glycosylation reactions either 
used basic activation of the alcohol acceptor181 or acidic activation of the glycosyl donor.182 
W. Koenigs und E. Knorr shortly afterwards reported reactions of C1 halogenated 
carbohydrates with alcohols and silver salts as promoters. The combination of a leaving 
group at C1 with a metal promoter provided irreversible glycosylations, which could be 
applied to various acceptors (figure 3.14). 
 
Figure 3.14: General acid catalyzed glycosylation with and without leaving group. LG = leaving group. E = 
electrophilic promoter/catalyst. 
Glycosyl halides are still very useful donors in glycosylation reactions, however they require 
stoichiometric amounts of a promoter that is consumed during the reaction (hence, not a 
catalyst). For a long time the Koenigs-Knorr glycosylation with glycosyl halides was the only 
reliable glycosylation method. In the last decades, further glycosylation strategies were 
established (figure 3.15). 
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Figure 3.15: Common leaving groups and corresponding promoters/catalysts for chemical glycosylations. 
Among the most commonly used glycosylation methods, besides the glycosyl halides, are 
glycosylations with thioglycosides and trichloroacetimidates. Because of their high stability, 
the thioalkyl/aryl moiety in thioglycosides can be introduced early in the synthesis of the 
buildings blocks and also function as anomeric protecting group. The thioglycosides are 
activated with thiophilic reagents commonly containing or generating iodonium- (e.g. 
iodonium dicollidine perchlorate (IDCP)183, NIS/TfOH184,185) or sulfonium-ions (e.g. 
dimethyldithiosulfonium triflate (DMTST)186). Furthermore, glycosyl thioglycosides are usually 
stable under glycosylation conditions required for other glycosylation methods and can 
therefore orthogonally act as glycosyl acceptors at other positions of the carbohydrate.187 
Glycosyl trichloroacetimidates (reactions are often referred to as “Schmidt-glycosylations”) 
are usually highly reactive and easy to handle.188,189 They can be activated with catalytic 
amounts of a lewis acid without any further promoter (hence a catalyst), e.g. trimethylsilyl-
triflate (TMSOTf), triflic acid (TfOH) or boron triflouride (BF3). 
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3.2.2 Protecting group chemistry  
A prerequisite for the successful synthesis of many different variants of complex glycans 
from basic building blocks, is a unified protecting group chemistry. Protecting groups allow 
temporary blocking of functional groups that would otherwise equally react and lead to 
unwanted results. Especially in carbohydrate synthesis, protecting groups have a significant 
influence on reactivity and stereoselectivity.190 B. Fraser-Reid rationalized the relation of 
electronic effects by protecting groups and the reactivity of glycosyl donors.191,192 Electron-
withdrawing acyl protecting groups decrease the reactivity of the donors by decreasing the 
nucleophilicity of the leaving group in comparison to donors protected with electron-donating 
ether groups. Decreased electron density at the anomeric center further destabilizes the 
intermediate oxonium ion. Hence, protecting groups were divided into “disarming” (esters, 
amides) and “arming” (ethers) groups. However, an ester group in 2-position of the 
carbohydrate ring can stabilize the oxonium ion after leaving group separation together with 
the lone pair electrons of the ring oxygen. Hence, participating groups in 2-position in 
combination with global ether protecting make very reactive glycosyl donors (figure 
3.16).193,194 
 
Figure 3.16: The general reactivity of glycosyl donors according to the armed/disarmed concept. 
Configurational changes on the carbohydrate have further influence on the donor reactivity 
and hence result in stereo-electronic effects. For example, axial configured substituents on 
the carbohydrate ring increase reactivity compared to equatorial oriented substituents and 
fused ring systems may disturb the planar sp2-geometry of the oxonium ion intermediate after 
leaving group separation.195,196  
Protecting groups at the 2-position have major influence on whether the glycosylation will 
give an α-(1,2-cis) or β-(1,2-trans) configured product.190 Esters, amides and carbamates in 
2-position behave as participating neighboring groups and will direct glycosylation reactions 
towards the β-product. Ethers and azides are non-participating neighboring groups and α- as 
well as β-glycosides can be formed (figure 3.17). 
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Figure 3.17: Influence of neighboring groups. A: Ether groups adjacent to the C1 position do not participate in the 
glycosylation. B: β-directing influence of neighboring ester groups. C: β-directing influence of neighboring amide 
groups via an oxazoline intermediate. 
Due to the directing influence of participating neighboring groups, stereoselective formation 
of 1,2-trans-glycosides is rather predictable, although unexpected exceptions may be 
possible. Synthesis of 1,2-cis-glycosides requires the absence of a participating group and it 
is challenging to perform the glycosylation with full stereoselectivity. Although the α-anomer 
is favored due the anomeric effect, diastereoselective mixtures are commonly obtained.197 
The strategies for preparing 1,2-cis-selective reactions are permanently extended since the 
need for comprehensive methods is still high. A widely-used method is the intramolecular 
aglycon delivery (IAD) introduced by O. Hindsgaul for the preparation of β-mannosides 
(figure 3.18, A).198 The glycosyl donor and acceptor are first linked by a protecting group at 
the 2-position of the donor (an isopropenyl ether in the original publication) and upon 
activation of the leaving group an intramolecular SN2-transfer of the acceptor takes place to 
form the 1,2-cis-linkage. Several modifications of IAD using different tethers are reported. A 
recent example by Y. Ito describes the oxidative coupling of donor and acceptor with a 2-
naphtylmethyl ether group as tether.199 The group of G.J. Boons presented an approach that 
makes use of a chiral auxiliary as protecting group in 2-position (figure 3.18, B).200,201 A (S)-
phenylthiomethylbenzyl ether participates by forming a six-membered ring, fused to the 
carbohydrate ring. Due to the equatorial orientation of the two phenyl groups, a trans-decalin-
like intermediate favors an attack from the cis-face of the acceptor. A strategy for trans-
selective glycosylations without an acyl group in 2-position was introduced by A.V. 
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Demchenko (figure 3.18, C). A 2-O-picolinyl ether group at the 2-position occupies the cis-
site and forms stereoselectively 1,2-trans-glycosides. Recently, the same group described 
participation of picolinyl- and picoloyl substituents, also when located on one of the other 
positions of the carbohydrate ring. In this case, the participating group does not block the 
anomeric center from one site, but the pyridine ring presumably participates by hydrogen 
bonding with the hydrogen of the nucleophilic alcohol, facilitating deprotonation and putting 
the reaction partners in close proximity. The acceptor is syn-oriented with regards to the 
picolinyl/picoloyl-group. Depending on which position of the carbohydrate ring is substituted 
by the participating ether, either cis- or trans-products can be formed stereoselectively. This 
method for remote stereoselective control was termed H-bond mediated aglycone delivery 
(HAD).202,203 Several more strategies for stereoselective glycosylations are reported and the 
field is permanently extended.204 
 
Figure 3.18: Selected examples for stereoselective glycosylation methods. 
 
  
4 RESULTS AND DISCUSSION 
4.1 Part 1 – Synthesis of core 1, 2 and 3 glycosylated amino acids 
4.1.1 Retrosynthetic considerations for glycosyl amino acid building block 
synthesis 
Based on the inherent structural canon of mucin O-glycan biosynthesis (chapter 1.1), a 
retrosynthesis route for the complex core 1, 2 and 3 amino acid building blocks was 
envisioned. Biosynthetic backbone elongation happens by the combined alternating action of 
a β1,3-GlcNAc-transferase, followed by either a β1,3-Gal-transferase or a β1,4-Gal-
transferase. The alternating transfer of either a 1,3- or 1,4-linked βGal and a βGlcNAc results 
in elongation by type-1 (Galβ1,3-GlcNAcβ) or type-2 (Galβ1,4-GlcNAcβ) N-acetyllactosamine 
disaccharides.17,205,206 Thus, a synthetic route was imagined that includes chemically 
preformed type-1 and type-2 disaccharide units, with proper protecting groups for further 
glycosylation reactions and if possible already for later Fmoc-SPPS. The type-1 disaccharide 
27 and type-2 disaccharide 31 for later elongation of the core structures should be formed in 
trichloroacetamide couplings of donor 18 and acceptors 24 (glycosylation I) and acceptor 30 
(glycosylation II) (figure 4.1).  
 
Figure 4.1: Retrosynthesis of the type-1 and type-2 LacNAc disaccharide building blocks. 
The disaccharides were chosen to be thioglycosyl donors, since the thiophenyl group in 
acceptors 24 and 30 is orthogonal to several glycosylation conditions and can be installed 
prior to trichloroacetamide couplings.187 
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In mucin glycoproteins, the O-glycans are linked to threonine and serine amino acid by an 
initial αGalNAc. In this synthetic approach the glycans are build-up on an appropriately 
protected threonine amino acid. Thus, the threonine amino group is protected by a Fmoc-
group, according to the Fmoc-SPPS-protocol, while the carboxyl group is permanently 
blocked by a tert-butyl-ester during glycan assembly and cleaved off just before SPPS. The 
attachment of the first αGalNAc to the protected threonine amino acid to form the TN-antigen 
12 is to be carried out using a galactosyl bromide with a classical AgClO4/Ag2CO3 promoter 
system, according to reported procedures.207,208 Glycosylation of donors 27 and 31 with 
acceptor 12 will be carried out to give extended core 3 structures 35 and 39 (figure 4.2, III). 
Similarly, the extended core 1 tetrasaccharides amino acids 49 and 54 should be 
synthesized with the preceding glycosylation of the monosaccharide thiophenyl glycoside 
donor 42 (figure 4.2, IV+V). Finally the extended core 2 hexasaccharide amino acids 58 and 
62 are branched from the synthesis routes of the extended core 1 structures by a further 
thioglycoside coupling with donors 27 and 31 in 6-position of the primary αGalNAc (figure 
4.2, IV+V+VI). 
 
Figure 4.2: Retrosynthesis of core 3 (glycosylation III), core 1 (glycosylations IV+V) and core 2 (glycosylations 
IV+V+VI) glycosylated threonine amino acids. 
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The final glycosyl amino acids for SPPS will be globally protected with O-acetyl-esters on the 
carbohydrate hydroxyl groups. Acetyl groups are known to stabilize glycosidic bonds due to 
electron withdrawing effects, especially during acidic trifluoroacetic acid treatment required 
for release of the synthesized glycopeptides from the resins.209,210 After glycopeptide 
synthesis the acetyl groups can be cleaved by mild treatment with sodium methoxide in 
methanol (Zemplén conditions) or sodium hydroxide in methanol.211 The temporary 
protecting group strategy relies on the use of silyl-ethers, acetyls and acetals for the 
carbohydrate hydroxyl-groups, while 2-O-deoxy-acetamide groups are protected by 
trichloroethoxycarbonyl groups (Troc) or are masked as azides.212 The initial 2-amino-groups 
of the D-sugars are not directly converted to acetamide groups. During further glycosylations, 
the neighboring acetamide group would participate and stabilize the intermediate 
oxocarbenium ion by rapidly rearranging to an 1,2-oxazoline (figure 3.17, B). The 1,2-
oxazoline intermediates are known to be rather stable and are poor glycosyl donors. In 
carbamates, in contrast to amides, the likeliness to form rather stable oxazolines is reduced 
because of the additional electron donating alkoxy group.213 Therefore, the glycosyl donor 
reactivity, especially in the case of Troc-protection, is known to be increased during 
glycosylations.214 Azides are employed during glycosylations either when a non-participating 
neighboring group is required for α-anomeric stereoselectivity, or when due to steric 
hindrance a small and linear group is beneficial. To keep the number of different protecting 
groups low, regioselective glycosylation preferences are used within the reactions. According 
to the slogan “The best protecting group is no protecting group”,212 this represents an elegant 
way to minimize yield repressing and time consuming steps. For example, the superior 
reactivity of the equatorial 3-OH of galactose can often be used in glycosylations, without any 
protection on positions 2 and 4.215,216,217 In contrast, equatorial 4-OH in GlcNAc is 
preferentially glycosylated over the equatorial 3-OH.218,219 Further the advanced reactivity of 
primary alcohols over secondary alcohols can be used to glycosylate the carbohydrate in 6-
position, without effecting the unprotected 4-position.220 
The synthesis is highly convergent, meaning that from a few common buildings blocks in 
stock, a high diversity of various glycosyl amino acids can be obtained. The retrosynthetic 
strategy is finally based on four basic building blocks, namely the type-1 and -2 LacNAc 
disaccharides 27 and 31 as glycosyl donors and the TN- and T-antigen as acceptors 12 and 
44 (figure 4.3, A). Apart from the here presented core 1, 2 and 3 glycans, different synthesis 
variations thereof are further possible. Based on the developed synthesis route, core 2 
tetrasaccharide and core 4 pentasaccharide were also synthesized outside the frame of this 
thesis during the course of this project (figure 4.3, B).  
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Figure 4.3: A: Basic building blocks used for convergent core structure synthesis presented in this work. B: 
Core 2 and core 4 structures for further syntheses. 
 
4.1.2 Examples for syntheses of glycosylated amino acids/glycopeptides in 
the field and comparison to the strategy of this work 
Selected examples for core 1 structures came from early reports of H. Paulsen and J.-P. 
Hölck221 and sialylated core 1 building blocks from H. Kunz,222,223 applied in Fmoc-SPPS. In 
an approach to simplify the synthesis of core structures K.J. Bock and H. Paulsen reported a 
synthesis for the basic core 1-4 structures without further elongation or termination, ready for 
Fmoc-SPPS.224 Elongated core 3 type-2 and core 1 type-2 amino acids are reported by S.J. 
Danishefsky as part of Ley-antigens through glycal assembly and were incorporated into 
peptides.225 There are some examples for core syntheses using a type-2 disaccharide for 
core extension by Y. Nakahara (core 1 and core 3 type-2),226,227 C.R. Bertozzi (core 1 type-
2)216 and H. Kunz (core 2 type-2).228 The protecting group and building block strategy of 
these examples were directed towards certain structures, specifically terminated (e.g. 
fucosylated) and therefore less universal for the design of various core structures, in contrast 
to the strategy presented in this thesis. The possibilities for glycan termination by means of 
chemical building blocks were not in the focus, but rather the convergent build-up of several 
scaffold core structures with the possibility of increasing the glycan diversity in a later step on 
glycopeptide level by a chemoenzymatic approach. Hence the protecting group chemistry 
should be kept as simple as possible for a high variability in core synthesis using only few 
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building blocks. Examples for chemoenzymatic modifications of mucins carrying a chemical 
presynthesized basic core 2 trisacharide are reported by S.-I. Nishimura.229,230 The variable 
building block system presented in this research work, also includes type-1 elongation of 
core glycans, which has so far not been reported. 
 
4.1.3 Synthesis of the TN-antigen glycosyl acceptor  
According to the mentioned convergent synthesis strategy (chapter 4.1.1), the synthesis of 
all mucin-type O-glycan core structures is based upon the generation of a central N-
acetylgalactosamine glycosylated threonine amino acid (TN-antigen), the fundamental motif 
for mucin-type glycosylation. The first GalNAc amino acid synthesis, employing the serine 
equivalent, has been described by T.Osawa et al.231 B. Ferrari and A. A. Paviat later reported 
the synthesis of the threonine conjugate.232 The methodology applied in this work is based on 
reported methodology developed by H. Paulsen and J.-P. Hölck using silver 
perchlorate/carbonate mixtures as glycosylation promoters.221 The 3,4,6-tri-O-acetyl-2-azido-
2-deoxy-galactosyl bromide donor 8 used in a Keonigs-Knorr glycosylation,233 was generated 
from D-galactose in four steps. Initially, the D-galactose was peracetylated with acetic 
anhydride and catalytic amounts of perchloric acid. Subsequential addition of phosphorus 
tribromide and water results in the α-anomeric galactosylbromide 5. The product was then 
reduced with zinc dust activated by copper(II) sulfate to give the 3,4,6-tri-O-acetyl-galactal 
6.234,235 The galactal was further treated with cerium(IV) ammonium nitrate and sodium azide 
in dry acetonitrile. A radical mechanism for the azidonitration was proposed by R.U. 
Lemieux.236 The product 3,4,6-tri-O-acetyl-2-azido-2-deoxy-galactosyl nitrate 7 was obtained 
as an anomeric mixture of α/β (1:1). Next, compound 7 was treated with lithium bromide in 
dry acetonitrile to give the desired α-anomer of the halide donor 3,4,6-tri-O-acetyl-2-azido-2-
deoxy-galactosyl bromide 8.236 Donor 8 was synthesized in 4 steps in an overall yield of 32 % 
(figure 4.4). 
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Figure 4.4: Synthesis of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-galactosyl bromide 8. 
For the synthesis of the amino acid glycosyl acceptor, L-threonine was protected with an N-
(9-fluorenyl)-methoxycarbonyl-group (Fmoc) as a base labile protecting group during SPPS. 
Initially, L-threonine was reacted with N-(9-fluorenyl)-methoxycarbonyl-succinimidylcarbonate 
(Fmoc-OSu) under alkaline conditions.237 The Fmoc amino acid 2 was then esterified with 
tert-butanol in a copper(I) catalyzed reaction with N,N’-dicylcohexylcarbodiimid (DCC) as 
coupling reagent to give glycosyl acceptor 3 (figure 4.5).238,239,240 
 
Figure 4.5: Synthesis of threonine galactosyl acceptor 3. 
For the esterification, tert-butanol was initially activated with DCC catalyzed by copper(I). The 
O-tert-butyl-N,N’-isourea I was then treated with the amino acid to result in the ester product 
III and N,N’-dicyclohexyl urea II (figure 4.6).238,239 
 
Figure 4.6: Mechanism of DCC and copper(I) mediated esterification. 
Finally, galactosylbromide 8 and amino acid acceptor 3 were glycosylated to form the acetyl 
protected TN-antigen 9. The Koenigs-Knorr reaction was performed with water-free silver 
perchlorate and silver carbonate as glycosylation promoters in an unpolar solvent mixture of 
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dry toluene/dichloromethane (1:1).221,207,241 The azide group in 2-position of the galactosyl 
donor acts as a non-participating protecting group, promoting the α-anomer as the favored 
glycosylation product in a yield of 60% (figure 4.7). 
 
Figure 4.7: Synthesis of Fmoc-Thr(αAc3GalN3)-OtBu 9. 
Compound 9 was reduced to the acetamide using thioacetic acid (figure 4.8, A).242 The 
reaction is base-promoted by pyridine and the azide is reduced to the acetamide via a 
thiatriazoline intermediate I with final loss of nitrogen and elemental sulfur (figure 4.8, B).243  
 
Figure 4.8: A: Synthesis of 10 by reduction of 9. B: Mechanism of the base promoted amidation. 
The acetyl groups of compound 10 were removed by transesterification under Zemplén 
conditions with sodium methoxide in methanol.211 These conditions are regarded as a mild 
deacetylation procedure and the pH is usually not raised above 8.5 in order to preserve the 
base labile Fmoc-group.208 However, deacetylation was slow with reaction times of several 
hours to a few days and usually showed partial loss of Fmoc. It was found more convenient 
to transesterify at pH 10-10.5 in shorter times with direct subsequent re-protection of the α-
amino group using Fmoc-OSu.237 The amount of cleaved Fmoc was followed by thin layer 
chromatography (TLC) and an estimated amount of 0.5 eq of Fmoc-OSu was enough for 
complete re-protection. Further, β-elimination or epimerization by base-catalyzed removal of 
the Hα of threonine was not observed under these conditions.180 Next, the 4-OH and 6-OH 
positions were protected with para-methoxybenzaldehyde dimethyl acetal in acetonitrile at 
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50°C and catalytic amounts of para-toluenesulfonic acid (p-TsOH) to give the corresponding 
acetal protected glycosyl acceptor 12. The three modifications on the TN-antigen from 
compound 9 gave 12 in 73% overall yield (figure 4.9). 
 
Figure 4.9: Synthesis of TN-antigen glycosyl acceptor 12. 
 
4.1.4 Synthesis of the T-antigen amino acid  
The T- or TF-antigen (Galβ1,3GalNAcαThr, Thomsen-Friedenreich antigen) was prepared 
from the suitable TN-antigen 12 and the galactosyl bromide 5, employing coupling conditions 
according to a Koenigs-Knorr variant developed by Helferich employing mercury(II) cyanide 
in dry nitromethane/dichloromethane (2:1).244,245,220 As expected, only β-anomer of T-antigen 
13 was obtained in 70% yield. The para-methoxybenzylidene group was hydrolyzed under 
acidic conditions and the liberated hydroxyl groups were acetylated with acetic anhydride to 
give compound 14. Finally the tert-butyl ester was cleaved with trifluoroacetic acid and 
anisole as cation-scavenger, resulting in the peracetylated and Fmoc-protected T-antigen 
building block 15 ready for use in SPPS (figure 4.10).220 
 
Figure 4.10: Synthesis of T-antigen amino acid building block 15 for use in SPPS. 
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4.1.5 Synthesis of the type-1 N-acetyllactosamine glycosyl donor 
The syntheses of the type-1 and type-2 disaccharide building blocks share the common 
trichloroacetimide galactosyl donor 18. D-Galactose was peracetylated under the same 
conditions as mentioned for galactosyl bromide 8 generating peracetylated galactose 16. The 
acetyl group on the anomeric position, forming an acetal, has an improved electrophilicity 
compared to the other acetyl groups and was selectively cleaved with hydrazine acetate in 
DMF. The resulting anomeric mixture of 2,3,4,6-tetra-O-acetyl-galactose 17 was then treated 
with trichloroacetonitrile and catalytic amounts of DBU (1,8-diazabicylo[5.4.0]undec-7-ene) to 
give the trichloroacetimidate donor 18.246 Donor 18 was synthesized in three steps in 66% 
yield (figure 4.11). 
 
Figure 4.11: Synthesis of galactosyl trichloroacetimidate donor 18. 
Galactosyl trichloroacetimidate 18 was obtained exclusively in α-configuration from the 
anomeric 2,3,4,6-tetra-O-acetyl-α/β-galactose 17. In this base-catalyzed glycosylation, the 
intermediate anomeric oxyanion can either give α-anomer under thermodynamic control, 
stabilized by the anomeric effect, or β-anomeric product under kinetic control, due to the 
higher nucleophilicity of the β-oxyanion intermediate. Depending on the strength of the base 
that is used to deprotonate the anomeric OH-group, the kinetically formed β-anomeric 
product can react back, anomerize and finally form the α-anomer under thermodynamic 
reaction control. Bases like DBU or sodium hydride are strong enough to elicit retro-reaction, 
while potassium carbonate is commonly used to generate the β-anomer, since it is not able 
to deprotonate the β-imidate and initiate the back-reaction (figure 4.12).247   
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Figure 4.12: Formation of α-imidates under kinetic control and formation β-imidates under thermodynamic 
control. 
As acceptor for the synthesis of the type-1 disaccharide, the phenyl 2-azido-2-deoxy-4,6-
benzylidene-1-thio-β-D-glucopyranoside 24 was synthesized. The 2-acetamido-group at the 
GlcNAc unit of the later disaccharide was initially masked as an azide during disaccharide 
formation. The azide group was introduced with the diazotransfer reagent imidazole-1-
sulfonyl-azide hydrochloride 19. Therefore, sodium azide was suspended in acetonitrile and 
sequentially treated with sulfurylchloride under ice-cooling followed by addition of imidazole. 
The imidazole-1-sulfonyl-azide was finally precipitated as the hydrochloride salt 19 with 
acetyl chloride in methanol (figure 4.10).248 The hydrochloride 19 is regarded as less 
explosive and more shelf stable than other common diazotransfer reagents, e.g. 
trifluoromethanesulfonyl azide (TfN3).
248 Anyhow, also compound 19 is impact sensitive and 
thermally labile, like other low-molecular weight azides, attached to electron withdrawing 
substituents. Concentration of mother liquids after filtration of the precipitated hydrochloride 
salt must be omitted, the hygroscopic salt must be stored dry to avoid water uptake 
(formation of hydrazoic acid) and the compound should always be added or used in solution 
for better heat dissipation.249,250 The diazotransfer reagent 19 transferred a diazo group to the 
amine in 2-position of D-glucosamine in a copper(II) catalyzed reaction. Subsequentially, a 
peracetylation with acetic anhydride in pyridine was performed to give an anomeric mixture 
of 1,3,4,6-tetra-O-2-azido-2-deoxy-glucosylpyranoside 21 (figure 4.13).248 
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Figure 4.13: Synthesis of 1,3,4,6-tetra-O-2-azido-2-deoxy-glucosylpyranoside 21 by diazotransfer with imidazole-
1-sulfonyl-azide hydrochloride 19. 
Next, the thiophenyl group was installed on the anomeric position. Because of the non-
participating azide on the 2-position, compound 21 was not transferred into the thiophenyl 
glucopyranoside directly, since the obtained thiophenyl donor would consist of a mixture of 
reactive β-anomer and less reactive, thermodynamically more stable α-anomer. Therefore, 
the anomeric acetyl group was first activated by the lewis acid titanium(IV) chloride with 
cleavage of the acetate and substitution by a chlorine atom, to result in the α-anomer of 
3,4,6-tri-O-acetyl-2-azido-2-deoxy-glucopyranosyl chloride 22.251,252,236 Then, the chloride 
was substituted by a thiophenyl group in a Walden inversion to give the phenyl 2-azido-2-
deoxy-1-thio-glucopyranoside 23.253 The 4- and 6-position were protected with an acid-labile 
benzylidene acetal to result in acceptor 24.254 The glycosyl acceptor 24 was synthesized in 4 
steps with an overall yield of 25% (figure 4.14).  
 
Figure 4.14: Synthesis of glycosyl acceptor 24. 
The following glycosylation of acceptor 24 and trichloroacetimidate donor 18, was performed 
according to a modified procedure originally described by Toepfer and Schmidt.255 The 
glycosyl donor was activated by catalytic amounts of trimethylsilyl trifluoromethanesulfate 
 4 RESULTS AND DISCUSSION 45 
 
 
(TMSOTf) in diethyl ether at room temperature. The protected type-1 disaccharide 25 was 
obtained in good yields between 85-92% (figure 4.15). 
 
Figure 4.15: Synthesis of type-1 disaccharide 25 by glycosylation of acceptor 24 with donor 18. 
Type-1 disaccharide 25, which already contains a trans-configurated thiophenyl leaving 
group at the reducing end, will act as a donor in later glycosylation steps. To achieve desired 
β-stereoselectivity, the azide was transformed into a participating N-Troc protecting group. 
Implementation of the Troc directly on the monosaccharide stage, instead of masking the 
amine as an azide, would have been more convenient. Direct use of a N-Troc-containing 
acceptor with donor 18 under common conditions used for trichloroacetimidate couplings 
(e.g. DCM, T ≤ -40°C, molecular sieve) resulted in breakdown of the reactants (table 4.1, 
entry a). Exchange of N-Troc to a N-phthalimido group, aided glycosylation, but formed 
exclusively orthoester product (table 4.1, entry b). Common methods to repress orthoester 
formation, like the use of bulky and electron-withdrawing difluorobenzoyl esters in 2-position 
of the donor (table 4.1, entry c) or more acidic conditions created by acid washed molecular 
sieves (AW MS) (table 4.1, entry d), helped to reduce orthoester formation in favor for 
disaccharide product.256,257 Reduction of the amount of molecular sieve eliminated orthoester 
formation in a test reaction (table 4.1, entry e), indicating beneficial effects from low or 
completely absent molecular sieve. However, keeping lower amount of AW MS again with a 
2-O-acetyl group on the donor instead of the difluorobenzoyl ester, increased orthoester 
generation (table 4.1, entry f). If the 2-O-acetyl group remained on the donor and the 
phthalimido group was exchanged with an azide group on position-2 of the acceptor, 
complete disaccharide production was observed (although in low yield, table 4.1, entry g). 
The scale of the reaction also influenced the amount of orthoester formation. Small scale 
reactions (≤ 50 mg acceptor) gave the desired glycoside as a major product, while larger 
reactions (≥ 100 mg acceptor) and especially gram scale reactions resulted in higher 
amounts of orthoester (compare entry g/h). Great influence was observed by the solvent. 
Replacing DCM by diethyl ether, without MS, finally provided pure disaccharide glycosylation 
product, also in large scale glycosylations (table 4.1, entry i). A reaction was performed in 
order to control if complete disaccharide formation could be achieved in a diethyl ether 
system, without any MS by keeping the N-Troc on the acceptor, as initially planned (table 
4.1, entry j), but similar to reaction conditions in entry a, no product formation was observed. 
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Table 4.1: Comparison of various reaction conditions and protecting group patterns for the synthesis of a type-1 
disaccharide. 
 
The methodology reported by Toepfer and Schmidt, using an azide acceptor and diethyl 
ether as solvent was successful, also in gram scale reactions.255 It is interesting, that 
especially a reaction in diethyl ether represses orthoester formation, since orthoester 
formation usually benefits from diethyl ether as a solvent.258 Sometimes orthoesters can 
rearrange into the corresponding glycosidic bond by treatment with higher amounts of lewis 
acids like TMSOTf.259 Here, these attempts lead to breakdown of the starting materials. The 
synthesis of type-1 LacNAc disaccharide, was dependent on subtle interactions of various 
reaction parameters, like protecting groups, solvents, batch scale or molecular sieve can 
influence the product formation in chemical glycosylations.  
After the 1,3-glycosylation was carried out, the azide-group was first reduced and 
subsequently protected with a N-Troc group. Disaccharide 25 was treated with activated zinc 
powder (previously suspensed in 1 M HCl and washed with water, methanol and diethyl 
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ether) in a mixture of 1,4-dioxane/acetic acid (10:1). Under these conditions the acidity was 
high enough to promote reduction of the azide with the zinc, while the acid labile benzylidene 
acetal remained stable. Then TrocCl was used to protect the free amine to give disaccharide 
26 in 72% yield (figure 4.16).  
 
Figure 4.16: Synthesis of compound 26. Change from azide to N-Troc protection. 
Considerations regarding the reactivity of the thiophenyl disaccharide 26 as glycosyl donor 
were made. The 4,6-O-benzylidene acetal group is well known to lower the reactivity of 
glycosyl donors. This effect was explained by a conformational lock of the pyranose in the 
4C1 chair configuration because of the rigidity introduced by the fused 1,3-dioxane ring. As a 
consequence, the formation of an intermediate oxocarbenium ion with planar sp2-geometry at 
C1, after separation of the leaving group, is hampered during glycosylation, due to non-
optimal orbital overlap of the π-orbital forming the double bond.196 Additionally to this 
torsional effect, reactivity is also reduced by an electronic effect.260 The C6-O6 bond (and the 
negative dipole it represents) can adopt three staggered conformations, the gg, gt and tg 
conformation. In gg and gt, the dipole is oriented more perpendicular to the positive 
oxocarbenium transition state, for better dipole-charge stabilization, while in tg the negative 
dipole is directed away from the positive center (figure 4.17). 
 
Figure 4.17: Torsional
196
 and electronic 
260
 disarming properties of 4,6-O-benzylidene acetal protecting groups.  
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Additionally to reactivity issues, retrosynthetic planning involved disaccharide extension of 
the T-antigen acceptor amino acid, forming a common core 1 tetrasaccharide amino acid, 
which contains an acid labile para-methoxy benzylidene acetal at the 6-position of the 
αGalNAc. For further extension of the core 1 tetrasaccharide, in order to form core 2 
structures, a step involving selective GalNAc benzylidene acetal removal was required 
before the core 2 structure branching could be established (retrosynthesis, figure 4.2). 
Therefore, the 4,6-O-benzylidene acetal at disaccharide 26 was exchanged to a 4-O-acetyl 
and 6-O-tert-butyldimethylsilyl protecting (TBS) group.261 The TBS-group has the advantage 
that it can be selectively cleaved by a fluoride source in the presence of other acid labile 
protecting groups, such as the benzylidene acetal on the αGalNAc of the glycosylated amino 
acids. The benzylidene acetal of compound 26 was cleaved in 80% acetic acid, followed by 
regioselective protection at 6-position with TBSCl and acetylation with acetic anhydride to 
give the final type-1 disaccharide donor 27 (figure 4.18). 
 
Figure 4.18: Change from a 4,6-O-benzylidene acetal to tert-butyldimethylsilyl ether and acetyl protecting groups 
for the synthesis of the type-1 thiophenyl donor 27. 
 
4.1.6 Synthesis of the type-2 N-acetyllactosamine glycosyl donor 
The type-2 disaccharide building block was formed from the described galactosylpyranosyl 
trichloroacetimidate donor 18 and glucosaminylpyranosyl thiophenol acceptor 30. Similar to 
the type-1 building block synthesis, the acceptor 30 contained a C1-thiophenyl leaving group 
for later elongation towards the desired extended core amino acids. To obtain acceptor 30, 
glucosamine hydrochloride was directly protected with a Troc group at position 2 and all 
further hydroxyl groups were acetylated to give compound 28 as an anomeric mixture (α/β = 
8.3 : 1). Next, the anomeric acetyl leaving group of compound 28 was activated with boron 
trifluoride and substituted with a thiophenyl group. Since compound 28 had the anomeric 
acetyl group predominantly in the thermodynamically stable α-anomeric configuration, the 
reaction was stirred for 3 d with excess of three equivalents of thiophenol for full conversion 
into the thioglycoside 29.262 In order to liberate the acetylated 4-position for glycosylation with 
donor 18, compound 29 was completely deacetylated with methanolic HCl solution, prepared 
from acetyl chloride in methanol. Standard basic alcoholysis for the removal of the acetyl 
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groups, converts the N-Troc group into the corresponding alkylcarbamate, which cannot be 
cleaved under reductive conditions commonly applied for N-Troc deprotection.214 As an 
alternative, a guanidine nitrate/sodium methoxide system was reported to deacetylate under 
basic conditions, without harming the N-Troc group.263 Subsequently the primary alcohol at 
the 6-position was protected with a TBS ether group to give glycosyl acceptor 30 in 3 steps 
and 60% yield (figure 4.19).  
 
Figure 4.19: Synthesis of type-2 glycosyl acceptor 30. 
Glycosyl acceptor 30 was regioselectively glycosylated in the more reactive214,219 4-position 
with trichloroacetimidate 18 and catalytic amounts of TMSOTf and subsequently acetylated 
in 3-position in 80% overall yield (figure 4.20). Problems with orthoester formation were not 
observed. 
 
Figure 4.20: Synthesis of type-2 thiophenyl donor 31. 
 
4.1.7 Synthesis of the galactose extended core 3 amino acids 
As outlined in the retrosynthetic analysis (figure 4.2), the synthesis of the core 3 amino acids 
was conducted by the glycosylation of the TN-antigen acceptor amino acid 12 with either the 
type-1 or type-2 disaccharide donor. For the synthesis of the type-1 core 3 building block, 
thioglycoside donor 31 was activated by the promoter-catalyst system N-iodosuccinimide 
(NIS) and trifluoromethanesulfonic acid (TfOH) (figure 4.21).184  
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Figure 4.21: Preparation of type-1 core 3 glycosylated amino acid 36.  
Although the N-Troc group is a participating neighboring group, directing glycosylations 
towards the β-anomer, a mixture of α/β-anomers (α/β = 1:1.2) of compound 36 was obtained 
in 71% yield. The thiophilic iodonium ion liberated from NIS at acidic conditions, was 
attacked by the phenyl sulfide to leave as phenylsulfenyl iodide. Since most of the product 
formed was the desired β-anomer, it can be assumed that the reaction proceeded by a SN1-
mechanism. The neighboring N-Troc group participated in the reaction, since more α-product 
instead of β-product would be expected due to the α-directing anomeric effect. However, N-
Troc participation was likely somehow hampered, since some donor was also attacking from 
the cis side, instead from the trans side of the oxazolinium intermediate (figure 4.22).  
 
 
Figure 4.22: Formation of an anomeric mixture of compound 36. 
Separation of the two diastereomeric forms of compound 36 was not possible by means of 
standard silica gel chromatography. The diastereomeric mixture was proceeded to the next 
step and treated with 80% acetic acid to remove the acid labile para-methoxybenzylidene 
acetal and the tert-butyldimethylsilyl ether to give compound 37 in 50% yield of the desired β-
anomer and 29% of the α-anomer. The anomeric products had sufficient distinct retention 
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times to be separated by silica gel chromatography. Next, the N-Troc group was cleaved 
under reductive conditions with zinc in acetic acid and the released amine was acetylated 
along with the remaining free hydroxyl groups to give compound 38 in 85% yield.264 In the 
final step, the tert-butyl group was removed in a mixture of TFA/DCM and anisole as a 
cation-scavenger. The type-1 core 3 building block was synthesized over 4 steps and in 26% 
yield starting from the TN-antigen acceptor 12 (figure 4.23).  
 
Figure 4.23: Synthesis of type-1 core 3 amino acid building block 39 for SPPS.  
The synthesis of the type-2 core 3 amino acid followed the same strategy as the 
corresponding type-1 extended amino acid. TN-antigen glycosyl acceptor 12 was 
glycosylated with the type-2 LacNAc thioglycoside donor 31 with NIS/TfOH as promoter 
system. The glycosylation product 32 was generated with full β-stereoselectivity as expected 
and in contrast to type-1 core 3 glycosylation product 37. However, a significant amount of 
the obtained product was an adduct consisting of the glycosylation product and the leaving 
phenyl sulfide group, as indicated by a mass increase of 108 u. NMR-spectroscopy showed 
proton-signal doubling and two-dimensional NMR-experiments showed two independent 
spin-systems. This separation indicated on one compounds with axial chirality due to 
restricted rotation around a single bond. Therefore it was assumed that the phenyl sulfide 
was added to the carbamate nitrogen of the N-Troc group. Different promoter systems did 
not improve reaction outcome. Dimethyl(methylthio)sulfonium trifluoromethanesulfate 
(DMTST)186 did not activate the reaction at all, while N-bromosuccinimide (NBS)/TfOH185 or 
52 4 RESULTS AND DISCUSSION
 
 
diphenyl sulfoxide (DPS)/Tf2O
265 showed the same results as the NIS/TfOH system. Thus, 
NIS was used and the phenyl sulfide adduct was obtained as the main product in 70% yield 
(figure 4.24, A).  
 
Figure 4.24: A: Glycosylation of donor 31 and acceptor 12 for preparation of type-1 core 3 glycosylated amino 
acid 32. B: Proposed formation of phenyl sulfide adduct 32. 
The glycosylation worked with full β-stereoselectivity, implying full neighboring group 
participation of the N-Troc group. The oxazoline intermediate may be attacked by the donor 
at C1 and probably along with oxazoline ring opening, the phenyl sulfide group added by 
substitution on sulfur (figure 4.23, B). According to Pauling electronegativity, sulfur is slightly 
positive polarized by the more electronegative iodine. Also, an orbital stabilization from the 
aromatic π-system to the transition state of a SN2-reaction in benzylic position may promote 
the substitution. Since the formation of the type-1 core 3 analogue 36 showed unexpected 
stereoselectivity and later glycosylations with the type-1 and type-2 donors on extended core 
1 and 2 glycans were not forming the phenyl sulfide byproducts, it was assumed that the 
sterical environment at the TN-antigen acceptor had a strong influence on the reaction 
outcome. T. Reipen and H. Kunz have reported unexpected orthoester formation on an 
equally protected serine analogue of the TN-antigen, when peracetylated 
galactosylpyranosides with halide or trichloroactimidate were evaluated as donors.223  
Compound 32 followed protecting group transformations according to the corresponding 
type-1 core 3 analog 36. The acid labile para-methoxybenzylidene acetal and the tert-
butyldimethylsilyl ether groups were hydrolyzed in 80% acetic acid to give compound 33. The 
N-Troc group was removed under reductive conditions with zinc in acetic acid with 
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simultaneous removal of the phenyl sulfide group. The remaining amine and the hydroxyl 
groups were further acetylated in pyridine and acetic anhydride (2:1). The tert-butyl group 
was removed in TFA/DCM with anisole as cation-scavenger. The type-2 core 3 amino acid 
building block was obtained in 4 steps and 41% yield overall, starting from the TN-antigen 
glycosyl acceptor 12 (figure 4.25).  
 
Figure 4.25: Synthesis of type-1 core 3 amino acid building block 35 for SPPS. 
 
4.1.8 Synthesis of the extended core 1 tetrasaccharide amino acids 
For the synthesis of the linear core 1 tetrasaccharides and branched core 2 hexasaccharides 
a common core 1 acceptor (a T-antigen acceptor) building block was constructed 
(retrosynthesis, figure 4.2, glycosylation IV). In contrast to the previously synthesized 
T-antigen building block 13 (figure 4.10), a different monosaccharide galactosyl donor was 
applied. The galactose donor was protected temporarily in 6-position with a protecting group, 
stable under the basic conditions which are used for deacetylation. Like this, the reactive 
primary alcohol was blocked, which later allowed regioselective modifications on the 
remaining secondary alcohol groups. A TBS-group was selected, which later was cleaved 
together with the TBS-group of the elongating LacNAc disaccharide units by using a fluoride 
source, orthogonal to the para-methoxy benzylidene acetal of the initial αGalNAc unit. 
Peracetylated galactose 16 was first transformed into the β-thiophenyl-galacosylpyranoside 
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40 using boron trifluoride as a lewis acid promoter and thiophenol as glycosyl acceptor. Due 
to the α-anomeric configuration of 16, excess of thiophenol (3 eq) was used and long 
reaction times were required for full conversion. The acetyl groups of the obtained 
thioglycoside 40 were then removed by transesterification with sodium methoxide, the 6-
position was selectively protected with a TBS group and the remaining hydroxyl groups were 
again acetylated. The thiophenyl glycoside 42266 was prepared in 3 steps and 57% yield 
starting from 1,2,3,4,6-penta-O-acetyl-α-galactosylpyranoside 16 (figure 4.26).  
 
Figure 4.26: Synthesis of glycosyl donor 42. 
The thiophenyl glycosyl donor 42 was glycosylated with the TN-antigen acceptor 12, 
promoted by a NIS/TfOH system. The glycosylation product 43 was obtained in 74% yield 
and with full β-stereoselectivity. No problems with stereoselectivity or orthoester formation 
were monitored in this reaction (compared with type-1 core 3 synthesis, chapter 4.1.5). The 
obtained compound 43 was deacetylated with sodium methoxide in methanol. The pH was 
set to 9.5 to efficiently remove the acetyl esters. A reaction to reinsert the partially removed 
Fmoc group followed. The core 1 glycosyl acceptor 44 was synthesized in 72% yield and 
displays unprotected hydroxyl groups 2, 3 and 4 on the galactose unit (figure 4.27).  
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Figure 4.27: Preparation of T-antigen 44 by glycosylation of donor 42 and acceptor 12. 
Next, T-antigen acceptor 44 was glycosylated with either the type-1 or type-2 LacNAc 
disaccharide in a [2+2]-block synthesis (the reaction pathways for both the disaccharides 
were analog from this stage, thus, presentation of both pathways will be presented 
simultaneously). The thioglycoside donors were activated by the approved conditions with 
NIS/TfOH in DCM. It is well known that equatorial hydroxyl groups tend to react preferentially 
in glycosylations, if a vicinal axial hydroxyl group is present. Therefore the hydroxyl group at 
the galactose position 3 of acceptor 44 was glycosylated regioselectively in the presence of 
the unprotected hydroxyl groups on position 2 and 4.222 Regioselectivity was proven by 
HMBQ-NMR spectrometry, which showed spin coupling between H1(donor)-C3’(acceptor) 
and H3’(acceptor)-C1(donor). Tetrasaccharide core 1 structures were obtained in 64% (45) 
and 65% (50) yields, respectively (figure 4.28).  
 
Figure 4.28: Glycosylations of glycosyl donors 27 and 32 with acceptor 44. 
The two TBS protecting groups of glycosylation products 45 and 50 were cleaved with tetra-
n-butylammonium fluoride (TBAF) trihydrate. The reasonable basicity of the fluoride anion in 
aprotic solvents demands addition of acetic acid to buffer the reaction and prevent unwanted 
cleavage of the Fmoc group.267,268 Subsequent, acetylation of the hydroxyl groups resulted in 
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compounds 46 and 51. Treatment with acetic anhydride in pyridine of the complex glycans 
required addition of catalytic amounts of 4-(dimethylamino)pyridine (DMAP, Steglich Base) 
for complete acetylation.269 Compounds 46 and 51 were treated with 80% acetic acid to 
hydrolyze the acid labile acetal, revealing 4- and 6-OH of the prime αGalNAc. The resulting 
compounds 47 and 52 in this stage represented branching points for either further protecting 
group manipulations to complete type-1 and -2 elongated core 1 glycosyl amino acids for 
SPPS or for selective glycosylations on 6-OH to give branched core 2 hexasaccharides 
(figure 4.29).  
 
Figure 4.29: Synthesis of the extended core 1 tetrasaccharides 47 and 52, as branching compounds in the 
synthesis routes of extended core 1 and core 2 structures.  
To continue the synthesis route of the linear elongated core 1 building blocks, the N-Troc 
groups on compounds 47 and 52 were removed by reduction using activated zinc in acetic 
acid and the obtained free amines and the unprotected hydroxyl groups were acetylated. In 
the final step, the tert-butyl esters on 48 and 53 were cleaved in TFA/DCM with anisole as a 
scavenger to give the type-1 and -2 elongated core 1 amino acids 49 and 54 ready for SPPS. 
Compounds 49 and 54 were both synthesized over 5 steps in 32% (type-1, 49) and 29% 
(type-2, 54) overall yield starting from the glycosylation with the common T-antigen acceptor 
12 (figure 4.30).  
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Figure 4.30: Syntheses of extended core 1 amino acid building blocks 49 and 54 for SPPS.  
 
4.1.9 Synthesis of the extended core 2 hexasaccharide amino acids 
The branched core 2 building blocks were constructed from the common tetrasaccharide 
building blocks 47 for type-1 and 52 for type-2 and were assembled in a [2+4] building block 
glycosylation (retrosynthesis, figure 4.2). In this work the two homogeneous variants core 2 
(type-1)2 and core 2 (type-2)2 were synthesized. For further biological evaluation on 
microarrays, it was considered more interesting to see effects of glycan size and core 2 
branching of homogenous glycans, for comparing the two different elongation variants. The 
type-1 tetrasaccharide acceptor 47 was reacted with type-1 disaccharide donor 27 and 
type-2 tetrasaccharide acceptor 52 with type-2 disaccharide donor 31 in a NIS/TfOH 
promoted glycosylation (figure 4.31). 
 
Figure 4.31: Glycosylation of donors 27 and acceptor 47 and glycosylation of donor 31 and acceptor 52. 
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Both reactions resulted in the corresponding core 2 hexasaccharides 55 ((Galβ1,3-GlcNβ)2) 
and 59 ((Galβ1,4-GlcNβ)2), in 78% and 69% yield, respectively. In both cases, full 
regioselectivity on position 6 of the acceptor amino acid, verified by HMBC-NMR 
spectroscopy, and full β-stereoselectivity was obtained. Next, the TBS groups were 
hydrolyzed in 80% acetic acid and acetylation of the free hydroxyl groups followed, resulting 
in compounds 56 and 60. The subsequent acetylation reactions after each protecting group 
manipulation step had the purpose to neutralize effects of acetyl migration, commonly 
observed with carbohydrates partly acetylated and partly unprotected.270 Here, intra- or 
intermolecular acetyl migrations lead to ambiguities during reaction monitoring by thin layer 
chromatography and purification by silica chromatography due to differently acetylated 
species of the same scaffold. After removal of the TBS groups, the two N-Troc groups on 
each hexasaccharide were removed with zinc in acetic acid and the amines were acetylated 
to give compounds 57 and 61, respectively. Finally, the tert-butyl ester at the carboxy-
terminus of the amino acid was removed using TFA/DCM with anisole to give the final core 2 
hexasaccharides 58 and 62, ready for SPPS (figure 4.32).  
 
 
Figure 4.32: Synthesis of extended core 2 amino acid building blocks 58 and 62 for SPPS.  
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4.2 Part 2 - Syntheses of mucin glycopeptide libraries 
4.2.1 Synthesis plan for MUC1 and MUC5B glycopeptide library build-up 
An extended library of mucin glycoproteins was synthesized with the synthetic TN- and T-
antigen and the extended core 1, 2 and 3 amino acids. These glycosylated amino acid 
building blocks were incorporated into the tandem repeat peptide sequences of MUC1 and 
MUC5B to generate several peptide isoforms/glycoforms for each of the mucins tandem 
repeat sequences. The different variants were chosen with respect to different glycosylation 
sites and multivalent occupation of these glycosylation sites. A MUC1 tandem repeat 
consists of 20 amino acids of the sequence PAHGVTSAPDTRPAPGSTAP. The sequence 
was first synthesized without glycosylation. The decision was made to synthesize a 19mer of 
the MUC1 peptide of the sequence PAHGVTSAPDTRPAPGSTA to avoid potential problems 
with diketopiperazine formation and increase the yields. The MUC1 19mer contains five 
potential glycosylation sites, of which three are composed of threonines and were occupied 
by the synthesized threonine amino acid building blocks. The MUC5B tandem repeat 
consists of 29 amino acids of the sequence ATGSTATPSSTPGTTHTPPVLTTTATTPT. For 
MUC5B the 13mer ATPSSTPGTTHTP from A6 to P18 was synthesized. It contains seven 
potential glycosylation sites, of which five are located on threonine. Figure 4.33 shows the 
chosen multivalent glycosylation pattern for the synthesis of the MUC1 and MUC5B peptides. 
This pattern was applied to the synthetic glycosylated amino acids. Like this, 8 (glycosylated 
amino acids) x 7 (peptide isoforms) = 56 MUC1(19mer) and 7 (glycosylated amino acids) x 5 
(peptide isoforms) = 42 MUC5B(13mer) glycopeptides were synthesized (figure 4.33). 
 
Figure 4.33: Synthesized MUC1(19mer) and MUC5B(13mer) glycopeptides. 
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In the case of the MUC1 peptides, which were already used in the first microarray studies, 
also three MUC1 22mers and a few MUC1 sequences with migrating PDTR and GSTA 
domains were synthesized. Full lists of all synthesized MUC1 and MUC5B peptides are 
shown in table 4.2 (MUC1, chapter 4.2.3) and in table 4.3 (MUC5B, chapter 4.2.4). 
 
4.2.2 Synthesis of a triethlyene glycol linker 
Each synthesized mucin sequence, was extended with a triethylene glycol (TEG) linker 
amino acid at the N-terminal end. In the synthesis of immunogenic vaccine conjugates based 
on (glyco-) peptide antigens, spacers between the antigen and applied carriers or mitogens 
provide spatial separation of the different components and prohibit unwanted conformational 
influences.271 Similar to this approach, the triethylene glycol attached to the N-terminus of the 
glycopeptides provides additional spacing to the surface of a microarray. In the field of 
carbohydrate microarrays it is common to use various spacers between the surface and the 
glycan.272 Signal intensity variations depending on the length of spacers are reported and 
due to steric hindrance, too short linkers usually disturb the interactions between the glycan 
and the protein binding partners.273 Oligoethylene glycol spacers are reported to have 
minimal nonspecific interaction with proteins on microarrays.274 The utilized amine reactive 
microarray slides have a three-dimensional hydrophilic polymer coating with a hydrophilic 
tether connected to the reactive site. The triethylene glycol spacer is incorporated 
additionally to the surface tether of the commercial slide. The spacer displays an amine 
group and is therefore suited for the use with functionalized amine reactive microarray slides. 
Furthermore, with a glycol spacer attached, each glycopeptide can be used also for the 
synthesis of mucin glycopeptide vaccine conjugates.271  
The synthesis of the triethylene glycol spacer amino acid followed a reported 
strategy.275,276,240 The alkoxide of triethylene glycol was initially reacted in a Michael-addition 
with tert-butylacrylate to give the 12-hydroxy-4,7,10-trioxa-dodecanate-tert-butylester 63.275 
The free hydroxyl group was transferred into a better leaving group by mesylation with 
methanesulfonyl chloride and then substituted with an azide group. The resulting 12-azido-
4,7,10-trioxa-dodecanate-tert-butylester 64 was further reduced with raney-nickel in 
isopropanol to give the corresponding amine 65.276 The free amine was then protected using 
Fmoc-OSu and the orthogonally protected Fmoc amino acid 66 was obtained.240 By 
deblocking the tert-butyl-carboxyl group in TFA, the adequate Fmoc amino acid 67 was 
received and ready for SPPS.240 Compound 67 was synthesized in five steps and 30% yield 
overall (figure 4.34). 
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Figure 4.34: Synthesis of triethylene glycol spacer amino acid 67. 
 
4.2.3 Synthesis of a MUC1 glycopeptide library 
Since all MUC1 as well as all MUC5B glycopeptides follow the same SPPS-protocol, 
representative syntheses are shown in detail only for MUC1(19mer) 108, MUC1(19mer) 109, 
MUC1(19mer) 98 and MUC5B(13mer) 161. Glycopeptide numbering, characteristic reaction 
parameters and yields for each synthesized glycopeptide are combined in table 4.2 (MUC1) 
and table 4.3 (MUC5B). 
The MUC1 glycopeptides were generated on TentaGel® R Trt-Ala Fmoc resins with loading 
capacities of 0.17 mmol/g or 0.15 mmol/g. The comparatively low loading capacities support 
good availability of reaction centers and prohibit peptide aggregation. The synthesis of 
glycopeptide 108 was initiated by the cleavage of the amino acid Fmoc protecting group on 
the preloaded resin by addition of 20% piperidine in DMF (figure 4.32). Automated chain 
elongation of the first eight amino acids followed. In each elongation cycle, eight equivalents 
of the standard Fmoc protected amino acid were utilized in a peptide coupling mediated by 
HBTU/HOBt. Each cycle was finished by Fmoc deprotection with 20% piperidine in DMF. 
The glycosylated type-2 core 1 amino acid 54 (1.5 eq) was preactivated with HATU/HOAt 
and DIPEA in DMF in a separate vessel and then manually pipetted to the synthesis reactor. 
The reaction was periodically shaken by vortex for 6 h. The two preceding amino acids after 
the glycosylated amino acids were coupled in double couplings. After the completion of the 
MUC1(19mer) sequence by automated synthesis steps, the Fmoc protected spacer amino 
acid 67 (3 eq) was preactivated with HBTU/HOBt and DIPEA and then added manually to the 
reactor. The reaction was shaken for 2 h. Final Fmoc deprotection preceded detachment of 
the peptide from the resin using TFA/TIPS/H2O (15:1:1) with simultaneous cleavage of all 
acid sensitive protecting groups on the side chains of the amino acids (figure 4.35). The 
crude peptide was lyophilized and then loaded onto a C18 cartridge (1 g) and desalted. The 
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glycopeptide was eluted successively with 30, 50, and 70% of acetonitrile in water. The 
eluted glycopeptide was again lyophilized before the following deacetylation step 
 
Figure 4.35: SPPS of MUC1 glycopeptide 108.  
In order to hydrolyze the acetyl groups of the glycan moiety, the glycopeptides were 
dissolved in methanol/water (1:1) and 150 mM NaOH solution was added in small portions 
until a pH of 11.5 was reached. Several additions were necessary, due to buffering effects. 
After completion of the deacetylation the reaction was acidified with acetic acid and 
glycopeptide 108 was purified by preparative HPLC. After lyophilization, glycopeptide 108 
was obtained in 53% yield overall, regarding the resin loading capacity (figure 4.36).  
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Figure 4.36: Deacetylation and synthesis of MUC1(19mer) 108. 
Standard deacetylation conditions, like the mentioned Zemplén deacetylation at pH 8.5,211 
were not sufficient to the remove all acetyl groups. Chromatographic and mass spectrometric 
analysis showed that under these mild conditions one acetyl group was omitted. S. Dziadek 
et al. reported the synthesis of α2,3-sialyl-T-antigen glycopeptides, where the 4ꞌ-position of 
the galactose unit was sterically hindered and required harsher conditions for 
deacetylation.215 Here, ESI-mass-spectrometry with collision induced dissociation (CID) 
fragmentation of monoacetylated compound 108 indeed revealed that a hydroxyl group of 
the core 1 galactose remained acetylated at standard Zemplén conditions. 
All glycopeptides carrying an elongated tetrasaccharide core 1 motif, including the elongated 
hexasaccharide core 2 structures, share the hindered 4ꞌ-OAc of the core 1 galactose. All of 
these glycopeptides were treated at higher pH (11.5) for full deacetylation. Extended core 3 
glycopeptides, devoid of a core 1 galactose, but also the not extended T-antigen 
glycopeptides, could be deacetylated under standard Zemplén conditions. Stringent 
chromatographic reaction control by HPLC was necessary to keep unavoidable β-elimination 
at pH 11.5 at acceptable levels. The sodium hydroxide solution was added carefully in small 
doses to the dissolved glycopeptide in the methanol/water mixture. Setting the pH to 11.5 
often took a long time, since glycopeptides with large glycans showed strong buffering 
effects, especially in the case multiglycosylated glycopeptides. The deacetylation step, 
resulting in glycopeptide 108, is shown in the HPLC chromatograms in figure 4.37. 
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Figure 4.37: Analytical HPLC control of deacetylation of glycopeptide 108. A: Structure of deacetylated product 
108. B: After 15 h (grad.: water/84% ACN + 0.1% TFA (95:5) → (40:60), 55 min = 1% min
-1
). Monoacetylated 
glycopeptide (blue curve) is left. All starting material (black curve) is completely consumed. C: Until 98 h (grad.: 
water/84% ACN + 0.1% TFA (95:5) → (79:21), 54 min, 0.3% min
-1
). Deacetylation of monoacetylated 
glycopeptide (+1xAcO) and increasing β-elimination at pH 11.5. 
Partial deacetylation commonly occurred during the release of the glycopeptides from the 
resin by the treatment with TFA (figure 4.37, B, black curve). After 15 h at pH 9.5, one acetyl 
group was left. Adjustment of the pH to 11.5 and HPLC monitoring with a slower gradient 
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(water/84% ACN (95:5)(79:21), 54 min, 0.3% min-1) enabled removal of the last acetyl 
group (figure 4.37, C). After 98 h only small amounts of monoacetylated product (+1x AcO) 
were left. Due to the increased pH, 14% of β-elimination was observed (by peak integration). 
Purification by preparative HPLC separated the main product peak from the leftover 
monoacetylated glycopeptide (figure 4.38). Analytical HPLC of the main fraction F1 showed a 
single product and with the expected molecular weight (figure 4.38, B and C). The separated 
fraction F2 was a mixture of fully deacetylated and monoacetylated 108 (figure 4.38, D). The 
last fraction F3 contained peptide with β-elimination (figure 4.38, E). 
 
Figure 4.38: HPLC and HR-ESI-MS analysis after deacetylation of 108. A: Preparative HPLC (grad.: water/84% 
acetonitrile + 0.1% TFA (95:5) → (79:21), 60 min = 0.26% min
-1
) separation of fractions F1 = 20-30, F2 = 31-36 
and F3 = 62-68. B: Analytical HPLC (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (21:79), 54 min = 0.27% 
min
-1
) of main peak F1 and F2. C: HR-ESI-MS of F1, m/z: 908.7621 ([M+3H]
3+
, calc. 908.7603); 681.8247 
([M+4H]
4+
, calc. 681.8220)  complete deacetylation. D: HR-ESI-MS of F1, m/z: 922.7644 ([M+3H]3+, calc. 
922.7638)  monoacetylation; E: HR-ESI-MS of F1, m/z: 659.0008 ([M+3H]3+, calc. 659.0007) β-elimination. 
Glycopeptide 109 carried the type-2 core 1 glycan in the GST*A domain. Deacetylation of 
109 was performed under the same conditions as 108. The majority of acetyl groups were 
hydrolyzed rapidly (figure 4.39, B), while further hydrolysis of the remaining 4ꞌ-OAc on 
galactose was again slow (figure 4.39, C).  
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Figure 4.39: Analytical HPLC control of deacetylation of glycopeptide 109. A: Structure of deacetylated product 
109. B: After 21 h (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (40:60), 55 min = 1% min
-1
): 
Monoacetylated glycopeptide (blue curve) is left. All starting material (black curve) is completely consumed. C: 
Until 118 h (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (21:79), 54 min = 0.3% min
-1
): No further product 
formation from 75 h. 
No further change was visible in the HPLC chromatogram after 75 h. ESI-MS analysis after 
separation of the main peak and the minor site product in preparative HPLC revealed that the 
minor product was not leftover monoactylated glycopeptide but a product with the same 
mass as the desired deacetylated glycopeptides (figure 4.40). It was assumed that the minor 
peak was epimerization product. Depending on the glycosylation site and extend of 
glycosylation this side reaction appeared for some peptides in varying amounts and the by-
product was usually effectively removed by preparative HPLC. 
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Figure 4.40: HPLC and HR-ESI-MS analysis after deacetylation of 109. A: Preparative HPLC (grad.: water/84% 
acetonitrile + 0.1% TFA (95:5) → (40:60), 55 min = 1% min
-1
) separation of fractions F1 = 17-21, F2 = 22-24. B: 
Analytical HPLC (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (79:21), 54 min = 0.3% min
-1
) of fractions F1 
(black curve) and F2 (blue curve). C: HR-ESI-MS of fraction F1, m/z: 908.7620 ([M+3H]
3+
, calc. 908.7603); 
681.8245 ([M+4H]
4+
, calc. 681.8220)  complete deacetylation. D: HR-ESI-MS of fraction F2, m/z: 908.7646 
([M+3H]
3+
, calc. 908.7603)  assumed epimerization. 
Glycopeptides without the internal galactose of the central core 1 motif, such as the T-
antigen or core 3 glycopeptides, were deacetylated at pH 9.5 in a few hours. As an example, 
figure 4.41 shows HPLC chromatograms of trivalent type-2 core 3 glycopeptide 98 (figure 
4.41, A), after SPPS (figure 4.41, B) and at deacetylation conditions (figure 4.41, C). The 
deacetylation reaction was stopped after 20 h by addition of acetic acid. 
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Figure 4.41: A: Structure of triglycosylated type-2 core 3 peptide 98. B: Analytical HPLC chromatogram after 
SPPS. C: Complete deacetylation after 20 h. (grad. in B and C: water/84% acetonitrile + 0.1% TFA (95:5) → 
(40:60), 55 min = 1% min
-1
). 
The MUC1 glycopeptide library was synthesized according to the examples shown above. 
MUC1(22mer) PAHGVTSAPDT*RPAPGS*T*APPA sequences 131-133 were synthesized 
according to the same SPPS protocol. The serine 211 and threonine 212 TN-antigen building 
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blocks for 131-133 and 69-75 were kindly provided by Dr. Hui Cai. Table 4.2 summarizes all 
synthesized MUC1 glycopeptides and relevant reaction parameters.  
Table 4.2: Overview of all synthesized MUC1 sequences with relevant reaction parameters.  
      SPPS deacetylation 
Glycan # Sequence 
eq 
glycosylated 
amino acid 
min reaction time 
glycosylated 
amino acid (h) 
pH 
reaction 
time (h) 
final 
overall 
yield 
(%) 
TN 68 PAHGVT*SAPDTRPAPGSTA 1.5 2  9.5 6 67 
 
69 PAHGVTSAPDT*RPAPGSTA 1.5 2  9.5 6 65 
 
70 PAHGVTSAPDTRPAPGST*A 1.5 2  9.5 6 70 
 
71 PAHGVT*SAPDT*RPAPGSTA 1.5 2  9.5 6 51 
 
72 PAHGVT*SAPDTRPAPGST*A 1.5 2  9.5 6 52 
 
73 PAHGVTSAPDT*RPAPGST*A 1.5 2  9.5 6 56 
 
74 PAHGVT*SAPDT*RPAPGST*A 1.5 2  9.5 6 40 
        
T 75 PAHGVT*SAPDTRPAPGSTA 1.5 2  9.5 14 85 
 
76 PAHGVTSAPDT*RPAPGSTA 1.5 2  9.5 14 85 
 
77 PAHGVTSAPDTRPAPGST*A 1.5 2  9.5 14 76 
 
78 PAHGVT*SAPDT*RPAPGSTA 1.5 2  9.5 14 67 
 
79 PAHGVT*SAPDTRPAPGST*A 1.5 2  9.5 14 85 
 
80 PAHGVTSAPDT*RPAPGST*A 1.5 2  9.5 14 62 
 
81 PAHGVT*SAPDT*RPAPGST*A 1.5 2  9.5 14 59 
 
82 PGSTAPPAHGVTSAPDT*RPA 1.5 2 9.5 4 71 
 
83 APDT*RPAPGSTAPPAHGVTSA 1.5 2 9.5 4 54 
 
84 APDT*RPA 1.5 2 9.5 15 66 
        
type-1 core 3 85 PAHGVT*SAPDTRPAPGSTA 1.5 5  9.5 16 60 
 
86 PAHGVTSAPDT*RPAPGSTA 1.5 5  9.5 16 74 
 
87 PAHGVTSAPDTRPAPGST*A 1.5 5  9.5 16 79 
 
88 PAHGVT*SAPDT*RPAPGSTA 1.5 5  9.5 16 37 
 
89 PAHGVT*SAPDTRPAPGST*A 1.5 5  9.5 16 75 
 
90 PAHGVTSAPDT*RPAPGST*A 1.5 5  9.5 24 47 
 
91 PAHGVT*SAPDT*RPAPGST*A 1.5 5  9.5 16 62 
        
type-2 core 3 92 PAHGVT*SAPDTRPAPGSTA 1.5 5  9.5 18 70 
 
93 PAHGVTSAPDT*RPAPGSTA 1.5 5  9.5 18 65 
 
94 PAHGVTSAPDTRPAPGST*A 1.5 5  9.5 27 72 
 
95 PAHGVT*SAPDT*RPAPGSTA 1.5 5  9.5 20 74 
 
96 PAHGVT*SAPDTRPAPGST*A 1.5 5  9.5 21 62 
 
97 PAHGVTSAPDT*RPAPGST*A 1.5 5  9.5 21 62 
 
98 PAHGVT*SAPDT*RPAPGST*A 1.5 5  9.5 20 59 
 
99 PAHGVT*SA 1.5 5 9.5 15 24 
        
type-1 core 1 100 PAHGVT*SAPDTRPAPGSTA 1.5 6  11.5 53 40 
 
101 PAHGVTSAPDT*RPAPGSTA 1.5 6  11.5 53 45 
 
102 PAHGVTSAPDTRPAPGST*A 1.5 6  11.5 80 43 
 
103 PAHGVT*SAPDT*RPAPGSTA 1.5 6  11.5 84 36 
 
104 PAHGVT*SAPDTRPAPGST*A 1.5 6  11.5 62 35 
 
105 PAHGVTSAPDT*RPAPGST*A 1.5 6  11.5 62 36 
 
106 PAHGVT*SAPDT*RPAPGST*A 1.5 6  11.5 84 27 
        
type-2 core 1 107 PAHGVT*SAPDTRPAPGSTA 1.5 6  11.5 84 49 
 
108 PAHGVTSAPDT*RPAPGSTA 1.5 6  11.5 98 53 
 
109 PAHGVTSAPDTRPAPGST*A 1.5 6  11.5 108 45 
 
110 PAHGVT*SAPDT*RPAPGSTA 1.5 6  11.5 119 34 
 
111 PAHGVT*SAPDTRPAPGST*A 1.5 6  11.5 95 26 
 
112 PAHGVTSAPDT*RPAPGST*A 1.5 6  11.5 80 29 
 
113 PAHGVT*SAPDT*RPAPGST*A 1.5 6  11.5 127 17 
 
114 GST*APPAHGVTSAPDTRPA 1.5 6 11.5 78 14 
 
115 PDTRPAPGST*APPAHGVTSA 1.5 6 11.5 80 41 
 
116 PDTRPAPGSTAPPAHGVT*SA 1.5 6 11.5 60 40 
        
 type-1 core 2 117 PAHGVT*SAPDTRPAPGSTA 2.0 10  11.5 81 36 
 
118 PAHGVTSAPDT*RPAPGSTA 2.0 10  11.5 82 34 
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      SPPS deacetylation 
Glycan # Sequence 
eq 
glycosylated 
amino acid 
min reaction time 
glycosylated 
amino acid (h) 
pH 
reaction 
time (h) 
final 
overall 
yield 
(%) 
 
119 PAHGVTSAPDTRPAPGST*A 2.0 10  11.5 103 37 
 
120 PAHGVT*SAPDT*RPAPGSTA 2.0 10  11.5 82 22 
 
121 PAHGVT*SAPDTRPAPGST*A 2.0 10  11.5 138 20 
 
122 PAHGVTSAPDT*RPAPGST*A 2.0 10  11.5 82 20 
 
123 PAHGVT*SAPDT*RPAPGST*A 2.0 10  11.5 129 9 
        
type-2 core 2 124 PAHGVT*SAPDTRPAPGSTA 2.0 10  11.5 90 43 
 
125 PAHGVTSAPDT*RPAPGSTA 2.0 10  11.5 120 33 
 
126 PAHGVTSAPDTRPAPGST*A 2.0 10  11.5 129 40 
 
127 PAHGVT*SAPDT*RPAPGSTA 2.0 10  11.5 96 18 
 
128 PAHGVT*SAPDTRPAPGST*A 2.0 10  11.5 129 8 
 
129 PAHGVTSAPDT*RPAPGST*A 2.0 10  11.5 149 14 
 
130 PAHGVT*SAPDT*RPAPGST*A 2.0 10  11.5 129 3 
        
*type-2 core 1 + 
#
2xTn 131 PAHGVTSAPDT*RPAPGS
#
T
#
APPA 3x1.5 9  11.5 106 16 
*type-2 core 3 + 
#
2xTn 132 PAHGVTSAPDT*RPAPGS
#
T
#
APPA 3x1.5 9 9.5 16 19 
*type-2 core 2 + 
#
2xTn 133 PAHGVTSAPDT*RPAPGS
#
T
#
APPA 1x2.0+2x1.5 9  11.5 106 8 
 
 
4.2.4 Synthesis of a MUC5B glycopeptide library 
MUC5B(13mer) glycopeptides were synthesized on TentaGel® R Trt-Pro Fmoc. The MUC5B 
tandem repeat consists of 29 amino acids of the sequence 
ATGSTATPSSTPGTTHTPPVLTTTATTPT with 16 potential serine or threonine glycosylation 
sites. The peptide sequence ATPSSTPGTTHTP was chosen for a feasible synthesis of a 
multivalent pattern, similar to the described MUC1 glycopeptides. This MUC5B(13mer) 
sequence contains seven O-glycosylation sites of which five could be addressed with the 
glycosylated threonine amino acids described herein.  
Triglycosylated MUC5B peptide 161 with type-1 core 2 hexasaccharide glycan decoration 
was synthesized according to the SPPS protocol displayed in figure 4.35. The type-1 core 2 
glycosylated amino acid building block 58 was incorporated at the threonine glycosylation 
sites T2, T6 and T9 and was applied in 2 eq excess with elongated reaction times (minimum 
10 h). Figure 4.42 shows the analytical HPLC chromatogram of acetylated glycopeptide 161 
after SPPS (figure 4.42, B) and the course of deacetylation to result in the final product 
sequence 161 (figure 4.42, C).   
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Figure 4.42: A: Structure of deacetylated product 161. B: Analytical HPLC of crude, acetylated glycopeptide 161 
after SPPS (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (30:70), 65 min, 1% min
-1
). C: Deacetylation of 
161 (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (16:84), 54 min, 0.2% min
-1
). 
The main peak in the chromatogram (figure 4.42, C) represented the desired fully 
deacetylated product, the triglycosylated type-2 core 2 glycopeptide 161. Fractions F1 and 
F2 were also isolated and analyzed my mass spectrometry (figure 4.43). Fraction F1 
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contains a mixture of product isomers, which might be peptide epimerization and product 
masses fitting for shorter, acetyl capped sequences (figure 4.43, A). The sequences were 
capped at the corresponding proline amino acids P7 and P3, after which a glycosylated amino 
acid was supposed to follow. Since the used glycosylated amino acid 58 was applied in the 
synthesis of various other MUC1 and MUC5B sequences, a contamination with acetic acid, 
leftover from silica column chromatography after tert-butyl ester removal, was excluded. It 
was assumed that intra- or intermolecular acetyl-migration took place during the coupling of 
the second and third glycosylated amino acid. The short distances between the selected 
glycosylation sites in the MUC5B sequence could have facilitated close proximities between 
terminal prolines and the previously installed glycan. Then, the elongated reaction times and 
slower reaction rates of the bulky hexasaccharide glycosylated amino acids could have 
promoted acetyl-migration. Fraction F2 contained a mixture of diglycosylated deletion 
sequences, missing a complete glycosylated amino acid and glycopeptides with a single β-
elimination site, having a unsaturated homoalanine instead of a glycosylated threonine 
(figure 4.43, B). 
 
Figure 4.43: Side products in SPPS of glycopeptide 161 in fractions F1 and F2.  
However, the desired glycopeptide product was obtained as the main product (figure 4.42, 
C). Glycopeptide 161 was obtained in 10% yield overall after the final deacetylation, based 
on the amount of initially employed SPPS-resin. The synthesis of glycopeptide 161 
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demonstrates the feasibility of SPPS of short peptide sequences (13 amino acids) with bulky 
glycans motifs, distributed on densely occupied glycosylation sites. The carbohydrate portion 
accounts for almost 70% of the overall weight of glycopeptide 161. The MUC5B glycopeptide 
library was synthesized according to the general SPPS protocol also applied for MUC1 
glycopeptide synthesis (figure 4.35). Relevant reaction parameters and overall yields for the 
synthesized MUC5B sequences are summarized in table 4.3. 
Table 4.3: Overview of all synthesized MUC5B sequences with relevant reaction parameters.  
      SPPS deacetylation 
Glycan # Sequence 
equiv 
glycosylated 
amino acid 
min reaction time 
for glycosylated 
amino acid/h 
pH time/h   final 
overall 
yield/% 
T 134 ATPSSTPGT*THTP 1.5 2  9.5 14 78 
 
135 AT*PSSTPGTTHTP 1.5 2  9.5 8 72 
 
136 AT*PSSTPGT*THTP 1.5 2  9.5 14 79 
 
137 AT*PSST*PGTTHTP 1.5 2  9.5 14 62 
 
138 AT*PSST*PGT*THTP 1.5 2  9.5 14 61 
 
139 T*GSTAT*PSST*PGT*THTP 1.5 2  9.5 18 33 
        
core 3 type1 140 ATPSSTPGT*THTP 1.5 5  9.5 12 72 
 
141 AT*PSSTPGTTHTP 1.5 5  9.5 12 70 
 
142 AT*PSSTPGT*THTP 1.5 5  9.5 16 61 
 
143 AT*PSST*PGTTHTP 1.5 5  9.5 12 54 
 
144 AT*PSST*PGT*THTP 1.5 5  9.5 21 62 
 
145 T*GSTAT*PSST*PGT*THTP 1.5 5  9.5 21 36 
        
core 3 type2 146 ATPSSTPGT*THTP 1.5 5  9.5 12 67 
 
147 AT*PSSTPGTTHTP 1.5 5  9.5 18 75 
 
148 AT*PSSTPGT*THTP 1.5 5  9.5 20 62 
 
149 AT*PSST*PGTTHTP 1.5 5  9.5 12 67 
 
150 AT*PSST*PGT*THTP 1.5 5  9.5 20 65 
 
151 T*GSTAT*PSST*PGT*THTP 1.5 5  9.5 18 49 
        
core 1 type 1  152 ATPSSTPGT*THTP 1.5 6  11.5 36 36 
 
153 AT*PSSTPGTTHTP 1.5 6  11.5 44 49 
 
154 AT*PSSTPGT*THTP 1.5 6  11.5 40 30 
 
155 AT*PSST*PGTTHTP 1.5 6  11.5 110 40 
 
156 AT*PSST*PGT*THTP 1.5 6  11.5 110 19 
 
157 T*GSTAT*PSST*PGT*THTP 1.5 6  11.5 110 10 
        
core 1 type2 158 ATPSSTPGT*THTP 1.5 6  11.5 140 17 
 
159 AT*PSSTPGTTHTP 1.5 6  11.5 67 37 
 
160 AT*PSSTPGT*THTP 1.5 6  11.5 38 22 
 
161 AT*PSST*PGTTHTP 1.5 6  11.5 113 22 
 
162 AT*PSST*PGT*THTP 1.5 6  11.5 87 15 
 
163 T*GSTAT*PSST*PGT*THTP 1.5 6  11.5 87 9 
        
core 2 type 1 164 ATPSSTPGT*THTP 2.0 10  11.5 185 20 
 
165 AT*PSSTPGTTHTP 2.0 10  11.5 175 28 
 
166 AT*PSSTPGT*THTP 2.0 10  11.5 146 16 
 
167 AT*PSST*PGTTHTP 2.0 10  11.5 143 21 
 
168 AT*PSST*PGT*THTP 2.0 10  11.5 101 10 
        
core 2 type2  169 ATPSSTPGT*THTP 2.0 10  11.5 185 15 
 
170 AT*PSSTPGTTHTP 2.0 10  11.5 196 28 
 
171 AT*PSSTPGT*THTP 2.0 10  11.5 190 17 
 
172 AT*PSST*PGTTHTP 2.0 10  11.5 143 21 
 
173 AT*PSST*PGT*THTP 2.0 10  11.5 124 9 
74 4 RESULTS AND DISCUSSION
 
 
4.2.5 Synthesis of sialylated MUC1 glycopeptides 
4.2.5.1 Enzymatic carbohydrate extension of MUC1 glycopeptides 
Sialylation is a frequent glycan modification, terminating carbohydrate chains in O- and N-
glycoproteins and glycolipids. In this context, glycans are usually decorated with N-
acetylneuraminic acid (Neu5Ac) α2,3- or α2,6-linked to terminal galactose, α2,6-linked to 
GalNAc or sometimes α2,8- or α2,9-linked to a preceding Neu5Ac.277 This type of 
glycosylation has significant effects on protein structure and is involved in a plethora of 
glycan-protein interactions.278 Neu5Ac adds a negative charge to a glycoprotein, increasing 
the hydrophilicity and providing charge repulsion of cells, for example sialylated erythrocytes 
in circulation. The half-life of serum glycoproteins is influenced, since non-sialylated glycans 
are recognized by asialoglycoprotein receptors on hepatocytes and are then cleared from 
circulation. α2,3-Sialylation together with 1,3/4-fucosylation on Galβ1,3-GlcNAcβ and 
Galβ1,4-GlcNAcβ chains, forms sLea and sLex (sialyl Lewis) glycans. Lewis structures are 
essential for leukocyte recruitment to inflamed tissues, due to binding to the corresponding 
selectins on the endothelial tissue, blood platelets or to the leukocyte itself. Further, 
generation of sialyl Lewis motifs on mucins is increased in most carcinomas facilitating 
metastasis by aforementioned selectin interaction. The α2,3-sialylation is in particular 
responsible for the binding of the human adopted influenza virus. Also, α2,6-sialylation may 
have strong influence on apoptotic effects mediated by galectins. Cancer cells are suspected 
make to use of this “carbohydrate on-off switch”, in order to avoid cell death by extracellular 
galectin-induced apoptosis.93 
A selection of the synthesized glycopeptides was enzymatically sialylated. Here, terminal 
sialylation of the T-antigen and extended core 1, 2 and 3 structures, represents the 
physiological glycosylation state of mucins and binding behavior of antibodies and lectins 
was evaluated with the sialylated glycopeptides.  
A chemoenzymatic approach on the peptide level was chosen, since it offers the option to 
modify certain peptides after SPPS, instead of preparing an extra set of chemically sialylated 
glycosyl amino acids before incorporation in SPPS. Chemoenzymatic glycosylation at the 
amino acid stage before Fmoc-SPPS would not be convenient because of protecting group 
issues. Several chemical methods of sialylation of complex carbohydrates have been 
presented on the level of oligosaccharides and glycosylated amino acids. Despite all efforts, 
chemical sialylations are still very challenging.279,280 The presence of an electron withdrawing 
carboxyl group at the anomeric center prompts elimination reactions towards 2,3-dehydro 
compounds, while the absence of a participating neighboring group at position 3 is 
unfavorable for the stereoselectivity of the glycosylation. Appropriate choices of anomeric C1 
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protecting groups and C2 leaving groups are essential for chemical sialylations. In contrast, 
enzymatic extension with sialyltransferases is reliable in terms of regio- and stereoselective 
sialylation outcome.19 The only drawback is the fairly high price of the nucleotide donor 
sugar, here cytidine-5´-monophospho-N-acetylneuraminic acid (CMP-Neu5Ac). Alternatively, 
it is possible to generate CMP-Neu5Ac in situ from cytidine triphosphate (CTP) and Neu5Ac 
and Neu5Ac from N-acetylmannosamine in a one-pot multienzyme system (OPME).281  
Three different commercial and one expressed (generously provided by Prof. Xi Chen) 
sialyltransferase were applied for glycopeptide sialylation in this work: 
1. Rat 2,3-OST: α2,3-(O)-Sialyltransferase from rat, recombinant (Spodoptera 
frugiperda)282 
2. PmST1 (PM0188): α2,3-(O)-Sialyltransferase from Pasteurella multocida, 
recombinant (Escherichia coli)283 
3. PmST3 (PM1174): α2,3-(O)-Sialyltransferase from Pasteurella multocida, 
recombinant (Escherichia coli), from Prof. X. Chen.284  
4. Pd2,6ST: α2,6-(O)-Sialyltransferase from Photobacterium damsela, recombinant 
(Escherichia coli)285 
Rat 2,3-OST is a α2,3-sialyltransferase with a reported specificity for the T-antigen (Galβ1,3-
GalNAcα) structure.282 In test-reactions with MUC1, carrying LacNAc (Galβ1,3/4-GlcNAcβ) 
terminated glycopeptides, no reactivity with rat 2,3-OST was observed. PmST1 and PmST3  
are a α2,3-O-sialyltransferases with reported reactivity towards LacNAc and lactose 
substrates and good reactivity with β-galactosides in general, and were used to α2,3-sialylate 
type-1 and type-2 LacNAc terminated glycopeptides.283 Pd2,6ST is a α2,6-sialyltransferase 
with a reported substrate specificity for β-linked Gal and GalNAc residues, but low activity on 
α-linked substrates.285 It was used to α2,6-sialylated the type-1 and type-2 terminated 
LacNAc glycopeptides (figure 4.44). 
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Figure 4.44: Sialyltransferases used for enzymatic termination. A: Rat 2,3-OST for α2,3-sialylation of T-antigen. 
B: PmST1/3 for α2,3-sialylation of type-1 and type-2 LacNAc. C: Pd2,6ST for 2,6-sialylation of type-1 and type-2 
LacNAc.  
A selection of 21 MUC1 glycopeptides was chosen for in-solution enzymatic sialylation. The 
peptides (0.5-1.5 mg) were dissolved in an appropriate reaction buffer and CMP-Neu5Ac and 
the particular enzyme was added. Usually after 3-6 h an extra portion of donor sugar and 
enzyme was added and the reaction was left for shaking overnight at 37°C. Progress was 
monitored by HPLC-ESI-MS and upon complete or almost complete conversion of the 
glycopeptide the reaction was stopped by addition of cold acetonitrile (15-20% end-
concentration). The reaction mixtures were desalted by solid phase extraction on a C18 
cartridge. In order to ensure high peptide purity before immobilization on the microarray, the 
desired products were further purified by semi-preparative HPLC-MS. All analytical and 
preparative HPLC steps were performed with 0.1% of formic acid (FA) as a comparably weak 
acid for ion-pairing, instead of TFA. TFA did not provide significant differences in retention 
times for the non-sialylated starting materials and the sialylated products. For illustration, 
figure 4.45 shows the enzymatic sialylation of glycopeptides 102 with Pd2,6ST (figure 4.45, 
A) and the preparative HPLC of the final product glycopeptide 191 (figure 4.45, B). 
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Figure 4.45: A: Enzymatic α2,6-sialylation of glycopeptide 102 with Pd2,6ST to afford product 191. B: Semi-
preparative HPLC-MS of glycopeptide 191 with leftover starting material (m/z 908.96), monosialylated main 
product (m/z 1006.01) and disialylated product (m/z 1103.08). 
Usually, treatment with Pd2,6ST resulted in pure monosialylated glycans (per equivalent 
LacNAc). The peptides with glycosylation in the GST*A site, also showed minor amounts of 
peptides with one extra Neu5Ac residue. It was recently reported that this bacterial 
sialyltransferase is also able to add Neu5Ac to internal galactose units of type-2 poly-LacNAc 
repeats.286,287 The equivalent human enzyme, ST6Gal-I, is solely an exo-glycosyltransferase, 
adding a single α2,6-linked Neu5Ac only to the non-reducing end. However, here the internal 
Gal is not part of a poly-LacNAc chain, as reported, but of a core 1 (Galβ1,3-GalNAcα) 
substructure. Mass spectrometric HCD-MS2 fragmentation revealed additional sialylation on 
the T-antigen glycopeptide fragment ion (m/z 1325.6202, z=3) of the minor disialylated 
product, compared to the monosialylated main product (figure 4.46, A and B). This fragment 
included no information whether Neu5Ac was located on Gal or GalNAc. However, no 2,6-
STN-antigen glycopeptide fragment ion could be observed, hinting that Neu5Ac is indeed 
located on Gal. Further HCD-MS3 fragmentation of ion m/z 1325.6202 showed ion m/z 
454.03, representing a Neu5Ac-Gal ion (figure 4.46, C) and confirming sialylation of the 
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internal galactose. Additionally, HCD-MS2 of the three times sialylated core 2 structure of 
glycopeptide 204, having the 6-OH position of the initial GalNAcα blocked with a 
lactosamine, also showed the fragment m/z 1325.6205 in HCD-MS2 and additionally 
disialylated core 1 hexasaccharide peptide m/z 1103.1065 (figure 4.46, D), further indicating 
sialylation on the galactose of the T-antigen substructure. Also, core 3 modified 
glycopeptides, lacking internal Gal, did not show any multiple sialylation products.       
 
Figure 4.46: A: HCD-MS2 fragmentation (20% NCE) of 2,6-monosialylated glycopeptide 191. B: Disialylated 
product 192 with additional T-antigen sialylation (m/z 1325.6202). Neu5Ac with indistinct glycosylation position is 
shown to be “disconnected”. C: HCD-MS3 fragmentation (30% NCE) with Neu5AcGal oxonium ion m/z 454.03. D: 
HCD-MS2 fragmentation of monosaccharide glycopeptide 204 with additional T-antigen sialylation (m/z 
1325.6202). 
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Minor internal sialylation by Pd2,6ST was observed on some glycopeptides with internal Gal, 
i.e. core 1 tetrasaccharide and core 2 hexasaccharides but only if the glycan was located in 
the GST*A region. Glycosylation in the VT*SA and PDT*R domains was not affected, at least 
not with the sialylation conditions applied here. The degree of internal sialylation is 
dependent on the conditions used. The applied conditions provided internal sialylation yields 
of 5-20%, except for glycopeptide 109 (type-2 core 1 on GST*A), yielding 50% of disialylated 
product (by HPLC peak integration). For three of the fourteen glycopeptides treated with 
Pd2,6ST, the minor by-product with a further α2,6-Neu5Ac residue was isolated (namely 192, 
198, 204, table 4.4, vide infra), which were appended to the library. 
The α2,3-sialyltransferases provided glycosylation products according to the expected 
specificities. Rat 2,3-OST generated exclusively sialylated T-antigen (Galβ1,3-GalNAcα) 
glycans. Test reactions with the T-antigen-specific rat 2,3-OST on type-1 and type-2 LacNAc 
extended peptides showed no activity, with the applied reaction conditions. Consequently, 
glycopeptide 174 with a core 2 tetrasaccharide, containing both, a type-2 LacNAc 
(Galβ1,4GlcNAcβ) branch and a T-antigen substructure (Galβ1,3GalNAcα), was only 
sialylated on the T-antigen motif to result in glycopeptide 205 (figure 4.47, reaction A). 
PmST3 was reported to sialylate terminal galactose and galactoside monosaccharides in 
general,283 including T-antigen (Galβ1,3-GalNAcα/β) structures on smaller MUC1 peptide 
fragments.288 However, no reactivity with the T-antigen MUC1 glycopeptides in test reaction 
was observed here. Accordingly, when employing PmST3 on core 2 glycopeptide 174, only 
one equivalent of Neu5Ac was transferred to the glycopeptide resulting in glycopeptide 206 
(figure 4.47, reaction B). No double sialylation was observed, although excess of CMP-
Neu5Ac was applied (total 3.5 eq). It was concluded that glycopeptide 174 was selectively 
sialylated on the LacNAc branch. 
 
Figure 4.47: Enzymatic α2,3-sialylation of glycopeptide 174 with rat 2,3-OST and PmST1 on different branches of 
the core 2 type-2 tetrasaccharide glycan, resulting in glycopeptides 205 and 206. 
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The LacNAc sialylation on glycopeptide 206 by PmST3 was further verified by microarray 
screening. The binding of the LacNAc-specific lectin Erythrina cristagalli (ECA) was 
completely abolished after sialylation and sialic acid binding lectin wheat germ agglutinin 
(WGA) recognized only T-antigen sialylation, as in 205 (see chapter 4.3.11.1; figure 4.75, A 
and E). Also, mass spectrometric HCD-MS2 fragmentation of the precursor ions of 205 and 
206, revealed the ST-antigen glycopeptide fragment m/z 1352.6160 (z = 2) for 205 (figure 
4.48, A), but not in the fragmentation spectrum of 206, which instead showed the sialyl-
LacNAc trisaccharide oxonium ion m/z 657.23, indicating LacNAc instead of T-antigen 
sialylation (figure 4.48, B).  
 
Figure 4.48: HCD-MS2 fragmentation spectra of glycopeptides 205 (A) and 206 (B), both recorded at 25% NCE.  
PmST3 was also not able to sialylate type-1 LacNAc containing glycopeptides, indicating   
low specificity for β1,3-linked disaccharides in general, in addition to the β1,3-linked T-
antigen. Further sialylation reactions on type-1 LacNAc units and as well type-2 containing 
glycopeptides were performed using commercial PmST1, which had a similar activity 
towards both LacNAc structures. Significant reaction parameters for all enzymatic α2,3- and 
α2,6- sialylations are summarized in table 4.4. 
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Table 4.4: α2,3-and α2,6-sialylated MUC1 sequences.  
MUC1 Acceptor Peptide  Conditions Product 
Glycan # Sequence enzyme  
reaction 
time (h) 
# 
conversion 
(%, by 
HPLC) 
T 75 PAHGVT*SAPDTRPAPGSTA rat2,3OST 20 175 97 
 
76 PAHGVTSAPDT*RPAPGSTA rat2,3OST 36 176 82 
 
77 PAHGVTSAPDTRPAPGST*A rat2,3OST 20 177 94 
 
78 PAHGVT*SAPDT*RPAPGSTA rat2,3OST 15 178 89 
 
79 PAHGVT*SAPDTRPAPGST*A rat2,3OST 15 179 100 
 
80 PAHGVTSAPDT*RPAPGST*A rat2,3OST 15 180 100 
 
81 PAHGVT*SAPDT*RPAPGST*A rat2,3OST 38 181 70 
       
type-2 core 3 92 PAHGVT*SAPDTRPAPGSTA PmST1 22 182 100 
93 PAHGVTSAPDT*RPAPGSTA PmST1 24 183 88 
94 PAHGVTSAPDTRPAPGST*A PmST1 22 184 94 
92 PAHGVT*SAPDTRPAPGSTA Pd2,6ST 15 185 97 
93 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 24 186 88 
94 PAHGVTSAPDTRPAPGST*A Pd2,6ST 15 187 100 
98 PAHGVT*SAPDT*RPAPGST*A Pd2,6ST 18 188 100 
       
type-1 core 1 101 PAHGVTSAPDT*RPAPGSTA PmST1 12 189 88 
102 PAHGVTSAPDTRPAPGST*A PmST1 12 190 85 
102 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 191 75 
 102 PAHGVTSAPDTRPAPGST*A  Pd2,6ST 12 192 17 
       
type-2 core 1 107 PAHGVT*SAPDTRPAPGSTA PmST1 18 193 97 
108 PAHGVTSAPDT*RPAPGSTA PmST1 39 194 100 
108 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 18 195 97 
109 PAHGVTSAPDTRPAPGST*A PmST1 18 196 97 
109 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 197 55 
109 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 198 40 
 113 PAHGVT*SAPDT*RPAPGST*A PmST1 18 199 81 
       
 type-1 core 2 119 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 200 91 
      
type-2 core 2 
(hexa-
saccharide) 
125 PAHGVTSAPDT*RPAPGSTA PmST1 36 201 66 
125 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 40 202 81 
 
126 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 203 84 
 126 PAHGVTSAPDTRPAPGST*A Pd2,6ST 12 204 16 
       type-2 core 2 
(tetra-
saccharide) 
174 PAHGVTSAPDT*RPAPGSTA rat2,3OST 22 205 100 
174 PAHGVTSAPDT*RPAPGSTA PmST3 40 206 69 
        
All Neu5Ac modified glycopeptides were synthesized in 0.5-1.5 mg scale of starting peptide. 
In most cases the glycosylation proceeded to almost full conversion with the depicted 
conditions. Since high purity was desired for microarray spotting, leftover starting material 
and possible oversialylated byproducts were separated. The crude reaction mixture was first 
desalted by solid phase extraction on C18 cartridges and the main product was then isolated 
by semi-preparative HPLC-MS. The scale of the synthesis was small and gravimetric 
determination of the received reaction products was not considered to be reliable. Instead, 
the glycopeptides were dissolved in water and the glycopeptide concentration of an aliquot 
was determined by amino acid analysis (AAA). Briefly, the peptides were hydrolyzed with 6 N 
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HCl in the gas phase at 120°C for 22h. The obtained free amino acids were conjugated at 
the amino group with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC).289 By HPLC 
with fluorescence detection, the signal intensity of each amino acid was compared with a 
likewise labeled norleucine internal standard. Considering the stoichiometric abundance of 
each amino acid, the overall peptide concentration in the glycopeptide solution was then 
deduced. 
 
4.2.6 Tandem MS of sialylated mucin O-glycopeptides - oxonium ion pattern 
analysis 
The analysis of protein glycosylation is a challenging task. One problem is the glycan 
heterogeneity at different or even the same glycosylation sites on a protein. The glycomic 
approach for saccharide identification and carbohydrate linkage elucidation usually involves 
chemical or enzymatic release from a protein, which prohibits information about glycosylation 
site occupation and site-specific glycan structures. Glycan removal itself can be problematic. 
N-glycan removal benefits from the existence of endoglycosydases PNGase F and A which 
enzymatically cleave the N-glycans at the linkage to the protein backbone. PNGases remove 
the glycan along with a change from the connecting asparagine to aspartate, indicating a 
former glycosylation site. In the case of O-glycans, no such endoglycosidases are known, 
except for O-glycanase from Streptococcus pneumonia, cleaving only the unmodified T-
antigen. A stepwise exoglycosidase treatment must be used to digest the O-glycans. 
Chemical methods, such as β-elimination or hydrazinolysis, for the carbohydrate part and 
subsequent reaction of the dehydro-peptide with a Michael-donor can be employed for 
glycosylation site determination.290 All this requires several wet lab manipulations on the 
precious samples. Furthermore, in order to elucidate the carbohydrate structure and linkage 
connectivity of the cleaved glycans, more modifications, such as glycan permethylation 
followed by hydrolysis, chemical reduction of the reducing end and sialic acid esterification 
are required, or the structure must be concluded by the digestion pattern of several 
glycosidases. In contrast to the glycomic approach, in a typical bottom-up 
proteome/glycoproteome analysis the (glyco-) proteins are digested by proteases and 
analyzed by mass spectrometry at the peptide level.291,292 This approach simplifies detection 
of glycosylation sites and the identity of the glycosylated protein can be deduced from the 
obtained glycopeptides. However, analysis on the glycopeptide level still requires 
methodologies for linkage elucidation, determination of anomeric configuration and 
discrimination of isobaric saccharides. A promising method reported lately for the use on 
glycoconjugates, is ion mobility mass spectrometry (IM-MS). Analytes are separated by 
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differences of their rotationally averaged collisional cross-sections (CSS) during MS or after 
MS/MS. It has been reported that by this method it is possible to distinguish isomeric 
oligosaccharides and saccharides fragments from glycopeptides,293,294 different glycosylation 
sites on otherwise identical glycopeptides,295 epimeric methylglycosides296 and may therefore 
be used in carbohydrate sequencing.  
Another way to explore the structure of saccharide epimers and their connectivity in complex 
glycans attached to glycopeptides, is the analysis of the oxonium ion fragmentation patterns 
in tandem MS. MS/MS-fragmentation by collisional induced dissociation (CID) or higher-
energy C-trap dissociation (HCD) allows stepwise detachment of the monosaccharides. HCD 
provides the advantage of simultaneous fragmentation of the peptide backbone and the 
carbohydrates, allowing analysis of glycopeptides in a single MS/MS run. Also high 
resolution MS2 spectra can be recorded.297 Fragmentation of glycans, results predominantly 
in isobaric hexose (Gal, Man, Glc) and isobaric hexosamine (GalNAc, GlcNAc) oxonium ion 
fragments. The relative intensities of the isobaric ion fragments derived from the HexNAc and 
also Neu5Ac units, can be used as reporter ions in CID or HCD fragmentation (table 4.5). 
Comparison of the relative ion intensities gives then glycan structure specific fragment 
patterns. 
Table 4.5: Characteristic HexNAc and Neu5Ac oxonium ions in tandem MS experiments. 
Fragment Ion Monoisotopic Mass  Composition 
126 126.055 
 
[HexNAc - C2H6O3]
+
 
138 135.055 
 
[HexNAc - CH6O3]
+
 
144 144.065 
 
[HexNAc - C2H4O2]
+
 
168 168.066 
 
[HexNAc - 2H2O]
+
 
186 186.076 
 
[HexNAc - H2O]
+
 
204 204.087 
 
HexNAc
+
 
274 274.092 
 
[Neu5Ac - H2O]
+
 
292 292.103 
 
Neu5Ac
+
 
366 366.140 
 
HexHexNAc
+
 
454 454.156 
 
Neu5AcHex
+
 
657 657.235 
 
Neu5AcHexHexNAc
+
 
 
For example, in cooperation with J. Nilsson (University of Gothenburg) it was demonstrated 
that isobaric αGalNAc and βGlcNAc glycan decoration can be distinguished by the HexNAc 
oxonium ion MS fragmentation pattern.298 MS2 fragmentation of a MUC1 peptide with 
αGalNAc (TN-antigen) glycosylation shows equally high intensities of fragments m/z 138, 
144, 186 and 204. However, a βGlcNAc modification at the same glycosylation site shows 
strong intensities for 138 and low intensities for m/z 144 and m/z 186. The two epimeric 
HexNAc+ oxonium ions of GalNAc+ and GlcNAc+, differing only in the configuration at C4, 
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have different fragmentation behaviors. This can be exploited by calculating the 
GlcNAc/GalNAc-ratio by the relative intensity ratio of m/z 138 + m/z 168 (GlcNAc) to 
m/z 126 + m/z 144 (GalNAc). Based on the developed method of calculating the 
GlcNAc/GalNAc-ratio, novel GlcNAcylated peptides, which were further extended on the 
GlcNAc unit while passing through the Golgi complex and loaded onto HLA I molecules, as 
well as normal mucin type GalNAc glycopeptides were recently identified.299 In collaboration 
with J. Nilsson, the type-1 and type-2 core 3 MUC1 glycopeptides 85-87 and 92-94, 
synthesized in this work, were also fragmented by HCD. The oxonium ion profile significantly 
differed between the type-1 and the type-2 LacNAc elongated glycans. In type-1 glycans 
strong intensities of m/z 204 and moderate intensities of m/z 186 were observed, while type-
2 glycans resulted in low intensities of m/z 204 and m/z 186 ions. Like this, the connectivity 
of the common 1,3- and 1,4-linked LacNAc disaccharide units can be deduced on the level of 
intact glycopeptides.  
In analogy to the experiments performed in collaboration with J. Nilsson et al., the sialylated 
glycopeptides, synthesized with PmST1/3 and Pd2,6ST were analyzed, whether the terminal 
sialylation influences oxonium ion profiling of glycan LacNAc elongation. Thus, selected 
sialylated glycopeptides with α2,3- and α2,6-linked Neu5Ac on either type-1 or type-2 
disaccharide units were subjected to HCD-MS2 fragmentation in an Orbitrap Fusion mass 
spectrometer. The normalized collision energy (NCE) was increased in 5% increments and 
relative intensities of relevant oxonium ions were recorded (figure 4.49, for fragment ion 
composition see table 4.5).  
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Figure 4.49: Oxonium Ion profiles and spectra of various mucin core glycopeptides terminated with sialic acid. 
Oxonium ions were generated by HCD-MS2 in 5% increments of NCE from 10-50% on an Orbitrap Fusion mass 
spectrometer. Profiles show relative ion intensities at different NCE levels and spectra show m/z 100-220 at 35% 
NCE. A: HexNAc
+
 fragmentation of type-1 glycans. B: HexNAc
+
 fragmentation of type-1 glycans.    
Type-1 disaccharide glycopeptides (191, 189, 190, 197, figure 4.49, A) showed oxonium ion 
profiles with high intensities of fragment m/z 204 relative to m/z 138 at NCEs of 30-35%. 
Fragment m/z 138 surpassed m/z 204 only in the highest energy settings of 45-50%. The 
MS2 spectra from m/z 100-220 at 35% NCE showed the uniform ion patterns with intensities 
in the order m/z 204>138>186>168 for all type-1 elongated glycopeptides. In contrast, the 
type-2 elongated glycopeptides (187, 194, 203, 206, figure 4.49, B) had similar intensities of 
ions m/z 138 and 204 in the area of 30-35% NCE. All spectra of the type-2 glycans at 35% 
NCE had again uniform oxonium ion levels in the order m/z 138>204>168>186, which was 
distinctly different to the type-1 glycopeptides. At NCE levels of 40%, type-1 glycopeptides 
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had approximately equal levels of m/z 138 and m/z 204, while in type-2 glycopeptides m/z 
204 was significantly lower than m/z 138. This is in accordance with the results reported for 
the not sialylated type-1 and type-2 glycopeptides.298 It was previously proposed that the 
lower levels of m/z 204 in type-2 glycans compared to type-1 could correspond to a higher 
acidity of H-5 in the GlcNA-ring, which is eliminated from the m/z 366 and possibly taken up 
by the galactose, leaving as neutral loss.300,301 Therefore, generation of m/z 204 from type-2 
HexHexNAc+ oxonium ions is to a large extend skipped in favor of direct formation of m/z 
186, which then loses another equivalent of water in order to aromatize to m/z 168 and finally 
gives away CH2O to result in m/z 138 (figure 4.50). 
 
Figure 4.50: Possible fragmentation mechanism of type-1 and type-2 derived oxonium ions.
300,301
  
Compared to the already published results with J. Nilsson et al., the oxonium ion profiles 
slightly differ in normalized collision energy levels. Such instrument specific variations were 
found when different mass spectrometers were used for HCD. In the already reported 
previous cases a Q-Exactive and a LTQ-Orbitrap Velos, both Thermo Fisher Scientific, were 
used. The instrument used for the here described measurements was an Orbitrap Fusion, 
also Thermo Fisher Scientific. However, the overall trends and relative intensities of the 
oxonium ions originating from the LacNAc disaccharides are according to the published 
results,298 although the LacNAc structures are now further terminated by a sialic acid. Also, 
different glycosylation sites (here PDT*R or GST*A), the core structures (core 1, core 2, core 
3) and the number of LacNAc units (core 2  2 eq LacNAc and core 1 or 3  1 equiv 
LacNAc) seemed to have no effects on these fragmentation differences. Some influence of of 
sialic acid attachment on the relative ion intensities of the GlcNAc+ derived oxonium ions 
could be monitored. Apparently, all glycopeptides with α2,6-sialylation showed elevated 
levels of m/z 204 in relation to m/z 138 (e.g. 187 and 203 vs 194 and 206, figure 4.49, B). It 
was assumed that sialylation on either 3- or 6-position of Gal differently influences the 
fragmentation behavior of Neu5AcHexHexNAc+ ion m/z 657, which probably alters 
aforementioned fragmentation mechanism of ion m/z 366 (figure 4.49). Exact elucidation of 
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the fragmentation mechanisms is a matter of further research. However, conjugation with 
α2,3- and α2,6-sialic acid does not prevent discrimination of the type-1 and type-2 
disaccharide structures by altered GlcNAc+ oxonium ion pattern profiling.  
Due to the modification with Neu5Ac, further characteristics of relative oxonium ion 
intensities were monitored in the area of m/z 250-660.  
 
Figure 4.51: Oxonium-ion profiles and spectra of various mucin core glycopeptides terminated with sialic acid. 
Profiles show relative ion intensities at different NCE levels and spectra show m/z 200-660 at 35% NCE. A: 
HexNAc and Neu5Ac fragmentation of α2,6-Neu5Ac glycans. B: HexNAc and Neu5Ac fragmentation of α2,6-
Neu5Ac glycans. 
In general, Neu5Ac was represented strongest by oxonium ion m/z 274 (figure 4.51), which 
corresponds to Neu5Ac+ with loss of one equivalent of water (table 4.5). The Neu5AcHex+ 
ion m/z 454 was seen in small intensities and the oxonium ion m/z 657 of the trisaccharide 
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Neu5AcHexHexNAc+ ion was dominating the profile for low collisional energies (10-20%), but 
decays swiftly with increasing energy levels. α2,6-Neu5Ac modified glycopeptides showed a 
strong plateau of the HexNAc+ ion m/z 204 at NCEs of 20-30% (figure 4.51, A). The Neu5Ac 
derived ion m/z 274 showed weaker intensities relative to m/z 204. Oxonium ion signal m/z 
366 was high in relative intensities at NCEs around 20%. The spectra of all α2,6-Neu5Ac 
terminated glycans at 35% NCE showed similar fragment profiles with signal intensities in the 
order m/z 204 > 274 = 366 > 657. In contrast, α2,3-Neu5Ac glycosylated peptides showed 
Neu5Ac derived ion m/z 274 dominating the profile with highest ion intensities for NCEs 
≥20% and HexNAc+ ion m/z 204 being relatively weaker than m/z 274 (figure 4.51, B). 
Oxonium ion m/z 366 of HexHexNAc+ was also weaker compared to m/z 274. The overall 
ionization pattern for α2,3-Neu5Ac modified glycopeptides at 35% NCE was found to be m/z 
274>204>366>657. In fact, the relative intensity profiles for m/z 204 (HexNAc) and m/z 274 
(Neu5Ac) showed reversed behavior for α2,6- and α2,3-Neu5Ac modified glycopeptides. 
To conclude, in addition to oxonium ion discrimination of β1,3- and β1,4-linked LacNAc 
disaccharide glycans, assignment of the connectivity of the terminal sialylation was possible 
by comparing also the relative Neu5Ac derived oxonium ions. The two different types of 
terminal sialylation had an influence on the fragmentation behavior of HexHexNAc ion m/z 
366. In case of α2,6-Neu5Ac glycopeptides, fragments of β1,3/4-LacNAc appear dominantly, 
namely m/z 204 and m/z 366. In the case of α2,3-Neu5Ac, the sialic acid derived ion m/z 274 
had the strongest intensities. The mechanism by which the two kinds of sialic acids are 
fragmented are apparently different, generating higher levels of Neu5Ac oxonium ions in the 
case of α2,3-Neu5Ac glycosylation. Also, in the case of α2,3-Neu5Ac modification, higher 
intensities of the in general low abundant Neu5AcHex+ m/z 454 were present, especially in 
combination with type-1 modified glycopeptides (peptides 189 and 190, figure 4.51, B). This 
could be related to the lower intensities of HexHexNAc+ ion m/z 366. 
The demonstrated examples carried different mucin type core structures, which all have in 
common that the first monosaccharide attached to the peptide backbone is a αGalNAc. In the 
aforementioned fragmentation experiments of the sialylated glycopeptides, all HexNAc+ 
oxonium ions m/z 204 were related to the GlcNAc in the LacNAc structures, ignoring the 
present GalNAc. By CID-MS3 experiments, J. Nilsson et al. demonstrated that the HexNAc+ 
oxonium ions used for profiling, are merely derived from the terminal βGlcNAc of the 
elongating chains and not from the internal αGalNAc.298 Similar results were observed by 
HCD-MS2 fragmentation. Additionally to these previous experiments, the same conclusion 
could be obtained here, by comparing core 1 (T-antigen) and branched core 2 MS2 
fragmentation profiles (figure 4.52).      
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Figure 4.52: Comparison of GalβGlcNAc- and GalβGalNAc-fragmentation. Profiles show relative ion intensities at 
different NCE levels and spectra show m/z 100-400 at 35% NCE. A: Core 1 (T-antigen) glycopeptide 76. B: Core 
1 (ST-antigen) glycopeptides 176. C: Core 2 glycopeptide 174. D: Core 2 glycopeptide 205 with “T-antigen-like” 
sialylation. E: Core 2 glycopeptide 206 with LacNAc-sialylation. 
Glycopeptide 76 with T-antigen glycosylation showed a typical αGalNAc derived oxonium ion 
profile (figure 4.52, A).298 Fragmentation of the sialyl-T (ST-antigen) glycopeptide 176 (figure 
4.52, B) further produced Neu5Ac derived reporter ions, for relative comparison with the 
HexNAc (=GalNAc) derived oxonium ions. Fragmentation of the ST-antigen of glycopeptide 
176 revealed oxonium ion m/z 274 ([Neu5Ac - H2O]
+) as the most abundant ion in the profile 
over all collision energy settings, completely overwhelming the intensity of the αGalNAc ion 
profile, compared to not sialylated glycopeptide 76. The oxonium ion pattern was clearly 
dominated by the Neu5Ac fragmentation. The Neu5AcHexHexNAc+ ion m/z 657 and 
HexHexNAc+ ion m/z 366 were only weak, compared to m/z 274. On the other hand, if a 
LacNAc is attached to the T-antigen in 6-position of the αGalNAc, like in the core 2 
glycopeptide 205 (figure 4.52, D), the same Neu5Ac ion signal was itself overwhelmed by 
peak m/z 138, which must therefore mainly derive from the branched βGlcNAc. This 
demonstrates that, HexNAc fragmentation was almost independent from the internal 
αGalNAc. Further, the Galβ1,4GlcNAc ion m/z 366 was present in significant amounts for 10-
35% NCE. The unsialylated core 2 glycopeptide equivalent 174 (figure 4.52, C) was virtually 
fragmenting according to 205 (figure 4.52, D), except without the Neu5Ac reporter ions m/z 
274 and m/z 292. In contrast to 205 (figure 4.52, D), sialylated at the inner core 
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Galβ1,3GalNAc, the ion profile of the core 2 modified glycopeptide 206 (figure 4.52, E), 
sialylated at the LacNAc branch instead, showed strong Neu5Ac reporter ions m/z 274 and 
m/z 292. Compared to the ST-antigen peptide 176 (figure 4.52, B), glycopeptide 206 (figure 
4.52, E) additionally showed m/z 366 and m/z 657 ions, which were absent or low in ST-
antigen peptide 176 (figure 4.52, B). The low abundance of these di- and trisaccharides in 
176 (figure 4.52, B) and their high profile in 205 (figure 4.52, D) and 206 (figure 4.52, E), can 
probably be explained by the higher stability of the αGalNAc (α-anomers are 
thermodynamically favored), directly connected to the peptide backbone.  
To conclude, with the two common forms of sialylation (α2,3- and α2,6-Neu5Ac), terminating 
type-1 or type-2 LacNAc disaccharides, four isobaric trisaccharide units can be formed. The 
oxonium ion pattern analysis of the synthesized sialylated O-glycopeptides revealed that it is 
possible to distinguish between these four isobaric structures by the abundance of the 
HexNAc- and Neu5Ac-derived oxonium ions, in ion-trap HCD tandem MS experiments. The 
analysis on the tested MUC1 glycopeptides is independent from glycosylation site or core 
structure. Further does the initial αGalNAc not hamper with the GlcNAc fragmentation of the 
type-1 and -2 disaccharides. The isobaric Neu5AcHexHexNAc trisaccharides are common 
terminating sugar units, not only on mucin type O-glycosylation but also on α-O-
mannosylated proteins, α-O-fucosylated proteins and of course on N-glycans of the complex 
and hybrid type. Lately, complex mucin type glycosylation was discovered on tyrosine 
residues on amyloid precursor proteins,15 and afterwards on several (but still few in total 
numbers) other proteins, e.g. by Simple Cell technology.16,302 This still unexplored type of 
glycosylation was shown to develop complex O-glycan motifs,15 but tyrosine O-glycosylation 
is not amenable for chemical glycan cleavage by β-elimination and relies on glycoproteomic 
elucidation on the glycopeptide level. Discrimination of sialic acid linkage connectivities is 
commonly done by exoglycosidase digest and intermediate MS control. For example, α2,3-
sialidase digest may be applied and if a α2,3-connected sialic acid is present, the 
corresponding mass reduction will be observed. This is laborious and in the case of β1,3/4-
galactosidases, no such enzymatic discrimination is possible and requires even more 
laborious glycan removal, carbohydrate permethylation and hydrolysis steps combined with 
MS control. Comparison of relative oxonium ion intensities might facilitate glycan sequencing 
directly on the glycopeptide level. On the glycopeptide level, the information of glycosylation 
site occupancy and the identity of the correlating glycoprotein are retained. Therefore, 
knowledge about the fragmentation behavior of common glycan structures may help to 
elucidate the glycoproteome. This further underlines the importance of chemical and 
chemoenzymatic glycan synthesis strategies, for generation of defined glycan/glycopeptide 
reference molecules.   
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4.3 Part 3 – Microarray studies with glycopeptide binding proteins 
4.3.1 Introduction on microarray development 
Microarray based technologies were first applied in analysis of DNA-arrays as tools in 
genomic and transcriptomic research.303 With the advent of high throughput molecular 
biology, the increasing interest in expression studies and whole genome sequencing, the 
ability of performing hundreds or thousands of reactions to study binding events in 
miniaturized experiments matched with the biological needs of the time. Oligonucleotide 
synthesis and polymerase chain reaction (PCR) technology enables scientists to build-up 
polynucleotide libraries and microarrays represented a methodology for fast screening of 
many samples in parallel with consumption of only minute amounts. In genetic analysis, 
microarrays are used for sequencing, to detect single nucleotide polymorphisms (SNPs) or 
mutations or for expression analysis.304 In a typical expression analysis, messenger RNA 
(mRNA) strands are isolated and transferred to complementary DNA (cDNA) by the action of 
reverse transcriptase. The amplified product is fluorescently labeled and screened against an 
immobilized library of single stranded DNA. Hybridization reveals the existence and relative 
amount of a transcript, which allows drawing conclusions about the expression level of a 
certain protein. However, mRNA levels, protein expression and protein interactions do not 
always correlate. Protein splicing and post-translational modifications often change the 
protein functionality and dictate behavior in cellular pathways or interaction with binding 
partners, which cannot be explained solely by evaluation of protein expression. After 
sequencing the human genome and that of other organisms, the function and abundance of 
the expression products has attracted more attention. Thus, the development of protein 
microarray platforms for interaction studies was the logical continuation.305 While DNA/RNA 
substrates are uniform, negatively charged and hydrophilic molecules, build from only four 
different nucleotides, proteins on the other hand consist of up to twenty amino acids creating 
macromolecules with varying hydrophilicity/hydrophobicity and differently folded 
conformations, that need to be conserved during microarray experiments. Protein 
microarrays are employed in studies of protein/protein-, antigen/antibody-, 
enzyme/substrate-, protein/DNA- and ligand/receptor-interactions and offer a high throughput 
alternative to commonly used enzyme-linked immunosorbent assays (ELISA) or western 
blots. The great versatility of protein arrays makes them useful as tools in clinical biomarker 
detection, drug discovery or elucidation of proteomic interaction networks.306 Consequently, 
microarray technology was also transferred to carbohydrate analytics shortly after the first 
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protein applications. Like protein microarrays, carbohydrate microarrays benefit even more 
from the multivalent presentation of densely immobilized test molecules, since most 
carbohydrate binding proteins, like lectins or antibodies, are dependent on multivalent 
recognition for strong binding.307 The Consortium for Functional Glycomics (CFG) is an 
international research initiative, providing the research community with a comprehensive 
collection of glycans on a glycoarray platform. The current array version (v5.2) contains 609 
carbohydrate structures. Mentionable in this context, are the efforts of high throughput 
characterization of the receptor specificities of hemagglutinins from pandemic influenza 
viruses, for example from modern H5N1 or the 1918 H1N1 virus heamagglutinins.308,309 Like 
this, mutations in the virus genome can be directly correlated with changes in binding 
preferences, enabling for example avian specific viruses to become infectious for human 
hosts. Carbohydrates can also be arrayed as glycoconjugates. Glycopeptide arrays offer the 
possibility to evaluate carbohydrate-protein binding events with carbohydrates presented on 
a natural scaffold.310 The peptide backbone is sometimes included in part or completely in 
the binding epitope, whose binding is either modulated or prevented by the glycan.311 
 
4.3.2 Immobilization methods for glycopeptide microarrays 
Microarrays have been established on spherical polymer beads, gold surfaces, nitrocellulose 
membranes or coated glass slides, with the latter being the most used surface when applied 
with fluorescence detection. The functional groups of the surface coating determine the kind 
of connection established and must fit the criteria of the probes that are supposed to be 
immobilized. The binding methodology also determines whether a molecule is attached to 
the surface in a random orientation or oriented by site-specific interactions.312,313 Methods for 
random orientation in protein immobilization often involve direct binding to the surface by 
amino acids residues. Lysine residues and the protein N-terminus can be linked to aldehyde, 
epoxy, isothiocyanate or N-hydroxysuccinimide (NHS) ester modified surfaces (figure 4.53, 
A). Cysteine residues can connect via a thioether or disulfide bond (figure 4.53, B). 
Alternatively, cysteines can adhere non-covalently to gold surfaces. The drawback of non-
site-specific attachment is that the active site of proteins might on part be covered and 
activity is lost. Installation of remote reaction sites in the proteins, distant from the active site, 
helps to preserves activity. Proteins can be expressed with affinity tags for non-covalent and 
site-directed adhesion, i.e. hexahistidine (His6-tag) sequences for nitrilotriacetic acid (NTA) 
surfaces or glutathione-S-transferase (GST-tag) for glutathione modified surfaces. Proteins 
can also be expressed as intein-fusion-proteins and then conjugated site-specifically with a 
biotinylated peptide by expressed protein ligation (EPL). Alternatively, bio-orthogonal 
chemical groups may be inserted into the probe, for instance azides, alkines, 
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cyclopentadienes, to feature site specific reactions, such as 1,3-dipolar cycloadditions, 
Staudinger ligations or Diels-Alder reactions (figure 4.53, C). Like this, probes will be linked 
with a uniform orientation. 
 
Figure 4.53: Overview of common covalent non-site-(A and B) and site-specific (C) immobilization strategies for 
microarray application. 
Site-directed and covalent immobilization techniques are often advantageous for protein 
activity.312 Especially the selective, covalent immobilization of unpurified expressed proteins 
directly from cell lysates represents a highly efficient method of protein microarray 
fabrication. The group of H. Waldmann presented the immobilization of oxyamine-modified 
proteins from cell lysates.314 The proteins of interest were overexpressed as fusion proteins 
with intein domains in E.coli. After cell lysis, the lysate was treated with 2-
mercaptoethanesulfonate (MESNA) to generate a C-terminal thioesters on the expressed 
proteins, which was then transferred into the oxyamine by addition of bis(oxyamine)ethane. 
The high reactivity of the C-terminal oxyamine was used to form a stable oxime bond with a 
ketone functionalized surface. In another approach, proteins were expressed with a “CaaX-
box”, a C-terminal tetrapeptide sequence which is recognized by protein 
farnesyltransferases. Farnesylation of the target proteins occurred in vivo when the protein 
expressing E.coli were additionally transfected with a farnesyltransferase encoding vector. 
94 4 RESULTS AND DISCUSSION
 
 
After cell lysis, the lysate was incubated on a thiol-functionalized microarray slide and 
irradiated with UV-light. This initiated a thiol-ene reaction with the olefinic isoprenoid groups 
and selectively attached the lipidated proteins to the surface.315 
Commercial microarray slides are available for all kinds of application featuring various 
chemical immobilization strategies. Nexterion® slide H microarray slides (Schott GmbH, 
Mainz, Germany) are used in this work. The hydrogel coated slides have been used 
successfully for glycan and glycopeptide microarray serum analysis before.59,60,310,316 The 
glass slides are coated with a cross-linked hydrophilic polymer. Hydrophilic spacers are 
crafted onto the polymer network with amine reactive NHS-esters at the ends (figure 4.54).  
 
Figure 4.54: Schematic representation of Nexterion® slide H composition. 
The polymer and the spacer are supposed to generate spatial distance between the 
immobilized probes and the samples screened on the microarray. Sensible protein probes or 
samples may denature due to contact with the surface. Also, the hydrophilic network mimics 
a “in-solution” environment, supposed to support probe accessibility and maintain protein 
specificity and conformation. The absence of any free amine residue, except for the primary 
amine of the spacer amino acid at the N-terminal end of the MUC1 and MUC5B tandem 
repeat peptides, results in N-terminal attachment only and uniform orientation of the 
glycopeptides.  
 
4.3.3 Principle of serum screening by glycopeptide microarrays 
Glycopeptides were delivered to the NHS-functionalized microarray slides by piezo driven 
non-contact spotting. The slides were left for incubation at high humidity (70-100%), to 
complete the covalent coupling between the surface NHS-esters and the N-terminal amine of 
the glycopeptides. Unreacted NHS-ester groups were quenched with ethanolamine. A 
silicone superstructure was used to form different reaction wells. The antiserum was 
incubated on the array surface and the polyclonal antibodies bound with certain affinities to 
 4 RESULTS AND DISCUSSION 95 
 
 
the various glycopeptides. After incubation, the slides were washed with buffer to remove all 
unbound antibodies. Then, a secondary antibody with affinity for the Fc part of the primary 
serum antibodies was incubated on the slide. The secondary antibody was conveniently 
labeled, e.g. with a fluorophore for detection with a fluorescence scanner (figure 4.55). 
 
 
Figure 4.55: Principle of glycopeptide microarray analysis with fluorescence detection. 
 
4.3.4 Evaluation of mucin anti-tumor vaccines by glycopeptide microarray 
analysis of induced antibody responses 
The MUC1 glycoprotein is a promising target for biomarker tumor diagnostics and a lead 
structure for the development of active anti-tumor vaccines.317 The MUC1 is ubiquitously 
found on the surface of epithelial cells and is overexpressed by breast-, colon-, pancreas-, 
prostate- and ovary-carcinomas.22 Other characteristics of the mucins on cancer cells are 
aberrant and truncated glycosylation causing loss of apical cell polarization, alteration of 
adhesion and anti-adhesion events and stimulation of downstream signaling, contributing to 
the establishment of a reactive tumor microenvironment. The aberrant glycosylation on tumor 
cells is partly caused by mutation of the Cosmc chaperone essential for T-synthase activity,40 
downregulation of the core 2 β-1,6-N-acetylglucosaminyltransferase-1 (C2GnT-1) and 
premature sialylation through increased sialyltransferase expression.318,319 As a result, mucin 
type core 1 O-glycosylation, e.g. sialyl-T-, T-antigen and the shorter structures sialyl-TN- and 
TN-antigen, dominate over branched and extended core 2 structures. Thereby, unique 
peptide epitopes, previously shielded by the large core 2 glycans, are exposed to the 
immune system.30,320,321 
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Induction of humoral immune responses directed to these structurally different MUC1 
glycopeptide epitopes, possibly accompanied with cytotoxic effects would be valuable assets 
for tumor immunotherapy. A synthetic vaccine has to meet high expectations. It needs to be 
safe in its application, elicit a strong immune response, overcome immune tolerance and 
create an immunological memory. On the other hand, it needs to be selective in eradication 
of tumor cells without creating autoimmune damages in clinical settings.111,225 Several 
successful methodologies, which reliably increase antigenicity of mucin glycopeptides have 
been reported in the last years. MUC1 glycopeptide B-cell epitopes were conjugated to 
different immune stimulants like carrier proteins, T-cell epitope peptides and/or mitogens to 
form di- and tripartite vaccine candidates, or immune silent polymers for multivalent epitope 
presentation.271,322 Thus, the question of how to break the immune tolerance to self antigens 
with concomitant strong immune stimulation is effectively addressed, but nevertheless, a 
deeper insight into quality and specificity of the raised polyclonal, humoral reactions are to 
date missing. This is due to the limited availability of glycopeptide probes for bioassays, as 
e.g. ELISA, microarray or SPR. As a consequence, only a few noteworthy examples have 
been reported for the extensive screening of tumor associated anti-MUC1 antibodies.60,323,324 
In order to screen the specificity of polyclonal antibodies and humoral immune response 
upon stimulation with synthetic glycopeptide vaccine constructs, a unique MUC1 
glycopeptide library is introduced for MUC1 glycopeptide microarray generation. 
Glycopeptide chip analysis enables screening of immune serum antibody specificity and 
cross-reactivity after induction by different MUC1 vaccine candidates. 
The final MUC1 glycopeptide library features more than 130 synthetic MUC1 tandem repeat 
entries with tumor associated TN- and T-antigen, as well as further elongated and branched, 
core 1, 2 and 3 structures in multivalent presentation mode. The extended carbohydrate core 
structures represent model glycopeptides that expect to resemble the glycosylation status in 
a non-diseased cells surface environment. The use of chemically defined glycopeptide 
structures, was aimed to answer questions about the different characteristics of the MUC1 
tandem repeat glycosylation sites, VT*S*A, PDT*RP and GS*T*A, interactions between this 
domains and the different carbohydrate haptens. Influences on the antibody specificity due to 
the use of different immune stimulants were further visible. 
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4.3.5 Vaccine candidates for induction of immune response and antisera 
generation in mice 
The sera of mice treated with several MUC1 vaccine candidates were screened on the 
MUC1 microarray chip (figure 4.56). The induced sera of the following vaccines were kindly 
provided and pre-evaluated (antibody titer, antibody isotype analysis, T-cell response and 
binding) by group team members and collaborators. 
 
Figure 4.56: Structures of the vaccine candidates used for antiserum generation in mice. 
 Vaccine candidate 1 (CHSynB) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. Ulrika Westerlind. Two-component vaccine of a N-terminal MUC(20mer) B-
cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent αGalNAc (TN-antigen) 
glycosylation and P30 peptide FNNFTVSFWLRVPKVSASHLE as T-cell epitope. 
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Administration of the vaccine to three BALB/c mice was performed in the group of 
Prof. E. Schmitt, Institute of Immunology, Johannes Gutenberg University, Mainz. 
 Vaccine candidate 2 (HC12) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. U. Westerlind. Three-component vaccine of a N-terminal MUC(20mer) B-
cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent αGalNAc (TN-antigen) 
glycosylation, a P30 peptide FNNFTVSFWLRVPKVSASHLE as T-cell epitope and a 
Pam3CSK4 lipopeptide as mitogen. Administration of the vaccine to three CL57B/6 
mice was performed in the group of Prof. M. Lu, Institute of Virology, University 
Hospital of Essen.   
 Vaccine candidate 3 (HC11) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. U. Westerlind. Three-component vaccine of a N-terminal MUC(20mer) B-
cell epitope HGVTSAPDTRPAPGS*TAPPA with single αGalNAc (TN-antigen) 
glycosylation, a P30 peptide FNNFTVSFWLRVPKVSASHLE as T-cell epitope and a 
C-terminal Pam3CSK4 lipopeptide as mitogen. Administration of the vaccine to three 
CL57B/6 mice was performed in the group of Prof. M. Lu, Institute of Virology, 
University Hospital of Essen.   
 Vaccine candidate 4 (NG5)126 
Synthesized by Dr. N. Gaidzik at Johannes Gutenberg University Mainz, work group 
of Prof. Dr. H. Kunz. Two-component vaccine of a N-terminal MUC(22mer) B-cell 
epitope PAHGVTSAPDTRPAPGS*TAPPA with trivalent αGalNAc (STN-antigen) 
glycosylation, conjugated to a tetanus toxoid carrier protein. One serum (mouse 5) 
from administration of the vaccine to one BALB/c mouse, performed in the group of 
Prof. E. Schmitt, Institute of Immunology, Johannes Gutenberg University, Mainz.  
 Vaccine candidate 5 (SH127) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. Ulrika Westerlind. Two-component vaccine of a N-terminal MUC(20mer) B-
cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent αGalNAc (TN-antigen) 
glycosylation, conjugated to a tetanus toxoid carrier protein. Administration of the 
vaccine to three Balb/c mice was performed in the group of Prof. E. Schmitt, Institute 
of Immunology, Johannes Gutenberg University, Mainz. 
 Vaccine candidate 6 (AuNP) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. Ulrika Westerlind. Three-component vaccine of a N-terminal MUC(20mer) 
B-cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent αGalNAc (TN-antigen) 
glycosylation, a P30 peptide FNNFTVSFWLRVPKVSASHLE as T-cell epitope and 
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coupled to gold nanoparticles. Administration of the vaccine to three Balb/c mice was 
performed in the group of Prof. E. Schmitt, Institute of Immunology, Johannes 
Gutenberg University Mainz. 
 Vaccine candidate 7 (HC1) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences -ISAS-, work 
group Dr. Ulrika Westerlind. Three-component vaccine of a N-terminal MUC(20mer) 
B-cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent αGalNAc (TN-antigen) 
glycosylation, a P30 peptide FNNFTVSFWLRVPKVSASHLE as T-cell epitope and 
coupled to gold nanoparticles. Administration of the vaccine to three CL57B/6 mice 
was performed in the group of Prof. M. Lu, Institute of Virology, University Hospital of 
Essen. 
 Vaccine candidate 8 (HC2) 
Synthesized by Dr. H. Cai, Leibniz Institute for Analytical Sciences –ISAS-, work 
group Dr. Ulrika Westerlind. Three-component vaccine of a N-terminal MUC(20mer) 
B-cell epitope HGVTSAPDT*RPAPGAS*T*APPA with trivalent Galβ1,3-GalNAcα (T-
antigen) glycosylation, a P30 peptide, FNNFTVSFWLRVPKVSASHLE as T-cell 
epitope and coupled to gold nanoparticles. Administration of the vaccine to three 
CL57B/6 mice was performed in the group of Prof. M. Lu, Institute of Virology, 
University Hospital of Essen. 
 
 
4.3.6 Utilized microarray platforms for antisera, plant lectin and galectin-3 
screening 
The MUC1 glycopeptide sequence library, synthesized in this work, was appended by MUC1 
glycopeptides previously synthesized by Dr. U. Westerlind325,310 and Dr. H. Cai326. Five 
different MUC1 microarrays were established and utilized for antisera, plant lectin and 
galectin-3 screening (for detailed spotting pattern information on the different microarray 
formats and a summary list of all containing peptides see chapter 6.3.4). Microarray 1 (MA1) 
consists of one of three MUC1 B-cell epitope sequences used for vaccine candidate 
development (glycopeptides 232, 234 and 237). This array format was initially used to 
determine antibody titer values of the induced antisera, in order to estimate the antibody 
concentration before proceeding with further experiments in larger glycopeptide microarray 
formats. The antisera were incubated on the wells in different dilutions series (chapter 4.3.7). 
Microarray format 2 (MA2) contained 85 MUC1 glycopeptides and was used for the 
evaluation of serum antibody specificities of the induced antisera. Microarray format 3 (MA3) 
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contained further 19 MUC1 glycopeptides for giving more specific insights into antibody 
specificity, after screening experiments with MA2 (chapter 4.3.8). Microarray format 4 (MA4) 
contained 55 glycopeptides containing sialylated glycopeptides and the corresponding non-
sialylated precursors, in order to evaluate the influence of complex glycan sialylation on 
antibody binding. MA4 was further used to evaluate the O-glycan specificity of galectin-3 
(chapter 4.3.11.3). Microarray format 5 (MA5) contained 132 MUC1 glycopeptides for 
screening the carbohydrate specificity of several plant lectins (chapter 4.3.11.1). 
 
4.3.7 Antibody titer determination of antisera induced by MUC1 vaccine 
candidates 
Before the sera were administered to the MUC1 microarray chips, adequate concentrations 
for incubations were determined. Therefore, only the antigenic MUC1 sequence of the 
corresponding vaccine was immobilized on the microarray slide in relative small wells (MA1, 
3 x 3 mm, 5 μL incubation volume) and incubated with dilution series of the antisera. Peptide 
spotting concentration and spotting droplet size were equal to the spotting parameters of the 
full library (experimental details, chapter 6.4). Like this, saturation concentrations for binding 
to the B-cell epitope were monitored. Accordingly, further incubations of the complete MUC1 
library were made using antibody concentrations close to the saturation limit, in order to also 
detect weak antibody recognition to bound MUC1 glycopeptides. Well replicates were also 
prepared with lower serum concentrations underneath the saturation level of the antigenic 
MUC1 glycopeptide. In extreme cases, the more dilute antibody sera only show reactivity to 
the antigenic B-cell epitope sequence and all other signals disappeared in the background. 
This may give the impression, that a polyclonal serum is very specific only for the antigen 
sequence. To generate a complete picture of weak and strong binders, several 
concentrations of serum must be tested. Due to differences in induced antibody titers 
between different individuals, the sera from immunized mice must be compared in terms of 
specificity, depending on the measured antibody concentrations. Similar to titer determination 
by enzyme linked immunosorbent assay (ELISA), the antibody binding concentrations 
towards the antigen can be directly evaluated on a microarray slide. In ELISA optical density 
(extinction) of a colorimetric reaction is measured and results are usually plotted in a half-
logarithmic correlation. Here, fluorescence of a fluorophore tagged secondary antibody is 
detected and directly plotted against the concentration (figure 4.57).  
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Figure 4.57: Dilution series of all tested vaccine candidates on MA1. 
The microarray results were in accordance with ELISA tests performed by Dr. Hui Cai. The 
sera of mouse 1 and 3 induced by the tetanus toxoid conjugated with vaccine 5 show by far 
the highest antibody titers, confirming the strong immune response elicited by tetanus toxoid 
conjugated vaccines.128 Also, mouse 1 of vaccine candidate 1 gave a strong immune 
response. Based upon the dilution series, concentrations for incubations were estimated and 
compared among the vaccines.  
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4.3.8 Elucidation of antibody specificity from vaccination experiments using 
the MUC1 glycopeptide microarray 
4.3.8.1 Vaccine candidate 1 (3TN-MUC1-P30, CHSynB) 
 
The Two component vaccine candidate 1 consisted of the B-cell epitope 
(HGVTSAPDT*RPAPGS*T*APPA) with TN-antigen glycosylation in the PDT*R domain and in 
the GS*T*A domain, both on serine and threonine. The PDT*R domain is known to be 
immune relevant and glycosylation on this domain enhances cancer derived monoclonal 
antibody recognition.327 The GSTA domain has been identified as an immunogenic domain 
due to findings of monoclonal antibodies and auto-antibodies from cancer patients. The 
second part of the vaccine consisted of the peptide T-cell epitope P30, a peptide sequence 
FNNFTVSFWLRVPKVSASHLE derived from the immunogenic tetanus toxoid protein. The 
vaccine was immunized in mice without extra addition of an adjuvant. The vaccine generated 
high antibody titers directed to the B-cell epitope in all sera, mouse 1 had a very strong 
immune response. IgG1 was the dominating antibody isotype. Breast cancer tumor cells from 
the T47D and MCF-7 cell lines were recognized in all sera. In addition to the evaluation of 
the vaccine induced antibody response, antibody glycopeptide binding epitopes were 
evaluated by microarray analysis (MA2: figure 4.58, MA3: figure 4.59). 
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Figure 4.58: Binding of vaccine candidate 1 (CHSynB) antisera (mouse 1-3) on microarray MA2. A: Full peptide 
list. B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site.  
104 4 RESULTS AND DISCUSSION
 
 
 
Figure 4.59: Binding of vaccine candidate 1 (CHSynB) antisera (mouse 1-3) on microarray MA3. 
The vaccine candidate 1 generated antisera from all three mice, showed low antibody 
specificity for the unglycosylated peptide sequences 207 and 241, demonstrating that 
glycosylation was mandatory for strong antibody binding. 
 
Mouse 1 serum (dilution: 1/500): 
The mouse 1 serum antibodies had a mixed specificity for both glycosylation sites of the 
antigen structure, PDT*R and GS*T*A. Apart from strong binding to the B-cell epitope 
sequence 232, monoglycosylated peptides with TN-antigen glycosylation in PDT*R (70, 72, 
74, 75, figure 4.58) were well recognized. Deviations to different extended glycans other than 
TN-antigen in PDT*R on the MUC1(19mer) resulted in no significant binding. Sole 
glycosylation with TN-antigen in the GSTA region on the serine (237, figure 4.59) or threonine 
(236, figure 4.59) composed only weak epitopes for the antibodies (figure 4.59). However, 
glycopeptide 233 with clustered TN-antigen glycosylation in the GS*T*A site was highly 
recognized by the antibodies, proposing that the GSTA domain must be glycosylated at both 
amino acids. On the other hand, clustered glycosylation in the GSTA domain with T–antigen 
alone (235) or with additional glycosylation in PDT*R (234) resulted in very weak antibody 
affinity. Thus, glycosylation with TN-antigen exclusively in PDT*R as well as in GS*T*A 
contribute or add up to overall antibody binding (figure 4.59). Larger type-2 core 3, core 1 
and core 2 glycans 131-133 in PDT*R reduce binding, but are tolerated to a certain extent, 
as long as GS*T*A carries clustered glycosylation with TN-antigen. The equivalent 
MUC1(19mer) sequences without glycosylation in GS*T*A (93, 108 and 125, figure 4.58) 
were not recognized. Peptides glycosylated with TN-antigen in the VT*SA region alone, were 
not recognized, since this domain is not part of the binding epitope. The C-terminal PPA 
sequence, which is not present in the MUC1(19mer) (ending with GSTA) and some of the 
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MUC1(20mer) (ending with GSTAP) sequences, has only a minor effect on the overall 
antibody recognition, e.g. observed by comparing of the sequences 239/73 and 204/69  
(figure 4.59). Among the rest of the glycopeptides, e.g. for the block of MUC1(19mer) 75-
113, a low basal antibody recognition was observed, that obliterates towards the larger 
hexasaccharide decorated sequences 117-130, except for the core 2 hexasaccharides in 
GST*A (119, 126), which still showed weak antibody reactivity.  
Mouse 2 and mouse 3 sera (dilution: 1/10): 
Mouse 2 and 3 sera showed very similar binding specificity with preference for peptides 
glycosylated with TN-antigen in PDT*R and GS*T*A. Mouse 2 serum antibodies had stronger 
reactivity towards clustered TN-antigen GS*T*A epitopes, while mouse 3 serum antibodies 
preferred the glycosylated PDT*R domain. In accordance with mouse 1 serum, sequence 
233 with double TN-antigen glycosylation in GSTA was well recognized by both sera and 
antibody reactivity towards single glycosylation on serine or threonine (236, 237) was weak. 
The equivalent sequence 235 with clustered T-antigen glycosylation was not detected (figure 
4.58). Like the mouse 1 serum antibodies, clustered glycosylation with TN-antigen on serine 
and threonine in GS*T*A was a prerequisite for contribution to antibody binding. In contrast 
to mouse 1 antibodies, glycosylation in PDTR was allowed to deviate to glycan structures 
other than TN-antigen and strong antibody reactivity was observed on virtually all 
MUC1(19mer) peptides with glycosylation ranging from monosaccharide to core 1 
tetrasaccharide structures in PDTR (e.g. 69 with TN-antigen and 108 with type-2 core 1, 
figure 4.58). The GS*T*A epitope on the other hand, only contributes when carrying 
exclusively the TN-antigen on both serine and threonine. Sequences with PDT*R and single 
threonine glycosylation in the GS*T*A site are recognized as well as PDT*R glycosylation 
alone. Single glycosylation in the VT*SA site was not recognized by the antibodies and 
glycosylation in the VT*SA combined with glycosylation in the PDT*R even reduced the 
antibody reactivity towards the PDT*R binding epitope. Glycopeptide sequences with glycans 
up to the size of linear tetrasaccharides in the PDTR site, were well recognized, binding to 
branched core 2 hexasaccharides were strongly reduced. In particular, serum of mouse 3 
showed significant stronger fluorescence intensities for the linear type-2 core 1 
tetrasaccharide glycopeptide 108 than for the branched type-2 core 2 tetrasaccharide 
glycopeptide 174 (figure 4.59). The branched type-2 core 2 hexasaccharide peptide 125, 
sharing the same linear tetrasaccharide substructure with peptide 108, showed the same 
antibody reactivity as the branched tetrasaccharide glycopeptide 205. This demonstrates that 
the branching of the inner αGalNAc influences the antibody recognition and antibodies prefer 
core 1 over core 2 glycosylation, rather than being negatively influenced in antibody 
recognition by the glycan size in terms of numbers of saccharides. Also glycopeptides 131 
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(tetra core 1) and 133 (hexa core 2) show this trend, albeit less pronounced, since antibodies 
in the immune sera compensate for this effect by recognition of the additional GS*T*A 
binding epitope glycosylated with clustered TN-antigen (figure 4.59).  
For all trivalent MUC1(19mer) glycopeptides (VT*SA+PDT*R+GST*A) with linear core 3 and 
core1 glycosylation (74, 81, 91, 98, 106, 113, figure 4.58, B) no obvious shielding effect by 
the high glycan density influenced antibody recognition to the PTDR epitope. These peptides 
were all recognized by the antibody sera, as well as the equivalent divalent peptides with 
glycosylation in VT*SA+PDT*R or PDT*R+GST*A. The reactivity of the divalent peptides, 
glycosylated in VT*SA and PDT*R, was weaker than divalent peptides with PDT*R+GST*A 
glycosylation. Divalent glycopeptides with PDT*R+GST*A-glycosylation were recognized as 
effective as monovalent peptides with glycosylated PDT*R region alone. Hence, even for 
trivalent glycopeptides with three core 1 tetrasaccharides, no significant reduction in antibody 
binding was observed due to multivalent glycosylation. However, trivalent core 2 
hexasaccharide glycopeptides (t1c2 and t2c2, VT*SA+PDT*R+GST*A, figure 4.58, B) were 
not recognized any more by the antibodies, probably because of steric reasons and the 
above mentioned unfavorable core 2 recognition. These peptides may therefore be regarded 
as mucin tandem repeats completely shielded by O-glycans, which are found to a large 
extend on healthy epithelial cells. 
 
4.3.8.2 Vaccine candidate 2 (3TN-MUC1-P30-Pam3CSK4, HC12) 
 
The three component vaccine candidate 2 consisted of the same B-cell epitope as vaccine 
candidate 1, (HGVTSAPDT*RPAPGS*T*APPA) with TN-antigen glycosylation in the PDT*R 
domain and in the GS*T*A domain, both on serine and threonine. The B-cell epitope was 
additionally connected to the P30 T-cell epitope and the toll-like receptor-2 ligand 
Pam3CysK4, which functions as a build-in immunoadjuvant. The vaccine was immunized in 
mice without extra addition of an external adjuvant. The vaccine generated high antibody 
titers directed to the B-cell epitope in all sera. A mixed IgG response was generated, with 
IgG1 as the dominating antibody isotype and some IgG2b and IgG3 antibodies. Breast cancer 
 4 RESULTS AND DISCUSSION 107 
 
 
tumor cells from the T47D and MCF-7 cell lines were recognized in all sera, pancreas capan-
1 and -2 tumor cells were here not recognized. Microarray analysis for evaluation of antibody 
glycopeptide binding epitopes is shown below (MA2: figure 4.60, MA3: figure 4.61). 
 
Figure 4.60: Binding of vaccine candidate 2 (HC12) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site.  
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Figure 4.61: Binding of vaccine candidate 2 (HC12) antisera (mouse 1-3) on microarray MA3. 
All sera induced by vaccine candidate 2 showed no recognition of unglycosylated MUC1 
sequences 207 and 241 (figure 4.60, figure 4.61). Glycosylation was mandatory. Mouse 2 
and 3 had in principle similar affinities like mouse 2 and 3 of vaccine candidate 1. 
Mouse 1 serum (dilution 1/20): 
Serum antibodies of mouse 1 were very specific for glycopeptides with single TN-antigen 
glycosylation on threonine in GST*A. The glycopeptide 19mer 70 (ending with GST*A, figure 
4.60) and the 20mer 237 with serine glycosylation in GS*TAPPA were not bound by the 
antibodies. The threonine glycosylated C-terminal T*APPA (e.g. in 236) was the major 
antibody binding epitope (figure 4.61). 
Mouse 2 serum (dilution 1/20): 
The antibodies were almost only dependent on the glycosylated PDT*R domain. Single or 
double glycosylation in the GSTA region, no matter of the glycan structure, only provided 
weak interaction with the antibodies. In accordance with the mouse 2 and 3 sera of vaccine 
candidate 1, antibodies were accepting various linear glycans in the PDT*R epitope, e.g. TN-
antigen, T-antigen, extended core 3 and core 1 (figure 4.60, A). Branched core 2 glycans in 
PDT*R provided again lower affinity to the antibodies than the core 1 glycans (figure 4.61). In 
multivalent glycopeptides, glycosylation in VT*SA had a negative effect on binding, while 
single glycosylation on threonine in GST*A was tolerated (figure 4.60, B). Strong reduction of 
binding was observed for glycopeptides with multivalent core 2 hexasaccharide glycosylation 
(figure 4.60, B). 
Mouse 3 serum (dilution 1/20): 
Mouse 3 serum antibodies had a mixed PDT*R and GS*T*A dependency. Glycosylation in 
the GS*T*A region must be clustered TN-antigen glycosylation (compare 233 and 235, figure 
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4.61). Glycosylation in PDT*R had strongest effects when TN-antigen glycosylation was 
present, albeit other glycans in this domain were accepted with lower affinity (131, 132, 132, 
232, figure 4.61). Core 1 over core 2 specificity in PDT*R was present, but at a weak level 
due to overall weaker affinity to PDT*R, compared to GS*T*A. 
 
4.3.8.3 Vaccine candidate 3 (TN-MUC1-P30-Pam3CSK4, HC11) 
 
The three component vaccine candidate 3 consisted of the same B-cell epitope peptide 
sequence as vaccine candidate 1 and 2, but with TN-antigen glycosylation only in the GS*TA 
domain (HGVTSAPDTRPAPGS*TAPPA). In accordance to vaccine candidate 2, the B-cell 
epitope was connected to the P30 T-cell epitope and the toll-like receptor-2 ligand 
Pam3CysK4. The vaccine candidate was administered to the mice without addition of an 
external adjuvant. The vaccine generated high antibody titers directed to the B-cell epitope in 
all sera. A mixed IgG response was generated, consisting of IgG1, IgG2b and IgG3 antibodies, 
mouse serum 1 additionally had high levels of IgM antibodies. Strong recognition of breast 
cancer MCF-7 tumor cells and pancreas capan-1 and -2 tumor cells was mainly observed in 
the mouse 2 serum. The mouse 2 serum antibodies further recognized tumor cells from 
patient breast cancer tumor cells, evaluated on a tumor tissue array including 360 patient 
samples. Glycopeptide microarray analysis for evaluation of the induced antibody 
glycopeptide binding epitopes is shown below (MA2: figure 4.62, MA3: figure 4.63). 
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Figure 4.62: Binding of vaccine candidate 3 (HC12) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site. 
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Figure 4.63: Binding of vaccine candidate 3 (HC12) antisera (mouse 1-3) on microarray MA3. 
The B-cell epitope sequence HGVTSAPDTRPAPGS*TAPPA with TN-antigen glycosylation 
was not included in the MUC1 chip MA2 (figure 4.62). Peptide 
HGVTSAPDTRPAPGS*TAPPA 237 was included in MA3 (figure 4.63).  
Mouse 1 serum (dilution 1/10): 
The serum antibodies recognized unglycosylated 207 and 241 (figure 4.62, figure 4.63). 
Peptides 207 (unglycosylated), 208 (VT*SA), 209 (PDT*R) and 210 (GST*A) imply that 
VTSA is an epitope, but must not be glycosylated for binding (figure 4.62). Short 
glycopeptide 221 without VTSA domain is also not bound by the antibodies. Further, the C-
terminal STAPPA sequence seemed to be the second peptide binding epitope, as seen 
when 241 is compared to the 19mer sequences (figure 4.58). TN-antigen glycosylation on 
serine (237, figure 4.63), as in the B-cell epitope, slightly enhances antibody affinity. 
Additional glycosylation in PDT*R was tolerated for small TN-antigen glycosylation, while 
larger glycans in that domain prevent antibody binding (131, 132, 133, 232, figure 4.62). 
Also, peptides glycosylated on threonine in GST*A with STN-antigen, T-antigen and extended 
core 3, core 1 and core 2 were recognized. The monoglycosylated sequences 119 and 126, 
with branched core 2 hexasaccharide glycosylation, also showed strong antibody 
recognition, even stronger than sequences 102 and 109 with the smaller, unbranched core 1 
tetrasaccharide glycosylation (figure 4.62, A+B).  
Mouse 2 serum (dilution: 1/80): 
Unglycosylated MUC1 sequences 207 and 241 were recognized by the mouse 2 serum 
antibodies, proposing that the binding epitope is an unglycosylated peptide segment (figure 
4.62, figure 4.63). Further, all glycopeptides with glycosylation in the VT*SA and/or GST*A 
regions were all accepted by the antibodies. Recognition was lost when the PDT*R domain 
was glycosylated, demonstrating that the non-glycosylated PDTR domain was highly 
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important for antibody recognition. In GSTA, glycosylation in serine as well as threonine or 
both was tolerated, in VTSA however, only glycosylation in threonine was accepted, while 
glycosylation on serine obliterates all binding (222/223 and 227/228, figure 4.62). The 
minimum peptide binding epitope might therefore be unglycosylated SAPDTR.  
Mouse 3 serum (dilution: 1/20): 
The unglycosylated peptides 207 and 241 were not recognized (figure 4.62, figure 4.63). This 
antibody serum exclusively recognizes peptides with TN-antigen glycosylation in the GSTA 
region with remarkable specificity. No other glycans in this domain were accepted. The 
specificity was directed on the serine glycosylated with TN-antigen of the B-cell epitope 
sequence 237. The equivalent sequence with TN-antigen glycosylation on threonine, 
sequence 236 (figure 4.63) was not a binding epitope. Interestingly, TN-antigen glycosylation 
on threonine was accepted in the MUC(19mer) peptides with C-terminal GST*A (70, 72, 73, 
74, figure 4.62) and the MUC1(20mer) with C-terminal GST*AP (e.g. 215, 220, figure 4.62) in 
contrast to the GST*APPA terminated peptides. 
 
4.3.8.4 Vaccine candidate 4 (TN-MUC1-TT, NG5) 
 
The vaccine candidate 4 consisted of the same B-cell epitope as vaccine candidate 3, but 
with STN-antigen glycosylation instead of TN-antigen in the GS*TA domain 
(HGVTSAPDTRPAPGS*TAPPA). The B-cell epitope was here conjugated to a tetanus toxoid 
immune carrier protein. The vaccine candidate was administered to mice with addition of 
Freund’s adjuvant. The vaccine generated very high antibody titers directed to the B-cell 
epitope in all sera. IgG1 was the dominating antibody isotype. Breast cancer MCF-7 cells 
were recognized by all sera. The mouse 5 serum antibodies were further evaluated for 
recognition of tumor cells from breast cancer patients, the antibody staining was gradually 
increased by evaluation of stage 1 to stage 3 cancer patient tissues. These polyclonal 
antibodies were therefore considered interesting for glycopeptide microarray analysis 
(MA2+MA3: figure 4.64).  
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Figure 4.64: Binding of vaccine candidate 4 (NG5) antiserum on microarrays (dilution 1:100) MA2 and MA3. A: 
MA2: full peptide list. B: MA2: MUC(19mer) sequences, plotted as cumulative binding depending on the 
glycosylation site. C: MA3: full peptide list. 
The B-cell epitope sequence HGVTSAPDTRPAPGS*TAPPA with STN-glycosylation was not 
included in either of the two MUC1 chips. However, peptide sequence 
HGVTSAPDTRPAPGS*TAP 210 (figure 4.63, C), shorter by two N-terminal amino acids, was 
strongly recognized.  
The mouse 5 (NG5) antibody serum showed very broad glycopeptide recognition and almost 
all sequences were recognized by the antibodies including the unglycosylated peptides 207 
and 241 (figure 4.64, A+C). No distinct preferences were present, except for certain  
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peptides glycosylated in the immunodominant PDTR region. The only peptide not recognized 
was 213 (figure 4.64, A), consisting of a peptide lacking the PDTR domain. Binding of core 2 
hexasaccharide glycopeptides was less strong and vanishes completely for trivalent 
glycopeptides, which probably completely sterically hinder antibody recognition to peptide 
backbone epitopes. 
 
4.3.8.5 Vaccine candidate 5 (3TN-MUC1-TT, SH127)  
 
The vaccine candidate 5 consisted of the same B-cell epitope as vaccine candidate 1 and 2, 
(HGVTSAPDT*RPAPGS*T*APPA) with TN-antigen glycosylation in the PDT*R domain and in 
the GS*T*A domain, both on serine and threonine. The B-cell epitope was here conjugated 
to the tetanus toxoid immune carrier protein. The vaccine candidate was administered to 
mice with addition of Freund’s adjuvant. The vaccine candidate generated very high antibody 
titers directed to the B-cell epitope in all sera. IgG1 was the dominating antibody isotype. 
Breast cancer MCF-7 and T47D cells were recognized in all sera. Microarray analysis for 
evaluation of the induced antibody glycopeptide binding epitopes is shown below (MA2: 
figure 4.65, MA3: figure 4.66).  
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Figure 4.65: Binding of vaccine candidate 5 (SH127) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site. 
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Figure 4.66: Binding of vaccine candidate 5 (HC12) antisera (mouse 1-3) on microarray MA3. 
Mouse 1 serum (dilution: 1/4000), mouse 2 serum (dilution: 1/400) and Mouse 3 serum 
(dilution: 1/2000): 
The tetanus toxoid conjugate of B-cell epitope 232 induced three mouse antisera with very 
similar binding patterns. The B-cell epitope sequence 232 was detected strongest by the 
antibodies, but all other entries were also detected to a good extent. Peptides with 
glycosylation in PDT*R were slightly preferred by the antibodies of mouse serum 3 (figure 
4.64). All sera have slight preference for sequences with clustered TN-antigen glycosylation 
in GS*T*A (figure 4.65, B) but no further distinct preferences, neither for domains nor for 
specific glycan decoration existed. Unglycosylated peptides 207 and 241 were detected as 
well as most of the others. Only the short peptide 213, which completely lacks the 
immunodominant PDTR domain was not bound by any of the three sera. A shielding effect of 
the large and branched core 2 hexasaccharide structures existed, but was weaker than in the 
previous examples. Only glycopeptides with hexasaccharide decoration on all three 
glycosylation sites are effectively shielded from antibody recognition (figure 4.65, B). The 
well replicates using higher dilutions of each serum, showed the same overall patterns. 
Saturation effects can therefore be precluded. Vaccine candidate 5 shares the same B-cell 
epitope as the above described vaccine candidate 1 and 2, which shows that the choice of 
immune stimulant has a strong influence on the induced antibody specificity. 
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4.3.8.6 Vaccine candidate 6 (3TN-MUC1-P30-AuNP, AuNP) 
 
The three component vaccine candidate 6 consisted of the same B-cell epitope as vaccine 
candidate 1, 2 and 5, (HGVTSAPDT*RPAPGS*T*APPA) with TN-antigen glycosylation in the 
PDT*R domain and in the GS*T*A domain, both on serine and threonine. The B-cell epitope 
was additionally connected to the P30 T-cell epitope and gold nanoparticles (AuNPs) as 
carriers. The AuNPs were considered to contribute with multivalent presentation of the 
antigen structure, resulting in increased uptake by antigen presenting cells. The vaccine was 
administered to mice with addition of Freund’s adjuvant. High antibody titers directed to the 
B-cell epitope were generated in all sera, as depicted by ELISA. A mixed IgG response was 
present, consisting of IgG1, IgG2a and IgG2b isotype antibodies. Breast cancer tumor cells 
from MCF-7 cell lines were stained by the mouse 2 and 3 antisera in FACS, but not by the 
very specific mouse 1 serum. Microarray analysis for evaluation of antibody glycopeptide 
binding epitopes is shown below (MA2: figure 4.67, MA3: figure 4.68). 
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Figure 4.67: Binding of vaccine candidate 6 (AuNP) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site.   
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Figure 4.68: Binding of vaccine candidate 6 (AuNP) antisera (mouse 1-3) on microarray MA3. 
Mouse 1 serum (dilution: 1/5): 
Serum from mouse 1 had no preferences for unglycosylated peptides 207 and 241 (figure 
4.67, figure 4.68). The serum antibodies showed a very strong reactivity to the glycopeptide 
B-cell epitope sequence 232 (figure 4.68). As shown by peptide 233, glycosylation in both 
PDT*R and GS*T*A contribute to recognition by the antibodies. Peptides 235, 236 and 237 
demonstrated that the clustered TN-antigen glycosylation must be present in the GS*T*A 
binding epitope (figure 4.68). Interestingly, single glycosylation with TN-antigen in PDT*R 
resulted in rather weak antibody binding for the MUC1 20mers (240, figure 4.67) as well as 
for the MUC1 19mers (69, figure 4.68). A stronger antibody affinity was observed for the T-
antigen and the tetrasaccharide core 1 glycans, monoglycosylated in PDT*R. Again, 
antibodies universally accept larger glycans in the PDT*R binding epitope (131-133, figure 
4.68). An antibody preference for monoglycosylated core 1 over core 2 structures in the 
PDT*R epitope was present (76, 108, 174, figure 4.68).  
Mouse 2 serum (dilution: 1/20): 
The mouse 2 serum antibodies showed reactivity against the unglycosylated MUC1 
sequences 207 and 241 (figure 4.67, figure 4.68). A general binding to most of the 
glycopeptides on the chip was observed, with a preference for entries glycosylated in PDT*R. 
Only the short glycopeptide 213 (figure 4.67), devoid of a PDT*R domain, showed no signal. 
Still, a preference for core 1 over core 2 glycans was present (76, 108, 174 and 131, 132, 
133, figure 4.68) and a signal cut off for multivalent glycopeptides with large hexasaccharide 
glycans was observed.  
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Mouse 3 (dilution 1/80) 
Mouse 3 serum antibodies showed no recognition of unglycosylated 207 and 241 (figure 
4.67, figure 4.68). Antibodies mainly reacted on glycosylation in PDT*R, as observed also in 
other sera, with tolerance for various glycan structures. Glycosylation in the GSTA region 
was only found to be a minor binding epitope and was weakly recognized only when doubly 
glycosylated on the serine and threonine. TN-antigen glycosylation in PDT*R resulted in the 
strongest antibody binding. Unexpectedly, serum antibodies had a relatively strong binding to 
mono- and divalent glycosylated type-1 core 2 hexasaccharide modified sequences 118 and 
122 (figure 4.67). The antibodies showed only weak binding to the corresponding type-2 
glycopeptides 125 and 129 as well as the linear, unbranched type-1 tetrasaccharide 
structures 101. The preference of core 1 over core 2 glycans was here not present, as seen 
with glycopeptides 108, 174 and 125 (figure 4.68).  
 
4.3.8.7 Vaccine candidate 7 (3TN-MUC1-P30-AuNP, HC1) 
 
The vaccine candidate 7 is identical to vaccine 6 with the difference that the vaccine 
candidate was administered to the mice were without extra addition of an external adjuvant 
(Freund´s adjuvant in case of vaccine candidate 6). The adjuvant liposome formation was 
believed to disturb the multivalent AuNP antigen presentation, with the risk of encapsulation 
of the nanoparticles. The vaccine generated high antibody titers directed to the B-cell epitope 
in all sera. IgG1 was the dominating antibody isotype. Breast cancer T47D and MCF-7 cells 
and pancreas capan-1 and -2 tumor cells were recognized in all sera. The mouse 2 serum 
antibodies were selected and stained tumor cells from patient tissues, evaluated on a tumor 
tissue array including 360 patient samples. Glycopeptide microarray analysis for evaluation 
of antibody glycopeptide binding epitopes is shown below (MA2: figure 4.69, MA3: figure 
4.70). 
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Figure 4.69: Binding of vaccine candidate 7 (HC1) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site.  
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Figure 4.70: Binding of vaccine candidate 7 (HC1) antisera (mouse 1-3) on microarray MA3. 
Mouse 1 serum (dilution: 1/80), mouse 2 serum (dilution: 1/80) and mouse 3 serum (dilution: 
1/80): 
Unglycosylated peptides 207 and 241 were only weakly recognized by the antibody sera 
(figure 4.69, figure 4.70). The overall patterns for all three sera were similar and more 
homogenous compared to the aforementioned gold nanoparticle vaccine candidate 6 (AuNP) 
induced antisera. All sera from this vaccine candidate showed the same overall dependent 
binding on glycosylation in PDT*R. Dependency on glycosylation in GS*T*A for antibody 
recognition, was present in the mouse 1 serum, preferably with clustered TN-antigen 
presentation. Mouse 2 and 3 serum antibodies had weak (mouse 2) or no interactions 
(mouse 3) with the glycosylated GS*T*A domains (233, 236 and 237, figure 4.69, A and 
green bars in B, figure 4.69). In all three sera, weaker antibody affinity was observed for, the 
PDT*R core 2 glycopeptide peptide structures. As with core 2 tetrasaccharide 174 and the 
core 2 hexasaccharide 125, weaker antibody affinity was observed to branched core 2 
structures than to the linear core 1 structures, such as tetrasaccharide 108 (figure 4.70). 
According to the observations in the previous examples, preferences for core 1 over core 2 
glycosylation in PDT*R were present with the serum antibodies having high affinity to this 
glycosylated domain (76, 108, 174, figure 4.70). Shielding of the peptide backbone with core 
2 hexasaccharide triglycosylation was observed (figure 4.69, B), similar to the previous 
examples. 
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4.3.8.8 Vaccine candidate 8 (3T-MUC1-P30-AuNP, HC2) 
 
The vaccine candidate 8 is identical to vaccine 7 with the difference that the B-cell epitope 
presents the T-antigen structure instead of TN-antigen on the peptide tandem repeat. The 
vaccine candidate was administered to the mice without extra addition of an external 
adjuvant. The vaccine generated high antibody titers directed to the B-cell epitope in all sera. 
IgG1 was the dominating antibody isotype. Breast cancer T47D and MCF-7 cells and 
pancreas capan-1 and -2 tumor cells were recognized with all sera. Glycopeptide microarray 
analysis for evaluation of antibody glycopeptide binding epitopes is shown below (MA2: 
figure 4.71, MA3: figure 4.72). 
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Figure 4.71: Binding of vaccine candidate 8 (HC2) antisera (mouse 1-3) to microarray MA2. A: Full peptide list. 
B: MUC(19mer) sequences, plotted as cumulative binding depending on the glycosylation site.  
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Figure 4.72: Binding of vaccine candidate 8 (HC2) antisera (mouse 1-3) on microarray MA3. 
Mouse 1 serum (dilution: 1/20), mouse 2 serum (dilution: 1/20) and mouse 3 serum (dilution: 
1/20): 
The unglycosylated peptides 207 and 241 were recognized with weak affinity by the 
antibodies (figure 4.71, figure 4.72). Like vaccine candidate 7, the overall recognition pattern 
was rather homogenous for all three sera. The B-cell epitope sequence 234 was strongly 
recognized by the serum antibodies, but in contrast to the above described antibodies of 
vaccine candidate 7 (HC1), induced with the triple TN-antigen glycosylated analogues, 
several other MUC1 sequences had similar affinity like the B-cell epitope towards the 
antibodies. Glycosylation in GSTA with TN-antigen on the serine or threonine or (e.g. 225, 
226, figure 4.71; 233, 235, 236, 237, figure 4.72) double glycosylation with T-antigen in 
GS*T*A (235, figure 4.72) or any other glycan on threonine in this region (figure 4.71, green 
bars in B), resulted in very weak antibody binding. Only the mouse 2 serum showed some 
reactivity against clustered glycosylation with T-antigen in the GS*T*A domain. However, if 
additionally glycosylation in PDT*R was present or if PDT*R was the only glycosylated site, 
than strong binding was observed, demonstrating that antibody reactivity was directed mainly 
to the PDT*R epitope. A broad antibody recognition against entries with glycosylation in the 
PDT*R domain was observed (figure 4.71).  
Further, the change from TN- to T-antigen glycosylation of the B-cell epitope (vaccine 
candidate 7 compared to vaccine candidate 8), seemed to result in slightly higher antibody 
acceptance for larger glycans on the peptide backbone. The antibody cut-off for the core 2 
hexasaccharide peptides was not as pronounced (figure 4.71, B) as in vaccine candidate 7 
or the two-and three component vaccine candidates 1 and 2, sharing the same TN-antigen 
glycosylated B-cell epitope. Larger glycans in glycopeptide based cancer vaccines may 
therefore lead to a general higher tolerance for different glycan structures on the mucin 
peptide tandem repeats. Such vaccine constructs may therefore generate antibodies with 
lower specificity for small tumor-associated glycans.  
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Core 1 over core 2 glycan preference still existed, but the difference between glycopeptides 
108, 174 and 241 was not as pronounced as in the other vaccine candidate examples with 
TN-glycosylation (figure 4.72). 
 
4.3.9 Elucidation of antibody binding specificity towards sialylated MUC1 
glycopeptides on a microarray  
Sialylation at the terminal, non-reducing end is common for naturally occurring N- and O-
glycans. Sialic acids are hydrophilic, bulky and negatively charged monosaccharides, which 
commonly serve as recognition domains, but may at the same time shield other carbohydrate 
epitopes from recognition. These events usually rely on interactions of carbohydrate binding 
proteins such as bacterial and viral lectins, selectins or siglecs with sialic acid containing 
glycoproteins or glycolipids.328 Antibodies may further be directed to unique sialylated 
carbohydrate epitopes. Here, antibodies directed against tumor associated MUC1 
glycopeptides were evaluated for potential cross-reactivity to sialylated glycopeptides. The 
synthesized sialylated mucin glycopeptides were compared with the unsialylated 
glycopeptides, to elucidate the potential effects on antibody recognition by the additional 
sialylation.  
After the enzymatic glycosylation, yielding the synthesized sialylated glycopeptides, the low 
abundant products were quantified by amino acid analysis. To avoid any discrepancies 
between different methods of quantification of the glycopeptides used for microarray 
analysis, the corresponding unsialylated glycopeptides were as well determined by amino 
acid analysis instead of gravimetrical weighing. The unsialylated peptides and their sialylated 
counterparts were spotted on microarray format MA4. 
The sera of vaccine candidate 1 (CHSynB) mouse 2, vaccine candidate 2 (HC12) mouse 2, 
vaccine candidate 7 (HC1) mouse 3 and vaccine candidate 8 (HC2) mouse 2 and 3 were 
chosen for antibody screening. The antisera were chosen based on the strong dependency 
on the glycosylated PDT*R binding epitope. Antibodies directed to the GSTA domain were 
usually highly restricted to double (clustered) TN-antigen glycosylation and were therefore not 
selected for elucidation of antibody recognition to sialylated epitopes. Additionally, the 
commercial monoclonal IgG1 antibody Ma552 was screened on this array (figure 4.73, F). 
Ma552 originated from immunization of mice with ZR75-1 breast cancer cells. A broad set of 
glycopeptides were recognized by this antibody, although, similar to the probed vaccine 
candidates, this mAb targets the PDTRPAPGS binding epitope of the MUC1 tandem repeat, 
preferably if this domain is glycosylated.46,329,330  
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Figure 4.73: Comparison of antibody binding to sialylated glycopeptides and to the unglycosylated counterparts. 
Unsialylated glycopeptides are depicted in black, α2,6-sialylation in blue and α2,3-sialylation in green. Entries 232 
(A, B, C) and 234 (D, E) are the administered B-cell epitopes. 
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Sialylation with α2,3-Neu5Ac (in green) and α2,6-Neu5Ac (in blue) resulted in no significant 
changes in antibody reactivity compared with the unsialylated MUC1 glycopeptide epitopes 
(in black, figure 4.73). This means that the T-antigen and the ST-antigen, which are both 
tumor-associated antigens, as well as the linear sialylated extended core 1 and core 3 
glycopeptide epitopes were well recognized by the induced antibodies. Antibody reactivity to 
monoglycosylated sialylated and unsialylated core 2 epitopes was also observed. However, 
on certain core 2 glycopeptides, small but distinct effects of the sialylation were found. 
Peptide entry 201 with a bulky α2,3-disialylated core 2 octasaccharide in PDT*R seemed to 
slightly increase antibody recognition compared to the unglycosylated counterpart (125 vs 
201, figure 4.73). α2,6-Sialylation on the core 2 octasaccharide of glycopeptide 202 had a 
considerably decreasing effect for binding of antibodies, in particular observed in the antisera 
from vaccine candidate 2 mouse 2 (figure 4.73, B) and vaccine candidate 8 mouse 2 (figure 
4.73, D).  
The monoclonal antibody Ma552, induced from human breast cancer cells, generated a 
similar antibody recognition to the sialylated and to unsialylated MUC1 glycopeptides. The 
antibody cross-reactivity to different MUC1 glycopeptide structures was thus in general 
higher than for most of the antisera induced by the above described synthetic vaccines.  
 
 
4.3.10 Discussion of MUC1 serum antibody specificity elucidation 
4.3.10.1 The role of PDTR-glycosylation 
The PDTR peptide domain has been identified as an immuno-dominant region in the MUC1 
tandem repeat sequence. The ISOBM TD-4 workshop (San Diego, California, 1996) 
examined a comprehensive collection of 56 monoclonal antibodies directed against mucin 
glycoproteins or tumor associated carbohydrates with antigen structures derived from 
isolated mucins or tumor cells. About 34 antibodies were directed against the MUC1 peptide 
tandem repeat and 28 of them showed reactivity against epitopes including the core DTR. 
For the majority of most of the other antibodies, evidence for carbohydrate dependent 
epitopes were found. However, monoclonal antibody Ma552, which was also part of the 
ISOBM-investigation, was described to be PDTR-specific, although this investigation showed 
that Ma552 has merely a preference for PDTR and recognizes further MUC1 glycopeptides 
with lower affinity (figure 4.73, F). At the time of the ISOBM workshop, it was unclear if the 
immunogenicity of the PDTR domain solely relied on the peptide epitope and had a better 
accessibility when unglycosylated or if the glycosylation stabilized the formation of 
 4 RESULTS AND DISCUSSION 129 
 
 
immunogenic secondary turn structures. It was found that the majority of available 
monoclonal antibodies derived from tumor sources showed enhanced or even exclusive 
binding when the PDT*R motif was glycosylated with TN- or T-antigen.
327,330 It was therefore 
proposed, that a MUC1 peptide vaccine would be more potent when glycosylated in the 
PDTR domain.47  
Two- and three component vaccine candidates 1 and 2 and as well the gold-nanoparticle 
bound vaccine candidates 6 and 7 shared the same B-cell epitope, which include TN-antigen 
glycosylation in the PDTR and GSTA region and vaccine candidate 8 contains an analogue 
B-cell epitope with T-antigen decoration. All of them showed strong binding to the B-cell 
epitope 232 and all mouse sera except one (vaccine candidate 2 (HC12), mouse 1) showed 
broad recognition dependent on PDT*R glycosylation (14 out of 15 sera). Glycosylation was 
not restricted to the TN-antigen only, but also T-antigen and elongated core 3 trisaccharide 
and core 1 tetrasaccharide structures provide binding. To some degree even branched 
core 2 hexasaccharides were accepted in this domain. Thus, similar to the majority of 
monoclonal antibodies that have formerly been generated from tumor tissue or other MUC1 
sources (e.g. human milk, urine), vaccines of this kind indeed induce specificity for 
glycosylation in PDTR. Vice versa, the specificity of the known monoclonal antibodies 
derived from PDTR glycosylated source material, suggests that the PDTR domain often is 
glycosylated in tumor cell MUC1 glycoproteins. It is known that all glycosylation sites of the 
MUC1 tandem repeat are potential targets for the polypeptide glycosyltransferases in cancer 
cells.331 Also, some monoclonal antibodies were recently reported to have tolerance for TN-, 
T-, and ST- glycoforms in PDT*R, screened on a MUC1 microarray system.324 In the current 
thesis, a broad tolerance of glycoforms by the induced antibodies was shown not only for the 
TN-, T- and STN-antigen structures, but to some extend for linear and to sometimes even 
branched type-1 and -2 elongated mucin core structures that are not classic tumor-
associated antigens. Vaccine candidate 3 (HC11, figure 4.62 and 4.63), containing a B-cell 
epitope without glycosylation in PDTR induced three different antibody specificities in each of 
the three mice immune sera, of which only one recognized the unglycosylated PDTR domain 
(mouse 2), indicating that the glycosylated PDT*R indeed is more immunogenic than an 
unglycosylated PDTR and also more immunogenic than a single glycosylation on the serine 
of GS*TA. 
 
4.3.10.2 Role of GSTA glycosylation  
The results obtained in this work from the investigated murine antisera induced by vaccine 
candidates 1, 2, 6, 7, 8 containing a B-cell epitope with homogenous TN- or T-antigen 
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glycosylation in PDT*R and GS*T*A, showed a very narrow and specific dependence on 
glycosylated GS*T*A. The two- and three component vaccines candidates 1 and 2 induced 
antibodies, which showed significant binding to clustered TN-antigen glycosylation in the 
GS*T*A epitope (233). If the glycosylation in this domain was exchanged to clustered T-
antigen glycosylation (235) antibody binding was lost. Double glycosylation in this domain 
was mandatory, since single glycosylation in GSTA, whether with TN-antigen on serine or 
threonine (236 and 237) or a different core glycan on threonine, resulted in no or weak 
antibody binding. While glycosylation in the GS*T*A binding epitope needed to match the 
vaccine template, the PDT*R glycosylation often provided a broader spectrum of possible 
binding interactions and was therefore considered responsible for a major part of the 
antibody recognition. In contrast, vaccine candidate 3 (HC11) has a B-cell epitope only 
glycosylated on serine in the GS*TA region. The antibodies from two out of the three 
generated sera induced by vaccine candidate 3 (mouse serum 1 and 2) had peptide epitopes 
that neither relied on glycosylation nor on the GSTA domain. Only mouse 3 showed very 
specific reactivity for TN-antigen on either serine or threonine in GSTA. The immunogenicity 
of the monoglycosylated GS*TA domain was inferior to that of PDT*R. In the di- and tripartite 
vaccines with clustered TN-glycosylation in GSTA the immunogenicity was higher than 
monoglycosylation in GSTA of vaccine candidate 3 (HC11). The influence of GSTA domain 
glycosylation seems not to be very important in the case of the gold nanoparticle vaccine 
candidates 6, 7 and 8. Only 3 out of 9 mouse sera (vaccine 6 mouse 1, vaccine 7 mouse 1, 
vaccine 8 mouse 2) showed strong antibody interactions with double or monoglycosylated 
GSTA (e.g. 233, 235). Here, glycosylation in PDTR clearly dominates antibody binding in 
comparison to GSTA glycosylation, again highlighting the immunogenic relevance. In the 
AuNP based vaccines, the induced antibodies had a strong preference for the PDTR epitope 
in spite of the attached B-cell epitopes containing TN-antigen in both the PDTR and GSTA 
region, proposing that the latter has a lower immunogenicity. R. Cummings and D. Live 
administered MUC1 tandem repeat sequences on KLH to breast cancer patients in 
remission, containing either TN-antigen glycosylation in PDT*R or clustered in GS*T*A or in 
both epitopes.332 They identified both epitopes as immunogenic, however, the vaccine 
candidates containing glycosylation in both epitopes, generated polyclonal immune sera with 
higher affinity to the glycosylated PDT*R domain.  
It can be speculated, that the very narrow antibody specificity to clustered TN-antigen 
glycosylation in the GSTA domain was the result of the conformational influence of the 
carbohydrate decoration. GS*T*A with consecutive glycosylation on serine and threonine 
was found to be locked in a rigid and extended structure. F. Corzana et al. conducted 
molecular dynamics (MD) simulation with a serine-threonine dipeptide with clustered TN-
antigen glycosylation (S*T*, as in the GS*T*A domain) and found that the glycans adopted 
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an orientation similar to the orientation of monoglycosylated serine-threonine dipeptides 
without vicinal glycosylation (ST* or S*T).333 The vicinal glycans in diglycosylated peptides 
can occupy natural positions without sterical interferences. The superimposed MD structures 
showed low flexibility for this orientation, meaning that the glycans are fixed in their positions. 
Similar results were obtained by the groups R. Cummings and D. Live.332 NOE signals 
observed through NMR spectroscopy of synthetic TN-antigen glycosylated peptides were 
compared and peptides with vicinal, clustered TN-antigen glycosylation showed fortified NOE 
interactions between the peptide backbone and the carbohydrate moieties, indicating more 
rigid structures for glycopeptide with clustered glycosylation. The group around H. Kunz 
showed that a PAPGS*T*APPA decapeptide with clustered TN-glycosylation, adopts an 
extended “rod-like” structure.334 The rigid peptide conformation with fixed and inflexible 
clustered TN-antigen glycosylation in the GS*T*A domain of MUC1, may be recognized by 
the immune effector cells and translated into a very precise antibody design with high 
specificity for the template, but low flexibility for deviating structures.  
 
4.3.10.3 Role of the VTSA domain 
The VTSA domain of the vaccine candidates was not glycosylated and no antibody reactivity 
against the VTSA peptide domain, whether glycosylated or not, was observed here, with the 
exception of vaccine candidate 3 (HC11) mouse 1. The B-cell epitope of vaccine candidate 3 
had one TN-antigen in the GS*TA domain and produced different antibody specificities in all 
three mice.  
In the cases of the other vaccine candidates, glycosylation on threonine of VT*SA was here 
shown to decrease antibody reactivity to the glycosylated PDT*R motif in multivalent 
glycopeptides. PDT*R-specific antibodies often tolerated additional glycosylation in GST*A, 
without (almost) any decrease in binding affinity. Additional VT*SA glycosylation, however, 
often reduced binding to PDT*R. Hanisch et al. described disturbed antibody binding of 
monoclonal antibodies directed to unglycosylated PDTR in the presence of glycosylation in 
the VTSA region.335 Dziadek et al demonstrated that glycosylation with a α2,6-ST-antigen on 
Thr in VT*SA resulted in a long range effect on the conformation of the unglycosylated PDTR 
turn structure.54 The results from this work are in accordance with these findings, but 
appending that a conformational influence from VT*SA also influences glycosylated PDT*R 
domains and thereby modify antibody recognition. 
 
132 4 RESULTS AND DISCUSSION
 
 
4.3.10.4 Influence of glycan size, core branching and sialylation 
As stated above, elongated core 3 and core 1 structures in general do not obstruct antibody 
binding to the immuno-dominant PDTR motif and the antibodies directed to the PDTR 
epitope tolerate to some extend multivalent glycosylation on other glycosylations sites of 
MUC1, containing these glycans. A limitation in the recognition of the glycopeptides was set 
by the branched core 2 hexasaccharide structures. For direct comparison, glycopeptide 174, 
modified with a type-2 core 2 tetrasaccharide in PDT*R was added to microarray MA3 along 
with the corresponding linear core 1 tetrasaccharide sequence 108, core 2 hexasaccharide 
sequence 125 and the core 1 T-antigen peptide 76 (diagrams for MA3 in the corresponding 
chapter 4.3.8). Disaccharide decorated peptide 76 was usually recognized well and linear 
elongation with a lactosamine unit to form a core 1 tetrasaccharide as in glycopeptide 108 
was detected as good or moderately weaker. If glycan elongation with the lactosamine was 
in 6-position of the αGalNAc instead, to form the equivalent branched core 2 tetrasaccharide, 
recognition dropped significantly. Furthermore, if the core 2 glycan was further elongated, to 
give branched core 2 hexasaccharide glycopeptide 125, no further loss of recognition was 
accordingly observed. In fact, the core 2 tetrasaccharide, hexasaccharide and even 
disialylated octasaccharide on glycopeptide 201 (MA4, figure 4.73) decorated peptides 
showed approximately the same binding intensities by the induced antibodies (figure 4.74). 
 
Figure 4.74: General binding affinities of the PDT*R-specific serum antibodies depending on the O-glycosylation 
in this peptide domain. 
This demonstrates that linear core 1 structures are preferred over branched core 2 glycans in 
the immunodominant PDTR domain. The antisera induced by TN-antigen decorated vaccine 
candidates 1, 2, 6, 7, 8 show in general almost stable antibody recognition in terms of 
intensity for linear di-, tri- and tetrasaccharide glycan structures in the PDTR domain 
(diagrams for MA2 section B in chapter 4.3.8), but a significant drop in antibody recognition 
for the core 2 hexasaccharides. The reduced antibody preference for β1,6-branched glycans 
could either be a steric effect due to the branching or a conformational alteration of the 
secondary structure of the peptide backbone induced by the glycan. A αGalNAc in the 
PDT*R motif results in a conformational change in the PDTR turn structure.53,331 It is still not 
fully investigated how further core elongation may change the peptide conformation. 
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Previous NMR studies of extended glycosylation on non-MUC1 mucin glycopeptides showed 
that further glycan elongation, beyond the initial αGalNAc, does not have a great impact on 
the backbone conformation,336 including elongation in a core 2 fashion.337,57 On the other 
hand, H. Kunz showed, that peptides from LI-cadherin with various glycans attached, 
exhibited glycan dependent conformational changes in similar NMR experiments, when 
glycosylation was further extended on the αGalNAc monosaccharide.338 Based on the 
coupling constants and NOE coupling in NMR experiments, the group of S.-I. Nishimura 
reported that distal sialylation on an extended core 2 glycan at the PDT*R domain in a MUC1 
tandem repeat, had remote effects on the conformation in the domain, while sialylation of 
glycans in the VTSA and GSTA sites had no conformational effect on these glycosylation 
sites.57 Conformational effects are thus most likely sequence dependent and can therefore 
be a plausible reason for the reduced antibody affinity to the core 2 glycosylated PDT*R 
motifs. It may indicate that additionally to the conformational change in the PDTR domain, 
caused by glycosylation with the basic αGalNAc, the βGlcNAc linked to the 6-position of 
αGalNAc is also influencing the peptide backbone conformation. In contrast, elongation in 3-
position of the αGalNAc with β1,3Gal (core 1) or β1,3GalNAc (core 3) may not have a 
comparable conformational influence on the peptide, due to the similar binding affinities of 
the antibodies towards the core structures. 
The findings are interesting, since several studies, for instance with breast carcinoma cells, 
indicate that core 1 glycan decoration is more abundant than core 2 glycosylation on tumor 
cells, while core 2 glycans decoration is often found on healthy cells.30,321,339 The aberrant 
glycosylation on tumor cells has been associated with decreased expression of core 2 1,6-N-
acetylglucosaminyltransferase 1 (C2GnT-1) and upregulated expression of human α2,3-
sialyltransferase 1 (ST3Gal1) during oncogenesis.320 Further, high contents of secreted and 
shedded MUC1 carrying core 1 based glycans have been found in the sera of advanced 
breast cancer patients.34 Therefore it would be highly eligible, to produce antibodies that 
show higher affinity to tumor related core 1 glycoproteins on various adenocarcinomas.340 To 
some extent, this feature appears to be inherent in the presented vaccine candidates. The 
aberrant glycosylation on tumor cells is sometimes also caused by mutation of the Cosmc 
chaperone essential for T-synthase activity resulting in presentation of TN- and STN-antigen 
modified epitopes, structures which are also covered by the antibodies induced by the above 
described vaccines. 
Vaccine candidates 7 and 8 share the same B-cell epitope sequence with TN- and T-antigen 
as haptens, respectively, on a gold nanoparticle support. The three sera originating from the 
T-antigen glycosylated vaccine candidate 8 seemed to have a slightly higher tolerance for 
the sequences with the bulky core 2 hexasaccharides than the TN-antigen vaccine 7 (figures 
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4.69 and 4.71, B). It appears reasonable that the slightly bigger T-antigen hapten induced 
antibodies with specificity for somewhat larger glycans. This study clearly shows that there is 
a size tolerance for larger carbohydrates than the vaccinated haptens, at least in the 
immuno-dominant PDTR motif. This may in particular be problematic if the antibody 
discrepancy between core 1 and core 2 structures is lost with the risk of generating an 
immunological memory, also to normal healthy cells. The larger tumor-associated antigens, 
such as the ST- (Neu5Acα2,3-Galβ1,3-GalNAcα) trisaccharide or the di-ST-(Neu5Acα2,3-
Galβ1,3-[Neu5Acα2,6]-GalNAcα) tetrasaccharide may therefore not be the optimal choice for 
vaccination. Due to the potentially higher immunogenicity of the negatively charged sialic 
acid residues in these structures and the fact that sialylation seems to influence the MUC1 
peptide backbone conformation, these tumor-associated glycan structures may thus behave 
different from the above described T-antigen vaccine candidate 8. There is no defined 
threshold yet, that marks the borderline between tumor-associated and healthy, regarding 
the size and valency of carbohydrates that obstruct antibody epitopes, such as the PDTR 
domain. Information of this kind is important because of possible autoimmunity, induced by 
an inadequate, potential therapeutic vaccine.  
Finally, no significant differences in antibody recognition were monitored for type-1 or type-2 
core elongation. In general, the type of carbohydrate backbone elongation by type-1 or type-
2 LacNAc does not seem to have conformational influences on the tandem repeat peptide of 
MUC1. Only one antiserum from vaccine candidate 6 mouse 3 (figure 4.67, A+B) showed 
strong discrepancy for binding to peptides, glycosylated with core 2 type-1 hexasaccharides 
in PDT*R. Since the corresponding core 1 type-1 tetrasaccharide and the core 2 type-2 
hexasaccharide were not recognized, the antibodies must have a preference for the peptide 
epitope conformation induced by core 2 glycosylation with further β1,3-linked elongation, or 
directly to the carbohydrate structure itself. 
 
4.3.10.5 Antibody binding of multivalent peptides with glycosylation in different 
 domains 
Trivalent peptides with di- (basic core 1), tri- (extended core 3), tetra- (extended core 1) and 
pentasaccharides (sialylated, extended core 1) in all three glycosylation sites, still exhibit 
accessible epitopes for the induced antibodies. However, trivalent core 2 hexasaccharide 
decoration in all three glycosylation sites (HGVT*+PDT*R+GST*A, diagrams of MA2, section 
B in chapter 4.3.8) effectively prevents antibody binding and was therefore regarded as a 
model structure for a mucin peptide/protein backbone masked by extensive O-glycosylation. 
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These results suggest that multiple branched core 2 glycans are more effective in shielding 
the mucin proteins than linear core 1 or 3 glycans. 
 
4.3.10.6 Influence of the T-cell-epitopes, mitogens and carriers on antibody 
 binding 
All vaccine candidates, except for number 3, 4, and 8, share the same B-cell epitope 
sequence (HGVTSAPDT*RPAPGS*T*APPA, * = TN-antigen). However, differences in the 
antibody binding patterns were observed. Most obvious was the general low antibody 
specificity of the tetanus toxoid conjugated candidates 4 and 5 (chapter 4.3.8.4 and chapter 
4.3.8.5). Basically all sequences were recognized to a good extent, no matter if glycosylated 
or not. Only sequence 213, missing the PDTR domain, showed no reactivity with the 
antibodies. This clearly indicates that the tetanus toxoid vaccine induced antisera were 
specific for the PDTR sequence, and therefore also MUC1-specific. In this case, reduction of 
antibody binding to the large core 2 hexasaccharide peptides was observed, but was less 
pronounced. Still, trivalent hexasaccharide peptides were shielded by the glycans from 
antibody binding. To conclude, the tetanus toxoid vaccine candidates elicited uniform 
antibody specificity for MUC1 tandem repeats with an antibody binding epitope dependent on 
the PDTR domain and to a large extend independent from the glycosylation status. A cutoff 
for larger carbohydrate core 2 structures, which are found on healthy cells, was still 
observed. The glycan decoration of the B-cell epitope sequence, conjugated to the tetanus 
toxoid vaccine candidates, does not have great influence on accentuated antibody binding 
profiles with the glycopeptide library presented here, as can be seen by comparing vaccine 
candidate 4 and 5. Carrier proteins are known to produce a larger spectrum of antibodies 
also against peptide epitopes on the carrier protein, which in the worst case can overrule the 
hapten specific immune response.129,130 This should mainly influence the antibody titer of the 
immune response against a certain antigen. Here it seems that the strong immune response 
induced by the tetanus toxoid stimulant also induces less accentuated antibody specificity. 
The extraordinary strong immune response is combined with an expense of antibody binding 
specificity. Anyhow, as demonstrated by Gaidzik et al., mouse 5 of tetanus toxoid conjugated 
vaccine candidate 4 (NG5), tested on the MUC1 microarray in this work, elicited IgG-
antibodies in mice, that specifically showed high reactivity against advanced tumor cells (G3-
phase) in mammary carcinoma tissue sections, but only weak recognition of tumor tissue in 
the early phase (G1-phase).126 This could be the direct influence of the observed core 2 
affinity cutoff (more normal core 2 glycans on early phase tumor cells) or just a result of the 
dramatically increased expression of the MUC1 glycoprotein on the advanced tumor cells or 
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a combination of both effects. Such an immune response, combined with the general high 
antibody titers observed, may just be right to create an adequate therapeutic immune 
reaction or might be borderline, regarding the risks of inducing autoimmune reactions against 
normal cell surface glycosylation. 
The two- and three-compound vaccine candidates 1, 2 and 3 produced sera that were not 
uniform in the induced antibody profile. A minority of the antibody sera showed very specific 
binding to a few sequences including site specific TN-antigen glycosylation according to the 
induced antigen structure, while others showed showed broad recognition of differently 
glycosylated domains. The attached mitogen Pam3CSK4 in vaccine 2 and 3 does not have an 
obvious positive effect on the antibody profile compared to candidate 1. Thus, a larger 
variance of isotype antibody classes are formed by immune stimulation with the build-in 
adjuvant Pam3CSK4 vaccines, which might be favorable for an efficient immune response 
directed to tumor cells. 
The P30-AuNP conjugated vaccines 7 and 8 on the other hand, presented a more uniform 
induced antibody response in all of the mice. The immune sera were not only specific for the 
glycoform of the B-cell epitope, but showed in general broad acceptance of various PDTR 
glycosylated sequences. Generation of uniform immune reactions is an important feature of a 
safe vaccine. 
 
4.3.11 Binding of plant lectins to MUC1 glycopeptides on a microarray   
4.3.11.1 Glycopeptide microarray analysis with plant lectins 
Plant lectins are commonly used in carbohydrate structure analysis to detect specific 
recognition elements on glycoproteins or glycolipids. Specific lectins are also used in 
glycobiology and glycoproteomics for enrichment of certain glycoproteins and glycopeptides 
by lectin weak affinity chromatography (LWAC).341 The presented mucin glycopeptide 
microarray platform was used to evaluate interactions with lectins known to recognize 
specific carbohydrate binding elements. Effects on glycan presentation at different 
glycosylation sites, presentation in different core structures and influences by multivalent 
ligand effects in the lectin interactions were evaluated. A library of 132 MUC 1 glycopeptides 
was screened on microarray format MA5. Figure 4.75 only shows the positive binders of the 
library (for complete peptide list see chapter 6.3.4 and complete data chapter 8.3.4). 
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Figure 4.75: Binding of different plant lectins on the glycopeptide array platform MA5. A: Erythrina cristagalli 
(ECA, 100 µg/mL), B: Maackia amurensis I (MAL I, 80 µg/mL), C: Maackia amurensis II (MAL II, 20 µg/mL), D: 
Vicia villosa (VVL, 50 µg/mL), E: Wheat germ agglutinin (WGA, 50 µg/mL), F: Peanut agglutinin (PNA, 10 µg/mL), 
G: Sambucus nigra agglutinin (SNA, 20 mg/mL).  
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All lectins recognized the glycopeptides according to their reported carbohydrate binding 
specificities (figure 4.75).342 Additionally to HPLC and MS characterization, lectin binding 
validates the enzymatic α2,3- and α2,6-sialylation performed on glycopeptide level. The 
observed lectin binding specificities to the mucin core glycopeptides found on the microarray 
were as follows: 
A Erythrina cristagalli (ECA) 
ECA was reported to recognize terminal Galβ1,4-GlcNAc (type-2 LacNAc) structures 
and accordingly showed affinity to the type-2 terminated core 1, core 2 and core 3 
glycans of the MUC1 glycopeptides. As seen best in the core 3 glycosylated peptides 
92-99, multivalent presentation of the glycans on the peptide backbone multiplies 
binding affinity. Branched core 2 glycans with two terminal LacNAc extensions are 
recognized exponentially stronger than the corresponding unbranched core 1 or core 
3 glycans. α2,3- or α2,6-Sialylation blocks LacNAc recognition. Type-1 LacNAc 
terminated glycans were not recognized, as expected.  
 
B Maackia amurensis I (MAL I)  
MAL I was previously reported to recognize the terminal α2,3-sialylated type-2 
LacNAc trisaccharide structures. Evaluation on the glycopeptide array showed that 
the sialyl-LacNAc core 3 was a particular good ligand when presented in the VT*SA 
domain of peptide 182, compared to the other glycosylation sites, indicating a 
conformational interaction of glycan and peptide backbone. The α2,3-sialylated, type-
2 extended core 1 glycans of peptides 193, 194 and 196, which were not bound by 
WGA (E), were recognized by MAL-I, as expected. Furthermore, the sialylated 
LacNAc was recognized better, if attached in a linear mode, e.g. in an extended core 
1 glycopeptide (194), than in a branched fashion as a core 2 glycopeptide (206). 
 
C Maackia amurensis II (MAL II, MAH)  
MAL II was reported to recognize α2,3-sialylated T-antigen structures and binds to 
the ST-antigen glycopeptide motives on the microarray as expected. 
   
D Vicia villosa (VVL) 
VVL was reported to recognize terminal GalNAcα as in the TN-antigen and has been 
used in glycoproteomics to enrich GalNAcα glycopeptides from Simple cell lines. 
Simple cell lines were recently reported to be very useful in identification of O-
glycosylation sites, which is rather difficult with standard glycomics and proteomics 
techniques.16 Glycopeptide microarray analysis showed that the VVL lectin was very 
specific to the TN-antigen glycopeptides. Minor preference for threonine over serine 
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glycosylation was seen, e.g. 234 (Thr) versus 235 (Ser), which is in accordance with 
enzyme-linked lectin assay (ELLA) results by Madariaga et al., although the 
difference here on the microarray was not so pronounced.343 
 
E Wheat germ agglutinin (WGA, Triticum aestivum) 
WGA was reported to recognize terminal GlcNAcβ and sialic acid residues. The lectin 
is commonly used to enrich sialylated O-glycans, N-glycans and O-GlcNAcylated 
peptides from glycoproteomic tryptic samples. Here, the α2,3-sialylated T-antigen 
glycopeptides were very good ligands, better than terminally sialylated type-1 or -2 
LacNAc glycan conjugates. In fact, the sialyl type-1 extended core 1 peptides 189 
and 190 were weak to medium binders, while the type-2 analogs 194 and 196 show 
very low lectin binding. A 1,3-glycosidic bond between the Gal and the GlcNAc seems 
to be favored. The peptides with α2,3-Neu5Ac on the type-2 core 3 glycosylated 
peptides were not recognized. Even more surprising, the triglycosylated linear sialyl 
type-2 core 1 glycopeptide 199 was recognized very strong, although all the 
corresponding monovalent glycopeptides showed almost no affinity. This is an 
extreme example for lectin avidity. A significant lectin binding was also observed to 
multivalent, not sialylated type-2 extended core 2 hexasaccharide glycans on 
peptides 128-130. Binding was probably mediated by multivalent presentation of 
internal GlcNAcβ of this glycoform, although LacNAc is reported to be a poor ligand. 
The analog type-1 hexasaccharide modified peptides were not recognized. 
Glycopeptide 133 with an unsialylated core 2 type-2 hexasaccharide and GalNAcα at 
another glycosylation site, was weakly recognized, hinting on a cooperative effect 
between these glycans, which did not result in lectin binding itself on different 
peptides. In summary, additionally to the known binding specificity for sialic acids and 
terminal GlcNAcβ, WGA also interacts with various core 2 glycoforms which do 
neither posses terminal sialic acids nor terminal GlcNAcβ. Further, the connectivity 
between a sialylated Gal and HexNAc influences the binding, for instance a single 
α2,3-sialylated type-2 LacNAc was a poor ligand, while the equivalent type-1 LacNAc 
showed significant binding. Also, only α2,3-linked Neu5Ac was recognized and no 
affinity for α2,6-Neu5Ac was observed. 
 
F Peanut agglutinin (PNA, Arachis hypogaea) 
PNA was reported to recognize T-antigen structures and binds to the array as 
expected. Threonine glycosylation was preferred over serine glycosylation, as shown 
in glycopeptides 228 and 229. Core 2 glycosylation on the T-antigen, as in peptide 
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174 did not prohibit recognition. On the other hand, if the core 2 was α2,3-sialylated 
on the LacNAc side chain, as in glycopeptides 206, lectin recognition was prohibited. 
 
G Sambucus nigra agglutinin (SNA) 
SNA was reported to recognize terminal Neu5Acα2,6-Gal and as expected bound to 
glycopeptides containing this structure on the  microarray. α2,6-Sialylated type-2 
LacNAc is thereby preferred over sialylated type-1 LacNAc (e.g. 191 vs. 197). Also, 
internal α2,6-sialylation next to the type-1 prevents binding (192) , which is not the 
case when the internal sialylation is next to a type-2 structure (204). No binding to 
Neu5Acα2,6-GalNAcα or 2,3-sialylated structures was observed. 
 
In summary, all relevant glycoforms were addressed by the corresponding lectins and unique 
fine specificities were sometimes observed. 
By comparing the different glycosylation sites when decorated with the identical glycan, it 
became apparent that most lectins recognized the glycan stronger when attached to the 
glycosylation site at the free C-terminal end of the peptide and vice versa weaker if the 
glycan was attached to the glycosylation domain close to the N-terminal end, where the 
peptide was linked to the polymer of the hydrogel. In most of the glycopeptides, the 
glycosylation site at the C-terminal end was the GST*A domain and at the N-terminal end the 
VT*SA motif. This was seen very clearly in the case of ECA (figure 4.75, A, e.g. 124 vs. 125 
vs. 126), WGA (figure 4.75, E, e.g. 175 vs. 176 vs. 177) or MAL II (figure 4.75, C, e.g. 175 
vs. 176 vs. 177). In fact, the only lectin that does not follow this trend is MAL I (figure 4.75, B, 
184 vs. 185 vs. 186). It was not fully clear though, if this was a result of a sterical effect and 
that the lectins could simply approach glycans at the loose end of the peptide better than at 
the surface bound end. Alternatively, it could be a real conformational effect by which 
glycans are presented in a favorable way by the GSTA domain. Peptides with the VT*SA or 
PDT*R glycosylation sites present at different distance from the N-terminal end, were 
compared, e.g. 107 and 116 (figure 4.75, A, ECA, VT*SA) or 76, 82 and 83 (figure 4.75, F, 
PNA, PDT*R). An effect of reduced binding by the lectins if the glycan was closer to the 
immobilized N-terminal site was observed, although the difference in signal intensity is not 
large. To fully evaluate these effects, more peptides need to be synthesized. 
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4.3.12 Binding of galectin-3 to MUC1 glycopeptides on a microarray 
4.3.12.1 Introduction on the binding specificities of galectin-3 
Galectin-3 is involved in intracellular, carbohydrate-independent processes, which have in 
general anti-apoptotic effects and are therefore promoting cancer development. On the other 
hand, extracellular galectin-3 is recognized by protein receptors in a carbohydrate-dependent 
way and is suspected to have apoptotic effects on cells.344 For example, T-cells were shown 
to become apoptotic upon contact with galectin-3. Various kinds of tumor cells overexpress 
galectin-3 and it is believed that cancer cells gain advantage from intracellular anti-apoptotic 
galectin-3 effects with simultaneous immune suppression by expressed extracellular 
galectin-3.93 There is evidence that tumor cells protect themselves from the extracellular 
apoptotic effects by aberrant cell surface α2,6-sialylation. Furthermore, the characteristic 
surface glycosylation of cancer cells seems to be correlated with cancer cell progression.79,83 
The MUC1 glycoprotein is overexpressed on the surface of cancer cells and further exhibits 
tumor-associated glycosylation. Galectin-3 was observed to interact with the T-antigen 
structure on MUC1 and is probably involved in the extracellular, pro-metastatic effects, 
mediated by galectin-3.79 The established MUC1 tandem repeat glycopeptide array provides 
a platform for elucidation of galectin-3 binding preferences, facing typical tumor-associated 
glycan motifs, differently elongated O-glycan core structures, sialic acid termination and 
multivalent presentation branching on the glycan core structure or glycan decoration on 
several glycosylation sites. As a future perspective, such a glycopeptide array may provide a 
useful platform in the search of potent glycomimetics, such as competitive galectin-
inhibitors.345,346 
Galectins share a common preference for β-galactose, due to conserved sequence 
homology in their carbohydrate recognition domain (CRD). X-ray crystallography of the 
conserved galectin-3 CRD, complexed with Lac/LacNAc or T-antigen disaccharides, 
identified a binding groove with additional space at the non-reducing end of the 
carbohydrates.347,348 The suggested binding model comprises five subsites, namely A, B, C, 
D and E.349 Sites A-D cover an area large enough for a tetrasaccharide, while E can hold 
further saccharide residues or parts from the connected protein or lipid. Lactose or LacNAc 
as the central binding motifs for galectin CRDs, are located in sites C-D. The C-site features 
the mandatory contact to the axial 4’-OH and the 6’-OH of the galactose.347 The less 
restricted D-site houses the Glc, GlcNAc or GalNAc and contributes to overall binding (figure 
4.76). 
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Figure 4.76: Model of galectin-3 subsites with hydrogen bonding to N-acetyllactosamine (LacNAc). Sites C-D 
house the central disaccharide. Sites A, B and E are vacant and can be occupied by modifying residues. W1-3 
represent water molecules, participating in the LacNAc binding.  
The A, B and E sites vary in preference for the residues around the central Lac/LacNAc for 
the different members of the galectin family. Like this, the various galectins interact with 
different interaction partners and are able to fulfill distinct actions. Identifying the 
characteristic interaction partners and unique specificities of the galectins is therefore 
necessary to understand galectin functions.  
Several methods have been applied to study lectin-carbohydrate interaction and affinity of 
galectins to various biologically relevant carbohydrate structures. Solution-phase assays, 
such as fluorescence polarization,350 isothermal titration calorimetry (ITC),351 frontal affinity 
chromatography (FAC)67 and flow cytometry352 have been used to evaluate or quantify 
binding affinities to a specific ligand in solution. On the other hand, immobilized ligands on a 
surface permit multivalent interactions, crucial for avidity in biological processes. 
Carbohydrate microarrays,353,354,355,356 ELISA-like plate assays357 and SPR353,358 have been 
used to study galectin specificity. In the published literature, the data obtained from solution-
phase or surface assays are partly inconsistent within different studies of galectins.359,360 In 
the case of galectin-3 for example, the group around R.D. Cummings screened galectin-3 on 
a glycoarray by the Consortium for Functional Glycomics (CFG).353,361 The array failed to 
detect type-1 and type-2 LacNAc, the sialylated versions thereof, type-2 LacNAc terminated 
core 2 and core 4 glycans and the T-antigen, although the LacNAc disaccharide has before 
already been identified as the central galectin binding motif by other methodologies. H. 
Tetano et al. presented a glycoarray with glycans attached to a polyacrylamid backbone 
immobilized on epoxy slides on which binding to type-1 but not to type-2 LacNAc was 
observed.355 The Seeberger group immobilized glycans with a thiol-linker onto maleimide-
functionalized slides and observed stronger recognition of Lac than of LacNAc,356 although 
binding affinity was reported the other way around by several other studies. In general, the 
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way of presentation and the linker strategy, ligand concentrations, galectin preparation and 
detection method, may determine the result of galectin ligand profiling 
significantly.350,353,356,362  
Ultimately, studying specificity of galectin-3 to carbohydrates linked to tandem repeat 
peptides of the natural binding partner MUC1 was consequently reasonable, since the 
glycans are presented in a more natural way on the peptide backbone and in a multivalent 
mode. Also, no detailed study of extended O-glycan core structures as ligands for galectin-3 
was reported. The CFG glycoarray platform also features some shorter core structures, but 
the results with galectin-3 were not conclusive since LacNAc terminated O-glycans as well as 
the known ligand LacNAc itself failed to show binding in previous studies.353,361   
 
4.3.12.2 Incubation of the MUC1 microarray with galectin-3 
The MUC1 microarray MA4 was incubated with recombinant (His-tagged) human galectin-3 
expressed in E.coli. The lectin was detected by a secondary Alexa Fluor 488 anti-
mouse/human Mac-2/Galectin-3 antibody (dilution 1:500). Galectin-3 was applied in dilutions 
from 25 μg/mL (ca 0.89 μM) to 0.79 μg/mL (ca 28 nM) in PBST (0.2%) buffer (figure 4.77). 
Normal physiological serum levels of galectin-3 are around 10 ng/mL and around 100-
500 ng/mL in colorectal and breast cancer patients.95  
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Figure 4.77: Galectin-3 binding of MUC1 glycopeptide tandem repeats. Incubation with A: 25 μg/mL, B: 12.5 
μg/mL, C: 6.25 μg/mL, D: 3.13 μg/mL, E: 1.56 μg/mL, F: 0.79 μg/mL of galectin-3 in PBST (0.2%) buffer. 
Unsialylated glycopeptides are depicted in black, α2,6-sialylation in blue and α2,3-sialylation in green. 
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4.3.12.3 Galectin-3 binding to unsialylated type-1 and type-2 LacNAc structures  
At 25 µg/mL (figure 4.77, A) most of the surface bound glycopeptides were apparently 
saturated with galectin-3. Pronounced discrimination of binding specificities was best seen at 
concentration around 6.25 µg/mL (figure 4.77, C). At the lowest tested concentration of 0.78 
µg/mL (figure 4.77, F), the three highest signals belong to glycopeptides with multivalent 
glycan presentation at the peptide backbone. Of those, entries 110 and 199 carry three 
LacNAc extended core 1 glycans with α2,3-sialylation on the latter and entry 201 presents an 
octasaccharide with double α2,3-Neu5Ac-LacNAc termination. Interestingly, at high 
galectin-3 concentrations (25 µg/mL and 12.5 µg/mL) glycopeptide 232, decorated with three 
αGalNAc monosaccharides, was also recognized by galectin-3. The recognition of the sole 
TN-antigen was not described before in the literature. Glycopeptide 234, has the same 
glycosylation pattern as 232, but with three T-antigen (Galβ1,3-GalNAc) structures instead, 
which both showed only medium recognition at 12.5 µg/mL. The tumor-associated TN- and T-
antigen glycans decorating the mucin glycoproteins, might therefore be low-affinity binding 
partners for galectin-3 in cancer tissue, were elevated levels of this structure can be found on 
overexpressed mucins. 
The tumor relevant TN- and T-antigen were as well recognized at high galectin-3 
concentrations. However, LacNAc terminated glycans represent better binding partners, 
whereupon type-1 and type-2 LacNAc glycans were equally well bound. LacNAc being 
attached to the basic core 1 in a linear fashion (108) was preferred over LacNAc branched in 
a regioisomeric core 2 structure (174) (figure 4.78). The core 2 hexasaccharide (125) offering 
two terminal LacNAc units showed thus strongest binding, while T-antigen (76, basic core 1) 
was recognized only with high concentrations of galectin-3. 
 
Figure 4.78: A: Extract from full array MA4 (figure 4.77). Comparison of galectin-3 binding to LacNAc present in 
linear and branched O-glycan core structures at galectin concentrations of 6.25 μg/ml and 0.78 μg/ml. B: 
Structures of the compared glycans in order of recognition affinity by galectin-3. 
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Glycopeptide 174 presents two terminal galactose units, while glycopeptide 108 has one 
terminal galactose and one internal galactose unit. However, the long carbohydrate chain of 
108 (extended core 1) showed better recognition by galectin-3, than 108 (branched core 2). 
Therefore, the long chain variant further stabilizes the binding to the galectin by filling the 
vacant pockets of the binding groove, either by filling the A-B sites with the terminal LacNAc 
and the internal Galβ1,3GalNAc in C-D or with LacNAc in C-D and the internal galactose in 
the E site. 
Gabius et al. tested the binding of human galectin-3 to a selection of glycoproteins by their 
inhibitory potency on enzyme-linked lectinosorbent assay (ELLSA). It was found that 
LacNAc, as a terminal epitope in core 2 glycans on hog gastric mucin, possessed lower 
inhibitory potency relative to glycoproteins with terminal LacNAc in core 1 glycans, which is in 
accordance with the trend observed on the MUC1 glycopeptides.363  
 
4.3.12.4 Influence of α2,3-sialylation of terminal LacNAc on galectin-3 binding 
Further, direct influence of α2,3-sialylation was observed. According to the galectin binding 
model, modification on the terminal Gal residue in binding pocket B (figure 4.76) of the 
binding groove, was reported to have in many cases an affinity-enhancing effect on galectin-
3 binding. Such enhancing effects were mediated by 3’-O-α/β-galactosylation and 2’-O-
fucosylation of the galactose unit in pocket C.353,355,356 These kinds of modifications are for 
instance found in the blood group antigens. The reports about α2,3-sialylation in this position 
are however varying. While in some cases no significant influence on galectin-3 binding was 
found, some reports document a decrease or even complete blocking of galectin-3 
binding.351,352,353,364,365 However, sialylation with terminal α2,3-Neu5Ac on type-1 or type-2 
LacNAc or T-antigen structures on the MUC1 glycopeptide platform (figure 4.77, green 
entries), increases the binding affinity compared to the corresponding unsialylated 
glycopeptides (in black). Within the medium concentrations 6.25-1.56 µg/ml, the signal 
intensity doubled by α2,3-sialylation compared to the neutral glycans (e.g. 93 vs. 183, 108 
vs. 194, 125 vs. 201 etc., figure 4.77). The triglycosylated, core 1 decorated peptide 199 with 
α2,3-sialylation was in particular well recognized, even in the lowest applied galectin-3 
concentration (0.78 µg/ml). Clustered, α2,3-sialylated O-glycans, and probably also N-
glycans, would form formidable epitopes for galectin-3 according to this binding behavior. 
The reason why α2,3-sialylation was previously found to have either none or affinity 
decreasing effects in the former reports is unknown, though different assays and ligand 
substrates have been applied. The groups of R.D. Cummings and J. Hirabayashi used 
glycoarrays to assess the specificity of galectin-3.353,355 The former makes use of the glycan 
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array from the Consortium for Functional Glycomics (CFG) which failed to identify the basic 
well-known binding motif LacNAc and O-glycan core structures terminated with LacNAc even 
at high galectin-3 concentrations (1-10 µM).361,353 The second study strangely showed 
binding only to type-1 LacNAc, but not to type-2 LacNAc as galectin-3 binding partner. Other 
studies made use of ITC with galectin-3 and oligosaccharides,351 cell aggregation assays 
with galectin-3 and breast cancer cell lines,365 flow cytometry with chinese hamster ovary 
(CHO) glycosylation mutants,352 or co-immunoprecipitation of galectin-3 with MUC1 and 
EGFR.364 In all previous examples, α2,3-sialylation was proposed to have none or even a 
minor reducing effect towards galectin-3 binding. The influence of sialylation on T-antigens 
on mucins, expressed by cancer cells, is in particular interesting, since this glycoform has 
been associated with galectin-3 assisted metastasis of tumor cells.79 In this working model, 
overexpressed MUC1 on the cancer cell surface shields adhesion molecules needed for cell-
cell interaction in metastasis. Galectin-3 binds the tumor-associated T-antigen epitopes on 
the mucins, and locally concentrates MUC1, which liberates the adhesion proteins in other 
areas for cell-cell-interaction. It was shown that interaction of galectin-3 with 
immunoprecipitated MUC1 from HT29 colon cancer cells lines vanished, when treated with 
O-glycanase (T-antigen specific) or became intensified when sialic acids were removed by 
treatment with an unspecific 2,3-, 2,6-, 2,8-sialidase (A. ureafaciens).79 It was concluded that 
only unsubstituted T-antigen was responsible for binding. However, the presence of α2,6-
Neu5Ac on the T-antigen could have been responsible for diminished binding (see next 
chapter), while the tumor-associated 2,3-ST-antigen, according to the results of this work, is 
in fact a better epitope for galectin-3. It is also not known, if a α2,6-Neu5Ac located on the 
αGalNAc of the T-antigen would prevent galectin-3 from binding. The glycopeptides on this 
array were chemically precisely defined and binding to the different carbohydrate structures 
was validated with the according lectins, which gives confidence regarding the found 
specificities. 
 
4.3.12.5 Influence of α2,6-sialylation of terminal LacNAc on galectin-3 binding 
In contrast to α2,3-sialylation, binding of galectin-3 to α2,6-sialylated glycans was 
considerably reduced (figure 4.76, blue entries). According to the galectin binding model, a 
free 6’-OH on galactose is necessary for hydrogen bonding. Whether type-1 or type-2 
LacNAc was terminated by α2,6-sialic acid, did not make a difference. At high galectin-3 
concentrations (25-12.5 µg/mL) also α2,6-sialylated glycans were recognized to some extent, 
the three entries with further internal α2,6-linked sialic acid on the basic core 1 galactose 
(peptides 192, 198 and 204) were completely unavailable for galectin-3 binding. Similarly, 
glycopeptide 182 with a type-2 LacNAc extended core 3 glycan is not at all recognized and 
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the same glycoforms with the glycan in PDT*R (183) or GST*A (184) are considerably 
weaker bound than the corresponding peptides with the LacNAc extended core 1 (195 and 
197) (figure 4.79). 
 
Figure 4.79: Extract from array MA4 (figure 4.77). Comparison of α2,6-sialylated glycopeptides for evaluation of 
internal galactose binding by galectin-3 (concentration: 25 µg/mL). 
This shows that galectin-3 binds also the internal galactose of the core 1 motif in complex O-
glycans. In contrast to other galectins, galectin-3 recognizes internal LacNAc units, which 
strengthens binding affinity to poly-LacNAc chains.351 Glycopeptides with terminally α2,6-
sialylated glycans show significantly reduced reactivity with galectin-3. Terminal α2,6-
sialylation was also found to reduce galectin-3 binding in other assays.67,351,363,364 The 
biological interactions are intensively studied. This type of sialylation, which blocks the 
binding epitopes for many galectins including galectin-3, has been correlated with the 
expression levels of ST6Gal-I, which mainly sialylates N-glycans, but also O-glycoproteins 
and to some extend O-glycosphingolipids and ST6GalNAc-I, which mainly sialylates O-
glycans. ST6Gal-I is overexpressed on many cancer types,366 including breast,367 colon368 or 
ovary.369 In addition, also the levels of galectin-3 are elevated.370 In contrast to its anti-
apoptotic and carbohydrate-independent intracellular functions, extracellular galectin-3 has 
pro-apoptotic effects (see introduction, chapter 1.3). It was postulated that overexpression of 
ST6Gal-I and increase of extracellular sialylation counteracts the extracellular apoptotic 
mechanisms induced by galectin-3, additional to the simultaneous anti-apoptotic effects 
inside the cell. This would be advantageous for the survival of tumor cells.371 For example, 
when the β1-subunit of integrins is α2,6-sialylated, epithelial colon cancer cells do not 
respond to galectin-3 induced apoptosis anymore.93 Furthermore, sialylation of the β1-
integrin unit promotes cell migration and therefore tumor cell metastasis.372 
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4.3.12.6 Influence of the peptide backbone multivalent presentation 
Similar to the tested plant lectins described above, carbohydrate binding by galectin-3 was 
usually stronger, when the peptides were glycosylated at the C-terminal end (see chapter 
4.3.10.1), as can be seen with the T-antigen glycopeptides 75-81 or ST-antigen 
glycopeptides 175-181 (figure 4.77). The glycans on the C-terminal end of the peptides were 
better accessible for the carbohydrate binding proteins than the glycans on the N-terminal 
site, which was connected site-specifically to the hydrogel microarray surface. A randomized 
orientation on the surface was not possible, at least not without further chemical 
modifications, such as implementation of another amine reactive spacer at the C-terminal 
end.  
Some glycopeptides with multivalent glycan presentation were immobilized on MA4, such as 
the triglycosylated T- and ST-antigen peptides 81 and 181, the triglycosylated type-2 core 3 
and core 1 peptides 98, 113. Additionally, the core 2 hexa- or octasaccharides on peptides 
125 and 201, presented terminal LacNAc in a biantennary way. As expected, these 
multiglycosylated peptides were recognized better relative to the monoglycosylated 
equivalents. Mono- and trivalent variants of glycopeptides with the same glycan were 
compared by calculating the multivalency ratio, which is the signal intensity of trivalent 
conjugated peptides divided by the signal intensity of monovalent conjugated peptides. The 
multivalency ratio represents a factor for signal amplification due to multivalent binding 
modes (figure 4.80). 
 
Figure 4.80: Comparison of signal intensities at different galectin concentrations from mono- and triglycosylated 
peptides, represented by the multivalency ratio (= signal intensity [trivalent/monovalent] peptide). A: type-2 core 3 
peptides 94 and 98. B: type-2 core 1 peptides 109 and 113. C: Sialyl type-2 core 1 peptides 201 and 198. 
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Multivalent carbohydrate binding of galectin-3 did not follow a linear increase, since 
comparison of mono- and trivalent glycopeptide ligands should otherwise give a maximum 
multivalency ratio of 3, which would equal a three times higher affinity for triglycosylated 
peptides. At high concentrations of galectin-3 the ratio is around 1 because the system is 
saturated by the lectin. At concentrations around 1.5 µg/ml, approximately three times more 
galectin-3 is bound by the trivalent glycopeptides and at the lowest concentration the ratio 
showed a value around six, meaning that three equivalents of carbohydrate lead to an 
increase in binding by the factor of six at that galectin concentration. Galectin-3 therefore 
definitely recognized the carbohydrates by a multivalent binding mode, which increased in an 
exponential way if more carbohydrate structures were available for binding. It can be 
expected that the ratio would increase further if lower concentrations of galectin-3 were 
tested.  
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5 SUMMARY 
Tumor cells differ from normal cells by the glycosylation pattern on their cell surface proteins. 
Aberrant glycosylation on the mucin glycoproteins is based on the altered expression of 
several glycosyltransferases. The downregulation of core 2 
N-acetylglucosaminyltransferases and increased upregulation of sialyltransferases results in 
truncated and prematurely sialylated glycans. Mutations of the gene COSMC are responsible 
for lower C1GnT (T-synthase) levels and therefore hampered core 1 elongation. As a 
consequence, altered glycan structures are truncated and often prematurely sialylated. The 
smaller carbohydrate structures represent tumor-associated antigens, which make the 
peptide backbone accessible for tumor-specific antibodies. Serum auto-antibodies have been 
identified against these characteristic tumor structures and prove that a humoral immune 
response against altered tumor cell surface structures is feasible. Stimulation of the immune 
system with an adequate vaccine, directed against tumor-associated glycopeptide structures, 
would be a valuable therapeutic strategy to reduce the tumor burden, provide protection 
against metastasis and create long term protecting against relapses. 
One of the most promising targets for active vaccination in cancer immunotherapy is the 
MUC1 glycoprotein. This membrane-bound protein is found on epithelial cell tissues and is 
highly overexpressed and aberrantly glycosylated on carcinoma cells. Organic synthesis is a 
reliable way to generate precisely defined vaccines, based on the MUC1 tandem repeat 
structure, for the potential use in immunotherapy. The main challenges in this undertaking, is 
to overcome the self-tolerance of the immune system against these endogenous structures 
and in relation to that, provoke a guaranteed specificity against the tumor-associated 
structures.  
To study the induced antibody specificity of potential tumor-associated vaccine candidates, a 
MUC1 tandem repeat glycopeptide microarray platform was designed. For that purpose, a 
MUC1 glycopeptide library was prepared, with the premise to screen antibody sera for the 
binding specificities towards different glycopeptide epitopes. The antibody cross-reactivity of 
peptides, glycosylated with O-glycan core structures, such as extended core 1, 2 and 3 
structures, which likely represent the elaborate glycosylation status of the mucins on healthy 
cells, was compared with antibody recognition of peptides with shorter, tumor-associated 
structures. The glycans were presented on the peptide backbone in a systematic and 
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multivalent pattern, to mimic the structures on natural mucin glycoproteins. The 
glycopeptides were synthesized in a convergent strategy with presynthesized and 
appropriately protected glycosylated amino acids. These amino acids were synthesized from 
a small pool of common building blocks, which were assembled in a uniform fashion to 
generate several glycosylated threonine amino acids for solid phase peptide synthesis.  
The modular strategy involved the synthesis of type-1 (Galβ1,3-GlcNAcβ) and type-2 
(Galβ1,3-GlcNAcβ) N-acetyllactosamine disaccharides 27 and 31 for flexible elongation of 
threonine TN- and T-antigen acceptor amino acids. Trichloroacetimidate couplings were 
selected for the construction of the disaccharides, which themselves were further utilized in 
thioglycoside coupling reactions. The synthesis of the type-1 disaccharide, including a β1,3-
linkage, turned out to be synthetically more challenging, since problems with low reactivity 
and orthoester formation occurred. By improving the coupling conditions, the β1,3-connected 
type-1 disaccharide was finally prepared in high yields at a multigram scale. The synthesized 
β1,4- and β1,3-linked LacNAc thiophenyl donors approved to be universal building blocks as 
donors for appropriately protected amino acid acceptors 12 and 44. The products of the 
convergent synthesis approach were core 1, 2 and 3 mucin-type O-glycans, terminated by 
galactose. This strategy mimics the biosynthesis of complex O-glycans, which are 
enzymatically elongated by the alternating addition of N-acetylglucosamine followed by 
galactose (figure 5.1). 
 
Figure 5.1: Synthesized glycosylated amino acids for SPPS by convergent assembly of basic building blocks. 
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Glycosylation of the T-antigen acceptor 44 with either LacNAc donor 27 or 31 proceeded 
regioselectively on the more reactive 3-position of the galactose with full β-stereoselectivity. 
After changing the temporary protecting groups on the carbohydrate part to acetyl groups, 
the final type-1 core 1 and type-2 core 1 elongated amino acids 49 and 54, were ready to be 
applied in SPPS. The intermediate products 47 and 52 were also used for further 
regioselective glycosylation on the 6-position of the N-acetylgalactosamine with the 
thioglycoside donors 27 and 31, to result in the final core 2 hexasaccharide amino acids 58 
and 62 (figure 5.2).  
 
Figure 5.2: Synthesis route of extended core 1 and 2 amino acid building blocks. 
Glycosylations with the TN-antigen acceptor 12 and the thioglycoside donors 27 or 31 to form 
the corresponding elongated core 3 amino acids, gave unexpected results. Reaction of the 
type-1 donor 31 with acceptor 12 gave an anomeric mixture of the glycosylation product (α/β 
= 1:1.2). The diastereomers were separated after the successive hydrolysis of the 4,6-O-
para-methoxybenzylidene acetal and the 6’-O-tert-butyldimethylsilyl ether. Further protecting 
group manipulations provided the appropriately peracetylated type-1 core 3 amino acids for 
SPPS (figure 5.3, A). For formation of the type-2 core 3 trisaccharide amino acid, 
glycosylation with the type-2 donor 27 generated the desired β-anomer, but also formed a 
byproduct, with a phenyl sulfide group, attached to the nitrogen of the N-Troc carbamate 
(figure 5.3, B). Increased amounts of NIS as a promoter, were found to favor the formation of 
the phenyl sulfide adduct. Since the phenyl sulfide group could be removed in a later step 
along with N-Troc deprotection, increased amounts of NIS were applied, turning the 
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byproduct into the main product. After few protecting group manipulation steps the desired 
type-2 core 3 glycosylated amino acid was obtained, ready for SPPS. 
 
Figure 5.3: Glycosylation reactions for synthesis of extended core 3 amino acids. A: Reaction of donor 31 with 
acceptor 12 resulted in anomeric product 36 with type-1 extension. B: Reaction of donor 27 with acceptor 12 
resulted in product 32 with type-2 extension and N-phenyl sulfide group linked to N-Troc. 
The glycosylated amino acids were globally O-acetylated for protection of the carbohydrate 
moieties during Fmoc-SPPS. MUC1 tandem repeat glycopeptides were synthesized on 
Tentagel®-Trityl-resins. The glycosylated amino acids were incorporated at all three 
threonine glycosylation sites of the MUC1 tandem repeat to produce several variants of 
mono-, di- and triglycosylated MUC1 peptides. The amino acid sequences were equipped 
with an amino triethylene glycol spacer (TEG) on the N-terminus, as a linker for later 
immobilization to microarray chips (figure 5.4). 
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Figure 5.4: Synthesized MUC1 glycopeptide sequences. 
Further, the glycosylated amino acids were introduced into a sequence of the MUC5B 
tandem repeat. Similar to the synthesis of the MUC1 glycopeptides, several multivalent 
MUC5B glycopeptides were constructed (figure 5.5). MUC5B is one major protein involved in 
mucus formation in the lungs and respiratory pathways. In future works, these glycopeptides 
will be used for binding studies, for example with from Pseudomonas aeroginosa bacterial 
strains as well as the with the isolated bacterial lectins Lec A and Lec B. Pseudomonas 
aeroginosa is a contributor to chronic infections and inflammatory environment causing 
exacerbations in COPD and Asthma airway disease. 
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Figure 5.5: Synthesized MUC5B sequences. 
After solid phase peptide synthesis, the carbohydrate acetyl protecting groups were cleaved 
off in solution under basic conditions. TN-, T-antigen and core 3 structures were readily 
deprotected under Zemplén conditions. Elongated core 1 and core 2 glycopeptides required 
harsher conditions at pH of 11.5, in order to remove less the reactive 4’-O-acetyl group of the 
internal galactose unit. Certain β-elimination and some epimerization reactions were 
monitored by analytical HPLC and separated without problems from the desired products by 
preparative HPLC. 
A selected fraction of the chemically synthesized MUC1 glycopeptides were further 
employed in enzymatic termination of the peptide glycan chains by the use of the three α2,3-
sialyltransferases rat2,3OST (rat, recombinant, S. frugiperda), PmST1 and PmST3 (P. 
multocida) and the α2,6-sialyltransferase Pd2,6ST (P. damsela). The selection of peptides 
comprised representatives of various glycans with occupation of different glycosylation sites 
(figure 5.6). In continuing experiments, the variants of sialylated peptides will serve as 
standards for on-slide enzymatic modifications on glycopeptide microarray chips. During the 
course of this thesis, the sialylated MUC1 glycopeptides were already used in microarray 
evaluation of induced polyclonal antibody binding specificity against the sialylated MUC1 
glycopeptides as well as with carbohydrate binding plant lectins and human galectin-3. 
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Further, the fragmentation patterns of the sialylated peptides were analyzed by HCD-MS 
fragmentation. 
 
Figure 5.6: Synthesized MUC1 glycopeptides with terminal α2,3- or α2,6-N-acetylneuraminic acid. 
The α2,6-sialyltransferase Pd2,6ST has been reported to sialylate terminal as well as internal 
galactose units in poly-LacNAc oligosaccharide chains. Here, the enzyme was used to 
sialylate terminal type-2 and type-1 disaccharides and it was found capable to sialylate also 
internal galactose units of the fundamental core 1 substructure. However, the affinity to the 
internal core 1 galactose was lower and only peptides with glycosylation in the GSTA domain 
of the MUC1 tandem repeat were found to be partly sialylated (probably due to less sterical 
hindrance). The additional products, including an extra internal core 1 sialic acid, was 
collected if found in amounts significant enough for semi-preparative HPLC, as in peptides 
192, 198 and 204. The products of the enzymatic conversions were finally analyzed by 
analytical HPLC and high-resolution mass spectrometry. The characteristic HexNAc and 
Neu5Ac oxonium ions, originating from the glycans of the different glycopeptides by applying 
higher energy C-trap dissociation (HCD) fragmentation, were analyzed, regarding their 
relative intensities. It was found, that the ions of the HexNAc-fragmentation almost 
exclusively originate from βGlcNAc of the type-1 and type-2 LacNAc residues and not from 
the internal αGalNAc. The observed diagnostic oxonium ions could therefore be further used 
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to discriminate spectrometrically between the β1,3- and β1,4-linked LacNAc disaccharides, 
by comparing the relative ion intensities of the fragments, derived from HexNAc 
fragmentation. At the same time, the connectivity of the α2,3- and α2,6-linked Neu5Ac could 
be differentiated by comparing the relative intensities of the HexNAc+ and the Neu5Ac+ ions. 
Higher intensities of m/z 204 (HexNAc+) were found for peptides with α2,3-sialylation, while 
higher levels of m/z 274 (Neu5Ac+-H2O) were found in cases of α2,6-sialylation. These 
observations allowed distinguishing between the four isobaric trisaccharides residue variants 
(Neu5AcHexHexNAc), commonly terminating physiological glycan motifs on N- and O-
glycoproteins (table 5.1). 
Table 5.1: Oxonium ion profiles for isobaric Neu5AcHexHexNAc trisaccharide residues in HCD-MS fragmentation 
experiments (at 35% NCE). 
 
 
The oxonium ion pattern analysis may be integrated into standard glycoproteomic workflows. 
MS-analysis of the glycans after proteolytic digestion of the samples on the glycopeptide 
level would omit laborious wet lab modifications, such as β-elimination, hydrazinolysis and 
permethylation. Further, structural analysis on the intact glycopeptide, would retain the 
information of its origin from the former glycoprotein in complex samples. Oxonium ion profile 
analysis with CID or HCD for glycan sequencing paired with ETD or ECD for glycosylation 
site determination on the level of the glycopeptides may become extremely helpful in 
glycome and glycoproteome elucidation. The whole approach also underlines the importance 
of organic and chemoenzymatic carbohydrate and glycopeptide synthesis, providing useful 
standards for structural glycoproteomic analysis.  
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The synthesized mucin glycopeptide library was thus employed to study antibody and lectin 
interactions by microarray analysis. All glycopeptides were synthesized with a triethylene 
glycol spacer amino acid at the N-terminus with a single amine group for site selective and 
covalent immobilization to the amine reactive N-hydroxysuccinimide coated microarray 
surface. The prepared glycopeptide arrays were used to screen for polyclonal antibody 
binding specificity of murine antisera, induced by different synthetic anti-tumor vaccine 
candidates. The induced antibodies were obtained by immunization of mice with synthetic 
vaccine candidates, synthesized in the work group and by the collaborator, containing MUC1 
B-cell epitope glycopeptides and different immune stimulants (figure 5.7). 
 
Figure 5.7: Structures of synthetic vaccine candidates used for generation of polyclonal antibody immune sera in 
mice. 
The antisera of the mice were screened in various concentrations on the MUC1 microarray 
slides. The major findings were: 
 Vaccine candidates with TN-antigen glycosylation in both the immunodominant 
PDT*R region and the GS*T*A epitope domain of the MUC1 peptide tandem repeat, 
elicited antibodies with reactivity against the glycosylated PDT*R epitope. PDT*R-
specific antibodies, to a certain degree, tolerated extended core glycans in the 
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immunodominant domain in addition to the tumor-associated TN- or T-antigen 
structure that was included in the B-cell epitope of the vaccine. 
 Linear glycosylation (e.g. extended core 1 structures) in PDTR was preferred over 
branched core structures (e.g. extended core 2 structures). In the epithelial tissue of 
breast cells, core 2 glycans dominate cell surface glycosylation in the healthy state, 
compared to core 1 glycans in the tumor cells. This means that the induced serum 
antibodies discriminate to a great extent between healthy and cancerous cell surface 
glycosylation. 
 Triglycosylated MUC1 tandem repeat sequences with extended core 2 glycosylation 
on all three threonine glycosylation sites were typically not recognized by the serum 
antibodies. Thus, this glycoform variant is regarded as a mimic for MUC1 
glycosylation on healthy epithelial cells, which is entirely masking the protein 
epitopes. The induced antibodies are therefore expected to discriminate between 
extensive, healthy MUC1 cell glycosylation and malignant, truncated cancer 
glycosylation. 
 Immune reactivity directed against clustered (vicinal diglycosylated) TN-antigen 
glycosylation in the GS*T*A domain of the vaccine candidates, generated immune 
sera with restricted reactivity specifically for clustered TN-antigen glycosylation. In 
contrast to the immune response induced by PDT*R glycosylated with TN-antigen, no 
glycoform variation is tolerated by the antibodies. Hence, PDT*R and GS*T*A are 
fundamentally different classes of epitopes, according to the different reported 
peptide conformations. 
 Single glycosylation with tumor associated TN-antigen in GS*TA on a tripartite 
vaccine, elicited completely different antibody specificities in each of the three mice. 
Only one serum specificity was directed against glycosylation in GSTA. Single 
glycosylation in this domain appeared to be less immunogenic, compared to 
glycosylation in PDT*R. 
 B-cell epitope conjugation with a P30 T-helper-cell epitope alone (two-component 
vaccine), combined with P30 and Pam3CysSK4 TLR-2 ligand (three-component 
vaccine) or together with P30 conjugated to gold nanoparticles, produced similar 
antibody specificity profiles in several mice. However, different antibody isotype 
pattern and variances in antibody titers were observed. These factors are also 
important for vaccine efficiency. 
 B-cell epitope conjugation to tetanus toxoid resulted in very high antibody titers. The 
strong immune response appeared to create less glycoform and glycosylation site 
specific antibodies. However, the binding epitopes must contain the PDTR peptide 
sequence, hence the immune sera are still selective for the MUC1 tandem repeat 
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peptide sequence. Further, the antibody recognition was lost, when the MUC1 
tandem repeat peptides were glycosylated with extended core 2 hexasaccharides in 
all three threonine glycosylation sites. Discrimination of extensive glycosylation on 
proteins of healthy cells and truncated glycosylation of proteins on diseased cells may 
therefore occur by exclusion of glycan size and structure. 
In summary, the above described findings give new insights on antibody binding, elicited by 
synthetic vaccine constructs. Especially the contribution of the different glycosylation sites in 
MUC1 will help to understand the characteristics by which humoral immune responses react 
on tumor-associated MUC1 protein glycosylation and will aid with rationalizing vaccine 
designs. The presented glycoepeptide microarray system was for instance able to elucidate 
antibody cross-reactivity with various glycans at different sites, showing antibody 
discrimination between linear core 1 and branched core 2 structures. 
The glycopeptide library was further used to evaluate binding to plant lectins, with certain 
known glycan binding specificity. It was found, that the glycopeptide microarray platform was 
able to produce results according to the expected lectin binding. Additionally, new binding 
specificities for further fine-tuning of the known binding specificities were observed, such as 
discrimination for the sialylation site, structure of O-glycan core elongation, amino acid 
preferences and glycosylation site specificity. The glycopeptide array was further utilized to 
explore the binding behavior of recombinant human galectin-3 towards MUC1 glycopeptides 
decorated with typical mucin-type O-glycan decoration. The physiological and 
pathophysiological properties of the galectin family are under intensive research since they 
are involved in several intra- and extracellular processes, promoting tumor development. For 
instance, there is evidence that extracellular galectin-3 is involved in adhesion of circulating 
tumor cells to secondary epithelial sites. This adhesion process is facilitated by binding to 
overexpressed MUC1 via the tumor-associated T-antigen, influencing the MUC1 membrane 
localization and increasing the likeliness of selectin binding between the circulating tumor 
cells and the endothelial cell surface. 
Galectin-3 was incubated on the MUC1 glycopeptide chip at several concentrations. It was 
found that galectin-3 recognized the glycopeptides with tumor-associated TN- and T-antigen 
glycosylation as weak affinity ligands. The affinity for these antigens was however lower than 
for the core 1, core 2 and core 3 O-glycans. Glycopeptides with terminating α2,3-N-
acetylneuraminic acid showed increased recognition. This is interesting, since the influence 
of α2,3-sialylation is so far described as rather being tolerated by galectin-3 and in some 
reports even hindering interaction with glycoproteins. Previous studies have shown that 
modifications on the 2’- or 3’-position of N-acetyllactosamine with fucose, α-galactose or α-N-
acetylgalactosamine residues (but not yet N-acetylneuraminic acid) enhance binding by 
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fitting into the B-site of the galectin binding groove. In this study, it is shown that α2,3-
sialylation enhances galectin-3 affinity, supposedly by binding in this pocket. In accordance 
with already observed glycan recognition studies, α2,6-N-acetylneuraminic acid decorated 
glycopeptides showed decreased galectin-3 binding. Additional internal sialylation on the 
core 1 substructure further reduced galectin-3 binding, since galectin-3 is able to recognize 
internal galactose units. The α2,6-linked sialic acids have profound biological effects and are 
regarded as molecular switches, by which cells can regulate extracellular galectin-3 
mediated apoptosis. Although this kind of sialylation is predominantly found on N-glycans, 
the α2,6-sialylation on O-glycoproteins on tumor cells appears the to be increased. The 
found galectin-3 preferences are summarized in figure 5.8.  
 
Figure 5.8: Influence of O-glycan modifications on galectin-3 binding affinity. 
The use of glycopeptides with numerous occupied glycosylation sites allowed the evaluation 
of multivalent binding effects. Since the binding intensities increased exponentially from 
mono- to triglycosylated peptide variants, it was concluded that the binding mode is 
multivalent and must therefore be accompanied with galectin-3 oligomerization. 
In conclusion, the presented glycopeptide microarray platform is well equipped for evaluation 
of protein-glycan and protein-glycopeptide interactions. The glycopeptide library features a 
comprehensive selection of MUC1 peptides with various different core glycans presented in 
a multivalent fashion. Additionally, a MUC5B glycopeptide library was prepared, which can 
be used for further lectin binding studies. The constructed mucin glycopeptide library will also 
be modified by on-slide enzymatic glycosylation, in order to quickly produce more diverse 
glycan structures. Reactions with sialyl-, fucosyl-, α/β-galactosyl- or N-acetylgalactosaminyl- 
transferases can produce (sialyl-)Lewis antigens or blood group antigens. The synthesized 
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sialylated glycopeptides are a first step in this direction, since they will be used as standards 
for validation of on-slide enzymatic sialylation. In-solution chemoenzymatic syntheses were 
further used to optimize the enzyme reaction conditions and to test the enzyme substrate 
scope to different glycan structures. In addition to studies of human lectins, like the galectins, 
the constructed mucin glycopeptide array platform, will be used to study lectin interactions 
with viruses and bacteria, which e.g. are responsible for infections in airway diseases. 
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6 ZUSAMMENFASSUNG 
Tumorzellen unterscheiden sich von gesunden Zellen durch eine veränderte Glycosylierung 
der Proteine an der Zelloberfläche. Verminderte Expression von Core 2 
N-Acetylglucosaminyltransferase und erhöhte Expression von Sialyltransferasen, resultiert in 
verkürzten und vorzeitig sialylierten Glycanen. Mutationen des Gens COSMC sind 
verantwortlich für verminderte Level von C1Gn-T (T-synthase), wodurch die Ausbildung von 
Core 1 Glycanstrukturen unterbunden wird. Die verkürzten Kohlenhydrate repräsentieren 
Tumor-assoziierte Antigene und machen das Protein-Rückgrat zugänglich für Tumor-
spezifische Antikörper. Serum Autoantikörper gegen diese charakteristischen Strukturen 
wurden identifiziert und zeigen, dass eine Immunantwort gegen diese veränderten 
Zelloberflächenstrukturen möglich ist. Stimulation des Immunsystems mit geeigneten 
Vakzinen, welche gegen diese Strukturen gerichtet sind, könnten eine wertvolle Ergänzung 
der therapeutischen Methoden darstellen, um die Tumorlast zu senken, Schutz vor 
Metastasierung aufzubauen und Langzeitschutz gegen Rezidiven zu bilden.  
Ein vielversprechendes Ziel einer aktiven Vakzinierung in der Krebs-Immuntherapie, stellt 
das MUC1 Glycoprotein dar. Dieses membrangebundene Protein, welches sich an der 
Oberfläche von Epithelzellen befindet, wird auf Karzinomzellen überexprimiert und weist ein 
abnormes Glycosylierungsmuster auf. Organische Synthese ist eine zuverlässige Methode 
um definierte Vakzine darzustellen, welche auf der tandem repeat Peptidsequenz des 
MUC1-Proteins basieren und potentiell in der Immuntherapie eingesetzt werden können. 
Dabei besteht die Herausforderung darin, die Eigentoleranz des Immunsystems gegenüber 
diesen endogenen Strukturen zu überwinden, aber gleichzeitig eine garantierte Spezifität für 
die Tumor-assoziierten Strukturen zu erzeugen.  
Um die erzeugte Antikörperspezifität von potentiellen Vakzinen gegen Tumor-assoziierte 
MUC1 Strukturen untersuchen zu können, wurde im Rahmen dieser Arbeit ein MUC1 
Glycopeptid-Mikroarray System erstellt. Hierzu wurde eine Bibliothek von MUC1 
Glycopeptiden synthetisiert, welche dazu diente, die Bindungsspezifitäten von induzierten 
Antiköperseren zu evaluieren. So konnte die Kreuzspezifität der Antikörper für die 
erweiterten Core 1, 2 und 3 O-Glycan-Strukturen, welche dem Glycosylierungsmuster auf 
gesunden Epithelzellen entsprechen, mit der Spezifität für Peptide mit Tumor-assoziierten 
Antigenen, wie dem TN- und dem T-Antigen, verglichen werden. Dabei wurden die Glycane 
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auch in multivalenten Glycoformen der Peptide auf dem Array präsentiert, um die natürlichen 
Muster der zellulären Glycoproteine zu imitieren. Die Glycopeptide wurden in einer 
konvergenten Synthesestrategie, mit synthetischen glycosylierten Aminosäuren aufgebaut. 
Diese Aminosäuren wurden selbst aus einem Pool von wenigen Bausteinen synthetisiert, 
welcher es ermöglichte mehrere komplexe glycosylierte Aminosäuren zu erzeugen.   
Die modulare Strategie beinhaltete die Synthese von Type-1 (Galβ1,3-GlcNAcβ) und Type-2 
(Galβ1,3-GlcNAcβ) N-Acetyllactosamin Disacchariden 27 und 31, mit denen die TN- und T-
Antigen Glycosylakzeptoren flexibel erweitert werden konnten. Trichloracetimidat-vermittelte 
Kupplungen wurden für die Disaccharid-Synthesen ausgewählt, welche selbst als 
Thioglycoside in weiteren Glycosylierungen verwendet wurden. Die Synthese der Type-1 
Disaccharide war zunächst Aufgrund von Problemen mit niedrigen Reaktivitäten und 
Orthoester-Bildung synthetisch anspruchsvoller. Optimierung der Reaktionsbedingungen 
lieferte die β1,3-verknüpften Type-1 Disaccharide in hohen Ausbeuten auch in Multigramm-
Ansätzen. Die synthetisierten β1,4- und β1,3-verknüpften LacNAc Thioglycoside erwiesen 
sich als universelle Donoren für die entsprechend geschützten Aminosäure-Akzeptoren 12 
und 44. Die Produkte der konvergenten Synthese entsprachen Core 1, Core 2 und Core 3 O-
Glycanen mit terminalen Galactoseresten. Die verwendete Strategie imitierte die O-
Glycanbiosynthese, bei der die grundlegenden Core Strukturen enzymatisch durch 
alternierende Hinzufügung von N-Acetylglucosamin- und Galactose-Einheiten verlängert 
werden (Abbildung 5.1). 
 
Abbildung 6.1: Konvergente Synthese von glycosylierten Aminosäuren.   
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Glycosylierung des T-Antigen Akzeptors 44 mit den LacNAc-Donoren 27 oder 31 verlief 
regioselektiv an der reaktiveren 3‘-OH-Gruppe der Galactose mit voller β-Stereoselektivität. 
Nachdem die temporären Kohlenhydrat-Schutzgruppen gegen O-Acetylgruppen 
ausgetauscht wurden, konnten die finalen Type-1 und Type-2 Core 1 Aminosäuren 49 und 
54 in der Peptid-Festphasensynthese eingesetzt werden. Die Zwischenprodukte 47 und 52 
der Syntheseroute wurden für weitere Glycosylierungen in Position 6 des N-
Acetylgalactosamins mit Thioglycosid-Donoren 27 und 31 eingesetzt um, die Core 2 
Hexasaccharid-modifizierten Aminosäuren 58 und 62 darzustellen (Abbildung 5.2). 
 
Abbildung 6.2: Synthese der erweiterten core 1 und core 2 Aminosäuren.  
Bei den Glycosylierungen von TN-Antigen Akzeptor 12 mit den beiden Thioglycosid-Donoren 
zur  Darstellung der erweiterten Core 3 Aminosäuren, wurden unerwartete 
Reaktionsprodukte erhalten. Die Reaktion des Type-1 Donors 31 mit Akzeptor 12 lieferte ein 
anomeres Gemisch des Glycosylierungsprodukts (α/β = 1:1.2). Die Diastereomere konnten 
nach der folgenden sauren Hydrolyse der 4,6-O-para-Methoxybenzylidengruppe und der 6‘-
O-tert-Butyldimethylsilylethergruppe getrennt werden (Abbildung 5.3, A). Weitere 
Modifikationen des Schutzgruppenmusters ergab die peracetylierte Type-1 Core 3 
Aminosäure für den Einsatz in der Peptid-Festphasensynthese. Zur Darstellung der 
entsprechenden Type-2 Core 3 Trisaccharid-Aminosäure, lieferte die Glycosylierung mit 
Type-2 Donor 27 das erwünschte β-Anomer, allerdings mit einem Nebenprodukt, bei dem die 
Phenylsulfid-Abgangsgruppe an den Stickstoff des Carbamats der Troc-Schutzgruppe 
gebunden wurde (Abbildung 5.3, B). Reaktion mit N-Iodosuccinimid in hohem Überschuss, 
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lieferte das Phenylsulfid-Nebenprodukt als Hauptprodukt. Nach Anpassung der temporären 
Schutzgruppen, wurde die peracetylierte Type-2 Core 3 Aminosäure für die 
Festphasensynthese erhalten.  
 
Abbildung 6.3: Glycosylierungen zur Darstellung der Core 3 Aminosäure Bausteine. A: Reaktion des Donors 31 
mit Akzeptor 12 und Bildung des anomeren Produktgemischs 36. B: Reaktion von Donor 27 mit Akzeptor 12 
ergab Produkt 32 als Phenylsulfid-Addukt.   
Die MUC1 Peptidsequenzen wurden an Tentagel®-Trityl Harzen synthetisiert. Die 
Kohlenhydratreste waren während der Peptid-Festphasensynthese global mit O-
Acetylgruppen geschützt. Die glycosylierten Aminosäuren wurden an den drei Threonin-
Glycosylierungsstellen der Peptidsequenz eingebracht um verschiedene Glycoformen des 
mono-, di- und triglycosylierten MUC1 Peptids darzustellen. Um räumlichen Abstand 
zwischen der Mikroarray-Oberfläche und der Glycopeptidsequenz in folgenden 
Experimenten zu gewährleisten, wurden die Aminosäuresequenzen mit einer N-terminalen 
Triethylenglycol-Aminosäure (TEG)  synthetisiert (Abbildung 5.4).  
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Abbildung 6.4: Synthetisierte MUC1 Glycopeptid-Sequenzen. 
Weiterhin wurden die glycosylierten Aminosäuren in Peptid-Wiederholungssequenzen des 
Proteins MUC5B synthetisch eingebracht. Ähnlich der Synthese der MUC1 Glycopeptide, 
wurden multivalente Glycoformen der MUC5B-Sequenz hergestellt (Abbildung 5.5). MUC5B 
ist ein bedeutendes Glycoprotein, welches hauptsächlich für die Bildung von Mucus in den 
Atemwegen verantwortlich ist. In weiteren Studien, werden diese Glycopeptide für 
Bindungsstudien mit Atemwegs-infizierenden Bakterienstämmen, wie z.B. Pseudomonas 
aeroginosa, sowie isolierten bakteriellen Lektinen, wie z.B. Lec A und Lec B verwendet 
werden. Chronische Infektionen mit Pseudomonas aeroginosa und begleitenden 
Entzündungsprozessen stellen eine der Hauptfaktoren für schlechte Prognosen bei COPD 
(chronic obstructive pulmonary disease) und chronischen Asthmaerkrankungen dar.  
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Abbildung 6.5: Synthetisierte MUC5B-Glycopeptidsequenzen. 
Nach der Peptid-Festphasensynthese wurden die O-Acetylgruppen der Glycane unter 
basischen Bedingungen abgespalten. TN- und T-Antigen sowie Core 3 dekorierte 
Glycopeptide wurden problemlos unter standardmäßigen Zemplén Bedingungen bei pH 8,5 
entschützt. Erweiterte Core 1 und Core 2 Glycopeptide benötigten höhere pH-Werte (~11,5) 
um die reaktionsträgen 4‘-O-Acetylgruppe der internen Galactose zu hydrolsieren. Etwaige 
β-Eliminierungs- und Epimerisierungs-Produkte wurden mittels analytischer HPLC 
beobachtet und durch präparative HPLC abgetrennt.  
Ausgewählte MUC1 Glycopeptide wurden weiterhin durch enzymatische Sialylierung an den 
Glycanketten terminiert. Zum Einsatz kamen die drei α2,3-Sialyltransferasen Rat2,3OST (rat, 
recombinant, S. frugiperda), PmST1 und PmST3 (P. multocida) und die α2,6-
Sialyltransferase Pd2,6ST (P. damsela). Die Auswahl der Glycopeptide beinhaltete Vertreter 
mit verschiedenen Glycanen an unterschiedlichen Glycosylierungsstellen (Abbildung 5.6). In 
weiterführenden Experimenten können diese sialylierten Peptide als Standards für globale 
enzymatische Sialylierungen auf den Mikroarray Oberflächen dienen. Im Rahmen dieser 
Arbeit wurden die sialylierten MUC1 Peptide bereits verwendet um die Bindungsspezifitäten 
von polyklonalen Antikörpern aus Vakzinierungsexperimenten, sowie die 
Bindungsspezifitäten von Lektinen und humanem Galectin-3 zu evaluieren. Weiterhin 
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wurden die Fragmentierungsmuster der sialylierten Peptide durch HCD-MS Fragmentierung 
untersucht. 
 
Abbildung 6.6: MUC1 Glykopeptide mit terminaler α2,3- und α2,6-Sialylierung.  
Die Sialyltransferase Pd2,6ST ist in der Lage terminale, als auch interne Galactose-Einheiten  
in Type-2 poly-LacNAc Oligosacchariden zu sialylieren. In dieser Arbeit wurde das Enzym 
verwendet, um Sialinsäurereste an terminale type-2 und type-1 LacNAc-Reste zu binden. 
Dabei wurde festgestellt, dass Pd2,6ST auch in der Lage ist, die interne Galactose der 
Core 1 Substruktur von erweiterten Core 1 und Core 2 Glycanen zu modifizieren. Die Affinität 
des Enzyms zu der internen Galactose war geringer als zu terminalen Galactoseresten und 
ausschließlich Peptide mit Glycosylierung in der GSTA Domäne des MUC1-Peptids wurden 
zum Teil zusätzlich sialyliert (vermutlich aufgrund geringerer sterischer Behinderung). Dieses 
weitere Reaktionsprodukt, mit zusätzlicher interner Core 1 α2,6-Sialylierung wurde nach 
Möglichkeit ebenfalls isoliert, wie es bei den Glycopeptidsequenzen 192, 198 und 204 der 
Fall war. Die sialylierten Produkte aus den enzymatischen Reaktionen wurden mittels 
analytischer HPLC und hochauflösender Massenspektrometrie analysiert. Die 
charakteristischen HexNAc- und Neu5Ac-Oxoniumionen, welche unter HCD-
Fragmentierungsbedingungen (higher energy C-trap dissociation) auftraten, wurden 
bezüglich ihrer relativen Intensitäten untersucht. Es stellte sich heraus, dass es sich bei den 
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auftretenden HexNAc-Fragmentionen fast ausschließlich um Fragmente der β-GlcNAc aus 
den Type-1 und Type-2 LacNAc-Resten handelt und nur sehr wenig von den internen 
α-GalNAc Einheiten stammt. Die beobachteten, diagnostischen HexNAc-Fragmentionen 
konnten daher benutzt werden um spektrometrisch zwischen den β1,3- und β1,4-verknüpften 
LacNAc Disacchariden zu unterscheiden. Zusätzlich war es möglich, die Konnektivität der 
α2,3 oder α2,6 gebundenen Sialinsäurereste zu bestimmen, indem die relativen Intensitäten 
der HexNAc+-Ionen mit den Neu5Ac+-Ionen verglichen wurden. Höhere Intensitäten von m/z 
204 (HexNAc+) wurden für α2,6-Sialylierung gefunden, wobei hohe Level von m/z 274 
(Neu5Ac+-H2O) im Fall von α2,3-Sialylierung dominierten. Diese Beobachtungen 
ermöglichen es, die vier isobaren Trisaccharidreste, welche häufig physiologische N- und O-
Glycane terminieren, massenspektrometrisch zu unterscheiden (Tabelle 5.1). 
Tabelle 6.1: Intensitätsprofile der Oxoniumionen  für die vier isobaren Neu5AcHexHexNAc Trisaccharidreste in 
HCD-MS Fragmentierungsexperimenten (bei 35% NCE). 
 
 
Die Analyse von Oxoniumion-Profilen könnte standardmäßig in glycoproteomische 
Arbeitsabläufe eingefügt werden. Massenspektrometrische Analyse der Glycane nach dem 
proteolytischen Verdau der Proben auf Glycopeptid-Level, könnte aufwendige, nass-
chemische Methoden, wie β-Eliminierung, Hydrazinolyse und Permethylierung aussparen. 
Desweiteren würde die Strukturanalyse am intakten Glycopeptid die Information über seine 
Herkunft vom ursprünglichen Glycoprotein bewahren. Oxoniumionen-Analyse mittels CID 
oder HCD zur Glycansequenzierung, zusammen mit ETD oder ECD Fragmentierung zur 
Identifizierung der Glycosylierungsstellen auf Stufe des Glykopeptids, könnte ein hilfreiches 
Mittel sein in der Aufklärung des Glycoms und  Glycoproteoms. Desweiteren unterstreicht 
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dieser Ansatz die Wichtigkeit, von organischer und chemo-enzymatischer Synthese von 
Kohlenhydraten und Glycopeptiden, um wertvolle Standards für glycoproteomische 
Untersuchungen zu liefern.     
Die synthetische MUC1 Glycopeptidbibliothek wurde weiterhin benutzt um 
Wechselwirkungen mit Antikörpern und Lektinen durch Mikroarray-Analyse durchzuführen. 
Alle Glycopeptide wurden mit einer N-terminalen Triethylenglycol-Aminosäure als Linker 
synthetisiert, welche die einzige Aminogruppe des MUC1-Peptids beinhaltete. Somit wurden 
die Glycopeptide selektiv und gerichtet mit dem N-Terminus an N-
Hydroxysuccinimidgruppen-beschichtete Mikroarrays gebunden. Die so erhaltenen 
Glycopeptid-Arrays wurden benutzt um die Bindungsspezifität von polyklonalen Antikörpern 
aus murinen Antiseren zu untersuchen. Diese Antiseren wurden durch Immunisierung von 
Mäusen mit synthetischen Vakzin-Kandidaten erhalten, welche in der Arbeitsgruppe oder 
durch Kooperationspartner synthetisiert wurden. Die Vakzin-Kandidaten beruhten auf MUC1 
Glycopeptid-Strukturen als immunogene B-Zell-Epitope, konjugiert an diverse 
Immunstimulatoren. (Abbildung 5.7). 
 
Abbildung 6.7: Strukturen der synthetischen Vakzin-Kandidaten zur Erzeugung von Antiseren in Mäusen. 
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Die so erhaltenen Antiseren wurden in unterschiedlichen Konzentrationen auf den MUC1 
Glykopeptid-Mikroarrays auf Bindung untersucht. Die Ergebnisse dieser Untersuchungen 
waren:  
 Vakzin-Kandidaten mit TN-Antigen Glycosylierung in der immundominanten PDT*R 
Region und im GS*T*A Epitop des MUC1 Peptids, generieren Antikörper mit 
Spezifität für das glycosylierte PDT*R Epitop. PDT*R-spezifische Antikörper, 
tolerieren zu einem gewissen Grad erweiterte Core Glycane in der immundominanten 
Domäne, zusätzlich zu den Tumor-assoziierten TN- und T-Antigen Strukturen in den 
B-Zell Epitopen der Vakzin-Kandidaten. 
 Lineare Glycosylierung (z.B. erweiterte Core 1 Strukturen) in der PDTR Sequenz, 
wurde bevorzugt von den erzeugten Antikörpern erkannt, im Gegensatz zu 
verzweigter Glycosylierung (erweitere Core 2 Strukturen). Im Fall von 
Brustgewebszellen, dominiert verzweigte Core 2 Glycosylierung auf der Oberfläche 
gesunder Zellen, während auf Mammakarzinomzellen unverzweigte Core 1 
Strukturen überwiegen. Dies bedeutet, dass die erzeugten Antikörper zum großen 
Teil zwischen gesunder und krankhafter Zelloberflächenglycosylierung unterscheiden 
können.     
 Triglycosylierte MUC1 Peptidsequenzen mit erweiterter Core 2 Glycosylierung an 
allen drei Threonin-Glycosylierungsstellen, wurden durch die Antikörper kaum bis gar 
nicht erkannt. Daher können diese Glycoformen als repräsentativ für MUC1 
Glycosylierung auf gesunden Epithelzellen angesehen werden, welche die 
Proteinepitope komplett abschirmt. Es wird daher erwartet, dass die induzierten 
Antikörper zwischen extensiver MUC1 Glycosylierung auf gesunden Zellen und 
verkürzter Glycosylierung auf krankhaften Zellen unterscheiden können.  
 Immunreaktivität, welche sich gegen vicinale (clustered) TN-Antigen Glycosylierung in 
der GS*T*A Region der Vakzin-Kandidaten richtet, erzeugte Antiseren mit 
ausschließlicher Reaktivität der Antikörper für exakt diese vicinale TN-Antigen 
Glycosylierung. Im Gegensatz zu der Immunreaktivität, welche sich gegen die PDT*R 
Domäne mit nur einem TN-Antigen richtete, werden in der GS*T*A Sequenz keine 
anderen Glycoformen durch die Antikörper toleriert. Daher sind die beiden Domänen, 
einfach glycosylierte PDT*R Sequenz und vicinal glykosylierte GS*T*A Sequenz, als 
fundamental unterschiedliche Epitopklassen zu betrachten. Dies entspricht den in der 
Literatur beschriebenen Beobachtungen, dass die beiden glycoslierten 
Peptidsequenzen unterschiedliche Arten von Konformationen einnehmen.  
 Einzelne Glycosylierung mit TN-Antigen in der GS*TA Domäne eines Drei-
Komponenten Vakzin-Kandidaten, rief eine jeweils unterschiedliche 
Antikörperspezifität in den drei Mäusen hervor. Nur eines der drei Seren, zeigte dabei 
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eine Antikörperspezifität für die glycosylierte GS*TA Region. Einfache Glycosylierung 
mit nur einem Glycan in dieser Region scheint daher weniger immunogen zu sein, als 
doppelte, vicinale Glycosylierung in GS*T*A oder als entsprechende einfache 
Glycosylierung in der PDT*R Sequenz. 
 MUC1 B-Zell-Epitop, konjugiert mit einer P30 T-Zell-Epitop Peptidsequenz (Zwei-
Komponenten-Vakzine), kombinierte Konjugation mit P30 und Pam3CysSK4 (Drei-
Komponenten-Vakzine) oder Konjugation mit P30 an Goldnanopartikel, induzierte 
jeweils ähnliche Antikörper Spezifitäten in fast allen Mäusen. Dennoch unterschieden 
sich die verschiedenen Strategien in der Zusammensetzung der unterschiedlichen 
Antikörper-Isotypen und der Antikörpertiter. Hierbei handelt es ebenfalls um wichtige 
Parameter, welche die Effizienz eines Vakzins bestimmen.  
 Konjugation der MUC1 B-Zell-Epitope an ein Tetanus Toxoid Protein, induzierte sehr 
hohe Antikörpertiter. Die starke Immunreaktion scheint jedoch auf Kosten der 
Spezifität für Glycoformen und Glycosylierungstellen zu gehen. Dennoch musste das 
Peptidepitop die immundominante PDTR Sequenz enthalten, womit die Antiseren 
weiterhin eine Selektivität für die MUC1 Peptidsequenz aufwiesen. Weiterhin wurde 
die Erkennung durch die Antikörper stark beeinflusst, wenn alle Threonin-
Glycosylierungstellen mit verzweigten Core 2 Glycanen modifiziert waren. Eine 
Unterscheidung von MUC1 Proteinen auf gesunden oder erkrankten Zellen, scheint 
daher durch die ausgeprägten Glycanstrukturen zusammen mit einem hohen 
Glycosylierungsgrad möglich zu sein.   
Zusammenfassend lässt sich sagen, dass die beschriebenen Effekte neue Informationen 
über Bindungspezifitäten von Antikörpern geben, welche durch synthetische Vakzin-
Strukturen erzeugt wurden. Besonders deutlich wird die Beteiligung der unterschiedlichen 
Glycosylierungsstellen des MUC1 Peptids an der Erkennung durch die Antikörper. Dies trägt 
dazu bei, die Kriterien nach denen sich die humorale Immunreaktion gegen Tumor-
assoziierte Strukturen auf MUC1 Proteinen richtet, besser zu verstehen und Vakzin-Designs 
zu optimieren. Das vorgestellte Glycopeptid-Mikroarray System, konnte so zum Beispiel 
Antikörper-Kreuzreaktivität gegenüber verschiedenen Glycoformen aufzeigen, wie die 
Unterschiede zwischen Core 1 und Core 2 Erkennung 
Die Glycopeptidbibliothek wurde weiterhin dazu benutzt, um die Bindung von Lektinen zu 
evaluieren, deren Glycan-Spezifität bereits weitgängig bekannt ist. Der Glycopeptid-
Mikroarray bestätigte dabei die zu erwartenden Lektin-Bindungen. Es wurden allerdings auch 
einige neue Spezifitäten bezüglich unterschiedlicher gebundener Sialylierung, erweiterten O-
Glycan Core Strukturen und Aminosäure Präferenzen entdeckt, welche die bereits 
bekannten Spezifitäten weiter verfeinern. Der Glycopeptid-Mikroarray wurde auch benutzt 
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um das Bindungsverhalten von humanem Galectin-3 gegenüber O-Glycosylierung vom 
Mucin-Typ zu untersuchen. Die physiologischen und pathophysiologischen Funktionen der 
Galectine werden derzeit intensiv erforscht, besonders da sie an intra- und extrazellulären 
Prozessen beteiligt sind, welche die Entwicklung von Tumoren beeinflussen und fördern. 
Beispielsweise gibt es Hinweise darauf, dass extrazelluläres Galectin-3 an der Adhäsion von 
zirkulierenden Tumorzellen an epitheliale Oberflächen involviert ist. Diese 
Adhäsionsprozesse werden durch Bindung an Tumor-assoziiertes T-antigen auf 
überexprimiertem MUC1 begünstigt. Bindung von MUC1 durch Galectin-3 auf den 
zirkulierenden Tumorzellen führt vermutlich zu einer Lokalisierung des langen MUC1 
Proteins auf der Zelloberfläche, wodurch Zelladhäsionsproteine wie Selectine und 
Selectinliganden freigelegt werden und somit den Kontakt zu den Epithelzellen herstellen. 
Galectin-3 wurde auf einem MUC1 Glycopeptid-Array in unterschiedlichen Konzentrationen 
inkubiert. Dabei wurde beobachtet, dass sowohl die Tumor-assoziierten T-Antigene als auch 
die TN-Antigene Galectin-Bindungspartner darstellen. Die Affinität zu diesen Antigenen ist 
jedoch schwächer als die Bindungsaffinitäten zu den erweiterten Core 1, Core 2 und Core 3 
Glycanen. Glycopeptide mit terminierenden α2,3-N-Acetylneuraminsäureresten zeigten 
erhöhte Affinität zu Galectin-3. Dies ist interessant, da bisherige Studien α2,3-Sialylierung als 
Modifikation beschreiben, welche entweder ohne größeren Einfluss toleriert wird oder sogar 
die Affinität des Galectins zum Glycan senkt. Bisherige Studien zeigten weiterhin, dass 
Modifikation in 2‘- oder 3‘-Position von N-Acetyllactosamin mit Fucose, α-Galactose oder α-
N-Acetylgalactosamin die Bindung zu Galectin-3 verstärken, indem sie die B-Stelle der 
Glycanbindungstasche des Galectins besetzen. In dieser Arbeit wurde nun gezeigt, dass 
α2,3-Sialylierung die Bindungsaffinität gegenüber Galectin-3 steigert, vermutlich ebenfalls 
durch Anlagerung an die erwähnte B-Stelle. In Übereinstimmung mit bisherigen 
Erkenntnissen wurde beobachtet, dass Glycopeptide mit α2,6-Sialylierung, verringerte 
Bindung durch Galectin-3 aufwiesen. Weiterhin wurde die Bindung stark verringert, wenn die 
O-Glycane zusätzliche interne α2,6-Sialylierung aufwiesen, da Galectin-3 ebenfalls 
Galactose Einheiten binden kann, welche sich intern in einem Glycan befinden. Die 
Modifikation von Glycanen mit α2,6-verknüpfter Sialinsäure hat bedeutende biologische 
Funktionen. Sie wird als ein molekularer Schalter betrachtet, mit dem Zellen induzierte 
Apoptose durch extrazelluläres Galectin-3 regulieren können. Die gefundenen 
Bindungspräferenzen von Galectin-3 mit den präsentierten O-Glycanen sind in Abbildung 5.8 
zusammengefasst.  
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Abbildung 6.8: Einfluß von O-Glycan-Modifikationen auf Galectin-3 Bindungsaffinität. 
Die Benutzung von Glycopeptiden mit mehreren besetzten Glycosylierungsstellen, 
ermöglichte die Evaluierung von multivalenten Bindungseffekten. Da die 
Bindungsintensitäten exponentiell von mono- zu triglycosylierten Peptiden anstieg, kann 
gefolgert werden, dass es sich um einen multivalenten Bindungsmodus handelt, welcher 
Galectin-3 Oligomerisierung voraussetzt.  
Das im Rahmen dieser Arbeit vorgestellte Mikroarray System erwies als geeignet um 
Protein-Glycan und Protein-Glycopeptid Interaktionen zu untersuchen. Die 
Glycopeptidbibliothek umfasst eine umfangreiche Sammlung von MUC1 Glycopeptiden mit 
verschiedenen O-Glycanen in multivalenter Präsentation. Weiterhin wurde eine MUC5B 
Glycopeptidbibliothek dargestellt, welche ebenso für weitere Bindingsstudien mit Lektinen 
verwendet werden kann. Die Diversität der hergestellten Mucin Glycopeptidbibliothek wird in 
Zukunft durch enzymatische Modifikation direkt auf dem Mikroarray Chip erweitert werden. 
Durch Reaktionen mit Sialyl-, Fucosyl-, α/β-Galactosyl- oder 
N-Acetylgalactosaminyltransferasen lassen sich beispielsweise die biologisch relevanten 
(Sialyl-) Lewis- oder Blutgruppenantigene darstellen. Die synthetisierten, sialylierten 
Glycopeptide stellen einen ersten Schritt in diese Richtung dar, da sie als interne Standards 
zur Validierung der enzymatischen Sialylierung auf den Mikroarrays benutzt werden können. 
Die in Lösung durchgeführten enzymatischen Sialylierungen dienten auch der Optimierung 
der Reaktionsbedingungen und zum Testen der Substratspezifität der verwendeten 
Sialyltransferasen bezüglich komplexen O-glycosylierten Peptiden. Zusätzlich zur 
Untersuchung von verschiedenen Lektinen, kann das Glykopeptid-Arrays System in Zukunft 
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auch verwendet werden um Interaktionen mit ganzen Viren oder Bakterien zu untersuchen, 
welche zum Beispiel verantwortlich für Infektionen in den Atemwegen sind.  
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7 EXPERIMENTAL 
7.1 Syntheses of chapter 4.1 
7.1.1 General 
 
If not otherwise stated, all reactions were performed at room temperature. All distillations 
stated in vacuo, were performed at 40°C. 
 
Solvents: Solvents were purchased in the quality grade pro analysi (p.a.) and not further 
purified, if not otherwise stated. Drying of dichloromethane, chloroform and acetonitrile was 
performed by standing over calcium hydride and subsequent distillation under argon 
atmosphere. Analogous, nitromethane was dried with calcium chloride. Dry methanol, 
toluene and diethyl ether were purchased in septum-sealed bottles with molecular sieves 
(Acroseal®) from Acros Organics.     
 
Thin layer chromatography (TLC): Was performed using aluminum plates coated with 
silica gel (Kieselgel 60 F254) from Merck KGaA, Darmstadt. Spots were detected by: 
 UV light (254 nm) 
 “Sugar-stain”: 10% sulfuric acid in ethanol. Visualized by heat exposure.  
 Potassium permanganate solution (2 g KMnO4, 13.2 g K2CO3, 165 mg NaOH in 200 
mL H2O). Visualized by heat exposure. 
 
Optical rotation: Specific rotation (     
  ) was recorded on a Polaritronic HH8 from 
Schmidt + Heansch GmbH, Berlin at  λ = 598.5 (sodium D line). Solvents and concentrations 
are given with each compound.  
 
Flash column chromatography: Compounds were purified by flash column 
chromatography on silica gel (Kieselgel 60, 0.04-0.063 nm) from Carl Roth GmbH, Karlsruhe. 
Solvents were redistilled for further use in chromatography.  
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Mass spectrometry: ESI-spectra were measured with a Micromass LCT-spectrometer from 
Mircromass, Eschborn. High-resolution ESI-spectra were measured with a LTQ-FT ICR ultra 
mass spectrometer and Thermo Orbitrap Fusion Tribrid spectrometer, both Thermo 
Scientific. HPLC-MS was performed with the described analytical HPLC system coupled with 
a MSQ Plus spectrometer from Thermo Scientific.    
 
NMR-spectroscopy: 1H and 13C spectra were measured at the following instruments: 
 Varian Mercury 400, Agilent: 400 MHz 1H-NMR, 100.6 MHz 13C-NMR, COSY, 
TOCSY, HSQC, HMBC. 
 Advance DRX 500, Bruker: 500 MHz 1H-NMR, 125.8 MHz 13C-NMR, COSY, TOCSY, 
HSQC, HMBC. 
 Ascend 600, Bruker: 600 MHz 1H-NMR, 150.9 MHz 13C-NMR, COSY, TOCSY, 
HSQC, HMBC. 
All spectra were recorded at 295 K. The reported values for the chemical shifts δ (ppm) were 
calibrated to the residual proton or carbon resonance signal of the deuterated solvent, 
relatively correlated to the corresponding tetramethylsilane signal.373 Signal multiplicity is 
assigned as follows: s = singlet, d = duplet, t = triplet, q = quartet, m = multiplet, br = broad. 
Elucidation of the 1H and 13C signals was performed by usage of the gCOSY, gTOCSY, 
gHSQC and gHMBC correlation experiments as stated at the compound. For interpretation of 
the carbohydrate ring systems, the 1H and 13C signals are distinguished by assignment with 
apostrophes (ꞌ) as follows: 
 
Figure 7.1: Assignment of carbohydrate rings and atom positions. 
 ( ): α-N-acetyl-galactosamine (TN-Antigen) 
 (ꞌ): β-1,3-galactose (core 1, 2) or β-1,3-N-acetyl-glucosamine (core 3) 
 (ꞌꞌ): β-1,3-N-acetyl-glucosamine (core 1, 2) or β-1,3/4-galactose (core 3) 
 (ꞌꞌꞌ): β-1,3/4-galactose (core 1, 2) 
 (ꞌꞌꞌꞌ): β-1,6-N-acetyl-glucosamine (core 2) 
 (ꞌꞌꞌꞌꞌ): β-1,3/4-galactose (core 2) 
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Proton and carbon atoms of amino acids are assigned by indexed, greek letters.  
 
 
7.1.2 Synthesis of the TN-antigen glycosyl acceptor 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-L-threonine237 (2)  
(Fmoc-Thr-OH) 
 
 
 
To a solution of L-threonine 1 (10.14 g, 84.8 mmol) and sodium bicarbonate (7.44 g, 
88.1 mmol) in acetone/water (450 mL, 1:1) was added N-(9H-fluoren-9-yl)-methoxycarbonyl-
succinimidyl carbonate (28.55 g, 84.5 mmol) in portions and the reaction was stirred for 24 h. 
Then the reaction was acidified with 12 N HCl to pH 2. The acetone was removed in vacuo 
and the aqueous phase was extracted three times with dichloromethane (200 mL) and the 
combined organic phases were then washed two times with of 1 N HCl and two times with 
water (100 mL). The organic phase was dried over sodium sulfate, filtered and concentrated 
in vacuo. The residue was co-evaporated with toluene and dichloromethane (three times 
each).  
Yield: 28.0 g (82.0 mmol, 97%), pale yellow, amorphous solid, Rf = 0.24 (EtOAc + 1vol% 
AcOH).  
C19H19NO5 (M = 341.36 g/mol) [341.13]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.62 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.4 Hz), 
7.47 (m, 2H, H1-, H8-Fmoc), 7.27-7.16 (m, 4H, H2-, H3-, H6-, H7-Fmoc), 6.48 (sbr, 1H, OH), 
5.99 (d, 1H, NH, JNH,Tα = 9.3 Hz), 4.37-4.26 (m, 4H, CH2(Fmoc), T
α, Tβ), 4.07 (t, 1H, 
H9(Fmoc), JH9,CH2 = 7.1 Hz), 1.13 (d, 3H, T
γ, JTα,Tβ = 6.2 Hz). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-L-threonine-tert-butylester238,239,240 (3) 
(Fmoc-Thr-OtBu) 
 
 
 
A mixture of N,N´-dicyclohexylcarbodiimide (55.6 g, 270.0 mmol) and copper (I) chloride 
(650 mg, 6.6 mmol) in tert-butanol (25.53 g, 344.0 mmol) was stirred under argon 
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atmosphere in the dark for 3d. The mixture was then diluted with dry dichloromethane 
(30 mL) and cooled in an ice-bath. Fmoc-Thr-OH 2 (27.5 g, 80.6 mmol) was dissolved in dry 
dichloromethane (60 mL) and added dropwise to the stirred mixture. Stirring was continued 
for 45 min until TLC (toluene/acetone 4:1) indicated full consumption of Fmoc-Thr-OH 2. 
Precipitated urea was removed by filtration over Celite® and washed with dichloromethane. 
The organic phase was washed with saturated sodium bicarbonate solution (four times), 
dried over sodium sulfate and concentrated in vacuo. The residue was taken up in ethyl 
acetate (100 mL) and stored overnight at -20°C. Further precipitated urea was filtered off 
over Celite®. The solvent was concentrated in vacuo and the residue was purified by flash 
column chromatography on silica (CHex/EtOAc 4:1 → 3:1) and subsequent recrystallization 
from diethyl ether/petrol ether.  
Yield: 19.1 g (48.1 mmol, 60%), colorless crystals, Rf = 0.41 (
CHex/EtOAc 2:1). 
C23H27NO5 (M = 397.46 g/mol) [397.19]. 
ESI-MS (pos), m/z: 420.10 ([M+Na]+, calc. 420.18), 363.96 ([M-tBu+H]+, calc. 364.12). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.76 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.5 Hz), 
7.62 (d, 2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 7.6 Hz), 7.40 (t, 2H, H3-, H6-Fmoc, JH3,H2  = JH3,H4 
= JH6,H5 = JH6,H7 = 7.4 Hz), 7.31 (m, 2H, H2-, H7-Fmoc), 5.62 (d, 1H, NH, JNH,Tα = 9.0 Hz), 4.42 
(d, 2H, CH2(Fmoc), JCH2,H9 = 7.2 Hz), 4.30-4.22 (m, 3H, H9(Fmoc), T
α
, T
β), 2.14 (sbr, 1H, OH), 
1.49 (s, 9H, tBu), 1.24 (d, 3H, Tγ, JTγ,Tβ = 6.4 Hz). 
 
2,3,4,6-Tetra-O-acetyl-α-D-galactosylpyranosyl bromide (5) 
(αAc4GalBr) 
 
 
 
Acetic anhydride (600 mL, 6.4 mol) was cooled in an ice bath and perchloric acid (4 mL, 
60%) was added. D-(+)-galactose 4 (130.25 g, 722.7 mmol) was added in portions (with a 
spoon, waiting for the previous portion to dissolve) and stirred for 1 h at room temperature. 
The solution was cooled in an ice bath and phosphorus tribromide (391 g, 1.4 mol) was 
added dropwise, followed by slow dropwise addition of water (90 mL, 5.1 mol) in a way to 
prevent the temperature from rising above 20°C. The ice bath was removed and the reaction 
was stirred for 3 h. The reaction was diluted with dichloromethane (800 mL) and poured into 
ice-water (400 mL). The mixture was stirred until the ice was completely molten. The 
aqueous phase was separated and the organic phase washed with saturated sodium 
bicarbonate solution (two times). The organic phase was dried over magnesium sulfate, 
filtered and concentrated in vacuo. The residue was crystallized from of diethyl ether (150 
mL). The crystals were filtered off and washed with ice cold ether and cyclohexane. 
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Yield: 239.8 g (583.2 mmol, 81%), colorless crystals, Rf = 0.58 (Tol/EtOAc 3:2). 
C14H19BrO9 (M = 411.20 g/mol) [410.02]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.69 (d, 1H, H1, JH1,H2 = 4.0 Hz), 5.52 (dd, 1H, H4, 
JH4,H5 = 1.4 Hz, JH4,H3 = 3.3 Hz ), 5.40 (dd, 1H, H3, JH3,H4 = 3.3 Hz, JH3,H2 = 10.6 Hz), 5.04 (dd, 
1H, H2, JH2,H1 = 4.0 Hz, JH2,H3 = 10.6 Hz), 4.48 (m, 1H, H5), 4.14 (m, 2H, H6ab), 2.15, 2.11, 
2.05, 2.01 (4 x s; 4 x 3H, 4 x CH3(Ac)). 
 
 
3,4,6-Tri-O-acetyl-D-galactal234,235 (6) 
 
 
 
A mixture of water and acetic acid (700 mL) was cooled to -10°C. Zinc dust (112.73 g, 1.72 
mol) and copper (II) sulfate pentahydrate (12.32 g, 49.3 mmol) were added. After gas 
generation had started, αAc4GalBr 5 (110.11 g, 267.8 mmol) dissolved in dichloromethane 
(110 mL) was added dropwise. After addition, a second batch of zinc dust (55.09 g, 
840.1 mmol) and copper (II) sulfate pentahydrate (6.73 g, 27.0 mmol) was added. The 
reaction was stirred for another 3 h. The zinc was filtered off and washed with water/acetic 
acid (1:1) and with dichloromethane. The filtrate was transferred into a separation funnel and 
extracted with dichloromethane (three times). The organic phase was washed with water and 
saturated sodium bicarbonate solution. The organic phase was dried over magnesium 
sulfate, filtered and concentrated in vacuo. The product was obtained after flash column 
chromatography on silica (CHex/EtOAc 4:1).  
Yield: 58.7 g (215.6 mmol, 80%), colorless oil, Rf = 0.49 (Tol/EtOAc 3:2).  
C12H16O7 (M = 272.25 g/mol) [272.09]. 
ESI-MS (pos), m/z: 294.79 ([M+Na]+, calc. 295.08). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.41 (dd, 1H, H1, JH1,H2 = 7.1 Hz, JH1,H3 = 1.7 Hz), 5.52-
5.49 (m, 1H, H3), 5.38-5.36 (m, 1H, H4), 4.68 (ddd, 1H, H2, JH2,H1 = 6.3 Hz, JH2,H3 = 2.7 Hz, 
JH2,H4 = 1.5 Hz), 4.30-4.14 (m, 3H, H5, H6ab), 2.08, 2.03, 1.99 (3 x s, 3 x 3H, 3 x CH3(Ac)). 
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3,4,6-Tri-O-acetyl-2-azido-2-desoxy-α/β-D-galactosylpyranosyl nitrate236 (7)  
(α/βAc3GalN3-ONO2)  
 
 
 
Cerium (IV) ammonium nitrate (114.75 g, 209.2 mmol) and sodium azide (7.03 g, 
108.1 mmol (both thoroughly grinded in a mortar and vacuum-dried) were carefully added to 
dry acetonitrile, cooled to -20°C under argon atmosphere. Galactal 6 (18.66 g, 68.5 mmol) 
was dissolved in dry acetonitrile (150 mL) and added dropwise to the flask. The temperature 
was kept between -10°C and -20°C and the reaction was stirred until TLC (Tol/EtOAc 7:3) 
indicated full consumption of the starting material (after 5.5 h). The reaction mixture was 
diluted with diethyl ether (500 mL) and washed with ice cold water (three times, 300 mL 
each). The organic phase was dried over sodium sulfate and the solvent was concentrated in 
vacuo. The product was obtained from the residue after flash column chromatography on 
silica (CHex/EtOAc 4:1).  
Yield: 15.03 g (α/β 1:1, 39.9 mmol, 58 %), light yellow, amorphous solid, Rf = 0.56 
(Tol/EtOAc 7:3). 
C12H16N4O10 (M = 376.28 g/mol) [376.09]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.33 (d, 1H, H1
α, JH1α,H2α = 4.2 Hz), 5.58 (d, 1H, H1
β
, 
JH1β,H2β = 8.8 Hz), 5.49 (m, 1H, H4
α), 5.38 (m, 1H, H4β), 5.25 (dd, 1H, H3α, JH3α,H2α = 11.3 Hz, 
JH3α,H4β = 3.2 Hz), 4.96 (dd, 1H, H3
β, JH3β,H2β = 10.6 Hz, JH3β,H4β = 3.3 Hz), 4.36 (m, 1H, H5
α), 
4.14-4.03 (m, 6H, H2α, H5β, H6αab, H6
β
ab), 3.81 (dd, 1H, H2
β, JH2β,H1β = 8.8 Hz, JH2β,H3β = 10.6 
Hz), 2.16 (s, 6H, CH3(Ac
α), CH3(Ac
β)), 2.07, 2.06, 2.03, 2.02 (4 x s, 4 x 3H, CH3(Ac
α), 
CH3(Ac
β)). 
 
 
3,4,6-Tri-O-acetyl-2-azido-2-desoxy-α-D-galactosylpyranosyl bromide236 (8)  
(αAc3GalN3-Br) 
 
 
 
α/βAc3GalN3-ONO3 7 (14.52 g, 38.5 mmol) was dissolved in dry acetonitrile (300 mL). Lithium 
bromide (34.56 g, 397.2 mmol, vacuum-dried and grinded in a mortar before usage) was 
added and the suspension was stirred for 16 h. The reaction was diluted with 
dichloromethane (300 mL) and washed with brine (three times, 100 mL each). The organic 
phase was dried over sodium sulfate, concentrated in vacuo and the residue was purified by 
flash column chromatography on silica (CHex/EtOAc 4:1).  
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Yield: 12.83 g (32.7 mmol, 85%), colorless, amorphous solid, Rf = 0.64 (Tol/EtOAc 7:3). 
C12H16BrN3O7 (M = 394.18 g/mol) [393.04]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.46 (d, 1H, H1, JH1,H2 = 3.8 Hz), 5.49 (dd, 1H, H4, 
JH4,H3 = 3.2 Hz, JH4,H5 = 1.3 Hz), 5.33 (dd, 1H, H3, JH3,H2 = 10.7 Hz, JH3,H4 = 3.2 Hz), 4.47 (m, 
1H, H5), 4.19-4.11 (m, 2H, H6a,b), 3.97 (dd, 1H, H2, JH2,H3 = 10.7 Hz, JH2,H1 = 3.8 Hz), 2.15, 
2.05, 2.04 (3 x s, 3 x 3H, CH3(Ac)). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(3,4,6-tri-O-acetyl-2-azido-2-desoxy-α-D-
galactosylpyranosyl)-L-threonine-tert-butylester240,208,221,241 (9) 
(Fmoc-Thr(αAc3GalN3)-OtBu) 
 
 
 
 
Fmoc-L-threonine-OtBu 3 (22.24 g, 55.8 mmol) was dissolved in dry dichloromethane/toluene 
(300 mL, 1:1) and stirred with molecular sieves (20.3 g, 4Å) for 45 min under argon 
atmosphere. The mixture was cooled in an ice bath. Then silver carbonate (21.05 g, 76.1 
mmol, vacuum dried) and silver perchlorate monohydrate (3.42 g,15.2 mmol, three times 
carefully co-evaporated with 20 mL dry toluene each) in dry toluene (40 mL) were added and 
the reaction was stirred for 30 min in the dark. Then αAc3GalN3-Br 8 (19.85 g, 49.9 mmol) 
dissolved in dry dichloromethane/toluene (200 mL, 1:1) was added dropwise and the reaction 
was stirred for 24 h in the dark while the reaction warmed up to room temperature. The 
molecular sieves were filtered off over Celite® and washed with dichloromethane (400 mL). 
The solution was washed with saturated sodium bicarbonate solution (three times) and with 
water and brine (once each). The organic phase was separated, dried over sodium sulfate, 
filtered and the concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica (DCM/EtOAc 40:1).  
Yield: 21.39 g (30.1 mmol, 60%), colorless, amorphous solid, Rf = 0.34 (DCM/EtOAc 20:1). 
C35H42N4O12 (M = 710.73 g/mol) [710.28]. 
ESI-MS (pos), m/z: 710.80 ([M+H]+, calc. 711.28); 733.13 ([M+Na]+, calc. 733.72). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.76 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.5 Hz), 
7.63 (d, 2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 7.4 Hz), 7.42-7.31 (m, 4H, H2-, H7-, H3-, H6-
Fmoc), 5.65 (d, 1H, NH-Fmoc, JNH,Tα = 9.4 Hz), 5.47 (m, 1H, H4), 5.34 (dd, 1H, H3, JH3,H2 = 
11.2 Hz, JH3,H4 = 3.0 Hz), 5.11 (d, 1H, H1, JH1,H2 = 3.6 Hz), 4.45-4.25 (m, 6H, H9-, CH2(Fmoc), 
H5, Tα, Tβ), 4.13-4.09 (m, 2H, H6ab), 3.64 (dd, 1H, H2, JH2,H3 = 11.2 Hz, JH2,H1 = 3.7 Hz), 2.15, 
2.07, 2.04 (3x s, 3 x 3H, 3 x CH3(Ac)), 1.51 (s, 9H, tBu), 1.35 (d, 3H, T
γ, JTγ,Tβ =  6.4 Hz).  
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-3,4,6-tri-O-acetyl-2-desoxy-α-D-
galactosylpyranosyl)-L-threonine-tert-butylester243 (10)  
(Fmoc-Thr(αAc3GalNAc)-OtBu) 
 
 
 
 
Fmoc-Thr(αAc3GalN3)-OtBu 9 (21.33 g, 30.0 mmol) was dissolved in pyridine/thioacetic acid 
(100 mL, 1:1) and stirred at room temperature for 2 d. The precipitate was filtered off and 
washed with pyridine and toluene. The filtrate was co-evaporated with toluene. The residue 
was taken up with ethyl acetate (100 mL), further precipitate was filtered off, washed and the 
filtrate concentrated in vacuo. The product was purified by flash column chromatography on 
silica (CHex/EtOAc 1:1 → 1:2). 
Yield: 16.61 g (22.8 mmol, 76%), colorless, amorphous solid, Rf = 0.27 (
CHex/EtOAc 1:2).  
C37H46N2O13 (M = 726.77 g/mol) [726.30]. 
ESI-MS (pos), m/z: 748.98 ([M+Na]+, calc. 749.29), 727.01 ([M+H]+, calc. 727.31), 670.80 
([M-tBu+H]+, calc. 671.24). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.77 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.7 Hz), 
7.64 (d, 2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 7.6 Hz), 7.42-7.33 (m, 4H, H2-, H7-, H3-, H6-
Fmoc), 5.93 (d, 1H, NH-Fmoc, JNH,Tα = 9.8 Hz), 5.45 (d, 1H, NH-Ac, JNH,H2 = 9.4 Hz), 5.39 (m, 
1H, H4), 5.08 (dd, 1H, H3, JH3,H2 = 11.3 Hz, JH3,H4 = 3.2 Hz), 4.89 (d, 1H, H1, JH1,H2 = 3.7 Hz), 
4.61 (m, 1H, H2), 4.38 (m, 2H, CH2(Fmoc)), 4.22-4.12 (m, 4H, H9(Fmoc), H5, T
α, Tβ), 2.16, 
2.04, 2.00 (3 x s, 4 x 3H, 4 x CH3(Ac)), 1.46 (s, 9H, tBu), 1.26 (d, 3H, T
γ, JTγ,Tα = 6.4 Hz). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-2-desoxy-α-D-
galactosylpyranosyl)-L-threonine-tert-butylester208,237 (11)  
(Fmoc-Thr(αGalNAc)-OtBu) 
 
 
 
 
Fmoc-Thr(αAc3GalNAc)-OtBu 10 (27.98 g, 38.5 mmol) was dissolved in methanol (250 mL) 
and a solution of sodium methoxide (1 wt%) in methanol was added slowly in a dropwise 
manner, until pH 9.5 was established (wet pH paper). After 24 h TLC showed the main 
deacetylated product plus product with cleavage of the Fmoc-group. The reaction was 
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neutralized with acidic cation exchange resin (Dowex 50WX8). The resin was filtered off and 
the solvent removed in vacuo. The residue was taken up with 1,4-dioxane (150 mL) and a 
solution of sodium bicarbonate (4.09 g, 48.7 mmol) in water (150 mL) was added. Then N-9-
Fluorenylmethyloxycarbonyl-succinimidylcarbonate (6.89 g, 20.4 mmol) was added and the 
suspension was stirred for 16 h at room temperature. The majority of the 1,4-dioxane was 
removed in vacuo and of ethyl acetate (600 mL) was added. The organic phase was washed 
with saturated sodium bicarbonate, water and brine. The organic phase was dried over 
sodium sulfate, filtered and the concentrated in vacuo. The residue was purified by flash 
column chromatography on silica (EtOAc → EtOAc/MeOH 15:1).  
Yield: 21.00 g (35.0 mmol, 91%), colorless, amorphous solid, Rf = 0.26 (EtOAc/MeOH 15:1). 
C31H40N2O10 (M = 600.66 g/mol) [600.27]. 
ESI-MS (pos), m/z: 601.00 ([M+H]+, calc. 601.28). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.76 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.3 Hz), 
7.60 (d, 2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 7.6 Hz), 7.41-7.29 (m, 4H, H2-, H7-, H3-, H6-
Fmoc), 6.86 (d, 1H, NH-Ac, JNH,H2 = 7.8 Hz), 5.75 (d, 1H, NH-Fmoc, JNH,Tα = 9.4 Hz), 4.95 (sbr, 
1H, OH), 4.87 (d, 1H, H1, JH1,H2 = 3.0 Hz), 4.44-4.40 (m, 2H, CH2(Fmoc)), 4.31-4.24 (m, 3H, 
H9(Fmoc), H2, Tα), 4.14 (m, 1H, Tβ), 4.04 (m, 1H, H4), 3.92-3.82 (m, 5H, H3, H5, H6ab, OH), 
2.10 (s, 3H, CH3(Ac)), 1.44 (s, 9H, tBu), 1.29 (d, 3H, T
γ, JTγ,Tβ
 = 6.2 Hz). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 171.29, 171.06 (C=O(Ac), COOtBu), 156.66 
(C=O(Fmoc)), 143.28 (C1a-, C8a-Fmoc), 141.45 (C4a-, C5a-Fmoc), 127.91 (C3-, C6-Fmoc), 
127.22 (C2-, C7-Fmoc), 125.13 (C1-, C8-Fmoc), 120.14 (C4-, C5-Fmoc), 99.73 (C1), 83.44 
(Cq(tBu)), 76.51 (T
β), 71.01, 70.21, 69.92 (C3, C4, C5), 67.32 (CH2(Fmoc)), 62.70 (C6), 
59.12 (Tα), 50.99, 47.34 (C9(Fmoc), C2), 28.20 (tBu), 23.06 (CH3(Ac)), 21.18 (T
α).  
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-4,6-O-para-
methoxybenzylidenacetal-2-desoxy-α-D-galactosylpyranosyl)-L-threonine-tert-
butylester (12) 
(Fmoc-Thr(PMP-GalNAc)-OtBu) 
 
 
 
 
 
A solution of Fmoc-Thr(αGalNAc)-OtBu 11 (15.06 g, 25.8 mmol) and para-
methoxybenzaldehyde dimethyl acetal (5.94 g, 32.7 mmol) in dry acetonitrile (150 mL) was 
adjusted to pH 4.5 by addition of para-toluenesulfonic acid monohydrate (careful addition 
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with the tip of a spatula). The reaction was stirred for 2.5 h and then neutralized with a few 
drops of N,N-diisopropylethylamine. The solvent was removed in vacuo and the residue was 
purified by flash column chromatography on silica (CHex/EtOAc 1:1 → 1:2). 
Yield: 16.38 g (22.8 mmol, 91%), colorless, amorphous solid, Rf = 0.33 (Tol/EtOAc 1:2). 
C39H46N2O11 (M = 718.79 g/mol) [718.31]. 
ESI-MS (pos), m/z: 718.93 ([M+H]+, calc. 719.32), 741.13 ([M+Na]+, calc. 741.30), 1436.80 
([2M+H]+, calc. 1437.63). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.77 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.5 Hz), 
7.61 (d, 2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 8.0 Hz), 7.45-7.32 (m, 6H, H2-, H7-, H3-, H6-
Fmoc, H2-, H6-PMP), 6.88 (d, 2H, H3-, H5-PMP, JH2,H1 = JH3,H4 = 8.4 Hz), 6.50 (d, 1H, NH-
Fmoc, JNH,Tα = 8.6 Hz), 5.60 (d, 1H, NH-Ac, JNH,H2 = 9.5 Hz), 5.50 (s, 1H, CH(PMP)), 4.95 (d, 
1H, H1, JH1,H2 = 3.6 Hz), 4.52-4.43 (m, 3H, CH2(Fmoc), H2), 4.27-4.01 (m, 6H, H9(Fmoc), 
H5, H6a,b, T
α, Tβ), 3.88-3.83 (m, 1H, H3), 3.79 (s, 3H, CH3(PMP)), 3.68 (s, 1H, H4), 3.17 (sbr, 
1H, OH), 2.10 (s, 3H, CH3(Ac)), 1.46 (s, 9H, CH3(tBu)), 1.29 (d, 3H, T
γ, JTγ,Tβ = 5.9 Hz).   
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 172.54, 170.84 (C=O(Ac), COOtBu), 160.28 
(Cpara(PMP)), 156.59 (C=O(Fmoc)), 143.80 (C1a-, C8a-Fmoc), 141.45 (C4a-, C5a-Fmoc), 
132.11 (Carom(PMP)), 130.23 (Cipso(PMP)), 127.90, 127.81, 127.12 (C3-, C6-Fmoc, 
Carom(PMP)), 125.17 (C1-, C8-Fmoc), 120.14 (C4-, C5-Fmoc), 114.43, 113.69 (Carom(PMP)), 
101.27 (CH(PMP)), 100.58 (C1), 83.46 (Cq(tBu), 76.46 (T
β), 75.63 (C5), 69.72 (C3), 69.27 
(C6), 67.32 (CH2(Fmoc)), 63.77 (C4), 59.08 (T
α), 55.41 (CH3(PMP)), 47.33 (C9(Fmoc)), 
28.21 (tBu), 23.19 (CH3(Ac)), 19.13 (T
γ). 
 
7.1.3 Synthesis of the T-antigen amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-3-O-[2,3,4,6-tetra-O-acetyl-α-D-
galactosylpyranosyl]-4,6-O-para-methoxybenzylidenacetal-2-desoxy-α-D-
galactosylpyranosyl)-L-threonine-tert-butylester220,244,245 (13) 
(Fmoc-Thr(αAc4Gal-(13)-αPMP-GalNAc)-OtBu) 
 
 
 
 
 
Fmoc-Thr(PMP-GalNAc)-OtBu 12 (2.72 g, 3.78 mmol) was dissolved in a mixture of dry 
nitromethane and dry dichloromethane (105 mL, 2:1) under argon atmosphere. Activated 
molecular sieves (4 g, 4Å) and mercury (II) cyanide (2.87 g, 11.36 mmol) were added in the 
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dark. The mixture was stirred for 45 min and then αAc4GalBr 5 (4.69 g, 11.41 mmol) 
dissolved in dry dichloromethane (5 mL) was added in portions (1 mL) over 40 min and the 
reaction was stirred in the dark. After 3 h another of portion of mercury (II) cyanide (950 mg, 
3.76 mmol) was added and the reaction was stirred for 20 h in the dark. The molecular 
sieves were filtered off over Celite® and washed with dichloromethane. The dichloromethane 
phase was washed with saturated sodium hydrogen carbonate solution (three times, 100 mL 
each), saturated sodium iodide solution (two times, 80 mL each) and once with brine (100 
mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography on silica 
(CHex/EtOAc 1:1 → 1:2). 
Yield: 2.77 g (2.64 mmol, 70%), colorless, amorphous solid,      
   +74.76 (c = 0.49, CHCl3), 
Rf = 0.48 (Tol/EtOAc 1:3). 
C53H64N2O20 (M = 1048.41 g/mol) [1049.41]. 
ESI-MS (pos), m/z: 1071.20 ([M+Na]+, calc. 1071.39). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.71 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.2 Hz), 
7.54 (m, 2H, H1-, H8-Fmoc), 7.39 (d, 2H, H2-, H6-PMP, JH2,H3 = JH6,H5 = 8.6 Hz), 7.36-7.23 
(m, 4H, H2-, H3-, H6-, H7-Fmoc), 6.81 (d, 2H, H3-, H5-PMP, JH3,H2 = JH5,H6 = 8.8 Hz), 5.75 (d, 
1H, NH-Ac, JNH,H2 = 7.3 Hz), 5.50-5.44 (m, 2H, NH-Fmoc, CH(PMP)), 5.31 (s, 1H, H4ꞌ), 5.12 
(dd, 1H, H2ꞌ, JH2’,H1’ = 7.9 Hz, JH2’,H3’ = 9.7 Hz), 4.91-4.88 (m, 2H, H1, H3ꞌ), 4.66-4.60 (m, 2H, 
H1ꞌ, H2), 4.47-4.38 (m, 2H, CH2(Fmoc)), 4.18-3.82 (m, 10H, H3, H5, H6a,b, H5ꞌ, H6ꞌa,b, 
H9(Fmoc), Tα, Tβ), 3.72 (s, 3H, CH3(PMP)), 3.59 (m, 1H, H4), 2.28, 2.06, 1.97, 1.94, 1.90 (5 x 
s, 5 x CH3(Ac)), 1.39 (s, 9H, tBu), 1.23-1.18 (m, 3H, T
γ). 
13C-NMR (100.6 MHz, HSQC, CDCl3), δ (ppm): 170.50, 170.39, 170.27, 169.80, 169.56 
(C=O(Ac), COOtBu), 160.07 (Cpara(PMP)), 156.58 (C=O(Fmoc)), 143.78 (C1a-, C8a-Fmoc), 
141.46 (C4a-, C5a-Fmoc), 130.31 (Carom(PMP)), 129.13, 128.32, 127.94, 127.65, 127.19 (C3-, 
C6-, C2-, C7-Fmoc, 3 x Carom(PMP)), 125.39 (C1-, C8-Fmoc), 120.19 (C4-, C5-Fmoc), 
113.63 (Carom(PMP)), 101.38 (C1), 100.58 (CH(PMP)), 100.51 (C1ꞌ), 83.30 (Cq(tBu)), 76.46 
(Tβ), 75.69 (C5), 74.39 (C3), 71.02 (C3ꞌ, C5ꞌ), 69.16 (C6), 68.86 (C2ꞌ), 67.14 (C4ꞌ, 
CH2(Fmoc)), 63.82 (C4), 61.44 (C6ꞌ), 59.21 (T
α), 55.40 (CH3(PMP)), 47.96 (C2), 47.39 
(C9(Fmoc)), 28.21 (tBu), 23.60, 21.55, 20.82, 20.67 (CH3(Ac)), 19.07 (T
γ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-3-O-[2,3,4,6-tetra-O-acetyl-α-D-
galactosylpyranosyl]-4,6-O-acetyl-2-desoxy-α-D-galactosylpyranosyl)-L-threonine-tert-
butylester220 (14)  
(Fmoc-Thr(αAc4Gal-(13)-αAc2GalNAc)-OtBu) 
 
 
 
 
A solution of Fmoc-Thr(αAc4Gal-(1→3)-αPMP-GalNAc)-OtBu 13 (833 mg, 0.85 mmol) in 
80% acetic acid (15 mL) was stirred at 50°C for 4 h. The reaction was co-evaporated with 
toluene. The residue was taken up with pyridine/acetic anhydride (15 mL, 2:1) and stirred for 
16 h. The reaction was concentrated in vacuo and the residue was co-evaporated with 
toluene. The crude product was purified by flash column chromatography on silica 
(CHex/EtOAc 1:2).  
Yield: 782 mg (0.77 mmol, 90%), colorless, amorphous solid,      
   +50.20 (c = 0.51, CHCl3), 
Rf = 0.48 (Tol/EtOAc). 
ESI-MS (pos), m/z: 1014.93 ([M+H]+, calc. 1015.39). 
C49H62N2O21 (M = 1015.02 g/mol) [1014.38]. 
1H NMR (400 MHz, 25°C, internal CDCl3, δ(H) = 7.26 ppm): 7.78 (d, 
3J(H-4,H-3) = 3J(H-5,H-
6) = 7.6 Hz, 2H, H-4-, H-5-Fmoc), 7.61 (d, 3JH1,H2 = 
3JH8,H7 = 7.0 Hz, 2H, H-1-, H-8-Fmoc), 
7.42 (t, 3J(H-3,H-4) = 3J(H-3,H-2) = 3J(H-6,H-5) = 3J(H-6,H-7) = 7.5 Hz, 2H, H-3-, H-6-Fmoc), 
7.33 (t, 3J(H-2,H-3) = 3J(H-2,H-1) = 3J(H-7,H-8) = 3J(H-7,H-6) =  7.5 Hz, 2H, H-2-, H-7-Fmoc), 
5.99 (d, 3J(NH,H-2) = 9.8 Hz, 1H, NH-Ac), 5.44 (d, 3J(NH,H-2) = 8.9 Hz, 1H, NH-Fmoc), 5.37-
5.34 (m, 2H, H-4, H-4ꞌ), 5.09 (dd, 3J(H-2ꞌ,H-1ꞌ) = 7.7 Hz, 3J(H-2ꞌ, H-3ꞌ) = 10.5 Hz, 1H, H-2ꞌ), 
4.94 (dd, 3J(H-3ꞌ,H-2ꞌ) = 10.5 Hz, 3J(H-3ꞌ,H-4ꞌ) = 3.0 Hz), 4.83 (s, 1H, H-1), 4.59-4.49 (m, 4H, 
H-1ꞌ, H-2, CH2ab-Fmoc), 4.27-4.09 (m, 7H, H-6ab, H-6ꞌab, H-9-Fmoc, T
α, Tβ), 4.01-3.97 (m, 1H, 
H-5ꞌ), 3.88-3.85 (m, 1H, H-5ꞌ), 3.79 (d, 3J(H-3,H-2) = 8.5 Hz), 2.16, 2.13, 2.06, 2.05, 2.04, 
2.01, 1.97 (7 x s, 21 H, CH3-(Ac)), 1.46 (s, 9H, CH3-tBu), 1.29 (d, 
3J(Tγ,Tβ) = 5.5 Hz, 1H, Tγ). 
13C NMR (100.6 MHz, 25°C, internal CDCl3, δ(H) = 77.16 ppm): 170.54, 170.28, 170.00, 
169.66 (C=O-(Ac)), 156.04 (C=O-(Fmoc)), 143.79 (C1a-, C8a-Fmoc),  141.51 (C4a-, C5a-
Fmoc), 128.02 (C2-, C7-Fmoc), 127.26 (C3-, C6-Fmoc), 125.01 (C1-, C8-Fmoc), 120.26 (C4-
, C5-Fmoc), 101.08 (C-1, C-1ꞌ), 83.45 (Cquart-tBu), 78.0 (C-3), 76.5 (T
β), 73.39, 70.89, 70.85, 
69.27 (C-3ꞌ, C-4, C-5, C-5ꞌ), 68.17 (C-2ꞌ), 66.90 (C-4ꞌ, CH2-Fmoc), 63.14 (C-6), 61.14 (C-6ꞌ), 
59.18 (Tα), 48.57 (C-2), 47.43 (C-9-Fmoc), 28.25 (CH3-(tBu)), 20.87, 20.86, 20.84, 20.79, 
20.70 (CH3-(Ac)), 18.7 (T
γ).   
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamindo-3-O-[2,3,4,6-tetra-O-acetyl-α-D-
galactosylpyranosyl]-4,6-O-acetyl-2-desoxy-α-D-galactosylpyranosyl)-L-threonine220 
(15) 
(Fmoc-Thr(αAc4Gal-(13)-αAc2GalNAc)-OH) 
 
 
 
 
Fmoc-Thr(αAc4Gal-(1→3)-αAc2GalNAc)-OtBu 14 (750 mg, 0.74 mmol) was dissolved in 
dichloromethane (3 mL) and anisole (1 mL) and trifluoroacetic acid (9 mL) was added. The 
reaction was stirred for 5 h and then co-evaporated with toluene. The crude product was 
purified by flash column chromatography on silica (EtOAc→EtOAc/MeOH 10:1). 
Yield: 638 mg (0.67 mmol, 90%), colorless, amorphous solid,      
   +75.17 (c = 0.99, CHCl3) 
Rf  = 0.27 (EtOAc/MeOH 4:1). 
C45H54N2O21 (M = 958.91 g/mol) [958.32]. 
ESI-MS (pos), m/z: 958.93 ([M+H]+, calc. 959.33), 1917.46 ([2M+H]+, calc. 1917.65). 
1H-NMR (400 MHz, gCOSY, DMSO), δ (ppm): 7.90 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 7.8 
Hz), 7.74 (m, 2H, H1-, H8-Fmoc), 7.45-7.29 (m, 4H, H2-, H3-, H6-, H7-Fmoc), 5.30 (d, 1H, 
H4, JH4,H3 = 3.3 Hz), 5.24 (d, 1H, H4ꞌ, JH4’,H3’ = 3.6 Hz), 5.05 (dd, 1H, H3ꞌ, JH3’,H2’ = 10.4 Hz, 
JH3’,H4’ = 3.7 Hz), 4.84 (dd, 1H, H2ꞌ, JH2’,H1’ = 7.8 Hz, JH2’,H3’ = 10.2 Hz), 4.74 (d, 1H, H1ꞌ, JH1’,H2’ 
= 8.0 Hz), 4.70 (d, 1H, H1, JH1,H2 = 4.0 Hz), 4.54-4.44 (m, 2H, CH2-Fmoc), 4.32-4.26 (m, 2H, 
H9-Fmoc, Tβ), 4.13-4.02 (m, 6H, H2, H3, H5ꞌ, H6a, H6aꞌ, T
α), 3.93-3.84 (m, 3H, H5, H6b, H6bꞌ), 
2.10, 2.04, 2.00, 1.98, 1.90, 1.83 (6 x s, 6 x 3H, 6 x CH3-Ac), 1.15 (d, 3H, T
γ, JTγ,Tβ = 6.3 Hz).  
13C-NMR (100.6 MHz, HSQC, CDCl3), δ (ppm): 171.96, 171.69, 170.04, 169.90, 169.81, 
169.75, 169.49 (C=O(Ac)), 156.81 (C=O(Fmoc)), 143.71 (C1a-, C8a-Fmoc), 140.79 (C4a-, 
C5a-Fmoc), 128.31 (C2-, C7-Fmoc), 127.78 (C3-, C6-Fmoc), 125.82 (C1-, C8-Fmoc), 120.92 
(C4-, C5-Fmoc), 100.42 (C1ꞌ), 98.75 (C1), 84.78 (Cquart-tBu), 75.29 (T
γ), 74.47 (C5), 70.91 
(C3ꞌ), 70.24 (C4, C3), 69.14 (C2ꞌ), 68.01 (C5ꞌ), 67.79 (C4ꞌ), 66.23 (CH2-Fmoc), 63.78 (C6), 
61.49 (C6ꞌ), 59.19 (Tα), 48.50 (C2), 47.47 (C9-Fmoc), 31.28 (CH3-tBu), 22.72, 20.63, 20.48, 
20.45, 20.36, 20.30 (CH3-Ac), 18.41 (T
γ). 
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7.1.4 Syntheses of the type-1 N-acetyllactosamine glycosyl donor 
 
1,2,3,4,6-Penta-O-acetyl-α-D-galactosylpyranoside (16) 
(αAc5Gal) 
 
 
 
Perchloric acid (2 mL, 60%) was added to acetic anhydride (400 mL, 4.2 mol), cooled in an 
ice bath. D-(+)-Galactose 4 (70.82 g, 393 mmol) was added in portions (with a spoon, waiting 
for the previous portion to dissolve). After addition, the ice-bath was removed and the 
reaction was stirred for 4 h. Then the reaction was poured into ice water (1.2 L) and stirred 
for 1 h. The precipitate was filtered off and washed with water. The solid precipitate was 
dissolved in ethyl acetate (600 mL) and washed with saturated sodium hydrogen 
bicarbonate, water and brine (150 mL each). The organic phase was dried over sodium 
sulfate, filtered and the solvent removed in vacuo. The product was obtained by 
crystallization from ethyl acetate/cyclohexane. 
Yield: 122.7 g (314.4 mmol, 80 %), colorless crystals, Rf = 0.44 (Tol/EtOAc 3:2). 
C16H22O11 (M = 390.34 g/mol) [390.12]. 
1H-NMR (400 MHz, CDCl3), δ (ppm):  6.31 (d, 1H, H1, JH1,H2 = 2.5 Hz), 5.44 (m, 1H, H4), 5.27 
(m, 2H, H3, H2), 4.29 (m, 1H, H5), 4.06-4.02 (m, 2H, H6a,b), 2.10, 1.98, 1.96, 1.94 (4 x s, 5 x 
3H, 5 x CH3-Ac). 
 
2,3,4,6-Tetra-O-acetyl-α/β-D-galactosylpyranose (17) 
(α/βAc4Gal-OH) 
 
 
 
αAc5Gal 16 (45.24 g, 115.8 mmol) was dissolved in dry N,N-dimethylformamid (200 mL) and 
hydrazine acetate (12.45 g, 138.2 mmol) was added. The reaction was stirred for 3 h at 
50°C. Ethyl acetate (1 L) was added and washed with water (two times, 600 mL) and with 
brine (400 mL). The organic phase was dried over sodium sulfate, filtered and the solvent 
removed in vacuo. The product was purified by flash column chromatography on silica 
(Tol/EtOAc 2:1).  
Yield: 36.24 g (α/β 3.2:1, 104.0 mmol, 90%), colorless, viscous oil, Rf = 0.23 (Tol/EtOAc). 
C14H20O10 (M = 348.30 g/mol) [348.11]. 
1H-NMR (400 MHz, CDCl3), δ (ppm):  5.49 (t, 1H, H1, H1α, JH1α,H2α = JH1α,OHα = 3.6 Hz), 5.45 
(dd, 1H, H4α, JH4α,H3α = 3.4 Hz, JH4α,H5α = 1.2 Hz), 5.41-5.38 (m, 2H, H3α, H4β), 5.13 (m, 1H, 
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H2α), 5.07-5.05 (m, 2H, H2β, H3β), 4.71-4.67 (m, 1H, H1β), 4.47-4.44 (m, 1H, H5α), 4.14-
4.06 (m, 4H, H6α, H6β), 3.98-3.94 (m, 2H, H5β, OHβ), 3.68-3.67 (m, 1H, OHα), 2.12, 2.07, 
2.03, 1.97 (4 x s, 4 x 3H, 4 x CH3α(Ac)), 2.14, 2.08, 2.02, 1.98 (4 x s, 4 x 3H, CH3β(Ac)). 
 
 
2,3,4,6-Tetra-O-acetyl-α-D-galactosylpyranosyl-trichloroacetimidate246 (18) 
(αAc4Gal-trichloroacetimidate) 
 
 
 
 
To a solution of α/βAc4Gal-OH 17 (25.29 g, 72.6 mmol) in dry dichloromethane (200 mL) was 
added trichloroacetonitrile (30.1 mL, 145.0 mmol) and the solution was cooled in an ice-bath 
before 1,8-diazabicyclo[5.4.0]undec-7-ene (2.17 mL, 14.5 mmol) was added. The reaction 
was stirred for 2 h in the ice-bath. The solvent was removed in vacuo and the product 
crystallized from ethyl acetate/cyclohexane. 
Yield: 28.6 g (58.1 mmol, 82%), colorless crystals,      
   +100.60 (c = 0.50, CHCl3), Rf = 0.40 
(CHex/EtOAc 2:1). 
C16H20Cl3NO10 (M = 492.69 g/mol) [491.01]. 
ESI-MS (pos), m/z: 513.80 ([M+Na]+, calc. 514.00). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 8.66 (s, 1H, NH), 6.59 (d, 1H, H1, JH1,H2 = 3.4 Hz), 5.55 
(dd, 1H, H4, JH4,H3 = 3.1 Hz, JH4,H5 = 1.2 Hz), 5.41 (dd, 1H, H3, JH3,H4 = 3.1 Hz, JH3,H2 = 10.9 
Hz), 5.35 (dd, 1H, H2, JH2,H1
 = 3.5 Hz, JH2,H3 = 10.8 Hz), 4.44-4.41 (m, 1H, H5), 4.15 (dd, 1H, 
H6a, JH6a,H6b = 11.3 Hz, JH6a,H5 = 6.6 Hz), 4.07 (dd, 1H, H6b, JH6b,H6a = 11.3 Hz, JH6b,H5 = 6.7 Hz), 
2.15, 2.01, 2.00 (3 x s, 4 x 3H, 4 x CH3-Ac). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 170.42, 170.22, 170.20, 170.09 (C=O(Ac)), 161.10 
(C=NH), 93.71 (C1), 90.94 (CCl3), 69.16 (C3ꞌ), 67.67 (C5ꞌ), 67.54 (C2ꞌ), 67.07 (C4ꞌ), 61.41 
(C6), 20.80, 20.77, 20.74, 20.68 (CH3-Ac). 
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Imidazole-1-sulfonyl azide hydrochloride248 (19)  
 
 
 
A suspension of sodium azide (35.18 g, 541 mmol) in acetonitrile (650 mL) was cooled in an 
ice-bath. Then sulfuryl chloride (72.63 g, 537 mmol) was added dropwise and stirred for 18 h. 
Then, imidazole (69.63 g, 1.02 mol) was added in portions and stirred for 4 h. The mixture 
was diluted with ethyl acetate (1.2 L) and washed with water (two times, 400 mL) and with 
saturated sodium bicarbonate solution (400 ml). The organic phase was dried over sodium 
sulfate, filtered and cooled in an ice-bath. The cooled mixture was treated with hydrochloric 
acid in methanol (65 mL acetyl chloride previously dropped into 225 mL of ice-cooled dry 
methanol). The mixture was stored overnight at -20°C. The precipitated product was filtered 
off and washed with ethyl acetate. The mother liquor must not be concentrated after filtration 
(risk of explosion). 
Yield: 68.80 g (328.2 mmol, 61%), colorless crystals. 
C3H4ClN5O2S (M = 209.61 g/mol) [208.98].  
1H-NMR (400 MHz, D2O), δ (ppm): 7.65 (m, 1H, H4), 8.06 (m, 1H, H5), 9.42 (m, 1H, H2). 
 
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose248 (21) 
(α/βAc4GlcN3) 
 
 
 
To a suspension of potassium carbonate (80.72 g, 583 mmol) and (694 mg, 2.8 mmol) 
copper (II) sulfate pentahydrate in methanol (800 mL) were added first glucosamine 
hydrochloride 20 (60.88 g, 282 mmol) and then imidazole-1-sulfonyl azide hydrochloride 19 
(64.17 g, 306 mmol). The suspension was stirred with a mechanical stirrer for 4 h. The 
solvent was removed in vacuo and co-evaporated with toluene. The residue was dissolved in 
pyridine (600 mL) and cooled in an ice bath. Then acetic anhydride (300 mL, 3.2 mol) was 
added and the reaction was stirred for 18 h at room temperature. The reaction volume was 
split in two halves and water (500 mL each) was added. Each aqueous phase was extracted 
with ethyl acetate (four times, 500 mL each). The organic phase was dried over sodium 
sulfate, filtered and concentrated in vacuo. The black residue was purified by flash column 
chromatography on silica (CHex/EtOAc 3:1 → 2:1).  
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Yield: 80.3 g (α/β 1:2, 215.1 mmol, 77%), colorless oil,     
   +45.19 (c = 1.01, CHCl3), Rf = 
0.21 (CHex/EtOAc 3:1). 
C14H19N3O9 (M = 373.32 g/mol) [373.11]. 
ESI-MS (pos), m/z: 396.07 ([M+Na]+, calc. 396.10). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.28 (d, 1H, H1
α, JH1α,H2α = 3.6 Hz), 5.54 (d, 1H, H1
β
, 
JH1β,H2β = 8.6 Hz), 5.43 (dd, 1H, H3
α, JH3α,H2α = 9.4 Hz, JH3α,H4α = 10.4 Hz), 5.12-5.10 (m, 3H, 
H3β, H4α, H4β), 4.31-4.26 (m, 2H, H6αa, H6
β
a), 4.08-4.02 (m, 3H, H5
α, H6αb, H6
β
b), 3.79 (m, 
1H, H5β), 3.67-3.62 (m, 2H, H2α, H2β), 2.17, 2.09, 2.06, 2.03 (4 x s, 4 x CH3-Ac
α), 2.17, 2.08, 
2.06, 2.01 (4 x s, 4 x CH3-Ac
β). 
 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl chloride236,251,252 (22) 
(αAc3GlcN3-Cl) 
 
 
 
A solution of α/βAc4GlcN3 21 (80.2 g, 214 mmol) in dry chloroform (600 mL) was cooled in an 
ice-bath. Then titanium (IV) chloride (47.1 mL, 429.6 mmol) was added dropwise. The 
mixture turned yellow and a solid started to precipitate. The temperature was allowed to 
reach room temperature and was stirred for 45 min. Then the temperature was raised until 
reflux of the solvent. The solid dissolved and the solution turned brown. After 4.5 h stirring at 
reflux, the solution was diluted with dichloromethane and washed with saturated sodium 
bicarbonate solution (two times) and two times with brine. The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica (CHex/EtOAc 3:1).  
Yield: 69.1 g (197.4 mmol, 92 %), yellow oil, Rf = 0.52 (Tol/EtOAc 3:1). 
C12H16ClN3O7 (M = 349.72 g/mol) [349.07] 
ESI-MS (pos), m/z: 350.32 ([M+H]+, calc. 350.08) 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.11 (d, 1H, H1, JH1,H2 = 3.8 Hz), 5.50 (dd, 1H, H3, 
JH3,H2 = 10.2 Hz, JH3,H4 = 9.7 Hz), 5.10 (m, 1H, H4), 4.33-4.29 (m, 2H, H5, H6a), 4.10 (m, 1H, 
H6b), 3.85 (dd, 1H, H2, JH2,H3 = 10.3 Hz, JH2,H1 = 3.8 Hz), 2.09, 2.08, 2.04 (3 x s, 3 x CH3-Ac). 
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Phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside253 (23) 
(βGlcN3-SPh)  
 
 
 
Thiophenol (22.2 mL, 217 mmol) and potassium hydroxide (12.25 g, 217 mmol) was added 
to ethanol (400 mL). Then αAc3GlcN3-Cl 22 (69.18 g, 197.4 mmol) was dissolved in 
chloroform (400 mL) and added. The reaction was stirred for 3 h. The solution was diluted 
with dichloromethane and washed with saturated sodium bicarbonate (two times). The 
organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The residue 
was dissolved in 0.25 M sodium methoxide in methanol (400 mL) and stirred for 2 h. The 
solution was neutralized with acidic cation exchange resin (Dowex 50WX8). The resin was 
filtered off and the filtrate concentrated in vacuo. The residue was taken up with 
dichloromethane and washed with saturated sodium bicarbonate solution and with water 
(once each). The organic phase was dried over sodium sulfate, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography on silica (Tol/EtOAc 8:7). 
Yield: 28.3 g (95.2 mmol, 48%), colorless solid, Rf = 0.33 (100% EtOAc). 
C12H15N3O4S (M = 297.33 g/mol) [297.08] 
ESI-MS (pos), m/z: 298.30 ([M+H]+, calc. 298.09), 320.20 ([M+Na]+, calc. 320.07). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.53-7.51 (m, 2H, H2-, H6-SPh), 7.32-7.30 (m, 3H, H3-, 
H4-, H5-SPh), 4.53 (d, 1H, H1, JH1,H2 = 10.1 Hz), 3.91-3.81 (m, 2H, H6), 3.59 3.49 (2 x t, 2H, 
H3, H4), 3.34-3.29 (m, 2H, H2, H5). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 133.00 (C2-, C6-SPh), 131.90 (C1-SPh), 129.39 
(C3-, C5-SPh), 128.63 (C4-SPh), 87.02 (C1), 79.51 (C5), 77.18, 69.80 (C3, C4), 65.38 (C2), 
62.10 (C6). 
 
 
Phenyl 2-azido-2-deoxy-4,6-O-benzylidene-1-thio-β-D-glucopyranoside254 (24) 
(βBn-GlcN3-SPh)  
 
 
 
A solution of βGlcN3-SPh 23 (28.20 g 94.8 mmol) and benzylidene dimethyl acetal (21.4 mL, 
142.3 mmol) in dry acetonitrile (300 mL) set to pH 4.5 by addition of para-toluene sulfonic 
acid monohydrate (careful addition with the tip of a spatula). The solution was stirred at 50°C 
for 1.5 h. The reaction was neutralized with a few drops of N,N-diisopropylethylamine (wet 
pH paper). The reaction was concentrated in vacuo and the residue taken up with ethyl 
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acetate and washed with saturated sodium bicarbonate solution and with brine (once each). 
The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The 
product was obtained by recrystallization from ethyl acetate/cyclohexane.  
Yield: 27.0 g (70.0 mmol, 74%), pale yellow solid,     
   -72.13 (c = 0.50, CHCl3), Rf = 0.60 
(CHex/EtOAc). 
C19H19N3O4S (M = 385.44 g/mol) [385.11]. 
ESI-MS (pos), m/z: 386.42 ([M+H]+, calc. 386.12), 408.26 ([M+Na]+, calc. 408.10). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.59-7.56 (m, 2H, H2-, H6-Bn), 7.48-7.45 (m, 2H, H2-, 
H6-SPh), 7.38-7.35 (m, 6H, H3-, H4-, H5-Bn, H3-, H4-, H5-SPh), 5.53 (s, 1H, CH-Bn), 4.54 
(d, 1H, H1, JH1,H2 = 10.2 Hz), 4.38 (dd, 1H, H6a, JH6a,H6b = 10.4 Hz, JH6a,H5 = 4.7 Hz), 3.79-3.74 
(m, 2H, H3, H6b), 3.50-3.44 (m, 2H, H4, H5), 3.35 (dd, 1H, H2, JH2,H1 = 10.1 Hz, JH2,H3 = 9.0 
Hz), 2.79 (sbr, 1H, OH). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 133.83 (C2-, C6-SPh), 129.57, 129.29, 128.84, 
128.54 (C3-, C4-, C5-Bn, C3-, C4-, C5-SPh), 102.10 (CH-Bn), 86.99 (C1), 80.36 (C5), 74.26 
(C3), 70.43 (C4), 68.57 (C6), 65.35 (C2). 
 
 
Phenyl 3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-azido-4,6-O-benzylidene-2-
deoxy-1-thio-β-D-glucopyranoside255 (25) 
(βAc4Gal-(13)-βBn-GlcN3-SPh) 
 
 
 
 
βBn-GlcN3-SPh 24 (12.14 g, 31.5 mmol) and αAc4Gal-trichloroacetimidate 18 (15.54 g, 31.5 
mmol) were dissolved in dry diethyl ether (250 mL). A solution of trimethylsilyl 
trifluoromethansulfonate in diethyl ether (6.3 mL, 0.5 M, 3.15 mmol) was added dropwise. 
After 30 min of stirring, the reaction was neutralized by dropwise addition of triethylamine 
(wet pH paper). The mixture was diluted with diethyl ether (150 mL) and washed with 
saturated sodium bicarbonate solution, water and brine (once each). The organic phase was 
dried over sodium sulfate, filtered and the solvent removed in vacuo. The crude product was 
purified by flash column chromatography on silica (CHex/EtOAc 2:1). 
Yield: 19.22 (26.9 mmol, 85%), colorless, amorphous solid,     
   -26.11 (c = 1.01, MeOH), Rf 
= 0.52 (Tol/EtOAc 3:1). 
C33H37N3O13S (M = 715.72 g/mol) [715.20]. 
ESI-MS (pos), m/z: 733.07 ([M+NH4]
+, calc. 733.24), 738.20 ([M+Na]+, calc. 738.19). 
HR-ESI-MS (pos), m/z: 733.2387 ([M+NH4]
+, calc. 733.2391). 
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1H NMR (400 MHz, CDCl3, 25°C, internal CDCl3 δ(H)=7.26 ppm): δ= 7.59-7.56 (m, 2H, H-2-, 
H-6-Bn), 7.45-7.38 (m, 2H, H-2-, H-6-SPh), 7.38-7.35 (m, 6H, H-3-, H-4-, H-5-Bn, H-3-, H-4-, 
H-5-SPh), 5.54 (s, 1H, CH-Bn), 5.29 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.4 Hz, 1H, H-4ꞌ), 5.22 (dd, 3J(H-2ꞌ,H-
1ꞌ) = 8.0 Hz, 3J(H-2ꞌ,H-3ꞌ) = 10.4 Hz, 1H, H-2ꞌ), 4.95 (dd, 
3J(H-3ꞌ,H-2ꞌ) = 10.4 Hz, 
3J(H-3ꞌ,H-4ꞌ) 
= 3.4 Hz, 1H, H-3ꞌ), 4.77 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.0 Hz, 1H, H-1ꞌ), 4.50 (d, 
3J(H-1,H-2) = 10.1 Hz, 
1H, H-1), 4.37 (dd, 2J(H-6a,H-6b) = 10.6 Hz, 
3J (H-6a,H-5) = 4.9 Hz 1H, H-6a), 4.03 (dd, 
2J(H-
6ꞌb,H-6ꞌa) = 7.7 Hz, 
3J(H-6ꞌb,H-5ꞌ) = 11.1 Hz 1H, H-6ꞌb), 3.86-3.59 (m, 5H, H-6b, H-6bꞌ, H-5ꞌ, H-
4, H-3), 3.44-3.33 (m, 2H, H-5, H-2), 2.10, 2.05, 1.96, 1.91 (4 x s, 4 x 3H, 4 x CH3-Ac).
 
13C NMR (150.9 MHz, CDCl3, 30°C, internal CDCl3 δ(C)=77.16 ppm): δ = 170.36, 170.26, 
169.58 (C=O-(Ac)), 136.92 (C-1-SPh), 134.20 (C-2-, C-6-SPh), 130.11 (C-1-Bn), 129.42, 
129.34, 129.10 (C-3-, C-4-, C-5-Bn), 128.47 (C-3-, C-4-, C-5-SPh), 126.07 (C-2-, C-6-Bn), 
101.44 (CH-Bn), 101.39 (C-1ꞌ), 87.12 (C-1), 81.48 (C-3), 79.38 (C-4), 71.09 (C-3ꞌ), 70.92 (C-
5ꞌ), 70.62 (C-5), 69.53 (C-2ꞌ), 68.49 (C-6), 66.92 (C-4ꞌ), 64.53 (C-2), 61.05 (C-6ꞌ), 20.85, 
20.75, 20.70, 20.67 (CH3-(Ac)). 
 
 
Phenyl 3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-4,6-O-benzylidene-2-deoxy-1-
thio-2-N-(2,2,2-trichlorooxycarbonyl)-β-D-glucopyranoside (26) 
(βAc4Gal-(13)-βBn-GlcNHTroc-SPh) 
 
 
 
 
βAc4Gal-(1→3)-βBn-GlcN3-SPh 25 (19.20 g, 26.9 mmol) was dissolved in mixture of 
1,4-dioxane and acetic acid (220 mL, 10:1) and cooled in an ice bath. Zinc dust was 
activated by treatment with 1 N hydrochloric acid for a few minutes followed by washing with 
water, methanol and finally diethyl ether. Zinc dust (10.60 g, 161.4 mmol) was added to the 
solution and the reaction was stirred overnight, while the temperature rose to room 
temperature. The zinc dust was filtered off, washed with ethyl acetate (400 mL) and the 
filtrate was further diluted with ethyl acetate (400 mL). The organic phase was washed with 
saturated sodium bicarbonate solution (two times), water and brine (500 mL each). The 
organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The residue 
was dissolved in 1,4-dioxane (200 mL) and sodium bicarbonate (5.20 g, 61.8 mmol) 
dissolved in water was added (100 mL). The stirred suspension was cooled in an ice bath 
and a solution of 2,2,2-trichloroethyl chloroformate (6.84 g, 32.3 mmol) in 1,4-dioxane (40 
mL) was added dropwise. The ice bath was removed and the reaction was stirred further for 
3 h. The 1,4-dioxane was removed in vacuo and the aqueous phase was extracted with ethyl 
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acetate (500 mL). The ethyl acetate phase was washed with water (two times, 150 mL each) 
and with brine (once, 150 mL). The organic phase was dried over sodium sulfate, filtered and 
concentrated in vacuo. The product was purified by flash column chromatography on silica 
(toluene/EtOAc 3:1). 
Yield: 16.81 (19.4 mmol, 72%), colorless, amorphous solid,     
   -10.0° (c = 1.01, CHCl3); 
Rf = 0.37 (Tol/EtOAc 3:1). 
C36H40Cl3NO15S (M = 865.12 g/mol) [863.12]. 
HR-ESI-MS (pos), m/z: 864.1261 ([M+H]+, calc. 864.1257), 881.1525 ([M+NH4]
+, calc. 
881.1522), 886.1073 ([M+Na]+, calc. 886.1076). 
1H NMR (400 MHz, CDCl3, 25°C, internal CDCl3 δ(C)=7.26 ppm): δ= 7.47-7.45 (m, 4H, H-2-, 
H-6-SPh, H-2-, H-6-Bn), 7.37-7.36 (m, 3H, H-3-, H-4-, H-5-Bn), 7.32-7.31 (m, 3H, H-3-, H-4-, 
H-5-SPh), 5.53 (s, 1H, CH-(Bn)), 5.32 (d, 3J(NH,H-2) = 7.9 Hz, 1H, NH-Troc), 5.29 (d, 3J(H-
4ꞌ,H-3ꞌ) = 3.2 Hz, 1H, H-4ꞌ), 5.16 (m, 2H, H-2ꞌ, H-1), 4.92 (dd, 
3J(H-3ꞌ,H-2ꞌ) = 10.4 Hz, 3J(H-
3ꞌ,H-4ꞌ) = 3.2 Hz, 1H, H-3ꞌ), 4.82 (d, 2J(CH2a,CH2b) = 12.1 Hz, 1H, CH2a-(Troc)), 4.72-4.68 (m, 
2H, H-1ꞌ, CH2b-(Troc)), 4.36 (dd, 
3J(H-6a,H-6b) = 10.6 Hz, 
3J(H-6a,H-5) = 4.8 Hz, 1H, H-6a), 
4.29 (t, 3J(H-3,H-2) = 3J(H-3,H-4) = 8.9 Hz, 1H, H-3), 4.04 (m, 1H, H-6aꞌ), 3.82-3.77 (m, 2H, 
H-6b, H-6bꞌ), 3.67 (t, 
3J(H-4,H-3) = 
3J(H-4,H-5) = 9.2 Hz, 1H, H-4), 3.62 (m, 1H, H-5ꞌ), 3.56-
3.52 (m, 1H, H-5), 3.36 (m, 1H, H-2), 2.10, 1.99, 1.95, 1.94 (4 x s, 4 x 3H, CH3-(Ac)). 
13C NMR (150.9 MHz, CDCl3, 30°C, internal CDCl3 δ(H)=77.16 ppm): δ = 170.34, 170.23, 
169.50 (C=O-(Ac)), 153.76 (C=O-(Troc)), 137.08 (C-1-Bn), 133.03 (C-2-, C-6-SPh), 131.84 
(C-1-SPh), 129.41, 129.27 (C-3-, C-4-, C-5-Bn), 128.54, 128.45 (C-3-, C-4-, C-5-SPh), 
126.15 (C-2-, C-6-Bn), 101.48 (CH-(Bn)), 100.87 (C-1ꞌ), 95.41 (CCl3-(Troc)), 86.21 (C-1), 
79.96 (C-4), 79.18 (C-3), 74.61 (CH2-(Troc)), 71.04 (C-3ꞌ), 70.66 (C-5ꞌ), 70.52 (C-5), 69.41 
(C-2ꞌ), 68.67 (C-6), 66.87 (C-4ꞌ), 60.96 (C-6ꞌ), 56.53 (C-2), 20.80, 20.75, 20.71, 20.67 (CH3-
(Ac)). 
 
 
Phenyl 3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-4-O-acetyl-6-O-tert-
butyldimethysilyl-2-deoxy-1-thio-2-N-(2,2,2-trichloroethoxycarbonyl)-β-D-
glucopyranoside (27) 
(βAc4Gal-(13)-βAc-TBS-GlcNHTroc-SPh) 
 
 
 
 
βAc4Gal-(1→3)-βBn-GlcNHTroc-SPh 26 (8.08 g, 9.3 mmol) was dissolved in 80% acetic acid 
(80 mL) and stirred at 55°C for 7 h. The reaction was diluted and co-evaporated with toluene. 
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The residue was dissolved in dry N,N-dimethylformamide (80 mL). Imidazole (1.58 g, 23.3 
mmol) and tert-butyldimethylsilyl chloride (1.67 g, 11.1 mmol) were added. After stirring for 3 
h the reaction was diluted with ethyl acetate (400 mL) and washed with water (two times, 
400 mL each) and with brine (once, 200 mL). The organic phase was dried over sodium 
sulfate, filtered and concentrated in vacuo. The residue was dissolved in pyridine/acetic 
anhydride (150 mL, 2:1) and stirred for 16 h. Then the solvent was removed by co-
evaporation with toluene in vacuo. The crude was purified by column chromatography on 
silica (CHex/EtOAc 2:1). 
Yield: 7.82 g (8.4 mmol, 90%), colorless, amorphous solid,     
   +4.3° (c = 0.99, MeOH); Rf = 
0.34 (CHex/EtOAc 2:1). 
C37H52Cl3NO16SSi (M = 933,32 g/mol) [931.18]. 
HR-ESI-MS (pos), m/z: 932.1924 ([M+H]+, calc. 932.1914), 949.2182 ([M+NH4]
+, calc. 
949.2180), 954.1733 ([M+Na]+, calc. 954.1734). 
1H NMR (400 MHz, CDCl3, 25°C, internal CDCl3 δ(H)=7.26 ppm): δ= 7.52-7.49 (m, 2H, H-2-, 
H-6-SPh), 7.29-7.28 (m, 3H, H-3-, H-4-, H-5-SPh), 5.33 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.4 Hz, 1H, H-4ꞌ), 
5.14 (d, 3J(NH,H-2) = 8.4 Hz, 1H, NH-Troc), 5.06 (dd, 3J(H-2ꞌ,H-1ꞌ) = 7.8 Hz, 3J(H-2ꞌ,H-3ꞌ) = 
10.3 Hz, 1H, H-2ꞌ), 4.98 (d, 3J(H-1,H-2) = 10.4 Hz, 1H, H-1), 4.92 (dd, 3J(H-3ꞌ,H-2ꞌ) = 10.3 Hz, 
3J(H-3ꞌ,H-4ꞌ) = 3.4 Hz, 1H, H-3ꞌ), 4.86-4.80 (m, 2H, H-4, CH2a-(Troc)), 4.73 (d, 
2J(CH2a,CH2b) 
= 12.1 Hz, 1H, CH2b-(Troc)), 4.62 (d, 
3J(H-1ꞌ,H-2ꞌ) = 7.8 Hz, 1H, H-1ꞌ), 4.19 (t, 3J(H-3,H-2) = 
3J(H-3,H-4) = 9.4 Hz, 1H, H-3), 4.13-4.04 (m, 2H, H-6ꞌab), 3.84 (t, 
3J(H-5ꞌ,H-6ꞌab) = 6.8 Hz, 1H, 
H-5ꞌ), 3.70-3.68 (m, 2H, H-6ab), 3.59-3.55 (m, 1H, H-5), 3.44-3.37 (m, 1H, H-2), 2.14, 2.06, 
2.03, 1.95 (s, 5 x 3H, CH3-(Ac)), 0.89 (s, 9H, tBu-TBS), 0.06, 0.04 (s, 2 x 3H, CH3-(TBS)).  
13C NMR (150.9 MHz, CDCl3, 30°C, internal CDCl3 δ(C)=77.16 ppm): δ = 170.52, 170.29, 
170.18, 169.41, 169.32 (5 x C=O-(Ac)), 153.82 (C=O-(Troc)), 132.97 (C-1-SPh), 132.16 (C-
2-, C-6-SPh), 129.16 (C-3-, C-5-SPh), 128.03 (C-4), 100.96 (C-1ꞌ), 95.43 (CCl3-(Troc)), 85.92 
(CH-Bn), 79.39 (C-5), 79.03 (C-3), 74.62 (CH2-(Troc)), 71.05 (C-3ꞌ), 70.74 (C-5ꞌ), 69.41 (C-4), 
69.23 (C-2ꞌ), 66.99 (C-4ꞌ), 63.09 (C-6), 61.21 (C-6ꞌ), 56.96 (C-2), 26.00 (tBu-TBS), 21.00, 
20.87, 20.82, 20.78, 20.66 (5 x CH3-(Ac)), 18.47 (Cq-TBS), -5.15, -5.31 (CH3-(TBS)). 
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7.1.5 Syntheses of the type-2 N-acetyllactosamine glycosyl donor 
 
1,3,4,6-Tetra-O-acetyl-2-N-(2,2,2-trichloroethoxycarbonyl)-2-deoxy-α/β-D-
glucopyranoside (28) 
(α/βAc4-GlcNTroc) 
 
 
 
To a solution of N-glucosamine hydrochloride 20 (10.11 g, 46.8 mmol) in water (100 mL), 
was added sodium bicarbonate (8.79 g, 104.7 mmol). A solution of 2,2,2-trichloroethyl 
chloroformate (8.1 mL, 59.9 mmol) in 1,4-dioxane (50 mL) was added dropwise to the stirred 
solution. After 1.5 h the 1,4-dioxane was removed in vacuo. A white solid precipitated from 
the aqueous solution. The flask was stored for 5 h at 4°C. The precipitate was filtered off and 
washed with cold water and then with dichloromethane. The solid was dissolved in 
pyridine/acetic anhydride (120 mL, 2:1) and 4-(dimethylamino)pyridine (61 mg, 0.5 mmol) 
was added. After 4 h of stirring the reaction was co-evaporated es with toluene. The crude 
was purified by flash column chromatography on silica (CHex/EtOAc 2:1). 
Yield: 19.6 g (α/β 8.3:1, 37.5 mmol, 80%), colorless solid,     
   +67.13 (c = 0.50, CHCl3), Rf = 
0.22 (CHex/EtOAc). 
C17H22ClNO11 (M = 522.72 g/mol) [521.03]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 6.23 (d, 1H, H1
α, JH1α,H2α = 3.6 Hz), 5.73 (d, 1H, H1
β, 8.8 
Hz), 5.29-5.15 (m, 5H, NHα, H3α, H4α, H3β, H4β), 4.81 (d, 1H, CH2a
α(Troc), JCH2a,CH2b = 12.0 
Hz), 4.76-4.71 (m, 2H, CH2ab
β(Troc)), 4.62 (d, 1H, CH2b
α(Troc), JCH2b,CH2a = 12.0 Hz), 4.29-
3.99 (m, 6H, H2α, H6α, H6β, H5α), 3.95-3.93 (m, 1H, H2β), 3.84-3.80 (m, 1H, H5β), 2.19, 2.08, 
2.04, 2.03 (4 x s, 4 x 3H, 4 x CH3(Ac)). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm):  171.39, 170.76, 169.29, 168.71 (C=O(Ac)), 154.17 
(C=O(Troc)), 90.57 (CCl3(Troc)), 74.83 (C1), 70.54, 69.89, 67.69 (C3, C4, C5), 61.62 (C6), 
53.38 (C2), 21.05, 20.82, 20.79, 20.69 (CH3(Ac)). 
 
Phenyl 3,4,6-tetra-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-1-thio-β-D-
glucopyranoside262 (29) 
(βAc3GlcNTroc-SPh) 
 
 
 
Thiophenol (12.0 g, 109.0 mmol) was added to a solution of α/βAc4GlcNTroc 28 (19.0 g, 36.3 
mmol) in dry dichloromethane (200 mL) under argon atmosphere. Boron trifluoride diethyl 
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etherate (48%, 7.4 mL, 60.0 mmol) was added and the reaction stirred for 3 d. The reaction 
was neutralized with triethylamine and the solvent removed in vacuo. The residue was 
purified by flash column chromatography on silica (CHex/EtOAc 2:1). 
Yield: 19.3 g (33.6 mmol, 93%), colorless solid,     
   -3.33 (c = 1.00, CHCl3), Rf = 0.34 
(CHex/EtOAc 2:1). 
C21H24Cl3NO9S (M = 572.84 g/mol) [571.02]. 
ESI-MS (pos), m/z: 462.73 ([M-SPh]+, calc. 462.01), 571.67 ([M+H]+, calc. 572.03), 593.93 
([M+Na]+, calc. 594.01). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.52-7.49 (m, 2H, H2-, H6-SPh), 7.31-7.29 (m, 3H, H3-, 
H4-, H5-SPh), 5.43 (d, 1H, NH, JNH,H2 = 9.1 Hz), 5.28 (t, 1H, H3, JH3,H2 = JH3,H4 = 9.5 Hz), 5.01 
(t, 1H, H4, JH4,H3 = JH4,H5 = 9.6 Hz), 4.86 (d, 1H, H1, JH1,H2 = 10.4 Hz), 4.79 (d, 1H, CH2a(Troc), 
JCH2a,CH2b = 12.1 Hz), 4.71 (d, 1H, CH2b(Troc), JCH2b,CH2a = 12.1 Hz), 4.21-4.13 (m, 2H, H6), 
3.74-3.69 (m, 2H, H2, H5), 2.07, 2.00, 1.99 (3 x s, 3 x 3H, 3 x CH3(Ac)).  
 
 
Phenyl 6-O-tert-butyldimethylsilyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-1-thio-
β-D-glucopyranoside (30) 
(βTBS-GlcNTroc-SPh) 
 
 
 
Acetyl chloride (20 mL) was dropped into dry methanol (200 mL), cooled in an ice bath. After 
15 min, a solution of βAc3GlcNTroc-SPh 29 (19.24 g, 33.6 mmol) in dichloromethane (50 mL) 
was added dropwise. After complete addition the ice bath was removed and the reaction 
stirred for 6 h. Then the solvent was removed in vacuo and the residue taken up in ethyl 
acetate (400 mL). The ethyl acetate phase was washed with water, saturated sodium 
bicarbonate, water again and brine (150 mL each). The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The gel-like residue was dried at reduced 
pressure (10-2-10-1 mbar), until a white, amorphous solid was left. The solid was dissolved in 
160 mL of dry N,N-dimethylformamide under argon atmosphere. Imidazole (5.72 g, 84.0 
mmol) and tert-butyldimethylsilyl chloride (5.57 g, 37.0 mmol) were added. The reaction was 
stirred for 3 h. Then it was diluted with ethyl acetate (500 mL) and washed with water (two 
times, 150 mL) and with brine (once, 150 mL each). The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The crude was purified by flash column 
chromatography on silica (DCM→DCM/MeOH 15:1).  
Yield: 15.03 (26.8 mmol, 80%), pale yellow, amorphous solid,     
   +20.50 (c = 1.01, CHCl3), 
Rf = 0.15 (Tol/EtOAc 3:1), 0.52 (DCM/MeOH 10:1).  
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C21H32Cl3NO6SSi (M = 560.99 g/mol) [559.08]. 
ESI-MS (pos), m/z: 559.80 ([M+H]+, calc. 560.08). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.49-7.47 (m, 2H, H2-, H6-SPh), 7.28-7.26 (m, 3H, H3-, 
H4-, H5-SPh), 5.63 (d, 1H, NH, JNH,H2 = 8.0 Hz), 4.81-4.78 (m, 2H, H1, CH2a(Troc)), 4.70 (d, 
1H, CH2b(Troc), JCH2a,CH2b = 12.0 Hz), 3.90 (dd, 1H, H6, JH6a,H6b = 4.7 Hz, JH6a,H5 = 1.6 Hz), 
3.74 (t, 1H, H3, JH3,H4 = JH3,H2 = 9.2 Hz), 3.54 (t, 1H, H4, JH4,H3 = JH4,H5 = 9.4 Hz), 3.47-3.40 (m, 
2H, H2, H5), 0.91 (s, 9H, tBu(TBS)), 0.10, 0.09 (2 x s, 2 x 3H, 2 x Me(TBS). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 154.97 (C=O(Troc)), 132.33 (C2-, C6-SPh), 129.08 
(C3-, C4-, C5-SPh), 127.97 (C1-SPh), 95.55 (CCl3(Troc)), 86.45 (C1), 78.74 (C5), 76.02 
(C3), 74.85 (CH2(Troc)), 72.97 (C6), 64.48 (C2), 56.58 (C2), 26.01 (tBu(TBS)), 18.39 
(Cquart(TBS)), -5.26, -5.29 (Me(TBS)).  
 
 
Phenyl 3-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-6-O-tert-
butyldimethylsilyl-2-deoxy-1-thio-2-N-(2,2,2-trichloroethoxycarbonyl)-β-D-
glucopyranoside (31)  
(βAc4Gal-(14)-βAc-TBS-GlcNTroc-SPh) 
 
 
 
βTBS-GlcNTroc-SPh 30 (14.98 g, 26.70 mmol) and αAc4Gal-trichloroacetimidate 18 (13.15 
g, 26.70 mmol) were dissolved in dry dichloromethane (200 mL). Activated molecular sieves 
(15 g, 4Å) were added under argon atmosphere. The suspension was stirred for 1 h at room 
temperature and then cooled to -50°C. Trimethylsilyl trifluoromethanesulfonate (482 μL, 593 
mg, 2.67 mmol) in a suspension with dry dichloromethane (5 mL) was added dropwise via a 
syringe. The reaction was stirred at -50°C for 1.5 h and then quenched with triethylamine (5 
mL). The molecular sieves were filtered off over Celite® and washed with dichloromethane 
(200 mL). The filtrate was washed with saturated sodium bicarbonate, water and brine (150 
mL each). The organic phase was dried over sodium sulfate, filtered and concentrated in 
vacuo. The residue was dissolved in pyridine/acetic anhydride (225 mL, 2:1) and stirred for 
18 h. The reaction was co-evaporated with toluene in vacuo and the residue purified by flash 
column chromatography on silica (CHex:EtOAc 2.5:1). 
Yield: 19.15 g (20.5 mmol, 77%), colorless, amorphous solid,     
   -12.05 (c = 1.00, CHCl3), 
Rf = 0.34 (
CHex/EtOAc 2:1). 
C37H52Cl3NO16SSi (M = 933.32 g/mol) [931.18]. 
ESI-MS (pos), m/z: 932.80 ([M+H]+, calc.932.19); 948.67 ([M+NH4]
+, calc. 949.22); 1888.33 
([2M+Na]+, calc. 1887.36). 
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HR-ESI-MS (pos), m/z: 932.1922 ([M+H]+, calc. 932.1920), 822.1728 ([M-SPH]+, calc. 
822.1730). 
1H NMR (400 MHz, 25°C, internal CDCl3, δ(H)=7.26 ppm): δ= 7.50-7.47 (m, 2H, H-2-, H-6-
SPh), 7.29-7.27 (m, 3H, H-3-, H-4-, H-5-SPh), 5.37 (d, 3J(NH,H-2) = 9.8 Hz, 1H, NH-Ac), 
5.33 (dd, 3J(H-4ꞌ,H-3ꞌ) = 3.4 Hz, 3J(H-4ꞌ,H-5ꞌ) = 0.9 Hz, 1H, H-4ꞌ), 5.12-5.03 (m, 2H, H-3, H-
2ꞌ), 4.91 (dd, 3J(H3ꞌ,H2ꞌ) = 10.4 Hz, 
3J(H-3ꞌ,H-4ꞌ) = 3.6 Hz, 1H, H-3ꞌ), 4.79-4.70 (m, 3H, H-1ꞌ, 
CH2-(Troc)), 4.66 (d, 
3J(H-1,H-2) = 9.5 Hz, 1H, H-1), 4.09 (d, 2J(H-6aꞌ,H-6bꞌ) = 6.7 Hz, 2H, H-
6abꞌ), 3.93-3.79 (m, 4H, H-4, H-5ꞌ, H-6ab), 3.70 (q, 
3J(H-2,H-1) = 
3J(H-2,H-3) = 3J(H-2,NH) = 
9.8 Hz, 1H, H-2), 3.37-3.33 (m, 1H, H-5), 2.10, 2.04, 2.02, 2.00, 1.95 (5 x s, 15H, CH3-(Ac)), 
0.93 (s, 9H, tBu-(TBS)), 0.13, 0.10 (2 x s, 6H, Me-(TBS)).   
13C NMR (100.6 MHz, 25°C, internal CDCl3, δ(C)=77.16 ppm): δ= 170.78, 170.42, 170.27, 
170.20, 168.84 (C=O-(AcO)), 154.27 (C=O-(Troc)), 132.80 (C-1-SPh), 128.99, 128.03 (C-2-, 
C-3-, C-4-, C-5-, C-6-SPh), 100.36 (C-1ꞌ), 95.62 (CCl3-(Troc)), 87.03 (C-1), 79.68 (C-5), 
74.64 (CH2-(Troc)), 74.06 (C-4), 73.75 (C-3), 71.24 (C-3ꞌ), 70.78 (C-5ꞌ), 69.37 (C-2ꞌ), 67.01 
(C-4ꞌ), 61.20 (C-6), 55.19 (C-2), 26.01 (tBu-(TBS)), 20.92, 20.88, 20.75, 20.70, 20.66 (CH3-
(Ac)), 18.38 (Cquart-(TBS)), -4.87, -5.16 (CH3-(TBS)). 
 
7.1.6 Synthesis of the extended type-2 core 3 amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-{2-acetamido-2-deoxy-4,6-O-para-
methoxybenzylidene-3-O-[3-O-acetyl-6-O-tert-butyldimethylsilyl-2-deoxy-2-N-
(2,2,2-trichloroethoxycarbonyl)-2-N-phenylsulfide-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-galactosylpyranosyl}-L-
threonine-tert-butylester (32)  
(Fmoc-Thr(βAc4Gal-(14)-βAc-TBS-GlcN(SPh)Troc(13)-αPMP-GalNAc)-OtBu)  
 
 
 
 
 
Fmoc-Thr(αPMP-GalNAc)-OtBu 12 (1.50 g, 2.09 mmol) and βAc4Gal-(1→4)-βGlcNTroc-SPh 
31 (2.54 g, 2.72 mmol) were dissolved in dry dichloromethane (20 mL). Activated molecular 
sieves (2.0 g, 4Å) were added under argon atmosphere. The suspension was stirred for 1 h 
and then was cooled in an ice bath. Then N-iodosuccinimide (1.18 g, 5.23 mmol) was added 
followed by the dropwise addition of a suspension of trimethylsilyl trifluoromethanesulfonic 
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acid (55.5 μmol 94.1 mg, 0.63 mmol) in dry dichloromethane (300 μL) via a syringe. The 
reaction was stirred for 4.5 h and then diluted with dichloromethane (20 mL). The molecular 
sieves were filtered off and washed with dichloromethane. More dichloromethane was added 
to give a total volume of 150 mL. The dichloromethane phase was washed with 0.5 M 
sodium thiosulfate solution, saturated sodium bicarbonate, water and brine (60 mL each). 
The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography on silica (Tol/EtOAc 4:1).  
Yield: 2.41 g (1.46 mmol, 70%), colorless, amorphous solid,     
   +51.73 (c = 0.52, CHCl3), 
Rf = 0.53 (Tol/EtOAc 1:1). 
C76H96Cl3N3O27SSi (M = 1650.09 g/mol) [1647.48]. 
ESI-MS (pos), m/z: 1666.00 ([M+NH4]
+, calc. 1665.51).  
HR-ESI-MS (pos), m/z: 1648.4844 ([M+H]+, calc. 1648.4865).  
1H NMR (600 MHz, 25°C, [D4]MeOD, internal MeOH, δ(H)=4.87 ppm): δ= 7.86 (m, 4H, H-4-, 
H-5-Fmoc, N-H-Ac, N-H-Ac*), 7.71-7.69 (m, 2H, H-1-, H-8-Fmoc), 7.44-7.38 (m, 4H, H-2-, H-
7-Fmoc, H-2-, H-6-PMP), 7.35-7.30 (m, 4H, H-3-, H-6-Fmoc, 2 Harom-SPh), 7.25-7.19 (m, 3H, 
3 Harom-SPh), 6.72-6.89 (m, 2H, H-3-, H-5-PMP), 6.84-6.81 (m, 2H, H-3-, H-5-PMP*), 5.53 (s, 
1H, CH-(PMP)), 5.42-5.29 (m, 3H, H-4ꞌꞌ, H-4ꞌꞌ*, CH2a*-(Troc)), 5.24 (t, 
3J(H-3ꞌ,H-2ꞌ)  = 9.8 Hz, 
1H, H-3ꞌ), 5.09-5.07 (m, 1H, H-3ꞌ*), 5.00-4.95 (m, 2H, H-2ꞌꞌ, H-3ꞌꞌ), 4.93-4.86 (m, 3H, H-1ꞌꞌ*, H-
2ꞌꞌ*, H-3ꞌꞌ*), 4.82-4.68 (m, 5H, H-1ꞌꞌ*, H-1, H-1*, H-1ꞌ, H-1ꞌ*), 4.63-4.54 (m, 5H, H-2*, H-2ꞌ*, 
CH2ab-(Fmoc), CH2b-(Troc), CH*2b-(Troc)), 4.53-4.41 (m, 5H, H-2, H-2ꞌ, H-4, H-4*, T
β), 4.32-
4.29 (m, 1H, H-9-Fmoc), 4.18-4.03 (m, 5H, H-6ab, H-6abꞌꞌ, T
α), 4.00-3.85 (m, 6H, H-3, H-4ꞌ, H-
5ꞌꞌ, H-5ꞌꞌ*, H-6ꞌab), 3.81-3.76 (m, 5H, CH3-(PMP), H-5, T
α*), 3.49-3.45 (m, 1H, H-5ꞌ), 2.16-1.91 
(m, CH3-(Ac)), 1.45 (s, 9H, tBu-(Thr)), 1.23-1.22 (m, 3H, T
γ), 0.91 (s, 9H, tBu-(TBS)), 0.18-
0.13 (m, 12H, 2 Me-(TBS)). 
13C NMR (150.9 MHz, 25°C, [D4]MeOD, internal MeOH, δ(C)=49.00 ppm): δ= 172.02, 
171.94, 171.91, 171.88, 171.83, 171.73, 171.39, 171.36, 171.03, 170.91, 170.89, 170.83, 
170.82, 170.78, 170.62, 170.46 (C=O-(Ac), C=O-(tBu)), 161.50 (C-1-PMP), 159.13 (C=O-
(Fmoc)), 156.62 (C=O-(Troc)), 145.27, 145.15 (C-1a-, C-8a-Fmoc), 142.71 (C-4a-, C-5a-
Fmoc), 138.31 (C-1-SPh), 131.79, 131.66 (C-4-PMP), 130.20 (Carom-SPh), 128.84 (C-2-, C-7-
Fmoc), 128.22 (C-3-, C-6-Fmoc), 126.03 (C-1-, C-8-Fmoc), 121.06, 121.04 (C-4-, C-5-Fmoc), 
114.36 (C-3-, C-5-PMP), 103.90 (C-1ꞌ, C-1ꞌ*), 101.95 (CH-PMP), 101.37 (C-1ꞌꞌ, C-1ꞌꞌ*), 
100.91 (C-1, C-1*), 96.31, 95.97 (Cquart-(Troc)),  83.54 (Cquart-(tBu)), 77.59 (C-3, CH2ab-
(Troc)), 77.23 (C-4), 77.14 (CH2ab-(Troc*)), 76.44 (C-5ꞌ), 76.18 (C-4ꞌ), 75.50 (T
γ), 72.54 (C-
3ꞌꞌ), 72.04, 71.88 (C-5ꞌꞌ, C-5ꞌꞌ*), 71.55 (C-3ꞌ), 70.60 (C-2ꞌꞌ, C-2ꞌꞌ*), 70.23 (C-6ab), 68.68, 68.56 
(C-4ꞌꞌ, C-4ꞌꞌ*), 67.45 (CH2ab-(Fmoc)), 64.80, 64.65 (C-5), 63.55 (C-2ꞌ), 62.82, 62.50, 62.35 (C-
6ꞌ, C-6ꞌꞌ), 60.75, 60.72 (Tα, Tα*), 55.69 (CH3-PMP), 48.95 (C-2
#), 48.68 (C-9-(Fmoc)#), 28.40, 
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28.36 (tBu-(Thr), tBu-(Thr)*), 26.57 (tBu-(TBS)), 24.44, 24.00, 21.67-20.45 (CH3-(Ac)), 20.05 
(tBu), 19.21, 19.13 (Tγ).    
(*, rotational-isomers, if identifiable) 
(#,congruent with solvent peak, shift from HSQC) 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-{2-acetamido-2-deoxy-3-O-[3-O-acetyl-2-deoxy-
2-(2,2,2-trichloroethoxycarbonyl)-2-N-phenylsulfide-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-galactosylpyranosyl}-L-
threonine-tert-butylester (33) 
(Fmoc-Thr(βAc4Gal-(14)-βAcGlcN(SPh)Troc(13)-GalNAc)-OtBu)  
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→4)-βAc-TBS-GlcN(SPh)Troc(1→3)-αPMP-GalNAc)-OtBu) 32 (2.35 g, 
1.42 mmol) was dissolved in 80 vol% acetic acid (25 mL) and stirred for 18 h at 50°C. The 
solvent was removed in vacuo and the residue was co-evaporated with toluene. The crude 
was purified by flash column chromatography on silica (EtOAc→EtOAc/MeOH 25:1). 
Yield: 1.67 g (1.17 mmol, 82%), colorless, amorphous solid,     
   +26.08 (c = 0.51, CHCl3), 
Rf = 0.43 (EtOAc/MeOH 25:1). 
C62H76Cl3N3O26S (M = 1417.70 g/mol) [1415.35]. 
ESI-MS (pos), m/z: 1416.53 ([M+H]+, calc. 1416.36), 1433.80 ([M+NH4]
+, calc. 1433.38). 
HR-ESI-MS (pos), m/z: 1416.3584 ([M+H]+, calc. 1416.3582). 
1H NMR (600 MHz, 25°C, [D4]MeOD, internal MeOH, δ(H)=4.87 ppm): δ= 7.84-7.78 (m, 3H, 
H-4-, H-5-Fmoc, N-H-Fmoc), 7.71-7.68 (m, 2H, H-1-, H-8-Fmoc), 7.60-7.56 (sbr, 1H, N-H-Ac), 
7.43-7.24 (m, 9H, H-2-, H-3-, H-6-, H-7-Fmoc, Carom-SPh), 5.37-5.30 (m, 3H, H-4ꞌꞌ, H-4ꞌꞌ*, 
CH2a-(Troc)), 5.25 (d, 
2J(CH2a,CH2b) = 12.4 Hz, 1H, CH2b-(Troc)), 5.12-5.02 (m, 1H, H-3ꞌꞌ)
#, 
5.02-4.95 (m, 1H, H-3ꞌ), 4.94-4.88 (m, 2H, H-1ꞌ, H-2ꞌꞌ), 4.78-4.72 (m, 1H, H-1), 4.70-4.62 (m, 
4H, H-1ꞌꞌ, CH2a-(Fmoc), CH2b-(Troc), CH2b*-(Troc)), 4.42-4.33 (m, 2H, H-2, T
β), 4.29 (sbr, 1H, 
H-9-Fmoc), 4.25-4.15 (m, 2H, H-5, H-5*), 4.14-4.00 (m, 4H, H-5ꞌꞌ, H-6ꞌꞌ, Tα), 3.91-3.82 (m, 
3H, H-4, H-4ꞌ, H-6a), 3.80-3.64 (m, 4H, H-3, H-6b, H-6ꞌab), 3.48-3.41 (m, 1H, H-5ꞌꞌ), 2.13-1.75 
(m, 18H, CH3-(Ac)), 1.43 (s, 9H, tBu), 1.25 (m, 3H, T
γ).  
13C NMR (150.9 MHz, 25°C, [D4]MeOD, internal MeOH, δ(C)=49.00 ppm): δ=173.44, 171.84, 
171.37, 170.92, 170.73 (C=O-(Ac), C=O-(tBu)), 159.36, 159.23, (CH2ab-(Fmoc), CH2ab*-
(Fmoc)), 158.65, 158.33 (CH2ab-(Troc), CH2ab*-(Troc)), 145.30, 145.13 (C-1a-, C-8a-Fmoc), 
142.69 (C-4a-, C-5a-Fmoc), 138.08 (C-1-SPh), 130.27 (Carom-SPh), 128.84 (C-2-, C-7-Fmoc), 
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128.22 (C-3-, C-6-Fmoc), 126.03 (C-1-, C-8-Fmoc), 121.04 (C-4-, C-5-Fmoc), 103.49, 103.00 
(C-1ꞌ, C-1ꞌ*), 101.69, 101.45 (C-1, C-1*), 100.52, 100.44 (C-1ꞌꞌ, C-1ꞌꞌ*), 96.52, 96.38 (Cquart-
(Troc)), 83.40 (Cquart-(tBu)), 80.91, 80.41 (C-3, C-3*), 77.50, 77.21 (CH2ab-, CH2ab-*(Troc)), 
76.83 (C-4), 76.18 (C-5ꞌ), 75.77 (Tβ), 72.40 (C-3ꞌꞌ, C-4ꞌ), 71.65 (C-2ꞌꞌ, C-3ꞌ), 69.98, 69.35 (C-
5ꞌꞌ, C-5ꞌꞌ*), 68.51 (C-4ꞌꞌ, C-4ꞌꞌ*), 67.47 (CH2ab-(Fmoc)), 63.52, 63.04 (C-2ꞌ, C-2ꞌ*), 62.65, 62.60 
(C-6abꞌ), 62.29, 62.23 (C-6abꞌꞌ), 60.76 (T
α, C-6ab), 48.77 (C-2
#), 48.64 (C-9-(Fmoc)#), 24.87, 
24.52, 24.09, 20.77-20.47 (CH3-(Ac), CH3-(Ac)
*), 19.84 (Tγ). 
(*, rotational-isomers, if identifiable) 
(#, congruent with solvent peak, shift from HSQC) 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-{2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-[2-
acetamido-3,6-di-O-acetyl-2-deoxy-4-O-{2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl}-β-
D-glucopyranosyl]-α-D-galactosylpyranosyl}-L-threonine-tert-butylester (34) 
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-αAc2GalNAc)-OtBu)  
 
 
 
 
 
Zinc dust was preactivated by treating it for a few minutes with 1 N hydrochloric acid and 
then washed with water, methanol and diethyl etherr. Fmoc-Thr(βAc4Gal-(1→4)-
βGlcN(SPh)Troc(1→3)-GalNAc)-OtBu 33 (1.60 g, 1.13 mmol) was dissolved in acetic acid 
and preactivated zinc (1.11 g, 16.8 mmol) was added. The reaction was stirred at room 
temperature for 16 h. Then the same amount of zinc was additionally added and the reaction 
stirred for 20 h. The zinc powder was filtered off and washed with acetic acid. The filtrate was 
co-evaporated with toluene in vacuo. The residue was dissolved in pyridine/acetic anhydride 
(22.5 mL, 2:1) and stirred for 18 h. The solvent was removed in vacuo and the crude purified 
by flash column chromatography on silica (EtOAc→EtOAc/MeOH 25:1).  
Yield: 1.11 g (0.85 mmol, 75%), pale yellow, amorphous solid,     
   +47.45 (c = 0.51, 
CHCl3), Rf = 0.23 (EtOAc/MeOH 25:1). 
C61H79N3O28 (M = 1302.28 g/mol) [1301.49]. 
ESI-MS (pos), m/z: 1301.73 ([M+H]+, calc. 1302.49), 1318.30 ([M+NH4]
+, calc. 1319.52). 
HR-ESI-MS (pos), m/z: 1302.4927 ([M+H]+, calc. 1302.4928). 
1H NMR (400 MHz, 25°C, CDCl3, internal CHCl3, δ(H)=7.26 ppm): δ=  7.76 (d, 
3J(H-4,H-3) = 
3J(H-5,H-6) = 7.4 Hz, 2H, H-4-, H-5-Fmoc), 7.62 (d, 3J(H-1,H-2) = 3J(H-8,H-7) = 7.3 Hz, 2H, 
H-1-, H-8-Fmoc), 7.42-7.26 (m, 4H, H-2-, H-7-, H-3-, H-6-Fmoc), 6.46 (d, 3J (NH,H-2) = 9.3 
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Hz, 1H, NH-Ac), 6.03 (d, 3J(NH,Tα) = 9.5 Hz, 1H, NH-Fmoc), 5.92 (d, 3J(NHꞌ,H-2ꞌ) = 8.4 Hz, 
1H, NHꞌ-Ac), 5.33 (sbr, 1H, H-4ꞌꞌ), 5.29 (s, 1H, H-4), 5.16-5.07 (m, 2H, H-3ꞌ, H-2ꞌꞌ), 4.97 (dd, 
3J(H-3ꞌꞌ,H-2ꞌꞌ) = 10.4 Hz, 
3J(H-3ꞌꞌ,H-4ꞌꞌ) = 3.3 Hz, 1H, H-3ꞌꞌ), 4.82 (sbr, 1H, H-1), 4.73-4.70 (m, 
2H, H-1ꞌ, H-6aꞌ), 4.55-4.51 (m, 2H, H-1ꞌꞌ, CH2a-(Fmoc)), 4.46-4.42 (m, 2H, H-2, CH2b-(Fmoc)), 
4.26-4.19 (m, 3H, Tα,Tβ, H-9-Fmoc), 4.11-3.97 (m, H5, H-6ab, H-6bꞌ, H-6abꞌꞌ), 3.85-3.77 (m, 3H, 
H-3, H-4ꞌ, H-5ꞌꞌ), 3.68 (q, 3J(H-2ꞌ,H-1ꞌ) = 3J(H-2ꞌ,NHꞌ) = 3J(H-2ꞌ,H-3ꞌ) = 8.4 Hz, 1H, H-2ꞌ), 3.56 
(m, 1H, H-5ꞌ), 2.13-1.95 (m, 30H, CH3-(Ac)), 1.44 (s, 9H, tBu), 1.28 (d, 
3J(Tγ,Tβ) = 5.4 Hz, 3H, 
Tγ).  
13C NMR (100.6 MHz, 25°C, CDCl3, internal CHCl3, δ(H)=77.16 ppm): δ= 170.41-169.26 
(C=O-(Ac), C=O-(tBu)), 157.00 (C=O-(Fmoc)), 143.97, 143.85 (C-1a-, C-8a-Fmoc), 141.45 
(C-4a-, C-5a-Fomc), 127.90 (C-2-, C-7-Fmoc), 127.24 (C-3-, C-6-Fmoc), 125.21 (C-1-, C-8-
Fmoc), 120.15 (C-4-, C-5-Fmoc), 101.29 (C-1ꞌꞌ), 99.66 (C-1, C-1ꞌ), 83.19 (Cquart-(tBu)), 76.10 
(Tβ), 75.62 (C-4ꞌ), 73.41 (C-5ꞌ), 72.75 (C-3ꞌ), 72.28 (C-3), 70.98 (C-3ꞌꞌ), 70.77 (C-5ꞌꞌ), 69.29 
(C-4, C-2ꞌꞌ), 67.89 (C-5), 67.10 (CH2ab-(Fmoc)), 66.67 (C-4ꞌꞌ), 62.69 (C-6ab), 61.39 (C-6ꞌab), 
60.74 (C-6ꞌꞌab), 59.24 (T
α), 54.24 (C-2ꞌ), 48.82 (C-2), 47.39 (C-9-Fmoc), 28.22 (CH3-(tBu)), 
23.38, 21.02-20.66 (CH3-(Ac)), 19.08 (T
γ).  
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-{2-acetamindo-4,6-di-O-acetyl-2-deoxy-3-O-[2-
acetamido-3,6-di-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-
D-glucopyranosyl]-α-D-galactosylpyranosyl}-L-threonine (35) 
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-αAc2GalNAc)-OH)  
 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→4)-βAc2GlcN-(1→3)-αAc2GalNAc)-OtBu 34 (1.39 g, 1.07 mmol) was 
dissolved in dichloromethane (7.5 mL) and anisole (3 mL). Then trifluoroacetic acid (22.5 mL) 
was added and the solution was stirred for 2 h. The reaction was co-evaporated with toluene. 
The crude was purified by flash column chromatography on silica (EtOAc→EtOAc/MeOH 
25:1→10:1). 
Yield: 1.27 g (1.02 mmol, 95%), colorless, amorphous solid,     
   +53.60 (c = 0.99, CHCl3), 
Rf = 0.41 (EtOAc/MeOH 3:1). 
C57H71N3O28 (M = 1246.18 g/mol) [1245.42]. 
ESI-MS (pos), m/z: 1245.80 ([M+H]+, calc. 1246.43), 1262.47 ([M+NH4]
+, calc. 1263.46), 
1268.07 ([M+Na]+, calc. 1268.41). 
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HR-ESI-MS (pos), m/z: 1246.4297 ([M+H]+, calc. 1246.4302). 
1H NMR (600 MHz, 25°C, [D6]DMSO, internal DMSO, δ(H)=2.50 ppm): δ= 12.83 (sbr, 1H, 
COOH), 7.91, 7.90 (2 x d, JH-4,H-3 = JH-5,H-6 = 7.6 Hz, 2H, H-4-, H-5-Fmoc), 7.81 (d, JNH,H-2’ = 8.3 
Hz, 1H, N-Hꞌ-Ac), 2 x 7.73 (2 x d, JH-1,H-2 = JH-8,H-7 = 7.4 Hz, 2H, H-1-, H-8-Fmoc), 7.44-7.41 
(m, 2H, H-2-, H-7-Fmoc), 7.37 (d, JNH,Tα = 9.6 Hz, 1H, N-H-Fmoc), 7.34-7-31 (m, 2H, H-3-, H-
6-Fmoc), 7.21 (d, JNH,H2 = 9.2 Hz, 1H, N-H-Ac), 5.28 (d, JH-4,H-3 = 3.5 Hz, 1H, H-4), 5.22 (d, JH-
4’’,H-3’’ = 3.6 Hz, 1H, H-4ꞌ), 5.17 (dd, JH-3’’,H-4’’ = 3.6 Hz, JH-3’’,H-2’’ = 10.3 Hz, 1H, H-2ꞌꞌ), 5.09 (t, JH-
3’,H-4’ = JH-3’,H-2’ = 9.4 Hz, 1H, H-3ꞌ), 4.85-4.81 (m, 2H, H-1ꞌ, H-2ꞌꞌ), 4.75 (d, JH-1’’,H-2’’ = 8.0 Hz, 1H, 
H1ꞌꞌ), 4.74 (d, JH-1,H-2 = 4.0 Hz, 1H, H-1), 4.51-4-47 (m, 2H, CH2ab-Troc), 4.31 (t, JH-9,CH2 =6.7 
Hz, 1H, H-9-Fmoc), 4.27 (m, 1H, H-6ꞌa), 4.22-4.20 (m, 2H, H-5ꞌꞌ, T
β), 4.12 (dd, JTα,Tβ = 2.1 Hz, 
JTα,NH-Fmoc = 9.6 Hz), 4.09-4.02 (m, 4H, H-2, H-5, H-6a, H-6ꞌb, 4.00-3.97 (m, 2H, H-6ꞌꞌab), 3.86-
3.80 (m, 2H, H-3, H-6b), 3.65 (t, JH-4’,H-3’ = JH-4’,H-5’ = 9.4 Hz, 1H, H-4ꞌ), 3.57 (m, 1H, H5ꞌ), 3.25 
(m, 1H, H-2ꞌ), 2.09, 2.04, 2.03, 2.01, 2.00, 1.99, 1.95, 1.90, 1.83, 1.69 (each s, 30H, CH3-
(Ac)), 1.14 (d, JTγ,Tβ = 6.5 Hz, 1H, T
γ).  
13C NMR (150.9 MHz, 25°C, [D6]DMSO, internal DMSO, δ(H)=39.52 ppm): δ= 171.54, 
170.24, 170.12, 2 x 169.87, 169.53, 169.52, 169.38, 169.24, 169.18, 169.18, 169.17 (C=O-
(Ac), 156.79 (C=O-(Fmoc)), 143.77, 143.74 (C-1a-, C-8a-Fmoc), 140.82, 140.79 (C-4a-, C-5a-
Fmoc), 127.69, 127.65 (C-2-, C-7-Fmoc), 127.07 (C-3-, C-6-Fmoc), 125.16, 125.08 (C-1-, C-
8-Fmoc), 120.23, 120.18 (C-4-, C-5-Fmoc), 100.09 (C-1ꞌꞌ), 100.00 (C-1ꞌ), 98.93 (C-1), 76.67 
(C-4ꞌ), 75.02 (Tβ), 73.02 (C-3), 72.77 (C-3ꞌ), 71.49 (C-5ꞌ), 70.22 (C-3ꞌꞌ), 69.91 (C-4), 69.57 (C-
5ꞌꞌ), 68.99 (C-2ꞌꞌ), 67.03 (C-4ꞌꞌ, C-5), 65.50 (CH2ab-(Fmoc)), 62.75 (C-6ab), 61.98 (C-6ꞌab), 
60.72 (C-6ꞌꞌab), 58.57 (T
β), 54.43 (C-2ꞌ), 47.96 (C-2), 46.79 (C-9-Fmoc), 22.72, 22.65, 20.78-
20.33 (CH3-(Ac)), 18.72 (T
γ). 
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7.1.7 Synthesis of the extended type-1 core 3 amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-2-deoxy-4,6-O-para-
methoxybenzylideneacetal-3-O-{4-O-acetyl-6-O-tert-butyldimethysilyl-2-deoxy-2-N-
(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-α/β-D-
glucopyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-butylester (36)  
(βAc4Gal-(13)-α/βAc-TBS-GlcNHTroc-(13)-αPMP-GalNAc)-Thr-OtBu) 
 
 
 
 
 
 
Fmoc-Thr(αPMP-GalNAc)-OtBu 12 (1.51 g, 2.10 mmol) and βAc4Gal-(1→3)-βGlcNTroc-SPh 
27 (2.55 g, 2.73 mmol) were dissolved in dry dichloromethane (30 mL). Activated molecular 
sieves 4Å (2.1 g) were added under argon atmosphere. The suspension was stirred for 1 h 
and then cooled in an ice bath. N-iodosuccinimide (614 mg, 2.73 mmol) was added to the 
suspension, followed by the dropwise addition of a suspension of trifluoromethanesulfonic 
acid (37.2 μL, 63.0 mg, 0.42 mmol) in dry dichloromethane (300 μL) via a syringe. After 2 h 
the reaction was treated with another addition of 27 (255 mg, 0.27 mmol) and N-
iodosuccinimide (61 mg, 0.27 mmol). The reaction was stirred for 3 h under argon 
atmosphere and ice-cooling. The reaction was diluted with dichloromethane (20 mL). The 
molecular sieves were filtered off and washed with dichloromethane. The filtrate was further 
diluted with dichloromethane (total volume 180 mL). The dichloromethane phase was 
washed with a solution of 0.5 M sodium thiosulfate, saturated sodium bicarbonate, water and 
brine (60 mL each). The organic phase was dried over sodium sulfate, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography on silica 
(CHex/EtOAc 2:11:1), to give a mixture of the α- and β-anomer.  
Yield: 2.29 g (α/β (1:1.2), 1.48 mmol, 71%), colorless, amorphous solid,     
   +55.40 (c = 
1.00, CHCl3), Rf = 0.47 (
CHex/EtOac 1:1).  
C70H92Cl3N3O27Si (M = 1541.93 g/mol) [1539.48]. 
ESI-MS (pos), m/z: 1540.00 ([M+H]+, calc. 1540.48), 1562.20 ([M+Na]+, calc. 1562.47).  
HR-ESI-MS (pos), m/z: 1540.4824 ([M+H]+, calc. 1540.4831), 1562.4653 ([M+Na]+, calc. 
1562.4651). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)=2.50 ppm): δ= 7.92-7.88 (m, 4H, 
H-4αβ-, H-5αβ-Fmoc), 7.75-7.69 (m, 5H, H-1αβ-, H-8αβ-Fmoc, NHꞌβ-Troc), 7.56 (d, 
3J(NHα,T
α) = 
9.7 Hz, 1H, NHα-Fmoc), 7.51 (d, 
3J(NHβ,T
α) = 9.7 Hz, 1H, NHβ-Fmoc), 7.44-7.29 (m, 14H, 
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NHαβ-Ac, H2αβ-, H7αβ-Fmoc, H-3αβ-, H-6αβ-Fmoc, H-2αβ-, H-6αβ-SPh ), 7.07 (d, 1H, NHꞌα-Troc), 
6.96-6.93 (m, 4H, H-3αβ-, H-5αβ-SPh), 5.70 (s, 1H, CH-PMPα), 5.45 (s, 1H, CH-PMPβ), 5.26 
(d, 3J(H-4ꞌα,H-3ꞌα) = 3.4 Hz, H-4ꞌα), 5.22 (d, 
3J(H-4ꞌβ,H-3ꞌβ) = 3.2 Hz, H-4ꞌβ), 5.03 (d, 
3J(H-1ꞌα,H-
2ꞌβ) = 3.2 Hz, H-1ꞌα), 4.99-4.96 (m, 1H, H-3ꞌβ), 4.94-4.82 (m, 3H, H4ꞌα, H-3ꞌꞌβ, CH2a-Troc), 4.80-
4.72 (m, 7H, H-1α, H-1β, H-1ꞌꞌα, H-2ꞌꞌα, H-2ꞌꞌβ), CH2a-Troc, CH2b-Troc), 4.63-4.57 (m, 4H, H-1ꞌβ, 
H-1ꞌꞌβ, H-4ꞌβ, CH2b-Troc), 4.51-4.38 (m, 5H, H4α, CH2αβ-Fmoc), 4.33-4.24 (m, 6H, H-2β, H-4β, 
H-9αβ-Fmoc, T
β
αβ), 4.21-4.16 (m, 1H, H-2α), 4.14-3.90 (m, 14H, H-3ꞌβ, H-5ꞌꞌαβ, H-6abαβ, H-
6ꞌꞌabαβ), 3.82-3.74 (m, 8H, H-3α, H-3β, H-3ꞌα, CH3-PMPαβ), 3.69-3.54 (m, 9H, H-2ꞌα, H-5α, H-5β, 
H-5ꞌα, H-6ꞌabαβ), 3.37-3.34 (m,1H, H-5ꞌβ), 3.18-3.12 (m, 1H, H-2ꞌβ), 2.12, 2.08, 2.07, 2.02, 1.99, 
1.98, 1.96, 1.95, 1.92, 1.91, 1.90, 1.88, 1.87, 1.86 (m, 36H, CH3-(Ac)αβ), 1.36 (s, 18H, CH3-
(tBu)αβ), 1.17-1.13 (m, 6H, T
γ
αβ), 0.87, 0.83 (2 x s, 18H, CH3-TBSαβ), 0.06, -0.02, -0.03 (3 x s, 
Me-TBSαβ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 169.93, 
169.88, 169.87, 169.84, 169.84, 169.55, 169.46, 169.41, 169.37, 169.31, 169.21, 169.19, 
169.16, 169.12, 169.10, 169.07, 168.98, 168.46 (C=O-(Ac)), 159.55, 159.50 (C-1-PMPαβ) 
156.79, 156,75 (C=O-(Fmoc)αβ), 154.36, 153.64 (C=O-(Troc)αβ), 143.85, 143.72,143.68, 
143.65 (C-1a-, C-8b-Fmocαβ), 140.80, 140.77, 140.73 (C-4a-, C-5b-Fmocαβ), 130.74, 130.67 
(C-4-PMPαβ), 127.69, 127.66, 127.64, 127.60, 127.47, 127.02 (C-2-, C-7-Fmocαβ, C-2-, C-6-
PMPαβ), 125.22, 125.18, 125.16, 125.13, 124.85 (C-3-, C-6-Fmocαβ, C-1-, C-8-Fmocαβ), 
120.21, 120.17, 120.09 (C-4- ,C-5-Fmocαβ), 113.4, 113.35 (C-3-, C-5-PMPαβ), 101.93 (C-1ꞌβ), 
100.09 (CH-PMPβ), 99.99 (C-1ꞌꞌβ), 99.43 (CH-PMPα), 99.24, 99.07 (C-1α, C-1β, C-1ꞌꞌα), 97.14 
(C-1ꞌα), 96.09, 95.93, 95.74 (CCl3-Trocαβ), 81.42, 81.37 (Cq-tBu), 76.79 (C-3ꞌβ), 76.16 (C-3β), 
75.80 (C-4β), 75.39 (C-3ꞌα), 74.02 (C-3α), 73.90 (T
β
β), 73.82 (CH2-Troc), 73.61 (T
β
α), 73.18 ( 
C-5ꞌβ), 73.52 (CH2-Troc), 72.74 (C-4α), 70.33 (C-3ꞌꞌα), 70.29 (C-3ꞌꞌβ), 69.99 (C-5ꞌα), 69.77 (C-
5ꞌꞌα), 69.72 (C-5ꞌꞌβ), 68.89 (C-4ꞌα), 68.75 (C-2ꞌꞌα), 68.49, 68.46 (C-6αβ), 68.39 (C-2ꞌꞌβ), 67.84 (C-
4ꞌα), 67.20, 67.14 (C-4ꞌꞌαβ), 65.76, 65.57 (CH2-Fmocαβ), 62.76 (C-5α), 62.71 (C-5β), 62.18 (C-
6ꞌβ), 61.09, 60.97 (C-6ꞌꞌαβ), 60.84 (C-6ꞌα), 59.39, 59.24 (T
α
αβ), 57.31 (C-2ꞌβ), 55.54 (C-2ꞌα), 
55.10, 55.06 (CH3-PMPαβ), 47.28, 47.11 (C-2αβ), 46.78, 46.75 (C-9-Fmocαβ), 27.58, 25.74 
(CH3-(tBu)), 23.04, 22.97, 20.84, 20.75, 20.61, 20.53, 20.49, 20.44, 20.41, 20.33, 20.27, 
20.21 (CH3-(Ac)), 19.18, 19.17 (T
γ
αβ), -5.35, -5.39, -5.61, -5.70 (Me-TBSαβ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-3-O-{4-O-acetyl-2-deoxy-
2-N-(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-
α/β-D-glucopyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-butylester (37) 
(βAc4Gal-(13)-βAcGlcNHTroc-(13)-αGalNAc)-Thr-OtBu) 
 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→3)-α/βAc-TBS-GlcNHTroc(1→3)-αPMP-GalNAc)-OtBu 36 (2.03 g, 
1.32 g mmol) was dissolved in 80 vol% acetic acid (25 mL) and stirred 18 h at 40°C. The 
solvent was removed in vacuo by co-evaporation with toluene. The crude was purified by 
flash column chromatography on silica (CHex/EtOAc 1:2EtOAcEtOAc/MeOH 25:1). 
Yield:  β-Anomer: 861 mg (0.66 mmol, 50%), colorless, amorphous solid, [α]D
20 +29.93 (c = 
0.50, CHCl3), Rf = 0.30 (EtOAc/MeOH 20:1). 
α-Anomer: 502 mg (0.38 mmol, 29%), colorless, amorphous solid,     
   +56.47 (c = 0.51, 
CHCl3), Rf = 0.61 (EtOAc/MeOH 20:1). 
C56H72Cl3N3O26 (M = 1309.53 g/mol) [1307.35]. 
β-Anomer:  
ESI-MS (pos), m/z: 1307.93 ([M+H]+, calc. 1308.35). 
HR-ESI-MS (pos), m/z: 1308.3546 ([M+H]+, calc. 1308.3548). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)=2.50 ppm): δ= 7.91-7.89 (m, 2H, 
H-4-, H-5-Fmoc), 7.75 (m, 2H, H-1-, H-8-Fmoc), 7.57 (d, 3J(NH,H2ꞌ) = 9.2 Hz, 1H, NH-Troc), 
7.52 (d, 1H, 3J(NH,Tα) = 9.8 Hz, NH-Fmoc), 7.43-7.41 (m, 2H, H2-, H7-Fmoc), 7.36-7.29 (m, 
3H, NH-Ac, H-3-, H-6-Fmoc), 5.24 (d, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.8 Hz, 1H, H-4ꞌꞌ), 4.90 (dd, 
3J(H3ꞌꞌ,H4ꞌꞌ) 
= 3.7 Hz, 3J(H3ꞌꞌ,H2ꞌꞌ) = 10.5 Hz, 1H, H-3ꞌꞌ), 4.86 (d, 
2J(CH2a,CH2b) = 12.3 Hz, 1H, CH2a-
(Troc)), 4.78 (dd, 3J(H-2ꞌꞌ,H-3ꞌꞌ) = 10.2 Hz, 
3J(H-2ꞌꞌ,H-1ꞌꞌ) = 8.0 Hz, 1H, H-2ꞌꞌ), 4.73 (t, 3J(OH-
6ꞌ,H-6ꞌab) = 5.9 Hz, 1H, OH-6ꞌ), 4.65-4.63 (m, 2H, H-1ꞌꞌ, OH-6), 4.59-4.53 (m, 4H, H-1, H-1ꞌ, H-
4ꞌ, CH2b-(Troc)), 4.49 (dd, 
2J(CH2a,CH2b) = 11.0 Hz, 
3J(CH2a,H-9) = 6.9 Hz, 1H, CH2a-(Fmoc)), 
4.43 (dd, 2J(CH2b,CH2a) = 11.0 Hz, 
3J(CH2b,H-9) = 4.6 Hz, 1H, CH2b-(Fmoc)), 4.32-4.30 (m, 
2H, H-9-Fmoc, OH-4), 4.21-4.17 (m, 2H, H-2, Tβ), 4.12-4.09 (m, 1H, H-6ꞌa), 4.07-4.02 (m, 2H, 
H-5ꞌꞌ, Tα), 3.97-3.95 (m, 3H, H-4, H-3ꞌ, H-6ꞌꞌb), 3.69-3.67 (m, 1H, H-5), 3.57 (dd, 
3J(H-3,H-4) = 
2.9 Hz, 3J(H-3,H-2) = 11.1 Hz, 1H, H-3), 3.51-3.45 (m, 3H, H-6ꞌa, H-6ab), 3.37-3.34 (m, 3H, H-
2ꞌ, H-6ꞌb, H-5ꞌ), 2.09, 2.00, 1.98, 1.90, 1.88 (s, 6 x 3H, CH3-(Ac)), 1.34 (s, 9H, tBu), 1.17 (d, 
3J(Tγ,Tβ) = 4.7 Hz, 3H, T
γ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 172.00, 
169.91, 169.86, 169.37, 169.32, 169.20, 169.14, 169.01 (C=O-(Ac), C=O-(tBu)), 156.83 
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(C=O-(Fmoc)), 153.70 (C=O-(Troc)), 143.71, 143.69 (C-1a-, C-8a-Fmoc), 140.81, 140.76 (C-
4a-, C-5a-Fmoc), 127.71, 127.66 (C-2-, C-7-Fmoc), 127.07, 127.03 (C-3-,C-6-Fmoc), 125.31, 
125.16 (C-1-,C-8-Fmoc), 120.20, 120.15 (C-4-, C-5-Fmoc), 101.77 (C-1ꞌ), 99.98 (C-1ꞌꞌ), 98.96 
(C-1), 95.82 (CCl3-(Troc)), 81.22 (Cq-tBu), 77.18 (C-3ꞌ), 76.48 (C-3), 73.74 (CH2-(Troc), 73.66 
(C-5ꞌ),  73.53 (Tβ), 71.52 (C-5), 70.18 (C-3ꞌꞌ), 69.71 (C-5ꞌꞌ), 69.20 (C-4ꞌ), 68.41 (C-2ꞌꞌ), 67.86 
(C-4), 67.25 (C-4ꞌꞌ), 65.57 (CH2-(Fmoc)), 61.06 (C-6ꞌꞌ), 60.94 (C-6), 60.54 (C-6ꞌ), 59.42 (T
α), 
57.40 (C-2ꞌ), 47.22 (C-2), 46.76 (C-9-Fmoc), 27.62 (CH3-(tBu)), 22.93, 20.74, 20.59, 20.51, 
20.42, 20.36, 20.23 (CH3-(Ac)), 19.08 (T
γ). 
α-Anomer: 
ESI-MS (pos), m/z: 1308.00 ([M+H]+, calc. 1308.35). 
HR-ESI-MS (pos), m/z: 1308.3558 ([M+H]+, calc. 1308.3548). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.91-7.89 (m, 2H, 
H-4-, H-5-Fmoc),  7.78-7.71 (m, 3H, NH-Troc, H-1-, H-8-Fmoc), 7.60 (d, 3J(NH,Tα) = 9.8 
Hz, 1H, NH-Fmoc), 7.55 (d, 3J(NH,H-2) = 10.1 Hz, 1H, NH-Ac), 7.42-7.40 (m, 2H, H-2-, H-7-
Fmoc), 7.33-7.29 (m, 2H, H-3-, H-6-Fmoc), 5.25 (d, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.5 Hz, 1H, H-4ꞌꞌ), 5.05-
5.02 (m, 2H, H-3ꞌꞌ, CH2a-(Troc)), 4.88 (t, 
3J(H-4ꞌ,H-3ꞌ) = 3J(H-4ꞌ,H-3ꞌ) = 9.6 Hz, 1H, H-4ꞌ), 4.86 
(d, 3J(H-1ꞌ,H-2ꞌ) = 3.4 Hz, 1H, H-1ꞌ), 4.81 (dd, 3J(H-2ꞌꞌ,H-1ꞌꞌ) = 8.0 Hz, 
3J(H-2ꞌꞌ,H-3ꞌꞌ) =10.1 Hz, 
1H, H-2ꞌꞌ), 4.76 (d, 3J(H-1ꞌꞌ,H-2ꞌꞌ) = 8.0 Hz, 1H, H-1ꞌꞌ), 4.68-4.65 (m, 2H, OH-6, CH2b-(Troc)), 
4.61 (d, 3J(H-1,H-2) = 4.0 Hz, 1H, H-1), 4.53 (t, 
3J(OH-6ꞌ,H-6ꞌab) = 5.2 Hz, 1H, OH-6ꞌ), 4.48 (d, 
3J(OH-4,H-4) = 3.3 Hz, 1H, OH-4), 4.44 (dd, 
2J(CH2a,CH2b) = 10.7 Hz, 
3J(CH2a,H-9) = 6.9 Hz, 
1H, CH2a-(Fmoc)), 4.37 (dd, 
2J(CH2b,CH2a) = 10.7 Hz, 
3J(CH2b,H-9) = 6.9 Hz, 1H, CH2b-
(Fmoc)), 4.29-4.25 (m, 3H, H-2, H-9-(Fmoc), Tβ), 4.11-4.09 (m, 2H, H-5ꞌꞌ, H-6ꞌꞌa), 4.04-4.01 
(m, 2H, Tα, H-6ꞌꞌb), 3.87-3.83 (m, 2H, H-4, H-3ꞌ), 3.70-3.65 (m, 2H, H-5, H-5ꞌ), 3.59-3.51 (m, 
5H, H-3, H-2ꞌ, H-6ꞌa, H-6ab), 3.42-3.40 (m, 1H, H-6ꞌb), 2.10, 2.01, 1.99, 1.94, 1.90, 1.84 (6 x s, 
6 x 3H, CH3-(Ac)), 1.35, (s, 9H, CH3-(tBu)), 1.19 (d, 
3J(Tγ,Tβ) = 5.5 Hz, 3H, T
γ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 169.89, 
169.80, 169.39, 169.24, 169.19, 169.03, 168.88 (C=O-(Ac), C=O-(tBu)), 156.86 (C=O-
(Fmoc)), 154.57 (C=O-(Troc)), 143.71 (C-1a-, C-8a-Fmoc), 140.70 (C-4a-, C-5a-Fmoc), 127.62 
(C-2-, C-7-Fmoc), 127.00 (C-3-, C-6-Fmoc), 125.34 (C-1-, C-8-Fmoc), 120.07 (C-4-, C-5-
Fmoc), 99.99 (C-1ꞌꞌ), 98.64 (C-1), 97.96 (C-1ꞌ), 95.87 (CCl3-(Troc)), 81.22 (Cq-tBu), 78.37 (C-
3), 75.82 (C-3ꞌ), 73.52 (CH2-(Troc)), 73.11 (T
β), 71.33 (C-5), 70.30 (C-5ꞌ), 70.20 (C-3ꞌꞌ), 69.59 
(C-5ꞌꞌ), 68.81 (C-2ꞌꞌ), 68.17 (C-4ꞌ), 67.07 (C-4ꞌꞌ), 66.42 (C-4), 65.69 (CH2-(Fmoc)), 61.03, 
60.87 (C-6, C-6ꞌꞌ), 59.53 (C-6ꞌ), 59.26 (Tα), 55.40 (C-2ꞌ), 47.17, 46.69 (C-2, C-9-Fmoc), 27.58 
(CH3-(tBu)), 22.92, 20.60, 20.48, 20.32, 20.26, 20.19, (CH3-(Ac)), 19.12 (T
γ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-{2-N-
acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl}-
α-D-galactopyranosyl)-L-threonine-tert-butylester (38) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-αAc2GalNAc)-OtBu) 
 
 
 
 
 
Zinc dust was activated by treatment with 1 N hydrochloric acid for a few minutes followed by 
washing with water, methanol and finally diethyl ether. Fmoc-Thr(βAc4-Gal-(1→3)-
βAc2GlcNTroc-(1→3)-αGalNAc)-OtBu 37 (861 mg, 0.66 mmol) was dissolved in acetic acid 
and activated zinc was added. The reaction was stirred at room temperature for 16 h. Then 
more of the activated zinc (430 mg, 6.6 mmol) was added and the reaction stirred for 22 h. 
The zinc dust was filtered off and washed with acetic acid. The filtrate was co-evaporated 
with toluene in vacuo. The residue was dissolved in pyridine/acetic anhydride (15 mL, 2:1) 
and stirred overnight. The solvent was removed in vacuo by co-evaporation with toluene and 
the crude product was purified by flash column chromatography on silica (100% EtOAc). 
Yield: 724 mg (0.56 mmol, 85%), colorless, amorphous solid,     
   +56.39 (c = 0.49, CHCl3), 
Rf = 0.24 (EtOAc). 
C61H79N3O28 (M = 1302.28 g/mol) [1301.49]. 
ESI-MS (pos), m/z: 1302.00 ([M+H]+, calc. 1302.49), 1324.40 ([M+Na]+, calc. 1324.47). 
HR-ESI-MS (pos), m/z: 1302.4928 ([M+H]+, calc. 1302.4928). 
1H NMR (600 MHz, CDCl3, 30°C, internal CDCl3 δ(H)= 7.26 ppm): δ= 7.75 (d, 2H, 
3J(H-4,H-
3) = 
3J(H-5,H-6) = 7.6 Hz, H-4-, H-5-Fmoc), 7.61-7.60 (m, 2H, H-1-, H-8-Fmoc), 7.39 (t, 3J(H-
2,H-1) = 
3J(H-2,H-3) = 
3J(H-7,H-6) = 
3J(H-7,H-8) = 7.4 Hz, 2H, H-2-, H-7-Fmoc), 7.31-7.28 (m, 
2H, H-3-, H-6-Fmoc), 6.25-6.21 (m, 2H, NH-Ac, NHꞌ-Ac), 6.17 (d, 3J(NH,Tα) = 9.6 Hz, 1H, 
NH-Fmoc), 5.33 (d, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.5 Hz, 1H, H-4ꞌꞌ), 5.27 (d, 3J(H-4,H-3) = 2.7 Hz, 1H, H-4), 
5.06 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.4 Hz, 1H, H-1ꞌ), 5.04 (dd, 
3J(H-2ꞌꞌ,H-3ꞌꞌ) = 10.5 Hz, 
3J(H-2ꞌꞌ,H-1ꞌꞌ) = 
8.1 Hz, 1H, H-2ꞌꞌ), 4.94-4.90 (m, 2H, H-3ꞌꞌ, H-4ꞌ), 4.83 (d, 3J(H-1,H-2) = 3.7 Hz, 1H, H-1), 4.69 
(t, 3J(H-3ꞌ,H-2ꞌ) = 
3J(H-3ꞌ,H-4ꞌ) = 9.6 Hz, 1H, H-3ꞌ), 4.55-4.49 (m, 2H, H-6ꞌa, CH2a-(Fmoc)), 
4.46 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.0 Hz, 1H, H-1ꞌ), 4.44-4.37 (m, 2H, H-2, CH2b-(Fmoc)), 4.28-4.22 (m, 
3H, Tα, Tβ, H-9-Fmoc), 4.13-4.05 (m, 4H, H-5, H-6a, H-6ꞌꞌ), 4.01-3.97 (m, 2H, H-6b, H-6ꞌb), 
3.89 (dd, 3J(H-3,H-2) = 10.9 Hz, 
3J(H-3,H-4) = 2.6 Hz, 1H, H-3), 3.85 (m, 1H, -H5ꞌꞌ), 3.68 (m, 
1H, H-5ꞌ), 2.88 (q, 3J(H-2ꞌ,H-1ꞌ) = 3J(H-2ꞌ,H-3ꞌ) = 3J(H-2ꞌ,NH) = 8.4 Hz, 1H, H-2ꞌ), 2.13, 2.08, 
2.05, 2.04, 2.03, 1.99, 1.95 (m, 30 H, CH3-(Ac)), 1.44 (s, 9H, tBu), 1.30 (d, 
3J(Tγ,Tβ) = 6.4 Hz, 
3H, Tγ). 
214 7 EXPERIMENTAL
 
 
13C NMR (150.9 MHz, CDCl3, 30°C, internal CDCl3 δ(C)=77.16 ppm): δ= 171.94, 171.78, 
170.98, 170.66, 170.54, 170.51, 170.36, 170.28, 169.90, 169.38, 169.30 (C=O-(Ac), C=O-
(tBu)), 157.06 (C=O-(Fmoc)), 143.94, 143.89 (C-1a-, C-8a-Fmoc), 141.47 (C-4a-, C-5a-Fmoc), 
127.92, 127.90 (C-2-, C-7-Fmoc), 127.22, 127.18 (C-3-, C-6-Fmoc), 125.09 (C-1-, C-8-
Fmoc), 120.15 (C-4-, C-5-Fmoc), 101.07 (C-1ꞌꞌ), 99.85 (C-1), 97.74 (C-1ꞌ), 83.19 (Cq-tBu), 
76.46 (C-3ꞌ), 76.00 (Tβ), 72.49 (C-5ꞌ), 71.18 (C-3ꞌꞌ), 70.73 (C-5ꞌꞌ), 70.67 (C-3), 69.95 (C-4), 
69.45 (C-2ꞌꞌ), 68.77 (C-4ꞌ), 68.68 (C-2ꞌꞌ), 67.67 (C-5), 67.03 (CH2-(Fmoc)), 66.99 (C-4ꞌꞌ), 62.62 
(C-6ꞌꞌ), 61.82 (C-6ꞌ), 61.13 (C-6), 59.24 (Tα), 58.79 (C-2ꞌ), 48.33 (C-2), 47.38 (C-9-Fmoc), 
28.24 (tBu), 23.87, 23.47, 21.11, 21.00, 20.98, 20.92, 20.82, 20.80, 20.76, 20.68 (CH3-(Ac)), 
19.08 (Tγ). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-{2-N-
acetamido-4,6-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyl}-α-D-galactopyranosyl)-L-threonine (39) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-αAc2GalNAc)-OH) 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→3)-βAc2GlcNAc-(1→3)-αAc2GalNAc)-OtBu (1.27 g, 0.97 mmol) 38 
was dissolved in dichloromethane (5 mL) and anisole (1 mL). Then trifluoroacetic acid (15 
mL) was added and the solution was stirred for 2.5 h. The reaction was co-evaporated with 
toluene. The crude was purified by flash column chromatography on silica 
(EtOAcEtOAc/MeOH 20:1). 
Yield: 1.06 g (0.85 mmol, 87 %), colorless, amorphous solid,     
   +64.90 (c = 1.00, CHCl3), 
Rf = 0.35 (EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
C57H71N3O28 (M = 1246.18 g/mol) [1245.42]. 
HR-ESI-MS (pos), m/z: 1246.4301 ([M+H]+, calc. 1246.4302). 
1H NMR (500 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.91-7.89 (m, 2H, 
H-4-, H-5-Fmoc), 7.74 (d, 3J(H-1,H-2) = 
3J(H-8,H-7) = 7.4 Hz, 2H, H-1-, H-8-Fmoc), 7.69 (d, 
3J(NH,H-2ꞌ) = 7.1 Hz, 1H, NHꞌ-Ac), 7.45-7.30 (m, 5H, H-2-, H-3-, H-6-, H-7-Fmoc, NH-Fmoc), 
7.26 (d, 3J(NH,H-2) = 9.4 Hz, 1H, NH-Ac), 5.27 (d, 3J(H-4,H-3) = 3.4 Hz, 1H, H-4), 5.24 (d, 
3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.9 Hz, 1H, H-4ꞌꞌ), 5.08 (dd, 
3J(H-3ꞌꞌ,H-2ꞌꞌ) = 10.3 Hz, 
3J(H-3ꞌꞌ,H-4ꞌꞌ) = 3.6 Hz, 
1H, H-3ꞌꞌ), 4.77 (dd, 3J(H-2ꞌꞌ,H-3ꞌꞌ) = 10.2 Hz, 
3J(H-2ꞌꞌ,H-1ꞌꞌ) = 7.8 Hz, 1H, H-2ꞌꞌ), 4.74 (d, 
3J(H-
1,H-2) = 4.1 Hz, 1H, H-1), 4.64 (d, 
3J(H-1ꞌꞌ, H-2ꞌꞌ) = 8.1 Hz, 1H, H-1ꞌꞌ), 4.63-4.60 (m, 2H, H-1ꞌ, 
H-4ꞌ), 4.53-4.44 (m, 2H, CH2-(Fmoc)), 4.31 (t, 
3J(H-9,CH2a) = 
3J(H-9,CH2b) = 6.6 Hz, 1H, H-9-
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Fmoc), 4.26-4.24 (m, 1H, Tβ), 4.15-3.97 (m, 9H, H-2, H-5, H-5ꞌꞌ, H-6a,b, H-6ꞌa,b, H-6ꞌꞌa, T
α), 
3.88-3.85 (m, 1H, H-6ꞌꞌb), 3.80 (dd, 
3J(H-3,H-2) = 11.2 Hz, 
3J(H-3,H-4) = 3.4 Hz, 1H, H-3), 
3.65-3.62 (m, 1H, H-5ꞌ), 3.38 (m, 1H, H-2ꞌ), 2.09, 2.04, 2.01, 2.00, 1.99, 1.98, 1.89, 1.88, 1.98 
(s, 30 H, CH3-(Ac)), 1.16-1.14 (m, 3H, T
γ). 
13C NMR (125.8 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 171.55, 
170.24, 170.00, 169.99, 169.82, 169.60, 169.40, 169.35, 169.29, 169.16, 169.12 (C=O-(Ac)), 
156.74 (C=O-(Fmoc)), 143.73, 143.68 (C-1a-, C-8a-Fmoc), 140.78, 140.73 (C-4a-, C-5a-
Fmoc), 127.64, 127.59 (C-2-, C-7-Fmoc), 127.00 (C-3-, C-6-Fmoc), 125.16, 125.07 (C-1-, C-
8-Fmoc), 120.13, 120.07 (C-4-, C-5-Fmoc), 100.56 (C-1ꞌ), 99.87 (C-1ꞌꞌ), 98.82 (C-1), 76.80 
(C-3ꞌ), 74.65 (Tβ), 72.62 (C-3), 70.49, 70.38 (C-3ꞌꞌ, C-5ꞌ), 69.74 (C-4), 69.47 (C-5), 68.85 (C-
4ꞌ), 68.61 (C-2ꞌꞌ), 67.14 (C-4ꞌꞌ), 67.00 (C-5ꞌꞌ), 66.51 (CH2-(Fmoc)), 62.70 (C-6ꞌꞌ), 61.68, 61.07 
(C-6, C-6ꞌ), 58.49 (Tα), 47.09 (C-2), 46.78 (C-9-Fmoc), 22.83, 22.76, 20.68, 20.58, 20.48, 
20.43, 20.39, 20.27, 20.22 (CH3-(Ac)), 18.34 (T
γ). 
 
 
7.1.8 Synthesis of the T-antigen glycosyl acceptor building block 
 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactosylpyranoside (40) 
(βAc4Gal-SPh) 
 
 
 
αAc5Gal 16 (60.0 g, 153.7 mmol) and thiophenol (62.7 mL, 615 mmol) were dissolved in dry 
dichloromethane (400 mL). Boron trifluoride diethyl etherate (31.3 mL, 48%, 254.1 mmol) 
was added dropwise. The reaction was stirred for 5 d and then neutralized with triethylamine. 
The solvent was removed in vacuo. The crude was purified by flash column chromatography 
on silica (CHex/EtOAc 2:1). 
Yield: 55.0 g (124.9 mmol, 81%), colorless, amorphous solid, Rf = 0.48 (Tol/EtOAc 3:1). 
C20H24O9S (M = 440.46 g/mol) [440.11]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.53-7.50 (m, 2H, H2-, H6-SPh), 7.32-7.31 (m, 3H, H3-, 
H4-, H5-SPh), 5.41 (d, 1H, H4, JH4,H3 = 2.7 Hz), 5.24 (t, 1H, H2, JH2,H3 = JH2,H1 = 9.9 Hz), 5.05 
(dd, 1H, H3, JH3,H2 = 9.9 Hz, JH3,H4 = 3.3 Hz), 4.72 (d, 1H, H1, JH1,H2 = 10.0 Hz), 4.21-4.09 (m, 
2H, H6), 3.94 (t, 1H, H5, JH5,H6ab = 7.1 Hz), 2.12, 2.09, 2.04, 1.97 (4 x s, 4 x 3H, 4 x CH3(Ac)). 
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Phenyl 1-thio-β-D-galactosylpyranoside (41) 
(βGal-SPh) 
 
 
 
βAc4Gal-SPh 40 (55.05 g, 124.9 mmol) was added to a solution of sodium methoxide 
(1.08 g, 20.0 mmol) in methanol (400 mL) and the reaction was stirred for 3 h. It was 
neutralized with acidic cation exchange resin (Dowex 50WX8). After filtration of the resin, the 
filtrate was concentrated in vacuo and the residue purified by flash column chromatography 
on silica (DCM/MeOH 7:1).  
Yield: 33.1 g (121.6 mmol, 97%), colorless solid,     
   -31.29 (c = 1.01, CHCl3), Rf = 0.13 
(DCM/MeOH 7:1). 
C12H16O5S (M = 272.32 g/mol) [272.07]. 
1H-NMR (400 MHz, MeOH-d4, gCOSY, gHSQC), δ (ppm): 7.61-7.58 (m, 2H, H2-, H6-SPh), 
7.35-7.27 (m, 3H, H3-, H4-, H5-SPh), 4.58 (d, 1H, H1, JH1,H2 = 9.7 Hz), 3.95 (dd, 1H, H4, 
JH4,H3 = 3.3 Hz, JH4,H5 = 0.8 Hz), 3.84-3.3.74 (m, 2H, H6ab), 3.68-3.60 (m, 2H, H2, H5), 3.55 
(dd, 1H, H3, JH3,H2 = 9.2 Hz, JH3,H4 = 3.3 Hz).  
13C-NMR (100.6 MHz, MeOH-d4, gHSQY), δ (ppm): 136.02, 132.09, 129.85, 127.97 (PhS), 
90.25 (C1), 80.58 (H5), 76.32 (C3), 70.99 (C2), 70.40 (C4), 62.60 (C6).  
 
 
Phenyl 2,3,4-O-acetyl-6-tert-butyldimethylsilyl-1-thio-β-D-galactosylpyranoside266 (42) 
(βAc3TBS-Gal-SPh) 
 
 
 
Imidazole (10.0 g, 146.8 mmol) and tert-butyldimethylsilyl chloride (12.2 g, 80.8 mmol) was 
added to a solution of βGal-SPh 41 (20.1 g, 73.6 mmol) in dry N,N-dimethylformamide (150 
mL). The reaction was stirred for 3 h at room temperature. The reaction was diluted with 
ethyl acetate (600 mL) and washed with water (600 mL), saturated sodium bicarbonate (200 
mL) and brine (200 mL). The organic phase was dried over sodium sulfate, filtered and 
concentrated in vacuo. The residue was dissolved in pyridine and acetic anhydride (300 mL, 
2:1). The reaction was stirred for 18 h and then co-evaporated with toluene in vacuo. The 
crude was purified by flash column chromatography on silica (CHex/EtOAc 4:1). 
Yield: 27.3 g (53.2 mmol, 73%), colorless, amorphous solid,     
   +5.10 (c = 1.00, CHCl3), Rf 
= 0.4 (CHex/EtOAc 4:1). 
C24H36O8SSi (M = 512.69 g/mol) [512.19]. 
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1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC), δ (ppm): 7.50-7.48 (m, 2H, H2-, H6-SPh), 
7.30-7.28 (m, 3H, H3-, H4-, H5-SPh), 5.48 (d, 1H, H4, JH4,H3 = 3.2 Hz), 5.25-5.20 (m, 1H, H2), 
5.07-5.04 (m, 1H, H3), 4.74-4.71 (m, 1H, H1), 3.76-3.71 (m, 2H, H5, H6a), 3.63-3.58 (m, 1H, 
H6b), 2.10, 2.07, 1.96 (3 x s, 3 x 3H, 3 x CH3(Ac)), 0.84 (s, 9H, tBu(TBS)), 0.01, 0.00 (2 x s, 2 
x 3H,  Me(TBS)). 
13C-NMR (100.6 MHz, CDCl3, gHSQY), δ (ppm): 170.19, 170.14, 169.62 (C=O(Ac)), 133.28 
(C1-SPh), 132.11 (C2-, C6-SPh), 129.05 (H3-, H5-SPh), 127.98 (C4-SPh), 87.04 (C1), 77.55 
(C5), 72.48 (C3), 67.76 (C2), 67.39 (C4), 60.99 (C6), 21.00, 20.84, 20.77 (CH3(Ac)), 18.11 
(tBu(TBS)), -5.40,-5.56 (Me(TBS)). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-[2-acetamido-2-deoxy-4,6-O-para-
methoxybenzylidene-3-O-(2,3,4-O-acetyl-6-tert-butyldimethylsilyl-β-D-
galactopyranosyl)-α-D-galactopyranosyl]-L-threonine-tert-butylester (43)  
(Fmoc-Thr(βAc3TBS-Gal-(13)-αPMP-GalNAc)-OtBu) 
 
 
 
 
 
Fmoc-Thr(PMP-GalNAc)-OtBu 12 (13.93 g, 19.4 mmol) and βAc3TBS-Gal-SPh 42 (13.91 g, 
27.2 mmol) were dissolved in dry dichloromethane (200 mL) under argon atmosphere. 
Activated molecular sieves (15 g, 4Å) were added and the suspension was stirred for 1 h at 
room temperature before the mixture was cooled in an ice bath. N-iodosuccinimide (6.07 g, 
27.1 mmol) was added, followed by (336 μL, 570 mg, 3.8 mmol) trifluoromethanesulfonic 
acid in dichloromethane (4 mL). The reaction was stirred for 3 h in the ice bath and then 0.5 
h without cooling. The reaction was filtered over Celite® and washed with dichloromethane 
(200 mL). The dichloromethane phase was washed with 0.5 M sodium thiosulfate solution, 
sodium bicarbonate, water and brine (150 mL each). The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The crude was purified by flash column 
chromatography on silica (CHex/EtOAc 1:1). 
Yield: 16.08 g (14.3 mmol, 74%), colorless, amorphous solid,     
   +57.90 (c = 1.00, CHCl3), 
Rf = 0.31 (
CHex/EtOAc 2:3). 
C57H76N2O19Si (M = 1121.3 g/mol) [120.48]. 
ESI-MS (pos), m/z: 1003.13 ([M-PMP+H]+, calc. 1003.44), 1121.20 ([M+H]+, calc. 1121.49).  
HR-ESI-MS (pos), m/z: 1121.4875 ([M+H]+, calc. 1121.4890). 
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1H NMR (400 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ=
 7.90 (d, 3J(H-3,H-
4) = 3J(H-5,H-6) = 7.4 Hz, 2H, H-4-, H-5-Fmoc), 7.73 (d, 3J(H-1,H-2) = 3J(H-8,H-7) = 7.6 Hz, 
2H, H-1-, H-8-Fmoc), 7.48-7.29 (m, 7H, H-2-, H-7-, H-3-, H-6-Fmoc, NH-Ac, NH-Fmoc, H-3-, 
H-5-PMP), 6.94 (d, 3J(H-2,H-3) = 3J(H-6,H-5) = 9.0 Hz, 2H, H-2-, H-6-PMP), 5.53 (s, 1H, CH-
(PMP)), 5.32 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.6Hz, 1H, H-4ꞌ), 5.00 (dd, 
3J(H-3ꞌ,H-4ꞌ) = 3.5 Hz, 
3J(H-3ꞌ,H-2ꞌ) 
= 10.4 Hz, 1H, H-3ꞌ), 4.91 (m, 1H, H-2ꞌ), 4.76 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.0 Hz, 1H, H-1ꞌ), 4.72 (d, 
3J(H-1,H-2) = 3.8 Hz, 1H, H-1), 4.51-4.49 (m, 2H, CH2-(Fmoc)), 4.31-4.22 (m, 4H, H-2, H-5, 
H-9-Fmoc, Tβ), 4.11-4.00 (m, 3H, H-6abꞌ, T
α), 3.93 (t, 3J(H-5ꞌ,H-6aꞌ) = 3J(H-5ꞌ,H-6bꞌ) = 6.8Hz, 
1H, H-5ꞌ), 3.80 (dd, 3J(H-3,H-4) = 3.3 Hz, 
3J(H-3,H-2) = 11.4 Hz, 1H, H-3), 3.76 (s, 3H, CH3-
(PMP)), 3.66-3.64 (m, 2H, H-4, H-6a), 3.56-3.54 (m, 1H, H-6b), 2.09, 1.98, 1.89, 1.85 (each s, 
3H, CH3-(Ac)), 1.37 (s, 9H, tBu-(Thr)), 1.13 (d, 
3J(Tγ,Tβ) = 6.3 Hz, 3H, Tγ), 0.83 (s, 9H, tBu-
(TBS)), 0.02, 0.00 (each s, 3H, Me-(TBS)).  
13C NMR (100.6 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52 ppm): δ=
 169.82, 
169.55, 168.13, 168.93, 168.86 (C=O-(Ac), C=O-(tBu)), 159.53 (C-1-PMP), 156.75 (C=O-
(Fmoc)), 143.74, 143.60 (C-1a-,C-8b-Fmoc), 140.82, 140.79 (C-4a-, C-5b-Fmoc), 130.74 (C-4-
PMP), 127.72, 127.69, 127.63, 126.98 (C-2-, C-6-PMP, C-2-,C-7-, C-3-, C-6-Fmoc), 125.17, 
125.11 (C-1-, C-8-Fmoc), 120.22, 120.16 (C-4-, C-5-Fmoc), 113.38 (C-3-, C-5-PMP), 101.49 
(C-1ꞌ), 99.73 (CH-(PMP)), 99.21 (C-1), 81.45 (Cquart-(tBu)), 75.19 (T
β), 74.55 (C-3), 73.73 (C-
5), 72.42, 72.35 (C-5ꞌ)*, 70.74 (C-3ꞌ), 68.32 (C-2ꞌ, C-6ab), 66.89 (C-4ꞌ), 65.51 (CH2-(Fmoc)), 
62.89 (C-4), 60.43 (C-6abꞌ), 59.30 (T
α), 55.13 (CH3-(PMP)), 47.04 (C-2), 46.79 (C-9-(Fmoc)), 
27.59 (tBu-(Thr)), 25.64 (tBu-(TBS)), 22.97, 20.49, 20.41, 20.34 (CH3(Ac)), 19.89 (T
γ), 18.84 
(Cquart(TBS)), -6.09, -6.12 (Me(TBS)). 
 
*signal doubling due to conformers  
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-[2-acetamido-2-deoxy-4,6-O-para-
methoxybenzylidene-3-O-(6-tert-butyldimethylsilyl-β-D-galactopyranosyl)-α-D-
galactopyranosyl]-L-threonine-tert-butylester (44)  
(Fmoc-Thr(βTBS-Gal-(13)-αPMP-GalNAc)-OtBu) 
 
 
 
 
 
To a solution of Fmoc-Thr(βAc3TBS-Gal-(1→3)-βPMP-GalNAc)-OtBu 43 (14.74 g, 13.1 
mmol) in methanol (150 mL) was added small portions of a solution of sodium methoxide (1 
wt%) in methanol, to keep the pH at 9.5. After 36 h the solution was neutralized with acidic 
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cation exchange resin (Dowex 50 WX8). The resin was filtered off and washed with 
methanol. The filtrate was concentrated in vacuo. The residue was dissolved in 1,4-dioxane 
(150 mL) and a solution of sodium bicarbonate (1.50 g, 17.8 mmol) in water (150 mL) was 
added. N-9-Fluorenylmethyloxycarbonyl-succinimidylcarbonate (3.69 g, 10.9 mmol) was 
added and stirred for 3 h. The 1,4-dioxane was removed in vacuo, the aqueous phase diluted 
with water (150 mL) and extracted with ethyl acetate (500 mL and 200 mL). The combined 
organic phases were washed with water and brine, dried over sodium sulfate, filtered and 
concentrated in vacuo. The crude was purified by flash column chromatography on silica 
(CHex/EtOAc 1:2→ EtOAc). 
Yield: 9.42 g (9.47 mmol, 72%), colorless, amorphous solid,     
   +80.20 (c = 1.00, CHCl3), 
Rf = 0.19 (EtOAc).  
C51H70N2O16Si (M = 995.19 g/mol) [994.45]. 
ESI-MS (pos), m/z: 995.20 ([M+H]+, calc. 995.46), 1017.40 ([M+Na]+, calc. 1017.44). 
HR-ESI-MS (pos), m/z: 995.4569 ([M+H]+, calc. 995.4573), 881.3706 ([M-TBS+H]+, calc. 
881.3708).  
1H NMR (400 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.90 (d, 
3J(H-3,H-
4) = 3J(H-5,H-6) = 6.7 Hz, 2H, H-4-, H-5-Fmoc), 7.72 (d, 3J(H-1,H-2)  = 3J(H-8,H-7) = 7.5 Hz, 
2H, H-1-, H-8-Fmoc), 7.59 (d, 3J(NH,Tα) = 9.8 Hz, 1H, NH-Fmoc), 7.50 (d, 3J(NH,H-2) = 9.8 
Hz, 1H, NH-Ac), 7.43 (t, 3J(H-2,H-1) = 3J(H-2,H-3) = 3J(H-7,H-6) = 
3J(H-7,H-8) = 7.1 Hz, 2H, 
H2-, H-7-Fmoc), 7.37 (d, 3J(H-2,H-3) = 
3J(H-6,H-5) = 8.7 Hz, 2H, H-2-, H-6-PMP), 7.31 (t, 
3J(H-3,H-2) = 3J(H-3,H-4) = 3J(H-6,H-5) = 3J(H-6,H-7) = 7.1 Hz, 2H, H-3-, H-6-Fmoc), 6.94 (d, 
3J(H-3,H-4) = 3J(H-3,H-2) = 3J(H-6,H-5) = 3J(H-6,H-7) = 8.7 Hz, 2H, H-3-, H-6-PMP), 5.51 (s, 
1H, CH-(PMP)), 4.78-4.76 (m, 2H, H-1, OH-2ꞌ), 4.48-4.46 (m, 3H, CH2ab-(Fmoc), OH-4ꞌ), 
4.33-4.26 (m, 5H, H-1ꞌ, H-2, H-5, H-9-Fmoc, Tβ), 4.13-4.10 (m, 1H, Tα), 4.07-3.96 (m, 2H, H-
6ab), 3.81 (dd, 
3J(H-3,H-4) = 2.4 Hz, 3J(H-3,H-2) = 11.3 Hz, 1H, H-3), 3.76 (s, 3H, CH3-
(PMP)), 3.73-3.67 (m, 2H, H-6abꞌ), 3.63-3.59 (m, 2H, H-4, H-4ꞌ), 3.40 (t, 
3J(H-5ꞌ,H-6aꞌ), 
3J(H-
5ꞌ,H-6bꞌ) = 5.7 Hz, 1H, H-5ꞌ), 3.31-3.24 (m, 3H, H-2ꞌ, H-3ꞌ, OH-3ꞌ), 1.82 (s, 3H, CH3-(Ac)), 
1.37 (s, 9H, tBu-(Thr)), 1.12 (d, 3J(Tγ,Tβ) = 6.2 Hz, 3H, Tγ), 0.87 (s, 9H, tBu-(TBS)), 0.05 (s, 
6H, Me(TBS)). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52 ppm): δ= 169.44, 
169.02 (C=O-(Ac), C=O-(tBu)), 159.55 (C-1-PMP), 156.81 (C=O-(Fmoc)), 143.76, 143.58 (C-
1a-,C-8b-Fmoc), 140.80, 140.78 (C-4a-, C-5b-Fmoc), 130.84 (C-4-PMP), 127.73, 126.67 (C-2-, 
C-6-PMP, C-2-, C-7-, C-3-, C-6-Fmoc), 125.18, 125.15 (C-1-,C-8-Fmoc),  120.22, 120.16 (C-
4-, C-5-Fmoc), 113.31 (C-3-, C-5-PMP), 105.78 (C-1ꞌ), 99.85 (CH-(PMP)), 99.62 (C-1), 81.36 
(Cquart-(tBu)), 75.87 (T
β), 75.44 (C-5ꞌ), 74.62 (C-3), 73.86 (C-5), 72.28 (C-3ꞌ), 70.13 (C-2ꞌ), 
68.43 (C-6ab), 68.24 (C-4ꞌ), 65.53 (CH2ab-(Fmoc)), 63.07 (C-4), 62.77 (C-6abꞌ), 59.77 (T
α), 
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55.14 (CH3-(PMP)), 47.36 (C-2), 46.80 (C-9-Fmoc), 27.61 (tBu-(Thr)), 25.80 (tBu-(TBS)), 
23.01 (CH3-(N-H-Ac)), 19.29 (T
γ), 17.95 (Cquart-(TBS)), -5.29 (2 x Me-(TBS)).   
 
 
7.1.9 Synthesis of the extended type-1 core 1 amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-2-deoxy-4,6-O-para-
methoxybenzylideneacetal-3-O-{6-O-tert-butyldimethylsilyl-3-O-[4-O-acetyl-6-O-tert-
butyldimethysilyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-glucopyranosyl}-α-D-
galactopyranosyl)-L-threonine-tert-butylester (45) 
(Fmoc-Thr(βAc4Gal-(13)-βAc-TBS-GlcNAc-(13)-βTBS-Gal-(13)-αPMP-GalNAc)-
OtBu) 
 
 
 
 
Fmoc-Thr(βTBS-Gal-(1→3)-βPMP-GalNAc)-OtBu 44 (4.96 g, 4.99 mmol) and βAc4Gal-
(1→3)-βAc-TBS-GlcNHTroc-SPh 27 (5.91 g, 6.33 mmol) were dissolved in dry 
dichloromethane (100 mL) under argon atmosphere. Activated molecular sieves 4Å (6.31 g) 
were added and the suspension was stirred for 1 h before it was cooled in an ice bath. N-
iodosuccinimide (1.46 g, 6.33 mmol) was added followed by the dropwise addition of a 
suspension of trifluoromethanesulfonic acid (88 μL, 150 mg, 1.0 mmol) in dry 
dichloromethane (1 mL) via a syringe. After 2 h the reaction was treated with another 
addition of 27 (1.07 g, 1.0 mmol) and N-iodosuccinimide (225 mg, 1.0 mmol). The reaction 
was stirred for 1.5 h under and then diluted with dichloromethane (100 mL). The molecular 
sieves were filtered off and washed with dichloromethane (total volume 300 mL). The 
dichloromethane phase was washed with 0.5 M sodium thiosulfate solution, saturated 
sodium bicarbonate, water and brine (100 mL each). The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica (CHex/EtOAc 2:1→1:1). 
Yield: 5.81 g (3.2 mmol, 64%), colorless, amorphous solid,     
   +49.04 (c = 1.01, CHCl3), Rf 
= 0.30 (CHex/EtOAc). 
C82H116Cl3N3O32Si2 (M = 1818.33 g/mol) [1815.61]. 
ESI-MS (pos), m/z: 1816.87 ([M+H]+, calc. 1816.62). 1834.00 ([M+NH4]
+, calc. 1833.65), 
1838.00 ([M+Na]+, calc. 1838.60). 
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HR-ESI-MS (pos), m/z: 1816.6234 ([M+H]+, calc. 1816.6224). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.90-7.88 (m, 2H, 
H-4-, H-5-Fmoc), 7.75-7.72 (m, 2H, H-1-, H-8-Fmoc), 7.62 (d, 3J(NH,H-2ꞌꞌ) = 9.0 Hz, 1H, NH-
Troc), 7.52 (d, 3J(NH,Tγ) = 9.8 Hz, 1H, NH-Fmoc), 7.48 (d, 
3J(NH,H-2) = 9.6 Hz, 1H, NH-Ac), 
7.42 (t, 3J(H-2,H-7) = 
3J(H-2,H-1) = 3J(H-7,H-6) = 
3J(H-7,H-8) = 7.5 Hz, 2H, H-2-, H-7-Fmoc), 
7.36 (d, 3J(H-3,H-2) = 
3J(H-5,H-6) = 8.7 Hz, 2H, H-3-, H-5-PMP), 7.31 (t, 
3J(H-3,H-2) = 
3J(H-
3,H-4) = 3J(H-6,H-7) = 
3J(H-6,H-5) =7.6 Hz, 2H, H-3-, H-6-Fmoc), 6.94 (d, 
3J(H-2,H-3) = 
3J(H-
6,H-5) = 8.8 Hz, 2H, H-2-, H-6-PMP), 5.53 (s, 1H, CH-PMP), 5.21 (d, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.6 Hz, 
1H, H-4ꞌꞌ), 4.97 (dd, 3J(H-3ꞌꞌ,H-4ꞌꞌ) = 3.6 Hz, J(H-3ꞌꞌ,H-2ꞌꞌ) = 10.3 Hz, 1H, H-3ꞌꞌ), 4.83-4.81 (d, 
3J(CH2a,CH2b) = 12.2 Hz, 1H, (CH2a-Troc), 4.75 (m, 3H, H-1, H-1ꞌꞌ, H-2ꞌꞌꞌ), 4.70 (d, 
3J(CH2b,CH2a) = 12.2 Hz, CH2b-(Troc)), 4.67 (d, 
3J(H-1ꞌꞌ,H-2ꞌꞌ) = 8.0 Hz, 1H, H-1ꞌꞌꞌ), 4.56 (t, 
3J(H4ꞌꞌ,H3ꞌꞌ) = 3J(H-4ꞌꞌ,H-5ꞌꞌ) = 9.4 Hz, 1H, H-4ꞌꞌ), 4.47-4.44 (m, 3H, OH-2ꞌ, CH2-(Fmoc)), 4.38 
(d, 3J(OH-4ꞌ,H-4ꞌ) = 4.9 Hz, 1H, OH-4ꞌ), 4.34-4.27 (m, 5H, H-1ꞌ, H-2, H-5, Tγ, H-9-Fmoc), 4.13 
(d, 3J(Tα,Tβ) = 11.1 Hz, 1H, Tα), 4.09-4.02 (m, 3H, H-5ꞌꞌꞌ, H-6a, H-6ꞌꞌꞌa), 4.00-3.94 (m, 3H, H-3ꞌꞌ, 
H-6b, H-6ꞌꞌꞌb), 3.83 (dd, 
3J(H-3,H-4) = 2.0 Hz, 3J(H-3,H-2) = 11.2 Hz, 1H, H-3), 3.78-3.75 (m, 
4H, CH3-(PMP), H-4ꞌ), 3.72-3.65 (m, 2H, H-6ꞌꞌab), 3.64 (s, 1H, H-4), 3.61-3.51 (m, 2H, H-6ꞌab), 
3.45-3.42 (m, 1H, H-2ꞌ), 3.39-3.33 (m, 5H, H-2ꞌ, H-3ꞌ, H-5ꞌ, H-2ꞌꞌ, H-5ꞌꞌ), 2.09, 2.00, 1.99, 1.98, 
1.87, 1.84 (m, 18H, CH3-(Ac)), 1.38 (tBu-(Thr)), 1.12 (d, 
3J(Tγ,Tβ) = 7.2 Hz, 3H, Tγ), 0.86, 0.78 
(s, 2 x 9H, tBu-TBS), 0.05, -0.02, -0.03 (s, 4 x 3H, CH3-TBS).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 169.84, 
169.48, 169.37, 169.27, 169.07, 169.04 (C=O-(Ac), C=O-(tBu)), 159.49 (C-1-PMP), 156.66 
(C=O-(Fmoc)), 154.34 (C=O-(Troc)), 143.80, 143.51 (C-1a-, C-8b-Fmoc), 140.79 (C-4a-, C-5b-
Fmoc), 130.81 (C-4-PMP),  127.68, 127.64, 127.60 (C-2-, C-7-Fmoc, C-2-, C-6-PMP), 
126.99 (C-3-, C-6-Fmoc), 125.19 (C-1-, C-8-Fmoc), 120.16, 120.10 (C-4- ,C-5-Fmoc), 113.26 
(C-3-, C-5-PMP), 105.56 (C-1ꞌ), 101.39 (C-1ꞌꞌ), 100.05 (C-1ꞌꞌꞌ), 99.65 (CH-(PMP)), 99.60 (C-
1ꞌꞌ), 95.93 (CCl3-(Troc)), 81.40 (Cq-tBu(Thr)), 80.59 (C-3ꞌ), 77.55 (C-3ꞌꞌ), 75.77 (C-5), 75.14 
(C-5ꞌ), 74.88 (C-3), 74.09 (Tβ), 73.80 (C-5ꞌꞌ), 73.66 (CH2-(Troc)), 70.36 (C-3ꞌꞌꞌ), 69.78 (C-2ꞌ), 
69.61 (C-5ꞌꞌꞌ), 69.15 (C-4ꞌꞌ), 68.64 (C-2ꞌꞌꞌ), 68.40 (C-6), 67.28 (C-4ꞌ), 67.15 (C-4ꞌꞌꞌ), 65.59 (CH2-
(Fmoc)), 63.10 (C-4), 62.35 (C-6ꞌ), 62.21 (C-6ꞌꞌ), 60.87 (C-6ꞌꞌꞌ), 59.23 (Tα), 57.13 (C-2ꞌꞌ), 55.12 
(CH3-(PMP)), 47.41 (C-2), 46.78 (C-9-Fmoc), 27.61 (tBu-Thr), 25.78, 25.62 (tBu-TBS), 23.14, 
20.60, 20.48, 20.41, 20.35, 20.27 (CH3-(Ac)), 19.27 (T
γ), 17.95, 17.91 (Cq-TBS), -5.33, -5.37, 
-5.40, -5.44 (CH3-(TBS)). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-2-deoxy-4,6-para-
methoxybenzylideneacetal-3-O-{2,4,6-O-acetyl-3-O-[4,6-O-acetyl-2-deoxy-2-N-(2,2,2-
trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyl]-β-D-galactopyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-
butylester (46) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNHTroc-(13)-βAc3Gal-(13)-αPMP-GalNAc)-OtBu) 
 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→3)-βAc-TBS-GlcNHTroc-(1→3)-βTBS-Gal-(1→3)-βPMP-
GalNAc)-OtBu 45 (6.98 g, 3.84 mmol) in tetrahydrofuran (100 mL) was cooled in ice bath. A 
solution of tetra-n-butylammoniumfluoride trihydrate (14.54 g, 46.1 mmol) and acetic acid 
(7.69 mL, 8.07 g, 134.4 mmol) in tetrahydrofuran (40 mL) was added. After 1 h the ice bath 
was removed and the reaction stirred for 8 h until TLC (EtOAc/MeOH 25:1) indicated 
complete consumption. The reaction was diluted with ethyl acetate (600 mL) and the organic 
phase was washed with saturated bicarbonate solution and brine (two times, 600 mL, 1:1,) 
and with brine (once, 400 mL). The organic phase was dried over sodium sulfate, filtered and 
concentrated in vacuo. The residue was dissolved in pyridine (120 mL). Then N,N-
(dimethylamino)pyridine (45 mg, 0.37 mmol) was added, followed by addition of acetic 
anhydride (60 mL) and the reaction was stirred for 18 h. The solvent was removed by co-
evaporation with toluene in vacuo. The crude product was purified by flash column 
chromatography on silica (cHex/EtOAc 1:2). 
Yield: 4.96 g (2.82 mmol, 73%), colorless, amorphous solid,     
   +45.66 (c = 1.00, CHCl3), 
Rf = 0.34 (Tol/EtOAc 1:3). 
C78H96Cl3N3O36 (M = 1757.95 g/mol) [1755.48]. 
ESI-MS (pos), m/z: 1756.80 ([M+H]+, calc. 1756.49), 1773.87 ([M+NH4]
+, calc. 1773.52). 
HR-ESI-MS (pos), m/z: 1756.4936 ([M+H]+, calc. 1756.4917), 897.7234 ([M+K+H]2+, calc. 
897.7277). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.92-7-90 (m, 2H, 
H-4-,H-5-Fmoc), 7.75 (m, 2H, H-1-, H-8-Fmoc), 7.70 (d, 3J(NH,H-2ꞌꞌ) = 9.3 Hz, 1H, NH-Troc), 
7.44-7.41 (m, 4H, H-2-, H-7-Fmoc, NH-Fmoc, NH-Ac), 7.34-7.30 (m, 4H, H-3-, H-6-Fmoc, H-
2-, H-6-PMP), 6.93 (d, 3J(H-3,H-2) = 3J(H-5,H-4) = 8.8 Hz, 2H, H-3-, H-5-PMP), 5.46 (s, 1H, 
CH-(PMP)), 5.30 (d, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 3.9 Hz, 1H, H-4ꞌꞌ), 5.23 (d, 
3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.7 Hz, 1H, 
H-4ꞌꞌꞌ), 4.92 (dd, 3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.6 Hz, 
3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.3 Hz, 1H, H-3ꞌꞌꞌ), 4.86-4.80 (m, 
2H, H-2ꞌ, CH2a-(Troc)), 4.76 (dd, 
3J(H-2ꞌꞌꞌ,H-1ꞌꞌꞌ) = 7.9 Hz, 3J(H-2ꞌꞌꞌ,H-3ꞌꞌꞌ) = 10.3 Hz, H-2ꞌꞌꞌ), 
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4.71 (d, 3J(H-1,H-2) = 3.7 Hz, 1H, H-1), 4.65-4.60 (m, 3H, H-1ꞌ, H-1ꞌꞌꞌ, H-4ꞌꞌ), 4.55-4.44 (m, 
4H, H-1ꞌꞌ, CH2b-(Troc), CH2-(Fmoc)), 4.31 (t, 
3J(H-9,CH2-(Fmoc)) = 6.6 Hz, 1H, H-9-Fmoc), 
4.27-4.24 (m, 2H, H-5, Tβ), 4.19 (dt, 3J(H-2,H-1) = 3.5 Hz, 
3J(H-2,NH) = 
3J(H-2,H-3) = 10.4 Hz, 
1H, H-2), 4.13-3.90 (m, 12H, H-5ꞌ, H-3ꞌꞌ, H-5ꞌꞌꞌ, H-6ab, H-6ꞌab, H-6ꞌꞌab, H-6ꞌꞌꞌab, T
α), 3.83 (dd, 
3J(H-3ꞌ,H-2ꞌ) = 10.3 Hz, 
3J(H-3ꞌ,H-4ꞌ) = 3.7 Hz, 1H, H-3ꞌ), 3.77-3.75 (m, 4H, H-3, CH3-(PMP)), 
3.68-3.63 (m, 2H, H-4, H-5ꞌꞌ), 3.29-3.23 (q, 3J(H-2ꞌꞌ,H1ꞌꞌ) = 3J(H-2ꞌꞌ,H-3ꞌꞌ) = 3J(H-2ꞌꞌ,NH) = 9.2 
Hz, 1H, H-2ꞌꞌ), 2.09, 2.05, 2.04, 2.02, 2.01, 1.99, 1.97, 1.90, 1.88, 1.83 (m, 30H, CH3-(Ac)), 
1.36 (s, 9H, tBu), 1.14 (d, 3J(Tγ,Tβ) = 6.4 Hz, 3H, Tγ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 170.08, 
169.98, 169.88, 169.82, 169.31, 169.24, 169.18, 169.13, 168.73, 168.58 (C=O-(Ac), C=O-
(tBu)), 159.48 (CH-PMP), 156.73 (C=O-(Fmoc)), 153.80 (C=O-(Troc)), 143.70, 143.67 (C-1a-, 
C-8a-Fmoc), 140.81, 140.77 (C-4a-, C-5a-Fmoc), 130.74 (C-4-PMP), 127.71, 127.66 (C-2-, C-
7-Fmoc), 127.42 (C-3-, C-6-Fmoc), 127.03, 127.02 (C-3-, C-5-PMP), 125.24, 125.12 (C-1-, 
C-8-Fmoc), 120.20, 120.15 (C-4-, C-5-Fmoc), 113.37 (C-2-, C-6-PMP), 101.38 (C-1ꞌꞌꞌ), 
101.14 (C-1ꞌꞌ), 99.79 (C1ꞌ), 99.72 (CH-(PMP)), 99.01 (C-1), 95.54 (CCl3-(Troc)), 81.44 (Cq-
(tBu)), 77.10 (C-3ꞌ), 76.54 (C-3ꞌꞌ), 74.98 (Tβ), 74.75 (C-3), 73.96 (CH2-(Troc)), 73.41 (C-5), 
70.55 (C-5ꞌ), 70.19 (C-5ꞌꞌ), 70.14 (C-3ꞌꞌꞌ), 69.74 (C-5ꞌꞌꞌ), 69.48, 69.44 (C-2ꞌ, C-4ꞌ), 68.50 (C-6, 
C-2ꞌꞌꞌ), 68.29 (C-4ꞌꞌ), 67.22 (C-4ꞌꞌꞌ), 65.60 (CH2-Fmoc), 62.88 (C-4), 62.25 (C-6ꞌ), 61.52 (C-6ꞌꞌ), 
60.93 (C-6ꞌꞌꞌ), 59.28 (Tα), 56.95 (C-2ꞌꞌ), 55.10 (CH3-(PMP)), 46.91 (C-2), 46.77 (C-9-Fmoc), 
27.58 (tBu), 22.91, 20.76, 20.64, 20.60, 20.51, 20.47, 20.42, 20.34, 20.22 (CH3-(Ac)), 19.28 
(Tγ).  
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-2-deoxy-3-O-{2,4,6-O-acetyl-3-
O-[4,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-α-D-
galactopyranosyl)-L-threonine-tert-butylester (47) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNHTroc-(13)-Ac3Gal-(13)-α-GalNAc)-OtBu) 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→3)-βAc2GlcNHTroc-(1→3)-βAc3Gal-(1→3)-βPMP-
GalNAc)-OtBu 46 (4.84 g, 2.75 mmol) in 80% acetic acid (60 mL) was stirred for 2 h at 40°C. 
The solvent was removed by co-evaporation with toluene in vacuo. The crude product was 
purified by flash column chromatography on silica (CHex/EtOAc 1:3→EtOAc). 
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Yield: 4.05 g (2.47 mmol, 90%), colorless, amorphous solid,     
   +31.22 (c = 0.49, CHCl3), 
Rf = 0.19 (EtOAc). 
C70H90Cl3N3O35 (M = 1639.82 g/mol) [1637.44]. 
ESI-MS (pos), m/z: 1638.00 ([M+H]+, calc. 1638.45). 
HR-ESI-MS (pos), m/z: 1638.4506 ([M+H]+, calc. 1638.4499), 838.7021 ([M+K+H]2+, calc. 
838.7068). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.92-7.90 (m, 2H, 
C-4-, C-5-Fmoc), 7.76-7.71 (m, 3H, C-1-, C-8-Fmoc, NH-Troc), 7.44-7.41 (m, 4H, C-2-, C-7-
Fmoc, NH-Ac, NH-Fmoc), 7.33-7.31 (m, 2H, C-3-, C-6-Fmoc), 5.29 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.8 Hz, 
1H, H-4ꞌ), 5.24 (d, 3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.7 Hz, 1H, H-4ꞌꞌꞌ), 4.93 (dd, 3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.5 Hz, 
J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.6 Hz, 1H, H-3ꞌꞌꞌ), 4.90-4.85 (m, 2H, H-2ꞌ,CH2a-(Troc)), 4.77 (dd, 
3J(H-2ꞌꞌꞌ,H-
1ꞌꞌꞌ) = 7.9 Hz, 
3J(H-2ꞌꞌꞌ,H-3ꞌꞌꞌ) = 10.4 Hz, 1H, H-2ꞌꞌꞌ), 4.66-4.55 (m, 5H, H-1, H-1ꞌ, H-1ꞌꞌꞌ, H-4ꞌꞌꞌ, 
CH2b-(Troc)), 4.51-4.42 (m, 3H, H-1ꞌꞌ, CH2-(Fmoc)), 4.36 (d, 
3J(OH-4,H-4) = 5.4 Hz, 1H, OH-
4), 4.32 (t, 3J(H-9,CH2ab) = 6.8 Hz, 1H, H-9-Fmoc), 4.24-4.20 (m, 2H, H-2, T
β), 4.14-3.87 (m, 
11H, H-3ꞌꞌ, H-4, H-5ꞌ, H-5ꞌꞌꞌ, H-6ꞌab, H-6ꞌꞌab, H-6ꞌꞌꞌab, T
α), 3.83 (dd, 3J(H-3ꞌ,H-4ꞌ) = 3.3 Hz, 
3J(H-
3ꞌ,H-2ꞌ) = 9.9 Hz, 1H, H-3ꞌ), 3.67-3.61 (m, 2H, H5, H5ꞌꞌ), 3.54 (dd, 1H, H3, JH3,H4 = 2.2 Hz, 
JH3,H2 = 11.0 Hz), 3.48-3.46 (m, 2H, H-6), 3.28-3.26 (m, 1H, H-2ꞌꞌ), 2.09, 2.06, 2.04, 2.01, 
1.99, 1.98, 1.88, 1.85 (m, 30H, CH3-(Ac)), 1.35 (s, 9H, tBu), 1.16-1.15 (m, 3H, T
γ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 170.08, 
169.97, 169.88, 169.82, 169.65, 169.32, 169.23, 169.13, 168.11, 168.64 (C=O-(Ac), (C=O)-
tBu), 156.77 (C=O-(Fmoc)), 153.81 (C=O-(Troc)), 143.71, 143.65 (C-1a-, C-8a-Fmoc), 
140.81, 140.76 (C4a-, C5a-Fmoc), 127.71, 126.66 (C-2-, C-7-Fmoc), 127.04, 127.01 (C-3-, C-
6-Fmoc), 125.29, 125.15 (C-1-, C-8-Fmoc), 120.21, 120.15 (C-4-, C-5-Fmoc), 101.39 (C-1ꞌ), 
101.14 (C-1ꞌꞌ), 99.77 (C-1ꞌꞌꞌ), 98.91 (C-1), 95.54 (CCl3-Troc), 81.33 (Cq-tBu), 77.44 (C-3ꞌ), 
77.23 (C-3), 76.59 (C-3ꞌꞌ), 73.99 (CH2-(Troc)), 73.48 (T
β), 71.67 (C-5), 70.58 (C-5ꞌ), 70.21 (C-
5ꞌꞌ), 70.15 (C-3ꞌꞌꞌ), 69.75 (C-5ꞌꞌꞌ), 69.40 (C-2ꞌ, C-4ꞌ), 68.52 (C-2ꞌꞌꞌ), 68.25 (C-4ꞌꞌ), 67.43 (C-4), 
67.22 (C-4ꞌꞌꞌ), 65.58 (CH2a-(Fmoc)), 62.05 (C-6ꞌꞌꞌ), 61.54 (C-6ꞌꞌ), 60.92 (C-6ꞌ), 60.53 (C-6), 
59.35 (Tα), 56.93 (C-2ꞌꞌ), 47.04 (C-2), 46.77 (C-9-Fmoc), 27.59 (tBu), 22.94, 20.76, 20.62, 
20.53, 20.46, 20.43, 20.34, 20.24 (m, 30H, CH3-(Ac)), 19.05 (T
γ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-
{2,4,6-O-acetyl-3-O-[2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-α-D-
galactopyranosyl)-L-threonine-tert-butylester (48) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-Ac3Gal-(13)-αAc2GalNAc)-OtBu) 
 
 
 
 
Zinc dust was activated by treatment with 1 N hydrochloric acid for a few minutes followed by 
washing with water, methanol and diethyl ether. Fmoc-Thr(βAc4Gal-(1→3)-βAc2GlcNHTroc-
(1→3)-βAc3Gal-(1→3)-βGalNAc)-OtBu 47 (1.36 g, 0.83 mmol) was dissolved in acetic acid 
(20 mL) and pre-activated zinc (1.09 g, 16.6 mmol) was added. The reaction was stirred at 
40°C for 18 h. The zinc dust was filtered off and washed with acetic acid. The filtrate was co-
evaporated with toluene in vacuo. The residue was dissolved in pyridine/acetic anhydride (30 
mL, 2:1). Then 4-(dimethylamino)pyridine (10.1 mg, 0.08 mmol) was added and the solution 
stirred for 20 h. The solvent was removed by co-evaporation with toluene in vacuo and the 
crude product purified by flash column chromatography on silica (100% EtOAc). 
Yield: 1.23 g (0.77 mmol, 93%), colorless, amorphous solid,     
   +49.60 (c = 0.50, CHCl3), 
Rf = 0.26 (EtOAc). 
C73H95N3O36 (M = 1590.53 g/mol) [1589.57]. 
ESI-MS (pos), m/z: 1590.13 ([M+H]+, calc. 1590.58).  
HR-ESI-MS (pos), m/z: 1590.5772 ([M+H]+, calc. 1590.5774). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.92-7.90 (m, 2H, 
C-4-, C-5-Fmoc), 7.76-7.73 (m, 3H, C-1-, C-8-Fmoc), 7.69 (d, 3J(NHꞌꞌ,H2ꞌꞌ) = 9.2 Hz, 1H, NHꞌꞌ-
Ac), 7.50 (d, 3J(NH,H2) = 9.8 Hz, 1H, NH-Ac), 7.44-7.40 (m, 3H, C-2-, C-7-Fmoc, NH-Fmoc), 
7.34-7.30 (m, 2H, C-3-, C-6-Fmoc), 5.26 (m, 2H, H-4, H-4ꞌ), 5.23 (d, 3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.7 Hz, 
1H, H-4ꞌꞌꞌ), 5.08 (dd, 3J(H-3ꞌꞌꞌ, H-2ꞌꞌꞌ) = 10.3 Hz, 
3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.5 Hz, 1H, H-3ꞌꞌꞌ), 4.77-4.71 
(m, 2H, H-2ꞌ, H-2ꞌꞌꞌ), 4.68 (d, 3J(H-1,H-2) = 4.0 Hz, 1H, H-1), 4.66 (d, 
3J(H-1ꞌꞌꞌ,H-2ꞌꞌꞌ) = 8.0 Hz, 
1H, H-1ꞌꞌꞌ), 4.62 (t, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 
3J(H-4ꞌꞌ,H-2ꞌꞌ) = 9.7 Hz, 1H, H-4ꞌꞌ), 4.58 (d, 
3J(H-1ꞌ,H-2ꞌ) = 
7.9 Hz, 1H, H-1ꞌ), 4.52-4.43 (m, 3H, CH2-(Fmoc), H-1ꞌꞌ), 4.31 (t, 
3J(H-9,CH2ab) = 6.7 Hz, 1H, 
H-9-Fmoc), 4.22-4.15 (m, 2H, H-2, Tβ), 4.11-3.84 (m, 11H, H-5, H-5ꞌ, H-5ꞌꞌꞌ, H-6, H-6ꞌ, H-6ꞌꞌ, 
H-6ꞌꞌꞌ, Tα), 3.82-3.79 (m, 3H, H-3, H-3ꞌ, H-3ꞌꞌ), 3.70-3.68 (m, 1H, H-5ꞌꞌ), 3.56-3.47 (m, 1H, H-
2ꞌꞌ), 2.09, 2.05, 2.02, 2.01, 2.00, 1.99, 1.98, 1.98, 1.89, 1.84, 1.82 (m, 39H, CH3-(Ac)), 1.35 
(s, 9H, tBu), 1.16 (d, 3J(Tγ,Tβ) = 6.7 Hz, 3H, T
γ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 170.08, 
170.07, 169.95, 169.90, 169.88, 169.70, 169.52, 169.48, 169.37, 169.14, 169.08, 168.93, 
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168.79, 168.72 (C=O-(Ac), C=O-(tBu)), 156.74 (C=O-(Fmoc)), 143.71, 143.64 (C-1a-, C-8a-
Fmoc), 140.80, 140.77 (C-4a-, C-5a-Fmoc), 127.72, 127.67 (C-2-, C-7-Fmoc), 127.04, 127.01 
(C-3, C-6-Fmoc), 125.22, 125.10 (C-1-, C-8-Fmoc), 120.21, 120.16 (C-4-, C-5-Fmoc), 100.67 
(C-1ꞌꞌ), 100.45 (C-1ꞌ), 99.90 (C-1ꞌꞌꞌ), 98.69 (C-1), 81.48 (Cq-tBu), 77.15 (C-3ꞌꞌ), 76.40 (C-3ꞌ), 
74.02 (Tβ), 73.01 (C-3), 70.46 (C-3ꞌꞌꞌ), 70.28 (C-5), 70.24 (C-5ꞌꞌ), 69.72 (C-4ꞌ, C-2ꞌ), 69.47 (C-
5ꞌꞌꞌ), 68.99 (C-4), 68.55 (C-2ꞌꞌꞌ), 68.46 (C-4ꞌꞌ), 67.27 (C-5ꞌ), 67.15 (C-4ꞌꞌꞌ), 65.61 (CH2-(Fmoc)), 
63.03, 61.67, 61.46, 61.10 (C-6, C-6ꞌ, C-6ꞌꞌ, C-6ꞌꞌꞌ), 59.30 (Tα), 54.20 (C-2ꞌꞌ), 47.62 (C-2), 
46.75 (C-9-Fmoc), 27.58 (CH3-(tBu)), 22.82, 20.66, 20.58, 20.50, 20.47, 20.37, 20.33, 20.29 
(CH3-(Ac)), 18.74 (T
γ). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-
{2,4,6-O-acetyl-3-O-[2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-α-D-
galactopyranosyl)-L-threonine (49) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-Ac3Gal-(13)-αAc2GalNAc)-OH) 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→3)-βAc2GlcNAc-(1→3)-βAc3Gal-(1→3)-βAc2GalNAc)-OtBu 48 (1.20 
g, 0.75 mmol) was dissolved in dichloromethane (5 mL) and anisole (0.5 mL). Trifluoroacetic 
acid (15 mL) was added and the reaction was stirred for 90 min. The solvent was removed 
by co-evaporation with toluene. The crude product was purified by flash column 
chromatography on silica (EtOAc→EtOAc/MeOH 25:1). 
Yield: 933 mg (0.61 mmol, 81%), colorless, amorphous solid,     
   +57.92 (c = 1.01, CHCl3), 
Rf  = 0.24 (EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
C69H87N3O36 (M = 1534.43 g/mol) [1533.51]. 
MALDI-TOF-MS (dhb, pos), m/z: 1556.5294 ([M+Na]+, calc. 1556.4967), 1572.4962 ([M+K]+, 
calc. 1572.4706). 
HR-ESI-MS (pos), m/z: 1534.5143 ([M+H]+, calc. 1534.5148).  
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 12.96 (CO2H), 
7.92-7.90 (m, 2H, H-4-, H-5-Fmoc), 7.76-7.71 (m, 3H, H-1-, H-8-Fmoc, NHꞌꞌ-Ac), 7.47-7.30 
(m, 6H, H-2-, H-3-, H-5-, H-6-Fmoc, NH-Ac, NH-Fmoc), 5.27-5.25 (m, 2H, H-4, H-4ꞌ), 5.23 (d, 
3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.6 Hz, 1H, H-4ꞌꞌꞌ), 5.07 (dd, 
3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.6 Hz, 
3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.3 
Hz, 1H, H-3ꞌꞌꞌ), 4.77-4.73 (m, 2H, H-2ꞌ, H-2ꞌꞌꞌ), 4.71 (d, 3J(H1,H2) = 3.9 Hz, 1H, H-1), 4.67 (d, 
3J(H-1ꞌꞌꞌ,H-2ꞌꞌꞌ) = 7.9 Hz, 1H, H1ꞌꞌꞌ), 4.64-4.58 (m, 2H, H-1ꞌ, H-4ꞌꞌ), 4.52-4.43 (m, 3H, H-1ꞌꞌ, 
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CH2-Fmoc), 4.31 (t, 
3J(H-9,CH2) = 6.7 Hz, 1H, H-9-Fmoc), 4.27-4.25 (m, 1H, T
β), 4.14-4.03 
(m, 7H, H-2, H-5ꞌ, H-5ꞌꞌꞌ, H-6ꞌa, H-6ꞌꞌa, H-6ꞌꞌꞌa, T
α), 4.01-3.96 (m, 2H, H-6ꞌꞌa, H-6ꞌꞌꞌa), 3.93-3.78 
(m, 7H, H-3, H-3ꞌ, H-3ꞌꞌ, H-5, H-6ab, H-6ꞌb), 3.69-3.67 (m, 1H, H-5ꞌꞌ), 3.54-3.52 (m, 1H, H-2ꞌꞌ), 
2.09, 2.04, 2.02, 2.01, 2.00, 1.99, 1.97, 1.89, 1.84, 1.81 (s, 39H, CH3-(Ac)), 1.14 (d, 
3J(Tγ,Tβ) 
= 6.3 Hz, 3H, Tγ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 171.71, 170.10 
170.00, 169.92, 169.73, 169.55, 169.51, 169.51, 169.39, 169.16, 169.02, 168.95, 168.69 
(C=O-(Ac)), 156.78 (C=O-(Fmoc)), 143.76, 143.71 (C-1a-, C-8a-Fmoc), 140.77, 140.81, 
140.76 (C-4a-, C-5a-Fmoc), 127.72, 127.66 (C-2-, C-7-Fmoc), 127.05 (C-3-, C-6-Fmoc), 
125.26, 125.13 (C-1-, C-8-Fmoc), 120.21, 120.16 (C-4-, C-5-Fmoc), 100.67 (C-1ꞌꞌ), 100.56 
(C-1ꞌ), 99.91 (C-1ꞌꞌꞌ), 98.75 (C-1), 77.19 (C-3ꞌꞌ), 79.46 (C-3ꞌ), 74.44 (Tβ), 73.29 (C-3), 70.48 
(C-3ꞌꞌꞌ), 70.30 (C-5ꞌꞌ), 70.23 (C-5), 69.64 (C-2ꞌ, C-4ꞌ), 69.48 (C-5ꞌꞌꞌ), 69.00 (C-4), 68.56 (C-2ꞌꞌꞌ), 
68.46 (C-4ꞌꞌ), 67.26 (C-5ꞌ), 67.16 (C-4ꞌꞌꞌ), 65.57 (CH2-(Fmoc)), 63.05 (C-6ꞌ), 61.77 (C-6), 61.48 
(C-6ꞌꞌ), 61.11 (C-6ꞌꞌꞌ), 58.45 (Tα), 54.20 (C-2ꞌꞌ), 47.77 (C-2), 46.77 (C-9-Fmoc), 22.83, 22.79, 
20.66, 20.62, 20.58, 20.51, 20.39, 20.35, 20.31 (CH3-(Ac)), 18.43 (T
γ).  
 
 
7.1.10 Synthesis of the extended type-2 core 1 amino 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-4,6-O-para-
methoxybenzylidenacetal-3-O-{6-tert-butyldimethylsilyl-3-O-[3-O-acetyl-2-deoxy-6-tert-
butyldimethyldimethylsilyl-2-N-(2,2,2-trichloroethoxycarbonyl)-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-α-D-
galactopyranosyl)-L-threonine-tert-butylester (50) 
(Fmoc-Thr(βAc4Gal-(14)-βAc-TBS-GlcNHTroc-(13)-βTBS-Gal-(13)-αPMP-GalNAc)-
OtBu) 
 
 
 
 
Fmoc-Thr(βTBS-Gal-(1→3)-βPMP-GalNAc)-OtBu 39 (3.98 g, 4.00 mmol) and βAc4Gal-
(1→4)-βAc-TBS-GlcNHTroc-SPh 31 (4.88 g, 5.23 mmol) were dissolved in dry 
dichloromethane (60 mL) under argon atmosphere. Activated molecular sieves (5 g, 4Å) 
were added. The suspension was stirred for 1 h before it was cooled in an ice bath. N-
iodosuccinimide (1.18 g, 5.23 mmol) was added followed by the dropwise addition of a 
suspension of trifluoromethanesulfonic acid (53 μL, 91 mg, 0.61 mmol) in dry 
dichloromethane (1 mL) via a syringe. After 2.5 h the reaction was treated with another 
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addition of βAc4Gal-(1→4)-βAc-TBS-GlcNHTroc-SPh 31 (1.12 g, 1.20 mmol) and N-
iodosuccinimide (270 mg, 1.2 mmol). The reaction was stirred further for 1.5 h under argon 
atmosphere and ice-cooling. The reaction was diluted with dichloromethane (40 mL). The 
molecular sieves were filtered off and washed with dichloromethane (total volume of 200 
mL). The dichloromethane phase was washed with 0.5 M sodium thiosulfate solution, 
saturated sodium bicarbonate solution, water and brine (80 mL each). The organic phase 
was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography on silica (CHex/EtOAc 2:1→3:2→1:1).  
Yield: 4.71 g (2.59 mmol, 65%), colorless, amorphous solid,     
   +42.22 (c = 0.99, CHCl3), 
Rf = 0.45 (
CHex/EtOAc 2:3). 
C82H116Cl3N3O32Si2 (M = 1818.33 g/mol) [1815.61]. 
ESI-MS (pos), m/z: 1817.00 ([M+H]+, calc. 1816.62). 1833.93 ([M+NH4]
+, calc. 1833.65), 
1838.47 ([M+Na]+, calc. 1838.60). 
HR-ESI-MS (pos), m/z: 1816.6224 ([M+H]+, calc. 1816.6224), 1702.5239 ([M-TBS+H]+, calc. 
1702.5360). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.90-7.88 (m, 2H, 
H-4-, H-5-Fmoc), 7.76-7.73 (m, 2H, H-1-, H-8-Fmoc), 7.63 (d, 3J(N-H,H-2ꞌꞌ) = 8.3 Hz, 1H, N-
H-Troc,), 7.56 (d, 3J(N-H,Tα) = 9.8 Hz, 1H, N-H-Fmoc), 7.47 (d, 3J(N-H,H-2) = 9.7 Hz, 1H, N-
H-Ac), 7.42 (t, 3J(H-2,H-1) = 3J(H-2,H-3) = 3J(H-7,H-6) = 3J(H-7,H-8) = 7.4 Hz, 2H, H-2-, H-7-
Fmoc), 7.37 (d, 3J(H-2,H-3) = 3J(H-6,H-5) = 8.8 Hz, 2H, H-2-, H-6-PMP), 7.31 (t, 3J(H-3,H-4) 
= 3J(H-3,H-2) = 3J(H-6,H-7) = 3J(H-6,H-5) = 7.4 Hz, 2H, H-3-, H-6-Fmoc), 6.93 (d, 3J(H-3,H-2) 
= 3J(H-5,H-6) = 8.8 Hz, 2H, H-3-, H-5-PMP), 5.52 (s, 1H, CH-(PMP)), 5.24 (d, 3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) 
= 3.6 Hz, 1H, H-4ꞌꞌꞌ), 5.11 (dd, 3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.5 Hz, 3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.3 Hz, 1H, H-3ꞌꞌꞌ), 
4.98 (d, 3J(H-1ꞌꞌ,H-2ꞌꞌ) = 8.5 Hz, 1H, H-1ꞌꞌ), 4.93 (t, 3J(H-3ꞌꞌ,H-2ꞌꞌ) = 3J(H-3ꞌꞌ,H-4ꞌꞌ) = 6.6 Hz, 1H, 
H-3ꞌꞌ), 4.89 (d, 2J(CH2a,CH2b) = 12.4 Hz, 1H, CH2a-(Troc)), 4.83 (m, 1H, H-2ꞌꞌꞌ), 4.77 (d, 
3J(H-1,H-2) = 3.3 Hz, 1H, H-1), 4.72 (d, 3J(H-1ꞌꞌꞌ,H-2ꞌꞌꞌ) = 7.9 Hz 1H, H-1ꞌꞌꞌ), 4.68-4.65 (m, 2H, 
CH2b-(Troc), OH-2ꞌ), 4.48-4.40 (m, 3H, CH2ab-(Fmoc), OH-4ꞌ), 4.36-4.26 (m, 5H, H-2, H-5, H-
1ꞌ, H-9-Fmoc, Tβ), 4.15-4.10 (m, 2H, H-5ꞌꞌꞌ, Tα), 4.06-3.97 (m, 4H, H-6ab, H-6abꞌꞌꞌ), 3.83-3.62 
(m, 11H, H-3, H-4, H-4ꞌ, H-4ꞌꞌ, H-6abꞌ, H-6abꞌꞌ, CH3-PMP), 3.45-3.41 (m, 3H, H-2ꞌ, H-2ꞌꞌ, H-5ꞌꞌ), 
3.36-3.30 (m, 2H, H-5ꞌ, H-3ꞌ), 2.09-1.86 (m, 18H, CH3-(Ac)), 1.39 (s, 9H, tBu-(Thr)), 1.12 (d, 
3J(Tγ,Tβ) = 6.2 Hz, 3H, Tγ), 0.87, 0.83 (each s, 9H, tBu-(TBS)), 0.05, 0.04, 0.03 (each s, 3H, 
Me(TBS)).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.52 ppm): δ= 169.85, 
169.46, 169.34, 169.33, 169.01 (C=O-(Ac), C=O-(tBu)), 159.50 (C-1-PMP), 156.69 (C=O-
(Fmoc)), 154.39 (C=O-(Troc)), 143.83, 143.53 (C-1a-, C-8a-Fmoc), 140.77 (C-4a-, C-5a-
Fmoc), 130.82 (C-4-PMP), 127.62 (C-2-, C-7-Fmoc, C-2-, C-6-PMP), 126.99 (C-3-, C-6-
Fmoc), 125.21 (C-1-, C-8-Fmoc), 120.16, 120.10 (C-4-, C-5-Fmoc), 113.29 (C-3-, C-5-Pmb), 
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105.39 (C-1ꞌ), 100.26 (C-1ꞌꞌ),  2 x 99.75, 99.67 (C-1, C-1ꞌꞌꞌ, CH-(PMP)), 96.17 (Cquart-(tBu-
(TBS)), 81.39 (Cquart-(tBu-(Thr))), 80.43 (C-5ꞌꞌ), 75.78 (T
β), 75.61 (C-4ꞌꞌ), 75.08, 75.03, 74.99 
(C-3, C-3ꞌ, C-5ꞌ), 74.16 (C-5), 73.50 (C-3ꞌꞌ), 73.39 (CH2ab-(Troc)), 70.27 (C-3ꞌꞌꞌ), 69.94 (C-2ꞌ), 
69.77 (C-5ꞌꞌ), 69.04 (C-2ꞌꞌꞌ), 68.42 (C-6ab), 67.13 (C-4ꞌ), 67.03 (C-4ꞌꞌꞌ), 65.59 (CH2ab-(Fmoc)), 
63.10 (C-4), 62.09 (C-6ꞌab), 61.58 (C-6ꞌꞌab), 60.89 (C-6ꞌꞌꞌab), 59.25 (T
α), 55.82 (C-2ꞌꞌ), 55.12 
(CH3-(PMP)), 47.28, 46.79 (C-2, C-9-(Fmoc)), 27.61 (tBu-(Thr)), 25.79, 25.62 (2 tBu-(TBS)), 
23.22, 20.59, 2 x 20.45, 20.37, 20.33 (6 CH3-(Ac)), 19.31 (T
γ), 17.96, 17.90 (2 Cq(TBS)),  -
5.25, -5.34, -5.42 (4  Me(TBS)).   
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-4,6-O-para-
methoxybenzylidene-3-O-{2,4,6-tri-O-acetyl-3-O-[3,6-di-O-acetyl-2-deoxy-2-N-
(2,2,2-trichloroethoxycarbonyl)-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyl]-β-D-galactosylpyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-
butylester (51)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNHTroc-(13)-βAc3Gal-(13)-αPMP-GalNAc)-OtBu) 
 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→4)-βAc-TBS-GlcNHTroc-(1→3)-βTBS-Gal-(1→3)-βPMP-
GalNAc)-OtBu (3.80 g, 2.09 mmol) 50 in tetrahydrofuran (60 mL) was cooled in ice bath. A 
solution of tetra butylammoniumfluoride trihydrate (6.59 g, 20.9 mmol) and acetic acid (2.39 
mL, 41.8 mmol) in tetrahydrofuran (20 mL) was added. After 1 h the ice bath was removed 
and the reaction was further stirred for 16 h. The reaction was diluted with ethyl acetate (400 
mL) and the organic phase was washed with saturated sodium bicarbonate solution/brine 
(two times, 450 mL each, 1:1) and once with brine (200 mL). The organic phase was dried 
over sodium sulfate, filtered and concentrated in vacuo. The residue was dissolved in 
pyridine (60 mL). Then 4-(dimethylamino)pyridine (25 mg, 0.20 mmol) was added followed by 
acetic anhydride (30 mL) and the reaction was stirred for 24 h. The solvent was removed by 
co-evaporation with toluene in vacuo. The crude was purified by flash column 
chromatography on silica (CHex/EtOAc 1:2). 
Yield: 2.50 g (1.44 mmol, 68%), colorless, amorphous solid,     
   +56.94 (c = 0.49, CHCl3), 
Rf = 0.43 (Tol/EtOAc 1:3). 
C78H96Cl3N3O36 (M = 1757.95 g/mol) [1755.48]. 
ESI-MS (pos), m/z: 1756.93 ([M+H]+, calc. 1756.49), 1773.73 ([M+NH4]
+, calc. 1773.52). 
230 7 EXPERIMENTAL
 
 
HR-ESI-MS (pos), m/z: 1756.4922 ([M+H]+, calc. 1756.4917), 898.7227 ([M+K+H]2+, calc. 
897.7277). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.92-7.90 (m, 2H, 
H-4-, H-5-Fmoc), 7.81 (d, 3J(N-H,H-2) = 9.1 Hz, 1H, N-H-Troc), 7.77-7.34 (m, 1H, H-1, H-8-
Fmoc), 7.43-7.41 (m, 4H, H-2-, H-7-Fmoc, N-H-Ac, N-H-Fmoc), 7.34-7.30 (m, 4H, H-2-, H-6-
PMP, H-3-, H-6-Fmoc), 6.93 (d, 2H, H-3-, H-5-PMP, 3J(H-3,H-2) = 3J(H-5,H-4) = 8.8 Hz), 
5.44 (s, 1H, CH-(PMP)), 5.33 (m, 1H, H-4ꞌ), 5.22 (d, 3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.2 Hz, 1H, H-4ꞌꞌꞌ), 5.16 
(dd, 3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.3 Hz, 3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.3 Hz, 1H, H-3ꞌꞌꞌ), 4.98-4.97 (m, 2H, H-3ꞌꞌ, 
CH2a-(Troc)), 4.84-4.80 (m, 2H, H-2ꞌ, H-2ꞌꞌꞌ), 4.71-4.69 (m, 2H, H-1, H-1ꞌꞌꞌ), 4.63-4.61 (m, 2H, 
H-1ꞌ, H-1ꞌꞌ), 4.53-4.45 (m, 3H, CH2ab-(Fmoc), CH2b-(Troc)), 4.32 (t, 
3J(H-9,CH2ab) = 6.7 Hz, 
1H, H-9-Fmoc), 4.28-4.26 (m, 3H, H-5, H-6aꞌꞌ, T
α), 4.23-4.17 (m, 2H, H-2, H-5ꞌꞌꞌ), 4.09-3.99 
(m, 6H, H-6ab, H-6aꞌ, H-6abꞌꞌꞌ, T
α), 3.93-3.89 (m, 3H, H-5ꞌ, H-6bꞌ, H-6bꞌꞌ), 3.97 (dd, 
3J(H-3ꞌ,H-4ꞌ) = 
4.0 Hz, 3J(H-3ꞌ,H-2ꞌ) = 10.2 Hz, 1H, H-3ꞌ), 3.75-3.72 (m, 4H, H-3, CH3-PMP), 3.70-3.65 (m, 
2H, H-4, H-4ꞌꞌ), 3.54-3.51 (m, 1H, H-5ꞌꞌ), 3.29 (q, 3J(H-2ꞌꞌ,H-1ꞌꞌ) = 3J(H-2ꞌꞌ,N-Hꞌꞌ) = 
3J(H-2ꞌꞌ,H-3ꞌꞌ) 
= 9.1 Hz 1H, H-2ꞌꞌ), 2.09-1.83 (m, 30H, CH3-(Ac)), 1.36 (s, 9H, tBu), 1.15 (d, 
3J(Tγ,Tβ) = 6.2 
Hz, 3H, Tγ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.52 ppm): δ= 170.30, 
170.02, 169.87, 169.54, 169.50, 169.24, 169.19, 169.09, 168.71 (C=O-(Ac), C=O-(tBu)), 
159.51 (C1-PMP), 156.78 (C=O-(Fmoc)), 153.99 (C=O-(Troc)), 143.73, 143.70 (C-1a-, C-8a-
Fmoc), 140.83, 140.79 (C-4a-, C-5a-Fmoc), 130.75 (C-4-PMP), 127.67 (C-2-, C-6-PMP), 
127.04 (C-3-, C-6-Fmoc, C-2-, C-7-Fmoc), 125.25, 125.14 (C-1-, C-8-Fmoc), 120.21, 120,16 
(C-4-, C-5-Fmoc), 113.39 (C-3-, C-5-PMP), 101.46 (C-1ꞌ), 100.59 (C-1ꞌꞌ), 100.02 (C-1ꞌꞌꞌ), 
99.83 (CH-(PMP)), 99.06 (C-1), 96.08 (Cquart-(Troc)), 81.46 (Cquart-(tBu)), 78.13 (C-3ꞌ), 75.98 
(C-4ꞌꞌ), 75.05, 75.00 (Tβ, C-3), 73.40 (C-5, CH2ab-(Troc)), 72.75 (C-3ꞌꞌ), 71.51 (C-5ꞌꞌ), 70.67 
(C-5), 70.27 (C-3ꞌꞌꞌ), 69.61 (C-5ꞌꞌ), 69.42 (C-4ꞌ), 69.05, 68.92 (C-2ꞌ, C-2ꞌꞌ), 68.59 (C-6ab), 67.04 
(C-4ꞌꞌꞌ), 65.61 (CH2ab-(Fmoc)), 62.89 (C-4), 62.47 (C-6abꞌ), 61.79 (C-6abꞌꞌ), 60.81 (C-6abꞌꞌꞌ), 
59.29 (Tα), 55.78 (C-2ꞌꞌ), 55.11 (CH3-(PMP)), 46.86, 46.79 (C-2, C-9-Fmoc), 27.59 (tBu), 
22.92, 20.76, 20.69, 20.64, 20.49, 20.47, 20.46, 20.36, 20.33, 20.31 (CH3-(Ac)), 19.32 (T
γ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-3-O-{2,4,6-tri-O-acetyl-3-
O-[3,6-di-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-α-D-
galactopyranosyl)-L-threonine-tert-butylester (52)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNHTroc-(13)-βAc3Gal-(13)-αGalNAc)-OtBu) 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→4)-βAc2GlcNHTroc-(1→3)-βAc3Gal-(1→3)-βPMP-
GalNAc)-OtBu 51 (2.45 g, 1.39 mmol) in 80% acetic acid (50 mL) was stirred for 1 h at 40°C. 
The solvent was removed by co-evaporation with toluene in vacuo. The crude product was 
purified by flash column chromatography on silica (100% EtOAc). 
Yield: 2.05 g (1.25 mmol, 90%), colorless, amorphous solid,     
  +36.86 (c = 0.51, CHCl3), Rf 
= 0.27 (EtOAc). 
C70H90Cl3N3O35 (M = 1639.82 g/mol) [1637.44]. 
ESI-MS (pos), m/z: 1638.93 ([M+H]+, calc. 1638.45). 
HR-ESI-MS (pos), m/z: 1638.4480 ([M+H]+, calc. 1638.4499). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.92-7.90 (m, 2H, 
H-4-, H-5-Fmoc), 7.81 (d, 3J(N-H,H-2ꞌꞌ) = 9.1 Hz, 1H, N-H-Troc), 7.75 (t, 3J(H-1,H-2) = 3J(H-
8,H-7) = 7.7 Hz, 2H, H-1-, H-8-Fmoc), 7.46-7.41 (m, 4H, H-2-, H-7-Fmoc, N-H-Fmoc, N-H-
Ac), 7.34-7.29 (m, 2H, H-3-, H-6-Fmoc), 5.31 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.5 Hz, 1H, H-4ꞌ), 5.21 (d, 
3J(H-4ꞌꞌꞌ,H-3ꞌꞌꞌ) = 3.6 Hz, 1H, H-4ꞌꞌꞌ), 5.16 (dd, 3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.3 Hz, 3J(H-3ꞌꞌꞌ,H-4ꞌꞌꞌ) = 3.5 
Hz, 1H, H-3ꞌꞌꞌ), 4.99-4.97 (m, 2H, H-3ꞌꞌ, CH2a-(Troc)), 4.86 (t, 
3J(H-2ꞌ,H-3ꞌ) = 3J(H-2ꞌ,H-1ꞌ) = 8.2 
Hz, 1H, H-2ꞌ), 4.82 (dd, 3J(H-2ꞌꞌꞌ,H-3ꞌꞌꞌ) = 10.3 Hz, 3J(H-2ꞌꞌꞌ,H-1ꞌꞌꞌ) = 7.9 Hz, 1H, H-2ꞌꞌꞌ), 4.70-
4.58 (m, 4H, H-1, H-1ꞌ, H-1ꞌꞌ, H-1ꞌꞌꞌ), 4.52-4.49 (m, 2H, CH2b-(Troc), CH2a-(Fmoc)), 4.46-4.30 
(m, 1H, CH2b-(Fmoc)), 4.39 (d, 
3J(OH-4,H-4) = 5.4 Hz, 1H, OH-4,), 4.32 (t, 3J(H-9,CH2ab) = 
6.7 Hz, 1H, H-9-Fmoc), 4.26-4.20 (m, 4H, H-2, H-5ꞌꞌꞌ, H-6aꞌꞌ, T
β), 4.08-4.06 (m, 1H, Tα), 4.01-
3.91 (m, 6H, H-5ꞌ, H-6abꞌ, H-6bꞌꞌ, H-6abꞌꞌꞌ), 3.89-3.87 (m, 1H, H-4), 3.80-3.78 (m, 1H, H-3ꞌ), 3.68 
(t, 3J(H-4ꞌꞌ,H-3ꞌꞌ) = 
3J(H-4ꞌꞌ,H-5ꞌꞌ) = 9.5 Hz 1H, H-4ꞌꞌ), 3.63-3.61 (m, 1H, H-5), 3.55-3.82 (m, 2H, 
H-3, H-5ꞌꞌ), 3.48-3.46 (m, 1H, H-6ab), 3.33-3.29 (m, 2H, OH-6, H-2ꞌꞌ), 2.09- 1.85 (m, 30H, CH3-
(Ac)), 1.35 (s, 9H, tBu), 1.16-1.15 (m, 3H, Tγ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52 ppm): δ= 170.30, 
170.01, 170.00, 169.87, 169.59, 169.51, 169.23, 169.11, 169.08, 168.77, 168.64 (C=O-(Ac), 
C=O-(tBu)), 156.80 (C=O-(Fmoc)), 154.00 (C=O-(Troc)), 143.73, 143.66 (C-1a-, C-8a-Fmoc), 
140.82, 140.77 (C-4a-, C-5a-Fmoc), 127.73, 127.67 (C-2-, C-7-Fmoc), 127.03 (C-3-, C-6-
Fmoc), 125.30, 125.17 (C-1-, C-8-Fmoc), 120.22, 120.16 (C-4-, C-5-Fmoc), 101.42 (C-1ꞌ), 
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100.55 (C-1ꞌꞌ), 99.99 (C-1ꞌꞌꞌ), 98.94 (C-1), 96.07 (Cquart-(Troc)), 81.36 (Cquart-(tBu)), 78.33 (C-
3ꞌ), 77.43 (C-3), 75.91 (C-4ꞌꞌ), 73.49 (Tβ), 73.38 (CH2ab-(Troc)), 72.80 (C-3ꞌꞌ), 71.67 (C-5), 
71.51 (C-5ꞌꞌ), 70.68 (C-5ꞌ), 70.26 (C-3ꞌꞌꞌ), 69.59 (C-5ꞌꞌꞌ), 69.31 (C-4ꞌ), 69.05 (C-2ꞌ), 68.91 (C-
2ꞌꞌꞌ), 67.43 (C-4), 67.02 (C-4ꞌꞌꞌ), 65.58 (CH2ab-(Fmoc)), 62.22 (C-6ab), 61.80 (C-6abꞌꞌ), 60.81 (C-
6abꞌꞌꞌ), 60.54 (C-6ab), 59.36 (T
α), 55.75 (C-2ꞌꞌ), 46.99 (C-2), 46.79 (C-9-Fmoc), 27.59 (tBu), 
22.95, 20.76, 20.66, 20.64, 20.49, 20.45, 20.43, 20.36, 20.32, 20.30 (CH3-(Ac)), 19.09 (T
γ).  
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-4,6-O-acetyl-2-deoxy-3-O-{2,4,6-
tri-O-acetyl-3-O-[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactosylpyranosyl}-α-
D-galactosylpyranosyl)-L-threonine-tert-butylester (53)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-βAc3Gal-(13)-αAc2GalNAc)-OtBu) 
 
 
 
 
Zinc dust was activated by treatment with 1 N hydrochloric acid for a few minutes followed by 
washing with water, methanol and diethyl ether. Fmoc-Thr(βAc4Gal-(1→4)-βAc2GlcNHTroc-
(1→3)-βAc3Gal-(1→3)-βGalNAc)-OtBu 52 (492 mg, 0.29 mmol) was dissolved in acetic acid 
(6 mL) and preactivated zinc dust (393 mg, 6.0 mmol) was added. The reaction was stirred at 
40°C for 18 h. The zinc dust was filtered off and washed with acetic acid. The filtrate was co-
evaporated several times with toluene in vacuo. The residue was dissolved in pyridine/acetic 
anhydride (9 mL, 2:1). Then 4-(dimethylamino)pyridine (3.7 mg, 0.03 mmol) was added and 
the reaction was stirred for 20 h. The solvent was removed by co-evaporation with toluene in 
vacuo and the crude product purified by flash column chromatography on silica (100% 
EtOAc).  
Yield: 389 mg (0.25 mmol, 82%), colorless, amorphous solid,     
   +41.40 (c = 0.50, CHCl3), 
Rf = 0.21 (EtOAc/MeOH 20:1). 
C73H95N3O36 (M = 1590.53 g/mol) [1589.57]. 
HR-ESI-MS (pos), m/z: 1590.5763 ([M+H]+, calc. 1590.5774), 814.7661 ([M+K+H]2+, calc. 
814.7706). 
1H NMR (500 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.77 (d, 
3J(H-4,H-
3) = 3J(H-5,H-6) = 9.1 Hz, 2H, H-4-, H-5-Fmoc,), 7.62-7.59 (m, 2H, H-1-, H-8-Fmoc), 7.49-
7.46 (m, 2H, H-2-, H-7-Fmoc), 7.39-7.35 (m, 2H, H-3-, H-6-Fmoc), 6.22 (d, 3J(N-H,H-2) = 9.1 
Hz, 1H, N-H-Ac), 5.92 (d, 3J(N-H,Tα) = 9.1 Hz, 1H, N-H-Fmoc), 5.60-5.54 (m, 1H, N-Hꞌꞌ-Ac), 
5.32-5.29 (m, 3H, H-4, H-4ꞌ, H-4ꞌꞌꞌ), 5.15 (t, 3J(H-3ꞌꞌ, H-2ꞌꞌ) = 
3J(H-3ꞌꞌ,H-4ꞌꞌ) = 9.5 Hz, 1H, H-3ꞌꞌ), 
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5.07 (dd, 3J(H-2ꞌꞌꞌ,H-1ꞌꞌꞌ) = 8.0 Hz, 3J(H-2ꞌꞌꞌ,H-3ꞌꞌꞌ) = 10.3 Hz, 1H, H-2ꞌꞌꞌ), 4.98-4.95 (m, 2H, H-
2ꞌ, H-3ꞌꞌꞌ), 4.83 (sbr, 1H, H-1), 4.76-4.68 (m, 2H, H-1ꞌꞌ, H-6aꞌꞌ), 4.57 (d, 
3J(H-1ꞌ,H-2ꞌ) = 7.8 Hz, 
1H, H-1ꞌ), 4.51-4.49 (m, 2H, H-1ꞌꞌꞌ, H-2), 4.43 (m, 1H, CH2a-(Fmoc)), 4.35-4.31 (m, 1H, CH2b-
(Fmoc)), 4.25-4.17 (m, 3H, Tβ, Tα, H-9-Fmoc), 4.12-4.02 (m, 6H, H-5, H-6ab, H-6aꞌ, H-6abꞌꞌꞌ), 
3.99-3.90 (m, 3H, H-3, H-6bꞌ, H-6bꞌꞌꞌ), 3.86-3.50 (m, 3H, H-3ꞌ, H-5, H-5ꞌ), 3.77 (t, 
3J(H-4ꞌꞌ,H-3ꞌꞌ) 
= 3J(H-4ꞌꞌ,H-5ꞌꞌ) = 9.3 Hz, 1H, H-4ꞌꞌ), 3.58-3.52 (m, 2H, H-2ꞌꞌ, H-5ꞌꞌ), 2.11-1.87 (m, 39H, 
CH3(Ac)), 1.43 (s, 9H, tBu), 1.30 (m, 3H, T
γ).  
13C NMR (125.6 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.20 ppm: δ= 170.89, 
170.62, 170.50, 170.46, 170.27, 170.22, 170.16, 170.15, 170.00, 169.67, 169.26 (C=O-(Ac), 
C=O(tBu)), 156.63 (C=O-(Fmoc)), 143.82 (C-1a-, C-8a-Fmoc), 141.49 (C-4a-, C-5a-Fmoc), 
127.99 (C-2-, C-7-Fmoc), 127.27 (C-3-, C-6-Fmoc), 125.10 (C-1-, C-8-Fmoc), 120.24 (C-4-, 
C-5-Fmoc), 101.23 (C-1ꞌꞌꞌ), 100.60 (C-1ꞌ), 100.45 (C-1ꞌꞌ), 100.09 (C-1), 83.56 (Cquart-(tBu)), 
76.6 (Tβ), 76.13 (C-5), 75.94 (C-4ꞌꞌ), 72.68 (C-5ꞌꞌ), 71.92 (C-3, C-3ꞌꞌ), 71.33 (C-5ꞌ), 71.01 (C-
3ꞌꞌꞌ), 70.83 (C-3ꞌ), 70.70 (C-2ꞌ), 69.29 (C-4, C-4ꞌ), 69.19 (C-2ꞌꞌꞌ), 68.15 (C-5ꞌꞌꞌ), 67.20 (CH2ab-
(Fmoc)), 66.75 (C-4ꞌꞌꞌ), 63.16 (C-6abꞌ), 61.91 (C-6abꞌꞌꞌ), 60.90 (C-6ab, C-6abꞌꞌ), 59.20 (T
α), 55.30 
(C-2ꞌꞌ), 48.70 (C-2), 47.36 (C-9-(Fmoc)), 28.24 (tBu), 23.30-20.68 (CH3-(Ac)), 18.76 (T
γ).    
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-4,6-O-acetyl-2-deoxy-3-O-{2,4,6-
tri-O-acetyl-3-O-[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactosylpyranosyl}-α-
D-galactosylpyranosyl)-L-threonine (54)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-βAc3Gal-(13)-αAc2GalNAc)-OH) 
 
 
 
 
To a solution of Fmoc-Thr(βAc4Gal-(1→4)-βAc2GlcNAc-(1→3)-βAc3Gal-(1→3)-βAc2GalNAc)-
OtBu 53 (718 mg, 0.45 mmol) in dichloromethane (3 mL) and anisole (0.5 mL) was added 
trifluoroacetic acid (9 mL) and the reaction was stirred for 2.5 h. The solvent was removed by 
co-evaporation with toluene. The crude product was purified by flash column 
chromatography on silica (EtOAc→EtOAc/MeOH 25:1). 
Yield: 616 mg (0.40 mmol, 89%), colorless, amorphous solid,     
   +48.57 (c = 1.00, CHCl3) 
Rf  = 0.21 (EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
C69H87N3O36 (M = 1534.43 g/mol) [1533.51]. 
ESI-MS (pos), m/z: 1534.00 ([M+H]+, calc. 1534.51), 1556.33 ([M+Na]+, calc. 1556.50). 
HR-ESI-MS (pos), m/z: 1534.5139 ([M+H]+, calc. 1534.5148). 
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1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 12.90 (COOH), 
7.91, 7.90 (2 x d, JH-4,H-3 = JH-5,H-6 = 7.4 Hz, 2 x 1H, H-4-, H-5-Fmoc), 7.83 (d, JN-H’’,H-2’’ = 9.0 
Hz, 1H, N-Hꞌꞌ-Ac), 7.74 (m, 2H, H-1-, H-8-Fmoc), 7.45-7.30 (m, 6H, H-2-, H-3-, H-6-, H-7-
Fmoc, N-H-Fmoc, N-H-Ac), 5.28 (d, JH-4’,H-3’ = 3.7 Hz, 1H, H-4ꞌ), 5.27 (d, JH4,H3 = 3.4 Hz, 1H, 
H-4), 5.22 (d, JH-4’’’,H-3’’’ = 3.5 Hz, 1H, H-4ꞌꞌꞌ), 5.17 (dd, JH-3’’’,H-4’’’ = 3.5 Hz, JH-3’’’,H-2’’’ = 10.3 Hz, 
1H, H-3ꞌꞌꞌ), 5.00 (t, JH-3’’,H-4’’ = JH-3’’,H-2’’ = 9.5 Hz, 1H, H-3ꞌꞌ), 4.83 (dd, JH-2’’’,H-3’’’ = 10.3 Hz, JH-2’’’,H-
1’’’ = 8.0 Hz, 1H, H-2ꞌꞌꞌ), 4.74-4.69 (m, 4H, H-1, H-2, H-1ꞌꞌ, H-1ꞌꞌꞌ), 4.59 (d, JH-1’,H-2’ = 8.0 Hz, 1H, 
H-1ꞌ), 4.52-4.43 (m, 2H, CH2ab-(Fmoc)), 4.32-4.30 (m, 2H, H-9-(Fmoc), H-6aꞌꞌ), 4.27-4.25 (m, 
1H, Tβ), 4.21 (t, JH-5’’’,H-6’’’ = 6.8 Hz, 1H, H5ꞌꞌꞌ), 4.15-4.08 (m, 4H, H-2, H-5, H-6aꞌ, T
α), 4.00-3.98 
(m, 2H, H-6abꞌꞌꞌ), 3.94-3.79 (m, 6H, H-3, H-3ꞌ, H-5ꞌ, H-6ab, H-6bꞌ, H-6bꞌꞌ), 3.65 (t, JH-4’’,H-3’’ = JH-
4’’,H-5’’ = 9.5 Hz, 1H, H-4ꞌꞌ), 3.57-3.54 (m, 1H, H-5ꞌꞌ), 3.41-3.37 (m, 1H, H-2ꞌꞌ), 2.09-1.70 (m, 
39H, CH3-(Ac)). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.20 ppm: δ= 170.29, 
170.11, 170.01, 169.87, 169.73, 169.51, 169.43, 169.39, 169.13, 169.02, 168.82 (C=O-(Ac)), 
156.78 (C=O-(Fmoc)), 143.76, 143.72 (C-1a-, C-8a-Fmoc), 140.81, 140.77 (C-4a-, C-5a-
Fmoc), 127.71, 127.67 (C-2-, C-7-Fmoc), 127.06 (C-3, C-6-Fmoc), 125.27, 125.14 (C-1-, C-
8-Fmoc), 120.22, 120.16 (C-4-, C-5-Fmoc), 100.55 (C-1ꞌ), 100.00, 98.74 (C-1, C-1ꞌꞌ, C-1ꞌꞌꞌ), 
76.87 (C-3ꞌ), 76.14 (C-4ꞌꞌ), 74.45 (Tβ), 73.43 (C-3), 72.71 (C-3ꞌꞌ), 71.44 (C-5ꞌꞌ), 70.25 (C-5ꞌ,C-
3ꞌꞌꞌ), 69.67 (C-4), 69.56 (C-5ꞌꞌꞌ), 69.47 (C-2ꞌ), 69.04 (C-4ꞌ), 68.94 (C-2ꞌꞌꞌ), 67.26 (C-5), 67.03 
(C-4ꞌꞌ), 65.56 (CH2ab-(Fmoc)), 63.08 (C-6abꞌ), 61.77, 61.69 (C-6ab, C-6abꞌꞌ), 60.77 (C-6abꞌꞌꞌ), 
58.47 (Tα), 53.98 (C-2ꞌꞌ), 47.71 (C-2), 46.78 (C-9-Fmoc), 22.80, 2 x 22.63, 20.64-20.38 (CH3-
(Ac)), 18.43 (Tγ). 
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7.1.11 Synthesis of the extended type-1 core 2 amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-N-acetamido-2-deoxy-3-O-{2,4,6-O-acetyl-3-
O-[4,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroetoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-{4-O-acetyl-6-O-
tert-butyldimethylsilyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranosyl)-L-threonine-
tert-butylester (55)  
(Fmoc-Thr(βAc4Gal-(13)-βAc2-TBS-GlcNHTroc-(13)-Ac3Gal-(13)-{βAc4Gal-(13)-
βAc2-TBS-GlcNHTroc-(16)}-αGalNAc)-OtBu) 
 
 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→3)-βAc2GlcNHTroc-(1→3)-βAc3Gal-(1→3)-βGalNAc)-OtBu 47 (1.25 
g, 0.76 mmol) and βAc4Gal-(1→3)-βAc-TBS-GlcNHTroc-SPh 27 (933 mg, 1.00 mmol) were 
dissolved in dry dichloromethane (15 mL) under argon atmosphere. Activated molecular 
sieves 4Å (1 g) were added and the suspension was stirred for 1 h before it was cooled in an 
ice bath. N-iodosuccinimide (226 mg, 1.00 mmol) was added followed by the dropwise 
addition of a suspension of trifluoromethanesulfonic acid (13.5 μL, 23 mg, 0.15 mmol) in dry 
dichloromethane (100 μL) via a syringe. After 1.5 h the reaction was treated with another 
addition of 27 (95 mg, 0.1 mmol) and N-iodosuccinimide (28 mg, 0.1 mmol). The reaction 
was stirred for 2 h under argon atmosphere and ice-cooling. The reaction was diluted with 
dichloromethane (20 mL) and the molecular sieves were filtered off and washed with 
dichloromethane. The filtrate was diluted with dichloromethane (total volume of 100 mL). The 
dichloromethane phase was washed with 0.5 M sodium thiosulfate solution, saturated 
sodium bicarbonate solution, water and brine (30 mL each). The organic phase was dried 
over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography on silica (cHex/EtOAc 1:1→1:2). 
Yield: 1.47 g (0.597 mmol, 78%), colorless, amorphous solid,     
   +19.20 (c = 0.49, CHCl3), 
Rf = 0.41 (Tol/EtOAc 1:3). 
C101H136Cl6N4O51Si (M = 2462.96 g/mol) [2458.61]. 
MALDI-TOF-MS (dhb, pos), m/z: 2386.41 ([M-TBS+K]+, calc. 2386.48), 2500.40 ([M+K]+, 
calc. 2500.57). 
HR-ESI-MS (pos), m/z: 1250.7860 ([M+K+H]2+, calc. 1250.7896). 
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 1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.91-7.90 (m, 2H, 
H-4-, H-5-Fmoc), 7.76-7.70 (m, 4H, H-1-, H-8-Fmoc, NHꞌꞌ-Troc, NHꞌꞌꞌꞌ-Troc), 7.45-7.30 (m, 
6H, H-2-, H-7-Fmoc, C-3-, C-6-Fmoc, NH-Ac, NH-Fmoc), 5.30 (m, 1H, H-4ꞌ), 5.24-5.22 (m, 
2H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 5.01 (dd, 3J(H-3ꞌꞌꞌꞌꞌ,H-4ꞌꞌꞌꞌꞌ) = 3.5 Hz, 
3J(H-3ꞌꞌꞌꞌꞌ,H-2ꞌꞌꞌꞌꞌ) = 10.5 Hz, 1H, H-3ꞌꞌꞌꞌꞌ), 
4.93 (dd, 3J(H3ꞌꞌꞌ,H4ꞌꞌꞌ) = 3.5 Hz, 3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 10.4 Hz, 1H, H-3ꞌꞌꞌ), 4.88-4.85 (m, 2H, H-2ꞌ, 
CH2a-(Troc)), 4.81-4.75 (m, 3H, H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ, CH2a-(Troc)), 4.72-4.59 (m, 5H, H-1ꞌꞌꞌ, H-1ꞌꞌꞌꞌꞌ, H-
4ꞌꞌ, H-4ꞌꞌꞌꞌ, CH2b-(Troc)), 4.57-4.54 (m, 3H, H-1, H-1ꞌ, CH2b-(Troc)), 4.50-4.44 (m, 3H, H-1ꞌꞌ, 
CH2-(Fmoc)), 4.39-4.38 (d, 
3J(H1ꞌꞌꞌꞌ,H2ꞌꞌꞌꞌ) = 8.4 Hz, 1H, H-1ꞌꞌꞌꞌ), 4.32 (t, 3J(H-9,CH2) = 6.7 Hz, 
1H, H-9-Fmoc), 4.21-4.17 (m, 1H, H-2), 4.12-3.91 (m, 12H, H-3ꞌꞌ, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ, H-6ꞌab, H-6ꞌꞌab, 
H-6ꞌꞌꞌab, H-6ꞌꞌꞌꞌꞌab, T
α), 3.88-3.81 (m, 4H, H-3ꞌ, H-3ꞌꞌꞌꞌ, H-5ꞌ, H-6a), 3.78-3.73 (m, 2H, H-4, H-5), 
3.68-3.63 (m, 2H, H-6ꞌꞌꞌꞌa, H-5ꞌꞌ), 3.60-3.49 (m, 3H, H-3, H-6b, H-6ꞌꞌꞌꞌb), 3.47-3.45 (m, 1H, H-
5ꞌꞌꞌꞌ), 3.38 (q, 3J(H2ꞌꞌꞌꞌ,H3ꞌꞌꞌꞌ) = 
3J(H2ꞌꞌꞌꞌ, H1ꞌꞌꞌꞌ) = 
3J(H2ꞌꞌꞌꞌ,NH) = 9.3 Hz, 1H, H-2ꞌꞌꞌꞌ), 3.29-3.24 (m, 
1H, H-2ꞌꞌ), 2.09, 2.04, 2.03, 2.01, 2.00, 1.99, 1.98, 1.97, 1.96, 1.88, 1.84 (m, 45H, 15 x CH3-
(Ac)), 1.36 (s, 9H, tBu-(Thr)), 1.13 (d, 3J(Tγ,Tβ) = 6.0 Hz, 3H, Tγ), 0.85 (s, 9H, tBu-(TBS)), 
0.01, 0.00 (2 x s, 2 x 3H, 2 x CH3-(TBS)). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ=170.07, 170.02, 
169.88, 169.82, 169.73, 169.69, 169.64, 169.53, 169.53, 169.48, 169.38, 169.31, 169.25, 
169.23, 169.20, 169.13, 169.09, 169.04, 169.86, 168.66 (C=O-(Ac), C=O-(tBu)), 156.75 
(C=O-(Fmoc)), 154.08, 153.80 (2 x C=O-(Troc)), 143.68, 143.67 (C-1a-, C-8a-Fmoc), 140.80, 
140.76 (C-4a-, C-5a-Fmoc), 127.70, 127.66 (C-2-, C-7-Fmoc), 125.23, 125.12 (C-1-, C-8-
Fmoc), 120.21, 120.16 (C-4-, C-5-Fmoc), 101.44 (C-1ꞌ), 101.13 (C-1ꞌꞌ), 100.61 (C-1ꞌꞌꞌꞌ), 99.96 
(C-1ꞌꞌꞌꞌꞌ), 99.77 (C-1ꞌꞌꞌ), 99.05 (C-1), 95.89, 95.52 (2 x CCl3-(Troc)), 81.39 (Cq-tBu), 77.92 (C-
3ꞌꞌꞌꞌ), 77.31 (C-3ꞌ), 76.70 (C-3), 76.59 (C-3ꞌꞌ), 74.00 (Tβ, CH2-(Troc)), 73.55 (C-5ꞌꞌꞌꞌ), 73.49 
(CH2-(Troc)), 70.48 (C-5ꞌ), 70.33 (C-3ꞌꞌꞌꞌꞌ), 70.20 (C-5ꞌꞌ), 70.15 (C-3ꞌꞌꞌ), 70.06 (C-5), 69.75 (C-
5ꞌꞌꞌ, C-6), 69.60 (C-5ꞌꞌꞌꞌꞌ), 69.37 (C-2ꞌ), 69.24 (C-4ꞌ), 68.81 (C-4ꞌꞌꞌꞌ), 68.75 (C-2ꞌꞌꞌ), 68.53 (C-2ꞌꞌꞌꞌ), 
68.43 (C-4), 68.25 (C-4ꞌꞌ), 67.22, 67.18 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.60 (CH2-(Fmoc)), 62.03 (C-6ꞌꞌꞌꞌ), 
61.70 (C-6ꞌꞌ), 61.50 (C-6ꞌ), 60.92 (C-6ꞌꞌꞌ), 60.84 (C-6ꞌꞌꞌꞌꞌ), 59.57 (Tα), 56.93 (C-2ꞌꞌ), 56.62 (C-
2ꞌꞌꞌꞌ), 46.92 (C-2), 46.77 (C-9-Fmoc), 27.62 (Cq-tBu(Thr)), 25.74 (Cq-TBS), 22.95, 20.62, 
20.60, 20.50, 20.47, 20.42, 20.34, 20.27, 20.23 (CH3-(Ac)), 19.03 (T
γ), 18.02 (CH3-(tBu-
TBS)), -5.42, -5.44 (CH3-(TBS)). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(4-O-acetyl-2-N-acetamido-2-deoxy-3-O-{2,4,6-
O-acetyl-3-O-[4,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroetoxycarbonyl)-3-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-
{4,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-
butylester (56) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNHTroc-(13)-Ac3Gal-(13)-{βAc4Gal-(13)-
βAc2GlcNHTroc-(16)}-αGalNAc)-OtBu) 
 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→3)-βAc2-TBS-GlcNHTroc-(1→3)-βAc3Gal-(1→3)-
[βAc4Gal-(1→3)-βAc2-TBS-GlcNHTroc-(1→6)]-αGalNAc)-OtBu 55 (2.91 g, 1.18 mmol) in 
80% acetic acid (30 mL) was stirred for 17 h at 35°C. The solvent was removed by co-
evaporation with toluene in vacuo. The residue was dissolved in pyridine (20 mL) and cooled 
in an ice bath. Then 4-(dimethylamino)pyridine (15 mg, 0.12 mmol) and acetic anhydride (10 
mL) were added and the solution was stirred for 6.5 h. The crude product was purified by 
flash column chromatography on silica (CHex/EtOAc 1:3). 
Yield: 2.74 g (1.12 mmol, 95%), colorless, amorphous solid,     
   +26.70 (c = 0.50, CHCl3), 
Rf = 0.36 (Tol/EtOAc 1:4). 
C99H126Cl6N4O53 (M = 2432.77 g/mol) [2428.54]. 
MALDI-TOF-MS (dhb, pos), m/z: 2471.00 ([M+K]+, calc. 2470.51). 
HR-ESI-MS (pos), m/z: 1235.7530 ([M+K+H]2+, calc. 1235.7569). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.91-7.90 (m, 2H, 
H-4-, H-5-Fmoc), 7.79 (d, 3J(NH,H-2ꞌꞌꞌꞌ) = 9.7 Hz, 1H, NHꞌꞌꞌꞌ-Troc,), 7.76-7.73 (m, 2H, H-1-, H-
8-Fmoc), 7.68 (d, 3J(NH,H2ꞌꞌ) = 9.4 Hz, 1H, NHꞌꞌ-Troc), 7.49 (d, 
3J(NH,H-2) = 9.8 Hz, 1H, NH-
Ac), 7.43-7.41 (m, 3H, H-2-, H-7-Fmoc, NH-Fmoc), 7.34-7.29 (m, 2H, H-3-, H-6-Fmoc), 5.27 
(sbr, 1H, H-4ꞌ), 5.23-5.22 (m, 2H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 5.21 (sbr, 1H, H-4), 5.03 (dd, 
3J(H-3ꞌꞌꞌꞌꞌ,H-2ꞌꞌꞌꞌꞌ) 
= 10.3 Hz, 3J(H-3ꞌꞌꞌꞌꞌ,H-4ꞌꞌꞌꞌꞌ) = 3.6 Hz, 1H, H-3ꞌꞌꞌꞌꞌ), 4.93 (dd, 
3J(H-3ꞌꞌꞌ,H-2ꞌꞌꞌ) = 3.5 Hz, 
3J(H-3ꞌꞌꞌ,H-
4ꞌꞌꞌ) = 10.4 Hz, 1H, H-3ꞌꞌꞌ), 4.87-4.85 (d, 
2J(CH2a,CH2b) = 12.1 Hz, 1H, CH2a-(Troc)), 4.82-4.75 
(m, 3H, CH2a-(Troc), H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.73-4.67 (m, 4H, H-1ꞌꞌꞌꞌ, H-2, H-4ꞌꞌꞌꞌ, CH2b-(Troc)), 4.66-
4.58 (m, 3H, H-1, H-1ꞌꞌꞌ, H-4ꞌꞌ), 4.56-4.50 (m, 3H, H-1ꞌ, CH2b-(Troc), CH2a-(Fmoc)), 4.48-4.39 
(m, 3H, H-1ꞌꞌ, H-1ꞌꞌꞌꞌ, CH2b-(Fmoc)), 4.31 (t, 
3J(H-9,CH2) = 6.7 Hz, 1H, H-9-Fmoc), 4.14-4.01 
(m, 9H, H-2, H-6ꞌa, H-6ꞌꞌꞌa, H-6ꞌꞌꞌꞌa, H-5, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ, T
β), 3.99-3.93 (m, 5H, H-6ꞌb, H-6ꞌꞌꞌb, H-
6ꞌꞌꞌꞌb, H-6ꞌꞌꞌꞌꞌb, T
α), 3.92-3.87 (m, 3H, H-3ꞌꞌ, H-6ꞌꞌab), 3.86-3.81 (m, 3H, H-3ꞌ, H-3ꞌꞌꞌꞌ, H-5ꞌ), 3.80-
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3.73 (m, 2H, H-3, H-6a), 3.70-3.69 (m, 1H, H-5ꞌꞌꞌꞌ), 3.66-3.64 (m, 1H, H-5ꞌꞌ), 3.43-3.35 (m, 2H, 
H-6b, H-2ꞌꞌꞌꞌ),  3.26 (q, 
3J(H-2ꞌꞌ, H-3ꞌꞌ) = 
3J(H-2ꞌꞌ,H-1ꞌꞌ) = 3J(H-2ꞌꞌ,NH) = 9.5 Hz, 1H, H-2ꞌꞌ), 2.09, 
2.06, 2.02, 2.01, 2.00, 1.99, 1.98, 1.97, 1.96, 1.88 (m, 51H, CH3-(Ac)), 1.35 (s, 9H, tBu), 1.15 
(d, 3J(Tγ,Tβ) = 6.3 Hz, 3H, T
γ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.52 ppm): δ = 170.07, 
170.06, 169.92, 169.89, 169.83, 169.59, 169.39, 169.35, 169.32, 169.29, 169.24, 169.14, 
169.07, 168.76, 168.70 (C=O-(Ac), C=O-(tBu)), 156.77 (C=O-(Fmoc)), 154.05 (C=O-(Troc)), 
153.82 (C=O-(Troc)), 143.71, 143.67 (C-1a-, C-8a-Fmoc), 140.82, 140.77 (C-4a-, C-5a-Fmoc), 
127.69, 127.67 (C-2-, C-7-Fmoc), 127.03, 127.02 (C-3-, C-6-Fmoc), 125.23, 125.11 (C-1-, C-
8-Fmoc), 120.19, 120.14 (C-4-, C-5-Fmoc), 101.21 (C-1ꞌꞌ), 100.52 (C-1ꞌ), 100.50 C-1ꞌꞌꞌꞌ), 
99.91 (C-1ꞌꞌꞌꞌꞌ), 99.81 (C-1ꞌꞌꞌ), 98.74 (C-1), 95.84 (CCl3-Troc), 95.55 (CCl3-Troc), 81.48 (Cq-
tBu), 77.70 (C-3ꞌ), 76.81 (C-3ꞌꞌ), 76.58 (C-3ꞌꞌꞌꞌ), 74.18 (Tβ), 73.93 (CH2-(Troc)), 73.64 (CH2-
(Troc)), 73.30 (C-3), 70.60 (C-5ꞌꞌ), 70.24 (C-3ꞌꞌꞌꞌꞌ), 70.15 (C-3ꞌꞌꞌ, C-4, C-5ꞌ, C-5ꞌꞌꞌꞌ), 69.74 (C-
5ꞌꞌꞌꞌꞌ), 69.61 (C-2ꞌ, C-5ꞌꞌꞌ), 69.21 (C-4ꞌ), 68.98 (C-6), 68.86 (C-5, C-4ꞌꞌꞌꞌ), 68.75, 68.51 (C-2ꞌꞌꞌ, C-
2ꞌꞌꞌꞌꞌ), 68.32 (C-4ꞌꞌ), 67.23, 67.14 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.57 (CH2-Fmoc), 62.00 (C-6ꞌꞌꞌꞌ), 61.57 (C-
6ꞌꞌab), 61.45 (C-6ꞌab), 60.93 (C-6ꞌꞌꞌab), 60.80 (C-6ꞌꞌꞌꞌꞌab), 59.57 (T
α), 56.96 (C-2ꞌꞌꞌꞌ), 56.62 (C-2ꞌꞌ), 
47.62 (C-2), 46.78 (C-9-Fmoc), 27.61 (tBu), 22.82, 20.64, 20.60, 20.56, 20.51, 20.47, 20.44, 
20.41, 20.34, 20.27, 20.23 (CH3-(Ac)), 19.03 (T
γ). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(4-O-acetyl-2-N-acetamido-2-deoxy-3-O-{2,4,6-
O-acetyl-3-O-[2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-{2-N-acetamido-4,6-
O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyl}-α-D-galactopyranosyl)-L-threonine-tert-butylester (57) 
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-Ac3Gal-(13)-{βAc4Gal-(13)-
βAc2GlcNAc-(16)}-αGalNAc)-OtBu) 
 
 
 
 
 
Zinc dust was activated by treatment with 1 N hydrochloric acid for a few minutes followed by 
washing with water, methanol and finally diethyl ether. Fmoc-Thr(βAc4Gal-(1→3)-
βAc2GlcNHTroc-(1→3)-βAc3Gal-(1→3)-[βAc4Gal-(1→3)-βAc2GlcNHTroc-(1→6)]-
αAcGalNAc)-OtBu 56 (2.68 g, 1.10 mmol) was dissolved in acetic acid (35 mL) and activated 
zinc dust (2.16 g, 16.5 mmol) was added. The reaction was stirred at 35°C for 36 h. The zinc 
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was filtered off and washed with acetic acid. The filtrate was co-evaporated with toluene in 
vacuo. The residue was dissolved in pyridine/acetic anhydride (30 mL, 2:1). Then 4-
(dimethylamino)pyridine was added (7 mg, 0.06 mmol) and stirred for 17 h. The solvent was 
removed by co-evaporation with toluene in vacuo and the crude product purified by flash 
column chromatography on silica (EtOAc→EtOAc/MeOH 40:1). 
Yield: 1.91 g (0.88 mmol, 80%), colorless, amorphous solid,     
   +26.53 (c = 0.49, CHCl3), 
Rf = 0.30 (EtOAc/MeOH 25:1).  
C97H128N4O51 (M = 2166.05 g/mol) [2164.75]. 
MALDI-TOF-MS (dhb, pos), m/z: 2187.62 ([M+Na]+, calc. 2187.74), 2203.58 ([M+K]+, calc. 
2203.72). 
HR-ESI-MS (pos), m/z: 1083.8874 ([M+2H]2+, calc. 1083.8868), 1102.8611 ([M+K+H]2+, calc. 
1102.8647). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 7.91-7.88 (m, 2H, 
H-4-, H-5-Fmoc), 7.79 (d, 3J(NHꞌꞌꞌꞌ,H-2ꞌꞌꞌꞌ) = 7.6 Hz, 1H, NHꞌꞌꞌꞌ-Ac), 7.77-7.73 (m, 2H, H-1-, H-
8-Fmoc), 7.69 (d, 3J(NHꞌꞌ,H-2ꞌꞌ) = 9.3 Hz, 1H, NHꞌꞌ-Ac), 7.56 (d, 3J(NH,H-2) = 10.0 Hz, 1H, 
NH-Ac), 7.44-7.39 (m, 3H, H-2-, H-7-Fmoc, NH-Fmoc), 7.33-7.30 (m, 2H, H-3-, H-6-Fmoc), 
5.25 (sbr, 1H, H-4ꞌ), 5.23 (m, 1H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌ), 5.21 (sbr, 1H, H-4), 5.09-5.06 (m, 2H, H-3ꞌꞌꞌ, 
H3ꞌꞌꞌꞌꞌ), 4.77-4.74 (m, 2H, H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.71-4.70 (m, 2H, H-1ꞌꞌꞌꞌꞌ, H-2ꞌ), 4.66-4.60 (m, 4H, H-1, 
H-1ꞌꞌꞌ, H-4ꞌꞌ, H-4ꞌꞌꞌꞌ), 4.57 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.0 Hz, 1H, H-1ꞌ), 4.52-4.51 (m, 1H, CH2a-(Fmoc)), 
4.48-4.43 (m, 2H, H-1ꞌꞌ, CH2b-(Fmoc)), 4.38-4.37 (m, 1H, H-1ꞌꞌꞌꞌ), 4.31 (t, 
3J(H-9,CH2) = 6.7 
Hz, 1H, H-9-Fmoc), 4.18-3.96 (m, 13H, H-2, Tα ,Tβ, H-5, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ, H-6ꞌab, H-6aꞌꞌ, H-6ꞌꞌꞌab, 
H-6ꞌꞌꞌꞌab), 3.90-3.89 (m, 2H, H-6bꞌꞌ), 3.85-3.83 (m, 1H, H-5ꞌ), 3.80-3.73 (m, 7H, H-2ꞌꞌꞌꞌ, H-3, H-
3ꞌ, H-3ꞌꞌ, H-3ꞌꞌꞌꞌ, H-5ꞌꞌꞌꞌ, H-6a), 3.69-3.67 (m, 1H, H-5ꞌꞌ), 3.52-3.50 (m, 1H, H-2ꞌꞌ), 3.34-3.32 (m, 
1H, H-6b), 2.09, 2.05, 2.02-1.98, 1.91, 1.90, 1.88, 1.85, 1.83, 1.81 (m, 57H, CH3-(Ac)), 1.34 
(s, 9H, tBu), 1.13 (d, 3J(Tγ,Tβ) = 6.1 Hz, 3H, T
γ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 170.10, 
170.04, 169.99, 169.92, 169.89, 169.63, 169.50, 169.39, 169.27, 169.16, 168.93, 168.86, 
168.81, 168.75 (C=O-(Ac), C=O-(tBu)), 156.80 (C=O-(Fmoc)), 143.73, 143.67 (C-1a-, C-8a-
Fmoc), 140.82, 140.78 (C-4a, C-5a-Fmoc), 127.73, 127.70 (C-2-, C-7-Fmoc), 127.06, 127.03 
(C-3-, C-6-Fmoc), 125.28, 125.12 (C-1-, C-8-Fmoc), 120.21, 120.15 (C-4-, C-5-Fmoc), 
100.97 (C-1ꞌꞌꞌꞌ), 100.70 (C-1ꞌꞌ), 100.53 (C-1ꞌ), 99.97 (C-1ꞌꞌꞌꞌꞌ), 99.92 (C-1ꞌꞌꞌ), 98.33 (C-1), 81.42 
(Cq-tBu), 77.85 (C-3ꞌꞌꞌꞌ), 77.19 (C-3ꞌ), 76.47 (C-3ꞌꞌ), 73.58 (T
β), 73.30 (C-3), 70.57 (C-5ꞌꞌꞌꞌ), 
70.52, 70.48 (C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ), 70.29, 70.16 (C-5ꞌꞌ, C-5ꞌ), 69.92 (C-4), 69.61 (C-2ꞌ), 69.49 (C-5ꞌꞌꞌ, 
C-5ꞌꞌꞌꞌꞌ), 69.16 (C-6), 68.98 (C-4ꞌ), 68.68 (C-5), 68.63, 68.56 (C-2ꞌꞌꞌꞌꞌ, C-4ꞌꞌꞌꞌ), 68.47, 68.46 (C-
2ꞌꞌꞌ, C-4ꞌꞌ), 67.17 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.60 (CH2-(Fmoc)), 62.03 (C-6ꞌꞌꞌꞌab), 61.66 (C-6ꞌꞌab), 61.46 (C-
6ꞌab), 61.12 (C-6ꞌꞌꞌab), 61.05 (C-6ꞌꞌꞌꞌꞌab), 59.51 (T
α), 54.22 (C-2ꞌꞌ), 53.62 (C-2ꞌꞌꞌꞌ), 47.72 (C-2), 
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46.78 (C-9-Fmoc), 27.57 (tBu), 22.91, 22.82, 22.81, 20.76, 20.67, 20.58, 20.52, 20.47, 20.43, 
20.39, 20.35, 20.31 (CH3-(Ac)), 19.17 (T
γ). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(4-O-acetyl-2-N-acetamido-2-deoxy-3-O-{2,4,6-
O-acetyl-3-O-[2-N-acetamido-4,6-O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-{2-N-acetamido-4,6-
O-acetyl-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-
glucopyranosyl}-α-D-galactopyranosyl)-L-threonine (58)  
(Fmoc-Thr(βAc4Gal-(13)-βAc2GlcNAc-(13)-Ac3Gal-(13)-{βAc4Gal-(13)-
βAc2GlcNAc-(16)}-αGalNAc-OH) 
 
 
 
 
 
Trifluoroacetic acid (15 mL) was added to a solution of Fmoc-Thr(βAc4Gal-(1→3)-
βAc2GlcNAc-(1→3)-βAc3Gal-(1→3)-[βAc4Gal-(1→3)-βAc2GlcNAc-(1→6)]-αAcGalNAc)-OtBu 
57 (1.82 g, 0.84 mmol) and anisole (2 mL) in dichloromethane (5 mL) and the reaction 
mixture was stirred for 3 h. The solvent was removed by co-evaporation with toluene. The 
crude product was purified by flash column chromatography on silica 
(EtOAc→EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
Yield: 1.63 g (0.77 mmol, 92%), colorless, amorphous solid,     
   +34.36 (c = 1.00, CHCl3), 
Rf = 0.12 (EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
C93H120N4O51 (M = 2109.94 g/mol) [2108.69].  
MALDI-TOF-MS (dhb, pos), m/z: 2132.06 ([M+Na]+, calc. 2132.93), 2148.01 ([M+K]+, calc. 
2148.66). 
HR-ESI-MS (pos), m/z: 1055.8560 ([M+2H]2+, calc. 1055.8555), 1074.8302 ([M+K+H]2+, calc. 
1074.8334). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm): δ= 12.20 (s, 1H, 
COOH), 7.91 (m, 2H, H-4-, H-5-Fmoc), 7.81-7.79 (m, 1H, NHꞌꞌꞌꞌ-Ac), 7.77-7.73 (m, 3H, H-1-, 
H-8-Fmoc, NHꞌꞌ-Ac), 7.45-7.41 (m, 3H, H-2-, H-7-Fmoc, NH-Ac), 7.34-7.30 (m, 3H, H-3-, H-6-
Fmoc, NH-Fmoc), 5.25 (d, 3J(H4ꞌ,H3ꞌ) = 3.5 Hz, 1H, H-4ꞌ), 5.23-5.22 (m, 2H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 
5.21 (s, 1H, H-4), 5.09-5.06 (m, 2H, H-3ꞌꞌꞌ, H-3ꞌꞌꞌꞌꞌ), 4.77-4.73 (m, 2H, H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.72-4.69 
(m, 2H, H-1ꞌꞌꞌꞌꞌ, H-2ꞌ), 4.67-4.60 (m, 4H, H-1, H-1ꞌꞌꞌ, H-4ꞌꞌ, H-4ꞌꞌꞌꞌ), 4.56 (d, 3J(H1ꞌ,H2ꞌ) = 8.1 Hz, 
1H, H-1ꞌ), 4.52 (dd, 2J(CH2a,CH2b) = 10.8 Hz, 
3J(CH2a,H-9) = 6.7 Hz, 1H, CH2a-(Fmoc)), 4.47 
(m, 1H, H-1ꞌꞌ), 4.43 (dd, 2J(CH2b,CH2a) = 11 Hz, 
3J(CH2b,H-9) = 6.9 Hz, 1H, CH2b-Fmoc), 4.38-
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4.37 (m, 1H, H-1ꞌꞌꞌꞌ), 4.31 (t, 3J(H-9,CH2) = 6.8 Hz, 1H, H-9-Fmoc), 4.24-4.22 (m, 1H, T
β), 
4.15-4.04 (m, 8H, H-2, Tα, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ, H-6ꞌa, H-6ꞌꞌa, H-6ꞌꞌꞌa, H-6ꞌꞌꞌꞌꞌa), 4.03-3.95 (m, 5H, H-5, 
H-6ꞌb, H-6ꞌꞌb, H-6ꞌꞌꞌb, H-6ꞌꞌꞌꞌꞌb), 3.91-3.84 (m, 3H, H-5ꞌ, H-6ꞌꞌꞌꞌab) 3.82-3.71 (m, 7H, H-2ꞌꞌꞌꞌ, H-6a, H-
5ꞌꞌꞌꞌ, H-3, H-3ꞌ, H-3ꞌꞌ, H-3ꞌꞌꞌꞌ), 3.70-3.66 (m, 1H, H-5ꞌꞌ), 3.51 (sbr, 1H, H-2ꞌꞌ), 3.32-3.30 (m, 1H, H-
6b), 2.09, 2.04, 2.01, 2.00, 1.99, 1.98, 1.97, 1.91, 1.88, 1.85, 1.81 (m, 57H, CH3-(Ac)), 1.12 
(d, 3J(Tγ,Tβ) = 6.2 Hz, 3H, T
γ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)=39.51 ppm): δ= 170.09, 
170.05, 169.99, 169.92, 169.87, 169.59, 169.50, 169.38, 169.26, 169.16, 169.08, 169.08, 
168.93, 168.92, 168,71 (C=O-(Ac)), 156.76 (C=O-(Fmoc)), 143.76, 143.70 (C-1a-, C-8a-
Fmoc), 140.81, 140.75 (C-4a, C-5a-Fmoc), 127.70, 127.67 (C-2-, C-7-Fmoc), 127.06 (C-3-, C-
6-Fmoc), 125.29, 125.14 (C-1-, C-8-Fmoc), 120.19, 120.13 (C-4-, C-5-Fmoc), 100.90 (C-1ꞌꞌꞌꞌ), 
100.68 (C-1ꞌꞌ), 100.57 (C-1ꞌ), 99.94, 99.91 (C-1ꞌꞌꞌ, C-1ꞌꞌꞌꞌꞌ), 98.33 (C-1), 77.81 (C-3ꞌꞌꞌꞌ), 77.20 
(C-3ꞌꞌ), 76.49 (C-3ꞌ), 73.92 (Tβ), 73.46 (C-3), 70.60, 70.56 (C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ) 70.51 (C-5ꞌꞌꞌꞌ), 70.30, 
70.18 (C-4, C-5ꞌ), 69.62 (C-2ꞌ), 69.47 (C-5ꞌꞌꞌ, C-5ꞌꞌꞌꞌꞌ), 68.96 (C-4ꞌ, C-6), 68.70 (C-5), 68.62, 
68.55, (C-2ꞌꞌꞌ, C-2ꞌꞌꞌꞌꞌ, C-4ꞌꞌꞌꞌ), 68.46 (C-4ꞌꞌ) 67.15 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.58 (CH2-(Fmoc)), 62.03 (C-
6ꞌꞌꞌꞌ), 61.71 (C-6ꞌꞌ), 61.48 (C-6ꞌ), 61.10 (C-6ꞌꞌꞌ), 61.03 (C-6ꞌꞌꞌꞌꞌ), 58.52 (Tα), 54.20 (C-2ꞌꞌ), 53.66 
(C-2ꞌꞌꞌꞌ), 47.85 (C-2), 46.77 (C-9-Fmoc), 22.86, 22.82, 22.76, 20.76, 20.57, 20.51, 20.47, 
20.45, 20.43, 20.38, 20.34, 20.30 (CH3-(Ac)), 18.77 (T
γ).  
 
 
7.1.12 Synthesis of the extended type-2core 2 amino acid 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-3-O-{2,4,6-tri-O-acetyl-3-
O-[3,6-O-acetyl-2-N-(2,2,2-trichloroethoxycarbonylamino)-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-2-deoxy-β-D-glucopyranosyl]-β-D-
galactosylpyranosyl}-6-O-[3-O-acetyl-2-deoxy-6-O-tert-butyldimethylsilyl-2-N-
(2,2,2-trichloroethoxycarbonylamino)-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-
β-D-glucopyranosyl]-α-D-galactosylpyranosyl)-L-threonine-tert-butylester (59)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2-TBS-GlcNHTroc-(13)-βAc3Gal-(13)-[βAc4Gal-(14)-
βAc2-TBS-GlcNHTroc-(16)]-αGalNAc)-OtBu)  
 
 
 
 
 
Fmoc-Thr(βAc4Gal-(1→4)-βAc2-TBS-GlcNHTroc-(1→3)-βAc3Gal-(1→3)-βGalNAc)-OtBu 52 
(694 mg, 0.42 mmol) and βAc4Gal-(1→4)-βAc-TBS-GlcNTroc-SPh 31 (515 mg, 0.55 mmol) 
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were dissolved in dry dichloromethane (15 mL) and 0.6 g of activated molecular sieves 4Å 
were added under argon atmosphere. The suspension was stirred for 1 h before and then 
cooled in an ice bath. N-iodosuccinimide (124 mg, 0.55 mmol) was added followed by the 
dropwise addition of a suspension of trifluoromethanesulfonic acid (7.5 μmol, 0.09 mmol) in 
dry dichloromethane (100 μL) via a syringe. After 3 h the reaction was treated with another 
addition of βAc4Gal-(1→4)-βAc-TBS-GlcNTroc-SPh 31 (119 mg, 0.13 mmol) and N-
iodosuccinimide (28 mg, 0.13 mmol). The reaction was stirred further for 3.5 h under argon 
atmosphere and ice-cooling. The molecular sieves were filtered off and washed with 
dichloromethane. More dichloromethane was added (total volume of 120 mL). The 
dichloromethane phase was washed with of 0.5 M sodium thiosulfate solution, saturated 
sodium bicarbonate, water and brine (30 mL each). The organic phase was dried over 
sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica (CHex/EtOAc 1:1→1:3).  
Yield: 722 mg (0.29 mmol, 69%), colorless, amorphous solid,     
   +20.27 (c = 0.49, CHCl3), 
Rf = 0.39 (Tol/EtOAc 1:3). 
C101H136Cl6N4O51Si (M = 2462.96 g/mol) [2458.61]. 
MALDI-TOF-MS (dhb, pos), m/z: 2500.72 ([M+K]+, calc. 2500.57). 
HR-ESI-MS (pos), m/z: 1250.7862 ([M+K+H]2+, calc. 1250.7896). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm: δ=  7.92-7.88 (m, 2H, 
H-4-, H-5-Fmoc), 7.81-7.73 (m, 4H, H-1-, H-8-Fmoc, 2 N-H-Troc), 7.46-7.38 (m, 4H, H-2-, H-
7-Fmoc, N-H-Ac, N-H-Fmoc), 7.34-7.30 (m, 2H, H-3-, H-6-Fmoc), 5.32 (sbr, 1H, H-4ꞌ), 5.25 
(d, JH-4’’’’’,H-3’’’’’ = 3.6 Hz, 1H, H-4ꞌꞌꞌꞌꞌ), 5.22 (d, JH-4’’’,H-3’’’ = 3.6 Hz, 1H, H4ꞌꞌꞌ), 5.16 (dd, JH-3’’’,H-4’’’ = 
3.6 Hz, JH-3’’’,H-2’’’ = 10.2 Hz, 1H, H3ꞌꞌꞌ), 5.08 (dd, JH-3’’’’’,H-4’’’’’ = 3.6 Hz, JH3’’’’’,H2’’’’’’ = 10.3 Hz, 1H, 
H-3ꞌꞌꞌꞌꞌ), 4.98-4.88 (m, 4H, H-3ꞌꞌ, H-3ꞌꞌꞌꞌ, CH2aꞌꞌ-(Troc), CH2aꞌꞌꞌꞌ-(Troc)), 4.86-4.80 (m, 3H, H-2ꞌ, 
H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.72-4.69 (m, 2H, H-1ꞌꞌꞌ, H-1ꞌꞌꞌꞌꞌ), 4.63-4.59 (m, 2H, H-1ꞌꞌ, CH2bꞌꞌꞌꞌ-(Troc)), 4.57-
4.54 (m, 2H, H-1, H-1ꞌ), 4.52-4.44 (m, 4H, H-1ꞌꞌꞌꞌ, CH2bꞌꞌ-(Troc), CH2ab-(Fmoc)), 4.32 (t, JH-
9,CH2ab = 6.6 Hz, 1H, H-9-(Fmoc)), 4.27-4.25 (m, 1H, H-6aꞌꞌ), 4.23-4.19 (m, 2H, H-2, H-5ꞌꞌꞌ), 
4.08 (m, 10H, H-5ꞌꞌꞌꞌꞌ, H-6abꞌ, H-6bꞌꞌ,  H-6abꞌꞌꞌ, H-6abꞌꞌꞌꞌꞌ, T
α, Tβ), 3.88-3.85 (m, 1H, H-5ꞌꞌ), 3.84-
3.73 (m, 8H, H-3ꞌ, H-4, H-4ꞌꞌꞌꞌ, H-5, H-5ꞌ, H-6a, H-6abꞌꞌꞌꞌ), 3.68 (t, JH-4’’,H-3’’ = JH-4’’,H-2’’ = 9.3 Hz, 
1H, H-4ꞌꞌ), 3.56-3.48 (m, 3H, H-3, H-5ꞌꞌ, H-6b), 3.42-3.37 (m, 1H, H-2ꞌꞌꞌꞌ), 3.33-3.28 (m, 2H, H-
2ꞌꞌ, H-5ꞌꞌꞌꞌ), 2.10-1.84 (m, 45H, CH3-(Ac)), 1.35 (s, 9H, tBu-(Thr)), 1.09 (d, JTγ,Tβ = 6.1 Hz, 3H, 
Tγ), 0.88 (s, 9H, tBu-(TBS)), 0.07, 0.06 (each s, 3H, 2 Me-(TBS)).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52  ppm): δ= 170.30, 
169.86, 169.68, 169.40, 169.51, 169.45, 169.27, 169.07, 169.00, 168.80, 168.66 (C=O-(Ac), 
C=O-(tBu)), 156.76 (C=O-(Fmoc)), 154.13, 154.01 (2 C=O-(Troc)), 143.71, 143.66 (C-1a-, C-
8a-Fmoc), 140.83, 140.79 (C-4a-, C-5a-Fmoc), 127.66 (C-2-, C-7-Fmoc), 127.03 (C-3-, C-6-
Fmoc), 125.24, 125.14 (C-1-, C-8-Fmoc), 120.23, 120.17 (C-4-, C5-Fmoc), 101.48 (C-1ꞌ), 
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100.53 (C-1ꞌꞌ), 100.00 (C-1ꞌꞌꞌ, C-1ꞌꞌꞌꞌ), 99.63 (C-1ꞌꞌꞌꞌꞌ), 99.10 (C-1), 96.16, 96.07 (Cquart-(Troc)), 
81.40 (Cquart-(tBu)), 78.22 (C-3ꞌ), 76.78 (C-3), 75.89 (C-4ꞌꞌ), 74.75 (C-4ꞌꞌꞌꞌ), 74.52 (C-5ꞌꞌꞌꞌ), 
74.21 (Tβ), 73.40 (CH2abꞌꞌ-(Troc)), 73.31 (CH2abꞌꞌꞌꞌ-(Troc)), 72.80 (C-3ꞌꞌ, C-3ꞌꞌꞌꞌ), 71.53 (C-5ꞌꞌ), 
70.65 (C-5ꞌ), 70.26 (C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ, C-5), 70.04 (C-6ab), 69.94 (C-5ꞌꞌꞌꞌꞌ), 69.60 (C-5ꞌꞌꞌ), 69.20 (C-
4ꞌ), 68.99, 68.92 (C-2ꞌ, C-2ꞌꞌꞌ, C-2ꞌꞌꞌꞌꞌ), 68.58 (C-4), 67.10 (C-4ꞌꞌꞌꞌꞌ), 67.03 (C-4ꞌꞌꞌ), 65.57 (CH2ab-
(Fmoc)), 61.92 (C-6abꞌ), 61.76 (C-6abꞌꞌ), 61.06 (C-6abꞌꞌꞌꞌ, C-6abꞌꞌꞌꞌꞌ), 60.82 (C-6abꞌꞌꞌ), 59.57 (T
α), 
55.78 (C-2ꞌꞌ), 55.60 (C-2ꞌꞌꞌꞌ), 46.94 (C-2), 46.80 (C-9-(Fmoc)), 27.64 (tBu-(Thr)), 25.76 (tBu-
(TBS)), 22.99, 20.69-20.33 (CH3-(Ac)), 18.86 (T
γ), 17.96 (Cquart-(TBS), -5.23, -5.31 (2 
Me(TBS)). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-4-O-acetyl-2-deoxy-3-O-{2,4,6-tri-
O-acetyl-3-O-[3,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonylamino)-4-O-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-
galactopyranosyl}-6-O-[3,6-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycarbonyl)-4-O-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-
galactopyranosyl)-L-threonine-tert-butylester (60)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNHTroc-(13)-βAc3Gal-(13)-[βAc4Gal-(14)-βAc2-
GlcNHTroc-(16)]-αAcGalNAc)-OtBu)  
 
 
 
 
 
A solution of Fmoc-Thr(βAc4Gal-(1→4)-βAc2-TBS-GlcNHTroc-(1→3)-βAc3Gal-(1→3)-
[βAc4Gal-(1→4)-βAc2-TBS-GlcNHTroc-(1→6)]-αGalNAc)-OtBu 59 (1.66 g, 0.67 mmol) in of 
80% acetic acid (18 mL) was stirred for 20 h at 40°C. The solvent was removed by co-
evaporation with toluene in vacuo. The residue was dissolved in pyridine (20 mL) and cooled 
in an ice bath. Then 4-(dimethylamino)pyridine (8 mg, 0.07 mmol) and acetic anhydride (10 
mL) were added and the solution was stirred 18 h. The crude product was purified by flash 
column chromatography on silica (CHex/acetone 3:2→4:3). 
Yield: 1.48 g (0.61 mmol, 91%), colorless, amorphous solid,     
   +24.30 (c = 1.00, CHCl3), 
Rf = 0.48 (Tol/EtOAc 1:2). 
C99H126Cl6N4O53 (M = 2432.77 g/mol) [2428.54]. 
MALDI-TOF-MS (dhb, pos), m/z: 2455.04 ([M+Na]+, calc. 2455.76), 2471.01 ([M+K]+, calc. 
2471.87). 
HR-ESI-MS (pos), m/z: 1216.7809 ([M+2H]2+, calc. 1216.7790). 
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1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm: δ=  7.91-7.89 (m, 2H, 
H-4-, H-5-Fmoc), 7.76-7.72 (m, 4H, H-1-, H-8-Fmoc, 2 N-H-Troc), 7.45-7.41 (m, 4H, H-2-, H-
7-Fmoc, N-H-Ac, N-H-Fmoc), 7.33-7.31 (m, 2H, C-3-, C-6-Fmoc), 5.29 (Sbr, 1H, H-4ꞌ), 5.23-
5.21 (m, 3H, H-4, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 5.17-5.14 (m, 2H, H-3ꞌꞌꞌ, H-3ꞌꞌꞌꞌꞌ), 4.97-4.89 (m, 3H, H-3ꞌꞌ, H-
3ꞌꞌꞌꞌ, CH2aꞌꞌ-(Troc)), 4.91-4.89 (m, 1H, CH2aꞌꞌꞌꞌ-(Troc)), 4.83-4.80 (m, 2H, H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.73-
4.70 (m, 3H, H-1ꞌꞌꞌ, H-1ꞌꞌꞌꞌꞌ, H-2ꞌ), 4.63-4.55 (m, 4H, H-1, H-1ꞌ, H-1ꞌꞌ, CH2bꞌꞌꞌꞌ-(Troc)), 4.51-4.47 
(m, 4H, H-1ꞌꞌꞌꞌ, CH2bꞌꞌ-(Troc), CH2ab-(Fmoc)), 4.32-4.27 (m, 3H, H-9-(Fmoc), H-6aꞌꞌ, H-6aꞌꞌꞌꞌ), 
4.22-4.19 (m, 2H, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ), 4.14-4.09 (m, 3H, H-2, H-6bꞌꞌ, T
β), 4.05-3.99 (m, 6H, H-5ꞌꞌꞌꞌꞌ, 
H-6abꞌꞌꞌ, H-6abꞌꞌꞌꞌꞌ, T
α), 3.94-3.88 (m, 3H, H-6abꞌ, H-6bꞌꞌꞌꞌ), 3.81-3.76 (m, 3H, H-3, H-3ꞌ, H-6a), 
3.71-3.65 (m, 2H, H-4ꞌꞌ, H-4ꞌꞌꞌꞌ), 3.61-3.58 (m, 1H, H-5ꞌꞌ), 3.53-3.50 (m, 1H, H-5ꞌꞌꞌꞌ), 3.44 (q, JH-
2’’’’,H-3’’’’ = JH-2’’’’,H-4’’’’ = JH-2’’’,N-H  = 11.5 Hz, 1H, H-2ꞌꞌꞌꞌ), 3.35-3.27 (m, 2H, H-2ꞌꞌ, H-6b), 2.09-1.82 
(m, 51H, CH3(Ac)), 1.35 (s, 9H, tBu), 1.13 (d, JTγ,Tβ = 7.7 Hz, 3H, T
γ). 
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52  ppm): δ= 170.28, 
169.97, 169.90, 169.87, 169.60, 169.51, 169.30, 169.23, 169.19, 169.09, 168.80, 168.75 
(C=O-(Ac), C=O-(tBu)), 156.80 (C=O-(Fmoc)), 154.15, 153.99 (2 C=O-(Troc)), 143.75, 
143.65 (C-1a-, C-8a-Fmoc), 140.82, 140.78 (C-4a-, C-5a), 127.72, 127.67 (C-2-, C-7-Fmoc), 
127.03 (C-3-, C-6-Fmoc), 125.24, 125.13 (C-1-, C-8-Fmoc), 120.22, 120.17 (C-4-, C-5-
Fmoc), 100.63 (C-1ꞌꞌ), 100.55 (C-1ꞌ), 100.05 (C-1ꞌꞌꞌꞌ), 99.99, 99.89 (C-1ꞌꞌꞌ, C-1ꞌꞌꞌꞌꞌ), 99.76 (C-1), 
96.09, 96.02 (2 Cquart-(Troc)), 81.49 (Cquart-(tBu)), 77.62 (C-3ꞌ), 76.37 (C-4ꞌꞌꞌꞌ), 75.93 (C-4ꞌꞌ), 
74.28 (Tβ), 73.37, 73.34 (C-3, CH2abꞌꞌ-(Troc)), 73.34 (CH2abꞌꞌꞌꞌ-(Troc)), 72.72 (C-3ꞌꞌ, C-3ꞌꞌꞌꞌ), 
71.75 (C-5ꞌꞌ), 71.46 (C-5ꞌꞌꞌꞌ), 70.22 (C-4, C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ, C-5ꞌ), 69.66, 69.60 (C-5ꞌꞌꞌ, C-5ꞌꞌꞌꞌꞌ), 69.28 
(C-2ꞌ), 69.20 (C-4ꞌ, C-6ab), 68.91 (C-2ꞌꞌꞌ, C-2ꞌꞌꞌꞌꞌ), 68.87 (C-5), 67.04 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.62 
(CH2ab-(Fmoc)), 62.19 (C-6abꞌꞌ), 61.81, 61.69 (C-6abꞌ, C-6abꞌꞌꞌꞌ), 60.87, 60.81 (C-6abꞌꞌꞌ, C-6abꞌꞌꞌꞌꞌ), 
59.53 (Tα), 55.79 (C-2ꞌꞌ), 55.64 (C-2ꞌꞌꞌꞌ), 47.57 (C-2), 46.77 (C-9-Fmoc), 27.63 (tBu), 22.84, 
20.64-20.32 (CH3-(Ac)), 18.85 (T
γ). 
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N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-4-O-acetyl-2-deoxy-3-O-{2,4,6-tri-
O-acetyl-3-O-[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-
[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-
D-glucopyranosyl]-α-D-galactopyranosyl)-L-threonine-tert-butylester (61)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-βAc3Gal-(13)-[βAc4Gal-(14)-βAc2-
GlcNAc-(16)]-αAcGalNAc)-OtBu)  
 
 
 
 
 
Zinc dust was activated by treatment with 1 N hydrochloric acid for a few minutes followed by 
washing with water, methanol and finally diethyl ether. Fmoc-Thr(βAc4Gal-(1→4)-
βAc2GlcNHTroc-(1→3)-βAc3Gal-(1→3)-[βAc4Gal-(1→4)-βAc2-GlcNHTroc-(1→6)]-
αAcGalNAc)-OtBu) 60 (2.20 g, 0.90 mmol) was dissolved in acetic acid (30 mL) and 
preactivated zinc (1.18 g, 18.0 mmol) was added. The reaction was stirred at 40°C for 36 h. 
The solid was filtered off and washed with acetic acid. The filtrate was co-evaporated with 
toluene in vacuo. The residue was dissolved in pyridine/acetic anhydride (30 mL, 2:1). Then 
11 mg (0.09 mmol) 4-(dimethylamino)pyridine was added and stirred for 18 h. The solvent 
was removed by co-evaporation with toluene in vacuo and the crude product purified by flash 
column chromatography on silica (EtOAc→EtOAc/MeOH 20:1). 
Yield: 1.46 g (0.68 mmol, 75%), colorless, amorphous solid,     
   +21.05 (c = 0.51, CHCl3), 
Rf = 0.21 (EtOAc/MeOH 15:1).  
C97H128N4O51 (M = 2166.05 g/mol) [2164.75]. 
MALDI-TOF-MS (dhb, pos), m/z: 2204.37 ([M+K]+, calc. 2204.15). 
HR-ESI-MS (pos), m/z: 1083.8872 ([M+2H]2+, calc. 1083.8868). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm: δ=  7.91-7.89 (m, 2H, 
H-4-, H-5-Fmoc), 7.81-7.78 (m, 2H, N-Hꞌꞌ-Ac, N-Hꞌꞌꞌꞌ-Ac), 7.76-7.72 (m, 2H, H-1-, H-8-Fmoc), 
7.52 (d, JN-H,H-2 = 9.7 Hz, 1H, N-H-Ac), 7.45-7.41 (m, 2H, H-2-, H-7-Fmoc), 7.40-7.38 (m, 1H, 
N-H-Fmoc), 7.34-7.29 (m, 2H, H-3-, H-6-Fmoc), 5.27 (d, 3J(H4ꞌ,H3ꞌ) = 3.7 Hz, 1H, H-4ꞌ), 5.23-
5.21 (m, 2H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 5.19 (d, 3J(H-4,H-3) = 1.9 Hz, 1H, H-4), 5.18-5.15 (m, 2H, H-3ꞌꞌꞌ, 
H-3ꞌꞌꞌꞌꞌ), 5.00 (t, 3J(H-3ꞌꞌ,H-4ꞌꞌ) = 3J(H-3ꞌꞌ,H-2ꞌꞌ) = 9.3 Hz, 1H, H-3ꞌꞌ), 4.91 (t, 
3J(H-3ꞌꞌꞌꞌ,H-4ꞌꞌꞌꞌ) = 
3J(H-3ꞌꞌꞌꞌ,H-2ꞌꞌꞌꞌꞌ) = 9.3 Hz, 1H, H-3ꞌꞌꞌꞌ), 4.85-4.81 (m, 2H, H-2ꞌꞌꞌ, H-2ꞌꞌꞌꞌꞌ), 4.73-4.67 (m, 4H, H-1ꞌꞌ, 
H-1ꞌꞌꞌ, H-1ꞌꞌꞌꞌꞌ, H-2ꞌ), 4.60 (d, 3J(H-1,H-2) = 4.1 Hz 1H, H-1), 4.56 (d, 3J(H-1ꞌ,H-2ꞌ) = 8.0 Hz, 1H, 
H-1ꞌ), 4.52-4.45 (m, 3H, H-1ꞌꞌꞌꞌ, CH2ab-(Fmoc)), 4.33-4.26 (m, 3H, H-6aꞌꞌ, H-6aꞌꞌꞌꞌ, H-9-Fmoc), 
4.22-4.19 (m, 2H, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ), 4.15-4.11 (m, 2H, H-2, Tβ), 4.08-4.05 (m, 1H, H-6bꞌꞌ), 4.02-
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3.98 (m, 6H, H-5ꞌꞌꞌꞌꞌ, H-6abꞌꞌꞌ, H-6abꞌꞌꞌꞌꞌ, T
α), 3.94-3.89 (m, 3H, H-6abꞌ, H-6bꞌꞌꞌꞌ), 3.84 (t, 
3J(H-5ꞌ,H-
6ꞌ) = 5.9 Hz, 1H, H-5ꞌ), 3.80-3.74 (m, 3H, H-3ꞌ, H-3ꞌꞌꞌꞌꞌ, H-6a), 3.70-3.63 (m, 4H, H-2ꞌꞌꞌꞌ, H-4ꞌꞌ, H-
4ꞌꞌꞌꞌ, H-5ꞌꞌ), 3.56-3.54 (m, 1H, H-5ꞌꞌꞌꞌ), 3.39 (q, 3J(H-2ꞌꞌ,H-1ꞌꞌ) = 3J(H-2ꞌꞌ,H-3ꞌꞌ) = 3J(H-2ꞌꞌ,N-H) = 
9.3 Hz, 1H, H-2ꞌꞌ), 3.31-3.27 (m, 1H, H-6b), 2.09-1.69 (m, 57H, CH3-(Ac)), 1.34 (s, 1H, tBu), 
1.11 (d, JTγ,Tβ = 6.3 Hz, 3H, T
γ).  
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52  ppm): δ= 170.28, 
170.24, 170.00, 169.90, 169.87, 169.59, 169.51, 169.42, 169.42, 169.37, 169.34, 169.12, 
169.10, 169.01, 168.01, 168.87, 168.83 (C=O-(Ac), C=O-(tBu)), 156.80 (C=O-(Fmoc)), 
143.73, 143.66 (C-1a-, C-5a-Fmoc), 140.82, 140.78 (C-4a-, C-5a-Fmoc), 127.73, 127.69 (C-2-, 
C-7-Fmoc), 127.03 (C-3-, C-6-Fmoc), 125.25, 125.12 (C-1-, C-8-Fmoc), 120.22, 120.17 (C-4-
, C-5-Fmoc), 100.51 (C-1ꞌ), 100.42 (C-1ꞌꞌꞌꞌ), 100.02, 99.99, 99.91 (C-1ꞌꞌ, C-1ꞌꞌꞌ, C-1ꞌꞌꞌꞌꞌ), 98.44 
(C-1), 81.43 (Cquart-(tBu)), 76.81 (C-3ꞌ), 76.49 (C-4ꞌꞌꞌꞌ), 76.13 (C-4ꞌꞌ), 73.77 (T
β), 73.37 (C-3, C-
3ꞌꞌꞌꞌ), 72.72 (C-3ꞌꞌ), 71.68 (C-5ꞌꞌ), 71.43 (C-5ꞌꞌꞌꞌ), 70.22, 70.16, 70.05 (C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ, C-4, C-5ꞌ), 
69.62, 69.56 (C-5ꞌꞌꞌ, C-5ꞌꞌꞌꞌꞌ), 69.45 (C-2ꞌ), 69.13 (C-6ab), 68.99 (C-4ꞌ), 68.93, 68.91 (C-2ꞌꞌꞌ, C-
2ꞌꞌꞌꞌꞌ), 68.59 (C-5), 67.03, 67.02 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.60 (CH2ab-(Fmoc)), 62.23 (C-6abꞌꞌ), 61.56 (C-
6abꞌ, C-6abꞌꞌꞌꞌ), 60.82, 60.76 (C-6abꞌꞌꞌ, C-6abꞌꞌꞌꞌꞌ), 59.48 (T
α), 53.96 (C-2ꞌꞌ), 53.08 (C-2ꞌꞌꞌꞌ), 47.67 
(C-2), 46.77 (C-9-(Fmoc)), 27.57 (tBu), 22.81, 22.68, 22.62, 20.64-20.33 (CH3-(Ac)), 19.00 
(Tγ). 
 
 
N-(9H-fluoren-9-yl)-methoxycarbonyl-O-(2-acetamido-2-deoxy-4-O-acetyl-3-O-{2,4,6-tri-
O-acetyl-3-O-[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-β-D-galactopyranosyl}-6-O-
[2-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-
D-glucopyranosyl]-α-D-galactopyranosyl)-L-threonine (62)  
(Fmoc-Thr(βAc4Gal-(14)-βAc2GlcNAc-(13)-βAc3Gal-(13)-[βAc4Gal-(14)-βAc2-
GlcNAc-(16)]-αAcGalNAc)-OH)  
 
 
 
 
 
To a solution of Fmoc-Thr(βAc4Gal-(1→4)-βAc2GlcNAc-(1→3)-βAc3Gal-(1→3)-[βAc4Gal-
(1→4)-βAc2-GlcNAc-(1→6)]-αAcGalNAc)-OtBu 61 (1.82 g, 0.84 mmol) in dichloromethane (5 
mL) and anisole (2 mL) was added trifluoroacetic acid (15 mL) and the solution was stirred 
for 3 h. The solvent was removed by co-evaporation with toluene. The crude product was 
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purified by flash column chromatography on silica (EtOAc→EtOAc/MeOH/AcOH/H2O 
50:3:3:2). 
Yield: 1.629 mg (0.77 mmol, 92%), colorless, amorphous solid,     
   +27.60 (c = 1.00, 
CHCl3), Rf  = 0.23 (EtOAc/MeOH/AcOH/H2O 50:3:3:2). 
HR-ESI-MS (pos), m/z: 1055.8560 ([M+2H]2+, calc. 1055.8555), 1074.8311 ([M+K+H]2+, calc. 
1074.8334). 
1H NMR (600 MHz, [D6]DMSO, 30°C, internal DMSO δ(H)= 2.50 ppm: δ=  7.91-7.90 (m, 2H, 
H-4-, H-5-Fmoc), 7.83-7.79 (m, 2H, NHꞌꞌꞌ-Ac, NHꞌꞌꞌꞌꞌ-Ac), 7.77-7.73 (m, 2H, H-1-, H-8-Fmoc), 
7.45-7.41 (m, 3H, NH-Ac, H-2-, H-7-Fmoc), 7.34-7.31 (m, 3H, NH-Fmoc, H-3-, H-6-Fmoc), 
5.28 (d, 3J(H-4ꞌ,H-3ꞌ) = 3.5 Hz, 1H, H-4ꞌ), 5.23-5.22 (m, 1H, H-4ꞌꞌꞌ, H-4ꞌꞌꞌꞌꞌ), 5.20 (d, 1H, H-4), 
5.18-5.15 (m, 2H, H-3ꞌꞌꞌ, H-3ꞌꞌꞌꞌꞌ), 5.00 (t, 3J(H-3ꞌꞌ,H-2ꞌꞌ) = 3J(H-3ꞌꞌ,H-4ꞌꞌ), 1H, H-3ꞌꞌ) = 9.5 Hz), 
4.91 (t, 3J(H-3ꞌꞌꞌꞌ,H-2ꞌꞌꞌꞌ) = 3J(H-3ꞌꞌꞌꞌ,H-4ꞌꞌꞌꞌ) = 9.5 Hz, 1H, H-3ꞌꞌꞌꞌ), 4.85-4.82 (m, 2H, H-2ꞌꞌꞌ, H-
2ꞌꞌꞌꞌꞌ), 4.73-4.68 (m, 4H, H-1ꞌꞌ, H-1ꞌꞌꞌ, H-1ꞌꞌꞌꞌꞌ, H-2ꞌ), 4.64 (d, 3J(H-1,H-2) = 4.1 Hz, 1H, H-1), 4.56 
(d, 3J(H-1ꞌ,H-2ꞌ) = 7.9 Hz 1H, H-1ꞌ), 4.52-4.43 (m, 3H, H-1ꞌꞌꞌꞌ, CH2ab-(Fmoc)), 4.32-4.30 (m, 
2H, H-9-Fmoc, H-6ꞌꞌꞌꞌa), 4.28-4.26 (m, 1H, H-6ꞌꞌa), 4.23-4.20 (m, 3H, H-5ꞌꞌꞌ, H-5ꞌꞌꞌꞌꞌ, T
β), 4.12-
4.05 (m, 3H, H-2, H-6ꞌꞌb, T
β), 4.02-3.98 (m, 4H, H-6ꞌꞌꞌab, H-6ꞌꞌꞌꞌꞌab), 3.94-3.85 (m, 3H, H-6ꞌab, H-
6ꞌꞌꞌꞌb, H-5ꞌ), 3.81-3.77 (m, 2H, H-3, H-3ꞌ), 3.75-3.73 (m, 1H, H-6a), 3.71-3.63 (m, 4H, H-2ꞌꞌꞌꞌ, H-
4ꞌꞌ, H-4ꞌꞌꞌꞌ, H-5ꞌꞌ), 3.56-3.54 (m, 1H, H-5ꞌꞌꞌꞌ), 3.41-3.36 (m, 1H, H-2ꞌꞌ), 3.31-3.27 (m, 1H, H-6b), 
2.30, 2.09, 2.08, 2.07, 2.02, 2.01, 2.00, 1.99, 1.98, 1.95, 1.94, 1.91, 1.90, 1.89, 1.84, 1.74, 
1.69 (m, 57H, CH3-(Ac)), 1.10 (d, 3H, T
γ, 3J(Tγ,Tβ) = 6.4 Hz).    
13C NMR (150.9 MHz, [D6]DMSO, 30°C, internal DMSO δ(C)= 39.52  ppm): δ= 172.02, 
171.80, 170.26, 170.23, 170.00, 169.89, 169.85, 169.55, 169.50, 169.41, 169.37, 169.35, 
169.11, 169.09, 169.02, 168.95, 168.83 (C=O-(Ac)), 156.80 (C=O-(Fmoc)), 143.77, 143.72 
(C-1a-, C-8a-Fmoc), 140.82, 140.77 (C-4a-, C-5a-Fmoc), 127.71, 127.67 (C-2-, C-7-Fmoc), 
127.06 (C-3-, C-6-Fmoc), 125.27, 125.14 (C-1-, C-8-Fmoc), 120.19, 120.14 (C-4-, C-5-
Fmoc), 100.60 (C-1ꞌ), 100.37 (C-1ꞌꞌꞌꞌ), 100.03, 100.00, 99.93 (C-1ꞌꞌ, C-1ꞌꞌꞌ, C-1ꞌꞌꞌꞌꞌ), 98.46 (C-
1ꞌꞌꞌꞌ), 76.82 (C-3ꞌ), 76.54 (C-4ꞌꞌꞌꞌ), 76.14 (C-4ꞌꞌ), 74.08 (Tβ), 73.47 (C-3), 73.37 (C-3ꞌꞌꞌꞌ), 72.72 
(C-3ꞌꞌ), 71.70 (C-5ꞌꞌ), 71.47 (C-5ꞌꞌꞌꞌ), 70.25, 70.19, 70.13 (C-4, C-3ꞌꞌꞌ, C-3ꞌꞌꞌꞌꞌ, C-5ꞌ), 69.65, 
69.59, 69.50 (C-2ꞌ, C-5ꞌꞌꞌ, C-5ꞌꞌꞌꞌꞌ), 69.00, 68.96, 68.93 (C-4ꞌ, C-2ꞌꞌꞌ, C-2ꞌꞌꞌꞌꞌ, C-6ab), 68.57 (C-5), 
67.06 (C-4ꞌꞌꞌ, C-4ꞌꞌꞌꞌꞌ), 65.58 (CH2ab-(Fmoc)), 62.27 (C-6ꞌꞌab), 61.70 (C-6ꞌ, C-6ꞌꞌꞌꞌab), 60.84, 60.77 
(C-6ꞌꞌꞌab, C-6ꞌꞌꞌꞌꞌab), 58.59 (T
α), 53.99 (C-2ꞌꞌ), 53.12 (C-2ꞌꞌꞌꞌ), 47.83 (C-2), 46.80 (C9-Fmoc), 
22.78, 22.65, 22.61, 21.04, 20.62, 20.61, 20.57, 20.54, 20.52, 20.49, 20.45, 20.35, 20.32, 
20.30 (CH3-(Ac)), 18.68 (T
γ).   
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7.2 Syntheses of chapter 4.2 
 
7.2.1 General 
Solid phase peptide synthesis: SPPS of peptides and glycopeptides was carried out on a 
Syro I peptide synthesizer by Multisyntech GmbH. Solid phase resins were purchased from 
Rapp Polymere GmbH. Protected amino acid building blocks for Fmoc-SPPS 
(Novabiochem®) were purchased from Merck KGaA, and Merck Schuchardt OHG. N,N-
dimethylformamide, N-methypyrrolidone, trifluoroacetic acid and piperidine were purchased 
from Biosolve Chimie SARL. Coupling reagents HBTU and HATU (Novabiochem®) were 
purchased from Merck KGaA. HOBt monohydrate was purchased from Sigma-Aldrich GmbH 
and recrystallized from absolute ethanol and dried at reduced pressure. HOAt was 
purchased from GL Biochem, Shanghai.  
 
RP-HPLC: Analytic RP-HPLC was performed on a Dionex U-3000 (Thermo Scientific) 
system (DR-3600 six channel degasser, LPG-3x00 pump, TCC-3100 column compartment, 
DAD-3000 UV/VIS diode array detector, WPS-3000 autosampler). A Luna C18(2) column (3 
μm, 100Å, 150 x 2.0 mm) from Phenomenex was applied for analytical HPLC.  
Semi-preparative RP-HLPC was performed on the same Dionex HPLC setup as for 
analytical RP-HPLC with a InertSustain C18 (5 µm, 250 x 6.0 mm) from GL Sciences Inc.  
Preparative RP-HPLC was performed on a Dionex U-3000 system (HPG-3200P, VWD-3400 
UV/VIS detector, AFC-3000 sampler). A Luna C18(2) column (10 μm, 100Å, 250 x 21.2 mm) 
from Phenomenex was applied for preparative HPLC. The flow rate was set to 20 mL/min.  
(Glyco-)Peptides were detected at λ = 214 nm. Both systems were operated and 
chromatograms analyzed with Dionex Chromeleon (version 6.80DU10a Build 2826(171948)).  
 
7.2.2 Synthesis of the triethylene glycol spacer amino acid 
 
12-Hydroxy-4,7,10-trioxa-dodecanate-tert-butylester275 (63)  
(HO-{TEG}-COOtBu) 
 
 
 
Triethylene glycol (33.6 g, 223.7 mmol) was given into dry THF under argon atmosphere and 
sodium (50 mg, 2.2 mmol) was added in small portions. After the sodium had completely 
dissolved, tert-butyl-acrylate (9.3 g, 72.6 mmol) was added and stirred for 20 h. The reaction 
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was neutralized with 1 N hydrochloric acid (2 mL) and the solvent was removed in vacuo. 
The residue was taken up with brine (70 mL) and was then extracted with ethyl acetate (four 
times, 50 mL each). The combined organic phases were washed with brine (30 mL), dried 
over magnesium sulfate and filtered. The solvent was removed in vacuo and the product was 
used further without any more purification. 
Yield: 15.56 g (55.9 mmol, 77%), pale yellow liquid, Rf = 0.28 (EtOAc). 
C13H26O6 (M = 278.34 g/mol) [278.17]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 3.67-3.53 (m, 14H, OCH2), 2.96 (s, 1H, OH), 2.44 (t, 
1H, 2-CH2, JCH2,CH2 = 6.5 Hz), 1.38 (s, 9H, tBu).    
 
 
12-Azido-4,7,10-trioxa-dodecanate-tert-butylester276 (64)  
(N3-{TEG}-COOtBu) 
 
 
 
A solution of 12-hydroxy-4,7,10-trioxa-dodecansäure-tert-butylester 63 (15.12 g, 54.3 mmol) 
and triethylamine (20.1 mL, 145.3 mmol) in 20 mL dry dichloromethane was cooled in an ice-
bath and methanesulfonyl chloride (10.1 mL, 132.3 mmol) was added dropwise. After stirring 
for 5 h, the mixture was filtered over Celite® and washed with dichloromethane (100 mL). 
The filtrate was washed with ice-water (60 mL) and with brine (two times, 50 mL). The 
organic phase was dried over magnesium sulfate, filtered and the solvent removed in vacuo. 
The residue was taken up with N,N-dimethylformamide (20 mL) and sodium azide (21.72 g, 
333.8 mmol) was added. The reaction was stirred at 60°C for 18 h. The solvent was removed 
in vacuo and the residue was taken up with water (80 mL). The aqueous phase was 
extracted with diethyl ether (three times). The combined ether phases were dried over 
magnesium sulfate, filtered and the solvent removed in vacuo. The crude product was 
purified by flash column chromatography on silica (CHex/EtOAc 4:1). 
Yield: 10.92 g (36.1 mmol, 67%) colorless oil, Rf = 0.23 (
CHex/EtOAc). 
C13H25N3O5 (M = 303.35 g/mol) [303.18]. 
ESI-MS (pos), m/z: 326.07 ([M+H]+, calc. 326.34). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 3.68-3.57 (m, 12H, 6 x OCH2), 3.36 (t, 2H, 12-OCH2), 
2.47 (t, 2H, 2-CH2), 1.42 (s, 9H, tBu).  
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12-Amino-4,7,10-trioxa-dodecanate-tert-butylester276 (65)  
(H2N-{TEG}-COOtBu) 
 
 
 
To a suspension of a nickel-aluminum alloy (Raney-Nickel, 8.5 g) in water (250 mL), were 
given sodium hydroxide pellets until no further gas generation could be observed. The water 
was decanted and the solid washed with water until the supernatant remained neutral. Then 
it was washed several times with 2-propanol. The Raney-Nickel was given to a solution of 
N3-{TEG}-COOtBu 64 (10.81 g, 35.6 mmol) in 2-propanol (80 mL). The reaction flask was 
evacuated several times via a membrane pump in order to remove dissolved air, before the 
flask was flushed with hydrogen and stirred for 16 h. The Raney-Nickel was filtered off over 
Celite® and the solvent was removed in vacuo. The crude product was purified by flash 
column chromatography on silica (Et2O→Et2O/MeOH 1:1). 
Yield: 6.69 g (24.1 mmol, 68%), yellow oil. 
C13H27NO5 (M = 277.36 g/mol) [277.19]. 
ESI-MS (pos), m/z: 278.07 ([M+H]+, calc. 278.36). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 3.63 (t, 2H, 3-CH2, JCH2,CH2 = 6.5 Hz), 3.59-3.52 (m, 8H, 
4 x OCH2), 3.43 (t, 2H, OCH2, JCH2,CH2 = 5.3 Hz), 2.79 (t, 2H, OCH2, JCH2,CH2 = 5.2 Hz), 2.42 (t, 
2H, OCH2, JCH2,CH2 = 6.5 Hz), 1.71 (sbr, 2H, NH2), 1.36 (s, 9H, tBu).  
 
 
N-(9H-Fluoren-9-yl)-methoxycarbonyl-amido-4,7,10-trioxa-dodecanate-tert-butylester240 
(66)  
(FmocHN-{TEG}-CO2tBu) 
 
 
 
To a solution of H2N-{TEG}-CO2tBu 65 (6.38 g, 23.0 mmol) in a mixture of water and acetone 
(160 mL, 1:1) was added sodium bicarbonate (2.10 g, 25.0 mmol). Fmoc-OSu (8.00 g, 23.7 
mmol) was added in portions to the solution and the reaction was stirred for 18 h. Then, the 
reaction was acidified to pH 6 using 6 N hydrochloric acid. The acetone was removed in 
vacuo and the remaining aqueous phase was extracted with dichloromethane (four times, 
100 mL each). The combined organic phases were dried over magnesium sulfate, filtered 
and the solvent removed in vacuo. The crude product was purified by flash column 
chromatography on silica (CHex/EtOAc 2:1). 
Yield: 9.75 g (19.5 mmol, 85%), yellow oil, Rf = 0.26 (
CHex/EtOAc 1:1). 
 7 EXPERIMENTAL 251 
 
 
C28H37NO7 (M = 499.60 g/mol) [499.26]. 
1H-NMR (400 MHz, CDCl3), δ (ppm): 7.76 (d, 2H, H4-, H5-Fmoc, JH4,H3 = JH5,H6 = 6.7), 7.60 (d, 
2H, H1-, H8-Fmoc, JH1,H2 = JH8,H7 = 7.6 Hz), 7.39 (t, 2H, H2-, H7-Fmoc, JH2,H3 = JH2,H1 = JH7,H6 = 
JH7,H8 = 7.5 Hz), 7.33-7.29 (m, 2H, H3-, H6-Fmoc), 5.43 (sbr, 1H, NH), 4.40 (d, 2H, 
CH2(Fmoc), JCH2,H9 = 7.0 Hz), 4.22 (t, 1H, H9(Fmoc), JH9,CH2 =7.0 Hz), 3.69 (t, 2H, 11-CH2, 
JCH2,CH2 = 6.5 Hz), 3.63-3.57 (m, 10, 5 x OCH2), 3.41-3.39 (m, 2H, 12-CH2), 2.49 (t, 2H, 2-
CH2, JCH2,CH2 = 6.5 Hz), 1.43 (s, 9H, tBu). 
 
 
N-(9H-Fluoren-9-yl)-methoxycarbonyl-amido-4,7,10-trioxa-dodecanate240 (67) 
(FmocHN-{TEG}-CO2H) 
 
 
 
FmocHN-{TEG}-CO2tBu 66 (9.51 g, 19.0 mmol) was dissolved in a mixture of trifluoroacetic 
acid and water (22 mL, 10:1) and stirred for 2 h. The solvent was removed by co-evaporation 
with toluene and dichloromethane. The crude product was purified by flash column 
chromatography on silica (DCM/MeOH/AcOH 100:2:1). The product was co-evaporated, with 
toluene and dichloromethane (three times each). 
Yield: 8.4 g (24.3 mmol, quant.), pale yellow oil, Rf = 0.46 (DCM/MeOH/AcOH 100:2:1). 
C24H29NO7 (M = 443.49 g/mol) [443.19]. 
ESI-MS (pos), m/z: 466.31 ([M+Na]+, calc. 466.18). 
1H-NMR (400 MHz, CDCl3), δ (ppm): 9.69 (sbr, 1H, COOH), 7.76 (d, 2H, H4-, H5-Fmoc, JH4,H3 
= JH5,H6 = 7.6), 7.60 (m, 2H, H1-, H8-Fmoc), 7.40 (t, 2H, H2-, H7-Fmoc, JH2,H3 = JH2,H1 = JH7,H6 
= JH7,H8 = 7.4 Hz), 7.31 (t, 2H, H3-, H6-Fmoc, JH3,H2 = JH3,H4 = JH6,H5 = JH6,H7 = 7.4Hz), 5.57 (sbr, 
1H, NH),  4.43-4.22 (m, 2H, CH2(Fmoc)), 4.24-4.22 (m, 1H, H9(Fmoc)), 3.75-3.72 (m, 2H, 
11-CH2), 3.62-3.56 (m, 10H, 5 x OCH2), 3.40-3.39 (m, 2H, 12-CH2), 2.60 (t, 2H, 2-CH2, 
JCH2,CH2 = 6.2 Hz). 
13C-NMR (100.6 MHz, CDCl3), δ (ppm): 175.68 (COOH), 156.81 (C=O(Fmoc), 144.03 (C1a-, 
C8a-Fmoc), 141.36 (C4a-, C5a-Fmoc), 127.72 (C3-, C6-Fmoc), 127.11 (C2-, C7-Fmoc), 
125.13 (C1-, C8-Fmoc), 120.00 (C4-, C5-Fmoc), 70.57, 70.43, 70.33, 70.12 (4 x OCH2), 
66.72 (CH2(Fmoc)), 66.43 (11-CH2), 47.30 (C9(Fmoc)), 40.98 (12-CH2), 34.84 (2-CH2). 
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7.2.3 General protocol for MUC1 and MUC5B solid phase glycopeptide 
synthesis 
 
Automated steps of the solid phase peptide synthesis: The peptide syntheses were 
carried out automatically on a peptide synthesizer following a standard protocol for Fmoc 
solid phase peptide synthesis until the peptides were cleaved from the resin. The reservoir 
bottles of the peptide synthesizer were loaded with 0.5 M Fmoc-aa-OH in DMF, 0.45 M 
(each) HBTU and HOBt in DMF and 2 M DIPEA in NMP. The preloaded TentaGel-Fmoc-aa-
Trt resins (batch size shown with each peptide below) were given into 2 mL synthesis 
reactors equipped with an filter frit and swollen with of DCM (0.5-1 mL each) for 30 min. The 
Fmoc-protecting group of the preloaded resin amino acid was initially cleaved through a triple 
addition of 20 vol% piperidine in DMF (46.2 µL per 1 µmol batch size; 2 x 3 min + 1 x 9 min; 
15s vortex, 45 s break). After the deprotection, the resin was washed with DMF (46.2 µL per 
1 µmol batch size; 6 x 1 min, 15 s vortex; 45 s break). In automated reaction cycles the 
corresponding Fmoc-aa-OH (8 eqiuv.), HBTU (7.6 eq), HOBt (8 eq) and DIPEA (16 eq) were 
added automatically and the reaction was shaken by vortex (40 min reaction time, 15 s 
vortex; 2.75 min break). A reaction cycle was concluded by Fmoc-deprotection before the 
next cycle was carried out.  
 
Manual coupling steps with glycosylated amino acids: The glycosylated amino acids 
were dissolved in DMF (23 µL per 1 µmol batch size) in an external vessel and pre-activated 
with the coupling reagents HATU, HOAt and DIPEA. The glycosylated amino acids 15, 35, 
39, 49, 54, 242 were applied in 1.5 equivalents excess with 1.45 eq HATU/HOAt and 3 eq 
DIPEA. The glycosylated amino acids 58 and 62 were applied in 2.0 equivalents excess with 
1.9 eq HATU/HOAt and 4 eq DIPEA. After 2-3 min of pre-activation the reaction mixtures 
were manually pipetted into the synthesis reactor and shaken by vortex (15 s vortex; 2.45 
min break). The minimum reaction times for glycosylated amino acids were: 15, 242: 2h; 35, 
39: 5h; 49, 54: 6h; 58, 62: 10h. All coupling reactions were performed at room temperature. 
After the reaction, the resin was washed with DMF (46.2 µL per 1 µmol batch size; 6 x 1 min, 
15 s vortex; 45 s break). After manual coupling steps with a glycosylated amino acids the two 
following standard amino acids were coupled via a double coupling.  
 
Manual coupling steps with spacer amino acid 67: The triethylene glycol spacer amino 
acid 67 was N-terminally linked to the mucin tandem repeat peptide sequences. Amino acid 
67 was dissolved in DMF (23µL per 1 µmol batch size) in an external vessel and pre-
activated with HBTU/HOBt and DIPEA. The spacer amino acid 67 was applied in 3 eq 
excess with 2.8 eq HBTU/HOBt and 6 eq DIPEA. After 2-3 min of pre-activation time the 
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reaction mixture was added to the synthesis reactor. The synthesis was occasionally shaken 
by vortex (15 s vortex; 2.45 min break) for 2 h at room temperature. Afterwards, the resin 
was washed with DMF (6 x 1 min 6 x 500 μL, 15 s vortex; 45 s break). The Fmoc-group was 
removed by triple addition of 20 vol% piperidine in DMF (500 μL each, 3 x 3 x 9 min; 15s 
vortex, 45 s break) and the resin was washed with DMF (6 x 1 min 6 x 500 μL, 15 s vortex; 
45 s break). 
 
Release of the peptides from the solid phase resin: After peptide synthesis the resin was 
washed with dichloromethane, isopropanol and diethyl ether (5 x 500 μL each; 5 x 1 min; 15 
s vortex; 45 s break). The resin was dried in an airstream for 30 min and then transferred 
from the synthesis reactor into a 2 mL syringe clogged by a filter frit. The glycopeptides were 
cleaved from the resin by three additions of TFA/TIPS/H2O 15:1:1 (1 x 120 min + 2 x 10 min; 
15 s vortex; 2.45 min break). The combined filtrates were co-evaporated with toluene in 
vacuo. The residue was taken up with water (2 x 5 mL), 30% buffer B, 50% buffer B and 70% 
buffer B (5 mL each; in this order) and passed over a C18-column (Waters Sep-Pak® Vac 
6cc (1 g)). The fractions containing buffer B were combined, the acetonitrile evaporated in 
vacuo and the aqueous residue was lyophilized to give the crude glycopeptide product. 
 
Removal of the carbohydrate acetyl protecting groups: The crude glycopeptides carrying 
glycosylated amino acids 15, 35, 39, 242 were dissolved in methanol (10 mL) and were 
treated with portions of 1% sodium methoxide in methanol until a pH of 9.5 was reached (wet 
pH paper). The reaction was stirred at room temperature and the reaction was followed by 
analytical HPLC (6-18 h).  
Crude glycopeptide carrying glycans from glycosylated amino acids 49, 54, 58, 62 were 
dissolved in water (4.5 mL) and methanol (3.9 mL) and a solution sodium methoxide in water 
(600 μL, 150 mM) was added. The reaction is treated carefully with injections (100-300 μL) of 
the sodium methoxide solution to slowly raise the pH to 11.5 (wet pH paper) and the reaction 
was followed by analytical HPLC (36-168 h). The reaction was acidified with 20 μL of acetic 
acid and the solvents evaporated in vacuo. The crude glycopeptide was purified by 
preparative HPLC and the product was lyophilized from water.  
 
 
7.2.4 Synthesis of MUC1 glycopeptides 
All MUC1-glycopeptides 68-133 were synthesized following the general procedure reported 
in chapter 6.3.2.1. For MUC1 sequences, TentaGel R Fmoc-Ala-Trt resin (loading: 0.17 
mmol/g; Rapp Polymere, Tübingen) was used. HPLC eluents were composed of gradients of 
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modifier A: water + 0.1% TFA and modifier B: 84% acetonitrile + 0.1% TFA. Peptide bonds 
were detected at λ = 214 nm during HPLC. The threonine TN-antigen building block 242 in 
glycopeptides 68-74 and 131-133 and the serine building block 243 in glycopeptides 131-133 
were kindly provided by Dr. H. Cai.  
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (68) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
Analytical HPLC Rt = 17.85 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 15.27 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
733.0323 ([M+3H]3+, calc. 733.0319);  Yield: 67% (14.6 mg, 6.7 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (69) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
Analytical HPLC Rt = 18.30 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 15.91 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
733.0320 ([M+3H]3+, calc. 733.0319); Yield: 65% (14.3 mg, 6.5 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (70) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
Analytical HPLC Rt = 18.95 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 16.12 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
733.0324 ([M+3H]3+, calc. 733.0319); Yield: 70% (15.4 mg, 7.0 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (71) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
Analytical HPLC Rt = 17.52 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 14.72 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
800.7258 ([M+3H]3+, calc. 800.7251); Yield: 51% (12.2 mg, 5.1 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (72) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
Analytical HPLC Rt = 17.85 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 15.08 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
800.7260 ([M+3H]3+, calc. 800.7251); Yield: 52% (12.5 mg, 5.3 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (73) 
The glycopeptide was synthesized on 58.5 mg (10 μmol) of resin. 
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Analytical HPLC Rt = 18.46 min (A/B, (95:5) → (70:30), flow: 200 μL/min, 25 min); 
Preparative HPLC Rt = 15.64 min (A/B, (95:5) → (70:30), flow: 20 mL/min, 25 min); HR-ESI-
MS, m/z: 800.7260 ([M+3H]3+, calc. 800.7251); Yield: 56% (13.4 mg, 5.6 μmol). 
 
MUC1(19mer) TN-antigen: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (74) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 17.34 min (A/B, (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 14.52 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
868.4197 ([M+3H]3+, calc. 868.4182), 651.5677 ([M+4H]4+, calc. 651.5655); Yield: 40% (10.4 
mg, 4.0 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (75) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.42 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 14.49 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
787.0485 ([M+3H]3+, calc. 787.0495), 600.0255 ([M+4H]4+, calc. 600.0279); Yield: 85% (26.2 
mg, 11.1 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (76) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 17.33 min (A/B, (95:5) → (50:50), 200 μL/min, 45 min); Preparative 
HPLC Rt = 15.69 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
787.0495 ([M+3H]3+, calc. 787.0485); Yield: 85% (25.9 mg, 11.0 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (77) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 17.46 min (A/B, (95:5) → (50:50), 200 μL/min, 50 min); Preparative 
HPLC Rt = 15.98 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
787.0486 ([M+3H]3+, calc. 787.0495); Yield: 76% (23.4 mg, 9.9 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (78) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.6 min (A/B, (95:5) → (65:35), 200 μL/min, 35 min); Preparative 
HPLC Rt = 13.35 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
908.7603 ([M+3H]3+, calc. 908.7603); Yield: 67% (23.8 mg, 8.7 μmol). 
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MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (79) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.19 min (grad.: water/84% acetonitrile + 0.1% TFA (95:5) → (65:35), 
200 μL/min, 35 min, wavelength = 214 nm); Preparative HPLC Rt = 13.67 min (A/B, (95:5) → 
(70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 908.7610 ([M+3H]3+, calc. 908.7603); Yield: 
76% (27.0 mg, 9.9 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (80) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.39 min (A/B, (95:5) → (65:35), 200 μL/min, 35 min); Preparative 
HPLC Rt = 14.63 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
908.7598 ([M+3H]3+, calc. 908.7603) 691.3084 ([M+3H+K]4+, calc. 691.3110), 553.2481 
([M+4H+K]5+, calc553.2502); Yield: 62% (22.1 mg, 8.1 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (81) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.51 min (A/B, (95:5) → (65:35), flow: 200 μL/min, 35 min); 
Preparative HPLC Rt = 12.78 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, 
m/z: 1030.4723 ([M+3H]3+, calc 1030.4723); Yield: 58% (23.6 mg, 7.6 μmol). 
 
MUC1(20mer) T-antigen: H2N-(TEG)-PGSTAPPAHGVTSAPDT*RPA-OH (82) 
The glycopeptide was synthesized on 66.7 mg (10 μmol) of resin. 
Analytical HPLC Rt = 18.95 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 15.64 min (A/B, (95:5) → (65:35), 20 mL/min, 30 min); HR-ESI-MS, m/z: 
819.4007 ([M+3H]3+, calc. 819.4005), Yield: 71% (16.7 mg, 7.1 μmol). 
 
MUC1(21) T-antigen: H2N-(TEG)-APDT*RPAPGSTAPPAHGVTSA-OH (83) 
The glycopeptide was synthesized on 66.7 mg (10 μmol) of resin. 
Analytical HPLC Rt = 18.88 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 15.67 min (A/B, (95:5) → (65:35), 20 mL/min, 30 min); HR-ESI-MS, m/z: 
843.0798 ([M+3H]3+, calc.843.0795), Yield: 54% (13.1 mg, 5.3 μmol). 
 
MUC1(19mer) T-antigen: H2N-(TEG)-APDT*RPA-OH (84) 
The glycopeptide was synthesized on 46.7 mg (7 μmol) of resin. 
Analytical HPLC Rt = 15.68 min (A/B, (95:5) → (79:21), flow: 200 μL/min, 54 min); 
Preparative HPLC Rt = 11.89 min (A/B, (95:5) → (75:25), flow: 20 mL/min, 20 min); HR-ESI-
MS, m/z: 648.3143 ([M+2H]2+, calc. 648.3154); Yield: 66% (5.9 mg, 4.6 μmol). 
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MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (85) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 18.65 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 14.89 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1099.0464 ([M-{Galβ(1,3)-GlcNac}+2H]2+, calc. 1099.0443); 854.7428 ([M+3H]3+, calc. 
854.7427); 650.7965 ([M+K+3H]4+, calc. 650.7978); Yield: 60% (20.0 mg, 7.81 μmol). 
 
MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (86) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 19.66 min (A/B, (95:5) → (70:30), 200 μL/min, 30 min); Preparative 
HPLC Rt = 15.35 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1099.0464 ([M-{Galβ(1,3)-GlcNac}+2H]2+, calc. 1099.0443); 854.7429 ([M+3H]3+, calc. 
854.7427); 650.7963 ([M+K+3H]4+, calc. 650.7978); Yield: 74% (24.2 mg, 9.6 μmol). 
 
MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (87) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 20.34 min (A/B, (95:5) → (70:30), 200 μL/min, 30 min); Preparative 
HPLC Rt = 15.87 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1098.5453 ([M-{Galβ(1,3)-GlcNac}+2H]2+, calc. 1099.0443); 862.0710 ([M+Na+2H]3+, 
862.0700); 854.7430 ([M+3H]3+, calc. 854.7427); 646.8051 ([M+K+3H]4+, calc. 646.8043); 
Yield: 79% (26.4 mg, 10.3 μmol). 
 
MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (88) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 33.36 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 12.98 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS (Orbitrap 
Fusion), m/z: 1044.1473 ([M+3H]3+, calc. 1044.1465); 783.3623 ([M+4H]4+, calc. 783.3617); 
Yield: 37% (15.1 mg, 4.8 μmol). 
 
MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (89) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 34.70 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 13.44 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1044.1491 ([M+3H]3+, calc. 1044.1465); 783.3648 ([M+4H]4+, calc. 783.3617); Yield: 75% 
(30.5 mg, 9.7 μmol). 
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MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (90) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 38.93 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 14.49 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1044.1489 ([M+3H]3+, calc. 1044.1465); 783.3647 ([M+4H]4+, calc. 783.3617); Yield: 47% 
(14.8 mg, 4.7 μmol). 
 
MUC1(19mer) type-1 core 3: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (91) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 31.50 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 12.52 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1233.5506 ([M+3H]3+, calc. 1233.5504), 925.4160 ([M+4H]4+, calc. 925.4146); Yield: 62% 
(29.8 mg, 8.1 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (92) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.91 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 14.03 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1099.0472 ([M-{Galβ(1,4)-GlcNac}+2H]2+, calc. 1099.0443); 997.0067 ([M-{Galβ(1,4)-
GlcNacβ(1,3)-GalNAc}+2H]2+, calc. 997.0029); 854.7432 ([M+3H]3+, calc. 854.7427), 
366.1399 ([βGal(1,4)-βGlcNac]+, calc. 366.1400); Yield: 70% (23.2 mg, 9.1 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (93) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.80 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 14.94 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1099.0455 ([M-{Galβ(1,4)-GlcNac}+2H]2+, calc. 1099.0443); 997.0057 ([M-{Galβ(1,4)-
GlcNacβ(1,3)-GalNAc}+2H]2+, calc. 997.0029); 854.7432 ([M+3H]3+, calc. 854.7427); 
650.7965 ([M+K+3H]4+, calc. 650.7978), 366.1398 ([βGal(1,4)-βGlcNac]+, calc. 366.1400); 
Yield: 65% (21.4 mg, 8.4 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (94) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 20.34 min (A/B, (95:5) → (70:30), 200 μL/min, 30 min); Preparative 
HPLC Rt = 15.87 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1099.0450 ([M-{Galβ(1,4)-GlcNac}+2H]2+, calc. 1099.0443); 997.5067 ([M-{Galβ(1,4)-
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GlcNacβ(1,3)-GalNAc}+2H]2+, calc. 997.5046); 854.7431 ([M+3H]3+, calc. 854.7427); Yield: 
72% (23.7 mg, 9.3 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (95) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.76 min (A/B, (95:5) → (65:35), 200 μL/min, 35 min); Preparative 
HPLC Rt = 12.87 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1383.1496 ([M-{Galβ(1,4)-βGlcNac}+2H]2+, calc. 1383.1500); 1200.5839 ([M-{Galβ(1,4)-
GlcNac}+2H]2+, calc. 1200.5839); 1044.1468 ([M+3H]3+, calc. 1044.1465), 922.4361 ([M-
{Galβ(1,4)-GlcNac}+3H]3+, calc. 922.4358), 366.1395 ([Galβ(1,4)-GlcNac]+, calc. 366.1400); 
Yield: 74% (30.4 mg, 9.7 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (96) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.63 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.55 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1044.1503 ([M+3H]3+, calc. 1044.1465); 783.3658 ([M+4H]4+, calc. 783.3617); Yield: 89% 
(44.0 mg, 11.6 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (97) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 15.98 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 14.47 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1044.1502 ([M+3H]3+, calc. 1044.1465); 783.3655 ([M+4H]4+, calc. 783.3617); Yield: 89% 
(44.0 mg, 11.6 μmol). 
 
MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (98) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.13 min (A/B, (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.25 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1233.8912 ([M+3H]3+, calc. 1233.8848), 1111.8482 (M-{Galβ(1,4)-GlcNac}+3H]3+, calc. 
1111.8396), 1124.4968 (M-{Galβ(1,4)-GlcNac}+Na+2H]2+, calc. 1124.4916), 944.3933 
([M+2K+2H])4+, calc. 944.3925), 935.1564 ([M+K+3H])4+, calc. 935.1544), 925.4198 
([M+4H]4+, calc. 925.4146), 755.9159 ([M+2K+3H]5+, calc. 755.9162), 748.1260 ([M+5H]5+, 
calc. 748.1243), 366.1402 ([Galβ(1,4)-GlcNac]+, calc. 366.1400); Yield: 62% (21.0 mg, 8.1 
μmol). 
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MUC1(19mer) type-2 core 3: H2N-(TEG)-PAHGVT*SA-OH (99) 
The glycopeptide was synthesized on 46.7 mg (7 μmol) of resin. 
Analytical HPLC Rt = 14.826 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 12.37 min (A/B, (95:5) → (75:25), 20 mL/min, 20 min); HR-ESI-MS, m/z: 
755.8554 ([M+2H]2+, calc. 755.8540); Yield: 24% (2.51 mg, 1.7 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (100) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 36.32min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 14.03 min (A/B, (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
908.7662 ([M+3H]3+, calc. 908.7603); Yield: 40% (14.3 mg, 5.2 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (101) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 40.72 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 46.12 min (A/B, (95:5) → (82:18), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
908.7633 ([M+3H]3+, calc. 908.7603); 681.8250 ([M+4H]4+, calc. 681.8220); Yield: 45% (16.2 
mg, 5.9 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (102) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 43.20 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 41.25 min (A/B, (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
908.7615 ([M+3H]3+, calc. 908.7603); 681.8239 ([M+4H]4+, calc. 681.8220); Yield: 43% (15.2 
mg, 5.6 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (103) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 35.04 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 29.07 min (A/B, (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1152.1842 ([M+3H]3+, calc. 1152.1817); 864.3899 ([M+4H]4+, calc. 864.3881); Yield: 36% 
(16.1 mg, 4.7 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (104) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 35.88 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 32.64 min (A/B, (95:5) → (79:21), flow: 20 mL/min, 60 min); HR-ESI-MS, m/z: 
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1152.1831 ([M+3H]3+, calc. 1152.1817); 864.3892 ([M+4H]4+, calc. 864.3881); Yield: 35% 
(15.4 mg, 4.5 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (105) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 38.81 min (A/B, (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 34.15 min (A/B, (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1152.1839 ([M+3H]3+, calc. 1152.1817); 864.3893 ([M+4H]4+, calc. 864.3881); Yield: 36% 
(16.3 mg, 4.7 μmol). 
 
MUC1(19mer) type-1 core 1: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (106) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 32.87 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 27.15 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1423.2668 ([M+2Na+K]3+, calc. 1423.2442 ([M+3H]3+, calc. 1395.9376), 1067.7021 
([M+2Na+K+H]4+, calc. 1067.6850), 1051.4628 ([M+NH4+3H]
4+, calc. 1051.4617), 1047.2058 
([M+4H]4+, calc. 1047.2051); Yield: 27% (14.5 mg, 3.5 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (107) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 38.86 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 33.31 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
908.7606 ([M+3H]3+, calc. 908.7603); 691.3096 ([M+K+3H]4+, calc. 691.3110); Yield: 49% 
(17.4 mg, 6.4 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (108) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 41.53 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 38.52 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
908.7621 ([M+3H]3+, calc. 908.7603); 681.8247 ([M+4H]4+, calc. 681.8220); Yield: 53% (18.9 
mg, 6.9 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (109) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 42.95 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 38.39 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
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908.76199 ([M+3H]3+, calc. 908.7603); 681.8245 ([M+4H]4+, calc. 681.8220); Yield: 45% 
(15.8 mg, 5.8 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (110) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 31.33 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 38.84 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1152.1847 ([M+3H]3+, calc. 1152.1817); 869.8854 ([M+4H]4+, calc. 869.8836), 864.3898 
([M+4H]4+, calc. 864.3881); Yield: 34% (15.3 mg, 4.4 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (111) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 35.57 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 33.41 min (A/B: (95:5) → (82:18), 20 mL/min, 49 min); HR-ESI-MS, m/z: 
1152.5247 ([M+3H]3+, calc. 1152.5247); 864.6428 ([M+4H]4+, calc. 864.6390); Yield: 26% 
(11.6 mg, 4.5 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (112) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 38.80 min ( (95:5) → (79:21), 200 μL/min, 54 min); Preparative HPLC 
Rt = 36.41 min (A/B: (95:5) → (79:21), flow: 20 mL/min, 60 min); HR-ESI-MS, m/z: 1152.1841 
([M+3H]3+, calc. 1152.1817); 864.3894 ([M+4H]4+, calc. 864.3881); Yield: 29% (12.8 mg, 3.7 
μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (113) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 32.26 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 28.57 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1395.9435 ([M+3H]3+, calc. 1395.9376), 1047.2065 ([M+4H]4+, calc. 1047.2051); Yield: 17% 
(9.0 mg, 2.2 μmol). 
 
MUC1(19mer) type-2 core 1: H2N-(TEG)-GST*APPAHGVTSAPDTRPA-OH (114)  
The glycopeptide was synthesized on 53.3 mg (10 μmol) of resin. 
Analytical HPLC Rt = 37.31 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 42.17 min (A/B: (95:5) → (82:18), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
908.7609 ([M+3H]3+, calc. 908.7603); Yield: 14% ( 3.1 mg, 1.1 μmol). 
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MUC1(20mer) type-2 core 1: H2N-(TEG)-PDTRPAGST*APPAHGVTSA-OH (115) 
The glycopeptide was synthesized on 53.3 mg (8 μmol) of resin.  
Analytical HPLC Rt = 39.38 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 45.54 min (A/B: (95:5) → (82:18), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
941.1122 ([M+3H]3+, 941.1112 calc.); Yield: 41% (9.4 mg, 3.3 μmol). 
 
MUC1(20mer) type-2 core 1: H2N-(TEG)-PDTRPAGSTAPPAHGVT*SA-OH (116) 
The glycopeptide was synthesized on 53.3 mg (8 μmol) of resin.  
Analytical HPLC Rt = 39.02 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 44.37 min (A/B: (95:5) → (82:18), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
941.1125 ([M+3H]3+, 941.1112 calc.); Yield: 40% (9.1 mg, 3.2 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (117) 
The glycopeptide was synthesized on 47.1 mg (8 μmol) of resin. 
Analytical HPLC Rt = 33.24 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 34.12 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1030.4716 ([M+3H]3+, calc. 1030.4710); 777.3636 ([M+NH4+3H]
4+, calc. 777.3617); Yield: 
36% (9.1 mg, 2.9 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (118) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 37.54 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 36.80 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1030.4734 ([M+3H]3+, calc. 1030.4710); 773.1071 ([M+4H]4+, calc. 773.1051); Yield: 34% 
(10.6 mg, 3.4 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (119) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 40.91 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 41.18 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1030.4717 ([M+3H]3+, calc. 1030.4710); 773.1062 ([M+4H]4+, calc. 773.1051); Yield: 37% 
(11.5 mg, 3.7 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (120) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 29.84 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 27.75 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
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1395.9406 ([M+3H]3+, calc. 1395.9391); 1047.2064 ([M+4H]4+, calc. 1047.2062); Yield: 22% 
(9.3 mg, 2.2 μmol). 
 
MUC1(19mer) type-1 core 2:H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (121) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 31.83 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.32 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1395.9406 ([M+3H]3+, calc. 1395.9439); 1047.2073 ([M+4H]4+, calc. 1047.2062); Yield: 20% 
(8.4 mg, 2.0 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (122) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 34.49 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 32.69 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1395.9427 ([M+3H]3+, calc. 1395.9439); 1047.2072 ([M+4H]4+, calc. 1047.2062); Yield: 20% 
(8.3 mg, 2.0 μmol). 
 
MUC1(19mer) type-1 core 2: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (123) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 27.69 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 24.15 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1321.0576 ([M+4H]4+, calc. 1321.0542), 1057.2493 ([M+5H]5+, calc. 1057.2455); Yield: 9% 
(4.8 mg, 0.9 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVT*SAPDTRPAPGSTA-OH (124) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 36.45 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 31.71 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1057.7999 ([M+Na+2H]3+, calc. 1057.7969), ([M+3H]3+, calc. 1030.4710); 773.1058 
([M+4H]4+, calc. 773.1051); Yield: 43% (13.2 mg, 4.3 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVTSAPDT*RPAPGSTA-OH (125) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 38.36 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 36.59 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1030.4716 ([M+3H]3+, calc. 1030.4710); 773.1068 ([M+4H]4+, calc. 773.1051); Yield: 34% 
(10.6 mg, 3.4 μmol). 
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MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVTSAPDTRPAPGST*A-OH (126) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 40.94 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 40.43 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1030.4726 ([M+3H]3+, calc. 1030.4710); 773.1067 ([M+4H]4+, calc. 773.1051); Yield: 40% 
(12.4 mg, 4.0 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVT*SAPDT*RPAPGSTA-OH (127) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 30.19 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 27.62 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1051.4627 ([M+NH4+H]
4+, calc. 1051.4606), 1395.9391 ([M+3H]3+, calc. 1395.9391); 
1047.2065 ([M+4H]4+, calc. 1047.2062); Yield: 18% (7.5 mg, 2.2 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVT*SAPDTRPAPGST*A-OH (128) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 32.06 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.09 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1395.9425 ([M+3H]3+, calc. 1395.9439); 1047.2076 ([M+4H]4+, calc. 1047.2062); 845.5567 
([M+K+4H]5+, calc. 845.5567); Yield: 8% (3.4 mg, 0.8 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVTSAPDT*RPAPGST*A-OH (129) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 33.61 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 33.09 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1395.9433 ([M+3H]3+, calc. 1395.9439); 1047.2074 ([M+4H]4+, calc. 1047.2062); Yield: 14% 
(5.8 mg, 1.4 μmol). 
 
MUC1(19mer) type-2 core 2: H2N-(TEG)-PAHGVT*SAPDT*RPAPGST*A-OH (130) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 26.71 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 24.59 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1321.3103 ([M+4H]4+, calc. 1321.3050), 1057.0485 ([M+5H]5+, calc. 1057.0448); Yield: 3% 
(1.7 mg, 0.3 μmol). 
 
 
 
266 7 EXPERIMENTAL
 
 
MUC1(22mer) type-2 core 1 (Thr11) + 2xTn (Ser15, Thr16):  
H2N-(TEG)-PAHGVTSAPDT*RPAPGS*T*APPA-OH (131) 
The glycopeptide was synthesized on 66.7 mg (10 μmol) of resin (0.15 mmol/g). 
Analytical HPLC Rt = 40.42 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 44.71 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1132.5323 ([M+3H]3+, calc. 1132.5274), 849.6495 ([M+4H]4+, calc. 849.6474); Yield: 16% 
(5.3 mg, 1.6 μmol). 
 
MUC1(22mer) type-2 core 3 (Thr11) + 2xTn (Ser15, Thr16)  
H2N-(TEG)-PAHGVTSAPDT*RPAPGS*T*APPA-OH (132) 
The glycopeptide was synthesized on 66.7 mg (10 μmol) of resin (0.15 mmol/g). 
Analytical HPLC Rt = 39.31 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 44.72 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1078.5148 ([M+3H]3+, calc. 1078.5098), 809.1357 ([M+4H]4+, calc. 809.1342); Yield: 19% 
(6.1 mg, 1.9 μmol). 
 
MUC1(22mer) type-2 core 2 (Thr11) + 2xTn (Ser15, Thr16)  
H2N-(TEG)-PAHGVTSAPDT*RPAPGS*T*APPA-OH (133) 
The glycopeptide was synthesized on 66.7 mg (10 μmol) of resin (0.15 mmol/g). 
Analytical HPLC Rt = 36.18 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 41.24 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1254.2446 ([M+3H]3+, calc. 1254.2381), 940.9311 ([M+4H]4+, calc. 940.9304); Yield: 8% (2.9 
mg, 0.77 μmol). 
 
 
7.2.5 Synthesis of MUC5B glycopeptides 
The MUC5B glycopeptides 134-174 were synthesized following the general procedure 
reported in chapter 6.3.2.1. For MUC5B sequences, TentaGel R Fmoc-Pro-Trt resin (loading: 
0.19 mmol/g) was used.  
 
MUC5B(13mer) T-antigen: H2N-(TEG)-ATPSSTPGT*THTP-OH (134) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.11 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.65 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
911.9250 ([M+2H]2+, calc. 911.9257), 608.2862 ([M+3H]3+, calc. 608.2862); Yield: 78% (18.4 
mg, 10.1 μmol). 
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MUC5B(13mer) T-antigen: H2N-(TEG)-AT*PSSTPGTTHTP-OH (135) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.15 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.85 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
911.9263 ([M+2H]2+, calc. 911.9257), 608.2869 ([M+3H]3+, calc. 608.2862); Yield: 72% (17.0 
mg, 9.9 μmol). 
 
MUC5B(13mer) T-antigen: H2N-(TEG)-AT*PSSTPGT*THTP-OH (136) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.24 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.63 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1094.9937 ([M+2H]2+, calc. 1094.9934), 730.3307 ([M+3H]3+, calc. 730.3314), 557.4867 
([M+K+3H]4+, calc. 557.4893); Yield: 79% (22.3 mg, 10.2 μmol). 
 
MUC5B(13mer) T-antigen: H2N-(TEG)-AT*PSST*PGTTHTP-OH (137) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.22 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.86 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1094.9930 ([M+2H]2+, calc. 1094.9934), 911.9259 ([M-{Galβ(1,4)-GalNac}+2H]2+, calc. 
911.9353), 366.1395 ([Galβ(1,4)-GalNac]+, calc. 366.1395); Yield: 62% (17.7 mg, 8.1 μmol). 
 
MUC5B(13mer) T-antigen: H2N-(TEG)-AT*PSST*PGT*THTP-OH (138) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 13.79 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.82 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1277.5626 ([M+2H]2+, calc. 1277.5595), 852.0418 ([M+3H]3+, calc. 852.0421), 648.7709 
([M+K+3H]4+, calc. 648.7724); Yield: 61% (20.2 mg, 8.1 μmol). 
 
MUC5B(17mer) T-antigen:H2N-(TEG)-T*GSTAT*PSST*PGT*THTP-OH (139) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 13.16 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 11.71 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1089.1364 ([M+3H]3+, calc. 1089.1358), 826.5911 ([M+K+3H]4+, calc. 826.5926); Yield: 33% 
(18.1 mg, 4.2 μmol). 
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MUC5B(13mer) type-1 core 3: H2N-(TEG)-ATPSSTPGT*THTP-OH (140) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin.  
Analytical HPLC Rt = 16.41 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.37 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1013.9677 ([M+2H]2+, calc. 1013.9670), 683.3074 ([M+3H]3+, calc. 683.3066); Yield: 72% 
(19.0 mg, 9.4 μmol). 
 
MUC5B(13mer) type-1 core 3: H2N-(TEG)-AT*PSSTPGTTHTP-OH (141) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.34 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.35 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1013.9695 ([M+2H]2+, calc. 1013.9670), 683.3086 ([M+3H]3+, calc. 683.3066); Yield: 70% 
(18.3 mg, 9.0 μmol). 
 
MUC5B(13mer) type-1 core 3: H2N-(TEG)-AT*PSSTPGT*THTP-OH (142) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.03 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.32 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1298.0817 ([M+2H]2+, calc. 1298.0728), 871.3967 ([M+NH4+2H]
3+, calc. 871.3931), 865.7193 
([M+3H]3+, calc. 865.7176); Yield: 61% (20.6 mg, 7.9 μmol). 
 
MUC5B(13mer) type-1 core 3: H2N-(TEG)-AT*PSST*PGTTHTP-OH (143) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 15.26 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.63 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1298.0780 ([M+2H]2+, calc. 1298.0728), 871.3954 ([M+NH4+2H]
3+, calc. 871.3931), 865.7190 
([M+3H]3+, calc. 865.7176); Yield: 54% (18.1 mg, 7.0 μmol). 
 
MUC5B(13mer) type-1 core 3: H2N-(TEG)-AT*PSST*PGT*THTP-OH (144) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin.  
Analytical HPLC Rt = 14.58 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 11.79 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1055.1250 ([M+2H]2+, calc. 1055.1215); Yield: 62% (25.6 mg, 8.1 μmol). 
 
MUC5B(17mer) type-1 core 3: H2N-(TEG)-T*GSTAT*PSST*PGT*THTP-OH (145) 
The glycopeptide was synthesized on 41.2 mg (7 μmol) of resin. 
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Analytical HPLC Rt = 37.98 min (A/B: (95:5) → (84:16), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.06 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1365.9219 ([M+NH4+3H]
4+, calc. 1365.9183), 1360.2442 ([M+3H]3+, calc. 1360.2427), 
1029.9224 ([M+K+3H]4+, calc. 1029.9228); Yield: 36% (10.2 mg, 2.5 μmol). 
 
MUC5B(13mer) type-2 core 3: H2N-(TEG)-ATPSSTPGT*THTP-OH (146) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.73 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.15 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1013.9674 ([M+2H]2+, calc. 1013.9670), 830.8999 ([M-{Galβ(1,4)-GlcNAc}+2H]2+, calc. 
830.8992), 366.1398 ([Galβ(1,4)-GlcNAc]+, calc 366.1395); Yield: 66% (17.5 mg, 8.6 μmol). 
 
MUC5B(13mer) type-2 core 3: H2N-(TEG)-AT*PSSTPGTTHTP-OH (147) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.96 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.17 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1013.9673 ([M+2H]2+, calc. 1013.9670), 830.8999 ([M-{Galβ(1,4)-GlcNAc}+2H]2+, calc. 
830.8992), 688.6289 ([M+K+2H]3+, calc. 688.6313), 366.1397 ([Galβ(1,4)-GlcNAc]+, calc 
366.1395); Yield: 75% (17.6 mg, 9.7 μmol). 
 
MUC5B(13mer) type-2 core 3: H2N-(TEG)-AT*PSSTPGT*THTP-OH (148) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 13.71 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 11.99 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1298.0751 ([M+2H]2+, calc. 1298.0728), 1115.5072 ([M-{βGal(1,4)-GlcNAc-OH}+2H]2+, calc. 
1115.5056), 865.7179 ([M+3H]3+, calc. 865.7176), 366.1396 ([βGal(1,4)-GlcNAc-OH]+, calc 
366.1395); Yield: 62% (21.0 mg, 8.1 μmol). 
 
MUC5B(13mer) type-2 core 3:H2N-(TEG)-AT*PSST*PGTTHTP-OH (149) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 13.96 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 12.28 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1298.0784 ([M+2H]2+, calc. 1298.0728), 878.3700 ([M+K+2H]3+, calc. 878.3696), 871.3954 
([M+NH4+2H]
3+, calc. 871.3931), 865.7190 ([M+3H]3+, calc. 865.7176), 659.0281 
([M+K+3H]4+, calc. 659.0279); Yield: 67% (22.5 mg, 8.7 μmol). 
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MUC5B(13mer) type-2 core 3: H2N-(TEG)-AT*PSST*PGT*THTP-OH (150) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 13.28 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 11.81 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1399.6147 ([M-{Galβ(1,4)-GlcNAc}+2H]2+, calc. 1399.6125), 1062.4496 ([M+Na+2H]3+, calc. 
1062.4488), 1055.1222 ([M+3H]3+, calc. 1055.1215); Yield: 65% (26.6 mg, 8.4 μmol). 
 
MUC5B(17mer) type-2 core 3: H2N-(TEG)-T*GSTAT*PSST*PGT*THTP-OH (151) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 12.91 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 10.94 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1360.2452 ([M+3H]3+, calc. 1360.2427), 1020.4353 ([M+4H]4+, calc. 1029.4339); Yield: 49% 
(26.1 mg, 6.4 μmol). 
 
MUC5B(13mer) type-1 core 1: H2N-(TEG)-ATPSSTPGT*THTP-OH (152) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.01 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.21 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1094.9953 ([M+2H]2+, calc. 1094.9934), 730.3317 ([M+3H]3+, calc. 730.3314); Yield: 36% 
(8.0 mg, 3.6 μmol). 
 
MUC5B(13mer) type-1 core 1: H2N-(TEG)-AT*PSSTPGTTHTP-OH (153) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 16.23 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 13.66 min (A/B: (95:5) → (70:30), 20 mL/min, 25 min); HR-ESI-MS, m/z: 
1094.9991 ([M+2H]2+, calc. 1094.9934), 730.3324 ([M+3H]3+, calc. 730.3314); Yield: 49% 
(8.3 mg, 3.8 μmol). 
 
MUC5B(13mer) type-1 core 1: H2N-(TEG)-AT*PSSTPGT*THTP-OH (154) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 14.11 min (A/B: (95:5) → (70:30), 200 μL/min, 25 min); Preparative 
HPLC Rt = 29.06 min (A/B: (95:5) → (82:18), 20 mL/min, 49 min); HR-ESI-MS, m/z: 
973.7534 ([M+3H]3+, calc. 973.7528); Yield: 30% (11.5 mg, 3.9 μmol). 
 
MUC5B(13mer) type-1 core 1: H2N-(TEG)-AT*PSST*PGTTHTP-OH (155) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
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Analytical HPLC Rt = 31.77 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 29.54 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
979.4302 ([M+NH4+2H]
3+, calc. 979.4284) 973.7534 ([M+3H]3+, calc. 973.7528); Yield: 40% 
(15.3 mg, 5.2 μmol). 
 
MUC5B(13mer) type-1 core 1: H2N-(TEG)-AT*PSST*PGT*THTP-OH (156) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 29.77 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 28.28 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1222.8532 ([M+NH4+2H]
3+, calc. 1222.8498),  1217.1760 ([M+3H]3+, calc.1217.1728); Yield: 
19% (9.1 mg, 2.5 μmol). 
 
MUC5B(17mer) type-1 core 1: H2N-(TEG)-T*GSTAT*PSST*PGT*THTP-OH (157) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 28.56 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 31.41 min (A/B: (95:5) → (82:18), 20 mL/min, 65 min); HR-ESI-MS, m/z: 
1581.9901 ([M+NH4+2H]
3+, calc. 1581.9887), 1576.3150 ([M+3H]3+, calc. 1576.3132), 
1186.7444 ([M+NH4+3H]
4+, calc. 1186.7633), 1182.4878 ([M+4H]4+, calc. 1182.4867); Yield: 
9% (5.0 mg, 1.1 μmol). 
 
MUC5B(13mer) type-2 core 1: H2N-(TEG)-ATPSSTPGT*THTP-OH (158) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 34.41 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 33.94 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1094.9950 ([M+2H]2+, calc. 1094.9934), 730.3325 ([M+3H]3+, calc. 730.3314); Yield: 17% 
(3.7 mg, 1.7 μmol). 
 
MUC5B(13mer) type-2 core 1: H2N-(TEG)-AT*PSSTPGTTHTP-OH (159) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 34.21 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 31.85 min (A/B: (95:5) → (82:18), 20 mL/min, 49 min); HR-ESI-MS, m/z: 
1094.9938 ([M+2H]2+, calc. 1094.9934), 730.3318 ([M+3H]3+, calc. 730.3314); Yield: 37% 
(10.4 mg, 4.8 μmol). 
 
MUC5B(13mer) type-2 core 1: H2N-(TEG)-AT*PSSTPGT*THTP-OH (160) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
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Analytical HPLC Rt = 14.67 min (A/B: (95:5) → (65:35), 200 μL/min, 30 min); Preparative 
HPLC Rt = 28.02 min (A/B: (95:5) → (82:18), 20 mL/min, 49 min); HR-ESI-MS, m/z: 
979.4328 ([M+NH4+2H]
3+, calc. 979.4284), 973.7551 ([M+3H]3+, calc. 973.7528); Yield: 22% 
(8.4 mg, 2.9 μmol). 
 
MUC5B(13mer) type-2 core 1: H2N-(TEG)-AT*PSST*PGTTHTP-OH (161) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 32.66 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 25.87 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
973.7535 ([M+3H]3+, calc. 973.7528); Yield: 22% (8.4 mg, 2.9 μmol). 
 
MUC5B(13mer) type-2 core 1: H2N-(TEG)-AT*PSST*PGT*THTP-OH (162) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 29.55 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 25.67 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1244.8405 ([M+2Na+K]3+, calc. 1222.8153), ([M+NH4+2H]
3+, calc. 1222.8498), 1217.1770 
([M+3H]3+, calc. 1217.1728), 913.3859 ([M+4H]4+, calc. 913.3834); Yield: 15% (7.3 mg, 2.0 
μmol). 
 
MUC5B(17) type-2 core 1: H2N-(TEG)-T*GSTAT*PSST*PGT*THTP-OH (163) 
The glycopeptide was synthesized on 76.5 mg (13 μmol) of resin. 
Analytical HPLC Rt = 28.36 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 25.67 min (A/B: (95:5) → (79:21), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1576.3150 ([M+3H]3+, calc. 1576.3132), 1186.7467 ([M+NH4+3H]
4+, calc. 1186.7633), 
1182.4892 ([M+4H]4+, calc. 1182.4867); Yield: 9% (5.0 mg, 1.1 μmol). 
 
MUC5B(13mer) type-1 core 2: H2N-(TEG)-ATPSSTPGT*THTP-OH (164) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 40.52 min (A/B: (95:5) → (84:16), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.09 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1277.5636 ([M+2H]2+, calc. 1277.5595), 852.0428 ([M+3H]3+, calc. 852.0421); Yield: 20% 
(5.2 mg, 2.0 μmol). 
 
MUC5B(13mer) type-1 core 2: H2N-(TEG)-AT*PSSTPGTTHTP-OH (165) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin.  
Analytical HPLC Rt = 30.78 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.23 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
 7 EXPERIMENTAL 273 
 
 
1277.5644 ([M+2H]2+, calc. 1277.5595), 852.0431 ([M+3H]3+, calc. 852.0421); Yield: 28% 
(7.2 mg, 2.8 μmol). 
 
MUC5B(13mer) type-1 core 2: H2N-(TEG)-AT*PSSTPGT*THTP-OH (166) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 25.40 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 23.29 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1222.8551 ([M+NH4+2H]
3+, calc. 1222.8498), 1217.1780 ([M+3H]3+, calc. 1217.1743); Yield: 
16% (5.9 mg, 1.6 μmol). 
 
MUC5B(13mer) type-1 core 2: H2N-(TEG)-AT*PSST*PGTTHTP-OH (167) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 24.17 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 21.78 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1217.1779 ([M+3H]3+, calc. 1217.1743); Yield: 21% (7.8 mg, 2.1 μmol). 
 
MUC5B(17mer) type-1 core 2: H2N-(TEG)-AT*PSST*PGT*THTP-OH (168) 
The glycopeptide was synthesized on 47.1 mg (8 μmol) of resin. 
Analytical HPLC Rt = 27.35 min (A/B: (95:5) → (84:16), 200 μL/min, 54 min); Preparative 
HPLC Rt = 24.57 min (A/B: (95:5) → (86:14), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1582.6435 ([M+3H]3+, calc. 1582.6410), 1196.7215 ([M+K+3H]4+, calc. 1196.7215), 
1191.4909 ([M+NH4+3H]
4+, calc. 1191.4892), 1187.2341 ([M+4H]4+, calc. 1187.2325); Yield: 
10% (3.7 mg, 0.8 μmol). 
 
MUC5B(13mer) type-2 core 2: H2N-(TEG)-ATPSSTPGT*THTP-OH (169) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 41.00 min (A/B: (95:5) → (84:16), 200 μL/min, 54 min); Preparative 
HPLC Rt = 30.49 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1277.5644 ([M+2H]2+, calc. 1277.5595), 852.0429 ([M+3H]3+, calc. 852.0421); Yield: 28% 
(7.3 mg, 2.8 μmol). 
 
MUC5B(13mer) type-2 core 2: H2N-(TEG)-AT*PSSTPGTTHTP-OH (170) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 30.90 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 29.55 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1277.5644 ([M+2H]2+, calc. 1277.5595), 852.0433 ([M+3H]3+, calc. 852.0421); Yield: 28% 
(7.2 mg, 2.8 μmol). 
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MUC5B(13mer) type-2 core 2: H2N-(TEG)-AT*PSSTPGT*THTP-OH (171) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 25.40 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 23.27 min (A/B: (95:5) → (80:20), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1222.8551 ([M+NH4+2H]
3+, calc. 1222.8498), 1217.1769 ([M+3H]3+, calc. 1217.1743), 
922.6223 ([M+4H]4+, calc. 922.6215); Yield: 17% (6.2 mg, 1.7 μmol). 
 
MUC5B(13mer) type-2 core 2: H2N-(TEG)-AT*PSST*PGTTHTP-OH (172) 
The glycopeptide was synthesized on 58.8 mg (10 μmol) of resin. 
Analytical HPLC Rt = 24.63 min (A/B: (95:5) → (79:21), 200 μL/min, 54 min); Preparative 
HPLC Rt = 24.27 min (A/B: (95:5) → (82:18), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1217.1770 ([M+3H]3+, calc. 1217.1743); Yield: 21% (7.7 mg, 2.1 μmol). 
 
MUC5B(13mer) type-2 core 2: H2N-(TEG)-AT*PSST*PGT*THTP-OH (173) 
The glycopeptide was synthesized on 47.1 mg (8 μmol) of resin. 
Analytical HPLC Rt = 28.32 min (A/B: (95:5) → (84:16), 200 μL/min, 54 min); Preparative 
HPLC Rt 25.57 = min (A/B: (95:5) → (86:14), 20 mL/min, 60 min); HR-ESI-MS, m/z: 
1582.6453 ([M+3H]3+, calc. 1582.6410), 1196.7216 ([M+K+3H]3+, calc. 1196.7215), 
1191.4916 ([M+NH4+3H]
4+, calc. 1191.4892), 1187.2346 ([M+4H]4+, calc. 1187.2325); Yield: 
9% (3.4 mg, 0.7 μmol). 
 
 
7.2.6 Synthesis of α2,3- and α2,6-sialylated MUC1 glycopeptides 
7.2.6.1 General procedure for enzymatic sialylations 
Utilized Sialyltransferases: 
1. For α2,3-sialylation of T-antigen containing peptides: 
Rat 2,3-OST: α2,3-(O)-Sialyltransferase from rat, recombinant (Spodoptera 
frugiperda)282, (Calbiochem) Merck KGaA. 
2. For α2,3-sialylation of type-1 and -2 LacNAc containing peptides: 
PmST1: α2,3-(O)-Sialyltransferase from Pasteurella multocida, recombinant 
(Escherichia coli BL21(DE3))283, Sigma Aldrich Inc. 
3. For α2,3-sialylation of type-2 LacNAc containing peptide (only 174): 
PmST3: α2,3-(O)-Sialyltransferase from Pasteurella multocida, recombinant 
(Escherichia coli BL21(DE3)), Prof. Dr X. Chen, University of California.284 
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4. For α2,6-sialylation of LacNAc structures: 
Pd2,6ST: α2,6-(O)-Sialyltransferase from Photobacterium damsela, recombinant 
(Escherichia coli BL21(DE3))285, Sigma Aldrich Inc. 
The MUC1 glycopeptide (0.5-1.5 mg) was transferred into a 500 µL reaction vial and 
dissolved in corresponding reaction buffer (Rat 2,3-OST: 100 mM sodium cacodylate, pH 
6.0; PmST1 and Pd2,6ST: 100 mM tris(hydroxymethyl)aminomethane hydrochloride 
(TRIS HCl), pH 8.5). Citidin-5´-monophospho-N-actylneuraminc acid (CMP-Neu5Ac) was 
dissolved in reaction buffer and added to the glycopeptide (2.5 eq per carbohydrate 
substrate) in the reaction vial. Then the sialyltransferase in reaction buffer was added to the 
reaction mixture (see table 6.1 for quantity in mU). The final glycopeptide concentration in the 
reaction was 4 mM. The reaction vial was shaken overnight at 37°C. The reaction was 
followed by analytic HPLC and eventually readjusted by further addition of CMP-Neu5Ac and 
sialyltransferase (see table 6.1). The reaction was stopped by addition of cold acetonitrile 
(20% end concentration). The solvent was evaporated in vacuo and the residue loaded on a 
solid phase extraction (SPE) column for desalting. The SPE column (Agilent Spec 3 mL 
C18AR 15mg) was previously equilibrated with acetonitrile (3 x 500 µL) and 0.05% FA (3 x 
500 µL). Crude glycopeptide was taken up with 0.05% FA (3 x 100 µL), loaded onto the SPE 
cartridge and washed with 0.05% FA (3 x 300 µL). The glycopeptide was eluted with 30% 
acetonitrile + 0.05% FA (2 x 300 µL) and 50% acetonitrile + 0.05% FA (1 x 300 µL). The 
combined acetonitrile fractions were concentrated in vacuo and the finally lyophilized from 
water. The lyophilisate was purified by semi-preparative HPLC-MS (see chapter 6.2.1 for 
used HPLC systems). The amount of sialylated glycopeptide product was determined by 
amino acid analysis. Table 6.1 summarizes relevant reaction parameter. 
Table 7.1: Summary of reaction parameters for enzymatic α2,3- and α2,6-sialylation. 
MUC1 Acceptor Peptide  Conditions Product 
Glycan # Sequence enzyme  
eq CMP-
Neu5Ac 
reaction 
time (h) 
enzyme 
activity 
(mU) 
buffer # Neu5Ac 
T 75 PAHGVT*SAPDTRPAPGSTA rat2,3OST 2.0 20 5.6 1 175 α2,3 
 
76 PAHGVTSAPDT*RPAPGSTA rat2,3OST 2.0+0.5 36 5.0+1.4 1 176 α2,3 
 
77 PAHGVTSAPDTRPAPGST*A rat2,3OST 2.0 20 5.6 1 177 α2,3 
 
78 PAHGVT*SAPDT*RPAPGSTA rat2,3OST 4.0+2.0 15 4.2+1.4 1 178 α2,3 
 
79 PAHGVT*SAPDTRPAPGST*A rat2,3OST 4.0+2.0 15 4.2+1.4 1 179 α2,3 
 
80 PAHGVTSAPDT*RPAPGST*A rat2,3OST 4.0+2.0 15 4.2+1.4 1 180 α2,3 
 
81 PAHGVT*SAPDT*RPAPGST*A rat2,3OST 6.0 38 10.5 1 181 α2,3 
          
type-2 core 3 92 PAHGVT*SAPDTRPAPGSTA PmST1 2.5+1.0 22 5+2 2 182 α2,3 
93 PAHGVTSAPDT*RPAPGSTA PmST1 2.5+1.0 24 5+2 2 183 α2,3 
94 PAHGVTSAPDTRPAPGST*A PmST1 2.5+1.0 22 5+2 2 184 α2,3 
92 PAHGVT*SAPDTRPAPGSTA Pd2,6ST 2.5+1.0 15 20+12.5 2 185 α2,6 
93 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 2.5+1.0 24 20+12.5 2 186 α2,6 
94 PAHGVTSAPDTRPAPGST*A Pd2,6ST 2.5+1.0 15 20+12.5 2 187 α2,6 
98 PAHGVT*SAPDT*RPAPGST*A Pd2,6ST 7.5+3.0 18 30+15 2 188 α2,6 
276 7 EXPERIMENTAL
 
 
MUC1 Acceptor Peptide  Conditions Product 
Glycan # Sequence enzyme  
eq CMP-
Neu5Ac 
reaction 
time (h) 
enzyme 
activity 
(mU) 
buffer # Neu5Ac 
          
type-1 core 1 101 PAHGVTSAPDT*RPAPGSTA PmST1 2.0+1.0 12 6 2 189 α2,3 
102 PAHGVTSAPDTRPAPGST*A PmST1 2.0+1.0 12 6 2 190 α2,3 
102 PAHGVTSAPDTRPAPGST*A Pd2,6ST 2.0+1.0 12 25 2 191 α2,6 
102 PAHGVTSAPDTRPAPGST*A Pd2,6ST 2.0+1.0 
   
192 2x(α2,6) 
          
type-2 core 1 110 PAHGVT*SAPDTRPAPGSTA PmST1 2.5+1.0 18 5+2 2 193 α2,3 
111 PAHGVTSAPDT*RPAPGSTA PmST1 2.0+1.0 39 6 2 194 α2,3 
111 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 2.5+1.0 18 20 2 195 α2,6 
112 PAHGVTSAPDTRPAPGST*A PmST1 2.0+1.0 18 6 2 196 α2,3 
112 PAHGVTSAPDTRPAPGST*A Pd2,6ST 2.0+1.0 12 25 2 197 α2,6 
112 PAHGVTSAPDTRPAPGST*A Pd2,6ST 2.0+1.0 12 25 2 198 2x(α2,6) 
 116 PAHGVT*SAPDT*RPAPGST*A PmST1 7.5+3.0 18 10+4 2 199 α2,3 
          
 type-1 core 2 119 PAHGVTSAPDTRPAPGST*A Pd2,6ST 4.0+2.0 12 25 2 200 α2,6 
         
type-2 core 2 
(hexa- 
saccharide) 
125 PAHGVTSAPDT*RPAPGSTA PmST1 4.0+2.0 36 4.2+1.4 2 201 α2,3 
125 PAHGVTSAPDT*RPAPGSTA Pd2,6ST 4.0+2.0 40 30 2 202 α2,6 
 
126 PAHGVTSAPDTRPAPGST*A Pd2,6ST 4.0+2.0 12 25 2 203 α2,6 
 126 PAHGVTSAPDTRPAPGST*A Pd2,6ST 4.0+2.0 12 25 2 204 3x(α2,6) 
          type-2 core 2 
(tetra- 
saccharide) 
174 PAHGVTSAPDT*RPAPGSTA rat2,3OST 2.5+1.0 22 4.2+1.4 1 205 α2,3 
174 PAHGVTSAPDT*RPAPGSTA PmST3 2.5+1.0 40 19 µg 2 206 α2,3 
          
          
          buffers:  1 = 100 mM cacodylate pH 6.0 
       
 
2 = 100 mM TRIS HCl pH 8.5 
       
 
7.2.6.2 Sialylated MUC1 glycopeptides 175-206 
Yields are represented by glycopeptide conversion observed by analytical HPLC and after 
SPE and semi-preparative HPLC quantified by amino acid analysis HPLC eluents were 
composed of gradients of modifier A: water + 0.1% FA and modifier B: 84% acetonitrile + 
0.1% FA. Peptide bonds were detected at λ = 214 nm during HPLC. In order to prevent 
overloading the HPLC column, only a fraction of the crude glycopeptide was purified and 
yields from amino acid analysis (AAA) were correlated to the amount of starting material.   
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVT*SAPDTRPGSTA-OH (175) 
Glycopeptide 75 (1.34 mg, 568 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 26.81 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 27.83 min (A/B: (95:5) → (82:18), 1.5 mL/min, 35 min); HR-ESI-MS, m/z: 
884.0827 ([M+3H]3+, calc. 884.0813), 663.3131 ([M+4H]4+, calc. 663.3128); Yield: 97 % 
(conversion by HPLC), 45% (253 µmol, AAA). 
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MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (176) 
Glycopeptide 76 (1.62 mg, 686 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 29.76 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 27.83 min (A/B: (95:5) → (78:22), 1.5 mL/min, 45 min); HR-ESI-MS, m/z: 
884.0823 ([M+3H]3+, calc. 884.0813), 663.3131 ([M+4H]4+, calc. 663.3128); Yield: 82 % 
(conversion by HPLC), 47% (322 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (177) 
Glycopeptide 77 (1.58 mg, 669 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 30.74 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 27.27 min (A/B: (95:5) → (78:22), 1.5 mL/min, 45 min); HR-ESI-MS, m/z: 
884.0824 ([M+3H]3+, calc. 884.0813), 663.3131 ([M+4H]4+, calc. 663.3128); Yield: 94 % 
(conversion by HPLC), 45% (303 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVT*SAPDT*RPGSTA-OH (178) 
Glycopeptide 78 (0.80 mg, 294 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 28.45 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 26.08 min (A/B: (95:5) → (78:22), 1.5 mL/min, 45 min); HR-ESI-MS, m/z: 
1102.8255 ([M+3H]3+, calc. 1102.8239), 827.3724 ([M+4H]4+, calc. 827.3697); Yield: 89% 
(conversion by HPLC), 28% (81 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVT*SAPDTRPGST*A-OH (179) 
Glycopeptide 79 (0.99 mg, 364 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 29.54 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 26.84 min (A/B: (95:5) → (78:22), 1.5 mL/min, 45 min); HR-ESI-MS, m/z: 
1102.8251 ([M+3H]3+, calc. 1102.8239), 1102.8251 ([M+4H]4+, calc. 827.3697); Yield: 100% 
(conversion by HPLC), 26% (94 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVTSAPDT*RPGST*A-OH (180) 
Glycopeptide 80 (0.78 mg, 286 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 32.60 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 28.84 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1102.8249 
([M+3H]3+, calc. 1102.8239), 827.3717 ([M+4H]4+, calc. 827.3697); Yield: 100 % (conversion 
by HPLC), 41% (118 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl T: H2N-(TEG)-PAHGVT*SAPDT*RPGST*A-OH (181) 
Glycopeptide 81 (1.52 mg, 492 µmol) was sialylated with rat 2,3-OST.  
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Analytical HPLC Rt = 30.85 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 25.44 min (A/B: (95:5) → (78:22), 1.5 mL/min, 45 min); HR-ESI-MS, m/z: 
1321.9009 ([M+3H]3+, calc. 1321.5664), 991.6781 ([M+4H]4+, calc. 991.6764); Yield: 70 % 
(conversion by HPLC), 55% (272 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 3: H2N-(TEG)-PAHGVT*SAPDTRPGSTA-OH (182) 
Glycopeptide 92 (0.73 mg, 285 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 26.68 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 26.39 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7759 
([M+3H]3+, calc. 951.7745), 714.0831 ([M+4H]4+, calc. 714.0827); Yield: 100% (conversion by 
HPLC), 48% (136 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 3: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (183) 
Glycopeptide 93 (0.70 mg, 273 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 29.794 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 28.05 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7756 
([M+3H]3+, calc. 951.7745), 714.0832 ([M+4H]4+, calc. 714.0827); Yield: 88% (conversion by 
HPLC), 43% (118 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 3: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (184) 
Glycopeptide 94 (0.62 mg, 242 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 30.89 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 29.55 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7758 
([M+3H]3+, calc. 951.7745), 714.0833 ([M+4H]4+, calc. 714.0827); Yield: 94% (conversion by 
HPLC), 46% (110 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 3: H2N-(TEG)-PAHGVT*SAPDTRPGSTA-OH (185) 
Glycopeptide 92 (0.66 mg, 258 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 26.51 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 25.62 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7759 
([M+3H]3+, calc. 951.7745), 714.0834 ([M+4H]4+, calc. 714.0827); Yield: 97% (conversion by 
HPLC), 57% (147 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 3: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (186) 
Glycopeptide 93 (0.79 mg, 273 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 29.14 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt= 28.17 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7754 
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([M+3H]3+, calc. 951.7745), 714.0831 ([M+4H]4+, calc. 714.0827); Yield: 88% (conversion by 
HPLC), 57% (176 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 3: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (187) 
Glycopeptide 94 (0.64 mg, 250 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 30.56 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 29.09 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 951.7755 
([M+3H]3+, calc. 951.7745), 714.0833 ([M+4H]4+, calc. 714.0827); Yield: 100% (conversion by 
HPLC), 67% (166 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 3: H2N-(TEG)-PAHGVT*SAPDT*RPGST*A-OH (188) 
Glycopeptide 98 (0.80 mg, 216 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 29.65 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 24.97 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 1143.9884 
([M+4H]4+, calc.1143.9870), 915.3914 ([M+5H]5+, calc. 915.3911); Yield: 100% (conversion 
by HPLC), 10% (23 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-1 core 1: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (189) 
Glycopeptide 101 (0.83 mg, 304 µmol) was sialylated with PmST1.  
Analytical HPLC Rt = 28.97 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 25.98 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7932 
([M+3H]3+, calc. 1005.7921), 754.5964 ([M+4H]4+, calc. 754.5959); Yield: 88% (conversion by 
HPLC), 38% (133 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-1 core 1: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (190) 
Glycopeptide 102 (0.69 mg, 253 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 30.13 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 27.17 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7968 
([M+3H]3+, calc. 1005.7921), 754.5996 ([M+4H]4+, calc. 754.5959); Yield: 85% (conversion by 
HPLC), 44% (111 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-1 core 1: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH  
(191) + (192) 
Glycopeptide 102 (0.67 mg, 246 nmol) was sialylated with Pd2,6ST.  
191 (monosialylated main product): Analytical HPLC Rt = 29.34 min (A/B: (95:5) → (85:15), 
200 μL/min, 40 min); Preparative HPLC Rt = 28.99 min (A/B: (95:5) → (82:18), 1.5 mL/min, 
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min); HR-ESI-MS, m/z: 1005.7938 ([M+3H]3+, calc. 1005.7921), 754.5972 ([M+4H]4+, calc. 
754.5959); Yield: 75% (conversion by HPLC), 36% (89 nmol, AAA). 
192 (disialylated by-product): Analytical HPLC Rt = 33.88 min (A/B: (95:5) → (85:15), 200 
μL/min, 40 min); Preparative HPLC Rt = 31.11 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); 
HR-ESI-MS, m/z: 1102.8253 ([M+3H]3+, calc. 1102.8239), 827.3719 ([M+4H]4+, calc. 
827.3697); Yield: 17% (conversion by HPLC), 15% (36 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 1: H2N-(TEG)-PAHGVT*SAPDTRPGSTA-OH (193) 
Glycopeptide 110 (0.75 mg, 304 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 25.54 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 25.73 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7947 
([M+3H]3+, calc. 1005.7921), 754.5963 ([M+4H]4+, calc. 754.5959); Yield: 97% (conversion by 
HPLC), 42% (115 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 1: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (194) 
Glycopeptide 111 (0.95 mg, 349 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 29.23 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.99 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7937 
([M+3H]3+, calc. 1005.7921), 754.5963 ([M+4H]4+, calc.754.5959); Yield: 100% (conversion 
by HPLC), 58% (202 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 1: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (195) 
Glycopeptide 111 (0.80 mg, 294 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 28.82 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 27.83 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7931 
([M+3H]3+, calc. 1005.7921), 754.5963 ([M+4H]4+, calc. 754.5959); Yield: 97% (conversion by 
HPLC), 38% (110 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 1: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (196) 
Glycopeptide 112 (0.69 mg, 253 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 30.26  min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 28.37 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7936 
([M+3H]3+, calc. 1005.7921), 754.5965 ([M+4H]4+, calc. 754.5959); Yield: 97% (conversion by 
HPLC), 38% (95 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 1: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH  
(197) + (198) 
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Glycopeptide 112 (0.63 mg, 231 nmol) was sialylated with Pd2,6ST.  
197 (monosialylated main product): Analytical HPLC Rt = 29.75 min (A/B: (95:5) → (85:15), 
200 μL/min, 40 min); Preparative HPLC Rt = 27.06 min (A/B: (95:5) → (78:22), 1.5 mL/min, 
min); HR-ESI-MS, m/z: 1005.7934 ([M+3H]3+, calc. 1005.7921), 754.5966 ([M+4H]4+, calc. 
754.5959); Yield: 55% (conversion by HPLC), 20% (47 nmol, AAA). 
198 (disialylated by-product): Analytical HPLC Rt = 34.00 min (A/B: (95:5) → (85:15), 
200 μL/min, 40 min); Preparative HPLC Rt = 28.95 min (A/B: (95:5) → (78:22), 1.5 mL/min, 
min); HR-ESI-MS, m/z: 1102.8250 ([M+3H]3+, calc. 1102.8239), 827.3714 ([M+4H]4+, calc. 
827.3697); Yield: 40% (conversion by HPLC), 18% (38 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 1: H2N-(TEG)-PAHGVT*SAPDT*RPGST*A-OH (199) 
Glycopeptide 116 (0.63 mg, 231 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 28.42 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 24.00 min (A/B: (95:5) → (82:18), 1.5 mL/min, min); HR-ESI-MS, m/z: 1265.5250 
([M+4H]4+, calc. 1265.5266), 1012.6191 ([M+5H]5+, calc. 1012.6228); Yield: 81% (conversion 
by HPLC), 42% (63 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-1 core 2: (H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (200) 
Glycopeptide 119 (0.64 mg, 151 nmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 31.39 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.26 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1224.5352 
([M+3H]3+, calc. 1224.5346), 918.6557 ([M+4H]4+, calc. 918.6528); Yield: 91% (conversion by 
HPLC), 68% (141 nmol, AAA). 
 
MUC1(19mer) α2,3-sialyl type-2 core 2: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (201) 
Glycopeptide 125 (0.69 mg, 223 nmol) was sialylated with PmST1.  
Analytical HPLC Rt = 30.68 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.19 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1224.5350 
([M+3H]3+, calc. 1224.5346), 918.6555 ([M+4H]4+, calc. 918.6528); Yield: 66% (conversion by 
HPLC), 52% (116 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 2: H2N-(TEG)-PAHGVTSAPDT*RPGSTA-OH (202) 
Glycopeptide 125 (0.78 mg, 396 µmol) was sialylated with Pd2,6ST.  
Analytical HPLC Rt = 29.63 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.29 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1224.5352 
([M+3H]3+, calc. 1224.5346), 918.6553 ([M+4H]4+, calc. 918.6528); Yield: 81% (conversion by 
HPLC), 15% (61 nmol, AAA). 
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MUC1(19mer) α2,6-sialyl type-2 core 2: H2N-(TEG)-PAHGVTSAPDTRPGST*A-OH (203) + 
(204) 
Glycopeptide 126 (0.61 mg, 198 µmol) was sialylated with Pd2,6ST.  
203 (monosialylated main product): Analytical HPLC Rt = 32.08 min (A/B: (95:5) → (85:15), 
200 μL/min, 40 min); Preparative HPLC Rt = 26.79 min (A/B: (95:5) → (78:22), 1.5 mL/min, 
min); HR-ESI-MS, m/z: 1224.5350 ([M+3H]3+, calc. 1224.5346), 918.6553 ([M+4H]4+, calc. 
918.6528); Yield: 84% (conversion by HPLC), 76% (150 nmol, AAA). 
204 (disialylated by-product): Analytical HPLC Rt = 36.31 min (A/B: (95:5) → (85:15), 
200 μL/min, 40 min); Preparative HPLC Rt = 28.05 min (A/B: (95:5) → (78:22), 1.5 mL/min, 
min); HR-ESI-MS, m/z: 1321. 9008 ([M+3H]3+, calc. 1321.9009), 991.6779 ([M+4H]4+, calc. 
991.6775); Yield: 16% (conversion by HPLC), 10% (21 nmol, after semi-prep HPLC). 
 
MUC1(19mer) α2,3-sialyl type-2 core 2: H2N-(TEG)-PAHGVTSAPDTRPGSTA-OH (205) 
Glycopeptide 174 (0.64 mg, 235 nmol) was sialylated with rat 2,3-OST.  
Analytical HPLC Rt = 26.82 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.46 min ( (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7929 
([M+3H]3+, calc. 1005.7921), 754.5967 ([M+4H]4+, calc. 754.5959); Yield: 100% (conversion 
by HPLC), 42% (99 nmol, AAA). 
 
MUC1(19mer) α2,6-sialyl type-2 core 2: H2N-(TEG)-PAHGVTSAPDTRPGSTA-OH (206) 
Glycopeptide 174 (0.73 mg, 268 nmol) was sialylated with PmST3.  
Analytical HPLC Rt = 27.13 min (A/B: (95:5) → (85:15), 200 μL/min, 40 min); Preparative 
HPLC Rt = 26.58 min (A/B: (95:5) → (78:22), 1.5 mL/min, min); HR-ESI-MS, m/z: 1005.7935 
([M+3H]3+, calc. 1005.7921), 754.5966 ([M+4H]4+, calc. 754.5959); Yield: 69% (conversion by 
HPLC), 26% (69 nmol, AAA). 
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7.3 Microarray experiments with immobilized MUC1 glycopeptides 
 
7.3.1 General 
Microarray Spotting: Microarray chips were spotted with an iTwo 400 spotter from M2-
Automation equipped with a humidity control unit. The Nexterion H® microarray slides were 
purchased from Schott GmbH, Mainz. Glycopeptide substrates for spotting were pipetted into 
Nunc® 384-well plates from Thermo Scientific and loaded into the microarray spotter. 
 
Microarray Scanning: Scanning of the microarray slides was performed with a Typhoon 
Trio+ by Amersham Biosciences (GE Healthcare). The photo-multiplier tube voltage was set 
to 480 V or 500 V and it was scanned at 10 μm resolution. Excitation of Alexa Fluor 488 
conjugates (Exmax: 495 nm, Emmax: 519 nm) was performed with a blue laser (488 nm) and a 
520 nm band-pass emission filter. Excitation of Cy5 conjugates (Exmax: 650 nm, Emmax: 670 
nm) was performed with a red laser (633 nm) and a 670 nm band-pass emission filter. 
 
Microarray data processing: Data was obtained with Amersham Typhoon Array software. 
Background was substracted by spot edge average background substraction. Data was 
processed with Microsoft Excel. Given values in the diagrams represent the mean of the spot 
replicates with standard deviation. 
 
Antibodies and lectins:  
Secondary goat-anti-mouse antibody used for detection of primary serum antibodies and 
primary anti-MUC1 Ma552 antibody:  
 Alexa Fluor® 488 goat-anti-mouse IgG (H+L, 2 mg/mL) was purchased from 
LifeTechnologies (Thermo Fisher Scientific), Eugene, OR, USA. Experimental 
dilution: 1:3000 (0.67 µg/ml). 
 Mouse monoclonal IgG1 antibody NCL-MUC1 core glycoprotein Ma552, human 
breast cancer cell line ZR75-1, 25 µg/ml, Leica Biosystems, Newcastle Ldt, UK. 
Experimental dilution: 12.5 µg/ml. 
Biotinylated plant lectins were purchased from Vector Laboratories Inc:  
 Biotinylated Erythrina cristagalli (ECA), 5mg/ml. 
 Biotinylated Wheat germ agglutinin (WGA, Triticum aestivum), 5mg/ml. 
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 Biotinylated Maackia amurensis I (MAL I), 2 mg/ml. 
 Biotinylated Maackia amurensis II (MAL II), 1 mg/ml. 
 Biotinylated Peanut agglutinin (PNA, Arachis hypogaea), 5mg/ml. 
 Biotinylated Vicia villosa (VVL), 2 mg/ml. 
 Biotinylated Sambucus nigra agglutinin (SNA), 2 mg/ml. 
Streptavidin-Cy5-conjugate for detection of the biotinylated lectin: 
 Cy5-Streptavidin conjugate (ZyMax™ Grade), 1mg/ml, Invitrogen (Thermo Scientific). 
Experimental dilution 1:1500 (0.67 µg/ml). 
Galectin-3 and anti-galectin-3 antibody: 
 Human, His-tagged, recombinant (E.coli) galectin-3 (1-250aa), ATGen Ltd, South 
Korea.  
 Alexa Fluor® 488 anti-mouse/human Mac-2 (Galectin-3), 0.5 mg/mL, Biolegends Inc, 
San Diego, USA. Experimental dilution: 1:500 (1 µg/ml). 
 
 
7.3.2 Nexterion slide H microarray loading capacity 
 
The standard protocol for NHS-coated Nexterion H® microarray slides from Schott 
recommends surface loading with concentrations of 0.1-1 mg/mL for proteins (antibodies). 
The smaller MUC1 glycopeptides contain one reactive amine group on the N-terminus for 
covalent surface bonding. MUC1(19mer) 69 [(TEG)3-PAHGVTSAPDT(TN)RPAPGSTA] was 
spotted on two Nexterion slides, incubated with vaccine candidate 5 mouse 1 (SH127, 
1:2000) and detected by addition with either goat-anti-mouse-IgG-Cy5 or goat-anti-mouse-
IgG-AlexaFluor488 in concentrations ranging from 5 to 250 μM was performed to evaluate 
best spotting conditions (figure 6.1).  
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Figure 7.2: Loading capacity of Nexterion slide H. 
Each bar represents the mean of 672 spots per well. Slide saturation is reached between 50 
and 100 μM, according a previous publication on a glycoarray using Nexterion H® slides.316 
Higher spotting concentrations only increased standard deviation. Best spotting conditions in 
terms of best signal to standard deviation ratios are found between 25 and 50 μM. For 
highest signals intensity all further microarray spotting was carried out in concentrations of 50 
μM which equals 0.11-0.26 mg/mL, depending on the molecular weight of each glycopeptide.  
 
 
7.3.3 General spotting conditions  
 
Reagents: 
 Spotting buffer: 150 mM NaH2PO4/Na2HPO4 buffer (pH 8.5)  
Glycopeptides were dissolved and diluted to a spotting concentration of 50 mM in spotting 
buffer. A volume of 20 μL of each glycopeptide solution was pipetted into a Nunc® 384-well 
plate. The 384-well plate and the Nexterion H® slides were loaded in the spotter. Droplets 
were generated by piezo-driven droplet generation. The spotter settings were adjusted to 
generate substrate spots from single droplets of 100 pL ± 3 pL onto the microarray slides. 
During spotting, humidity in the spotting chamber was kept between 50-60%. After the 
spotting process, microarray slides were kept at 90-99% relative humidity overnight, to 
complete surface immobilization. Not immediately used slides are stored below -20°C, until 
further use. 
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7.3.4 Spotting of MUC1 microarrays MA1, MA2, MA3, MA4, MA5 
 
Five different microarray formats (MA1-MA5) were spotted for the different applications and 
with growing size of the MUC1 glycopeptide library: 
 MA1: Serum antibody titer microarray (chapter 4.3.7) 
 MA2: Serum antibody microarray 1 (chapter 4.3.8) 
 MA3: Serum antibody microarray 2 (chapter 4.3.8) 
 MA4: Serum antibody microarray 3 and galectin microarray (chapter 4.3.9; chapter 
4.3.11.3) 
 MA5: Plant lectin microarray (chapter 4.3.11.1) 
The glycopeptide library synthesized in the course of this work was appended by 
glycopeptides previously synthesized by M.Sc. M.Schorlemer, Leibniz-Institut für Analytische 
Wissenschaften -ISAS- e.V., (entry 174), Dr. U. Westerlind and Dr. H. Cai Leibniz-Institut für 
Analytische Wissenschaften-ISAS-e.V., Dortmund and Johannes-Gutenberg-Universität 
Mainz, laboratory of Prof. Dr. H. Kunz (entries 207-241). Table 6.2 lists all glycopeptides 
utilized for microarray spotting and the according microarray format. 
Table 7.2: Full list of MUC1 glycopeptides utilized for microarray spotting of the microarray formats MA1, MA2, 
MA3, MA4, MA5 with positions of the glycopeptide entries on the arrays. (-) indicates absence of the according 
glycopeptide.  
Peptide 
number 
MUC1 sequence Glycan Origin 
Peptide position on Microarray 
MA1 MA2 MA3 MA4 MA5 
68 PAHGVT*SAPDTRPAPGSTA TN This thesis - 27 - - 21 
69 PAHGVTSAPDT*RPAPGSTA TN This thesis - 28 14 - 22 
70 PAHGVTSAPDTRPAPGST*A TN This thesis - 29 - - 23 
71 PAHGVT*SAPDT*RPAPGSTA TN This thesis - 30 - - 24 
72 PAHGVT*SAPDTRPAPGST*A TN This thesis - 31 - - 25 
73 PAHGVTSAPDT*RPAPGST*A TN This thesis - 32 12 - 26 
74 PAHGVT*SAPDT*RPAPGST*A TN This thesis - 33 - - 27 
75 PAHGVT*SAPDTRPAPGSTA T This thesis - 34 - 1 37 
76 PAHGVTSAPDT*RPAPGSTA T This thesis - 35 15 3 38 
77 PAHGVTSAPDTRPAPGST*A T This thesis - 36 - 5 39 
78 PAHGVT*SAPDT*RPAPGSTA T This thesis - 37 - 7 40 
79 PAHGVT*SAPDTRPAPGST*A T This thesis - 38 - 9 41 
80 PAHGVTSAPDT*RPAPGST*A T This thesis - 39 - 11 42 
81 PAHGVT*SAPDT*RPAPGST*A T This thesis - 40 - 13 43 
82 PGSTAPPAHGVTSAPDT*RPA T This thesis - - - - 34 
83 APDT*RPAPGSTAPPAHGVTSA T This thesis - - - - 35 
 7 EXPERIMENTAL 287 
 
 
Peptide 
number 
MUC1 sequence Glycan Origin 
Peptide position on Microarray 
MA1 MA2 MA3 MA4 MA5 
84 APDT*RPA T This thesis - - - - 36 
85 PAHGVT*SAPDTRPAPGSTA type-1 core 3 This thesis - 41 - - 52 
86 PAHGVTSAPDT*RPAPGSTA type-1 core 3 This thesis - 42 - - 53 
87 PAHGVTSAPDTRPAPGST*A type-1 core 3 This thesis - 43 - - 54 
88 PAHGVT*SAPDT*RPAPGSTA type-1 core 3 This thesis - 44 - - 55 
89 PAHGVT*SAPDTRPAPGST*A type-1 core 3 This thesis - 45 - - 56 
90 PAHGVTSAPDT*RPAPGST*A type-1 core 3 This thesis - 46 - - 57 
91 PAHGVT*SAPDT*RPAPGST*A type-1 core 3 This thesis - 47 - - 58 
92 PAHGVT*SAPDTRPAPGSTA type-2 core 3 This thesis - 48 - 15 59 
93 PAHGVTSAPDT*RPAPGSTA type-2 core 3 This thesis - 49 - 18 60 
94 PAHGVTSAPDTRPAPGST*A type-2 core 3 This thesis - 50 - 29 61 
95 PAHGVT*SAPDT*RPAPGSTA type-2 core 3 This thesis - 51 - - 62 
96 PAHGVT*SAPDTRPAPGST*A type-2 core 3 This thesis - 52 - - 63 
97 PAHGVTSAPDT*RPAPGST*A type-2 core 3 This thesis - 53 - - 64 
98 PAHGVT*SAPDT*RPAPGST*A type-2 core 3 This thesis - 54 - 32 65 
99 PAHGVT*SA type-2 core 3 This thesis - - - - 73 
100 PAHGVT*SAPDTRPAPGSTA type-1 core 1 This thesis - 55 - - 74 
101 PAHGVTSAPDT*RPAPGSTA type-1 core 1 This thesis - 56 - 35 75 
102 PAHGVTSAPDTRPAPGST*A type-1 core 1 This thesis - 57 - 37 76 
103 PAHGVT*SAPDT*RPAPGSTA type-1 core 1 This thesis - 58 - - 77 
104 PAHGVT*SAPDTRPAPGST*A type-1 core 1 This thesis - 59 - - 78 
105 PAHGVTSAPDT*RPAPGST*A type-1 core 1 This thesis - 60 - - 79 
106 PAHGVT*SAPDT*RPAPGST*A type-1 core 1 This thesis - 61 - - 80 
107 PAHGVT*SAPDTRPAPGSTA type-2 core 1 This thesis - 62 - 41 85 
108 PAHGVTSAPDT*RPAPGSTA type-2 core 1 This thesis - 63 16 43 86 
109 PAHGVTSAPDTRPAPGST*A type-2 core 1 This thesis - 64 - 46 87 
110 PAHGVT*SAPDT*RPAPGSTA type-2 core 1 This thesis - 65 - - 88 
111 PAHGVT*SAPDTRPAPGST*A type-2 core 1 This thesis - 66 - - 89 
112 PAHGVTSAPDT*RPAPGST*A type-2 core 1 This thesis - 67 - - 90 
113 PAHGVT*SAPDT*RPAPGST*A type-2 core 1 This thesis - 68 - 50 91 
114 GST*APPAHGVTSAPDTRPA type-2 core 1 This thesis - - - - 94 
115 PDTRPAPGST*APPAHGVTSA type-2 core 1 This thesis - - - - 93 
116 PDTRPAPGSTAPPAHGVT*SA type-2 core 1 This thesis - - - - 92 
117 PAHGVT*SAPDTRPAPGSTA 
 type-1 core 2 
(hexa) 
This thesis - 69 - - 107 
118 PAHGVTSAPDT*RPAPGSTA 
 type-1 core 2 
(hexa) 
This thesis - 70 - - 108 
119 PAHGVTSAPDTRPAPGST*A 
 type-1 core 2 
(hexa) 
This thesis - 71 - 53 109 
120 PAHGVT*SAPDT*RPAPGSTA 
 type-1 core 2 
(hexa) 
This thesis - 72 - - 110 
121 PAHGVT*SAPDTRPAPGST*A 
 type-1 core 2 
(hexa) 
This thesis - 73 - - 111 
122 PAHGVTSAPDT*RPAPGST*A 
 type-1 core 2 
(hexa) 
This thesis - 74 - - 112 
123 PAHGVT*SAPDT*RPAPGST*A 
 type-1 core 2 
(hexa) 
This thesis - 75 - - 113 
124 PAHGVT*SAPDTRPAPGSTA 
type-2 core 2 
(hexa) 
This thesis - 76 - - 115 
125 PAHGVTSAPDT*RPAPGSTA 
type-2 core 2 
(hexa) 
This thesis - 77 17 55 116 
126 PAHGVTSAPDTRPAPGST*A 
type-2 core 2 
(hexa) 
This thesis - 78 - 58 117 
127 PAHGVT*SAPDT*RPAPGSTA 
type-2 core 2 
(hexa) 
This thesis - 79 - - 118 
128 PAHGVT*SAPDTRPAPGST*A 
type-2 core 2 
(hexa) 
This thesis - 80 - - 119 
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Peptide 
number 
MUC1 sequence Glycan Origin 
Peptide position on Microarray 
MA1 MA2 MA3 MA4 MA5 
129 PAHGVTSAPDT*RPAPGST*A 
type-2 core 2 
(hexa) 
This thesis - 81 - - 120 
130 PAHGVT*SAPDT*RPAPGST*A 
type-2 core 2 
(hexa) 
This thesis - 82 - - 121 
131 PAHGVTSAPDT*RPAPGS#T#APPA 
*type-2 core 1 
+ 
#
2xTn 
This thesis - - 1 - 130 
132 PAHGVTSAPDT*RPAPGS#T#APPA 
*type-2 core 3 
+ 
#
2xTn 
This thesis - - 2 - 131 
133 PAHGVTSAPDT*RPAPGS#T#APPA 
*type-2 core 2 
+ 
#
2xTn 
This thesis - - 3 - 132 
174 PAHGVTSAPDT*RPAPGSTA 
type-2 core 2 
(tetra) 
M. Sc. M. 
Schorlemer 
- - 18 61 127 
175 PAHGVT*SAPDTRPAPGSTA ST This thesis - - - 2 44 
176 PAHGVTSAPDT*RPAPGSTA ST This thesis - - - 4 45 
177 PAHGVTSAPDTRPAPGST*A ST This thesis - - - 6 46 
178 PAHGVT*SAPDT*RPAPGSTA ST This thesis - - - 8 47 
179 PAHGVT*SAPDTRPAPGST*A ST This thesis - - - 10 48 
180 PAHGVTSAPDT*RPAPGST*A ST This thesis - - - 12 49 
181 PAHGVT*SAPDT*RPAPGST*A ST This thesis - - - 14 50 
182 PAHGVT*SAPDTRPAPGSTA 
2,3-sialyl type-
2 core 3 
This thesis - - - 17 66 
183 PAHGVTSAPDT*RPAPGSTA 
2,3-sialyl type-
2 core 3 
This thesis - - - 24 67 
184 PAHGVTSAPDTRPAPGST*A 
2,3-sialyl type-
2 core 3 
This thesis - - - 31 68 
185 PAHGVT*SAPDTRPAPGSTA 
2,6-sialyl type-
2 core 3 
This thesis - - - 16 70 
186 PAHGVTSAPDT*RPAPGSTA 
2,6-sialyl type-
2 core 3 
This thesis - - - 19 71 
187 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
2 core 3 
This thesis - - - 30 72 
188 PAHGVT*SAPDT*RPAPGST*A 
2,6-sialyl type-
2 core 3 
This thesis - - - 34 69 
189 PAHGVTSAPDT*RPAPGSTA 
2,3-sialyl type-
1 core 1 
This thesis - - - 36 83 
190 PAHGVTSAPDTRPAPGST*A 
2,3-sialyl type-
1 core 1 
This thesis - - - 40 84 
191 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
1 core 1 
This thesis - - - 38 81 
192 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
1 core 1 
This thesis - - - 39 82 
193 PAHGVT*SAPDTRPAPGSTA 
2,3-sialyl type-
2 core 1 
This thesis - - - 42 98 
194 PAHGVTSAPDT*RPAPGSTA 
2,3-sialyl type-
2 core 1 
This thesis - - - 45 99 
195 PAHGVTSAPDT*RPAPGSTA 
2,6-sialyl type-
2 core 1 
This thesis - - - 44 95 
196 PAHGVTSAPDTRPAPGST*A 
2,3-sialyl type-
2 core 1 
This thesis - - - 49 100 
197 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
2 core 1 
This thesis - - - 47 96 
198 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
2 core 1 
This thesis - - - 48 97 
199 PAHGVT*SAPDT*RPAPGST*A 
2,3-sialyl type-
2 core 1 
This thesis - - - 51 102 
200 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
1 core 2 
(hexa) 
This thesis - - - 54 114 
201 PAHGVTSAPDT*RPAPGSTA 
2,3-sialyl type-
2 core 2 
(hexa) 
This thesis - - - 57 126 
202 PAHGVTSAPDT*RPAPGSTA 
2,6-sialyl type-
2 core 2 
(hexa) 
This thesis - - - 56 122 
203 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
2 core 2 
(hexa) 
This thesis - - - 59 123 
204 PAHGVTSAPDTRPAPGST*A 
2,6-sialyl type-
2 core 2 
(hexa) 
This thesis - - - 60 124 
205 PAHGVTSAPDT*RPAPGSTA 
2,3-sialyl 
(core1) type-2 
core 2 (tetra) 
This thesis - - - 62 128 
206 PAHGVTSAPDT*RPAPGSTA 
2,3-
sialyl(LacNAc) 
type-2 core 2 
(tetra) 
This thesis - - - 63 129 
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Peptide 
number 
MUC1 sequence Glycan Origin 
Peptide position on Microarray 
MA1 MA2 MA3 MA4 MA5 
207 PAHGVTSAPDTRPAPGSTAP - 
Dr. U. 
Westerlind 
- 1 - - - 
208 PAHGVT*SAPDTRPAPGSTAP STN 
Dr. U. 
Westerlind 
- 2 - - 2 
209 PAHGVTSAPDT*RPAPGSTAP STN 
Dr. U. 
Westerlind 
- 3 - - 3 
210 PAHGVTSAPDTRPAPGST*AP STN 
Dr. U. 
Westerlind 
- 4 - - 4 
211 PAHGVT*SAPDTRPAPGST*AP STN 
Dr. U. 
Westerlind 
- 5 - - 5 
212 PAHGVT*SAPDTRPAP STN 
Dr. U. 
Westerlind 
- 6 - - 6 
213 GSTAPPAHGVT*SAP * STN, ° TN 
Dr. U. 
Westerlind 
- 7 - - 7 
214 PAHGVT*SAPDTRPAPGST°AP * STN, ° TN 
Dr. U. 
Westerlind 
- 8 - - 8 
215 PAHGVT*SAPDT°RPAPGST*AP * STN, ° TN 
Dr. U. 
Westerlind 
- 9 - - 9 
216 
PAHGVT*SAPDTRPAPGST°APPA
HGVT*SAPDTRPAPGST°AP 
* STN, ° TN 
Dr. U. 
Westerlind 
- 10 - - 10 
217 PAHGVT*SAPDTRPAPGSTAP TN 
Dr. U. 
Westerlind 
- 11 - - - 
218 PAHGVTS*APDTRPAPGSTAP TN 
Dr. U. 
Westerlind 
- 12 - - 11 
219 PAHGVTSAPDTRPAPGS*TAP TN 
Dr. U. 
Westerlind 
- 13 - - 12 
220 PAHGVTSAPDT*RPAPGS*TAP TN 
Dr. U. 
Westerlind 
- 14 - - - 
221 APDTRPAPGST*AP TN 
Dr. U. 
Westerlind 
- 15 - - 13 
222 PAHGVT*SAPDTRPAPGSTAP  T 
Dr. U. 
Westerlind 
- 16 - - - 
223 PAHGVTS*APDTRPAPGSTAP  T 
Dr. U. 
Westerlind 
- 17 - - 28 
224 PAHGVTSAPDT*RPAPGSTAP  T 
Dr. U. 
Westerlind 
- 18 - - - 
225 PAHGVTSAPDTRPAPGS*TAP  T 
Dr. U. 
Westerlind 
- 19 - - 29 
226 PAHGVTSAPDTRPAPGST*AP  T 
Dr. U. 
Westerlind 
- 20 - - - 
227 PAHGVT*SAPDTRPAP  T 
Dr. U. 
Westerlind 
- 21 - - 30 
228 PAHGVTS*APDTRPAP  T 
Dr. U. 
Westerlind 
- 22 - - 31 
229 PAHGVTSAPDTRPAPGS*TAP αGlcNAc 
Dr. U. 
Westerlind 
- 83 - - - 
230 PAHGVT*SAPDTRPAPGSTAP αGlcNAc 
Dr. U. 
Westerlind 
- 84 - - - 
231 PAHGVTS*APDTRPAPGSTA αGlcNAc 
Dr. U. 
Westerlind 
- 85 - - - 
232 HGVTSAPDT*RPAPGS*T*APPA TN Dr. H. Cai 1 23 4 64 14 
233 HGVTSAPDTRPAPGS*T*APPA TN Dr. H. Cai - 24 5 65 15 
234 HGVTSAPDT*RPAPGS*T*APPA  T Dr. H. Cai 1 25 6 - 32 
235 HGVTSAPDTRPAPGS*T*APPA  T Dr. H. Cai - 26 7 - 33 
236 HGVTSAPDTRPAPGST*APPA TN Dr. H. Cai - - 8 - 16 
237 HGVTSAPDTRPAPGS*TAPPA TN Dr. H. Cai 1 - 9 - 17 
238 HGVTSAPDT*RPAPGS*TAPPA TN Dr. H. Cai - - 10 - 18 
239 HGVTSAPDT*RPAPGST*APPA TN Dr. H. Cai - - 11 - 19 
240 HGVTSAPDT*RPAPGSTAPPA TN Dr. H. Cai - - 13 - 20 
241 HGVTSAPDTRPAPGSTAPPA - Dr. H. Cai - - 19 - 1 
 
7.3.4.1 Format of microarray MA1 
Microarray MA1 was utilized for antibody titer determination (chapter 4.3.7). MA1 was 
spotted homogenously with each of the corresponding antigen peptides of the vaccine 
candidates 229, 231 or 234 (table 6.1). The glycopeptide was spotted in 39 arrays with 7 x 7 
= 49 replicates. The pitch was set to 450 μM in each direction (figure 6.2).  
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Figure 7.3: Format of microarray MA1. 
The murine serum antibodies were detected with Alexa Fluor® 488 goat-anti-mouse IgG 
(1:3000) as described in the general procedure for array incubation (chapter 6.3.5). Central 
nine replicates were chosen for data acquisition. 
 
7.3.4.2 Format of microarray MA2  
Microarray MA2 was utilized for serum antibody screening (chapter 4.3.8). Glycopeptides 
were arranged in seven rectangular arrays per slide. The barcode area was left unspotted. 
Each array consisted of four identical sub-blocks of eight columns and 22 rows, resulting in 
maximum 176 spots per sub-block and 4 x 176 = 704 possible spots per array. In total 85 
MUC1 glycopeptides were spotted two times into each sub-block (2 x 85 = 170 spots; 176 
(max) - 170 (used) = 6 spots unused), resulting in eight spot replicates per array. Peptides 
were spotted in the order according to table 6.1. Pitch spacing was set to 335 μm in x-
direction and 327 μm y-direction (figure 6.3). 
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Figure 7.4: Format of microarray MA2. 
The murine serum antibodies from synthetic vaccine candidates 1-8 were detected with 
Alexa Fluor® 488 goat-anti-mouse IgG (1:3000) as described in the general procedure for 
array incubation (chapter 6.3.5). 
 
7.3.4.3 Format of microarray MA3 
Microarray MA3 was utilized in serum antibody screening (chapter 4.3.8). Glycopeptides 
were arranged in 16 wells on the microarray slide. Each array was spotted in a 12 x 12 = 144 
spots pattern. The glycopeptides were spotted with 7 replicates each (figure 6.3). Pitch 
spacing was set to 380 μm in x-direction and 410 μm y-direction (figure 6.4) 
 
Figure 7.5: Format of microarray MA3. 
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The murine serum antibodies from synthetic vaccine candidates 1-8 were detected with 
Alexa Fluor® 488 goat-anti-mouse IgG (1:3000) as described in the general procedure for 
array incubation (chapter 6.3.5). 
 
7.3.4.4 Format of microarray MA4 
Microarray MA4 was utilized in serum antibody screening and galectin-3 screening (chapter 
4.3.9 and chapter 4.3.11.3). Glycopeptides were arranged in eight arrays per slide. Each 
array consisted of two identical sub-blocks of 12 columns and 17 rows, resulting in maximum 
204 spots per sub-block and 2 x 204 = 408 spots per array. In total 65 MUC1 glycopeptides 
were spotted three times into each sub-block (3 x 65 = 195 spots; 204 (max) - 195 (used) = 9 
spots unused), resulting in seven spot replicates per array. Peptides were spotted in the 
order according to table 6.1. Pitch spacing was set to 400 μm in x-direction and 400 μm y-
direction (figure 6.5). 
 
Figure 7.6: Format of microarray MA4. 
The murine serum antibodies from synthetic vaccine candidates 1-8 were detected with 
Alexa Fluor® 488 goat-anti-mouse IgG (1:3000) and galectin-3 was detected with Alexa 
Fluor® 488 anti-mouse/human MAC2/galectin-3 (1:500) an as described in the general 
procedure for array incubation (chapter 6.3.5). 
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7.3.4.5 Format of microarray MA5 
Microarray MA5 was utilized in plant lectin screening (chapter 4.3.11.1). Glycopeptides were 
arranged in eight arrays per slide. Each array contained spots arranged in 16 columns and 
42 rows, resulting in maximum 672 spots per array. In total 132 MUC1 glycopeptides were 
spotted five spot replicates per array (5 x 132 = 660 spots; 672 (max) - 660 (used) = 12 spots 
unused). Peptides were spotted in the order according to table 6.1. Pitch spacing was set to 
340 μm in x-direction and 343 μm in y-direction (figure 6.6). 
 
Figure 7.7: Format of Microarray MA5. 
The biotinylated plant lectins were detected with Cy5-Streptavidin Conjugate (1:1500) as 
described in the general procedure for array incubation (chapter 6.3.5). 
 
7.3.5 General protocol for microarray assays with antiserum or lectin samples 
 
Reagents: 
 Block-buffer: 25 mM ethanolamine in 100 mM sodium tetraborate buffer (pH 9.0) 
 Incubation-buffer: PBST-buffer (0.2% Tween-20): 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4, 0.2% Tween-20.  
 Wash-buffer 1: PBST-buffer (0.05%)   
 Wash-buffer 2: PBS-buffer  
The volumes for all incubation and washing steps were depended on the corresponding well 
size of the microarray:  
294 7 EXPERIMENTAL
 
 
 MA1: 3 x 3 mm  5 μL  
 MA2, MA4, MA5: 6.59 x 15.58 mm  100 μL 
 MA3: 6.59 x 6.59 mm  50 μL 
General incubation procedure for microarray assay: 
Blocking: 
1. The slides are immersed in a bath of block-buffer. No further blocking with a protein 
component (i.e. BSA) is required.  
2. The slides are rinsed three times with water and then spin dried in a centrifuge. 
3. The slide is mounted into a slide holder with a well-forming silicone superstructure. 
4. Incubation with antiserum or lectin: 
The antiserum/lectin is diluted in incubation-buffer and pipetted into the wells. The 
slide holder is positioned into a humidity chamber (70% RH) and gently shaken for 
60 min.  
5. The wells are washed two times wash buffer 1 and once with wash buffer 2 for 15 
min each.  
6. Incubation with secondary antibody:   
Wash-buffer is carefully pipetted out of the wells and of secondary antibody diluted in 
incubation-buffer is added. The slide holder is positioned into a humidity chamber 
(70% RH) and gently shaken for 60 min.   
7. Washing according to step 5. 
8. Slides are removed from the slide holder, the silicone superstructure is removed and 
the slides are generously rinsed with water and spin-dried. 
9. Slides are scanned for fluorescence.  
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9.1 Spectroscopic data 
Compound 27 
 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (100.6 MHz, CDCl3) 
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Compound 31 
 
1H NMR (600 MHz, DMSO-d6) 
 
13C NMR (150.9 MHz, CDCl3) 
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Compound 44 
 
1H NMR (400 MHz, DMSO-d6) 
 
 
13C NMR (100.6 MHz, DMSO-d6) 
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Compound 32 
 
1H NMR (600 MHz, MeOD-d4) 
 
 
13C NMR (150.9 MHz, MeOD-d4) 
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Compound 35 
 
 
1H NMR (600 MHz, MeOD-d4) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 36 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 39 
 
1H NMR (600 MHz, DMSO-d6) 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 45 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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1H-13C-HMBC 
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Compound 49 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 50 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 54 
 
1H NMR (600 MHz, DMSO-d6) 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 55 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
 
 9 APPENDIX 329 
 
 
 
1H-13C-HMBC 
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Compound 58 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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Compound 59 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6) 
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1H-13C-HMBC 
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Compound 62 
 
1H NMR (600 MHz, DMSO-d6) 
 
 
13C NMR (150.9 MHz, DMSO-d6)
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9.2 HPLC chromatograms 
9.2.1 MUC1 glycopeptides 
9.2.1.1 TN-antigen glycopeptides 
 
9.2.1.2 T-antigen glycopeptides 
 
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 34.0 36.0 38.0 40.0 42.0 44.0 46.0 48.1
-200
0
125
250
375
500
625
750
875
1,000
1,125
1,250
1,375
1,600
1 - CHRISTIAN_PETT_ANA #1146 [modified by pb2hplc] Pep125Deac_081113_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #1147 [modified by pb2hplc, normalized] Pep126Deac_081113_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #1148 [modified by pb2hplc, normalized] Pep127Deac_081113_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #1149 [modified by pb2hplc, normalized] Pep128Deac_081113_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1150 [modified by pb2hplc, normalized] Pep129Deac_081113_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1151 [modified by pb2hplc, normalized] Pep130Deac_081113_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #1152 [modified by pb2hplc, normalized] Pep131Deac_081113_NP UV_VIS_1
mAU
min
7
1 - 18.297
6
1 - 17.850
5
1 - 17.517
4
1 - 18.953
3
1 - 18.460
2
1 - 17.850
1
1 - 17.343
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 63.0
-1,000
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
1 - CHRISTIAN_PETT_ANA #134 [modified by pb2hplc] Pep57Deac_300113_NP_ANA UV_VIS_1
2 - CHRISTIAN_PETT_ANA #135 [modified by pb2hplc, normalized] Pep58Deac_300113_NP_ANA UV_VIS_1
3 - CHRISTIAN_PETT_ANA #137 [normalized] Pep59Deac_300113_NP_ANA UV_VIS_1
4 - CHRISTIAN_PETT_ANA #138 [modified by pb2hplc, normalized] Pep60Deac_300113_NP_ANA UV_VIS_1
5 - CHRISTIAN_PETT_ANA #139 [normalized] Pep61Deac_300113_NP_ANA UV_VIS_1
6 - CHRISTIAN_PETT_ANA #165 [modified by pb2hplc, normalized] Pep20Deac_190912_ANA_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #184 [modified by pb2hplc, normalized] Pep18Deac__ANA_NP UV_VIS_1
8 - CHRISTIAN_PETT_ANA #1635 [modified by pb2hplc, normalized] Pep140Deac_261214_NP UV_VIS_1
9 - CHRISTIAN_PETT_ANA #1636 [normalized] Pep141Deac_261214_NP UV_VIS_1
mAU
min
9
8
1 - 18.950
7
1 - 14.513
6
1 - 15.187
5
4
1 - 15.600
3
2
1 - 17.380
1
1 - 16.420
WVL:214 nm
(68) PAHGVT*SAPDTRPAPGSTA 
(71) PAHGVT*SAPDT*RPAPGSTA 
(70) PAHGVTSAPDTRPAPGST*A 
(69) PAHGVTSAPDT*RPAPGSTA 
(72) PAHGVT*SAPDTRPAPGST*A 
(73) PAHGVTSAPDT*RPAPGST*A 
(74) PAHGVT*SAPDT*RPAPGST*A 
* = 
 
(75) PAHGVT*SAPDTRPAPGSTA 
 
(76) PAHGVTSAPDT*RPAPGSTA 
(77) PAHGVTSAPDTRPAPGST*A 
(78) PAHGVT*SAPDT*RPAPGSTA 
(79) PAHGVT*SAPDTRPAPGST*A 
(80) PAHGVTSAPDT*RPAPGST*A 
(81) PAHGVT*SAPDT*RPAPGST*A 
(82) PGSTAPPAHGVTSAPDT*RPA 
(83) APDT*RPAPGSTAPPAHGVTSA 
* = 
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9.2.1.3 Core 3 type-1 glycopeptides 
 
9.2.1.4 Core 3 type-2 glycopeptides 
 
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 66.0
-300
-200
-100
0
100
200
300
400
500
600
700
Pep142 UV_VIS_1
mAU
min
#1
 - 
15
.6
75
WVL:214 nm
Flow: 200 µl/min
%B: 5.0 %
21.0
90.0
5.0
%C: 0.0 %
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 87.1
-500
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
1 - CHRISTIAN_PETT_ANA #766 [modified by pb2hplc] Pep106Deac_080713_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #1141 [modified by pb2hplc, normalized] Pep28Deac_301012_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #1142 [modified by pb2hplc, normalized] Pep29Deac_301012_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #1143 [modified by pb2hplc, normalized] Pep27Deac_301012_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1222 [modified by pb2hplc, normalized] Pep32Deac_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1223 [modified by pb2hplc, normalized] Pep33Deac_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #1224 [modified by pb2hplc, normalized] Pep34Deac_NP UV_VIS_1
mAU
min
7
1 - 34.740
6
1 - 33.360
5
1 - 31.497
4
1 - 18.653
3
1 - 20.337
2
1 - 19.657
1
1 - 38.930
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 85.0 90.5
-500
0
500
1,000
1,500
2,000
2,500
3,000
3,500
1 - CHRISTIAN_PETT_ANA #167 [modified by pb2hplc] Pep49Deac_170113_ANA_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #169 [modified by pb2hplc, normalized] Pep42Deac_101212_ANA_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #172 [modified by pb2hplc, normalized] Pep43Deac_101212_ANA_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #173 [modified by pb2hplc, normalized] Pep39Deac_031212_ANA_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #176 [modified by pb2hplc, normalized] Pep38Deac_031212_ANA_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #183 [modified by pb2hplc, normalized] Pep44Deac_170113_ANA_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #185 [modified by pb2hplc, normalized] Pep37Deac__ANA_NP UV_VIS_1
8 - CHRISTIAN_PETT_ANA #1618 [modified by pb2hplc, normalized] Pep138Deac_071114_NP UV_VIS_1
mAU
min
8
1 - 39.310
7
1 - 15.907
6
1 - 15.627
5
1 - 16.800
4
1 - 17.283
3
1 - 14.763
2
1 - 14.133
1
1 - 15.977
WVL:214 nm
(84) APDT*RPA 
(85) PAHGVT*SAPDTRPAPGSTA 
 
(86) PAHGVTSAPDT*RPAPGSTA 
 
(87) PAHGVTSAPDTRPAPGST*A 
 
(88) PAHGVT*SAPDT*RPAPGSTA 
 
(89) PAHGVT*SAPDTRPAPGST*A 
 
(90) PAHGVTSAPDT*RPAPGST*A 
 
(91) PAHGVT*SAPDT*RPAPGST*A 
 
(92) PAHGVT*SAPDTRPAPGSTA 
 
(93) PAHGVTSAPDT*RPAPGSTA 
 (94) PAHGVTSAPDTRPAPGST*A 
 (95) PAHGVT*SAPDT*RPAPGSTA 
 
(96) PAHGVT*SAPDTRPAPGST*A 
 
(97) PAHGVTSAPDT*RPAPGST*A 
 
(98) PAHGVT*SAPDT*RPAPGST*A 
 
(132) PAHGVTSAPDT*RPAPGS°T°APPA 
 
* = 
 
* = 
 
° = 
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9.2.1.5 Core 1 type-1 glycopeptides 
 
9.2.1.6 Core 1 type-2 glycopeptides 
 
0.0 10.0 20.0 30.0 40.0 50.0 60.0 66.0
-100
200
400
600
900
Pep143 UV_VIS_1
mAU
min
#1 
- 1
4.8
26
WVL:214 nm
Flow: 200 µl/min
%B: 5.0 %
21.0
90.0
5.0
%C: 0.0 %
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 87.1
-200
-100
0
100
200
300
400
500
600
700
800
900
1,000
1,100
1,200
1 - CHRISTIAN_PETT_ANA #432 [modified by pb2hplc] Pep70Deac_15-20_160413_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #434 [modified by pb2hplc, normalized] Pep71Deac_13-18_160413_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #437 [modified by pb2hplc, normalized] Pep72Deac_11-15_160413_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #536 [modified by pb2hplc, normalized] Pep76Deac_220413_26-36_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #547 [modified by pb2hplc, normalized] Pep77Deac_220413_23-30_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1137 [modified by pb2hplc, normalized] Pep50Deac_220113_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #1144 [modified by pb2hplc, normalized] Pep51Deac_220113_NP UV_VIS_1
mAU
min
7
1 - 40.717
6
1 - 36.317
5
1 - 32.870
4
1 - 35.040
3
1 - 38.810
2 - 39.240
2
1 - 35.883
1
1 - 43.200
WVL:214 nm
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 101
-200
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
1 - CHRISTIAN_PETT_ANA #439 [modified by pb2hplc] Pep73Deac_17-21_160413_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #441 [modified by pb2hplc, normalized] Pep74Deac_15-22_160413_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #443 [modified by pb2hplc, normalized] Pep75Deac_27-31_160413_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #475 [modified by pb2hplc, normalized] Pep79Deac_20-30_220413_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #486 [normalized] Pep81Deac_220413_26-31_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #550 [modified by pb2hplc, normalized] Pep78Deac_220413_12-22_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #1221 [modified by pb2hplc, normalized] Pep80Deac_NP UV_VIS_1
8 - CHRISTIAN_PETT_ANA #1526 [modified by pb2hplc, normalized] Pep134Deac_250814_NP UV_VIS_1
9 - CHRISTIAN_PETT_ANA #1527 [modified by pb2hplc, normalized] Pep136Deac_250814_NP UV_VIS_1
10 - CHRISTIAN_PETT_ANA #1528 [modified by pb2hplc, normalized] Pep135Deac_250814_NP UV_VIS_1
11 - CHRISTIAN_PETT_ANA #1617 [modified by pb2hplc, normalized] Pep137Deac_071114_NP UV_VIS_1
mAU
min
11
1 - 40.417
10
1 - 39.383
9
1 - 37.307
8
1 - 39.023
7
1 - 31.333
6
1 - 38.863
5
4
1 - 41.527
3
1 - 38.797
2 - 39.287
2
1 - 34.753
2 - 35.570
1
1 - 42.953
2 - 43.527
WVL:214 nm
(100) PAHGVT*SAPDTRPAPGSTA 
 
(101) PAHGVTSAPDT*RPAPGSTA 
 
(102) PAHGVTSAPDTRPAPGST*A 
 
(103) PAHGVT*SAPDT*RPAPGSTA 
 
(104) PAHGVT*SAPDTRPAPGST*A 
 
(105) PAHGVTSAPDT*RPAPGST*A 
 
(106) PAHGVT*SAPDT*RPAPGST*A 
 
* = 
 
* = 
 
(107) PAHGVT*SAPDTRPAPGSTA 
 
(108) PAHGVTSAPDT*RPAPGSTA 
 
(109) PAHGVTSAPDTRPAPGST*A 
 
(110) PAHGVT*SAPDT*RPAPGSTA 
 
(111) PAHGVT*SAPDTRPAPGST*A 
 
(112) PAHGVTSAPDT*RPAPGST*A 
 
(113) PAHGVT*SAPDT*RPAPGST*A 
 
(114) GST*APPAHGVTSAPDTRPA 
 
(115) PDTRPAPGST*APPAHGVTSA 
 
(116) PDTRPAPGSTAPPAHGVT*SA 
 
(115) PAHGVTSAPDT*RPAPGS°T°APPA 
 ° = 
 
(99) PAHGVT*SA 
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9.2.1.7 Core 2 type-1 glycopeptides 
 
9.2.1.8 Core 2 type-2 glycopeptides 
 
 
 
 
 
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 87.1
-200
0
200
400
600
800
1,000
1,200
1,400
1,600
1 - CHRISTIAN_PETT_ANA #827 [modified by pb2hplc] Pep103Deac_080713_67-75_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #829 [modified by pb2hplc, normalized] Pep93Deac_080713_32-40_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #831 [modified by pb2hplc, normalized] Pep94Deac_080713_11-16_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #833 [modified by pb2hplc, normalized] Pep104Deac_080713_22-27_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #835 [modified by pb2hplc, normalized] Pep105Deac_080713_36-41_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #875 [modified by pb2hplc, normalized] Pep107Deac_180713_38-42_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #1139 [modified by pb2hplc, normalized] Pep92Deac_170613_NP UV_VIS_1
mAU
min
7
1 - 33.240
6
1 - 27.690
5
1 - 34.490
4
1 - 31.830
3
1 - 29.837
2
1 - 37.537
1
1 - 40.913
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 85.0 90.5
-100
0
100
200
300
400
500
600
700
1 - CHRISTIAN_PETT_ANA #553 [modified by pb2hplc] Pep89Deac_220513_38-47_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #800 [modified by pb2hplc, normalized] Pep95Deac_100613_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #801 [modified by pb2hplc, normalized] Pep96Deac_100613_10-17_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #879 [modified by pb2hplc, normalized] Pep108Deac_180713_107-115_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #881 [modified by pb2hplc, normalized] Pep109Deac_180713_63-68_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #883 [modified by pb2hplc, normalized] Pep111Deac_180713_39-43_NP UV_VIS_1
7 - CHRISTIAN_PETT_ANA #887 [modified by pb2hplc, normalized] Pep110Deac_180713_75-81_NP UV_VIS_1
8 - CHRISTIAN_PETT_ANA #1619 [modified by pb2hplc, normalized] Pep139Deac_071114_NP UV_VIS_1
mAU
min
8
1 - 36.180
7
1 - 33.613
6
1 - 26.713
5
1 - 32.060
4
1 - 40.940
3
1 - 30.190
2
1 - 38.360
1
1 - 36.453
WVL:214 nm
* = 
 
(124) PAHGVT*SAPDTRPAPGSTA 
 
* = 
 (117) PAHGVT*SAPDTRPAPGSTA 
 
(118) PAHGVTSAPDT*RPAPGSTA 
 
(119) PAHGVTSAPDTRPAPGST*A 
 
(120) PAHGVT*SAPDT*RPAPGSTA 
 
(121) PAHGVT*SAPDTRPAPGST*A 
 
(122) PAHGVTSAPDT*RPAPGST*A 
 
(123) PAHGVT*SAPDT*RPAPGST*A 
 
(125) PAHGVTSAPDT*RPAPGSTA 
 
(126) PAHGVTSAPDTRPAPGST*A 
 
(127) PAHGVT*SAPDT*RPAPGSTA 
 
(128) PAHGVT*SAPDTRPAPGST*A 
 
(129) PAHGVTSAPDT*RPAPGST*A 
 
(130) PAHGVT*SAPDT*RPAPGST*A 
 
(133) PAHGVT*SAPDT*RPAPGS°T°APPA 
 
° = 
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9.2.2 MUC5B glycopeptides 
9.2.2.1 T-antigen glycopeptides 
 
9.2.2.2 Core 3 type-1 glycopeptides 
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 52.5 56.3
-500
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
1 - CHRISTIAN_PETT_ANA #127 [modified by pb2hplc] Pep55Deac_300113_NP_ANA UV_VIS_1
2 - CHRISTIAN_PETT_ANA #128 [modified by pb2hplc, normalized] Pep56Deac_300113_NP_ANA UV_VIS_1
3 - CHRISTIAN_PETT_ANA #161 [modified by pb2hplc, normalized] Pep62Deac_060313_NP_ANA UV_VIS_1
4 - CHRISTIAN_PETT_ANA #162 [modified by pb2hplc, normalized] Pep63Deac_060313_NP_ANA UV_VIS_1
5 - CHRISTIAN_PETT_ANA #168 [modified by pb2hplc, normalized] Pep16Deac_040912_ANA_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #186 [modified by pb2hplc, normalized] Pep14Deac__ANA_NP UV_VIS_1
mAU
min
6
1 - 15.150
5
1 - 14.217
4
1 - 13.790
3
1 - 13.160
2
1 - 15.110
1
1 - 14.243
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 67.0
-500
0
500
1,000
1,500
2,000
2,500
1 - CHRISTIAN_PETT_ANA #1076 [modified by pb2hplc] Pep124Deac_090913_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #1450 [modified by pb2hplc, normalized] Pep25Deac_301012_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #1451 [modified by pb2hplc, normalized] Pep26Deac_301012_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #1452 [modified by pb2hplc, normalized] Pep31Deac_181212_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1453 [modified by pb2hplc, normalized] Pep47Deac_170113_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1454 [modified by pb2hplc, normalized] Pep30Deac_181212_NP UV_VIS_1
mAU
min
6
1 - 14.583
5
1 - 15.260
4
1 - 15.303
3
1 - 16.337
2
1 - 16.413
1
1 - 37.977
WVL:214 nm
(134) ATPSSTPGT*THTP 
 
(135) AT*PSSTPGTTHTP 
 
(136) AT*PSSTPGT*THTP 
 
(137) AT*PSST*PGTTHTP 
 (138) AT*PSST*PGT*THTP 
 (139) T*GSTAT*PSST*PGT*THTP 
 
* = 
 
(140) ATPSSTPGT*THTP 
 
(141) AT*PSSTPGTTHTP 
 
(142) AT*PSSTPGT*THTP 
 
(143) AT*PSST*PGTTHTP 
 
(143) AT*PSST*PGT*THTP 
 
(144) T*GSTAT*PSST*PGT*THTP 
 
* = 
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9.2.2.3 Core 3 type-2 glycopeptides 
 
9.2.2.4 Core 1 type-1 glycopeptides 
 
9.2.2.5 Core 1 type-2 glycopeptides 
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 52.5 56.3
-500
0
500
1,000
1,500
2,000
2,500
1 - CHRISTIAN_PETT_ANA #164 [modified by pb2hplc, normalized] Pep40Deac_060313_ANA_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #166 [modified by pb2hplc] Pep35Deac_101212_ANA_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #174 [modified by pb2hplc, normalized] Pep41Deac_101212_ANA_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #175 [modified by pb2hplc, normalized] Pep36Deac_031212_ANA_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #177 [modified by pb2hplc, normalized] Pep48Deac_170113_ANA_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #196 [modified by pb2hplc, normalized] Pep65Deac_180313_ANA_NP UV_VIS_1
mAU
min
6
1 - 12.913
5
1 - 13.960
4
1 - 14.963
3
1 - 13.707
2
1 - 14.727
1
1 - 13.277
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 77.0
-100
-50
0
50
100
150
200
250
300
350
1 - CHRISTIAN_PETT_ANA #317 [modified by pb2hplc] Pep66Deac_080413_ANA_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #693 [modified by pb2hplc, normalized] Pep82Deac_020513_47-51_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #699 [modified by pb2hplc, normalized] Pep83Deac_020513_20-24_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #706 [modified by pb2hplc, normalized] Pep88Deac_020513_26-32_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1455 [modified by pb2hplc, normalized] Pep52Deac_020513_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1456 [modified by pb2hplc, normalized] Pep53Deac_220113_NP UV_VIS_1
mAU
min
6
1 - 16.227
5
1 - 16.010
4
1 - 31.770
3
1 - 29.770
2
1 - 28.560
1
1 - 14.110
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.0 83.8
-200
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
1 - CHRISTIAN_PETT_ANA #636 [modified by pb2hplc] Pep67Deac_1_020513_ANA_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #642 [modified by pb2hplc, normalized] Pep86Deac_10-14_020513_ANA_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #649 [modified by pb2hplc, normalized] Pep87Deac_1_020513_ANA_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #939 [modified by pb2hplc, normalized] Pep69Deac_180813_80-84_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1457 [modified by pb2hplc, normalized] Pep68Deac_080413_NP UV_VIS_1
6 - CHRISTIAN_PETT_ANA #1458 [modified by pb2hplc, normalized] Pep85Deac_020513_NP UV_VIS_1
mAU
min
6
1 - 28.100
5
1 - 14.667
4
1 - 34.407
3
1 - 32.663
2
1 - 29.547
2 - 30.257
1
1 - 34.210
WVL:214 nm
(146) ATPSSTPGT*THTP 
 
* = 
 
(147) AT*PSSTPGTTHTP 
 (148) AT*PSSTPGT*THTP 
 
(149) AT*PSST*PGTTHTP 
 
(150) AT*PSST*PGT*THTP 
 
(151) T*GSTAT*PSST*PGT*THTP 
 
(152) ATPSSTPGT*THTP 
 
(153) AT*PSSTPGTTHTP 
 
(154) AT*PSSTPGT*THTP 
 
(155) AT*PSST*PGTTHTP 
 
(156) AT*PSST*PGT*THTP 
 
(157) T*GSTAT*PSST*PGT*THTP 
 
* = 
 
(158) ATPSSTPGT*THTP 
 
(159) AT*PSSTPGTTHTP 
 
(160) AT*PSSTPGT*THTP 
 
(161) AT*PSST*PGTTHTP 
 
(162) AT*PSST*PGT*THTP 
 
(163) T*GSTAT*PSST*PGT*THTP 
 
* = 
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9.2.2.6 Core 2 type-1 glycopeptides 
 
9.2.2.7 Core 2 type-2 glycopeptides 
 
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.4
-200
500
1,000
1,600
1 - CHRISTIAN_PETT_ANA #984 [modified by pb2hplc] Pep115Deac_160813_35-39_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #996 [modified by pb2hplc, normalized] Pep114Deac_160813_34-39_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #1048 [modified by pb2hplc, normalized] Pep118Deac_280813_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #1095 [normalized] Pep119Deac_020913_61-66_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1108 [modified by pb2hplc, normalized] Pep112Deac_130813_80-84_NP UV_VIS_1
mAU
min
5
1 - 40.517
4
3
1 - 24.167
2
1 - 30.777
1
1 - 25.397
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 70.0 75.0 80.4
-200
500
1,000
1,500
1,800
1 - CHRISTIAN_PETT_ANA #998 [modified by pb2hplc] Pep116Deac_160813_61-67_NP UV_VIS_1
2 - CHRISTIAN_PETT_ANA #1000 [modified by pb2hplc, normalized] Pep117Deac_160813_34-39_NP UV_VIS_1
3 - CHRISTIAN_PETT_ANA #1049 [modified by pb2hplc, normalized] Pep120Deac_280813_38-43_NP UV_VIS_1
4 - CHRISTIAN_PETT_ANA #1098 [modified by pb2hplc, normalized] Pep121Deac_020913_64-69_NP UV_VIS_1
5 - CHRISTIAN_PETT_ANA #1110 [modified by pb2hplc, normalized] Pep113Deac_130813_65-69_NP UV_VIS_1
mAU
min
5
1 - 41.000
4
1 - 28.323
3
1 - 24.627
2
1 - 25.403
1
1 - 30.903
WVL:214 nm
* = 
 
(164) ATPSSTPGT*THTP 
 
(165) AT*PSSTPGTTHTP 
 
(166) AT*PSSTPGT*THTP 
 
(167) AT*PSST*PGTTHTP 
 
(168) AT*PSST*PGT*THTP 
 
(169) ATPSSTPGT*THTP 
 
(170) AT*PSSTPGTTHTP 
 
(171) AT*PSSTPGT*THTP 
 
(172) AT*PSST*PGTTHTP 
 
(173) AT*PSST*PGT*THTP 
 
* = 
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9.2.3 Sialylated MUC1 glycopeptides 
9.2.3.1 2,3-ST-antigen glycopeptides 
 
9.2.3.2 Sialylated core 3 type-2 glycopeptides 
 
 
 
 
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 67.6
-1,500
-1,200
-1,000
-800
-600
-400
-200
0
200
400
600
800
1,000
1 Pep59Sia F6-7 2,3OST_NP UV_VIS_1
2 Pep18Sia F39+45 2,3OST_NP UV_VIS_1
3 Pep58Sia F41-42 2,3OST_NP UV_VIS_1
4 Pep61Sia F48 2,3OST_NP UV_VIS_1
5 Pep20Sia F52 2,3OST_NP UV_VIS_1
6 Pep60Sia F55 2,3OST_NP UV_VIS_1
7 Pep57Sia F30-31 2,3OST_NP UV_VIS_1
mAU
min
7
#
1
 -
 2
6
.8
0
5
6
#
1
 -
 2
8
.4
5
4
5
#
1
 -
 2
9
.5
3
8
4
#
1
 -
 3
2
.5
9
5
3
#
1
 -
 2
9
.7
5
8
2
#
1
 -
 2
7
.3
3
4
#
2
 -
 3
0
.8
5
3
1
#
1
 -
 3
0
.7
3
6
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 67.6
-2,000
-1,500
-1,000
-500
0
500
1,000
1,500
1 Pep38Sia F57-58 PmST3_NP UV_VIS_1
2 Pep37Sia F82-83 PmST1_NP UV_VIS_1
3 Pep38Sia F7-8 Pd2,6ST_NP UV_VIS_1
4 Pep39Sia F14-15 Pd2,6ST_NP UV_VIS_1
5 Pep39Sia F17-18 PmST1_NP UV_VIS_1
6 Pep37Sia F23-24 Pd2,6ST_NP UV_VIS_1
7 Pep42Sia F28 Pd2,6ST_NP UV_VIS_1
mAU
min
7
#
1
 -
 2
9
.6
4
8
6
#
1
 -
 2
6
.5
1
1
5
#
1
 -
 3
0
.8
9
4
4
#
1
 -
 3
0
.5
5
9
3
#
1
 -
 2
9
.1
4
0
2
#
1
 -
 2
6
.6
7
8
1
#
1
 -
 2
9
.7
9
4
WVL:214 nm
(175) PAHGVT*SAPDTRPAPGSTA 
 
(176) PAHGVTSAPDT*RPAPGSTA 
 
(177) PAHGVTSAPDTRPAPGST*A 
 
(178) PAHGVT*SAPDT*RPAPGSTA 
 
(179) PAHGVT*SAPDTRPAPGST*A 
 
(180) PAHGVTSAPDT*RPAPGST*A 
 
(181) PAHGVT*SAPDT*RPAPGST*A 
 
* = 
 
(182) PAHGVT*SAPDTRPAPGSTA 
 
(183) PAHGVTSAPDT*RPAPGSTA 
 
(184) PAHGVTSAPDTRPAPGST*A 
 
(185) PAHGVT°SAPDTRPAPGSTA 
 
(186) PAHGVTSAPDT°RPAPGSTA 
 
(187) PAHGVTSAPDTRPAPGST°A 
 
(188) PAHGVT°SAPDT°RPAPGST°A 
 
* = 
° = 
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9.2.3.3 Sialylated core 1 type-1 glycopeptides 
 
9.2.3.4 Sialylated core 1 type-2 glycopeptides 
 
 
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 59.8
-1,000
-800
-600
-400
-200
0
200
400
600
800
1 Pep51Sia F11-12 PmST1_NP UV_VIS_1
2 Pep70Sia F17-18 Pd2,6St_NP UV_VIS_1
3 Pep70Sia F19+42 Pd2,6St_NP UV_VIS_1
4 Pep70Sia F31-32+59-60 PmST1_NP UV_VIS_1
mAU
min
4
#
1
 -
 3
0
.1
2
9
3
#
1
 -
 3
3
.8
8
4
2
#
1
 -
 2
9
.3
3
6
1
#
1
 -
 2
8
.9
6
8
WVL:214 nm
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 67.6
-500
0
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1,000
1,500
2,000
2,500
3,000
1 Pep73Sia F14 Pd2,6St_NP UV_VIS_1
2 Pep73Sia F15 Pd2,6St_NP UV_VIS_1
3 Pep79Sia F34-35+62-63 PmST1_NP UV_VIS_1
4 Pep73Sia F66-67 PmST1_NP UV_VIS_1
5 Pep78Sia F10-11 PmST3_NP UV_VIS_1
6 Pep79Sia F20-21 PmST3_NP UV_VIS_1
7 Pep79Sia F25-26 Pd2,6ST_NP UV_VIS_1
mAU
min
7
#
1
 -
 2
8
.8
2
5
6
#
1
 -
 2
9
.1
4
9
5
#
1
 -
 2
5
.5
4
4
4
#
1
 -
 3
0
.2
6
3
3
#
1
 -
 2
9
.2
3
2
2
#
1
 -
 3
4
.0
0
0
1
#
1
 -
 2
9
.7
5
2
WVL:214 nm
(189) PAHGVTSAPDT*RPAPGSTA 
 
(191) PAHGVTSAPDTRPAPGST°A 
 
(190) PAHGVTSAPDTRPAPGST*A 
 
(192) PAHGVTSAPDTRPAPGST
#
A 
 
* = ° = # = 
(193) PAHGVT*SAPDTRPAPGSTA 
 
(194) PAHGVTSAPDT*RPAPGSTA 
 
(195) PAHGVTSAPDT°RPAPGSTA 
 
(196) PAHGVTSAPDTRPAPGST*A 
 
(197) PAHGVTSAPDTRPAPGST°A 
 
(198) PAHGVTSAPDTRPAPGST
#
A 
 
(199) PAHGVT*SAPDT*RPAPGST*A 
 
* = 
° = 
#
 = 
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9.2.3.5 Sialylated core 2 type-1 glycopeptides 
 
9.2.3.6 Sialylated core 2 type-2 hexasaccharide glycopeptides 
 
9.2.3.7 Sialylated core 2 type-2 tetrasaccharide glycopeptides 
 
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 52.0
-600
-400
-200
0
200
400
600
800
1,000
Pep103Sia F24+53 Pd2,6St_NP UV_VIS_1
mAU
min
#1
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3
WVL:214 nm
Flow: 200 µl/min
%B: 5.0 %
15.0
90.0
5.0
%C: 0.0 %
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 59.8
-800
-600
-400
-200
0
200
400
600
800
1,000
1 Pep108Sia F21+50 Pd2,6St_NP UV_VIS_1
2 Pep108Sia F22+51 Pd2,6St_NP UV_VIS_1
3 Pep95Sia F29+57 PmST1_NP UV_VIS_1
4 Pep95Sia F62-63 Pd2,6ST_NP UV_VIS_1
mAU
min
4
#
1
 -
 2
9
.6
2
7
3
#
1
 -
 3
0
.6
8
3
2
#
1
 -
 3
6
.3
1
2
1
#
1
 -
 3
2
.0
8
0
WVL:214 nm
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 54.6
-600
-250
0
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500
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1,000
1 MSP27Sia F72-73 PmST3_NP UV_VIS_1
2 MSP27Sia F77-78 2,3OST_NP UV_VIS_1
mAU
min
2
#
1
 -
 2
6
.8
1
5
1
#
1
 -
 2
7
.1
2
5
WVL:214 nm
(200) PAHGVTSAPDTRPAPGST*A 
 
* = 
(201) PAHGVTSAPDT*RPAPGSTA 
 
(202) PAHGVTSAPDT°RPAPGSTA 
 
(203) PAHGVTSAPDTRPAPGST°A 
 
(204) PAHGVTSAPDTRPAPGST
#
A 
 
* = ° = # = 
(205) PAHGVTSAPDT*RPAPGSTA 
 
(206) PAHGVTSAPDT°RPAPGSTA 
 
* = ° = 
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9.3 Microarray data 
9.3.1 Microarray format 1 (MA1) 
 
dilutions 
CHSynB mouse1 CHSynB mouse2 CHSynB mouse3 
MEAN SD MEAN SD MEAN SD 
1/50 54946 3310   
 
  
 
1/100 53555 4396   
 
  
 
1/200 51492 6835   
 
  
 
1/400 40443 4856   
 
  
 
1/800 36667 1125   
 
  
 
1/1600 26935 1258   
 
  
 
1/3200 16533 1234   
 
  
 
1/6400 6657 393   
 
  
 
1/12800 2088 228   
 
  
 
1/25600 405 45   
 
  
 
1/51200 42 29   
 
  
 
        
 
  
 
1/2.5     43349 1473 42988 1744 
1/5     38635 955 43571 934 
1/10     33123 990 40318 1125 
1/20     23765 664 30123 479 
1/40     14461 349 21954 1445 
1/80     7101 341 11775 708 
1/160     2398 154 5780 164 
1/320     793 59 1770 120 
1/640     225 56 418 59 
1/1280     13 18 90 47 
1/2560       
 
7 9 
        
 
  
 
  HC12 mouse 1  HC12 mouse 2 HC12 mouse 3 
1/2.5 64563 2516 49077 2142 63379 3050 
1/5 66021 1736 43833 1444 66021 1736 
1/10 65771 3095 43975 954 50004 1244 
1/20 66284 3071 37130 973 32381 2388 
1/40 60681 1472 25189 997 27774 447 
1/80 51283 2650 14614 462 11048 894 
1/160 26617 715 7508 658 4561 317 
1/320 12247 664 2684 177 1447 147 
1/640 2589 200 566 65   
 
1/1280 137 33   
 
  
 
        
 
  
 
  HC11 mouse 1  HC11 mouse 2 HC11 mouse 3 
1/2.5 19840 1509 51786 1310 78344 7167 
1/5 16338 698 51147 2626 70605 5704 
1/10 8226 294 52594 8161 54613 3986 
1/20 2988 92 49326 4533 30509 1261 
1/40 1251 83 46371 2668 12502 525 
1/80 424 42 31703 949 3910 186 
1/160 163 29 19683 1188 1244 67 
1/320 44 21 9051 245 315 21 
1/640     3540 113 145 30 
1/1280     1176 56 7 10 
1/2560     255 29   
 
1/5120     55 21   
 
        
 
  
 
 
 
 
 
 
 
 
 
 
dilutions 
SH127 mouse 1 SH127 mouse 2 SH127 mouse 3 
MEAN SD MEAN SD MEAN SD 
1/200 62590 5033 11584 418 110210 2384 
1/400 59026 1334 5723 222 110609 1827 
1/800 58486 1001 2117 243 85695 2251 
1/1600 57341 1196 302 109 54822 2209 
1/3200 50479 1217   
 
35390 1341 
1/6400 43329 426   
 
19952 413 
1/12800 37002 505   
 
10754 635 
1/25600 19144 750   
 
3439 249 
1/51200 7800 389   
 
583 74 
1/102400 1913 144   
 
45 25 
1/204800 134 121   
 
  
 
        
 
  
 
  AuNP mouse 1 AuNP mouse 2 AuNP mouse 3 
1/1 21494 619 64996 4537 103300 5189 
1/5 7099 399 53141 1939 91688 3829 
1/10 2568 89 26825 1411 79229 3538 
1/20 684 108 11868 420 54220 4860 
1/40 80 36 4570 265 29669 1997 
1/80 38 12 1544 138 14841 521 
1/160 20 19 7 8 6674 377 
1/320 6 8 319 118 2267 270 
1/40 4 11 62 16 827 86 
1/1280     8 11 132 32 
1/2560     6 11 58 24 
1/5120     4 8 26 27 
        
 
  
 
  HC1 mouse1 HC1 mouse2 HC1 mouse3 
1/2.5 63527 5046 54111 2154 50186 3917 
1/5 62061 2206 47775 1067 40651 731 
1/10 50415 1463 49493 1610 44398 1059 
1/20 46051 2159 33947 619 43962 1607 
1/40 38956 1901 27338 1554 31643 1434 
1/80 25783 1341 12514 447 21719 1111 
1/160 12102 896 5187 154 10735 252 
1/320 5732 329 1266 37 5295 236 
1/640 2317 122 211 45 2155 108 
1/1280 1058 165   
 
1032 73 
1/2560 21 15   
 
96 35 
        
 
  
 
  HC2 mouse 1 HC2 mouse 2 HC2 mouse 3 
1/2.5 9654 422 15349 360 7498 206 
1/5 8013 438 13160 236 5283 180 
1/10 5924 315 10729 386 3557 196 
1/20 3043 90 8176 360 1540 88 
1/40 1523 103 4699 219 523 66 
1/80 423 37 2556 156 191 82 
1/160 128 71 933 113   
 
1/320     382 57   
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9.3.2 Microarray format 2 (MA2) 
Vaccine candidate 1 (CHSynB): 
Peptides 
mouse1 (1/500) mouse1 (1/2500) mouse1 (1/10000) mouse2 (1/10) mouse2 (1/50) mouse2 (1/200) mouse3 (1/10) mouse3 (1/50) mouse3 (1/200) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 6010 1416 842 108 33 34 1387 484 125 57 14 6 15 17 1 2 4 7 
230 11369 3288 1875 339 66 50 2162 743 220 120 9 10 41 48 2 4 7 7 
229 8767 2074 1546 221 2 4 1924 88 179 28 4 5 21 12 2 4 1 2 
130 2 4 2 4 10 8 6 8 0 0 1 2 324 239 2 4 1 1 
129 25 33 7 9 4 4 13 24 1 1 1 2 4641 1213 2141 646 420 91 
128 7718 2380 963 230 30 28 16 13 3 4 1 2 7 11 1 2 4 6 
127 10 12 2 4 2 4 10 17 0 0 1 2 1107 501 207 222 118 67 
126 15996 3144 3707 321 181 83 1646 539 290 51 7 7 26 23 1 3 0 0 
125 449 246 5 9 5 8 585 153 0 0 2 3 10493 1793 4351 410 1574 388 
124 4627 1108 421 69 2 3 62 53 11 11 2 2 2 3 3 4 4 9 
123 3 4 7 7 2 2 0 0 0 0 4 5 127 81 0 1 16 11 
122 11 13 2 2 5 6 102 99 0 1 0 0 2321 150 699 490 44 58 
121 1909 252 27 31 0 0 2 4 0 0 0 0 6 6 0 0 3 3 
120 3 3 3 6 0 0 9 15 17 2 3 4 195 126 0 0 1 2 
119  16138 2989 3230 393 51 57 1769 312 151 30 1 2 61 46 1 2 2 3 
118 42 30 1 2 4 6 1583 246 57 54 1 2 6325 691 2124 430 500 195 
117 1038 270 32 39 8 8 6 10 0 0 3 4 14 20 7 7 0 0 
113 1835 177 207 192 13 13 599 150 59 14 4 5 14137 2481 6412 539 2630 409 
112 6427 1603 853 208 38 41 5447 1080 558 125 10 11 28876 2971 13074 1292 6403 907 
111 4044 551 358 75 22 31 4 6 2 2 1 2 15 26 1 2 2 4 
110 1052 226 12 15 0 0 1408 600 138 59 0 1 13287 3574 5090 794 1301 576 
109 15335 3620 2585 512 113 42 2084 660 173 103 2 4 49 44 8 10 0 0 
108 6378 826 733 161 21 36 8416 1375 1443 240 20 22 33052 3498 13834 1183 6165 406 
107 2801 590 191 52 5 12 131 37 6 9 1 2 17 22 2 2 8 9 
106 2109 433 148 109 7 11 1168 230 34 30 5 4 12375 1296 7915 532 2781 547 
105 7120 1379 951 239 14 22 3802 982 552 113 32 14 21963 2167 13186 3696 5915 618 
104 5109 1383 619 193 5 9 18 14 3 4 2 2 17 22 0 0 4 6 
103 1427 232 89 84 4 5 1982 385 134 51 1 2 14304 1646 6385 748 2210 183 
102 16976 1144 3096 310 75 64 1931 242 202 122 5 6 134 69 1 1 1 2 
101 5755 1393 657 208 16 22 7318 1866 795 438 19 17 29024 4648 12716 1696 5198 370 
100 3282 710 205 89 16 17 242 106 8 14 1 1 20 28 6 8 2 3 
98 2794 477 240 44 3 5 2535 397 310 71 7 7 15090 1669 8031 510 2764 277 
97 7863 1123 1123 151 8 15 7083 769 684 83 35 17 19981 2369 12812 818 6530 486 
96 6057 1371 670 235 0 1 59 52 4 5 3 4 3 5 9 7 3 4 
95 2137 593 98 80 12 14 2501 550 489 119 2 4 12303 1606 7403 582 3131 271 
94 14767 1690 2723 233 30 39 2437 434 261 118 0 0 452 113 1 2 0 0 
93 6995 677 927 122 14 30 8499 1328 1396 334 21 15 26195 2553 13519 639 5643 588 
92 3293 1057 293 109 17 22 771 326 135 94 1 2 15 26 0 1 3 5 
91 3974 668 238 153 4 9 2933 388 315 77 5 9 18856 2492 8406 934 3592 238 
90 7894 1014 1308 122 16 17 6030 811 919 94 34 29 21028 2451 13039 829 6817 477 
89 5915 1328 861 190 23 16 188 62 7 8 0 0 21 23 3 4 0 0 
88 3308 842 310 79 8 11 3231 500 406 42 16 13 14385 1548 8525 836 3739 393 
87 18379 2837 4480 463 88 75 3400 776 308 59 14 12 423 205 0 0 1 2 
86 7820 964 1142 128 14 34 10067 1451 1629 175 17 37 34835 2865 17083 1241 7097 513 
85 3216 559 296 71 20 30 555 262 60 64 3 6 13 18 1 2 1 2 
81 4391 952 430 161 2 3 4405 1026 561 227 1 2 18446 2709 8953 823 4113 657 
80 8638 1525 1262 219 16 18 8070 554 1503 227 38 33 22901 3166 12935 1505 7092 656 
79 6374 1028 511 87 4 10 49 29 20 5 0 0 16 18 2 4 1 3 
78 3129 471 160 81 0 0 4027 645 445 55 2 6 13150 1623 8024 625 2837 228 
77 17397 2514 3135 677 11 20 2840 544 431 54 8 8 646 322 0 0 0 0 
76 8554 1688 1353 294 0 0 10346 2211 1239 197 68 34 28294 2854 12731 1697 6036 655 
75 1928 313 168 28 6 7 251 126 2 3 1 2 8 13 5 5 3 4 
235 10150 786 1866 152 50 59 517 74 14 17 2 4 1094 363 0 0 0 0 
234 7632 877 1256 119 3 8 4598 802 408 54 2 4 18117 2034 9722 880 5465 607 
228 3051 684 343 41 1 3 3549 526 369 157 9 14 9 7 3 8 2 4 
227 9076 1495 1553 314 11 20 1293 153 106 32 10 12 137 52 0 0 17 5 
226 10731 1846 1270 360 12 21 3165 547 189 47 21 8 223 116 1 3 0 1 
225 4834 994 373 131 51 36 2030 455 207 42 2 4 15 16 5 7 3 8 
224 5104 489 528 81 0 0 5080 761 615 163 4 4 12681 1579 8922 504 4438 537 
223 2281 377 170 89 3 4 1030 176 23 15 1 3 13 14 1 2 0 0 
222 3456 874 283 68 17 12 478 154 19 11 4 4 16 17 3 5 0 0 
74 28170 1568 10374 1098 2551 260 4644 707 588 191 11 15 13788 1913 6683 713 2215 444 
73 31497 3484 11156 1603 2924 738 6198 1447 685 288 0 0 16760 2936 8984 993 4794 556 
72 6916 1249 847 220 8 20 355 133 6 9 4 5 13 13 3 6 13 12 
71 30311 2240 9646 830 2410 276 4000 609 436 99 21 24 12379 2043 7260 431 2353 355 
70 11487 1649 2126 196 11 22 2328 465 363 46 0 0 94 74 4 6 1 2 
69 29778 4701 10354 1156 2810 214 5628 857 598 47 7 14 15223 2730 7373 420 3883 513 
68 3797 850 266 113 39 35 156 76 2 4 1 3 9 6 5 8 4 5 
233 57695 6613 27832 4021 8541 947 24507 2227 15729 1063 4329 718 23589 3268 8603 671 3543 652 
232 124412 5754 55900 2607 13999 618 27929 2653 18701 1646 6538 633 45354 5204 22225 1117 11450 377 
221 4762 832 594 57 50 52 1783 343 163 46 16 12 32 28 0 0 0 0 
220 45824 5949 15433 2753 4285 359 8581 1821 966 403 79 31 22310 3606 12588 614 6638 453 
219 10912 2427 2493 444 42 47 2359 411 328 137 4 7 668 147 0 0 9 9 
218 9828 1437 1591 309 0 0 1842 746 198 66 3 5 152 104 0 0 6 6 
217 3621 784 359 72 16 38 315 162 0 0 6 8 6 7 5 6 4 4 
216 10447 1170 1652 245 80 62 3226 662 385 53 16 16 27 32 6 8 2 4 
215 26176 2031 10181 694 2299 617 5988 914 770 160 23 20 13231 1580 9296 1068 3943 735 
214 347 252 4 6 3 6 28 23 2 3 2 4 6 7 2 3 3 6 
213 2 2 0 0 2 4 0 0 1 2 2 4 12 14 1 2 7 8 
212 1232 418 148 82 14 14 1466 290 194 7 12 9 16 13 2 3 11 11 
211 3212 577 224 118 5 8 1665 218 177 145 13 10 8 8 0 1 4 4 
210 11650 1846 1989 300 11 19 4071 963 352 164 20 19 192 102 10 11 6 7 
209 18990 2697 5887 1203 1303 789 5209 1256 465 103 11 9 16848 2706 8841 1103 4244 648 
208 2490 370 170 52 0 0 724 146 120 43 15 11 14 19 0 0 3 6 
207 10539 2774 1616 375 7 14 4030 1015 457 71 22 15 238 167 0 0 9 12 
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Vaccine candidate 2 (HC12): 
Peptides 
mouse1 (1/80) mouse2 (1/20) mouse2 (1/80) mouse2 (1/320) mouse3 (1/20) mouse3 (1/80) mouse3 (1/320) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 285 295 4140 1061 957 292 280 148 61 72 74 30 11 14 
230 515 249 7671 1798 2352 296 553 97 209 106 3 7 6 16 
229 517 194 4513 888 1209 450 246 133 400 144 69 74 20 30 
130 79 103 509 191 17 26 16 40 12 20 0 0 9 23 
129 41 41 5360 1114 2821 1133 747 158 18 0 115 55 37 42 
128 32 48 1911 672 442 159 200 65 50 91 84 18 7 17 
127 52 60 1347 436 400 81 0 0 81 73 44 65 65 68 
126 87 112 5278 1136 1627 352 337 119 139 109 5 7 6 15 
125 190 147 21159 3045 9723 1637 3162 627 110 145 6 12 40 47 
124 5 12 1830 590 287 161 8 19 #DIV/0! #DIV/0! 11 11 44 60 
123 77 88 111 144 20 38 38 54 0 0 2 6 0 0 
122 27 40 5250 447 1716 171 428 143 39 53 8 16 50 54 
121 71 77 520 179 68 84 1 2 71 93 17 27 25 45 
120 38 62 335 85 90 94 10 26 13 25 0 0 0 0 
119  32 42 5007 994 1440 353 401 113 16 21 9 15 30 52 
118 45 50 11781 1216 3979 666 913 192 60 71 0 0 45 58 
117 18 #DIV/0! 666 195 80 82 0 0 38 67 20 33 59 61 
113 5 7 15563 2886 5564 1386 1978 413 10117 2317 2312 430 534 85 
112 182 142 39780 4491 21732 4387 7805 1605 23033 4963 5674 1330 1290 188 
111 28 50 1152 393 148 112 41 43 39 74 2 6 0 0 
110 73 112 10984 2613 4899 1441 1749 687 9252 2565 2731 144 437 108 
109 9 0 4842 962 1269 375 238 173 2 4 53 72 2 5 
108 216 76 49570 5503 32235 6459 12460 2592 33136 7091 7156 1371 1690 378 
107 24 32 1297 301 191 78 17 44 29 67 41 41 14 19 
106 103 87 19665 2156 8241 1217 2643 403 12026 2473 2671 569 496 115 
105 283 127 43452 4252 27105 5753 9525 2362 26141 5597 7650 1301 1837 316 
104 21 38 924 417 18 52 14 33 0 0 2 5 24 41 
103 15 #DIV/0! 24290 3118 11334 1237 3797 405 13973 2304 3240 548 660 113 
102 67 78 4289 717 1140 250 142 127 36 79 8 19 20 28 
101 256 135 51469 6287 31766 6502 12296 1443 31948 7253 6470 417 1842 140 
100 56 71 1421 377 34 53 31 51 0 0 0 0 27 51 
98 3 6 29085 900 17214 2901 6190 825 19430 3939 4545 669 1161 324 
97 305 131 44296 3214 31058 6052 11889 2466 28230 6415 6582 1320 1836 211 
96 48 72 1776 390 226 127 15 22 0 0 17 26 64 58 
95 131 123 30585 3740 16491 3355 6120 1195 14640 2927 3749 447 776 106 
94 35 61 6812 903 2085 381 463 90 0 0 0 0 6 14 
93 255 167 47111 3694 32655 5930 11927 1898 29076 5130 7255 1651 1730 227 
92 76 81 1265 657 146 169 8 14 0 0 7 13 10 25 
91 458 142 32310 4165 18388 3088 6749 790 17814 3450 3962 262 1066 178 
90 780 170 45941 3114 34396 6338 13343 2303 29378 6202 7449 1461 1832 517 
89 254 164 2435 500 496 153 59 84 718 278 83 59 3 7 
88 212 191 31226 2905 17738 3109 6215 1219 14406 3272 3347 691 635 130 
87 318 107 6697 1127 2070 410 582 150 445 240 53 73 0 0 
86 519 116 57473 5293 38106 5438 15094 2569 30977 5280 7845 1335 1507 262 
85 87 78 1364 379 51 72 4 9 0 0 0 0 0 0 
81 75 56 23830 3812 13930 2806 5346 637 18137 5275 3809 274 1068 156 
80 374 242 40973 4364 30298 6147 12106 1943 30103 7526 6966 517 1711 311 
79 81 92 1351 579 151 150 18 29 0 0 0 0 0 0 
78 14 16 22916 1042 13990 1328 4823 553 18844 4578 4389 646 875 281 
77 31 31 5897 1002 1703 455 487 116 0 0 0 0 6 17 
76 366 212 44528 3635 30909 5700 11396 2212 33250 9052 8340 2048 1727 332 
75 23 25 853 214 154 229 20 32 0 0 0 0 1 3 
235 36 0 6263 817 1704 350 461 110 66 90 6 13 20 35 
234 277 255 36034 3457 27116 5715 10297 1630 21610 4818 6124 724 1121 190 
228 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
227 86 97 4896 681 1504 346 488 104 33 55 0 0 8 20 
226 82 93 5245 628 1556 333 390 132 0 0 0 0 0 0 
225 45 57 2905 858 625 339 82 101 23 44 33 53 13 23 
224 268 159 39462 4672 29860 6533 11219 2750 28321 5469 8419 1145 1657 327 
223 59 68 1193 427 66 92 26 47 0 0 0 0 7 13 
222 0 0 1934 693 349 155 5 9 0 0 0 0 1 2 
74 482 162 35506 4509 22892 3290 9119 1453 48502 8424 14789 2817 2665 394 
73 0 0 48848 7328 36080 5806 17037 1835 71673 17470 19680 4186 4951 723 
72 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
71 25 42 44014 5145 28797 5009 12019 1387 69022 13907 20336 2730 4190 733 
70 401 193 3459 553 780 287 190 145 0 0 0 0 0 0 
69 74 68 49615 5734 34132 6039 13678 2278 75144 15585 25984 4313 4639 1108 
68 62 67 1172 213 162 149 35 51 8 22 0 0 0 0 
233 80240 9915 9613 408 2905 1050 1127 247 55347 10674 41623 1902 12489 1193 
232 99975 8144 73219 14051 52716 10248 25362 3627 174478 19804 83163 7569 24558 2462 
221 0 0 214 313 7 18 13 35 0 0 0 0 0 0 
220 777 295 61437 9992 45267 8929 21971 4495 96356 20976 32171 4204 7197 1363 
219 25 43 5620 1048 1807 459 451 71 0 0 0 0 0 0 
218 75 78 6826 1182 2302 360 586 53 140 155 18 24 18 44 
217 49 68 2556 641 519 382 51 72 0 0 64 86 4 6 
216 591 256 5063 957 1155 499 263 149 0 0 0 0 25 39 
215 1007 232 35987 5917 23597 4716 9671 1115 51160 12135 18211 2618 3939 779 
214 149 127 552 281 74 103 40 62 17 38 0 0 2 6 
213 49 118 9 15 8 11 145 109 8 23 17 23 51 70 
212 28 45 295 207 18 51 0 0 0 0 0 0 0 0 
211 45 93 1970 462 417 155 123 82 73 94 0 0 36 50 
210 99 107 5857 1073 1607 457 349 98 22 39 0 0 14 35 
209 419 187 25605 4027 12394 3054 4894 596 15751 1904 7731 772 1603 520 
208 58 94 1865 474 411 234 51 46 89 104 16 19 0 0 
207 76 89 4905 1200 1273 360 434 79 0 0 0 0 27 32 
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Vaccine candidate 3 (HC11): 
Peptides 
mouse1 (1/10) mouse1 (1/40) mouse2 (1/80) mouse2 (1/640) mouse3 (1/20) mouse3 (1/80) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
(231) 13 13 3 4 29194 4645 7165 747 4 8 1 2 
(230) 32 26 12 14 32993 7474 9463 1283 40 25 4 5 
(229) 2018 750 316 218 36824 19343 13071 3662 16 16 5 5 
(130) 9 11 11 13 0 1 6 6 12 15 5 8 
(129) 12 13 10 10 6 10 6 12 13 11 1 1 
(128) 12 12 4 6 13134 2147 2128 653 7 11 7 9 
(127) 4 9 8 10 9 12 7 15 8 9 3 6 
(126) 1553 415 187 117 15160 1880 4016 913 11 15 4 6 
(125) 23 17 5 7 11 17 5 11 13 16 6 6 
(124) 8 12 8 12 19320 4034 4059 582 11 18 12 9 
(123) 2 3 3 6 2 2 6 11 9 9 8 8 
(122) 13 13 2 4 4 8 4 7 8 10 2 5 
(121) 10 10 7 10 9441 1601 1489 528 4 9 0 0 
(120) 1 2 8 8 9 13 2 6 5 7 0 0 
(119)  2190 499 295 128 17694 1507 4788 1306 7 10 0 1 
(118) 22 22 4 4 10 11 7 7 1 3 2 4 
(117) 16 13 7 9 26021 4143 5191 648 9 9 0 0 
(113) 12 14 7 9 5 10 12 11 7 10 5 5 
(112) 10 14 11 14 5 12 7 7 12 11 0 1 
(111) 3 6 3 4 15546 4804 2915 1073 7 12 2 3 
(110) 10 15 3 5 6 10 9 11 10 9 10 11 
(109) 591 343 59 39 26147 3666 5852 1399 11 14 14 7 
(108) 40 35 10 15 21 47 4 10 8 6 10 13 
(107) 8 13 5 6 31235 2675 7071 1293 8 13 5 6 
(106) 7 12 1 2 8 15 5 6 15 17 1 3 
(105) 9 13 6 8 8 17 5 13 9 9 2 4 
(104) 16 16 6 5 14706 3675 3025 977 3 6 0 0 
(103) 3 5 5 6 8 16 5 7 2 3 1 3 
(102) 855 447 102 97 22349 2730 4795 1200 9 16 4 5 
(101) 22 30 1 2 4 5 6 12 10 14 6 10 
(100) 61 153 11 14 37276 2080 7776 1929 11 18 2 3 
(98) 7 10 5 8 11 14 9 13 7 13 1 3 
(97) 36 50 5 13 2 4 8 8 8 10 1 2 
(96) 12 15 5 8 15875 2810 4210 765 5 7 7 10 
(95) 11 9 6 11 4 8 8 11 7 9 3 4 
(94) 2762 527 574 149 19597 3471 5783 1411 13 15 2 5 
(93) 18 14 3 6 6 9 5 13 5 7 0 0 
(92) 14 24 9 14 25536 3944 5691 1423 5 9 2 3 
(91) 264 144 48 29 16 19 9 6 15 11 14 13 
(90) 686 173 221 405 147 387 3 9 6 9 8 10 
(89) 298 367 22 29 17044 1411 4284 623 8 8 1 1 
(88) 8 9 14 17 15 19 6 7 15 14 0 1 
(87) 3349 775 678 204 21710 3698 5474 1210 6 11 0 0 
(86) 272 138 52 32 8 14 7 12 13 15 5 3 
(85) 6 8 1 4 25502 3963 6232 1195 1 3 3 4 
(81) 8 11 10 15 20 25 3 7 9 14 1 2 
(80) 669 300 95 39 13 15 5 6 13 15 0 0 
(79) 14 11 8 12 18230 1709 4841 513 5 8 1 2 
(78) 11 9 8 12 2 5 5 5 5 9 5 7 
(77) 2627 569 460 144 21699 3079 6130 1118 8 6 2 3 
(76) 529 236 53 43 55 130 17 24 7 9 2 3 
(75) 1 4 3 4 21663 3450 5413 1088 4 7 8 7 
(235) 6376 689 1638 337 28699 5535 8133 1225 65 48 102 77 
(234) 3017 329 474 136 1 3 7 8 6 9 122 30 
(228) 5 7 13 12 3794 715 562 255 6 11 144 81 
(227) 2375 336 379 114 19610 2065 5988 788 26 21 1 2 
(226) 2931 546 493 112 18026 2790 5787 968 15 20 87 42 
(225) 2 3 17 22 13846 2530 5222 771 9 15 1 1 
(224) 545 127 9 14 2 5 1 2 1 3 4 4 
(223) 5 8 9 12 3715 1409 600 329 10 9 15 4 
(222) 10 14 9 12 20001 7630 5027 1087 11 12 9 11 
(74) 111 89 13 13 10 13 5 6 461 168 391 60 
(73) 1216 392 192 84 20 15 6 11 369 172 478 59 
(72) 333 181 80 36 17446 3069 5134 578 522 230 6 5 
(71) 9 13 8 15 13 14 4 7 0 0 10 11 
(70) 2217 473 373 135 21623 3321 5458 889 505 77 7 9 
(69) 591 287 81 62 29 46 8 11 1 3 5 6 
(68) 14 18 11 12 16095 1789 4432 651 8 13 4 4 
(233) 5535 1107 1455 392 39520 13835 12917 2944 1180 507 1 2 
(232) 5189 861 1376 355 12 19 10 19 1658 428 2 4 
(221) 20 23 5 6 13758 1392 5112 653 406 161 109 41 
(220) 3164 398 510 124 48 64 3 6 793 150 215 74 
(219) 3399 547 533 183 42443 3655 11112 2243 542 158 161 32 
(218) 5 7 5 6 16928 3291 5003 897 10 8 6 7 
(217) 9 12 12 13 16423 2750 4802 683 2 3 5 7 
(216) 370 184 60 62 28335 4874 7721 900 474 140 110 36 
(215) 391 206 97 46 6 9 4 7 606 200 73 72 
(214) 81 54 18 21 8622 3662 2718 560 279 72 87 6 
(213) 4 7 11 12 3 5 0 0 3 4 3 5 
(212) 2 4 3 7 3207 469 375 294 4 5 6 5 
(211) 12 13 4 6 16153 1251 4479 625 9 11 3 5 
(210) 3584 920 675 241 20917 3603 6301 773 9 10 2 3 
(209) 1486 503 232 64 56 107 11 14 8 12 2 4 
(208) 9 12 3 7 17259 1349 5224 621 14 17 9 8 
(207) 2453 501 434 126 21645 1729 6190 884 13 10 4 6 
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Vaccine candidate 4 (NG5): 
Peptides 
NG5 mouse 5 (1/100) 
MEAN SD 
231 5130 977 
230 6400 1155 
229 4846 2365 
130 572 162 
129 1873 387 
128 1968 677 
127 1423 389 
126 4599 649 
125 3394 466 
124 3725 844 
123 467 217 
122 1778 503 
121 1410 222 
120 830 328 
119  4167 877 
118 4003 726 
117 3410 529 
113 3863 702 
112 4520 1495 
111 2606 634 
110 3903 947 
109 4491 1611 
108 6081 1414 
107 4717 943 
106 3515 592 
105 4809 685 
104 2726 793 
103 4547 1231 
102 4602 1104 
101 4849 1708 
100 4407 946 
98 4032 778 
97 5541 829 
96 3435 383 
95 4477 1248 
94 4779 1078 
93 5601 1268 
92 3420 1042 
91 3270 807 
90 5077 671 
89 3415 404 
88 4842 715 
87 4454 1181 
86 6373 1458 
85 3854 804 
81 3859 985 
80 5305 1316 
79 3002 679 
78 5131 997 
77 5175 711 
76 6150 1645 
75 3629 805 
235 3256 610 
234 3431 700 
228 5202 1237 
227 3412 552 
226 4523 671 
225 3975 962 
224 3318 2612 
223 4708 1052 
222 4125 1176 
74 4570 1031 
73 4570 1724 
72 2698 636 
71 5046 1019 
70 4310 694 
69 5823 856 
68 2863 854 
233 3283 996 
232 4967 1315 
221 3685 777 
220 5925 1089 
219 4413 783 
218 4811 876 
217 3528 857 
216 4822 981 
215 5156 980 
214 2024 526 
213 30 59 
212 4873 774 
211 4065 495 
210 5902 896 
209 4776 1303 
208 4043 864 
207 5691 1386 
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Vaccine candidate 5 (SH127): 
Peptides 
mouse1 (1/4000) mouse1 (1/12000) mouse1 (1/50000) mouse2 (1/400) mouse2 (1/800) mouse3 (1/2000) mouse3 (1/4000) mouse3 (1/12000) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 35080 7913 29892 5585 4686 845 10046 3619 8281 2592 45083 10129 28889 5921 10733 2479 
230 45055 17929 41075 8165 6659 1043 13027 4900 10408 2733 83811 50026 43405 9376 16840 4344 
229 41988 11650 35275 9803 6825 649 12194 2871 10948 3057 52428 10408 35236 7172 14191 3459 
130 5130 1342 2235 884 624 598 1040 255 2465 735 3603 1277 1740 579 331 225 
129 16992 3011 9909 1659 2954 723 2517 683 3737 1034 14137 2509 8253 1374 3022 513 
128 16955 3311 12877 3883 2973 794 4147 1210 4948 771 17350 2023 11071 2145 4262 852 
127 11009 1376 8180 2055 1859 124 2689 854 4030 906 8783 1562 5516 1037 2107 502 
126 27194 5630 23147 6028 4918 708 9377 2898 6940 1751 36601 4902 23837 3876 9810 2205 
125 22840 3954 16773 2865 4081 598 5720 1990 5507 1199 27329 3330 17561 2211 6558 1163 
124 27266 10875 23949 3887 4186 848 8615 2994 6450 1361 30156 6135 20574 3620 8137 1931 
123 3788 1688 1189 766 26 51 788 190 1408 890 2349 855 885 609 169 217 
122 16690 3501 11157 1146 3106 300 2601 536 3892 734 15358 1479 9514 1089 3562 537 
121 16885 3146 11921 1379 2696 301 3800 844 5070 765 14929 2865 9792 1568 3742 591 
120 12114 2531 7644 1817 742 539 1986 504 2840 465 8908 1977 5511 845 1863 306 
119  30382 3752 26965 4071 4862 555 9769 2725 8028 1474 38027 4822 26288 2607 10966 1827 
118 34750 8355 24829 3694 5547 833 7645 2506 8605 1955 48064 5796 27345 3157 10370 1694 
117 36034 6587 26370 4852 4803 413 9451 2625 10013 1951 42352 4163 27699 3851 9377 2591 
113 23729 9471 20527 2991 4190 525 7341 1931 6263 1099 29739 3210 18709 1987 7280 1432 
112 34128 9960 27667 7819 5630 728 9043 3177 8963 1626 41318 5064 25451 3843 10241 1852 
111 30236 5959 22073 2990 3221 367 7238 1742 6597 1544 23288 2698 14970 1653 6095 640 
110 31662 6262 25075 4526 5288 619 9055 2249 8363 1295 36156 5434 23493 3137 9314 1426 
109 37920 8264 33350 7468 5559 978 10507 3502 8069 1695 49456 6837 33226 5189 13566 1559 
108 35924 7497 38868 5785 8035 886 12429 3789 9961 1408 60325 8062 40097 5251 16723 2751 
107 39545 10548 37802 5854 5605 398 12490 3724 10401 2609 50845 4472 32518 3702 12488 1961 
106 23108 4688 17190 4283 3943 502 7111 1829 5572 1285 28970 2680 18351 1693 7114 1055 
105 33531 13468 30425 5221 5824 764 10306 2679 6844 1189 44642 5943 30145 4292 11875 2164 
104 25641 6933 17290 7827 4113 650 6109 3045 6559 1295 24653 4226 13523 6078 5383 1369 
103 36422 6205 30001 4771 5370 820 10568 2118 8120 1617 50429 3172 32375 4068 12116 1489 
102 32106 6799 28107 5039 5917 835 9392 2547 7498 1670 42418 5241 26132 4481 10931 1933 
101 36891 8751 33942 7130 6747 1108 11432 3912 8453 1363 60605 8933 40366 5764 16529 1933 
100 40439 9748 36606 6583 4593 545 11427 4160 8058 1127 48084 6157 32863 4574 13703 2532 
98 21324 4414 18868 3207 4937 707 7741 2095 6141 1062 29496 3328 19903 2604 8298 1459 
97 30872 5506 28499 4073 4476 561 10699 2492 5624 1083 42683 3973 29097 3110 11652 1830 
96 24385 3906 19644 3153 3864 438 7266 1771 5651 819 21626 3142 15524 2645 6460 1120 
95 29850 6054 24022 4934 5229 574 9655 2755 5594 694 41569 6310 28682 5230 11441 1943 
94 30415 4847 26773 5469 4124 805 10019 2699 6451 1466 41337 3533 28153 4183 11160 1663 
93 31940 6982 33943 4382 5360 955 12615 3422 8448 1186 52420 6417 34116 4690 14753 2353 
92 31994 7504 28199 7078 4177 515 9885 3793 6697 1835 40059 6537 26983 4604 12176 2531 
91 20003 2736 17592 4276 4688 850 6933 2839 5732 1008 24227 3625 18099 2436 8013 1354 
90 33516 4514 28720 5891 4266 712 10858 2800 5448 926 45419 5727 30699 3921 12288 2301 
89 23392 3816 20262 3534 4096 867 7858 1437 5289 951 26962 3325 18080 2461 7082 1105 
88 28329 4364 24050 4285 5126 832 10896 1725 6229 1049 41709 6788 27827 4332 11562 1794 
87 29482 4038 24508 5683 4729 585 9913 3074 5745 798 41391 7188 27777 5111 11799 2247 
86 37796 6087 36351 5711 7216 1018 12175 4363 8459 942 68600 5297 41511 5932 17737 3682 
85 31940 6396 31205 5627 4156 316 10687 2925 6484 772 44241 7522 30095 5243 12850 2278 
81 25776 3778 22152 4340 4874 585 8536 2630 5533 899 37798 4899 24543 3986 10880 2421 
80 35760 3795 32133 6842 5235 649 11589 3525 7906 2227 51638 6383 35793 5686 16176 3517 
79 25951 3607 19275 4458 3983 521 7339 1754 4582 650 26216 3388 16574 2770 7204 1796 
78 31059 4409 27205 4867 4998 594 11208 2457 6080 1546 47391 5454 32410 5577 13993 3189 
77 34530 5775 30482 4118 4461 709 12271 1493 6369 1782 47363 8398 34073 6927 14645 3579 
76 40739 8142 36737 5535 5911 1739 13078 4587 7817 1580 68936 10651 45091 8177 19366 4802 
75 28428 5803 21959 5514 3385 612 7564 2442 3996 880 35472 4229 24161 4432 10032 2292 
235 26268 5083 18800 3746 3783 426 6954 2171 4480 943 26852 2996 19179 3749 7452 1531 
234 18104 4175 15757 3075 3756 798 6047 1389 5045 1270 22047 2732 15765 2540 6623 1557 
228 24843 5574 21009 4043 3426 290 10179 2168 4938 1492 37705 4861 29076 5462 12447 2480 
227 20217 3468 17532 2894 4029 430 7610 1218 4291 562 24639 3010 19141 3700 7577 1776 
226 25255 4869 21902 3876 4734 559 10162 1606 5552 1029 33785 5459 27030 5981 10847 2678 
225 27641 6240 23953 4939 4000 469 9749 3498 5133 1286 41629 5673 30378 7354 12217 2509 
224 23556 5109 21369 4188 3919 323 7680 3230 4793 1043 36640 3836 24136 4174 11419 5486 
223 31943 8275 25258 5354 3680 344 10833 2533 5196 1107 28483 7084 24100 5576 11604 2934 
222 35714 7341 27647 5109 4256 1021 10647 2216 5562 1033 43982 3827 30242 6199 12139 2527 
74 23300 3780 21581 3802 4781 443 8866 2253 5670 1176 34180 3905 23786 2813 10998 2318 
73 26291 5041 26892 6630 4204 289 9691 2750 5937 1315 45004 6087 32081 6232 14013 2982 
72 15872 3275 14331 4326 3641 452 5861 1943 4195 672 21323 2393 14522 3653 6626 2124 
71 29456 4374 25749 5010 4464 496 10218 2184 4679 858 45604 5087 31304 6733 13812 3400 
70 28786 4245 26242 5569 4152 650 10195 1877 5458 1346 40422 4367 29007 6421 12678 2848 
69 28788 3221 27512 5862 4602 1083 10755 1904 6615 1794 44228 5797 32327 7246 14175 3228 
68 20100 4437 16687 5105 3156 438 6579 2487 4272 793 23446 3869 18082 4908 7122 2197 
233 62741 11405 50046 9740 13449 2027 12148 2658 9153 2130 47069 6057 34425 7015 15581 4078 
232 96702 9112 75487 13115 18032 4031 16823 3374 10451 2851 77477 7961 52849 7689 23513 4841 
221 11561 3245 11271 2173 4287 516 8295 1464 4714 866 22597 3426 16494 3065 7498 1768 
220 32181 8393 28696 3350 4678 556 12886 2085 6872 1669 46245 3353 33020 4381 13007 2603 
219 35886 8709 28528 2459 4197 537 11538 1518 5330 1317 44659 4620 31190 5075 12440 1757 
218 29054 6691 23530 3142 3770 371 10879 1336 4617 1077 41445 6301 29938 6196 11723 1948 
217 22873 5701 19828 3992 3935 410 7130 2616 4330 520 31373 4702 21712 5017 8088 1547 
216 32973 8843 30484 4022 5684 733 12996 3439 6572 749 44881 5359 28870 3668 13652 2555 
215 23810 5851 20850 4689 4692 530 10537 1463 5619 867 38740 3041 27034 5906 11183 1934 
214 11250 2289 9669 1660 2540 610 4267 494 3327 771 15945 2180 10567 1667 4295 969 
213 0 0 0 0 6 13 0 0 5 8 0 0 0 0 0 0 
212 27166 5994 22093 2636 3923 919 10156 2015 4965 1250 33099 2912 24612 4597 10651 1782 
211 24039 5893 19678 2269 4804 1110 9742 1548 6011 855 31882 2863 22914 2951 9755 1567 
210 34100 7690 28567 3430 4838 1093 13914 2180 6905 939 46952 8087 34013 4180 14307 2555 
209 27499 7939 23595 5036 4614 1002 9033 2671 5422 956 43796 4964 27802 4277 10869 2021 
208 28028 7993 25672 3929 3468 494 9381 2505 4347 557 36839 4093 25547 4066 10899 2137 
207 33647 9920 30117 6265 3934 632 11925 2343 6515 2249 52751 5600 36013 5624 14217 3612 
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Vaccine candidate 6 (AuNP): 
Peptides 
mouse1 (1/5) mouse2 (1/10) mouse2 (1/20) mouse2 (1/80) mouse3 (1/80) mouse3 (1/160) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 4 7 23575 6331 16119 3755 4172 855 4 5 2 4 
230 4 5 31990 11851 22119 4212 5149 1032 1498 610 3274 1669 
229 6 7 32995 7952 22269 3802 6054 957 273 223 1383 524 
130 8 11 658 307 442 359 18 29 4 7 6 4 
129 9 10 4847 1181 3943 1121 690 300 6 11 1448 548 
128 8 11 6297 2517 3958 1058 914 229 2 5 7 16 
127 5 13 2498 822 2517 434 451 153 9 13 4 10 
126 5 9 20928 3742 17620 2554 5224 683 521 278 1921 485 
125 5 5 14002 3274 11200 1682 3163 532 1286 328 4108 1077 
124 9 12 14971 3976 7233 1391 1529 548 2 3 11 13 
123 5 8 576 314 609 322 26 24 6 11 505 600 
122 20 19 7326 1409 6081 817 1495 204 9985 1580 15752 1641 
121 3 5 4431 1424 3558 791 669 205 4 7 3 5 
120 10 16 1926 727 1884 565 249 140 425 247 2287 761 
119  9 11 19653 3229 16405 1950 4711 538 525 236 1889 401 
118 18 20 24144 5237 13964 1588 3591 453 11410 1738 17837 2361 
117 2 3 17212 4015 9449 1707 1623 278 2 4 4 7 
113 60 85 13164 2196 11745 1414 2861 1198 6 12 0 0 
112 1811 666 31609 6228 24526 3005 7527 1016 1379 853 4572 1472 
111 4 6 11021 2951 5570 1602 1315 349 7 13 9 10 
110 3 6 23125 4093 16672 2334 4378 897 3 5 2 4 
109 13 12 27265 6332 21210 3523 5741 1071 8 17 673 454 
108 1138 203 53168 8914 37834 3417 11706 1511 2425 475 6009 1011 
107 2 6 27722 7070 14498 2151 2965 446 10 14 5 8 
106 151 144 12523 1882 13378 1505 3264 442 2 4 2 4 
105 2035 658 27027 2713 26688 2631 8245 1182 1935 777 5701 1568 
104 3 5 10544 3510 6578 1208 1352 267 4 8 3 5 
103 44 45 23543 3678 19868 2396 5078 688 2 5 5 6 
102 6 10 27016 5186 17892 1955 5134 1092 173 178 1231 503 
101 1294 527 45692 9933 34008 5106 10477 1432 2147 730 5359 1470 
100 7 13 22928 6840 13700 1812 3243 563 11 10 7 12 
98 443 269 16666 2301 17265 1946 5429 518 4 8 1047 506 
97 2680 465 26111 2600 26693 2740 8561 759 9517 1447 14302 3043 
96 4 8 13449 2884 8386 1428 2101 322 6 7 8 12 
95 54 76 23057 4493 21480 3119 6549 887 3 4 1410 730 
94 10 13 25458 4246 19214 2668 5826 744 1977 333 4711 1416 
93 1991 465 41826 5835 35767 2948 10962 1922 9531 1186 14342 1689 
92 6 7 22318 6250 11474 1965 2954 370 3 5 7 13 
91 625 269 20258 3664 16203 1848 4749 571 5 13 1085 279 
90 3176 337 26665 2978 26012 3137 7814 910 8510 1084 14083 1999 
89 9 14 11631 2122 10009 1540 2392 230 14 25 0 0 
88 139 103 21549 2915 17073 1774 4911 660 1 3 488 556 
87 10 8 26690 5704 15415 2433 4838 596 1806 452 4412 1077 
86 2899 472 51347 7490 38250 5085 11539 1859 9968 1708 15735 2241 
85 9 10 19477 3185 13898 1817 3647 805 15 14 1 2 
81 650 164 24896 4345 16235 2185 5131 1236 264 255 1707 626 
80 2970 465 34276 4864 30197 3091 9302 1261 9795 1417 14934 2101 
79 4 6 11891 2691 8235 1640 1742 261 15 18 8 10 
78 354 152 24749 2476 22987 2669 6741 651 239 236 1902 411 
77 9 15 24438 3180 19977 2611 5877 645 2066 545 4860 997 
76 2761 813 53133 10514 42777 8846 13392 1634 10778 2467 15946 2789 
75 4 6 17727 4148 9774 2603 2454 347 5 10 10 11 
235 7 7 11572 2917 8446 1341 2092 429 1347 218 3419 586 
234 2673 331 18392 2976 13175 1598 4491 760 6697 1156 10777 1339 
228 370 181 23446 4212 17769 3108 5673 964 5 7 4 9 
227 3 5 14892 2713 11100 1784 3468 454 1095 179 3029 619 
226 6 8 21031 2948 12279 1983 4079 627 1378 413 3512 523 
225 7 9 18193 4030 16997 3380 5630 1091 7 11 7 14 
224 2619 488 23315 1629 25565 4256 7962 1823 7744 1736 11412 1211 
223 352 239 20618 5070 13396 2500 3823 983 6 10 5 8 
222 10 11 16804 4581 11561 2582 3369 769 10 12 5 11 
74 17 19 24341 2703 15696 1613 4809 843 3461 652 6652 721 
73 437 169 33410 6868 27513 4482 8836 1473 12679 2072 17433 1950 
72 6 14 11260 3912 6003 1031 1531 293 7 10 4 6 
71 16 26 26035 4482 22408 2912 7255 1073 5496 974 9738 1221 
70 7 12 17724 2665 15523 1931 4783 676 506 266 1854 659 
69 67 71 31572 4502 26429 3352 8110 1101 11162 1720 15877 1858 
68 4 5 12149 3785 6759 1420 1650 256 3 6 200 559 
233 4589 987 25340 4763 16765 3081 5623 883 6071 1075 10537 1368 
232 12076 1747 35971 7291 34799 5527 10789 1454 21420 3051 29896 2440 
221 1 4 12649 1812 12398 1871 4415 657 10 16 4 7 
220 1426 173 41949 8916 35763 6448 11504 2090 15230 2571 20941 2750 
219 1 4 25378 5615 13933 2601 4873 830 1990 456 4628 756 
218 11 8 20691 4436 16384 2871 5118 1026 4797 1148 9091 1441 
217 7 11 14288 4304 10341 2581 2894 546 0 0 4 9 
216 11 13 28711 4666 16348 3627 5389 1436 11 12 8 13 
215 12 13 25998 4116 22988 3848 8463 2722 5478 862 9567 1382 
214 6 14 7153 1800 5198 1380 1493 331 3 4 3 5 
213 10 11 4 7 5 7 8 12 7 7 4 6 
212 317 209 18378 3943 13560 2564 4597 791 3 6 2 3 
211 1 2 17113 3869 14090 2696 4634 700 7 11 3 9 
210 10 11 25201 5184 23432 4501 7423 1434 2053 547 4954 1334 
209 520 291 28085 7220 24431 5429 8055 1881 6731 1489 10761 1975 
208 9 8 14052 3335 14111 3240 4289 1040 5 9 5 6 
207 8 6 30499 8588 20103 4493 6341 1300 1345 457 3242 1052 
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Vaccine candidate 7 (HC1): 
Peptides 
mouse1 (1/80) mouse1 (1/230) mouse2 (1/80) mouse2 (1/320) mouse3 (1/80) mouse3 (1/320) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 283 119 54 35 3701 1636 1370 391 3 7 534 163 
230 2952 1229 185 130 4547 1773 1699 630 50 107 1193 352 
229 927 456 45 54 1356 997 349 395 5 5 298 117 
130 615 319 63 62 6 9 10 13 370 192 6093 997 
129 7122 1743 902 359 11 16 11 18 2386 644 12341 472 
128 92 34 30 25 196 143 6 17 10 13 68 53 
127 4427 1113 346 230 8 10 11 17 1511 442 9655 990 
126 1507 610 90 44 919 462 31 43 16 20 319 75 
125 13360 2582 2703 873 8 11 5 9 5655 652 16879 1143 
124 127 68 23 19 131 170 55 84 14 14 931 146 
123 61 31 27 24 6 9 8 15 601 263 3033 591 
122 6546 1343 630 233 6 9 20 22 4299 1093 11248 1329 
121 25 25 6 12 18 20 14 20 3 6 52 36 
120 340 216 9 12 9 10 6 10 1021 392 4797 725 
119  1488 458 106 67 1323 570 201 230 52 44 362 99 
118 8766 1488 1527 456 9 11 46 43 8396 1030 22204 1488 
117 79 56 20 21 45 55 22 30 12 17 798 337 
113 11265 2775 1775 592 5018 1422 1470 592 5792 961 11681 1260 
112 21569 3701 6012 1592 9594 2857 4421 985 10548 2505 20417 1673 
111 42 41 13 23 16 22 11 17 12 19 24 26 
110 9452 1935 1121 682 4186 1382 841 322 5708 1158 12921 1509 
109 416 251 27 26 1216 595 138 217 20 22 560 144 
108 22594 2667 6169 1153 14468 3567 4104 681 13549 1610 32028 3239 
107 171 71 39 33 42 52 2 3 3 5 661 240 
106 12005 1516 2030 417 4937 1480 1417 364 6164 765 12153 887 
105 22308 3237 6396 1491 11015 2822 4362 1123 10858 1586 21050 2197 
104 82 72 25 27 52 60 36 32 2 4 270 375 
103 10079 1378 2230 468 6313 2114 1142 758 7345 1085 17681 1314 
102 845 361 50 43 1260 569 149 223 8 15 505 103 
101 19230 3740 5889 1066 12230 3112 3471 758 13189 2925 29030 3283 
100 111 69 40 34 51 86 26 37 8 8 1120 189 
98 14535 1474 3492 503 7276 1833 2248 485 7709 975 14313 971 
97 21403 1937 7003 969 10621 2036 5065 1046 11534 1424 21888 1454 
96 190 67 46 30 149 176 8 14 5 13 267 100 
95 14800 2005 3722 675 6626 2186 2026 748 7174 1151 16404 1529 
94 5109 935 301 84 2364 1108 409 597 140 152 1266 199 
93 20968 2265 6956 1585 11831 3834 5072 954 13376 1392 25454 2883 
92 174 69 43 34 90 92 30 50 7 10 340 130 
91 16408 1531 4768 932 6776 1997 2048 487 8986 1250 12604 997 
90 21838 1814 7289 841 9611 2268 5341 867 13349 1684 21477 1688 
89 151 80 35 31 434 530 0 0 1697 280 641 141 
88 13960 1646 4047 654 6952 1995 2382 663 6986 1123 14884 1608 
87 4803 1431 280 144 2273 1348 314 381 1344 277 1572 331 
86 28277 3235 9037 1261 14506 5530 4910 751 17253 2642 36287 6115 
85 140 110 23 33 37 89 23 43 467 135 402 171 
81 12921 1620 3388 522 6980 2375 2514 557 5308 1132 12677 3066 
80 19573 1992 6562 1285 13189 3438 6074 943 10388 1862 22041 1234 
79 48 35 7 11 38 72 5 9 4 5 200 84 
78 12792 861 3280 498 7364 2244 2391 382 5948 1150 13368 891 
77 5556 1412 378 90 2542 1017 574 618 163 126 1841 452 
76 23215 3400 6759 1121 12247 4798 5547 838 11758 2747 28347 3193 
75 76 72 27 32 29 41 25 32 8 8 260 117 
235 6070 1042 3390 514 2425 1168 1 3 218 149 6350 968 
234 17884 2139 6989 1021 8782 2109 3280 809 9764 1729 13503 3561 
228 122 111 39 40 103 78 0 0 4 8 996 258 
227 3722 668 4231 472 1819 858 0 0 5 8 581 49 
226 4037 1007 80 60 2437 646 319 355 2 4 1090 251 
225 219 134 5945 613 415 445 4 8 4 10 694 153 
224 16351 1765 32 11 9697 2216 4297 681 8168 1918 16422 1834 
223 144 125 521 139 18 19 4 4 13 7 271 130 
222 162 109 6314 914 72 105 7 11 3 3 405 271 
74 11947 1212 11702 1966 12202 3485 6462 783 4500 823 10380 892 
73 20096 2183 21911 3152 15507 4184 7852 1422 10444 1721 13553 4693 
72 174 123 13 16 589 405 0 0 6 9 943 187 
71 15708 1206 207 105 12059 3225 7644 1093 4987 957 12411 845 
70 2103 380 269 75 2142 723 183 287 0 0 1251 84 
69 17732 2174 77 48 15402 4523 8054 1311 9503 1780 14868 1814 
68 138 60 5737 947 0 0 71 50 3 7 160 47 
233 28215 1846 41 35 3147 1070 1367 414 816 269 3183 1319 
232 48720 3281 52 51 22339 6452 12638 2218 18557 3094 22629 1861 
221 1147 155 81 45 411 346 0 0 123 107 269 64 
220 25778 2947 9558 1672 18708 6134 10008 1642 14027 3222 17970 1460 
219 5310 1201 449 47 3635 1370 1602 408 177 138 1413 129 
218 1690 897 114 37 3789 1442 1994 341 3 5 1291 237 
217 294 183 35 35 318 540 8 19 2 4 508 235 
216 381 215 71 46 2201 1362 24 46 49 65 2269 332 
215 17412 2642 5064 947 11635 2589 8533 1399 7375 1405 13320 1292 
214 77 76 32 13 10 14 13 16 14 14 61 87 
213 10 16 11 18 7 11 17 18 4 7 12 11 
212 125 134 27 17 10 13 11 15 12 15 357 105 
211 186 158 48 41 482 420 45 85 8 13 513 54 
210 3996 1310 293 78 2959 1371 948 596 29 39 1773 255 
209 15785 3124 4570 1077 7939 2373 5025 1008 9874 2097 15392 1481 
208 209 172 46 33 82 97 44 82 6 12 278 117 
207 4241 1208 277 159 2794 1042 781 516 44 54 1293 249 
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Vaccine candidate 8 (HC2): 
Peptides 
mouse1 (1/20) mouse1 (1/80) mouse2 (1/20) mouse2 (1/80) mouse3 (1/20) mouse3 (1/80) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
231 4160 809 925 417 1281 495 392 152 534 163 141 97 
230 6955 1214 1844 557 3694 1162 1193 466 1193 352 292 170 
229 5572 2299 1550 594 1258 500 265 171 298 117 36 51 
130 8271 2124 1723 631 6695 900 2717 664 6093 997 2217 671 
129 18712 2138 8428 1960 13532 2582 6265 1263 12341 472 6869 988 
128 1080 510 263 110 2115 1227 599 196 68 53 15 28 
127 16329 2836 4866 1131 11349 1694 4737 984 9655 990 4537 765 
126 5279 1062 1749 207 5579 1095 1955 347 319 75 90 77 
125 26430 2070 13825 1291 19689 1285 10234 1427 16879 1143 10249 1467 
124 2429 444 704 233 891 258 205 76 931 146 231 72 
123 5345 2352 1376 702 3124 1133 860 336 3033 591 851 282 
122 23053 1550 11262 2629 12786 1220 5319 1034 11248 1329 6691 1046 
121 613 178 173 70 1224 489 252 89 52 36 19 21 
120 8690 3502 2033 513 798 394 164 62 4797 725 1830 668 
119  5322 684 1735 175 7937 616 3361 454 362 99 444 1068 
118 44652 4132 19263 475 18005 1270 6858 887 22204 1488 12596 1813 
117 2324 135 654 119 299 73 55 44 798 337 200 40 
113 20655 2105 10104 1580 18825 1961 10474 1058 11681 1260 6222 1206 
112 35612 17186 27148 7177 31599 7619 15500 5907 20417 1673 11456 4300 
111 1517 251 410 169 3460 779 793 253 24 26 43 59 
110 26158 2146 12573 1520 19017 985 8609 809 12921 1509 6866 1255 
109 4362 1991 1506 349 6530 2678 2665 751 560 144 146 66 
108 52376 4837 30489 2319 32691 1556 19731 1398 32028 3239 19960 2766 
107 3947 549 1042 141 552 64 116 56 661 240 140 50 
106 18465 1844 10400 305 17715 1204 10497 1214 12153 887 6974 783 
105 41853 3019 26481 2662 29571 4299 17401 1407 21050 2197 13713 2038 
104 1747 997 645 187 4673 1597 1347 659 270 375 26 29 
103 25373 1589 12932 1890 19925 811 11645 1167 17681 1314 10599 1171 
102 6067 781 1758 395 8306 1346 3272 427 505 103 93 66 
101 40022 14642 26679 2022 24858 10682 17123 4427 29030 3283 16649 5622 
100 2879 401 748 269 497 145 131 48 1120 189 241 82 
98 20811 1760 13819 1397 21734 1288 14487 870 14313 971 9515 992 
97 31811 3690 23767 466 27592 2131 19441 1037 21888 1454 15593 1611 
96 3079 711 941 130 5685 1237 1815 319 267 100 53 46 
95 23808 6400 15538 1998 18802 4860 12622 1574 16404 1529 10104 1249 
94 5953 782 1978 345 10343 697 4774 441 1266 199 275 74 
93 39446 3477 24103 1271 25551 1840 16467 1222 25454 2883 17126 2390 
92 3191 1056 1128 221 1458 714 415 140 340 130 203 260 
91 24909 2808 16119 801 22307 1176 13732 1225 12604 997 8353 1149 
90 35780 2905 24545 910 29193 886 20304 1220 21477 1688 15766 2107 
89 2913 333 953 130 5361 1191 2156 523 641 141 157 71 
88 23322 2131 15430 852 21523 1113 13926 987 14884 1608 9776 1355 
87 5242 1913 1942 360 7839 3147 4019 1470 1572 331 328 91 
86 53256 4463 32892 1430 36883 1792 23689 1958 36287 6115 22615 2559 
85 3800 454 1034 336 1701 456 420 129 402 171 56 61 
81 21613 1610 14911 1208 20458 8002 13428 4088 12677 3066 7240 4454 
80 35894 2677 24409 1029 30238 1375 20623 971 22041 1234 15731 1993 
79 2274 222 594 164 4091 630 1436 240 200 84 42 45 
78 21763 1313 13037 413 18965 803 12018 1022 13368 891 8914 1073 
77 6307 412 2265 312 10350 742 5167 397 1841 452 531 181 
76 40997 10966 26331 2084 25363 10352 19065 2722 28347 3193 18458 2213 
75 2678 315 826 213 745 163 142 74 260 117 67 43 
235 5421 1053 1608 174 12574 1380 6384 788 6350 968 2260 290 
234 24624 2312 21709 7390 28681 5798 18520 1075 13503 3561 11923 1684 
228 2291 314 628 119 190 91 41 30 996 258 281 150 
227 4578 405 1438 213 3762 320 1159 128 581 49 74 29 
226 4937 515 1820 188 7979 951 3527 718 1090 251 236 53 
225 4016 1436 1404 199 892 425 186 116 694 153 162 86 
224 26818 2723 18345 958 20470 1643 13288 5558 16422 1834 12885 1846 
223 887 375 204 97 62 58 31 21 271 130 84 41 
222 3675 751 1007 312 518 259 128 92 405 271 114 94 
74 16713 1085 9444 728 16714 730 10802 799 10380 892 6794 1031 
73 26247 2015 16233 1435 19517 7514 13951 3439 13553 4693 8803 5415 
72 2489 316 785 123 3751 341 1263 282 943 187 254 53 
71 20076 1485 11036 704 16677 963 10969 859 12411 845 8115 948 
70 5180 397 1655 211 5873 612 2215 361 1251 84 299 114 
69 24341 1583 14187 1003 17887 1238 12213 1046 14868 1814 10237 1534 
68 1959 631 557 159 690 329 122 53 160 47 22 24 
233 5882 891 1959 392 8366 3477 4434 1850 3183 1319 752 474 
232 54024 4232 30433 1156 50857 2285 29449 1725 22629 1861 16851 2226 
221 4387 594 1430 273 1934 218 535 111 269 64 54 49 
220 35511 3107 22399 1028 28382 1203 17446 1129 17970 1460 13268 1615 
219 5401 566 1709 341 3848 495 1370 226 1413 129 205 96 
218 4500 573 1441 171 8954 1197 4576 958 1291 237 336 83 
217 3024 1211 1021 232 933 425 237 91 508 235 141 42 
216 7220 558 2496 239 11560 661 5039 632 2269 332 562 111 
215 21976 1286 13483 623 22146 1160 14674 630 13320 1292 8603 1435 
214 1814 212 449 206 625 297 139 70 61 87 43 44 
213 8 13 10 18 2 5 3 8 12 11 9 9 
212 1097 267 309 83 117 43 28 30 357 105 258 418 
211 4839 297 1645 173 1460 337 356 84 513 54 123 49 
210 6017 513 2082 270 4912 849 2035 443 1773 255 467 109 
209 21286 5776 11320 1251 15857 7549 8885 1827 15392 1481 10978 1334 
208 4578 426 1459 192 949 160 207 93 278 117 72 60 
207 5954 1080 1992 200 3614 810 1186 227 1293 249 263 200 
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9.3.3 Microarray format 3 (MA3) 
Vaccine candidate 1 (CHSynB): 
Peptides 
mouse1 (1/500) mouse2 (1/10) mouse3 (1/10) 
MEAN SD MEAN SD MEAN SD 
131 57882 6416 73120 5436 103813 10930 
132 74588 8265 91741 5622 141171 13257 
131 35286 1682 59962 4098 61466 7631 
232 124478 15093 122011 6687 157653 10346 
233 72519 8612 97213 12853 80421 8515 
234 13089 1352 12167 742 83237 9233 
235 14344 2500 3123 250 3289 611 
236 11591 1422 10038 1116 965 352 
237 9556 1175 4688 424 679 607 
238 73126 5870 21275 1244 97831 11661 
239 79197 3946 31088 2258 126685 8678 
73 55546 6345 20448 1582 72588 12727 
240 72725 5859 25113 1325 95025 9781 
69 56557 3723 18187 965 61983 7120 
76 22764 1660 31217 2618 114389 13153 
108 11131 337 20132 1628 89257 5513 
174 2899 388 7977 607 39184 5024 
125 2064 457 4511 523 36106 2908 
241 12112 2129 11834 1708 1270 351 
 
Vaccine candidate 2 (HC12): 
Peptides 
mouse1 (1/20) mouse1 (1/80) mouse2 (1/20) mouse2 (1/80) mouse3 (1/20) mouse3 (1/80) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
131 164069 22915 132231 15283 86560 7519 35836 2825 53449 6425 35836 2825 
132 188231 25918 150696 12036 120432 16975 49358 4561 57456 7389 49358 4561 
131 145285 22504 114453 10958 34814 3682 12519 1523 37529 5569 12519 1523 
232 215669 41099 178899 24204 152563 24984 79916 12567 91559 20960 79916 12567 
233 206897 36939 173373 33755 21974 3689 7272 1013 64730 11339 7272 1013 
234 1426 297 381 417 66632 7691 34380 3390 14239 3040 34380 3390 
235 99 89 18 30 14643 2124 4241 437 26 68 4241 437 
236 150875 20431 101993 11001 15026 2226 3442 300 15243 2132 3442 300 
237 281 268 18 49 11550 1947 2702 272 0 0 2702 272 
238 2423 395 263 115 128820 24936 68268 5448 34934 7377 68268 5448 
239 188153 33369 126531 12177 151022 28596 80588 5828 49621 4924 80588 5828 
73 908 330 117 147 101923 16539 53625 5585 28554 5236 53625 5585 
240 1695 271 202 87 120544 8654 63508 3728 33014 6468 63508 3728 
69 777 256 129 137 89533 5637 45929 2449 31275 5880 45929 2449 
76 2281 201 389 158 122083 17351 52682 4953 19883 3013 52682 4953 
108 1367 210 86 108 91320 10647 38125 3786 10024 2291 38125 3786 
174 1112 142 168 174 43074 5041 16376 1463 0 0 16376 1463 
125 1037 172 204 206 39360 4627 14784 1129 5 14 14784 1129 
241 86 78 42 49 11813 1793 2832 509 15 41 2832 509 
 
Vaccine candidate 3 (HC11): 
Peptides 
mouse1 (1/10) mouse2 (1/80) mouse3 (1/20) 
MEAN SD MEAN SD MEAN SD 
131 200 121 0 0 1950 600 
132 140 131 0 0 2188 935 
131 66 87 43 57 1419 382 
232 3845 464 0 0 2435 309 
233 4021 496 106152 9251 3047 1340 
234 1079 238 2 6 140 202 
235 4761 654 103567 18278 247 145 
236 4754 513 88708 17379 3049 457 
237 10230 635 98174 18693 105321 14728 
238 6302 426 93 123 117705 15619 
239 4598 483 34 50 4740 1660 
73 834 200 0 0 280 164 
240 5492 569 139 118 809 506 
69 203 171 0 0 133 130 
76 273 112 29 51 108 123 
108 24 36 0 0 23 62 
174 207 104 0 0 33 82 
125 57 123 8 14 78 146 
241 8495 986 97155 14076 1100 237 
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Vaccine candidate 5 (SH127): 
Peptides 
mouse1 (1/4000) mouse2 (1/400) mouse3 (1/2000) 
MEAN SD MEAN SD MEAN SD 
131 128338 14333 21782 2404 105023 9068 
132 162584 26962 30644 4371 147196 18220 
131 116628 13062 15968 1742 72784 8482 
232 162063 27150 27982 3816 143294 19326 
233 158482 10402 26156 4328 135604 10927 
234 59276 9528 14654 2868 64077 9330 
235 79853 19167 17444 4274 87442 17171 
236 70784 11619 19485 3602 99445 13230 
237 64402 20246 17120 3385 82826 12676 
238 72857 14295 21350 2617 100452 11497 
239 86948 21886 23107 2988 113567 13409 
73 58846 9303 18870 2245 81870 5966 
240 81047 15151 21879 2003 102670 12115 
69 63402 15611 19604 2924 89155 11699 
76 83213 14775 23261 3071 116405 10740 
108 67808 19929 19885 2354 97728 9360 
174 69127 10759 17684 2179 86765 7022 
125 60733 10443 14783 2579 69345 8168 
241 73298 16092 19572 3596 108315 12974 
 
Vaccine candidate 6 (AuNP): 
Peptides 
mouse1 (1/5) mouse2 (1/20) mouse3 (1/80) 
MEAN SD MEAN SD MEAN SD 
131 6855 544 50840 4994 16422 2055 
132 9775 652 67905 6959 33075 3050 
131 3853 185 14364 1320 12630 1057 
232 11089 752 74968 6173 62812 5343 
233 3416 225 38421 3472 13654 1328 
234 3149 258 29992 2365 10677 764 
235 30 70 25815 1845 1622 415 
236 28 43 45073 4319 1626 373 
237 56 112 31369 2974 1132 290 
238 1822 214 57253 5491 35485 2330 
239 2769 727 78499 7209 47882 3091 
73 1338 819 55129 5721 27876 2137 
240 1453 184 73573 8370 38397 3787 
69 581 185 61664 5252 28458 4989 
76 3940 275 86737 4209 20452 1489 
108 1945 177 58947 4621 8249 1131 
174 196 204 39685 4552 8447 1058 
125 317 255 23645 3016 5016 773 
241 20 26 51457 9125 1720 377 
 
Vaccine candidate 7 (HC1): 
Peptides 
mouse1 (1/80) mouse1 (1/320) mouse2 (1/80) mouse2 (1/320) mouse3 (1/80) mouse3 (1/320) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
131 62600 5878 16228 2088 26662 3931 5660 530 30368 2727 6783 653 
132 88754 6996 25862 3322 41043 3921 8695 1417 44403 3851 10572 694 
131 50080 3700 12692 1456 0 0 9 24 15253 1199 3571 292 
232 118232 9563 29439 3610 98205 11874 19597 3016 71566 7544 18944 2156 
233 60763 6652 14538 2005 13321 1714 3632 732 1882 175 383 122 
234 30313 2182 7496 767 24868 2826 5256 884 30155 2267 7232 521 
235 2183 433 189 141 5015 935 956 158 388 157 26 34 
236 25845 2086 5383 622 7581 967 1399 195 494 145 84 84 
237 1177 303 182 121 9487 1789 1932 441 536 249 134 159 
238 49457 2842 11281 1388 89653 7263 18904 1693 50435 2725 13547 926 
239 91194 6223 22790 2210 97478 8706 21176 3283 61149 2387 16399 1263 
73 35600 2412 7997 934 65439 6502 15526 2130 33550 1271 9386 740 
240 42424 1949 9994 852 81902 5758 17345 2254 39588 1451 9817 650 
69 28352 1560 7009 565 57757 2901 14492 1247 24952 1315 6976 281 
76 43614 3804 9447 884 52855 5495 10637 1647 39056 3816 8920 962 
108 29910 3708 6998 623 31060 4700 6567 1754 26675 3234 6100 980 
174 16989 1253 3784 173 0 0 22 51 13274 1208 3106 518 
125 14528 948 3124 322 51 136 66 78 12421 1246 2800 234 
241 1696 462 284 184 9286 1275 1914 226 454 124 51 74 
 
 9 APPENDIX 355 
 
 
Vaccine candidate 8 (HC2): 
Peptides 
mouse1 (1/20) mouse1 (1/80) mouse2 (1/20) mouse2 (1/80) mouse3 (1/20) mouse3 (1/80) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
131 106588 8739 50155 7518 96477 7665 40498 5452 70262 5367 26820 2098 
132 140794 9337 74318 13406 144198 10160 65560 9663 106447 8141 42146 4998 
131 62314 4945 20596 3744 55932 3790 20125 2539 46326 3295 14947 1789 
232 150340 11567 71911 13504 157447 8972 72032 11861 104507 4116 40914 7027 
233 16765 2096 4335 1018 30611 3137 9423 1779 5794 598 1313 156 
234 100920 4040 50846 6075 110827 8407 49692 8359 64324 5783 27260 2904 
235 14567 1846 3534 480 57616 6285 16580 2522 10895 815 2544 367 
236 18258 3145 4597 793 23941 1806 5782 669 5673 374 1181 237 
237 11700 1928 2811 821 3641 864 993 308 1117 266 200 189 
238 110176 5031 52842 9650 93693 5387 39075 6261 80679 3637 34050 3777 
239 135253 11877 69781 14076 155948 10564 67836 10756 118626 7699 52367 6037 
73 76074 9580 34465 8066 80761 7824 37144 4908 67026 6688 29038 2953 
240 97484 14127 45224 8870 87212 6895 36378 4753 89285 8219 37705 4265 
69 65749 8511 24893 3850 59338 4424 24594 4317 63303 5144 24349 3017 
76 137940 16497 66770 9485 128750 10481 58564 11644 124577 8596 52015 5875 
108 108355 13308 47653 7497 93281 5223 40412 8521 96129 2812 39273 3168 
174 70158 5605 20924 3397 63657 5575 22364 4456 70379 6210 23921 2707 
125 66499 6012 19246 2747 59138 6074 20673 4694 68300 9096 21408 3232 
241 18108 2047 4268 924 8865 2736 1836 385 4062 338 857 146 
 
9.3.4 Microarray format 4 (MA4) 
Serum antibody microarray: 
Peptides 
CHSynB mouse1 
(1/20) 
HC12 mouse 2 
(1/20) 
HC1 mouse 3 
(1/80) 
HC2 mouse 2 
(1/20) 
HC2 mouse 3 
(1/20) 
Ma552 (25μg/mL) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
75 1402 263 3356 326 80 69 786 108 830 233 7826 1249 
175 2993 422 4297 443 67 104 1960 355 1567 161 11716 1876 
76 28044 4891 61421 2991 28628 4435 65868 5268 59313 6407 27128 2681 
176 37426 7411 65827 4764 26557 4850 72185 5807 68085 7655 31576 2181 
77 8194 1612 12771 1209 169 142 19482 1574 1258 179 4245 405 
177 9644 1346 13986 995 188 121 20911 2008 1644 338 6879 713 
78 12814 1649 27934 2939 12853 1823 48124 3958 36037 3829 27231 2202 
178 21144 3254 22809 4457 11328 1224 50945 5026 48300 3348 29640 2013 
79 443 149 3446 389 23 36 5053 757 42 58 6482 1046 
179 923 196 4726 458 49 111 12515 955 518 155 11428 2901 
80 22504 3408 61417 2105 28042 5037 69995 7576 54579 8338 25907 3618 
180 28380 6064 57695 4557 21899 5064 64289 6746 58010 7234 26328 3405 
81 10850 863 25906 3104 12551 1094 54807 5248 33112 2686 24960 2447 
181 17278 1553 17833 2644 11702 926 51334 4957 42642 3202 24910 2593 
92 2284 335 3761 278 8 20 1013 184 584 170 7680 1229 
185 4045 377 4490 472 17 27 1668 271 622 107 10142 1646 
182 3846 308 4489 318 18 29 1488 243 660 260 9330 1636 
93 25412 3744 63252 1945 28943 3075 70204 4997 66851 5246 28154 1823 
186 29995 5232 61639 708 29389 3544 68500 5735 66348 6724 29135 2335 
183 33515 6539 66533 7642 31329 6246 76575 11097 76180 10782 33111 4257 
94 8413 470 12031 1067 130 129 20133 2434 1116 122 3938 486 
187 10736 925 11949 1468 206 101 20807 1873 1404 211 4922 503 
184 12518 974 13803 1488 189 131 21464 1680 1715 293 5362 723 
98 9497 785 31753 2812 16264 2076 59448 5037 40358 2260 24848 1650 
188 12141 1721 12543 1089 13695 1519 46458 3510 37812 3094 20843 1085 
101 21504 3793 60618 5030 24779 3530 64217 5980 62922 1664 25489 2616 
189 26331 6114 58618 5094 23439 4500 62972 7923 61648 8648 27428 2152 
102 6990 569 10343 1737 58 50 15835 1654 894 202 3439 619 
191 9053 536 10312 1365 109 88 17411 1686 1144 199 4336 868 
192 11027 1070 10813 1375 80 79 15579 1069 1310 185 4581 906 
190 11422 749 11706 1369 91 52 20333 2041 1562 366 4893 742 
107 1503 271 3102 169 52 50 721 239 2116 151 5976 1032 
193 2408 299 3866 508 153 59 805 65 2664 176 8942 1259 
108 21411 2814 58120 3782 25308 2500 59947 6985 56781 1669 25287 1880 
195 25455 4229 54414 5067 23849 3245 54255 6584 54753 2616 27781 1866 
194 31264 6772 62395 4016 28091 3631 67152 6165 66597 5105 32037 2995 
109 8806 1219 9347 856 173 119 15436 1559 1230 99 3301 459 
197 10922 1956 9637 1063 132 149 16502 1209 1296 168 3930 687 
198 12401 2448 9784 1631 93 105 13474 1197 1135 169 4182 582 
196 12626 1511 11151 1766 74 97 17909 1608 1587 185 4371 994 
113 5315 375 15371 2473 12566 1499 50786 8682 32367 1813 22597 815 
199 9566 665 9895 1459 12495 1471 51981 7096 37311 2592 25201 3194 
119 6031 454 9326 1817 56 63 10553 1243 353 150 2344 435 
200 8812 1034 8971 1697 157 91 16275 2056 303 185 4117 483 
125 3660 634 19094 2928 11773 1145 40045 4540 42156 3301 15720 1117 
202 3766 163 8784 1460 10152 1204 15830 2771 33459 1659 19112 1385 
201 11014 1702 26530 850 15233 1444 49464 4835 55301 5406 25783 2663 
126 6974 956 9400 1288 142 148 5400 345 448 117 2158 409 
203 9735 1484 9532 1577 108 93 2914 274 214 72 2987 488 
204 10300 1795 7991 1235 54 84 1635 144 243 144 2647 448 
174 7819 134 19242 2823 11155 1023 45566 6602 47324 2363 15731 1577 
205 12167 604 19558 2530 6119 407 46288 6816 54816 356 24939 837 
206 12886 1217 26919 3188 14412 2193 52254 6187 48411 5982 24276 2704 
232 64309 6944 75609 7913 44169 5505 84912 12634 48522 4819 23459 2770 
234 12770 1802 46217 5793 26256 3880 64302 10446 34915 2878 17442 1877 
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Galectin-3 microarray: 
Peptides 
Gal-3 (25 μg/mL) Gal-3 (12.5 μg/mL) Gal-3 (6.25 μg/mL) Gal-3 (3.13 μg/mL) Gal-3 (1.56 μg/mL) Gal-3 (0.78 μg/mL) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
75 10468 1367 2524 697 35 66 28 41 7 17 72 50 
175 17134 1877 7615 1821 138 113 147 144 90 88 70 78 
76 14667 2136 5453 699 58 89 144 132 96 101 60 86 
176 24358 2352 12175 2544 705 205 236 179 92 103 53 99 
77 18426 2127 7343 1564 262 199 222 157 117 106 54 82 
177 25532 2746 13667 2741 1315 435 636 198 291 200 72 71 
78 16563 2728 5918 1435 335 126 115 89 36 42 68 78 
178 25320 2706 14565 2666 2155 475 518 251 329 178 97 105 
79 17686 2981 7518 841 528 121 258 167 188 214 177 130 
179 29966 1085 19332 1510 3381 534 970 304 660 147 188 157 
80 23525 2183 9650 1201 596 248 465 151 248 136 48 94 
180 33222 2152 21487 3413 4266 976 1610 569 1128 269 260 144 
81 19950 3894 12347 3979 852 384 542 221 270 94 134 149 
181 33103 2810 23600 2460 5618 1227 1687 665 1283 336 454 193 
92 24762 2345 16242 2128 3351 373 1474 599 807 215 316 176 
185 158 201 87 71 101 121 77 122 56 63 70 96 
182 35660 2698 26460 2401 11037 1460 5374 1949 3092 483 1368 235 
93 26523 2557 17552 2962 4194 894 2479 547 1476 489 471 211 
186 9854 2475 1763 584 66 92 49 97 62 56 40 97 
183 37977 1929 27187 2894 12743 2179 5449 1272 3839 368 1655 490 
94 31144 2395 19921 2072 5222 1014 3090 699 1535 429 652 184 
187 14288 1749 6591 1736 90 146 27 50 85 132 0 0 
184 39784 3123 31472 1962 16479 2022 7409 1257 5365 992 2594 187 
98 34742 3408 29654 2939 17697 2660 8476 2139 6824 1004 4230 716 
188 20592 3415 11911 1989 401 145 161 121 94 134 104 106 
101 27882 2617 19195 1862 6123 1186 2965 731 2247 399 1082 316 
189 33287 1510 25458 2161 12125 1649 5094 990 3694 356 1837 152 
102 29040 2964 19880 2287 6649 1122 3437 1211 2218 500 1011 362 
191 20932 2383 11049 1871 1354 387 463 232 279 143 111 141 
192 222 277 61 72 11 22 31 49 10 20 94 117 
190 37973 4384 30124 1931 14809 973 6038 1281 4591 647 2514 315 
107 25499 3370 17645 2578 5069 660 2970 627 1616 297 595 144 
193 34728 1248 27923 326 14002 1253 6596 113 4538 733 1901 196 
108 26860 2349 18922 1223 6719 1097 3589 437 2382 433 1092 166 
195 22159 1687 13991 1520 2377 247 903 174 464 190 88 137 
194 33899 2447 27322 2418 14887 1619 7031 1306 5031 736 2530 177 
109 31774 791 21522 1911 8672 1237 4488 1290 3645 948 1436 451 
197 26902 1650 17082 1598 3909 583 1928 559 1521 674 495 236 
198 167 118 39 44 67 96 109 63 55 70 59 69 
196 40403 2096 32493 1400 18481 2430 9072 2786 6696 1317 3724 609 
113 30168 2671 25885 2202 18246 3198 9608 2625 10211 2095 7644 1411 
199 36728 2479 34065 1070 29124 2872 19015 4241 20703 3668 21353 1976 
119 30991 3937 23931 2144 11447 1058 6632 1762 4758 1128 2393 315 
200 22027 3053 15391 2342 2899 480 752 147 487 107 119 188 
125 29081 3161 22638 1581 10397 1286 5478 1123 3973 887 1788 369 
202 21885 1800 15854 2018 3831 514 1183 459 792 80 197 96 
201 41111 1374 33978 2109 24385 4347 14364 2646 10188 1998 6898 1334 
126 33682 2752 24694 1270 12609 2357 6335 1534 5522 1207 2952 679 
203 25628 2262 19043 1142 7703 786 2508 280 2016 301 562 212 
204 1508 220 769 175 85 110 36 48 51 84 117 129 
174 24522 3475 15584 393 3254 263 1675 417 1104 314 385 141 
205 30399 3092 22067 313 6349 598 2952 1029 1967 542 746 71 
206 29988 3344 22658 1348 9085 713 3996 1257 2843 713 1376 305 
232 14145 2031 3395 908 57 2 99 124 170 75 62 17 
234 17631 3109 8294 1425 776 308 414 72 202 218 32 55 
 
  
 9 APPENDIX 357 
 
 
9.3.5 Microarray format 5 (MA5) 
Plant lectin microarray: 
Peptides 
ECA (0.1 
mg/mL) 
MAL I (0.08 
mg/mL) 
MAL I (0.2 
mg/mL) 
PNA (0.01 
mg/mL) 
PNA (0.05 
mg/mL) 
WGA( 0.02 
mg/mL) 
VVL (0.05 
mg/mL) 
SNA (0.01 
mg/mL) 
MAL II (0.02 
mg/mL) 
MAL II (0.04 
mg/mL) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
238 0 0 0 0 20 28 1 2 0 0 0 0 19 26 0 0 8 18 0 0 
208 0 0 31 46 24 43 16 23 3 7 0 0 33 48 0 0 32392 72431 0 0 
209 0 0 83 136 0 0 8 10 14 32 0 0 3309 462 0 0 450 1006 849 1898 
210 0 0 21 29 25 46 7 15 1 2 0 0 1665 441 1 1 160 358 0 0 
211 0 0 1 2 21 47 55 74 0 0 0 0 763 129 2 2 2 4 0 0 
212 29 34 21 48 31 69 12 26 0 0 873 1951 24 50 0 1 0 0 0 0 
213 35 34 28 33 24 27 15 21 22 49 0 0 387 135 0 0 0 0 0 0 
214 0 0 90 20 94 46 27 29 43 37 7 16 126463 7432 0 0 0 0 0 0 
215 0 0 133 50 200 34 7 16 0 0 1816 2013 311410 5651 0 0 0 0 0 0 
216 26 37 112 60 141 97 24 39 0 0 43621 5531 321832 22256 18 39 0 0 0 0 
218 9 11 16 16 89 128 40 48 3 6 0 0 95403 16207 0 0 0 0 0 0 
219 0 0 49 33 54 70 38 40 0 0 0 0 209901 7765 1 2 0 0 0 0 
221 13 21 1 1 36 38 16 23 0 0 0 0 162420 9806 0 0 0 0 0 0 
229 0 0 360 389 214 39 17 39 12 26 0 0 391474 6195 0 0 15 33 0 0 
230 40 47 96 58 168 109 26 32 23 34 0 0 266799 17576 0 0 0 0 0 0 
233 0 0 57 45 262 358 0 0 0 0 506 695 204769 8114 0 0 1 2 0 0 
234 0 0 136 198 41 66 0 0 9 21 0 0 155377 9169 0 0 2940 6570 0 0 
235 10 13 60 23 67 43 12 26 0 0 0 0 359530 8347 0 0 0 0 0 0 
236 0 0 139 46 158 63 4 8 14 31 0 0 395243 7838 0 0 0 0 8 17 
237 0 1 50 52 103 132 4 8 0 0 0 0 210199 9057 0 0 0 0 3 7 
68 0 0 70 65 41 54 48 48 122 274 980 2190 100512 8717 0 0 0 0 0 0 
69 18 27 42 35 21 26 12 22 2 4 0 0 203227 4688 0 0 0 0 0 0 
70 25 26 82 54 139 109 15 21 21 23 0 0 221546 7616 0 0 0 0 1 1 
71 4 5 59 54 112 131 2 4 27 42 0 0 326556 13399 1 1 120 268 0 0 
72 29 23 173 83 448 115 7 15 16 23 55 118 250424 4922 0 0 0 0 3 8 
73 29 28 183 75 318 39 7 14 10 23 64 144 274312 8069 5 9 0 0 0 0 
74 40 44 303 50 485 77 0 0 0 0 14 30 293559 7352 1 2 0 0 0 0 
223 0 0 22 22 41 71 22293 2156 43512 4627 0 0 57 78 2 4 0 0 0 0 
225 36 39 32 29 0 0 35583 3141 58511 4602 39 86 19 42 0 0 0 0 0 0 
227 18 19 6 11 0 0 69884 4029 87404 4260 0 0 0 0 0 0 0 0 0 0 
228 20 19 0 1 15 33 33815 1839 59174 2049 20 45 20 45 0 0 9 21 4 10 
231 0 0 18 40 0 0 144346 3638 165444 5302 0 0 53 99 0 0 8 19 0 0 
232 0 0 33 32 1 1 162176 759 205987 29492 0 0 11 24 0 0 0 0 0 0 
82 27 27 4 9 30 42 42065 5115 81476 3888 0 0 223 185 0 0 0 0 1 2 
83 0 0 15 22 27 59 29131 2563 55157 1423 11972 26769 0 0 0 0 0 0 0 0 
84 0 0 13 18 25 30 41871 3221 62466 2033 0 0 7 17 0 0 0 0 224 502 
75 48 50 295 625 15 34 16966 2078 40901 3745 100 224 101 146 0 1 2 4 0 0 
76 0 0 4 8 11 19 38338 3758 72944 3206 0 0 10 23 0 0 0 0 0 0 
77 0 0 14 19 14 15 110741 4872 140381 6589 0 0 0 0 0 0 123 276 0 0 
78 10 10 12 27 114 238 79986 1597 134500 5583 715 1599 0 0 0 0 0 0 0 0 
79 0 0 56 72 12 26 129919 1972 168728 4154 0 0 38 85 0 0 218 488 0 0 
80 15 22 14 21 54 89 143042 6180 173478 6313 0 0 29 30 0 0 0 0 0 0 
81 25 23 4 8 31 52 149370 5365 170956 3871 0 0 158 117 5 10 9 21 0 0 
175 0 0 24 33 31 42 43 39 49 49 3446 1090 15 31 1 2 446 263 851 70 
176 0 0 26 40 51 115 0 0 14 32 19688 1667 53 52 0 0 885 130 1764 90 
177 24 27 23 39 56 39 0 0 11 25 42712 4142 671 1473 0 0 24173 2293 38883 2271 
178 0 0 13 23 48 48 0 0 46 104 63847 6216 2 4 0 0 5441 736 9734 972 
179 0 0 53 48 35 66 14 16 0 0 92101 5365 78 120 0 0 35455 2651 52153 3344 
180 24 28 50 49 48 50 0 0 26 59 93971 4922 170 184 0 0 40098 2499 59695 2171 
181 0 0 71 50 76 55 356 157 1046 232 109496 3629 100 141 0 0 45996 3692 66923 3007 
85 44 15 25 34 6 13 14 32 11 25 0 0 10 23 0 0 9 20 0 0 
86 0 0 31 42 33 31 12 21 4 6 32 72 1 1 0 0 6 13 0 0 
87 36 31 24 24 4 9 43 50 13 28 0 0 74 122 1 1 0 0 0 0 
88 79 70 11 14 1 2 12 17 18 40 0 0 20 19 0 0 194 434 25 55 
89 101 55 20 20 13 19 22 41 0 0 0 0 44 51 0 0 0 0 0 0 
90 185 149 41 42 18 19 9 16 309 691 0 0 51 105 0 0 0 0 4 9 
91 323 229 24 18 0 0 16 24 0 0 0 0 135 104 0 0 20 45 24 53 
92 5939 744 281 90 369 118 33 72 7 14 0 0 47 50 0 0 858 1815 170 356 
93 6641 1191 22 32 36 63 29 62 1 3 3029 6772 42 93 2 4 22 31 0 0 
94 15030 2441 14 31 46 79 6 9 38 31 0 0 4562 10158 112 87 0 0 2 3 
95 20513 1585 421 48 651 90 9 20 0 0 0 0 30 51 38 45 14 31 20 44 
96 25775 598 656 79 1106 171 20 25 0 0 0 0 111 126 427 241 25 57 0 0 
97 36176 1352 38 24 31 44 0 1 8 17 0 0 72 161 454 204 39 88 0 0 
98 43758 2103 1044 163 1817 146 27157 60675 12 16 0 0 104 130 1119 270 652 1363 0 0 
182 0 0 14 21 29 29 16 25 3 6 0 0 18 40 50529 9384 49 109 0 0 
183 0 0 23 25 25 37 12 23 4443 9914 0 0 2 4 48869 15337 0 0 0 0 
184 0 0 47 54 77 68 32 51 27 60 0 0 14 31 66615 13788 4 8 0 0 
188 0 0 87 53 138 92 20 19 10 22 0 0 84 117 132000 15488 0 0 0 0 
185 17 17 48751 3636 50902 5206 20 27 31 37 0 0 78 69 4 6 1089 285 1812 376 
186 0 0 4751 805 5914 1995 29 27 17 38 46 71 60 113 6 10 52 55 285 113 
187 0 0 14896 2495 16591 5305 148 191 32 39 665 188 81 83 3 6 150 103 309 199 
99 6093 780 217 59 290 97 6 13 154 291 0 0 71 67 162 120 33 34 70 102 
100 2 3 30 42 300 410 19 42 34 48 0 0 48 72 1 1 26 58 10 23 
101 3 4 0 0 26 36 56 34 23 32 516 1154 59 59 1 1 31 70 39 74 
102 56 55 27 29 11 23 55 17 17 38 111 248 19 20 0 1 0 0 12 20 
103 96 59 1 1 19 33 69 45 6 13 0 0 81 127 2 3 82 166 6 14 
104 154 97 38 55 55 123 123 218 81 56 0 0 2567 5497 0 0 0 0 0 0 
105 217 15 12 15 67 116 16 35 9 20 0 0 81 97 6 13 29 64 46 78 
106 552 76 11 15 136 305 21 22 36 47 0 0 141 170 0 1 68 138 0 0 
191 0 0 55 37 41 53 36 36 23 22 0 0 6 13 15357 9072 8 18 7 17 
192 2 3 17 25 387 795 14 32 5 10 818 1830 74 91 9492 8982 0 0 0 0 
189 16 16 4 10 19 32 36 50 30 41 25726 5337 37 53 0 0 0 0 9 21 
190 0 0 30 32 2 4 27 31 66 147 19554 1790 39 48 0 0 0 0 0 0 
107 8113 918 100 35 150 106 9 19 160 291 244 546 58 51 23 22 5 7 0 0 
108 8994 248 15 22 3 6 50 39 13 12 309 454 38 54 82 64 0 0 40 41 
109 11025 1195 23 31 46 43 6 13 8 19 40 87 104 47 458 205 24 55 0 0 
110 33612 1458 405 59 731 111 2 3 45 78 555 290 498 869 164 95 17 38 0 0 
111 35445 2152 348 49 481 284 877 1910 20 30 291 367 56 51 584 381 0 0 7 16 
112 34019 2843 168 59 368 95 8 15 0 1 651 371 127 86 1011 641 183 350 0 0 
113 56040 2686 1063 51 2127 184 1 2 21 22 1584 1028 138 58 1027 294 0 0 0 0 
116 11541 1137 331 54 380 226 182 59 123 43 48 68 460 84 319 226 78 97 52 44 
115 10694 956 46 44 46 72 35 24 51 63 7395 16515 82 96 15 34 13 30 7 16 
114 6073 620 47 42 92 115 632 1202 102 171 191 378 85 107 12 16 91 190 34 48 
195 0 0 48 44 31 62 24 34 24 33 0 0 85 70 35234 9529 31 47 22 49 
197 0 0 15 34 50 54 57 47 15 34 0 0 66 94 44965 11090 86 193 0 0 
198 0 0 28 36 58 50 16 23 10 14 0 0 30 59 47423 12883 0 0 0 0 
193 0 0 38562 3257 35347 12939 11 24 5 11 849 318 39 88 1 2 778 252 1340 259 
194 6 8 36143 3007 35557 8592 35 37 35 69 4456 636 54 56 0 0 683 323 1048 295 
196 0 0 40235 3733 38200 9417 18 25 30 44 2660 571 23 51 0 0 893 826 898 615 
199 0 0 131226 16508 144436 6836 15 22 69 74 144420 7746 0 0 0 0 3908 1933 5435 1213 
117 157 49 46 52 22 26 715 1520 38 64 42 93 36 42 1 1 5 12 15 24 
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Peptides 
ECA (0.1 
mg/mL) 
MAL I (0.08 
mg/mL) 
MAL I (0.2 
mg/mL) 
PNA (0.01 
mg/mL) 
PNA (0.05 
mg/mL) 
WGA( 0.02 
mg/mL) 
VVL (0.05 
mg/mL) 
SNA (0.01 
mg/mL) 
MAL II (0.02 
mg/mL) 
MAL II (0.04 
mg/mL) 
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
118 85 55 40 38 12 21 72 46 5525 12218 116 212 65 65 0 0 33 46 3 6 
119 296 79 38 54 48 108 30 34 41 45 37 83 64 98 32 57 62 138 23 34 
120 707 116 4 8 189 362 98 143 198 192 0 0 197 111 1 1 0 0 24 43 
121 3101 512 12 18 22 31 164 91 573 318 0 0 341 577 88 59 0 0 0 0 
122 2315 425 17 39 26 41 111 88 228 131 10 22 10 20 69 86 87 195 0 0 
123 5202 1593 25 55 9 9 220 38 1036 334 15 34 64 62 63 53 12 26 6 13 
200 0 0 28 38 38 79 19 22 510 1039 42 94 28 48 23355 12956 36 71 0 0 
124 29499 1345 329 98 496 86 26 31 0 0 131 146 0 0 102 103 25 55 0 0 
125 33534 2314 111 81 222 125 10 15 67 53 2545 489 0 0 49 54 16 35 8 17 
126 43986 5539 76 58 44 45 3 7 41 46 11244 2716 72 82 3791 6814 16 36 21 39 
127 43891 1219 882 236 1775 133 52 59 19 33 318 699 22 48 505 599 0 0 5 12 
128 72387 4720 1331 325 2595 278 16 22 284 545 26340 3019 138 57 1887 999 13 28 0 0 
129 59980 944 736 138 1508 64 161 313 0 1 37044 5313 162 75 4723 4934 2 5 7 16 
130 65921 3674 3407 362 5852 702 20 35 14 13 49210 6387 167 145 2821 1730 49 104 0 0 
202 0 0 41 48 256 472 13 14 37 46 42 63 72 98 91985 29520 0 0 6 14 
203 0 0 31 36 68 58 17 28 118 180 187 419 39 36 78743 25824 8 19 198 444 
204 0 0 59 48 45 43 14 23 17 27 0 0 132 111 73735 15447 598 1337 0 0 
201 8 10 66275 5354 74780 6251 4 7 348 675 83394 4029 4 9 2 3 843 385 2094 222 
174 9967 1069 3 6 34 33 54124 5719 88028 2766 201 141 134 136 6 13 0 0 576 1149 
205 7065 1214 44 53 30 59 65 49 95 58 43927 6005 64 81 0 0 416 242 790 221 
206 5 5 11388 1480 11958 3915 2082 788 10047 3663 2836 359 0 0 0 0 308 100 552 74 
131 8068 1417 165 47 241 173 36 36 83 176 3563 774 397756 19688 19 26 0 0 37 63 
132 9728 1639 204 29 384 387 32 45 68 47 497 190 626925 7760 0 0 0 0 12 27 
133 20246 2681 241 53 510 116 7 12 18 27 15987 1935 485644 38920 69 101 24 35 11 23 
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